"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,CN,A,CN 115552242 A,018-937-664-560-93X,2022-12-30,2022,CN 202080099431 A,2020-12-04,US 202063030492 P;;US 2020/0063437 W,2020-05-27,Glucose prediction using machine learning and time series glucose measurements,"Glucose prediction using machine learning (ML) and time series glucose measurements is described. In view of a large number of people wearing glucose monitoring devices, and since some wearable glucose monitoring devices can continuously produce measurements, the platform providing such devices may have a large amount of data. In practice, even not in practice, humans cannot process this amount of data, and this amount of data covers a huge amount of state space, which is impossible to be covered if there is no huge amount of data. In an embodiment, a glucose monitoring platform includes an ML model trained using historical time series glucose measurements of a user population. The ML model predicts an upcoming glucose measurement for a particular user by receiving a time series of glucose measurements prior to a time and determining an upcoming glucose measurement for the particular user within an interval after the time based on a pattern learned from historical time series of glucose measurements.",DEXCOM INC,DEREZINSKI MICHAEL;;PARK ALEXANDER S,,https://lens.org/018-937-664-560-93X,Patent Application,no,0,0,9,9,0,A61B5/0004;;A61B5/0022;;A61B5/14532;;A61B5/6833;;A61B5/7267;;A61B5/746;;A61B5/7275;;G16H50/20;;G16H50/70;;G16H40/63;;G16H40/67;;G06N3/08;;G06N3/048;;G06N3/044;;G16H40/67;;G16H50/20;;G06N3/08;;G16H40/63;;G06F17/18;;A61B5/0004;;A61B5/0015;;A61B5/14532;;A61B5/6801;;A61B5/7275;;A61B5/746;;G06N3/044;;H04L67/12;;A61B5/74;;G06N3/02;;G06N3/0442,G01N33/48;;A61B5/00,,0,0,,,,PENDING
2,CN,A,CN 1042503 A,016-509-607-723-970,1990-05-30,1990,CN 89108162 A,1989-10-21,US 26930788 A,1988-11-10,METHOD OF SURFACE BONDING METERIALS TOGETHER BY USE OF METAL MATRIX COMPOSITE AND PRODUCTS PRODUCED THEREBY,"The present invention relates to forming a metal matrix composite (3) between at least two bodies (1) having a similar or a different chemical composition, the metal matrix composite functioning as a bonding means which bonds or fixes the bodies (1) together. Particularly, a metal matrix composite is produced by a spontaneous infiltration technique by providing a filler material (2) or preform with an infiltration enhancer and/or an infiltration enhancer precursor and/or an infiltrating atmosphere, which are in communication with the filler material or preform at least at some point during the process. Molten matrix metal then spontaneously infiltrates the filler material or preform, whereby the metal matrix composite serves to bond together two or more bodies.",LANXIDE TECHNOLOGY CO LTD,PARK EUGENE S;;AGHAJANIAN MICHAEL K,,https://lens.org/016-509-607-723-970,Patent Application,no,0,6,33,34,0,C04B37/005;;C04B37/006;;C04B37/023;;C04B37/025;;C04B37/026;;C04B2235/5248;;C04B2235/6567;;C04B2235/658;;C04B2237/06;;C04B2237/064;;C04B2237/08;;C04B2237/083;;C04B2237/09;;C04B2237/121;;C04B2237/126;;C04B2237/127;;C04B2237/128;;C04B2237/343;;C04B2237/52;;C04B2237/525;;C04B2237/592;;C04B2237/597;;C04B2237/60;;C04B2237/708;;C04B2237/72;;C04B37/023;;C04B2235/6567;;C04B2237/08;;C04B2237/525;;C04B37/006;;C04B2237/06;;C04B2237/52;;C04B2237/128;;C04B2235/658;;C04B2237/708;;C04B2235/5248;;C04B2237/343;;C04B2237/064;;C04B2237/09;;C04B2237/72;;C04B37/005;;C04B2237/592;;C04B2237/597;;C04B2237/121;;C04B2237/127;;C04B37/026;;C04B2237/083;;C04B37/025;;C04B2237/126;;C04B2237/60,B22D19/14;;B23K1/19;;C04B37/00;;C04B37/02;;C22C1/10;;C22C21/00;;C22C47/08;;C23C14/34,,0,0,,,,EXPIRED
3,CN,C,CN 1065849 C,099-839-564-666-736,2001-05-16,2001,CN 89108162 A,1989-10-21,US 26930788 A,1988-11-10,Method of surface bonding meterials together by use of metal matrix composite,"The present invention relates to forming a metal matrix composite (3) between at least two bodies (1) having a similar or a different chemical composition, the metal matrix composite functioning as a bonding means which bonds or fixes the bodies (1) together. Particularly, a metal matrix composite is produced by a spontaneous infiltration technique by providing a filler material (2) or preform with an infiltration enhancer and/or an infiltration enhancer precursor and/or an infiltrating atmosphere, which are in communication with the filler material or preform at least at some point during the process. Molten matrix metal then spontaneously infiltrates the filler material or preform, whereby the metal matrix composite serves to bond together two or more bodies.",LANXIDE TECHNOLOGY CO LTD,PARK EUGENE S;;AGHAJANIAN MICHAEL K,,https://lens.org/099-839-564-666-736,Granted Patent,no,4,0,33,34,0,C04B37/005;;C04B37/006;;C04B37/023;;C04B37/025;;C04B37/026;;C04B2235/5248;;C04B2235/6567;;C04B2235/658;;C04B2237/06;;C04B2237/064;;C04B2237/08;;C04B2237/083;;C04B2237/09;;C04B2237/121;;C04B2237/126;;C04B2237/127;;C04B2237/128;;C04B2237/343;;C04B2237/52;;C04B2237/525;;C04B2237/592;;C04B2237/597;;C04B2237/60;;C04B2237/708;;C04B2237/72;;C04B37/023;;C04B2235/6567;;C04B2237/08;;C04B2237/525;;C04B37/006;;C04B2237/06;;C04B2237/52;;C04B2237/128;;C04B2235/658;;C04B2237/708;;C04B2235/5248;;C04B2237/343;;C04B2237/064;;C04B2237/09;;C04B2237/72;;C04B37/005;;C04B2237/592;;C04B2237/597;;C04B2237/121;;C04B2237/127;;C04B37/026;;C04B2237/083;;C04B37/025;;C04B2237/126;;C04B2237/60,B22D19/14;;B23K1/19;;C04B37/00;;C04B37/02;;C22C1/10;;C22C21/00;;C22C47/08;;C23C14/34,,0,0,,,,EXPIRED
4,AT,T1,AT E452550 T1,105-140-718-146-108,2010-01-15,2010,AT 03708846 T,2003-01-21,US 5137102 A;;US 0301494 W,2002-01-22,FUSSBEKLEIDUNGSARTIKEL MIT ZELTARTIGEM OBERMATERIAL,"An article of footwear has an upper in a tented arrangement. The article of footwear includes a sole and an upper including a shroud. The article of footwear further includes a foot engaging system for joining a foot of a user to the sole, and a biasing system which includes one or more frame members that urges or influences the shroud away from the foot of the user. The one or more frame members may be coupled to the foot holding system on a medial and a lateral side. The article of footwear further includes a plurality of straps for holding the foot to the sole in which one of the straps engages the heel. The straps are located on an exterior surface of the shroud or alternatively they are located in the interior of the shroud. Air gaps are created between the shroud and the foot for ventilation. Several foot booties for holding a foot have aeration regions for providing air to ventilate the foot of a wearer. Further, the foot booties are combined with straps, in which the straps are disposed between the shroud and the foot booties. The upper has a flexible sheet of material that is interconnected with a plurality of frame members that urges the sheet away from the foot of a wearer. The upper may be removable and replaceable with the sole.",NIKE INTERNATIONAL LTD,HATFIELD TINKER;;AVENI MICHAEL;;FRITON MICHAEL;;DOLAN ROBERT;;PARK S,,https://lens.org/105-140-718-146-108,Granted Patent,no,0,0,10,10,0,A43B3/163;;A43B3/24;;A43B3/242;;A43B7/02;;A43B7/06;;A43B7/1495;;A43B13/12;;A43B19/00;;A43B23/047;;A43B23/07;;A43B23/22;;A43C1/00;;A43B23/0235;;A43B23/0245;;A43B3/242;;A43B23/07;;A43B7/1495;;A43C1/00;;A43B19/00;;A43B7/02;;A43B13/12;;A43B23/047;;A43B23/22;;A43B3/24;;A43B7/06;;A43B3/163;;A43B23/0245;;A43B23/0235,A43B3/16;;A43B3/24;;A43B7/02;;A43B7/06;;A43B7/14;;A43B11/00;;A43B13/12;;A43B19/00;;A43B23/00;;A43B23/02;;A43B23/04;;A43B23/07;;A43B23/22;;A43C1/00,,0,0,,,,EXPIRED
5,WO,A1,WO 2016/106151 A1,006-057-989-882-733,2016-06-30,2016,US 2015/0066898 W,2015-12-18,US 201514967222 A;;US 201462097046 P,2014-12-27,IMPLANTABLE FLOW CONNECTOR,"A system for coupling a first space within a body of a patient with a second space within the body of the patient including a flow connector insertable into the first and second spaces within the body and having a conduit having a wall forming a lumen therein and first and second orifices. A first retention member is engageable with a first portion of the first space within the body and has a first opening, and the flow connector is positioned within the first opening. A second retention member is engageable with the second space within the body, the second retention member has a second opening and the flow connector is positioned within the second opening. The second retention member interlocks with the first retention member.",BIOCONNECT SYSTEMS INC,PARK JIN S;;PARIS MICHAEL;;VALENTINE HUNTER;;ADAM DAKIN,,https://lens.org/006-057-989-882-733,Patent Application,yes,3,0,1,33,0,A61B17/0643;;A61B17/0644;;A61B17/11;;A61B17/12009;;A61B2017/00004;;A61B2017/00867;;A61B2017/00893;;A61B2017/00946;;A61B2017/1107;;A61B2017/1135;;A61B2090/061;;A61B2090/0807,A61B17/11;;A61B17/064,,0,0,,,,PENDING
6,WO,A3,WO 2002/077346 A3,116-066-510-920-199,2003-04-10,2003,US 0209247 W,2002-03-26,US 81667001 A,2001-03-26,APPLICATION OF ANTIMICROBIAL TO WARP YARN,"A process for imparting antimicrobial properties to textile fabrics (Fig. 1) by applying an antimicrobial substance to the fibers from which the textile is woven, knit or constructed. Preferably the antimicrobial substance is applied, prior to weaving, to wrap yarns on a slasher or warper or similar coating or finish application device before the warp ends are rolled up onto a loom or selection beam. The warp yarns are then woven with fill yarns, not treated with the antimicrobial, into a cloth which is then sold in the loom state or subjected to subsequent finishing. A preferred cloth end use is mattress ticking.",BURLINGTON INDUSTRIES INC,ESCHE SUSAN PARK;;BENNETH ERIN G;;SHOE MICHAEL S,,https://lens.org/116-066-510-920-199,Search Report,yes,6,0,4,4,0,D06M16/00;;D06M16/00;;D02H5/02;;D02H5/02,D02H5/02;;D06M16/00,,0,0,,,,PENDING
7,WO,A2,WO 2002/077346 A2,159-582-155-725-321,2002-10-03,2002,US 0209247 W,2002-03-26,US 81667001 A,2001-03-26,APPLICATION OF ANTIMICROBIAL TO WARP YARN,"A process for imparting antimicrobial properties to textile fabrics (Fig. 1) by applying an antimicrobial substance to the fibers from which the textile is woven, knit or constructed. Preferably the antimicrobial substance is applied, prior to weaving, to wrap yarns on a slasher or warper or similar coating or finish application device before the warp ends are rolled up onto a loom or selection beam. The warp yarns are then woven with fill yarns, not treated with the antimicrobial, into a cloth which is then sold in the loom state or subjected to subsequent finishing. A preferred cloth end use is mattress ticking.",BURLINGTON INDUSTRIES INC,ESCHE SUSAN PARK;;BENNETH ERIN G;;SHOE MICHAEL S,,https://lens.org/159-582-155-725-321,Patent Application,yes,0,0,4,4,0,D06M16/00;;D06M16/00;;D02H5/02;;D02H5/02,D02H5/02;;D06M16/00,,0,0,,,,PENDING
8,US,A1,US 2016/0096008 A1,075-337-538-630-018,2016-04-07,2016,US 201514967222 A,2015-12-11,US 201514967222 A;;US 201313792019 A;;US 201462097046 P;;US 201261624375 P,2012-04-15,IMPLANTABLE FLOW CONNECTOR,"A system for coupling a first space within a body of a patient with a second space within the body of the patient including a flow connector insertable into the first and second spaces within the body and having a conduit having a wall forming a lumen therein and first and second orifices. A first retention member is engageable with a first portion of the first space within the body and has a first opening, and the flow connector is positioned within the first opening. A second retention member is engageable with the second space within the body, the second retention member has a second opening and the flow connector is positioned within the second opening. The second retention member interlocks with the first retention member.",BIOCONNECT SYSTEMS INC,PARK JIN S;;PARIS MICHAEL;;VALENTINE HUNTER;;DAKIN ADAM,BIOCONNECT SYSTEMS INC (2016-01-28);;TVA MEDICAL INC (2016-11-14),https://lens.org/075-337-538-630-018,Patent Application,yes,4,25,4,33,0,A61B17/0643;;A61B17/0644;;A61B17/11;;A61B17/12009;;A61B2017/1107;;A61M27/002;;A61B2017/1135;;A61M27/002;;A61M1/3655;;A61M2205/04;;A61B2017/1135;;A61B17/0643;;A61B17/0644;;A61B17/11;;A61B17/12009;;A61B2017/1107,A61M27/00;;A61M1/36,,0,0,,,,ACTIVE
9,US,B1,US 6430789 B1,162-532-195-919-211,2002-08-13,2002,US 81667001 A,2001-03-26,US 81667001 A,2001-03-26,Application of antimicrobial to warp yarn,"
    A process for imparting antimicrobial properties to textile fabrics by applying an antimicrobial substance to the fibers from which the textile is woven, knit or constructed. Preferably the antimicrobial substance is applied, prior to weaving, to warp yarns on a slasher or warper or similar coating or finish application device before the warp ends are rolled up onto a loom or section beam. The warp yarns are then woven with fill yarns, not treated with the antimicrobial, into a cloth which is then sold in the loom state or subjected to subsequent finishing. A preferred cloth end use is mattress ticking. 
",BURLINGTON INDUSTRIES INC,ESCHE SUSAN PARK;;BENNETT ERIN G;;SHOE MICHAEL S,INTERNATIONAL TEXTILE GROUP INC (2007-01-22);;BURLINGTON INDUSTRIES LLC (2003-11-14);;BURLINGTON INDUSTRIES INC (2001-05-29);;CULP INC (2007-01-22),https://lens.org/162-532-195-919-211,Granted Patent,yes,13,14,4,4,0,D06M16/00;;D06M16/00;;D02H5/02;;D02H5/02,D02H5/02;;D06M16/00,28/166;;28/178;;28/179;;X139426 R,1,0,,,"Abstract: JP 11099589; ""Antimicrobial foil sheet textile fabric -has resin layer of predefined composition formed on thin metal foil layer"".",EXPIRED
10,US,A1,US 2012/0174156 A1,072-772-175-791-732,2012-07-05,2012,US 98293410 A,2010-12-31,US 98293410 A,2010-12-31,SYSTEM AND METHOD FOR PRESENTING INFORMATION ASSOCIATED WITH A CONTACT FOR VIDEO CALLING,"A method for presenting information associated with a contact for video calling is disclosed. The method comprises storing a list of favorite contacts of a user. In an electronic program guide (EPG) user interface, a plurality of contact identifiers corresponding to the list of favorite contacts is displayed together with program information. An input from the user is received to highlight a selected one of the contact identifiers. In the EPG user interface, a status video associated with a contact associated with the selected one of the contact identifiers is displayed.",PARK JOON YOUNG;;BEUHLER ALLYSON J;;THIEMS MICHAEL S;;GEN INSTRUMENT CORP,PARK JOON YOUNG;;BEUHLER ALLYSON J;;THIEMS MICHAEL S,GENERAL INSTRUMENT CORPORATION (2011-05-27);;MOTOROLA MOBILITY LLC (2013-05-28);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;GENERAL INSTRUMENT HOLDINGS INC (2013-04-15),https://lens.org/072-772-175-791-732,Patent Application,yes,4,11,1,1,0,H04N7/147;;H04N21/4532;;H04N21/4788;;H04N21/4821;;H04N21/485;;H04N21/47;;H04N21/4788;;H04N7/147;;H04N21/4532;;H04N21/4821;;H04N21/47;;H04N21/485,H04N7/173;;H04N5/445,725/40;;725/106,0,0,,,,DISCONTINUED
11,US,B2,US 10434293 B2,105-784-633-834-28X,2019-10-08,2019,US 201514967222 A,2015-12-11,US 201514967222 A;;US 201313792019 A;;US 201462097046 P;;US 201261624375 P,2012-04-15,Implantable flow connector,"A system for coupling a first space within a body of a patient with a second space within the body of the patient including a flow connector insertable into the first and second spaces within the body and having a conduit having a wall forming a lumen therein and first and second orifices. A first retention member is engageable with a first portion of the first space within the body and has a first opening, and the flow connector is positioned within the first opening. A second retention member is engageable with the second space within the body, the second retention member has a second opening and the flow connector is positioned within the second opening. The second retention member interlocks with the first retention member.",TVA MEDICAL INC,PARK JIN S;;PARIS MICHAEL;;VALENTINE HUNTER;;DAKIN ADAM,BIOCONNECT SYSTEMS INC (2016-01-28);;TVA MEDICAL INC (2016-11-14),https://lens.org/105-784-633-834-28X,Granted Patent,yes,297,17,4,33,0,A61B17/0643;;A61B17/0644;;A61B17/11;;A61B17/12009;;A61B2017/1107;;A61M27/002;;A61B2017/1135;;A61M27/002;;A61M1/3655;;A61M2205/04;;A61B2017/1135;;A61B17/0643;;A61B17/0644;;A61B17/11;;A61B17/12009;;A61B2017/1107,A61M1/36;;A61B17/064;;A61B17/11;;A61B17/12;;A61M27/00,,4,0,,,"International Search Report and Written Opinion issued by the International Bureau of WIPO in connection with International Patent Application No. PCT/US2011/052159.;;The Extended European Search Report for Application No. 08782616.0 or PCT/US2008/072166 dated Jun. 5, 2015.;;The Extended European Search Report for Application No. 08782617.8 or PCT/US2008/072167 dated Jun. 10, 2015.;;International Search Report and Written Opinion issued by the International Bureau of WIPO in connection with International Patent Application No. PCT/US2013/0033629 dated Oct. 1, 2013.",ACTIVE
12,US,A,US 5238045 A,148-937-990-397-633,1993-08-24,1993,US 67847391 A,1991-04-01,US 67847391 A;;US 26930788 A,1988-11-10,"Method of surface bonding materials together by use of a metal matrix composite, and products produced thereby","The present invention relates to forming a metal matrix composite between at least two bodies having a similar or a different chemical composition, the metal matrix composite functioning as a bonding means which bond to or fixes the bodies together. Particularly, a metal matrix composite is produced by a spontaneous infiltration technique by providing a filler material or preform with an infiltration enhancer and/or an infiltration enhancer precursor and/or and infiltrating atmosphere, which are in communication with the filler material or preform at least at some point during the process. Molten matrix metal then spontaneously infiltrates the filler material or preform, whereby the metal matrix composite serves to bond together two or more bodies.",LANXIDE TECHNOLOGY CO LTD,PARK EUGENE S;;AGHAJANIAN MICHAEL K;;KENNEDY CHRISTOPHER R,,https://lens.org/148-937-990-397-633,Granted Patent,yes,41,38,1,34,0,C04B37/005;;C04B37/006;;C04B37/025;;C04B37/026;;C04B2235/5248;;C04B2235/6567;;C04B2235/658;;C04B2237/06;;C04B2237/064;;C04B2237/08;;C04B2237/083;;C04B2237/09;;C04B2237/121;;C04B2237/126;;C04B2237/127;;C04B2237/128;;C04B2237/343;;C04B2237/52;;C04B2237/525;;C04B2237/592;;C04B2237/597;;C04B2237/708;;C04B2237/72;;C04B37/025;;C04B2237/127;;C04B37/026;;C04B2235/6567;;C04B37/005;;C04B2237/09;;C04B2237/343;;C04B2237/083;;C04B2237/06;;C04B2237/064;;C04B2235/5248;;C04B2237/597;;C04B2235/658;;C04B2237/121;;C04B2237/128;;C04B2237/525;;C04B2237/126;;C04B2237/708;;C04B2237/52;;C04B37/006;;C04B2237/08;;C04B2237/592;;C04B2237/72,C04B37/00;;C04B37/02,164/97;;164/98;;164/108,5,4,115-473-733-243-772;;168-759-695-575-069;;042-007-317-223-364;;115-663-184-208-209,10.1007/bf01160545;;10.1007/bf03257892;;10.1007/bf03258826;;10.1016/0010-4361(78)90516-5,"F. Delannay, L. Froyen, and A. Deruyttere, Review: The Wetting of Solids by Molten Metals and Its Relation to the Preparation of Metal Matrix Composites , Journal of Materials Science, vol. 22, No. 1, pp. 1 16, Jan. 1987.;;A. Mortensen, M. N. Gungor, J. A. Cornie, and M. C. Flemings, Alloy Microstructures in Cast Metal Matrix Composites , Journal of Metals, vol. 38, No. 3, pp. 30 35, Mar. 1986.;;G. R. Edwards and D. L. Olson, The Infiltration Kinetics of Aluminum in Silicon Carbide Compacts , Annual Report from Center for Welding Research, Colorado School of Mines, under ONR Contract No. M00014 85 K 0451, DTIC Report AD A184 682, Jul. 1987.;;A. Mortensen, J. A. Cornie, and M. C. Flemings, Solidification Processing of Metal Matrix Composites , Journal of Metals, vol. 40, No. 2, pp. 12 19, Feb. 1988.;;B. D. Sparks and F. W. Meadus, The Development of an Infiltrated Lead/Iron Composite Material For Use as a Non toxic Bird Shot , Composites, pp. 37 39, Jan. 1978.",EXPIRED
13,AU,A1,AU 2002/303154 A1,160-996-494-847-118,2002-10-08,2002,AU 2002/303154 A,2002-03-26,US 81667001 A;;US 0209247 W,2001-03-26,Application of antimicrobial to warp yarn,,BURLINGTON INDUSTRIES INC,ESCHE SUSAN PARK;;SHOE MICHAEL S;;BENNETH ERIN G,,https://lens.org/160-996-494-847-118,Patent Application,no,0,0,4,4,0,D06M16/00;;D06M16/00;;D02H5/02;;D02H5/02,D02H5/02;;D06M16/00,,0,0,,,,DISCONTINUED
14,KR,B1,KR 0146339 B1,190-044-740-051-909,1998-11-02,1998,KR 890014424 A,1989-10-07,US 26930788 A,1988-11-10,METHOD OF SURFACE BONDING MATERIALS TOGETHER BY USE OF A METAL MATRIX COMPOSITE,"The present invention relates to forming a metal matrix composite (3) between at least two bodies (1) having a similar or a different chemical composition, the metal matrix composite functioning as a bonding means which bonds or fixes the bodies (1) together. Particularly, a metal matrix composite is produced by a spontaneous infiltration technique by providing a filler material (2) or preform with an infiltration enhancer and/or an infiltration enhancer precursor and/or an infiltrating atmosphere, which are in communication with the filler material or preform at least at some point during the process. Molten matrix metal then spontaneously infiltrates the filler material or preform, whereby the metal matrix composite serves to bond together two or more bodies.",LANXIDE TECHNOLOGY CO LTD,AGAJANIAN MICHAEL KEVORK;;PARK EUGENE S;;KENNEDY CHRISTOPHER ROBIN,,https://lens.org/190-044-740-051-909,Granted Patent,no,0,1,33,34,0,C04B37/005;;C04B37/006;;C04B37/023;;C04B37/025;;C04B37/026;;C04B2235/5248;;C04B2235/6567;;C04B2235/658;;C04B2237/06;;C04B2237/064;;C04B2237/08;;C04B2237/083;;C04B2237/09;;C04B2237/121;;C04B2237/126;;C04B2237/127;;C04B2237/128;;C04B2237/343;;C04B2237/52;;C04B2237/525;;C04B2237/592;;C04B2237/597;;C04B2237/60;;C04B2237/708;;C04B2237/72;;C04B37/023;;C04B2235/6567;;C04B2237/08;;C04B2237/525;;C04B37/006;;C04B2237/06;;C04B2237/52;;C04B2237/128;;C04B2235/658;;C04B2237/708;;C04B2235/5248;;C04B2237/343;;C04B2237/064;;C04B2237/09;;C04B2237/72;;C04B37/005;;C04B2237/592;;C04B2237/597;;C04B2237/121;;C04B2237/127;;C04B37/026;;C04B2237/083;;C04B37/025;;C04B2237/126;;C04B2237/60,B23K1/19;;C04B37/00;;C04B37/02;;C22C1/10;;B22D19/14;;C22C21/00;;C22C47/08;;C23C14/34,,0,0,,,,EXPIRED
15,US,B2,US 11666737 B2,014-533-033-805-439,2023-06-06,2023,US 201916542372 A,2019-08-16,US 201916542372 A;;US 201514967222 A;;US 201313792019 A;;US 201462097046 P;;US 201261624375 P,2012-04-15,Implantable flow connector,"A system for coupling a first space within a body of a patient with a second space within the body of the patient including a flow connector insertable into the first and second spaces within the body and having a conduit having a wall forming a lumen therein and first and second orifices. A first retention member is engageable with a first portion of the first space within the body and has a first opening, and the flow connector is positioned within the first opening. A second retention member is engageable with the second space within the body, the second retention member has a second opening and the flow connector is positioned within the second opening. The second retention member interlocks with the first retention member.",TVA MEDICAL INC,PARK JIN S;;PARIS MICHAEL;;VALENTINE HUNTER;;DAKIN ADAM,BIOCONNECT SYSTEMS INC (2016-01-28);;TVA MEDICAL INC (2016-11-14),https://lens.org/014-533-033-805-439,Granted Patent,yes,299,0,4,33,0,A61B17/0643;;A61B17/0644;;A61B17/11;;A61B17/12009;;A61B2017/1107;;A61M27/002;;A61B2017/1135;;A61M27/002;;A61M1/3655;;A61M2205/04;;A61B2017/1135;;A61B17/0643;;A61B17/0644;;A61B17/11;;A61B17/12009;;A61B2017/1107,A61M27/00;;A61B17/064;;A61B17/11;;A61B17/12;;A61M1/36,,5,0,,,"International Search Report and Written Opinion issued by the International Bureau of WIPO in connection with International Patent Application No. PCT/US2011/052159.;;The Extended European Search Report for Application No. 08782616.0 or PCT/US2008/072166 dated Jun. 5, 2015.;;The Extended European Search Report for Application No. 08782617.8 or PCT/US2008/072167 dated Jun. 10, 2015.;;International Search Report and Written Opinion issued by the International Bureau of WIPO in connection with International Patent Application No. PCT/US2013/0033629 dated Oct. 1, 2013.;;Non-Final Office Action dated May 11, 2020 pertaining to U.S. Appl. No. 15/017,620.",ACTIVE
16,CA,A1,CA 2000789 A1,177-355-820-555-485,1990-05-10,1990,CA 2000789 A,1989-10-13,US 26930788 A,1988-11-10,METHOD OF SURFACE BONDING MATERIALS TOGETHER BY USE OF A METAL MATRIX COMPOSITE AND PRODUCTS PRODUCED THEREBY,"37 Abstract The present invention relates to forming a a metal matrix composite between at least two bodies having a similar or a different chemical composition, the metal matrix composite functioning as a bonding means which to bonds or fixes the bodies together. Particularly, a metal matrix composite is produced by a spontaneous infiltration technique by providing a filler material or preform with an infiltration enhancer and/or an infiltration enhancer precursor and/or and infiltrating atmosphere, which are in communication with the filler material or preform at least at some point during the process. Molten matrix metal then spontaneously infiltrates the filler material or preform, whereby the metal matrix composite serves to bond together two or more bodies.",LANXIDE TECHNOLOGY CO LTD,PARK EUGENE S;;AGHAJANIAN MICHAEL K;;KENNEDY CHRISTOPHER R,,https://lens.org/177-355-820-555-485,Patent Application,no,0,0,33,34,0,C04B37/005;;C04B37/006;;C04B37/023;;C04B37/025;;C04B37/026;;C04B2235/5248;;C04B2235/6567;;C04B2235/658;;C04B2237/06;;C04B2237/064;;C04B2237/08;;C04B2237/083;;C04B2237/09;;C04B2237/121;;C04B2237/126;;C04B2237/127;;C04B2237/128;;C04B2237/343;;C04B2237/52;;C04B2237/525;;C04B2237/592;;C04B2237/597;;C04B2237/60;;C04B2237/708;;C04B2237/72;;C04B37/023;;C04B2235/6567;;C04B2237/08;;C04B2237/525;;C04B37/006;;C04B2237/06;;C04B2237/52;;C04B2237/128;;C04B2235/658;;C04B2237/708;;C04B2235/5248;;C04B2237/343;;C04B2237/064;;C04B2237/09;;C04B2237/72;;C04B37/005;;C04B2237/592;;C04B2237/597;;C04B2237/121;;C04B2237/127;;C04B37/026;;C04B2237/083;;C04B37/025;;C04B2237/126;;C04B2237/60,B22D19/14;;B23K1/19;;C04B37/00;;C04B37/02;;C22C1/10;;C22C21/00;;C22C47/08;;C23C14/34,D30250123    M;;0130022    S,0,0,,,,DISCONTINUED
17,US,A,US 5004034 A,009-344-890-892-617,1991-04-02,1991,US 26930788 A,1988-11-10,US 26930788 A,1988-11-10,"Method of surface bonding materials together by use of a metal matrix composite, and products produced thereby","The present invention relates to forming a a metal matrix composite between at least two bodies having a similar or a different chemical composition, the metal matrix composite functioning as a bonding means which to bonds or fixes the bodies together. Particularly, a metal matrix composite is produced by a spontaneous infiltration technique by providing a filler material or preform with an infiltration enhancer and/or an infiltration enhancer precursor and/or and infiltrating atmosphere, which are in communication with the filler material or preform at least at some point during the process. Molten matrix metal then spontaneously infiltrates the filler material or preform, whereby the metal matrix composite serves to bond together two or more bodies.",LANXIDE TECHNOLOGY CO LTD,PARK EUGENE S;;AGHAJANIAN MICHAEL K;;KENNEDY CHRISTOPHER R,LANXIDE TECHNOLOGY COMPANY LP A CORP. OF DE (1988-12-22),https://lens.org/009-344-890-892-617,Granted Patent,yes,36,50,33,34,0,C04B37/005;;C04B37/006;;C04B37/023;;C04B37/025;;C04B37/026;;C04B2235/5248;;C04B2235/6567;;C04B2235/658;;C04B2237/06;;C04B2237/064;;C04B2237/08;;C04B2237/083;;C04B2237/09;;C04B2237/121;;C04B2237/126;;C04B2237/127;;C04B2237/128;;C04B2237/343;;C04B2237/52;;C04B2237/525;;C04B2237/592;;C04B2237/597;;C04B2237/60;;C04B2237/708;;C04B2237/72;;C04B37/023;;C04B2235/6567;;C04B2237/08;;C04B2237/525;;C04B37/006;;C04B2237/06;;C04B2237/52;;C04B2237/128;;C04B2235/658;;C04B2237/708;;C04B2235/5248;;C04B2237/343;;C04B2237/064;;C04B2237/09;;C04B2237/72;;C04B37/005;;C04B2237/592;;C04B2237/597;;C04B2237/121;;C04B2237/127;;C04B37/026;;C04B2237/083;;C04B37/025;;C04B2237/126;;C04B2237/60,B23K1/19;;B22D19/14;;C04B37/00;;C04B37/02;;C22C1/10;;C22C21/00;;C22C47/08;;C23C14/34,164/97;;164/98,3,2,115-473-733-243-772;;168-759-695-575-069,10.1007/bf01160545;;10.1007/bf03257892,"F. Delannay, L. Froyen, and A. Deruyttere, Review: The Wetting of Solids by Molten Metals and Its Relation to the Preparation of Metal Matrix Composites , Journal of Materials Science, vol. 22, No. 1, pp. 1 16, Jan. 1987.;;A. Mortensen, M. N. Gungor, J. A. Cornie, and M. C. Flemings, Alloy Microstructures in Cast Metal Matrix Composites , Journal of Metals, vol. 38, No. 3, pp. 30 35, Mar. 1986.;;G. R. Edwards and D. L. Olson, The Infiltration Kinetics of Aluminum in Silicon Carbide Compacts , Annual Report from Center for Welding Research, Colorado School of Mines, under ONR Contract No. M00014 85 K 0451, DTIC Report AD A184 682, Jul. 1987.",EXPIRED
18,US,A1,US 2019/0366062 A1,090-849-657-144-533,2019-12-05,2019,US 201916542372 A,2019-08-16,US 201916542372 A;;US 201514967222 A;;US 201313792019 A;;US 201462097046 P;;US 201261624375 P,2012-04-15,IMPLANTABLE FLOW CONNECTOR,"A system for coupling a first space within a body of a patient with a second space within the body of the patient including a flow connector insertable into the first and second spaces within the body and having a conduit having a wall forming a lumen therein and first and second orifices. A first retention member is engageable with a first portion of the first space within the body and has a first opening, and the flow connector is positioned within the first opening. A second retention member is engageable with the second space within the body, the second retention member has a second opening and the flow connector is positioned within the second opening. The second retention member interlocks with the first retention member.",TVA MEDICAL INC,PARK JIN S;;PARIS MICHAEL;;VALENTINE HUNTER;;DAKIN ADAM,BIOCONNECT SYSTEMS INC (2016-01-28);;TVA MEDICAL INC (2016-11-14),https://lens.org/090-849-657-144-533,Patent Application,yes,2,12,4,33,0,A61B17/0643;;A61B17/0644;;A61B17/11;;A61B17/12009;;A61B2017/1107;;A61M27/002;;A61B2017/1135;;A61M27/002;;A61M1/3655;;A61M2205/04;;A61B2017/1135;;A61B17/0643;;A61B17/0644;;A61B17/11;;A61B17/12009;;A61B2017/1107,A61M27/00;;A61M1/36,,0,0,,,,ACTIVE
19,US,A,US 5683573 A,013-436-974-775-779,1997-11-04,1997,US 63585796 A,1996-04-22,US 63585796 A;;AU 1997/043664 A;;CA 2219690 A;;CN 97114142 A;;EP 97308696 A;;JP 30223097 A;;RU 97118230 A;;US 36234394 A,1994-12-22,Continuous catalytic reforming process with dual zones,"A hydrocarbon feedstock is catalytically reformed in a sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone and continuous regeneration of catalyst particles, and a zeolitic-reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite. The process combination permits higher severity, higher aromatics yields and/or increased throughput in the continuous-reforming zone, thus showing surprising benefits over prior-art processes, and is particularly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP INC,HAIZMANN ROBERT S;;PARK JOHN Y G;;RUSS MICHAEL B,UOP (1996-04-19),https://lens.org/013-436-974-775-779,Granted Patent,yes,8,26,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G35/06;;C10G47/14;;C10G35/095;;C10G49/08;;C10G59/02,208/64;;208/63;;208/65,0,0,,,,EXPIRED
20,CN,A,CN 1216315 A,103-526-227-758-096,1999-05-12,1999,CN 97114124 A,1997-11-03,CN 97114124 A,1997-11-03,Continuous catalytic reforming combined with zeolitic reforming for increased BTX yield,"A naphtha feedstock is catalytically reformed in a combination sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone with continuous regeneration of catalyst particles, followed by a zeolitic-reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite operating on the effluent from the combination reforming zone. The unique process combination permits higher severity, higher BTX aromatics yields and/or increased throughput in the continuous-reforming zone, thus showing surprising benefits over prior-art processes, and is particularly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP INC,HAIZMANN ROBERT S;;RUSS MICHAEL B;;PARK JOHN Y G,,https://lens.org/103-526-227-758-096,Patent Application,no,0,1,2,2,0,,C10G35/06,,0,0,,,,EXPIRED
21,AT,T1,AT E230007 T1,133-531-558-916-110,2003-01-15,2003,AT 97308696 T,1997-10-30,AU 1997/043664 A;;CA 2219690 A;;CN 97114142 A;;EP 97308696 A;;JP 30223097 A;;RU 97118230 A;;US 63585796 A,1996-04-22,KONTINUIERLICHE KATALYTISCHE REFORMIERUNG KOMBINIERT MIT ZEOLIT-REFORMIERUNG FÜR VERBESSERTE BTX-AUSBEUTE,"A naphtha feedstock is catalytically reformed in a combination sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone with continuous regeneration of catalyst particles, followed by a zeolitic-reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite operating on the effluent from the continuous-reforming zone. The unique process combination permits higher severity, higher BTX aromatics yields and/or increased throughput in the continuous-reforming zone, thus showing surprising benefits over prior-art processes, and is particularly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP INC,HAIZMANN ROBERT S;;PARK JOHN Y G;;RUSS MICHAEL B,,https://lens.org/133-531-558-916-110,Granted Patent,no,0,0,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G47/14;;C10G35/06;;C10G35/095;;C10G49/08;;C10G59/02,,0,0,,,,DISCONTINUED
22,ES,T3,ES 2188874 T3,119-402-435-290-850,2003-07-01,2003,ES 97308696 T,1997-10-30,AU 1997/043664 A;;CA 2219690 A;;CN 97114142 A;;EP 97308696 A;;JP 30223097 A;;RU 97118230 A;;US 63585796 A,1996-04-22,REFORMADO CATALITICO CONTINUO COMBINADO CON REFORMADO ZEOLITICO PARA AUMENTAR EL RENDIMIENTO BTX.,"A naphtha feedstock is catalytically reformed in a combination sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone with continuous regeneration of catalyst particles, followed by a zeolitic-reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite operating on the effluent from the continuous-reforming zone. The unique process combination permits higher severity, higher BTX aromatics yields and/or increased throughput in the continuous-reforming zone, thus showing surprising benefits over prior-art processes, and is particularly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP INC,HAIZMANN ROBERT S;;PARK JOHN Y G;;RUSS MICHAEL B,,https://lens.org/119-402-435-290-850,Granted Patent,no,0,0,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G35/06;;C10G47/14;;C10G35/095;;C10G49/08;;C10G59/02,,0,0,,,,EXPIRED
23,EP,B1,EP 0913452 B1,158-219-383-129-406,2002-12-18,2002,EP 97308696 A,1997-10-30,EP 97308696 A;;AU 1997/043664 A;;CA 2219690 A;;CN 97114142 A;;JP 30223097 A;;RU 97118230 A;;US 63585796 A,1996-04-22,Continuous catalytic reforming combined with zeolytic reforming for increased btx yield,"A naphtha feedstock is catalytically reformed in a combination sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone with continuous regeneration of catalyst particles, followed by a zeolitic-reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite operating on the effluent from the continuous-reforming zone. The unique process combination permits higher severity, higher BTX aromatics yields and/or increased throughput in the continuous-reforming zone, thus showing surprising benefits over prior-art processes, and is particularly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP INC,HAIZMANN ROBERT S;;PARK JOHN Y G;;RUSS MICHAEL B,,https://lens.org/158-219-383-129-406,Granted Patent,yes,4,0,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G47/14;;C10G35/06;;C10G35/095;;C10G49/08;;C10G59/02,,0,0,,,,EXPIRED
24,JP,A,JP H11172261 A,181-994-427-145-039,1999-06-29,1999,JP 30223097 A,1997-11-04,JP 30223097 A;;AU 1997/043664 A;;CA 2219690 A;;CN 97114142 A;;EP 97308696 A;;RU 97118230 A;;US 63585796 A,1996-04-22,INCREASED BTX CONTINUOUS CATALYTIC REFORMING IN COMBINATION WITH ZEOLITE REFORMING,"PROBLEM TO BE SOLVED: To increase the yield of BTX components by contacting a naphtha raw material with a catalyst containing a platinum metal in a continuous reforming zone to obtain a first effluent containing BTX aromatic hydrocarbons and an inactive catalyst, regenerating the inactive catalyst in a regeneration zone and contacting the effluent with a zeolite reforming catalyst in another reforming zone. SOLUTION: A naphtha raw material is brought into contact with a bifunctional reforming catalyst containing a platinum metal in the presence of hydrogen in a continuous reforming zone at 100 kPa-1 MPa, at a space velocity of 0.2-10/min, at a hydrogen/C5 + hydrocarbon molar ratio of 0.1-10 and at 400-560 deg.C to produce a first effluent containing BTX aromatic hydrocarbons and an inactive catalyst particle. The catalyst particle is regenerated by a contact with a gas containing oxygen and then with a gas containing hydrogen in a regeneration zone. The first effluent is brought into contact with a zeolite reforming catalyst containing a non-acidic zeolite/an alkaline metal/a platinum metal in another reforming zone at 100 kPa-6 MPa, at a space velocity of 1-40/hr, and at 260-560 deg.C to obtain an effluent having a BTX content 10% or more than that of the first effluent.",UOP INC,ROBERT S HEISMAN;;JOHN Y G PARK;;MICHAEL B LUCE,,https://lens.org/181-994-427-145-039,Patent Application,no,0,2,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G35/06;;C10G35/095;;C10G49/08;;C10G47/14;;C10G59/02,,0,0,,,,PENDING
25,AU,A,AU 1997/043664 A,132-621-395-007-74X,1999-05-20,1999,AU 1997/043664 A,1997-10-31,AU 1997/043664 A;;CA 2219690 A;;CN 97114142 A;;EP 97308696 A;;JP 30223097 A;;RU 97118230 A;;US 63585796 A,1996-04-22,Continuous catalytic reforming combined with zeolitic reforming for increased BTX yield,,UOP INC,HAIZMANN ROBERT S;;RUSS MICHAEL B;;PARK JOHN Y G,,https://lens.org/132-621-395-007-74X,Patent Application,no,0,0,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G47/14;;C10G35/06;;C10G35/095;;C10G49/08;;C10G59/02,,0,0,,,,EXPIRED
26,US,A,US 5935415 A,038-417-276-945-412,1999-08-10,1999,US 96369397 A,1997-11-04,US 96369397 A;;US 63585796 A;;US 36234394 A,1994-12-22,Continuous catalytic reforming process with dual zones,"A hydrocarbon feedstock is catalytically reformed in a sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone and continuous regeneration of catalyst particles, and a zeolitic-reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite. The process combination permits higher severity, higher aromatics yields and/or increased throughput in the continuous-reforming zone, thus showing surprising benefits over prior-art processes, and is particularly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP LLC,HAIZMANN ROBERT S;;PARK JOHN Y G;;RUSS MICHAEL B,UOP LLC (1998-03-25),https://lens.org/038-417-276-945-412,Granted Patent,yes,9,59,1,14,0,C10G35/06;;C10G59/02;;C10G35/06;;C10G59/02,C10G35/06;;C10G59/02,208/64;;208/63;;208/65,0,0,,,,EXPIRED
27,CA,A1,CA 2219690 A1,115-850-326-861-208,1999-04-30,1999,CA 2219690 A,1997-10-30,CA 2219690 A;;AU 1997/043664 A;;CN 97114142 A;;EP 97308696 A;;JP 30223097 A;;RU 97118230 A;;US 63585796 A,1996-04-22,CONTINUOUS CATALYTIC REFORMING COMBINED WITH ZEOLITIC REFORMING FOR INCREASED BTX YIELD,"A naphtha feedstock is catalytically reformed in a combination sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone with continuous regeneration of catalyst particles, fol lowed by a zeolitic-reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite operating on the effluent from the combination reforming zone. The unique process combination permits higher severity, higher BTX aromatics yields and/or increased throughput in the continuous-reforming zone, thus showing surprising benefits over prior-art processes, and is particul arly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP INC,RUSS MICHAEL B;;HAIZMANN ROBERT S;;PARK JOHN Y G,,https://lens.org/115-850-326-861-208,Patent Application,no,0,0,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G47/14;;C10G35/06;;C10G35/095;;C10G49/08;;C10G59/02,,0,0,,,,EXPIRED
28,DE,T2,DE 69718001 T2,192-679-894-942-634,2003-09-25,2003,DE 69718001 T,1997-10-30,AU 1997/043664 A;;CA 2219690 A;;CN 97114142 A;;EP 97308696 A;;JP 30223097 A;;RU 97118230 A;;US 63585796 A,1996-04-22,Kontinuierliche katalytische Reformierung kombiniert mit Zeolit-Reformierung für verbesserte BTX-Ausbeute,"A naphtha feedstock is catalytically reformed in a combination sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone with continuous regeneration of catalyst particles, followed by a zeolitic-reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite operating on the effluent from the continuous-reforming zone. The unique process combination permits higher severity, higher BTX aromatics yields and/or increased throughput in the continuous-reforming zone, thus showing surprising benefits over prior-art processes, and is particularly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP DES PLAINES,HAIZMANN ROBERT S;;PARK JOHN Y G;;RUSS MICHAEL B,,https://lens.org/192-679-894-942-634,Granted Patent,no,0,0,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G47/14;;C10G35/06;;C10G35/095;;C10G49/08;;C10G59/02,,0,0,,,,EXPIRED
29,DE,D1,DE 69718001 D1,119-275-698-370-407,2003-01-30,2003,DE 69718001 T,1997-10-30,AU 1997/043664 A;;CA 2219690 A;;CN 97114142 A;;EP 97308696 A;;JP 30223097 A;;RU 97118230 A;;US 63585796 A,1996-04-22,Kontinuierliche katalytische Reformierung kombiniert mit Zeolit-Reformierung für verbesserte BTX-Ausbeute,"A naphtha feedstock is catalytically reformed in a combination sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone with continuous regeneration of catalyst particles, followed by a zeolitic-reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite operating on the effluent from the continuous-reforming zone. The unique process combination permits higher severity, higher BTX aromatics yields and/or increased throughput in the continuous-reforming zone, thus showing surprising benefits over prior-art processes, and is particularly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP DES PLAINES,HAIZMANN ROBERT S;;PARK JOHN Y G;;RUSS MICHAEL B,,https://lens.org/119-275-698-370-407,Granted Patent,no,0,0,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G47/14;;C10G35/06;;C10G35/095;;C10G49/08;;C10G59/02,,0,0,,,,EXPIRED
30,AU,B2,AU 743806 B2,152-389-736-481-442,2002-02-07,2002,AU 1997/043664 A,1997-10-31,AU 1997/043664 A;;CA 2219690 A;;CN 97114142 A;;EP 97308696 A;;JP 30223097 A;;RU 97118230 A;;US 63585796 A,1996-04-22,Continuous catalytic reforming combined with zeolitic reforming for increased BTX yield,"A naphtha feedstock is catalytically reformed in a combination sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone with continuous regeneration of catalyst particles, followed by a zeolitic-reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite operating on the effluent from the continuous-reforming zone. The unique process combination permits higher severity, higher BTX aromatics yields and/or increased throughput in the continuous-reforming zone, thus showing surprising benefits over prior-art processes, and is particularly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP INC,HAIZMANN ROBERT S;;RUSS MICHAEL B;;PARK JOHN Y G,,https://lens.org/152-389-736-481-442,Granted Patent,no,3,0,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G47/14;;C10G35/06;;C10G35/095;;C10G49/08;;C10G59/02,,0,0,,,,EXPIRED
31,EP,A1,EP 0913452 A1,071-508-576-934-504,1999-05-06,1999,EP 97308696 A,1997-10-30,EP 97308696 A;;AU 1997/043664 A;;CA 2219690 A;;CN 97114142 A;;JP 30223097 A;;RU 97118230 A;;US 63585796 A,1996-04-22,Continuous catalytic reforming combined with zeolytic reforming for increased btx yield,"A naphtha feedstock is catalytically reformed in a combination sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone with continuous regeneration of catalyst particles, followed by a zeolitic-reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite operating on the effluent from the continuous-reforming zone. The unique process combination permits higher severity, higher BTX aromatics yields and/or increased throughput in the continuous-reforming zone, thus showing surprising benefits over prior-art processes, and is particularly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP INC,HAIZMANN ROBERT S;;PARK JOHN Y G;;RUSS MICHAEL B,,https://lens.org/071-508-576-934-504,Patent Application,yes,4,2,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G47/14;;C10G35/06;;C10G35/095;;C10G49/08;;C10G59/02,,0,0,,,,EXPIRED
32,CN,A,CN 115397308 A,137-734-473-103-124,2022-11-25,2022,CN 202080099252 A,2020-12-07,US 202063017611 P;;US 2020/0063659 W,2020-04-29,Prediction of hypoglycemic events using machine learning,"Prediction of hypoglycemic events using machine learning is described. The CGM platform includes a machine learning model trained using historical timing glucose measurements of a user population. Once trained, the machine learning model predicts a hypoglycemia event for the user. When a hypoglycemic event is predicted, a timing of glucose measurements at daytime intervals is received. The glucose measurements at the timing of daytime intervals are provided by a CGM system worn by the user. The machine learning model predicts whether a hypoglycemia event may occur during a night time interval following the day time interval by processing the timing of glucose measurements using the trained machine learning model. The prediction of the hypoglycemic event is then output, for example by transmission and/or display of notifications regarding the prediction of the hypoglycemic event.",DEXCOM INC,ACCIAROL GIUSEPPE;;DEREZINSKI MICHAEL;;JEPSON LAUREN HELEN;;PARK ALEXANDER S,,https://lens.org/137-734-473-103-124,Patent Application,no,0,0,8,8,0,A61B5/14532;;G06N3/08;;G16H40/63;;G16H40/67;;G16H50/30;;G16H50/70;;G16H50/20;;A61B5/7275;;A61B2562/08;;A61B5/6833;;G06N7/01;;G06N3/044;;G06N3/045;;A61B5/14532;;G16H40/67;;G06N3/08;;G16H40/63,A61B5/00,,0,0,,,,PENDING
33,CA,C,CA 2219690 C,169-117-464-939-242,2006-05-09,2006,CA 2219690 A,1997-10-30,CA 2219690 A;;AU 1997/043664 A;;CN 97114142 A;;EP 97308696 A;;JP 30223097 A;;RU 97118230 A;;US 63585796 A,1996-04-22,CONTINUOUS CATALYTIC REFORMING COMBINED WITH ZEOLITIC REFORMING FOR INCREASED BTX YIELD,"A naphtha feedstock is catalytically reformed in a combination sequence comprising a continuous-reforming zone, consisting essentially of a moving-bed catalytic reforming zone with continuous regeneration of catalyst particles, followed by a zeolitic- reforming zone containing a catalyst comprising a platinum-group metal and a nonacidic zeolite operati ng on the effluent from the continuous-reforming zone. The unique process combination permits higher severity, higher BTX aromatics yields and/or increased throughput in the continuous- reforming zone, thus showing surprising benefits over prior-art processes, and is particularly useful in upgrading existing moving-bed reforming facilities with continuous catalyst regeneration.",UOP INC,HAIZMANN ROBERT S;;PARK JOHN Y G;;RUSS MICHAEL B,,https://lens.org/169-117-464-939-242,Granted Patent,no,0,0,13,14,0,C10G35/06;;C10G35/095;;C10G59/02;;C10G59/02;;C10G35/095;;C10G35/06,C10G35/095;;C10G47/14;;C10G35/06;;C10G49/08;;C10G59/02,,0,0,,,,EXPIRED
34,AU,A1,AU 2002/340437 A1,197-892-624-685-185,2003-05-26,2003,AU 2002/340437 A,2002-11-08,US 33776901 P;;US 0235941 W,2001-11-09,Crystals and structures of yiim proteins,,STRUCTURAL GENOMIX INC,PARK FRANCES;;GAJIWALA KETAN S;;SAUDER J MICHAEL;;BUCHANAN SEAN GRANT,,https://lens.org/197-892-624-685-185,Patent Application,no,0,0,4,4,0,C07K14/47;;C07K2299/00;;G16B15/00;;Y02A90/10;;G16B15/30;;C07K14/47;;C07K2299/00;;G16B15/00;;Y02A90/10;;G16B15/30,C07K14/47;;G16B15/30,,0,0,,,,DISCONTINUED
35,WO,A1,WO 1993/019109 A1,144-907-799-407-298,1993-09-30,1993,AU 1910/093001 W,1993-03-18,AU PL140492 A,1992-03-18,ABSORBENT FOR ISOCYANATE VAPOURS,The specification describes polyurethane foams for absorbing isocyanate vapours formed during the manufacture of polyurethane foam. The polyurethane foams are produced from an isocyanate and a polyether polyol and are porous and compression resistant. An apparatus for removing isocyanate vapours from off-gases produced during the manufacture of polyurethane foam is also disclosed. The apparatus includes a container packed with a polyether polyol derived polyurethane foam through which off-gases produced during the production of polyurethane foam are passed.,PACIFIC DUNLOP LTD,WOOD ALLEN;;PARK RONALD S;;GILLIVER DAVID M;;JOUBERT MICHAEL D,,https://lens.org/144-907-799-407-298,Patent Application,yes,3,0,1,2,0,B01J20/28045;;B01D53/02;;B01J20/26;;B01J20/28011;;C08G18/4833;;C08G2110/0008;;C08G2110/005,B01D53/02;;B01J20/26;;B01J20/28;;C08G18/48,B1L LAG           LAG4;;B1L L102          LAG4;;B1L L225          LAG4;;B1L L309          LAG4;;B1L L604          LAG4,2,0,,,"PATENT ABSTRACTS OF JAPAN, C-329, page 148; & JP,A,60 192 722 (KURASHIKI BOUSEKI K.K.), 1 October 1985.;;DERWENT ABSTRACT, Accession No. 92-070872/09, Class A88; & SU,A,1 637 846 (POLIMERSINTEZ RES), 30 March 1991.",PENDING
36,WO,A3,WO 2003/042232 A3,062-024-369-813-876,2004-02-26,2004,US 0235941 W,2002-11-08,US 33776901 P,2001-11-09,CRYSTALS AND STRUCTURES OF YIIM PROTEINS,"The present invention provides machine readable media embedded with the three-dimensional molecular structure coordinates of YiiM family members, and subsets thereof, including binding pockets, methods of using the structure to identify and design affecters, including inhibitors and activator, mutants of YiiM family members, and compounds and compositions that affect YiiM family members activity.",STRUCTURAL GENOMIX INC;;PARK FRANCES;;GAJIWALA KETAN S;;BUCHANAN SEAN GRANT;;SAUDER J MICHAEL,PARK FRANCES;;GAJIWALA KETAN S;;BUCHANAN SEAN GRANT;;SAUDER J MICHAEL,,https://lens.org/062-024-369-813-876,Search Report,yes,0,0,4,4,0,C07K14/47;;C07K2299/00;;G16B15/00;;Y02A90/10;;G16B15/30;;C07K14/47;;C07K2299/00;;G16B15/00;;Y02A90/10;;G16B15/30,C07K14/47;;G16B15/30,,5,5,115-546-710-000-924;;021-376-102-143-203;;069-450-943-413-364;;006-262-512-717-979;;034-069-053-755-933,10.1021/ci00007a012;;10.1021/ci00057a005;;7154081;;10.1016/0022-2836(82)90153-x;;10.1126/science.277.5331.1453;;9278503;;10.1093/nar/21.15.3391;;pmc331436;;8346018,"DALBY A. ET AL.: ""Description of several chemical structure file formats used by computer programs developed at molecular design limited"", JOURNAL OF CHEMICAL INFORMATICS AND COMPUTATIONAL SCIENCES, vol. 32, 1992, pages 244 - 255, XP000611886;;WEININGER D.: ""SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules"", JOURNAL OF CHEMICAL INFORMATICS AND COMPUTATIONAL SCIENCES, vol. 28, 1988, pages 31 - 36, XP000611887;;KUNTZ I.D. ET AL.: ""A geometric approach to macromolecule-ligand interactions"", JOURNAL OF MOLECULAR BIOLOGY, vol. 161, 1982, pages 269 - 288, XP000560868;;BLATTNER F.R. ET AL.: ""The complete genome sequence of escherichia coli K-12"", SCIENCE, vol. 277, 5 September 1997 (1997-09-05), pages 1453 - 1462, XP002937834;;PLUNKETT G. ET AL.: ""Analysis of the escherichia coli genome. III. DNA sequence of the region from 87.2 to 89.2 minutes"", NUCLEIC ACIDS RESEARCH, vol. 21, no. 15, 1993, pages 3391 - 3398, XP002929581",PENDING
37,AU,A1,AU 2002/365232 A1,071-921-894-299-314,2003-09-02,2003,AU 2002/365232 A,2002-11-27,US 33413201 P;;US 0238070 W,2001-11-28,CRYSTALS AND STRUCTURES OF A FLAVIN MONONUCLEOTIDE BINDING PROTEIN (FMNBP),,STRUCTURAL GENOMIX INC,PARK FRANCES;;GAJIWALA KETAN S;;BUCHANAN SEAN GRANT;;SAUDER J MICHAEL,,https://lens.org/071-921-894-299-314,Patent Application,no,0,0,5,5,0,C12N9/0004;;G01N33/54353;;G01N33/552;;G16B15/00;;G16B20/00;;G16B30/00;;G16C20/50;;G16B15/20;;G16B20/30;;C12N9/0004;;G01N33/552;;G01N33/54353;;G16B20/00;;G16B15/00;;G16B30/00;;G16C20/50;;G16B20/30;;G16B15/20,G16B15/20;;C12N9/02;;G01N33/543;;G01N33/552;;G06F19/00;;G16B20/30;;G16B30/00,,0,0,,,,DISCONTINUED
38,US,B1,US 7716022 B1,169-387-157-743-186,2010-05-11,2010,US 43111606 A,2006-05-09,US 43111606 A;;US 67909305 P,2005-05-09,Computer-implemented systems and methods for processing time series data,"Computer-implemented systems and methods for providing a forecast using time series data that is indicative of a data generation activity occurring over a period of time. Candidate models and candidate input variables are received. For each candidate model, transfer functions are determined for the candidate input variables in order to relate a variable to be forecasted to the time series data. For each candidate model there is a selection of which of the candidate input variables to include in each of the candidate models based upon the determined transfer functions. A model is selected from the candidate models to forecast the time series data using the selected input variables of the selected model.",SAS INST INC,PARK YOUNGJIN;;LEONARD MICHAEL J;;SELUKAR RAJESH S;;CHANG MING-CHUN,SAS INSTITUTE INC (2006-06-27),https://lens.org/169-387-157-743-186,Granted Patent,yes,49,77,5,6,0,G06Q10/10;;G06Q30/0201;;G06Q30/0202;;G06F17/18;;G06Q10/10;;G06Q30/0202;;G06Q30/0201;;G06F17/18,G06F17/10,703/2;;703/22;;702/181,31,6,019-184-368-932-762;;036-359-590-382-00X;;051-775-327-653-999;;049-421-467-589-888;;119-376-992-262-434;;009-876-099-668-514,10.1016/s0925-2312(01)00590-2;;10.1109/10.951514;;11585035;;10.1109/infvis.1999.801851;;10.1109/micro.1996.566457;;10.1137/1.9781611972719.1;;10.1016/s0377-2217(98)00037-x,"Choudhury et al., Forecasting of Engineering Manpower Through Fuzzy Associative Memory Neural Netwrok with ARIMA: A Comparative Study, Neurocomputing, vol. 47, Iss. 1-4, Aug. 2002, pp. 241-257.;;Lu et al., A New Algorithm for Linear and Nonlinear ARMA Model Parameter Estimation Using Affine Geometry, IEEE Tranactions oon Biomedical Engineering, vol. 48, No. 10, Oct. 2001, pp. 1116-1124.;;van Wijk, Jarke J. et al., ""Cluster and Calendar based Visualization of Time Series Data"", IEEE Symposium on Information Visualization (INFOVIS '99), San Francisco, pp. 1-6 [Oct. 25-26, 1999].;;Harrison, H.C. et al., ""An Intelligent Business Forecasting System"", ACM Annual Computer Science Conference, pp. 229-236 (1993).;;Jacobsen, Erik et al., ""Assigning Confidence to Conditional Branch Predictions"", IEEE, Proceedings of the 29th Annual International Symposium on Microarchitecture, 12 pp. (Dec. 2-4, 1996).;;Keogh, Eamonn J. et al., ""Derivative Dynamic Time Warping"", in First SIAM International Conference on Data Mining (SDM'2001), Chicago, USA, pp. 1-11 (2001).;;Abstract, Kobbacy, Khairy A.H., et al., ""Towards the development of an intelligent inventory management system"", Integrated Manufacturing Systems, vol. 10, Issue 6, 1999 (11 pp.).;;Kumar, Mahesh, ""Combining Forecasts Using Clustering"", Rutcor Research Report 40-2005, cover page and pp. 1-16 (Dec. 2005).;;Leonard, Michael, ""Promotional Analysis and Forecasting for Demand Planning: A Practical Time Series Approach"", with exhibits 1 and 2, SAS Institute Inc., Cary, North Carolina, 50 pp. (2000).;;Leonard, Michael, ""Large-Scale Automatic Forecasting: Millions of Forecasts"", abstract and presentation, International Symposium of Forecasting, 156 pp. (2002).;;Leonard, Michael et al., ""Mining Transactional and Time Series Data"", abstract and presentation, International Symposium of Forecasting, 23 pp. (2003).;;Leonard, Michael, ""Large-Scale Automatic Forecasting Using Inputs and Calendar Events"", abstract and presentation, International Symposium on Forecasting Conference, 56 pp. (Jul. 4-7, 2004).;;Leonard, Michael, ""Predictive Modeling Markup Language for Time Series Models"", abstract and presentation, International Symposium on Forecasting Conference, 35 pp. (Jul. 4-7, 2004).;;Leonard, Michael et al., ""Mining Transactional and Time Series Data"", abstract, presentation and paper, SUGI, 142 pp. (Apr. 10-13, 2005).;;Leonard, Michael, ""Large-Scale Automatic Forecasting Using Inputs and Calendar Events"", White Paper, pp. 1-27 (2005).;;Malhotra, Manoj K. et al., ""Decision making using multiple models"", European Journal of Operational Research, 114, pp. 1-14 (1999).;;McQuarrie, Allan D.R. et al., ""Regression and Time Series Model Selection"", World Scientific Publishing Co. Pte. Ltd., 40 pp. (1998).;;Abstract, Park, Kwan Hee, ""Development and evaluation of a prototype expert system for forecasting models"", Mississippi State University, 1990 (1 pg.).;;Abstract, Tashman, Leonard J. et al., ""Automatic Forecasting Software: A Survey and Evaluation"", International Journal of Forecasting, vol. 7, Issue 2, Aug. 1991 (1 pg.).;;Wang, Liang et al., ""An Expert System for Forecasting Model Selection"", IEEE, pp. 704-709 (1992).;;Product Brochure, ForecastPRO, 2000 (12 pp.).;;Automatic Forecasting Systems Inc., Autobox 5.0 for Windows User's Guide, 82 pp. (1999).;;Quest Software, ""Funnel Web Analyzer: Analyzing the Way Visitors Interact with Your Web Site"", http://www.quest.com/funnel-web/analyzer (2 pp.).;;Funnel Web Web site Analysis Report, Funnel Web Demonstration, Clients History, http://www/quest.com/funnel-web/analyzer/sample.ClientHist.html (2 pp.).;;Funnel Web Web site Analysis Report, Funnel Web Demonstration, Authenticated Users History, http://www.quest.com/funnel-web/analyzer/sample/UserHist.html (1 pg.).;;SAS Institute Inc., SAS/ETS User's Guide, Version 8, pp. 577-631 and 1307-1323 (1999).;;""Data Mining Group"", http://www.dmg.org, printed May 9, 2005, 3 pp.;;Crowe, Keith E. et al., U.S. Appl. No. 11/431,089, filed May 9, 2006 entitled ""Computer-Implemented System and Method for Generating Forecasts"".;;Crowe, Keith E. et al., U.S. Appl. No. 11/431,123, filed May 9, 2006 entitled ""Computer-Implemented Systems and Methods for Storing Data Analysis Models"".;;Jackson, Wilma S. et al., U.S. Appl. No. 11/431,127, filed May 9, 2006 entitled ""Computer-Implemented Systems and Methods for Defining Events"".;;Leonard, Michael James, U.S. Appl. No. 11/696,951, filed Apr. 5, 2007 entitled ""Systems and Methods for Mining Transactional and Times Series Data"".",ACTIVE
39,WO,A2,WO 2003/065978 A2,033-589-387-645-534,2003-08-14,2003,US 0238070 W,2002-11-27,US 33413201 P,2001-11-28,CRYSTALS AND STRUCTURES OF A FLAVIN MONONUCLEOTIDE BINDING PROTEIN (FMNBP),"The present invention provides machine readable media embedded with the three-dimensional molecular structure coordinates of putative flavin oxidoreductase, and subsets thereof, including binding pockets, methods of using the structure to identify and design affecters, including inhibitors and activator, mutants of FMNBP, and compounds and compositions that affect FMNBP activity.",STRUCTURAL GENOMIX INC;;PARK FRANCES;;GAJIWALA KETAN S;;BUCHANAN SEAN GRANT;;SAUDER J MICHAEL,PARK FRANCES;;GAJIWALA KETAN S;;BUCHANAN SEAN GRANT;;SAUDER J MICHAEL,,https://lens.org/033-589-387-645-534,Patent Application,yes,0,0,5,5,0,C12N9/0004;;G01N33/54353;;G01N33/552;;G16B15/00;;G16B20/00;;G16B30/00;;G16C20/50;;G16B15/20;;G16B20/30;;C12N9/0004;;G01N33/552;;G01N33/54353;;G16B20/00;;G16B15/00;;G16B30/00;;G16C20/50;;G16B20/30;;G16B15/20,G16B15/20;;C12N9/02;;G01N33/543;;G01N33/552;;G06F19/00;;G16B20/30;;G16B30/00,,0,0,,,,PENDING
40,AU,A,AU 1993/037397 A,071-286-701-301-976,1993-10-21,1993,AU 1993/037397 A,1993-03-18,AU 1993/037397 A;;AU PL140492 A,1992-03-18,Absorbent for isocyanate vapours,,PACIFIC DUNLOP LTD,WOOD ALLEN;;PARK RONALD S;;GILLIVER DAVID M;;JOUBERT MICHAEL D,,https://lens.org/071-286-701-301-976,Patent Application,no,0,0,1,2,0,,B01D53/02;;B01J20/26;;B01J20/28;;C08G18/48,,0,0,,,,PENDING
41,WO,A3,WO 2003/065978 A3,179-522-206-574-705,2007-02-01,2007,US 0238070 W,2002-11-27,US 33413201 P,2001-11-28,CRYSTALS AND STRUCTURES OF A FLAVIN MONONUCLEOTIDE BINDING PROTEIN (FMNBP),"The present invention provides machine readable media embedded with the three-dimensional molecular structure coordinates of putative flavin oxidoreductase, and subsets thereof, including binding pockets, methods of using the structure to identify and design affecters, including inhibitors and activator, mutants of FMNBP, and compounds and compositions that affect FMNBP activity.",STRUCTURAL GENOMIX INC;;PARK FRANCES;;GAJIWALA KETAN S;;BUCHANAN SEAN GRANT;;SAUDER J MICHAEL,PARK FRANCES;;GAJIWALA KETAN S;;BUCHANAN SEAN GRANT;;SAUDER J MICHAEL,,https://lens.org/179-522-206-574-705,Search Report,yes,1,0,5,5,0,C12N9/0004;;G01N33/54353;;G01N33/552;;G16B15/00;;G16B20/00;;G16B30/00;;G16C20/50;;G16B15/20;;G16B20/30;;C12N9/0004;;G01N33/552;;G01N33/54353;;G16B20/00;;G16B15/00;;G16B30/00;;G16C20/50;;G16B20/30;;G16B15/20,C12N9/02;;G16B15/20;;G01N33/543;;G01N33/552;;G06F7/00;;G06F19/00;;G11B5/00;;G16B20/30;;G16B30/00,,7,6,004-944-415-118-435;;056-272-332-212-79X;;015-629-862-687-938;;044-904-348-798-50X;;119-687-205-724-766;;131-716-762-776-491,15103641;;10.1002/prot.20086;;10.2210/pdb1al8/pdb;;9144771;;10.1002/pro.5560060506;;10.2210/pdb1al7/pdb;;pmc2143696;;10.1073/pnas.94.16.8411;;9237990;;pmc22938;;10.2210/pdb1amo/pdb;;10.1021/bi961400v;;8885832;;10.1021/jm00165a001;;2407844;;10469881,"PARK F. ET AL.: ""The 1.59 A resolution crystal structure of TM0096, a flavin mononucleotide binding protein from Thermotoga maritima"", PROTEIN, STRUCTURE, FUNCTION, AND BIOINFORMATICS 2004, vol. 55, 2004, pages 772 - 774, XP003007530;;DATABASE PUBMED [online] PARK ET AL.: ""Crystal structure of a putative flavin oxidoreductase with flavin"", XP003007531, accession no. NCBI Database accession no. (1VHN);;STENBERG K. ET AL.: ""Three-dimensional structure of glycolate oxidase with bound active-site inhibitor"", PROTEIN SCIENCE, vol. 6, 1997, pages 1009 - 1015, XP003007532;;WANG M. ET AL.: ""Three-dimensional structure of NADPH-cytochrome P450 reductase: Prototype for FMN- and FAD-containing enzymes"", PROC. NATL. ACAD. SCI. USA, vol. 94, August 1997 (1997-08-01), pages 8411 - 8416, XP003007533;;TANNER J.J. ET AL.: ""Flavin reductase-P; Structure of a dimeric enzyme that reduces flavin"", BIOCHEMISTRY, vol. 35, 1996, pages 13531 - 13539, XP003007534;;COHEN N.C. ET AL.: ""Molecular modeling software and methods for medicinal chemistry"", J. MED. CHEM., vol. 33, no. 3, March 1990 (1990-03-01), pages 883 - 894, XP002950820;;KIRKPATRICK D.L. ET AL.: ""Structure-based drug design: combinatorial chemistry and molecular modeling"", COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, vol. 2, 1999, pages 211 - 221, XP001094530",PENDING
42,US,A1,US 2003/0171549 A1,043-634-039-557-063,2003-09-11,2003,US 29119002 A,2002-11-08,US 29119002 A;;US 33776901 P,2001-11-09,Crystals and structures of YiiM proteins,"
   The present invention provides machine readable media embedded with the three-dimensional molecular structure coordinates of YiiM family members, and subsets thereof, including binding pockets, methods of using the structure to identify and design affecters, including inhibitors and activator, mutants of YiiM family members, and compounds and compositions that affect YiiM family members activity. 
",PARK FRANCES;;GAJIWALA KETAN S.;;BUCHANAN SEAN GRANT;;SAUDER J. MICHAEL,PARK FRANCES;;GAJIWALA KETAN S;;BUCHANAN SEAN GRANT;;SAUDER J MICHAEL,STRUCTURAL GENOMIX INC (2003-02-28),https://lens.org/043-634-039-557-063,Patent Application,yes,0,3,4,4,0,C07K14/47;;C07K2299/00;;G16B15/00;;Y02A90/10;;G16B15/30;;C07K14/47;;C07K2299/00;;G16B15/00;;Y02A90/10;;G16B15/30,C07K14/47;;G16B15/30,53035;;702/19,0,0,,,,DISCONTINUED
43,WO,A2,WO 2003/042232 A2,120-985-072-489-619,2003-05-22,2003,US 0235941 W,2002-11-08,US 33776901 P,2001-11-09,CRYSTALS AND STRUCTURES OF YIIM PROTEINS,"The present invention provides machine readable media embedded with the three-dimensional molecular structure coordinates of YiiM family members, and subsets thereof, including binding pockets, methods of using the structure to identify and design affecters, including inhibitors and activator, mutants of YiiM family members, and compounds and compositions that affect YiiM family members activity.",STRUCTURAL GENOMIX INC;;PARK FRANCES;;GAJIWALA KETAN S;;BUCHANAN SEAN GRANT;;SAUDER J MICHAEL,PARK FRANCES;;GAJIWALA KETAN S;;BUCHANAN SEAN GRANT;;SAUDER J MICHAEL,,https://lens.org/120-985-072-489-619,Patent Application,yes,0,0,4,4,0,C07K14/47;;C07K2299/00;;G16B15/00;;Y02A90/10;;G16B15/30;;C07K14/47;;C07K2299/00;;G16B15/00;;Y02A90/10;;G16B15/30,C07K14/47;;G16B15/30,,0,0,,,,PENDING
44,AU,A8,AU 2002/365232 A8,153-528-087-755-67X,2003-09-02,2003,AU 2002/365232 A,2002-11-27,US 33413201 P;;US 0238070 W,2001-11-28,Crystals and structures of a flavin mononucleotide binding protein (fmnbp),,STRUCTURAL GENOMIX INC,PARK FRANCES;;BUCHANAN SEAN GRANT;;GAJIWALA KETAN S;;SAUDER J MICHAEL,,https://lens.org/153-528-087-755-67X,Patent Application,no,0,0,5,5,0,C12N9/0004;;G01N33/54353;;G01N33/552;;G16B15/00;;G16B20/00;;G16B30/00;;G16C20/50;;G16B15/20;;G16B20/30;;C12N9/0004;;G01N33/552;;G01N33/54353;;G16B20/00;;G16B15/00;;G16B30/00;;G16C20/50;;G16B20/30;;G16B15/20,C12N9/02;;G16B15/20;;G01N33/543;;G01N33/552;;G06F7/00;;G06F19/00;;G11B5/00;;G16B20/30;;G16B30/00,,0,0,,,,DISCONTINUED
45,US,A1,US 2003/0187220 A1,136-229-526-169-132,2003-10-02,2003,US 30676202 A,2002-11-26,US 30676202 A;;US 33413201 P,2001-11-28,Crystals and structures of a flavin mononucleotide binding protein (FMNBP),"
   The present invention provides machine readable media embedded with the three-dimensional molecular structure coordinates of putative flavin oxidoreductase, and subsets thereof, including binding pockets, methods of using the structure to identify and design affecters, including inhibitors and activator, mutants of FMNBP, and compounds and compositions that affect FMNBP activity. 
",PARK FRANCES;;GAJIWALA KETAN S.;;BUCHANAN SEAN GRANT;;SAUDER J. MICHAEL,PARK FRANCES;;GAJIWALA KETAN S;;BUCHANAN SEAN GRANT;;SAUDER J MICHAEL,STRUCTURAL GENOMIX INC (2003-02-21),https://lens.org/136-229-526-169-132,Patent Application,yes,0,8,5,5,0,C12N9/0004;;G01N33/54353;;G01N33/552;;G16B15/00;;G16B20/00;;G16B30/00;;G16C20/50;;G16B15/20;;G16B20/30;;C12N9/0004;;G01N33/552;;G01N33/54353;;G16B20/00;;G16B15/00;;G16B30/00;;G16C20/50;;G16B20/30;;G16B15/20,G16B15/20;;C12N9/02;;G01N33/543;;G01N33/552;;G06F19/00;;G16B20/30;;G16B30/00,53035;;702/19;;703/11,0,0,,,,DISCONTINUED
46,EP,A4,EP 1467637 A4,180-848-011-158-846,2005-03-30,2005,EP 03708846 A,2003-01-21,US 0301494 W;;US 5137102 A,2002-01-22,ARTICLE OF FOOTWEAR INCLUDING A TENTED UPPER,"An article of footwear has an upper in a tented arrangement. The article of footwear includes a sole and an upper including a shroud. The article of footwear further includes a foot engaging system for joining a foot of a user to the sole, and a biasing system which includes one or more frame members that urges or influences the shroud away from the foot of the user. The one or more frame members may be coupled to the foot holding system on a medial and a lateral side. The article of footwear further includes a plurality of straps for holding the foot to the sole in which one of the straps engages the heel. The straps are located on an exterior surface of the shroud or alternatively they are located in the interior of the shroud. Air gaps are created between the shroud and the foot for ventilation. Several foot booties for holding a foot have aeration regions for providing air to ventilate the foot of a wearer. Further, the foot booties are combined with straps, in which the straps are disposed between the shroud and the foot booties. The upper has a flexible sheet of material that is interconnected with a plurality of frame members that urges the sheet away from the foot of a wearer. The upper may be removable and replaceable with the sole.",NIKE INTERNATIONAL LTD,HATFIELD TINKER L;;AVENI MICHAEL A;;FRITON MICHAEL R;;DOLAN ROBERT W;;PARK S H,"NIKE INNOVATE C.V., US (2015-04-20);;NIKE INNOVATE C.V. (KOMMANDITGESELLSCHAFT NIED, US (2015-04-01)",https://lens.org/180-848-011-158-846,Search Report,no,2,0,10,10,0,A43B3/163;;A43B3/24;;A43B3/242;;A43B7/02;;A43B7/06;;A43B7/1495;;A43B13/12;;A43B19/00;;A43B23/047;;A43B23/07;;A43B23/22;;A43C1/00;;A43B23/0235;;A43B23/0245;;A43B3/242;;A43B23/07;;A43B7/1495;;A43C1/00;;A43B19/00;;A43B7/02;;A43B13/12;;A43B23/047;;A43B23/22;;A43B3/24;;A43B7/06;;A43B3/163;;A43B23/0245;;A43B23/0235,A43B3/16;;A43B3/24;;A43B7/02;;A43B7/06;;A43B7/14;;A43B11/00;;A43B13/12;;A43B19/00;;A43B23/00;;A43B23/02;;A43B23/04;;A43B23/07;;A43B23/22;;A43C1/00,,0,0,,,,EXPIRED
47,DE,D1,DE 60330648 D1,000-782-975-578-128,2010-02-04,2010,DE 60330648 T,2003-01-21,US 5137102 A;;US 0301494 W,2002-01-22,FUSSBEKLEIDUNGSARTIKEL MIT ZELTARTIGEM OBERMATERIAL,"An article of footwear has an upper in a tented arrangement. The article of footwear includes a sole and an upper including a shroud. The article of footwear further includes a foot engaging system for joining a foot of a user to the sole, and a biasing system which includes one or more frame members that urges or influences the shroud away from the foot of the user. The one or more frame members may be coupled to the foot holding system on a medial and a lateral side. The article of footwear further includes a plurality of straps for holding the foot to the sole in which one of the straps engages the heel. The straps are located on an exterior surface of the shroud or alternatively they are located in the interior of the shroud. Air gaps are created between the shroud and the foot for ventilation. Several foot booties for holding a foot have aeration regions for providing air to ventilate the foot of a wearer. Further, the foot booties are combined with straps, in which the straps are disposed between the shroud and the foot booties. The upper has a flexible sheet of material that is interconnected with a plurality of frame members that urges the sheet away from the foot of a wearer. The upper may be removable and replaceable with the sole.",NIKE INTERNATIONAL LTD,HATFIELD TINKER L;;AVENI MICHAEL A;;FRITON MICHAEL R;;DOLAN ROBERT W;;PARK S H,,https://lens.org/000-782-975-578-128,Granted Patent,no,0,0,10,10,0,A43B3/163;;A43B3/24;;A43B3/242;;A43B7/02;;A43B7/06;;A43B7/1495;;A43B13/12;;A43B19/00;;A43B23/047;;A43B23/07;;A43B23/22;;A43C1/00;;A43B23/0235;;A43B23/0245;;A43B3/242;;A43B23/07;;A43B7/1495;;A43C1/00;;A43B19/00;;A43B7/02;;A43B13/12;;A43B23/047;;A43B23/22;;A43B3/24;;A43B7/06;;A43B3/163;;A43B23/0245;;A43B23/0235,A43B13/38;;A43B3/16;;A43B3/24;;A43B7/02;;A43B7/06;;A43B7/14;;A43B11/00;;A43B13/12;;A43B13/22;;A43B19/00;;A43B23/00;;A43B23/02;;A43B23/04;;A43B23/07;;A43B23/22;;A43C1/00,,0,0,,,,EXPIRED
48,EP,A1,EP 1467637 A1,163-429-084-925-206,2004-10-20,2004,EP 03708846 A,2003-01-21,US 0301494 W;;US 5137102 A,2002-01-22,ARTICLE OF FOOTWEAR INCLUDING A TENTED UPPER,"An article of footwear has an upper in a tented arrangement. The article of footwear includes a sole and an upper including a shroud. The article of footwear further includes a foot engaging system for joining a foot of a user to the sole, and a biasing system which includes one or more frame members that urges or influences the shroud away from the foot of the user. The one or more frame members may be coupled to the foot holding system on a medial and a lateral side. The article of footwear further includes a plurality of straps for holding the foot to the sole in which one of the straps engages the heel. The straps are located on an exterior surface of the shroud or alternatively they are located in the interior of the shroud. Air gaps are created between the shroud and the foot for ventilation. Several foot booties for holding a foot have aeration regions for providing air to ventilate the foot of a wearer. Further, the foot booties are combined with straps, in which the straps are disposed between the shroud and the foot booties. The upper has a flexible sheet of material that is interconnected with a plurality of frame members that urges the sheet away from the foot of a wearer. The upper may be removable and replaceable with the sole.",NIKE INTERNATIONAL LTD,HATFIELD TINKER L;;AVENI MICHAEL A;;FRITON MICHAEL R;;DOLAN ROBERT W;;PARK S H,"NIKE INNOVATE C.V., US (2015-04-20);;NIKE INNOVATE C.V. (KOMMANDITGESELLSCHAFT NIED, US (2015-04-01)",https://lens.org/163-429-084-925-206,Patent Application,yes,0,1,10,10,0,A43B3/163;;A43B3/24;;A43B3/242;;A43B7/02;;A43B7/06;;A43B7/1495;;A43B13/12;;A43B19/00;;A43B23/047;;A43B23/07;;A43B23/22;;A43C1/00;;A43B23/0235;;A43B23/0245;;A43B3/242;;A43B23/07;;A43B7/1495;;A43C1/00;;A43B19/00;;A43B7/02;;A43B13/12;;A43B23/047;;A43B23/22;;A43B3/24;;A43B7/06;;A43B3/163;;A43B23/0245;;A43B23/0235,A43B3/16;;A43B3/24;;A43B7/02;;A43B7/06;;A43B7/14;;A43B11/00;;A43B13/12;;A43B19/00;;A43B23/00;;A43B23/02;;A43B23/04;;A43B23/07;;A43B23/22;;A43C1/00,,0,0,,,,EXPIRED
49,CA,C,CA 2472741 C,196-205-038-424-587,2010-04-20,2010,CA 2472741 A,2003-01-21,US 5137102 A;;US 0301494 W,2002-01-22,ARTICLE OF FOOTWEAR INCLUDING A TENTED UPPER,"An article of footwear (100) has an upper in a tented arrangement. The article of footwear (100) includes a sole (110) and an upper including a shroud (138). The article of footwear (100) further includes a foot engaging system (140) for joining a foot of a user to the sole (110), and a biasing system which includes one or more frame members (122) that urge the shroud (138) away from the user's foot. The one or more frame members (122) may be coupled to the foot holding system on a medial (16) and lateral side (18). Several foot booties (146) for holding the foot have aeration regions (143, 145) for providing air to ventilate the foot of a wearer. The upper has a flexible sheet of material (138) that is interconnected with a plurality of frame members (122) that urge the sheet away from the user's foot.",NIKE INTERNATIONAL LTD,HATFIELD TINKER L;;AVENI MICHAEL A;;FRITON MICHAEL R;;DOLAN ROBERT W;;PARK S H,,https://lens.org/196-205-038-424-587,Granted Patent,no,0,0,10,10,0,A43B3/163;;A43B3/24;;A43B3/242;;A43B7/02;;A43B7/06;;A43B7/1495;;A43B13/12;;A43B19/00;;A43B23/047;;A43B23/07;;A43B23/22;;A43C1/00;;A43B23/0235;;A43B23/0245;;A43B3/242;;A43B23/07;;A43B7/1495;;A43C1/00;;A43B19/00;;A43B7/02;;A43B13/12;;A43B23/047;;A43B23/22;;A43B3/24;;A43B7/06;;A43B3/163;;A43B23/0245;;A43B23/0235,A43B23/00;;A43B3/16;;A43B3/24;;A43B7/02;;A43B7/06;;A43B7/14;;A43B11/00;;A43B13/12;;A43B13/38;;A43B19/00;;A43B23/02;;A43B23/04;;A43B23/07;;A43B23/22;;A43C1/00,,0,0,,,,EXPIRED
50,US,A1,US 2002/0124436 A1,064-035-428-875-214,2002-09-12,2002,US 5137102 A,2002-01-22,US 5137102 A;;US 62613900 A,2000-07-26,Article of footwear including a tented upper,"
   An article of footwear has an upper in a tented arrangement. The article of footwear includes a sole and an upper including a shroud. The article of footwear further includes a foot engaging system for joining a foot of a user to the sole, and a biasing system which includes one or more frame members that urges or influences the shroud away from the foot of the user. The one or more frame members may be coupled to the foot holding system on a medial and a lateral side. The article of footwear further includes a plurality of straps for holding the foot to the sole in which one of the straps engages the heel. The straps are located on an exterior surface of the shroud or alternatively they are located in the interior of the shroud. Air gaps are created between the shroud and the foot for ventilation. Several foot booties for holding a foot have aeration regions for providing air to ventilate the foot of a wearer. Further, the foot booties are combined with straps, in which the straps are disposed between the shroud and the foot booties. The upper has a flexible sheet of material that is interconnected with a plurality of frame members that urges the sheet away from the foot of a wearer. The upper may be removable and replaceable with the sole. 
",NIKE INC,HATFIELD TINKER L;;AVENI MICHAEL A;;FRITON MICHAEL R;;DOLAN ROBERT W;;PARK S H,NIKE INC (2002-04-26),https://lens.org/064-035-428-875-214,Patent Application,yes,0,21,10,10,0,A43B3/163;;A43B3/24;;A43B3/242;;A43B7/02;;A43B7/06;;A43B7/1495;;A43B13/12;;A43B19/00;;A43B23/047;;A43B23/07;;A43B23/22;;A43C1/00;;A43B23/0235;;A43B23/0245;;A43B3/242;;A43B23/07;;A43B7/1495;;A43C1/00;;A43B19/00;;A43B7/02;;A43B13/12;;A43B23/047;;A43B23/22;;A43B3/24;;A43B7/06;;A43B3/163;;A43B23/0245;;A43B23/0235,A43B3/16;;A43B3/24;;A43B7/02;;A43B7/06;;A43B7/14;;A43B11/00;;A43B13/12;;A43B19/00;;A43B23/00;;A43B23/02;;A43B23/04;;A43B23/07;;A43B23/22;;A43C1/00,36/45,0,0,,,,EXPIRED
51,CA,A1,CA 2472741 A1,180-867-999-550-98X,2003-07-31,2003,CA 2472741 A,2003-01-21,US 5137102 A;;US 0301494 W,2002-01-22,ARTICLE OF FOOTWEAR INCLUDING A TENTED UPPER,"An article of footwear (100) has an upper in a tented arrangement. The article of footwear (100) includes a sole (110) and an upper including a shroud (138). The article of footwear (100) further includes a foot engaging system (140) for joining a foot of a user to the sole (110), and a biasing system which includes one or more frame members (122) that urge the shroud (138) away from the user's foot. The one or more frame members (122) may be coupled to the foot holding system on a medial (16) and lateral side (18). Several foot booties (146) for holding the foot have aeration regions (143, 145) for providing air to ventilate the foot of a wearer. The upper has a flexible sheet of material (138) that is interconnected with a plurality of frame members (122) that urge the sheet away from the user's foot.",NIKE INTERNATIONAL LTD,PARK S H;;DOLAN ROBERT W;;FRITON MICHAEL R;;HATFIELD TINKER L;;AVENI MICHAEL A,,https://lens.org/180-867-999-550-98X,Patent Application,no,0,3,10,10,0,A43B3/163;;A43B3/24;;A43B3/242;;A43B7/02;;A43B7/06;;A43B7/1495;;A43B13/12;;A43B19/00;;A43B23/047;;A43B23/07;;A43B23/22;;A43C1/00;;A43B23/0235;;A43B23/0245;;A43B3/242;;A43B23/07;;A43B7/1495;;A43C1/00;;A43B19/00;;A43B7/02;;A43B13/12;;A43B23/047;;A43B23/22;;A43B3/24;;A43B7/06;;A43B3/163;;A43B23/0245;;A43B23/0235,A43B3/16;;A43B3/24;;A43B7/02;;A43B7/06;;A43B7/14;;A43B11/00;;A43B13/12;;A43B19/00;;A43B23/00;;A43B23/02;;A43B23/04;;A43B23/07;;A43B23/22;;A43C1/00,,0,0,,,,EXPIRED
52,WO,A1,WO 2003/061419 A1,137-703-714-977-059,2003-07-31,2003,US 0301494 W,2003-01-21,US 5137102 A,2002-01-22,ARTICLE OF FOOTWEAR INCLUDING A TENTED UPPER,"An article of footwear (100) has an upper in a tented arrangement. The article of footwear (100) includes a sole (110) and an upper including a shroud (138). The article of footwear (100) further includes a foot engaging system (140) for joining a foot of a user to the sole (110), and a biasing system which includes one or more frame members (122) that urge the shroud (138) away from the user&apos;s foot. The one or more frame members (122) may be coupled to the foot holding system on a medial (16) and lateral side (18). Several foot booties (146) for holding the foot have aeration regions (143, 145) for providing air to ventilate the foot of a wearer. The upper has a flexible sheet of material (138) that is interconnected with a plurality of frame members (122) that urge the sheet away from the user&apos;s foot.",NIKE INC;;NIKE INTERNATIONAL LTD;;HATFIELD TINKER L;;AVENI MICHAEL A;;FRITON MICHAEL R;;DOLAN ROBERT W;;PARK S H,HATFIELD TINKER L;;AVENI MICHAEL A;;FRITON MICHAEL R;;DOLAN ROBERT W;;PARK S H,,https://lens.org/137-703-714-977-059,Patent Application,yes,8,0,10,10,0,A43B3/163;;A43B3/24;;A43B3/242;;A43B7/02;;A43B7/06;;A43B7/1495;;A43B13/12;;A43B19/00;;A43B23/047;;A43B23/07;;A43B23/22;;A43C1/00;;A43B23/0235;;A43B23/0245;;A43B3/242;;A43B23/07;;A43B7/1495;;A43C1/00;;A43B19/00;;A43B7/02;;A43B13/12;;A43B23/047;;A43B23/22;;A43B3/24;;A43B7/06;;A43B3/163;;A43B23/0245;;A43B23/0235,A43B3/16;;A43B3/24;;A43B7/02;;A43B7/06;;A43B7/14;;A43B11/00;;A43B13/12;;A43B19/00;;A43B23/00;;A43B23/02;;A43B23/04;;A43B23/07;;A43B23/22;;A43C1/00,,0,0,,,,PENDING
53,EP,B1,EP 1467637 B1,166-235-006-584-366,2009-12-23,2009,EP 03708846 A,2003-01-21,US 0301494 W;;US 5137102 A,2002-01-22,ARTICLE OF FOOTWEAR INCLUDING A TENTED UPPER,"An article of footwear has an upper in a tented arrangement. The article of footwear includes a sole and an upper including a shroud. The article of footwear further includes a foot engaging system for joining a foot of a user to the sole, and a biasing system which includes one or more frame members that urges or influences the shroud away from the foot of the user. The one or more frame members may be coupled to the foot holding system on a medial and a lateral side. The article of footwear further includes a plurality of straps for holding the foot to the sole in which one of the straps engages the heel. The straps are located on an exterior surface of the shroud or alternatively they are located in the interior of the shroud. Air gaps are created between the shroud and the foot for ventilation. Several foot booties for holding a foot have aeration regions for providing air to ventilate the foot of a wearer. Further, the foot booties are combined with straps, in which the straps are disposed between the shroud and the foot booties. The upper has a flexible sheet of material that is interconnected with a plurality of frame members that urges the sheet away from the foot of a wearer. The upper may be removable and replaceable with the sole.",NIKE INTERNATIONAL LTD,HATFIELD TINKER L;;AVENI MICHAEL A;;FRITON MICHAEL R;;DOLAN ROBERT W;;PARK S H,"NIKE INNOVATE C.V., US (2015-04-20);;NIKE INNOVATE C.V. (KOMMANDITGESELLSCHAFT NIED, US (2015-04-01)",https://lens.org/166-235-006-584-366,Granted Patent,yes,8,4,10,10,0,A43B3/163;;A43B3/24;;A43B3/242;;A43B7/02;;A43B7/06;;A43B7/1495;;A43B13/12;;A43B19/00;;A43B23/047;;A43B23/07;;A43B23/22;;A43C1/00;;A43B23/0235;;A43B23/0245;;A43B3/242;;A43B23/07;;A43B7/1495;;A43C1/00;;A43B19/00;;A43B7/02;;A43B13/12;;A43B23/047;;A43B23/22;;A43B3/24;;A43B7/06;;A43B3/163;;A43B23/0245;;A43B23/0235,A43B13/38;;A43B3/16;;A43B3/24;;A43B7/02;;A43B7/06;;A43B7/14;;A43B11/00;;A43B13/12;;A43B13/22;;A43B19/00;;A43B23/00;;A43B23/02;;A43B23/04;;A43B23/07;;A43B23/22;;A43C1/00,,0,0,,,,EXPIRED
54,US,B2,US 7976678 B2,171-050-713-932-155,2011-07-12,2011,US 34668108 A,2008-12-30,US 34668108 A,2008-12-30,High-yield paper and methods of making same,"A high-yield paper sheet generally includes at least about 50 weight percent mechanical pulp, wherein the basis weight of the sheet is in the range of about 24 to about 60 pounds, and wherein the porosity of the sheet is in the range of about 40 to about 100 Sheffield porosity.",NORTH PACIFIC PAPER CORP NORPAC,DOUGHERTY MICHAEL J;;NEOGI AMAR N;;PARK DAVID W;;DALGARDNO BRIAN S,NORTH PACIFIC PAPER COMPANY LLC (2009-01-27),https://lens.org/171-050-713-932-155,Granted Patent,yes,20,4,2,2,0,D21H11/08;;D21H19/44;;D21H11/08;;D21H19/44,D21F11/00,162/135,0,0,,,,ACTIVE
55,US,A1,US 2007/0107143 A1,070-928-726-081-40X,2007-05-17,2007,US 65118307 A,2007-01-09,US 65118307 A;;GB 0128749 A;;GB 0106946 A;;US 66787803 A;;US 0208482 W,2001-03-20,Oxidative treatment of hair with reduced hair damage,"The present invention relates to hair care compositions comprising chelants and methods for reducing oxidative hair damage. The compositions contribute to reducing the oxidative damage sustained by keratinous fibers such as human hair during bleaching, dyeing, perming or other oxidative treatments. The compositions according to the present invention also provide excellent color evenness and color fastness.",PROCTER & GAMBLE,BOSWELL HENRY D;;MARSH JENNIFER M;;PARK JOHN S;;OLSHAVSKY MICHAEL A,,https://lens.org/070-928-726-081-40X,Patent Application,yes,19,4,3,68,0,A61K8/44;;A61K8/44;;A61K2800/51;;A61K2800/51;;A61Q5/04;;A61Q5/04;;A61Q5/08;;A61Q5/08;;A61Q5/10;;A61Q5/10,A61K8/00,8/405,0,0,,,,DISCONTINUED
56,US,A1,US 2007/0118999 A1,053-992-544-779-209,2007-05-31,2007,US 65118207 A,2007-01-09,US 65118207 A;;GB 0128752 A;;GB 0106946 A;;US 66795803 A;;US 0208477 W,2001-03-20,Compositions suitable for the treatment of hair comprising chelants and methods for reducing oxidative hair damage,"The present invention relates to hair care compositions comprising an oxidizing agent and chelants having a log K CuL /log K CaL ratio calculated at pH 10 of at least 3.20 wherein log K CuL is the common logarithm of the Conditional Stability Constant of said chelant with Cu 2+ and log K CaL is the common logarithm of the Conditional Stability Constant of said chelant with Ca 2+ . Suitable chelants are diamine-N,N′-dipolyacids or monoamine monoamide-N,N′-dipolyacids. The compositions according to the present invention contribute to reducing the oxidative damage sustained by a keratinous fiber such as hair during bleaching, dyeing, perming or other oxidative treatments. Especially preferred diamine dipolyacid is ethylenediamine-N,N′-disuccinic acid (EDDS).",PROCTER & GAMBLE,BOSWELL HENRY D;;MARSH JENNIFER M;;PARK JOHN S;;OLSHAVSKY MICHAEL A,,https://lens.org/053-992-544-779-209,Patent Application,yes,19,1,3,68,0,A61Q5/10;;A61Q5/10;;A61K8/44;;A61K8/44;;A61K2800/51;;A61K2800/51;;A61Q5/04;;A61Q5/04;;A61Q5/08;;A61Q5/08,A61K8/00,8/405,0,0,,,,DISCONTINUED
57,US,A1,US 2010/0163198 A1,123-827-576-633-878,2010-07-01,2010,US 34669008 A,2008-12-30,US 34669008 A,2008-12-30,High-Yield Paper and Methods of Making Same,"A method of making a high-yield paper sheet generally includes blending a pulp mixture including at least about 50 weight percent mechanical pulp, making an uncoated paper sheet from the pulp mixture, applying a surface layer to the paper sheet, the surface layer including nPCC, and drying the sheet, wherein the basis weight of the dried sheet is in the range of about 24 to about 60 pounds.",NORTH PACIFIC PAPER CORP NORPA,DOUGHERTY MICHAEL J;;NEOGI AMAR N;;PARK DAVID W;;DELGARDNO BRIAN S,NORTH PACIFIC PAPER CORPORATION (2009-01-27),https://lens.org/123-827-576-633-878,Patent Application,yes,11,2,1,1,0,D21H11/00;;D21H11/10;;D21H19/385;;D21H11/00;;D21H19/385;;D21H11/10,D21H19/00,162/162;;162/181.2,0,0,,,,DISCONTINUED
58,US,A1,US 2010/0163196 A1,120-927-070-932-52X,2010-07-01,2010,US 34668108 A,2008-12-30,US 34668108 A,2008-12-30,High-Yield Paper and Methods of Making Same,"A high-yield paper sheet generally includes at least about 50 weight percent mechanical pulp, wherein the basis weight of the sheet is in the range of about 24 to about 60 pounds, and wherein the porosity of the sheet is in the range of about 40 to about 100 Sheffield porosity.",NORTH PACIFIC PAPER CORP NORPA,DOUGHERTY MICHAEL J;;NEOGI AMAR N;;PARK DAVID W;;DALGARDNO BRIAN S,NORTH PACIFIC PAPER COMPANY LLC (2009-01-27),https://lens.org/120-927-070-932-52X,Patent Application,yes,11,6,2,2,0,D21H11/08;;D21H19/44;;D21H11/08;;D21H19/44,D21H19/00,162/135;;162/100,0,0,,,,ACTIVE
59,KR,A,KR 20100047554 A,016-509-723-245-662,2010-05-10,2010,KR 20080106499 A,2008-10-29,KR 20080106499 A,2008-10-29,RECOVERY OF CATALYSTS AND AROMATIC ACIDS FROM THE WASTES AROMATIC ACID PRODUCTION PLANTS,"PURPOSE: A collecting method of a catalyst, aromatic acid and benzoic acid from waste is provided to reduce the treatment cost of the waste, to improve the resource availability, and to minimize the environment contamination. CONSTITUTION: A collecting method of a catalyst, aromatic acid and benzoic acid from aromatic acid waste comprises the following steps: producing mixed slurry by inserting waste(1), water(2) and an organic solvent(3) during the manufacturing process of the aromatic acid; filtering the mixed slurry to collect the catalyst the benzoic acid(22), a filtrate(8) including an organic impurity, and the aromatic acid(7) including more than two solid carboxylic acid groups; and dividing the filtrate into an organic layer(11) including the benzoic acid and the organic impurity, and an aqueous layer(10) to collect the catalyst from the aqueous layer.",ANT ASIAN NEW TECH CORP,LEE MYRON MYON KEE;;PARK YONG TAEK;;FANG XIAOYI;;LEE MICHAEL S,,https://lens.org/016-509-723-245-662,Patent Application,no,0,1,2,2,0,C07B63/00;;C07C51/46;;C07C51/47,C07B63/00,,0,0,,,,ACTIVE
60,US,A1,US 2010/0163195 A1,098-656-460-779-586,2010-07-01,2010,US 34667008 A,2008-12-30,US 34667008 A,2008-12-30,High-Yield Paper and Methods of Making Same,"A high-yield paper sheet generally includes at least about 50 weight percent mechanical pulp, wherein the basis weight of the sheet is in the range of about 24 to about 60 pounds, and a surface layer on the sheet including nPCC pigment.",NORTH PACIFIC PAPER CORP NORPA,DOUGHERTY MICHAEL J;;NEOGI AMAR N;;PARK DAVID W;;DELGARDNO BRIAN S,NORTH PACIFIC PAPER COMPANY (2009-01-27),https://lens.org/098-656-460-779-586,Patent Application,yes,11,11,1,1,0,D21H11/08;;D21H11/08;;D21H19/385;;D21H19/385,D21H19/00,162/135,0,0,,,,DISCONTINUED
61,CA,C,CA 2776705 C,194-616-818-207-237,2019-11-19,2019,CA 2776705 A,2012-05-14,US 201113340085 A,2011-12-29,ADJUSTABLE RECESSED TRIM,Methods and apparatus related to adjustable recessed trim. An adjustable recessed trim (10) for a lighting fixture includes an enclosure with a light output opening (21) and a light source opening (31) provided upward from the light output opening (21). An adjustable cover piece (40) having a cover piece light source opening (41) is provided over the enclosure in registration with the enclosure light source opening (31) and is adjustable between at least a first position and a second position.,KONINL PHILIPS ELECTRONICS NV,PARK JOHN S;;JONES CLIFFORD RUSSELL;;RIPPEL GRAHAM MICHAEL;;JONES MARK OWEN,,https://lens.org/194-616-818-207-237,Granted Patent,no,0,0,5,5,0,F21V21/04;;F21V21/30;;F21S8/026;;F21V21/04;;F21V21/30;;F21S8/026,F21S8/02;;F21V21/14,,0,0,,,,INACTIVE
62,AU,A1,AU 2013/216804 A1,012-256-563-379-531,2014-08-21,2014,AU 2013/216804 A,2013-02-08,US 201213370196 A;;US 2013/0025434 W,2012-02-09,High-speed on demand droplet generation and single cell encapsulation driven by induced cavitation,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/012-256-563-379-531,Patent Application,no,0,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N35/08;;G01N1/28;;G01N15/14,,1,0,,,"Park et al. ""A pulse laser-driven microfluidic device for ultra-fast droplet generation on demand and single-cells encapsulation"" 14th International Conference on Miniaturised Systems for Chemistry and Life Sciences"", Groningen, 2010",ACTIVE
63,EP,A1,EP 3410124 A1,017-494-806-560-999,2018-12-05,2018,EP 18178872 A,2013-02-08,US 201213370196 A;;EP 13746888 A;;US 2013/0025434 W,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.
",UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/017-494-806-560-999,Patent Application,yes,8,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N35/08;;B01J13/04;;B01L3/00;;G01N1/28;;G01N15/10;;G01N15/14;;G01N21/64;;G01N29/24;;G05D11/13,,11,6,043-692-691-301-275;;053-533-406-972-85X;;017-259-129-188-463;;091-897-963-944-670;;005-008-241-554-062;;139-158-104-042-530,pmc3967743;;10.1039/c0lc00555j;;21290045;;16874381;;10.1039/b602240e;;10.1088/0960-1317/16/11/022;;10.1021/ac020269w;;12199600;;15548880;;10.1023/b:bmmd.0000048565.59159.c1;;18094763;;pmc4110104;;10.1039/b712116d,"SUNG-YONG PARK ET AL: ""A PULSE LASER-DRIVEN MICROFLUIDIC DEVICE FOR ULTRA-FAST DROPLET GENERATION ON DEMAND AND SINGLE-CELLS ENCAPSULATION"", 14TH INTERNATIONAL CONFERENCE ON MINIATURIZED SYSTEMS FOR CHEMISTRY AND LIFE SCIENCES 2010, GRONINGEN, THE NETHERLANDS, 1 January 2010 (2010-01-01), pages 2129 - 2131, XP055160919, Retrieved from the Internet <URL:http://www.rsc.org/binaries/LOC/2010/PDFs/Papers/724_0966.pdf> [retrieved on 20150109];;SUNG-YONG PARK ET AL: ""High-speed droplet generation on demand driven by pulse laser-induced cavitation"", LAB ON A CHIP, vol. 11, no. 6, 1 January 2011 (2011-01-01), pages 1010, XP055000498, ISSN: 1473-0197, DOI: 10.1039/c0lc00555j;;YOBAS ET AL., LAB ON A CHIP, vol. 6, 2006, pages 1073 - 1079;;ZENG ET AL., LAB ON A CHIP, vol. 9, 2009, pages 134 - 1343;;HSIUNG ET AL., J. MICROMECHANICS AND MICROENGINEERING, vol. 16, 2006, pages 2403 - 2410;;ZHAO ET AL., ANAL. CHEM., vol. 74, no. 16, 2002, pages 4259 - 4268;;CHENG; HSIUNG, BIOMEDICAL MICRODEVICES, vol. 6, no. 5, 2004, pages 341 - 347;;CHOUDHURY: ""Soc. Photo-Optical Instru. Engineer."", 1997, article ""The Handbook of Microlithography, ficromachining, and Microfabrication"";;BARD; FAULKNER, FUNDAMENTALS OF MICROFABRICATION;;ZHONG ET AL., LAB ON A CHIP, vol. 8, 2008, pages 68 - 74;;ZHONG ET AL., CURRO MED. CHEM., vol. 15, 2008, pages 2897 - 2900",ACTIVE
64,MX,A,MX 2012014357 A,091-552-933-133-849,2013-06-28,2013,MX 2012014357 A,2012-12-07,US 201113340085 A,2011-12-29,ADJUSTABLE RECESSED TRIM.,Methods and apparatus related to adjustable recessed trim. An adjustable recessed trim (10) for a lighting fixture includes an enclosure with a light output opening (21) and a light source opening (31) provided upward from the light output opening (21). An adjustable cover piece (40) having a cover piece light source opening (41) is provided over the enclosure in registration with the enclosure light source opening (31) and is adjustable between at least a first position and a second position.,KONINKL PHILIPS ELECTRONICS NV,JONES MARK OWEN;;RIPPEL GRAHAM MICHAEL;;PARK JOHN S;;JONES CLIFFORD RUSSELL JR,,https://lens.org/091-552-933-133-849,Patent Application,no,0,0,5,5,0,F21S8/026;;F21S8/026;;F21V21/04;;F21V21/04;;F21V21/30;;F21V21/30,F21V29/00;;F21V7/00,,0,0,,,,ACTIVE
65,EP,B1,EP 2812709 B1,129-510-815-872-511,2018-08-01,2018,EP 13746888 A,2013-02-08,US 201213370196 A;;US 2013/0025434 W,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,,UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/129-510-815-872-511,Granted Patent,yes,2,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,B01L3/00;;B01J13/04;;G01N15/10;;G01N15/14;;G01N21/64;;G01N29/24,,5,0,,,"Sung-Yong Park ET AL: ""A PULSE LASER-DRIVEN MICROFLUIDIC DEVICE FOR ULTRA-FAST DROPLET GENERATION ON DEMAND AND SINGLE-CELLS ENCAPSULATION"", 14TH INTERNATIONAL CONFERENCE ON MINIATURIZED SYSTEMS FOR CHEMISTRY AND LIFE SCIENCES 2010, GRONINGEN, THE NETHERLANDS, 1 January 2010 (2010-01-01), pages 2129-2131, XP055160919, Retrieved from the Internet: URL:http://www.rsc.org/binaries/LOC/2010/P DFs/Papers/724_0966.pdf [retrieved on 2015-01-09];;PARK ET AL.: 'A pulse laser-driven microfluidic device for ultra-fast droplet generation on demand and single-cells encapsulation' 14TH INTERNATIONAL CONFERENCE ON MINIATURIZED SYSTEMS FOR CHEMISTRY AND LIFE SCIENCES 2010, GRONINGEN, THE NETHERLANDS, pages 2129 - 2131, XP055160919;;PARK ET AL.: 'High-speed droplet generation on demand driven by pulse laser-induced cavitation' LAB ON A CHIP vol. 11, 2011, pages 1010 - 1012, XP055000498;;LI ET AL.: 'Fast on-demand droplet fusion using transient cavitation bubbles' LAP ON A CHIP vol. 11, 2011, pages 1879 - 1885, XP055160921;;HE ET AL.: 'Selective encapsulation of single cells and subcellular organelles into picoliter- and femtoliter-volume droplet' ANALYTICAL CHEMISTRY vol. 77, no. 6, 2005, pages 1539 - 1544, XP002529330",ACTIVE
66,US,A1,US 2012/0236299 A1,037-561-572-901-625,2012-09-20,2012,US 201213370196 A,2012-02-09,US 201213370196 A;;US 201161442009 P,2011-02-11,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A;;UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2012-03-22),https://lens.org/037-561-572-901-625,Patent Application,yes,19,38,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G05D11/00;;B05B7/00;;G01H5/00;;G01J3/44;;G01N21/49;;G01N21/64;;G01R19/00;;G01R33/10,356/301;;250/458.1;;356/337;;324/76.11;;324/200;;73/645;;137/87.01;;239/10;;137/1;;239/303,0,0,,,,ACTIVE
67,US,B2,US 9176504 B2,087-673-301-397-519,2015-11-03,2015,US 201213370196 A,2012-02-09,US 201213370196 A;;US 201161442009 P,2011-02-11,High-speed on demand droplet generation and single cell encapsulation driven by induced cavitation,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A;;UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2012-03-22),https://lens.org/087-673-301-397-519,Granted Patent,yes,28,28,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,B01L3/00;;B01J13/04;;G01N15/10;;G01N15/14;;G01N21/64;;G01N29/24;;G05D11/13,,56,44,013-647-321-368-80X;;050-093-421-570-837;;050-937-189-884-416;;087-228-441-640-087;;038-667-436-385-269;;020-739-741-693-619;;009-898-247-038-15X;;028-848-496-034-567;;049-812-244-268-065;;032-942-609-523-347;;066-388-072-519-871;;065-313-642-809-270;;015-611-201-016-250;;017-259-129-188-463;;055-357-361-080-905;;020-035-611-931-900;;032-312-942-956-334;;044-575-118-351-740;;006-830-816-180-659;;075-697-131-406-160;;047-560-104-035-680;;016-064-301-488-219;;004-152-446-889-990;;003-750-010-878-83X;;072-379-344-100-867;;181-912-790-585-571;;031-287-940-176-248;;012-757-814-332-443;;043-692-691-301-275;;032-780-230-076-862;;043-891-319-305-140;;051-275-543-439-072;;124-329-852-595-228;;093-532-855-011-436;;105-138-768-723-273;;083-250-300-840-048;;043-066-957-009-629;;018-247-911-841-125;;075-752-275-101-437;;100-279-031-995-941;;155-237-771-929-958;;018-522-746-962-540;;108-664-421-920-63X;;037-674-468-111-122,16511626;;10.1039/b512576f;;19532959;;10.1039/b902504a;;10.1038/nature03831;;16034413;;10.1039/c000136h;;pmc3118392;;20379604;;10.1073/pnas.0704958104;;18025477;;pmc2141878;;10.1016/j.canlet.2005.07.035;;16198049;;10.1038/15095;;10545919;;10.1021/ac0255330;;12069222;;10.1002/jbio.200810018;;pmc2746115;;19343660;;15762555;;10.1021/ac0480850;;10.1021/ac070081i;;17508715;;16234948;;10.1039/b507575k;;10.1039/b707507n;;17653348;;10.1088/0960-1317/16/11/022;;10.1021/ja057254a;;16464114;;14640622;;10.1021/ja037350g;;10.1039/b919495a;;20090998;;12565996;;10.1016/s0958-1669(02)00009-5;;10.1002/adma.200402068;;pmc3769100;;16511616;;10.1039/b515983k;;10.1038/31590;;10.1016/s0009-2509(00)00230-x;;17672779;;10.1063/1.2751414;;16163688;;10.1002/cyto.a.20160;;10.1021/ac0519460;;16642997;;10.1109/nems.2009.5068743;;10.1146/annurev.biophys.36.040306.132646;;17269901;;15748689;;10.1016/j.bioeng.2004.11.001;;pmc3967743;;10.1039/c0lc00555j;;21290045;;pmc1302982;;12770906;;10.1016/s0006-3495(03)75128-5;;10.1021/ac0511041;;16448041;;10.1016/j.sna.2006.06.047;;10.1007/s00340-005-2036-6;;10.1039/b618734j;;17538716;;10.1038/nbt1050;;15608628;;10.1364/oe.18.000938;;20173916;;pmc3369548;;10.1109/memsys.2012.6170196;;pmc3965373;;10.1039/c2lc21084c;;22361780;;10.1063/1.2998395;;10.1088/0960-1317/18/6/065020;;10.1117/1.2137321;;16409077;;10.1002/ceat.200407127;;10.1039/b821803j;;19417898;;10.2174/092986708786848721;;19075642;;20596559;;10.1039/c002363a,"U.S. Office Action dated Oct. 10, 2012 issued in U.S. Appl. No. 12/852,320.;;U.S. Final Office Action dated Aug. 1, 2013 issued in U.S. Appl. No. 12/852,320.;;U.S. Office Action dated Mar. 12, 2014 issued in U.S. Appl. No. 12/852,320.;;PCT International Search Report and Written Opinion dated Dec. 20, 2013 issued in PCT/US2013/025434.;;Applegate, Jr. et al., (2006) ""Microfluidic sorting system based on optical waveguide integration and diode laser bar trapping,"" Lab on a Chip, 6:422-426 [Downloaded by University of California-Los Angeles on Apr. 18, 2013 19:29:53. Published on Jan. 20, 2006 on http://pubs.rsc.org | doi:10.1039/B512576F].;;Baret et al., (2009) ""Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity,"" Lab on a Chip, 9:1850-1858. [Downloaded by University of California-Los Angeles on Apr. 18, 2013 19:18:09. Published on Apr. 23, 2009 on http://pubs.rsc.org | doi:10.1039/B902504A].;;Chiou et al., (Jul. 21, 2005) ""Massively parallel manipulation of single cells and microparticles using optical images,"" Nature, 436:370-372. [doi:10.1038/nature03831].;;Cho et al., (2010) ""Human mammalian cell sorting using a highly integrated micro-fabricated fluorescence-activated cell sorter (muFACS),"" Lab on a Chip, 10:1567-1573. [Downloaded by University of California-Los Angeles on Apr. 18, 2013 19:31:47. Published on Apr. 9, 2010 on http://pubs.rsc.org | doi:10.1039/C000136H].;;Di Carlo et al., (Nov. 27, 2007) ""Continuous inertial focusing, ordering, and separation of particles in microchannels,"" PNAS of the United States of America, 104(48):18892-18897.;;El-Sayed et al., (2006) ""Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles,"" Cancer Letters, 239:129-135.;;Fu et al. (Nov. 1999) ""A microfabricated fluorescence-activated cell sorter,"" Nature Biotechnology, 17:1109-1111 [© 1999 Nature America Inc. http://biotech.nature.com].;;Fu et al., (Jun. 1, 2002) ""An integrated microfabricated cell sorter,"" Analytical Chemistry, 74(11):2451-2457.;;Godin et al., (2008) ""Microfluidics and photonics for Bio-System-on-a-Chip: A review of advancements in technology towards a microfluidic flow cytometry chip,"" J. Biophoton., 1(5):355-376. [DOI 10.1002/jbio.200810018].;;He et al., (2005) ""Selective Encapsulation of Single Cells and Subcellular Organelles into Picoliter- and Femtoliter-Volume Droplets,"" Analytical Chemistry, 77(6):1539-1544.;;Hellman et al. (Jun. 15, 2007) ""Laser-Induced Mixing in Microfluidic Channels,"" Analytical Chemistry, 79(12):4484-4492.;;Hessel et al., (2004) Chemical Micro Process Engineering:Modelling and Reactions, New York: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 36 pages.;;Ho et al., (2005) ""Micromachined electrochemical T-switches for cell sorting applications,"" Lab on a Chip, 5:1248-1258. [Downloaded by University of California-Los Angeles on Apr. 18, 2013 19:05:23. Published on Sep. 21, 2005 on http://pubs.rsc.org | doi:10.1039/B507575K].;;Holmes et al., (2007) ""Bead-based immunoassays using a micro-chip flow cytometer,"" Lab on a Chip, 7:1048-1056. [Downloaded by University of California-Los Angeles on Apr. 18, 2013 19:09:02. Published on Jun. 14, 2007 on http://pubs.rsc.org | doi:10.1039/B707507N].;;Hsiung et al., (2006) ""Micro-droplet formation utilizing microfluidic flow focusing and controllable moving-wall chopping techniques,"" J. Micromechanics and Microengineering, 16:2403-2410 [Downloaded on Apr. 18, 2013 at 19:11, http://iopscience.iop.org/0960-1317/16/11/022].;;Huang et al., (2006) Cancer Cell Imaging and Photothermal Therapy in the Near-Infrared Region by Using Gold Nanorods, J. Am. Chemical Society, 128:2115-2120.;;Huh, et al. (2003) ""Reversible Switching of High-Speed Air-Liquid Two-Phase Flows Using Electrowetting-Assisted Flow-Pattern Change,"" JACS, 125:14678-14679.;;Hur et al., (2010) ""Sheathless inertial cell ordering for extreme throughput flow cytometry,"" Lab on a Chip, 10:274-280. [Downloaded by University of California-Los Angeles on Apr. 18, 2013 19:12:27. Published on Dec. 18, 2009 on http://pubs.rsc.org | doi:10.1039/B919495A].;;Ibrahim et al., (2003) ""High-speed cell sorting: fundamentals and recent advances,"" Current Opinion in Biotechnology 14(1):5-12.;;Idota et al., (2005) ""Microfluidic Valves Comprising Nanolayered Thermoresponsive Polymer-Grafted Capillaries,"" Advanced Materials, 17:2723-2727.;;Irimia, Daniel and Toner, Mehmet (Mar. 2006) ""Cell handling using microstructured membranes,"" Lab on a Chip, 6:345-352. [Downloaded by University of California-Los Angeles on Apr. 18, 2013 19:10:43. Published on Feb. 8, 2006 on http://pubs.rsc.org | doi:10.1039/B515983K].;;Jensen, K. (Jun. 25, 1998) ""Chemical kinetics-Smaller, faster chemistry,"" Nature, 393:735-737.;;Jensen, K.F. (Jan. 2001) ""Microreaction engineering-is small better?"" Chemical Engineering Science, 56:293-303.;;Kim et al., (Jul. 2007) ""Novel platform for minimizing cell loss on separation process: Droplet-based magnetically activated cell separator,"" Review of Scientific Instruments, 78:074301-1-7.;;Leary, James F., (2005) ""Ultra high-speed sorting,"" International Society for Analytical Cytology, Cytometry Part A 67A:76-85.;;Li et al., (2011) ""Fast on-demand droplet fusion using transient cavitation bubbles,"" Lap on a Chip, 11:1879-1885 [Published on Apr. 12, 2011. Downloaded by Korea Advanced Institute of Science & Technology / KAIST on Jan. 11, 2013 00:55:20.].;;Marcus et al., (May 1, 2006) ""Microfluidic single-cell mRNA isolation and analysis,"" Analytical Chemistry, 78(9):3084-3089.;;Mehta et al., (Jan. 5-8, 2009) ""Magnetic Nanowire-Enhanced Optomagnetic Tweezers,"" Proceeding of the 2009 4th IEEE International Conference on Nano/Micro Engineered and Molecular Systems, Shenzhen, China, pp. 1004-1007.;;Melin et al., (2007) ""Microfluidic Large-Scale Integration: The Evolution of Design Rules for Biological Automation,"" Annual Review of Biophysics and Biomolecular Structure, 36:213-231. [Annu Rev. Biophys. Biomol. Struct. 2007.36:213-231. Downloaded from www.annualreviews.org by University of California-Los Angeles-Law Library UCLA on Apr. 18, 2013. For personal use only.].;;Panaro et al., (Feb. 2005) ""Micropillar array chip for integrated white blood cell isolation and PCR,"" Biomolecular Engineering, 21:157-162.;;Park et al., (2010) ""A pulse laser-driven microfluidic device for ultra-fast droplet generation on demand and single-cells encapsulation,"" 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences, Groningen, The Netherlands, pp. 2129-2131.;;Park et al., (2011) ""High-speed droplet generation on demand driven by pulse laser-induced cavitation,"" Lab on a Chip, 11:1010-1012.;;Pitsillides et al., (Jun. 2003) ""Selective cell targeting with light-absorbing microparticles and nanoparticles,"" Biophys J, 84(6):4023-32.;;Shirasaki et al., (Feb. 1, 2006) ""On-Chip Cell Sorting System Using Laser-Induced Heating of a Thermoreversible Gelation Polymer to Control flow,"" Analytical Chemistry 78(3):695-701.;;Sun et al., (2007) ""Design, simulation and experiment of electroosmotic microfluidic chip for cell sorting,"" Sens. Actuators A. 133(2):340-348.;;Vogel et al. (Dec. 2005) ""Mechanisms of femtosecond laser nanosurgery of cells and tissues,"" Applied Physics B-Lasers and Optics, 81:1015-1047.;;Wang et al., (2007) ""High-density microfluidic arrays for cell cytotoxicity analysis,"" Lab on a Chip, 7:740-745. [Downloaded by University of California-Los Angeles on Apr. 18, 2013 19:50:05.Published on Apr. 4, 2007 on http://pubs.rsc.org | doi:10.1039/B618734J].;;Wang et al., (Jan. 2005) ""Microfluidic sorting of mammalian cells by optical force switching,"" Nature Biotechnology, 23(1):83-87.;;Wu et al., (Jan. 18, 2010) ""Image patterned molecular delivery into live cells using gold particle coated substrates,"" Optics Express, 18(2):938-946.;;Wu et al., (2012) ""Pulsed laser triggered high speed microfluidic fluorescence activated cell sorter,"" Lab on a Chip 12:1378-1383 [Downloaded by University of California-Los Angeles on Apr. 18, 2013 19:33:06. Published on Feb. 15, 2012 on http://pubs.rsc.org | doi:10.1039/C2LC21084C].;;Wu et al., (Oct. 6, 2008) ""Pulsed laser triggered high speed microfluidic switch,"" Appl. Phys. Lett. 93, 144102-1-3. [Downloaded Oct. 10, 2008 to 131.252.222.209. Redistribution subject to AIP license or copyright; see http://apl.aip.org/apl/copyright.jsp].;;Xu, Jie and Attinger, Daniel, (2008) ""Drop on demand in a microfluidic chip"" J. Micromechanics and Microengineering, 18:065020, 11 pp [downloaded on Apr. 18, 2013 at 19:43, http://iopscience.iop.org/0960-1317/18/6/065020].;;Yao et al., (Nov./Dec. 2005) ""Elevation of plasma membrane permeability by laser irradiation of selectively bound nanoparticles,"" J Biomed Opt, 10(6):064012-1-064012-8.;;Yoshida et al., (Mar. 2005) ""Enhancement of Chemical Selectivity by Microreactors,"" Chemical Engineering & Technology, 28(3):259-266.;;Zeng et al., (2009) ""Microvalve-actuated precise control of individual droplets in microfluidic devices"" Lab on a Chip, 9:1340-1343 [Downloaded by University of California-Los Angeles on Apr. 18, 2013 19:50:54. Published on Mar. 27, 2009 on http://pubs.rsc.org | doi:10.1039/B821803J].;;Zhong et al., (2008) ""A microfluidic processor for gene expression profiling of single human embryonic stem cells,"" Lab on a Chip, 8:68-74. [Downloaded on Apr. 18, 2013 19:20:57. Published on Nov. 2, 2007 on http://pubs.rsc.org | doi:10.1039/B712116D].;;Zhong et al., (2008) ""Microfluidic Devices for Investigating Stem Cell Gene Regulation via Single-Cell Analysis,"" Current Medicinal Chemistry, 15(28):2897-2900.;;U.S. Final Office Action dated Jan. 2, 2015 issued in U.S. Appl. No. 12/852,320.;;PCT International Preliminary Report on Patentability and Written Opinion dated Aug. 12, 2014 issued in PCT/US2013/025434.;;Li et al. (2010) Two Same-Sized Droplets Coalescence by Laser-Induced Cavitation Bubbles, pp. 1088-1090 In: 4th International Conference on Miniaturized Systems for Chemistry and Life Sciences Oct. 3-7, 2010, Groningen, The Netherlands.;;Tandiono et al. (2010) Lab Chip, 10: 1848-1855.;;Zwaan et al. (2007) Phys. Rev. Lett. 98: 2545.",ACTIVE
68,AU,B2,AU 2016/234996 B2,108-625-774-555-891,2018-12-06,2018,AU 2016/234996 A,2016-09-30,AU 2016/234996 A;;AU 2013/216804 A;;US 201213370196 A;;US 2013/0025434 W,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices. 715\. It 722inue 740 bbl Cube75 L~er N* ~50 Halt wave 4X Beam: 5 Fig. 7",UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/108-625-774-555-891,Granted Patent,no,0,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N1/28;;G01N15/14;;G01N35/08,,0,0,,,,ACTIVE
69,CA,A1,CA 2776705 A1,072-148-603-915-756,2013-06-29,2013,CA 2776705 A,2012-05-14,US 201113340085 A,2011-12-29,ADJUSTABLE RECESSED TRIM,Methods and apparatus related to adjustable recessed trim. An adjustable recessed trim (10) for a lighting fixture includes an enclosure with a light output opening (21) and a light source opening (31) provided upward from the light output opening (21). An adjustable cover piece (40) having a cover piece light source opening (41) is provided over the enclosure in registration with the enclosure light source opening (31) and is adjustable between at least a first position and a second position.,KONINKL PHILIPS ELECTRONICS NV,PARK JOHN S;;JONES CLIFFORD RUSSELL JR;;RIPPEL GRAHAM MICHAEL;;JONES MARK OWEN,,https://lens.org/072-148-603-915-756,Patent Application,no,0,0,5,5,0,F21S8/026;;F21S8/026;;F21V21/04;;F21V21/04;;F21V21/30;;F21V21/30,F21S8/02;;F21V21/14,,0,0,,,,INACTIVE
70,WO,A2,WO 2013/120016 A2,008-597-796-330-641,2013-08-15,2013,US 2013/0025434 W,2013-02-08,US 201213370196 A,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",UNIV CALIFORNIA;;CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/008-597-796-330-641,Patent Application,yes,0,9,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,,,0,0,,,,PENDING
71,CA,A1,CA 2864138 A1,112-885-012-918-639,2013-08-15,2013,CA 2864138 A,2013-02-08,US 201213370196 A;;US 2013/0025434 W,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/112-885-012-918-639,Patent Application,no,0,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N35/08;;G01N1/28;;G01N15/14,,0,0,,,,ACTIVE
72,US,B2,US 9429284 B2,149-931-006-298-899,2016-08-30,2016,US 201113340085 A,2011-12-29,US 201113340085 A,2011-12-29,Adjustable recessed trim,An adjustable recessed trim for a lighting fixture includes an enclosure with a light output opening and a light source opening provided upward from the light output opening. An adjustable cover piece having a cover piece light source opening is provided over the enclosure in registration with the enclosure light source opening and is adjustable between at least a first position and a second position.,PARK JOHN S;;JONES JR CLIFFORD RUSSELL;;RIPPEL GRAHAM MICHAEL;;JONES MARK OWEN;;KONINKLIJKE PHILIPS NV,PARK JOHN S;;JONES JR CLIFFORD RUSSELL;;RIPPEL GRAHAM MICHAEL;;JONES MARK OWEN,KONINKLIJKE PHILIPS N.V (2013-05-15);;SIGNIFY HOLDING B.V (2016-06-07),https://lens.org/149-931-006-298-899,Granted Patent,yes,8,1,5,5,0,F21S8/026;;F21S8/026;;F21V21/04;;F21V21/04;;F21V21/30;;F21V21/30,F21S8/02;;F21V21/04;;F21V21/30,,0,0,,,,ACTIVE
73,EP,A4,EP 2812709 A4,005-786-716-943-629,2016-01-27,2016,EP 13746888 A,2013-02-08,US 201213370196 A;;US 2013/0025434 W,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,,UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/005-786-716-943-629,Search Report,no,0,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N35/08;;B01J13/04;;G01N1/28;;G01N15/10;;G01N15/14;;G01N21/64;;G01N29/24;;G05D11/13,,1,0,,,"SUNG-YONG PARK ET AL: ""A PULSE LASER-DRIVEN MICROFLUIDIC DEVICE FOR ULTRA-FAST DROPLET GENERATION ON DEMAND AND SINGLE-CELLS ENCAPSULATION"", 14TH INTERNATIONAL CONFERENCE ON MINIATURIZED SYSTEMS FOR CHEMISTRY AND LIFE SCIENCES 2010, GRONINGEN, THE NETHERLANDS, 1 January 2010 (2010-01-01), pages 2129 - 2131, XP055160919, Retrieved from the Internet <URL:http://www.rsc.org/binaries/LOC/2010/PDFs/Papers/724_0966.pdf> [retrieved on 20150109]",ACTIVE
74,ES,T3,ES 2687684 T3,197-095-381-441-044,2018-10-26,2018,ES 13746888 T,2013-02-08,US 201213370196 A;;US 2013/0025434 W,2012-02-09,Generación de gotitas a demanda a alta velocidad y encapsulación de células individuales dirigida por una cavitación inducida,"Un método para la generación de gotitas en un dispositivo que comprende: proporcionar una primera trayectoria de fluido (620) que comprende un primer fluido (622); una segunda trayectoria de fluido (615) que comprende un segundo fluido (617); y una tercera trayectoria de fluido (610) que comprende un tercer fluido (612); y generar una burbuja de cavitación (660) en la primera trayectoria de fluido (620), en el que la burbuja de cavitación (660) imparte la suficiente velocidad a una porción del segundo fluido (617) para extruir una gotita que comprende un volumen controlado (670) del segundo fluido (617) en la tercera trayectoria de fluido (610); caracterizado por que hay una membrana flexible (635) interpuesta entre la primera trayectoria de fluido (620) y la segunda trayectoria de fluido (615), hay provista una abertura (630) entre la segunda trayectoria de fluido (615) y la tercera trayectoria de fluido (610), y la etapa de generar una burbuja de cavitación (660) en la primera trayectoria de fluido (620) deforma elásticamente una porción de la membrana flexible (635) en la segunda trayectoria de fluido (615), en el que la deformación elástica de la porción de la membrana flexible (635) imparte la suficiente velocidad a una porción del segundo fluido (617) para extruir dicha gotita (670) del segundo fluido (617) a través de la abertura (630) y hacia la tercera trayectoria de fluido (610).",UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/197-095-381-441-044,Granted Patent,no,0,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,B01L3/00;;B01J13/04;;G01N15/10;;G01N15/14;;G01N21/64;;G01N29/24,,0,0,,,,ACTIVE
75,US,A1,US 2013/0170232 A1,099-327-020-863-716,2013-07-04,2013,US 201113340085 A,2011-12-29,US 201113340085 A,2011-12-29,ADJUSTABLE RECESSED TRIM,Methods and apparatus related to adjustable recessed trim. An adjustable recessed trim ( 10 ) for a lighting fixture includes an enclosure with a light output opening ( 21 ) and a light source opening ( 31 ) provided upward from the light output opening ( 21 ). An adjustable cover piece ( 40 ) having a cover piece light source opening ( 41 ) is provided over the enclosure in registration with the enclosure light source opening ( 31 ) and is adjustable between at least a first position and a second position.,PARK JOHN S;;JONES JR CLIFFORD RUSSELL;;RIPPEL GRAHAM MICHAEL;;JONES MARK OWEN;;KONINKL PHILIPS ELECTRONICS NV,PARK JOHN S;;JONES JR CLIFFORD RUSSELL;;RIPPEL GRAHAM MICHAEL;;JONES MARK OWEN,KONINKLIJKE PHILIPS N.V (2013-05-15);;SIGNIFY HOLDING B.V (2016-06-07),https://lens.org/099-327-020-863-716,Patent Application,yes,8,65,5,5,0,F21S8/026;;F21S8/026;;F21V21/04;;F21V21/04;;F21V21/30;;F21V21/30,F21V15/00,362/364,0,0,,,,ACTIVE
76,EP,B1,EP 3410124 B1,096-825-056-261-875,2020-09-09,2020,EP 18178872 A,2013-02-08,US 201213370196 A;;EP 13746888 A;;US 2013/0025434 W,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,,UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/096-825-056-261-875,Granted Patent,yes,0,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N35/08;;B01J13/04;;B01L3/00;;G01N1/28;;G01N15/10;;G01N15/14;;G01N21/64;;G01N29/24;;G05D11/13,,2,0,,,"Sung-Yong Park ET AL: ""A PULSE LASER-DRIVEN MICROFLUIDIC DEVICE FOR ULTRA-FAST DROPLET GENERATION ON DEMAND AND SINGLE-CELLS ENCAPSULATION"", 14TH INTERNATIONAL CONFERENCE ON MINIATURIZED SYSTEMS FOR CHEMISTRY AND LIFE SCIENCES 2010, GRONINGEN, THE NETHERLANDS, 1 January 2010 (2010-01-01), pages 2129-2131, XP055160919, Retrieved from the Internet: URL:http://www.rsc.org/binaries/LOC/2010/P DFs/Papers/724_0966.pdf [retrieved on 2015-01-09];;SUNG-YONG PARK ET AL: ""High-speed droplet generation on demand driven by pulse laser-induced cavitation"", LAB ON A CHIP, vol. 11, no. 6, 1 January 2011 (2011-01-01), page 1010, XP055000498, ISSN: 1473-0197, DOI: 10.1039/c0lc00555j",ACTIVE
77,WO,A3,WO 2013/120016 A3,164-049-647-588-189,2014-02-20,2014,US 2013/0025434 W,2013-02-08,US 201213370196 A,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",UNIV CALIFORNIA;;CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/164-049-647-588-189,Search Report,yes,2,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N35/08;;G01N1/28;;G01N15/14,,4,3,043-692-691-301-275;;112-809-207-254-17X;;032-942-609-523-347,pmc3967743;;10.1039/c0lc00555j;;21290045;;10.1039/c0lc00661k;;21487578;;15762555;;10.1021/ac0480850,"PARK ET AL.: ""A pulse laser-driven microfluidic device for ultra-fast droplet generation on demand and single-cells encapsulation"", 14TH INTERNATIONAL CONFERENCE ON MINIATURIZED SYSTEMS FOR CHEMISTRY AND LIFE SCIENCES, 2010, GRONINGEN, THE NETHERLANDS, pages 2129 - 2131, XP055160919;;PARK ET AL.: ""High-speed droplet generation on demand driven by pulse laser-induced cavitation"", LAB ON A CHIP, vol. 11, 2011, pages 1010 - 1012, XP055000498;;LI ET AL.: ""Fast on-demand droplet fusion using transient cavitation bubbles"", LAP ON A CHIP, vol. 11, 2011, pages 1879 - 1885, XP055160921;;HE ET AL.: ""Selective encapsulation of single cells and subcellular organelles into picoliter- and femtoliter-volume droplet"", ANALYTICAL CHEMISTRY, vol. 77, no. 6, 2005, pages 1539 - 1544, XP002529330",PENDING
78,CN,A,CN 104321652 A,179-152-812-829-856,2015-01-28,2015,CN 201380016299 A,2013-02-08,US 2013/0025434 W;;US 201213370196 A,2012-02-09,High-speed on demand droplet generation and single cell encapsulation driven by induced cavitation,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/179-152-812-829-856,Patent Application,no,3,3,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N35/08;;G01N1/28;;G01N15/14,,2,0,,,"SUN-YONG PARK等: ""High-speed droplet generation on demand driven by pulse laser-induced cavitation"", 《LAB CHIP》, vol. 11, no. 6, 30 November 2011 (2011-11-30), XP 055000498, DOI: doi:10.1039/c0lc00555j;;SUNG-YONG PARK等: ""A pulse laser-driven microfluidic device for ultra-fast droplet generation on demand and single-cells encapsulation"", 《第14届关于化学与生命科学的微型系统的国际会议》, 31 October 2010 (2010-10-31)",ACTIVE
79,CN,A,CN 106732223 A,008-733-753-815-968,2017-05-31,2017,CN 201710078940 A,2013-02-08,US 201213370196 A;;CN 201380016299 A,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/008-733-753-815-968,Patent Application,no,3,5,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,B01J13/04;;G01N15/10;;G01N15/14;;G01N21/64;;G01N29/24,,2,1,043-692-691-301-275,pmc3967743;;10.1039/c0lc00555j;;21290045,"SUN-YONG PARK ET AL.: ""High-speed droplet generation on demand driven by pulse laser-induced cavitation"", 《LAB CHIP》;;SUNG-YONG PARK等: ""A pulse laser-driven microfluidic device for ultra-fast droplet generation on demand and single-cells encapsulation"", 《第14届关于化学与生命科学的微型系统的国际会议》",ACTIVE
80,ES,T3,ES 2832486 T3,149-214-739-524-919,2021-06-10,2021,ES 18178872 T,2013-02-08,US 201213370196 A,2012-02-09,Generación de gotitas a demanda a alta velocidad y encapsulación de células individuales dirigida por una cavitación inducida,"Un método de movilización de una cantidad controlada de un fluido que comprende: proporcionar: una primera corriente de fluido (720) que comprende un primer fluido (722) que fluye en un flujo laminar; una segunda corriente de fluido (715) que comprende un segundo fluido (717) que fluye en un flujo laminar adyacente a dicha primera corriente de fluido (720); y una tercera corriente de fluido (710) que comprende un tercer fluido (712) que fluye en un flujo laminar adyacente a dicha segunda corriente de fluido (715) de modo que dicha segunda corriente de fluido (715) se dispone entre dicha primera corriente de fluido (720) y dicha tercera corriente de fluido (710); en done dicha primera corriente de fluido (720), dicha segunda corriente de fluido (715), y dicha tercera corriente de fluido (710) se separaran por polaridad o hidrofobicidad o energía libre superficial de la superficie sobre la que están dispuestas, o mediante el uso de técnicas de electrohumedecimiento o mediante el uso de flujo laminar dirigido; el uso de un láser de pulsos (740) para generar una burbuja de cavitación (760) en dicho primer fluido (722), en donde la burbuja de cavitación (760) imparte una velocidad suficiente a una porción del primer fluido (722) para mover de este modo un volumen controlado de dicho segundo fluido (717) que está operativamente acoplado al primer fluido (722) en la tercera corriente de fluido (710) para formar una gotita de volumen controlado (770) en dicha tercera corriente de fluido (710); en donde el volumen controlado del segundo fluido (717) es de aproximadamente 1 microlitro o menos; y en donde la burbuja de cavitación (760) tiene una duración de aproximadamente 1 milisegundo o menos; y en donde la burbuja de cavitación (760) se genera mediante irradiación de un volumen del primer fluido (722) con el láser de pulsos (740).",UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/149-214-739-524-919,Granted Patent,no,0,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N35/08;;B01J13/04;;B01L3/00;;G01N1/28;;G01N15/10;;G01N15/14;;G01N21/64;;G01N29/24;;G05D11/13,,0,0,,,,ACTIVE
81,EP,A2,EP 2812709 A2,156-033-908-851-39X,2014-12-17,2014,EP 13746888 A,2013-02-08,US 201213370196 A;;US 2013/0025434 W,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,,UNIV CALIFORNIA,CHIOU PEI YU;;WU TING HSIANG S;;PARK SUNG YONG;;TEITELL MICHAEL A,,https://lens.org/156-033-908-851-39X,Patent Application,yes,0,2,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N35/08;;B01J13/04;;G01N1/28;;G01N15/10;;G01N15/14;;G01N21/64;;G01N29/24;;G05D11/13,,0,0,,,,ACTIVE
82,CA,C,CA 2864138 C,014-842-518-140-489,2021-04-06,2021,CA 2864138 A,2013-02-08,US 201213370196 A;;US 2013/0025434 W,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/014-842-518-140-489,Granted Patent,no,0,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N35/08;;G01N1/28;;G01N15/14,,0,0,,,,ACTIVE
83,JP,A,JP 2018034154 A,071-234-084-667-889,2018-03-08,2018,JP 2017172951 A,2017-09-08,US 201213370196 A,2012-02-09,HIGH-SPEED ON-DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,"PROBLEM TO BE SOLVED: To solve the problem of a digital microfluidic device requiring a mechanism for high-speed droplet generation with precise volume control in order to fully realize accurate, high throughput analysis.SOLUTION: Methods and devices for formation of droplets of a first fluid in a second fluid and encapsulation of particles or cells within such droplets are disclosed. Impetus for the droplet formation is provided by creation of a transient bubble, which may be induced using a pulsed laser. The droplet volume and the frequency at which the droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.SELECTED DRAWING: Figure 7",UNIV CALIFORNIA,CHIOU PEI-YU;;TING-HSIANG S WU;;PARK SOON-YONG;;MICHAEL A TEITELL,,https://lens.org/071-234-084-667-889,Patent Application,no,0,1,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,B01J19/00;;B01J19/12;;G01N35/08,,0,0,,,,PENDING
84,AU,B2,AU 2013/216804 B2,063-128-717-898-718,2016-06-30,2016,AU 2013/216804 A,2013-02-08,US 201213370196 A;;US 2013/0025434 W,2012-02-09,High-speed on demand droplet generation and single cell encapsulation driven by induced cavitation,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/063-128-717-898-718,Granted Patent,no,0,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N1/28;;G01N15/14;;G01N35/08,,1,0,,,"Park et al. ""A pulse laser-driven microfluidic device for ultra-fast droplet generation on demand and single-cells encapsulation"" 14th International Conference on Miniaturised Systems for Chemistry and Life Sciences"", Groningen, 2010",ACTIVE
85,AU,A1,AU 2016/234996 A1,194-737-675-831-358,2016-10-20,2016,AU 2016/234996 A,2016-09-30,AU 2016/234996 A;;AU 2013/216804 A;;US 201213370196 A;;US 2013/0025434 W,2012-02-09,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices. 715\. It 722inue 740 bbl Cube75 L~er N* ~50 Halt wave 4X Beam: 5 Fig. 7",UNIV CALIFORNIA,CHIOU PEI-YU;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/194-737-675-831-358,Patent Application,no,0,0,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,G01N1/28;;G01N15/14;;G01N35/08,,0,0,,,,ACTIVE
86,US,B2,US 8500038 B2,178-605-458-062-527,2013-08-06,2013,US 13085508 A,2008-05-30,US 13085508 A;;US 94142607 P,2007-06-01,Gas splattered fluid display,"A fluid display includes a fluid source, a gas source, and a light source. The fluid source coherently emits fluid along a first trajectory. The gas source emits gas along a second trajectory that intersects the first trajectory. The light source is directed toward the intersection of the first trajectory and the second trajectory. The second trajectory may intersect the first trajectory at an oblique angle. The fluid source and/or the gas source may emit intermittently. The fluid source may emit a laminar jet or spherical fluid globules. The gas source may intermittently emit a gas vortex. The gas may be a flammable gas. The fluid may be water and the gas may be air. The fluid display may provide a “water sparkler” effect.",FULLER MARK W;;BALDWIN MICHAEL JASON;;KALIS KEITH J;;PARK HELEN S;;YOO RIAE;;WET ENTPR INC,FULLER MARK W;;BALDWIN MICHAEL JASON;;KALIS KEITH J;;PARK HELEN S;;YOO RIAE,WET ENTERPRISES INC (2008-06-04),https://lens.org/178-605-458-062-527,Granted Patent,yes,37,3,2,2,0,B05B7/0807;;B05B17/08;;F21W2121/02;;B05B7/0807;;B05B17/08;;F21W2121/02,F21S8/00,239/18;;239/17;;239/22;;239/23;;239/77;;40/406;;40/407;;40/442;;472/57;;472/61;;472/65;;261/75;;261/118,0,0,,,,ACTIVE
87,US,A1,US 2008/0296787 A1,193-064-633-808-23X,2008-12-04,2008,US 13085508 A,2008-05-30,US 13085508 A;;US 94142607 P,2007-06-01,Gas Splattered Fluid Display,"A fluid display includes a fluid source, a gas source, and a light source. The fluid source coherently emits fluid along a first trajectory. The gas source emits gas along a second trajectory that intersects the first trajectory. The light source is directed toward the intersection of the first trajectory and the second trajectory. The second trajectory may intersect the first trajectory at an oblique angle. The fluid source and/or the gas source may emit intermittently. The fluid source may emit a laminar jet or spherical fluid globules. The gas source may intermittently emit a gas vortex. The gas may be a flammable gas. The fluid may be water and the gas may be air. The fluid display may provide a “water sparkler” effect.",WET ENTPR INC,FULLER MARK W;;BALDWIN MICHAEL JASON;;KALIS KEITH J;;PARK HELEN S;;YOO RIAE,WET ENTERPRISES INC (2008-06-04),https://lens.org/193-064-633-808-23X,Patent Application,yes,37,5,2,2,0,B05B7/0807;;B05B17/08;;F21W2121/02;;B05B7/0807;;B05B17/08;;F21W2121/02,B01F3/04,261/75,0,0,,,,ACTIVE
88,US,B2,US 10232368 B2,042-014-208-165-148,2019-03-19,2019,US 201514930054 A,2015-11-02,US 201514930054 A;;US 201213370196 A;;US 201161442009 P,2011-02-11,High-speed on demand droplet generation and single cell encapsulation driven by induced cavitation,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",UNIV CALIFORNIA,CHIOU PEI-YU E;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/042-014-208-165-148,Granted Patent,yes,45,4,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,B01L3/00;;B01J13/04;;G01N15/10;;G01N15/14;;G01N21/64;;G01N29/24;;G05D11/13,,75,44,013-647-321-368-80X;;050-093-421-570-837;;050-937-189-884-416;;038-667-436-385-269;;020-739-741-693-619;;009-898-247-038-15X;;028-848-496-034-567;;049-812-244-268-065;;032-942-609-523-347;;066-388-072-519-871;;065-313-642-809-270;;015-611-201-016-250;;017-259-129-188-463;;055-357-361-080-905;;020-035-611-931-900;;032-312-942-956-334;;044-575-118-351-740;;006-830-816-180-659;;075-697-131-406-160;;047-560-104-035-680;;016-064-301-488-219;;004-152-446-889-990;;003-750-010-878-83X;;072-379-344-100-867;;181-912-790-585-571;;031-287-940-176-248;;012-757-814-332-443;;043-692-691-301-275;;043-692-691-301-275;;032-780-230-076-862;;043-891-319-305-140;;051-275-543-439-072;;037-674-468-111-122;;124-329-852-595-228;;093-532-855-011-436;;105-138-768-723-273;;083-250-300-840-048;;043-066-957-009-629;;018-247-911-841-125;;075-752-275-101-437;;100-279-031-995-941;;155-237-771-929-958;;018-522-746-962-540;;108-664-421-920-63X,16511626;;10.1039/b512576f;;19532959;;10.1039/b902504a;;10.1038/nature03831;;16034413;;10.1073/pnas.0704958104;;18025477;;pmc2141878;;10.1016/j.canlet.2005.07.035;;16198049;;10.1038/15095;;10545919;;10.1021/ac0255330;;12069222;;10.1002/jbio.200810018;;pmc2746115;;19343660;;15762555;;10.1021/ac0480850;;10.1021/ac070081i;;17508715;;16234948;;10.1039/b507575k;;10.1039/b707507n;;17653348;;10.1088/0960-1317/16/11/022;;10.1021/ja057254a;;16464114;;14640622;;10.1021/ja037350g;;10.1039/b919495a;;20090998;;12565996;;10.1016/s0958-1669(02)00009-5;;10.1002/adma.200402068;;pmc3769100;;16511616;;10.1039/b515983k;;10.1038/31590;;10.1016/s0009-2509(00)00230-x;;17672779;;10.1063/1.2751414;;16163688;;10.1002/cyto.a.20160;;10.1021/ac0519460;;16642997;;10.1109/nems.2009.5068743;;10.1146/annurev.biophys.36.040306.132646;;17269901;;15748689;;10.1016/j.bioeng.2004.11.001;;pmc3967743;;10.1039/c0lc00555j;;21290045;;pmc3967743;;10.1039/c0lc00555j;;21290045;;pmc1302982;;12770906;;10.1016/s0006-3495(03)75128-5;;10.1021/ac0511041;;16448041;;10.1016/j.sna.2006.06.047;;20596559;;10.1039/c002363a;;10.1007/s00340-005-2036-6;;10.1039/b618734j;;17538716;;10.1038/nbt1050;;15608628;;10.1364/oe.18.000938;;20173916;;pmc3369548;;10.1109/memsys.2012.6170196;;pmc3965373;;10.1039/c2lc21084c;;22361780;;10.1063/1.2998395;;10.1088/0960-1317/18/6/065020;;10.1117/1.2137321;;16409077;;10.1002/ceat.200407127;;10.1039/b821803j;;19417898;;10.2174/092986708786848721;;19075642,"U.S. Office Action dated Oct. 10, 2012 issued in U.S. Appl. No. 12/852,320.;;U.S. Final Office Action dated Aug. 1, 2013 issued in U.S. Appl. No. 12/852,320.;;U.S. Office Action dated Mar. 12, 2014 issued in U.S. Appl. No. 12/852,320.;;U.S. Final Office Action dated Jan. 2, 2015 issued in U.S. Appl. No. 12/852,320.;;U.S. Office Action dated Jul. 16, 2015 issued in U.S. Appl. No. 12/852,320.;;U.S. Notice of Allowance dated Feb. 10, 2016 issued in U.S. Appl. No. 12/852,320.;;U.S. Office Action dated Jan. 2, 2014 issued in U.S. Appl. No. 13/370,196.;;U.S. Final Office Action dated Aug. 20, 2014 issued in U.S. Appl. No. 13/370,196.;;U.S. Advisory Action dated Mar. 5, 2015 issued in U.S. Appl. No. 13/370,196.;;U.S. Notice of Allowance dated Jun. 5, 2015 issued in U.S. Appl. No. 13/370,196.;;U.S. Notice of Allowance dated Jun. 24, 2015 issued in U.S. Appl. No. 13/370,196.;;PCT International Search Report and Written Opinion dated Dec. 20, 2013 issued in PCT/US2013/025434.;;PCT International Preliminary Report on Patentability and Written Opinion dated Aug. 12, 2014 issued in PCT/US2013/025434.;;Australian Patent Examination Report No. 1 dated Sep. 15, 2015 issued in AU 2013216804.;;Australian Patent Examination Report No. 2 dated Jun. 6, 2016 issued in AU 2013216804.;;Chinese Office Action (brief description in English) dated Jul. 24, 2015 issued in CN 201380016299.3.;;Chinese Second Office Action (brief description in English) dated Mar. 16, 2016 issued in CN 201380016299.3.;;European Extended Search Report dated Jan. 7, 2016 issued in EP 13 74 6888.;;Reply Letter to European Extended Search Report dated Aug. 3, 2016 in EP 13 74 6888.;;Japanese Office Action dated Oct. 7, 2016 issued in JP 2014-556753.;;Applegate, Jr. et al., (2006) “Microfluidic sorting system based on optical waveguide integration and diode laser bar trapping,” Lab on a Chip, 6:422-426 [Downloaded by University of California—Los Angeles on Apr. 18, 2013 19:29:53. Published on Jan. 20, 2006 on http://pubs.rsc.org | doi:10.1039/B512576F].;;Baret et al., (2009) “Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity,” Lab on a Chip, 9:1850-1858 [Downloaded by University of California—Los Angeles on Apr. 18, 2013 19:18:09. Published on Apr. 23, 2009 on http://pubs.rsc.org | doi:10.1039/B902504A].;;Chiou et al., (Jul. 21, 2005) “Massively parallel manipulation of single cells and microparticles using optical images,” Nature, 436:370-372 [doi :10.1038/nature03831].;;Cho et al., (2010) “Human mammalian cell sorting using a highly integrated micro-fabricated fluorescence-activated cell sorter (μFACS),” Lab on a Chip, 10:1567-1573 [Downloaded by University of California—Los Angeles on Apr. 18, 2013 19:31:47. Published on Apr. 9, 2010 on http://pubs.rsc.org | doi:10.1039/C000136H].;;Di Carlo et al., (Nov. 27, 2007) “Continuous inertial focusing, ordering, and separation of particles in microchannels,” PNAS of the United States of America, 104(48):18892-18897.;;El-Sayed et al., (2006) “Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles,” Cancer Letters, 239:129-135.;;Fu et al., (Nov. 1999) “A microfabricated fluorescence-activated cell sorter,” Nature Biotechnology, 17:1109-1111 [© 1999 Nature America Inc. http://biotech.nature.com].;;Fu et al., (Jun. 1, 2002) “An integrated microfabricated cell sorter,” Analytical Chemistry, 74(11):2451-2457.;;Godin et al., (2008) “Microfluidics and photonics for Bio-System-on-a-Chip: A review of advancements in technology towards a microfluidic flow cytometry chip,” J. Biophoton., 1(5):355-376. [DOI 10.1002/jbio.200810018].;;He et al., (2005) “Selective Encapsulation of Single Cells and Subcellular Organelles into Picoliter- and Femtoliter-Volume Droplets,” Analytical Chemistry, 77(6):1539-1544.;;Hellman et al., (Jun. 15, 2007) “Laser-Induced Mixing in Microfluidic Channels,” Analytical Chemistry, 79(12):4484-4492.;;Hessel et al., (2004) Chemical Micro Process Engineering:Modelling and Reactions, New York: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 36 pages.;;Ho et al., (2005) “Micromachined electrochemical T-switches for cell sorting applications,” Lab on a Chip, 5:1248-1258 [Downloaded by University of California—Los Angeles on Apr. 18, 2013 19:05:23. Published on Sep. 21, 2005 on http://pubs.rsc.org | doi:10.1039/B507575K].;;Holmes et al., (2007) “Bead-based immunoassays using a micro-chip flow cytometer,” Lab on a Chip, 7:1048-1056 [Downloaded by University of California—Los Angeles on Apr. 18, 2013 19:09:02. Published on Jun. 14. 2007 on http://pubs.rsc.org | doi:10.1039/B707507N].;;Hsiung et al., (2006) “Micro-droplet formation utilizing microfluidic flow focusing and controllable moving-wall chopping techniques,” J. Micromechanics and Microengineering, 16:2403-2410 [Downloaded on Apr. 18, 2013 at 19:11, http://iopscience.iop.org/0960-1317/16/11/022].;;Huang et al., (2006) “Cancer Cell Imaging and Photothermal Therapy in the Near-Infrared Region by Using Gold Nanorods,” J. Am. Chemical Society, 128:2115-2120.;;Huh et al., (2003) “Reversible Switching of High-Speed Air-Liquid Two-Phase Flows Using Electrowetting-Assisted Flow-Pattern Change,” JACS, 125:14678-14679.;;Hur et al., (2010) “Sheathless inertial cell ordering for extreme throughput flow cytometry,” Lab on a Chip, 10:274-280 [Downloaded by University of California—Los Angeles on Apr. 18, 2013 19:12:27. Published on Dec. 18, 2009 on http://pubs.rsc.org | doi:10.1039/B919495A].;;Ibrahim et al., (2003) “High-speed cell sorting: fundamentals and recent advances,” Current Opinion in Biotechnology, 14(1):5-12.;;Idota et al., (2005) “Microfluidic Valves Comprising Nanolayered Thermoresponsive Polymer-Grafted Capillaries,” Advanced Materials, 17:2723-2727.;;Irimia, Daniel and Toner, Mehmet (Mar. 2006) “Cell handling using microstructured membranes,” Lab on a Chip, 6:345-352 [Downloaded by University of California—Los Angeles on Apr. 18, 2013 19:10:43. Published on Feb. 8, 2006 on http://pubs.rsc.org | doi:10.1039/B515983K].;;Jensen, K. (Jun. 25, 1998) “Chemical kinetics—Smaller, faster chemistry,” Nature, 393:735-737.;;Jensen, K.F. (Jan. 2001) “Microreaction engineering—is small better?” Chemical Engineering Science, 56:293-303.;;Kim et al., (Jul. 2007) “Novel platform for minimizing cell loss on separation process: Droplet-based magnetically activated cell separator,” Review of Scientific Instruments, 78:074301-1-7.;;Leary, James F., (2005) “Ultra high-speed sorting,” International Society for Analytical Cytology, Cytometry Part A 67A:76-85.;;Li et al., (2010) “Two Same-Sized Droplets Coalescence by Laser-Induced Cavitation Bubbles,” 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences, Oct. 3-7, 2010, Groningen, The Netherlands, pp. 1088-1090.;;Li et al., (2011) “Fast on-demand droplet fusion using transient cavitation bubbles,” Lap on a Chip, 11:1879-1885 [Published on Apr. 12, 2011. Downloaded by Korea Advanced Institute of Science & Technology / KAIST on Jan. 11, 2013 00:55:20.].;;Marcus et al., (May 1, 2006) “Microfluidic single-cell mRNA isolation and analysis,” Analytical Chemistry, 78(9): 3084-3089.;;Mehta et al., (Jan. 5-8, 2009) “Magnetic Nanowire-Enhanced Optomagnetic Tweezers,” Proceeding of the 2009 4th IEEE International Conference on Nano/Micro Engineered and Molecular Systems, Shenzhen, China, pp. 1004-1007.;;Melin et al., (2007) “Microfluidic Large-Scale Integration: The Evolution of Design Rules for Biological Automation,” Annual Review of Biophysics and Biomolecular Structure, 36:213-231 [Annu. Rev. Biophys. Biomol. Struct. 2007.36:213-231. Downloaded from www.annualreviews.org by University of California—Los Angeles—Law Library UCLA on Apr. 18, 2013. For personal use only].;;Panaro et al., (Feb. 2005) “Micropillar array chip for integrated white blood cell isolation and PCR,” Biomolecular Engineering, 21:157-162.;;Park et al., (Jan. 2010) “A pulse laser-driven microfluidic device for ultrafast droplet generation on demand and single-cells encapsulation,” 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences, Groningen, The Netherlands, pp. 2129-2131.;;Park et al., (2011) “High-speed droplet generation on demand driven by pulse laser-induced cavitation,” Lab on a Chip, 11(6):1010-1012, 3 pages.;;Park et al., (2011) “High-speed droplet generation on demand driven by pulse laser-induced cavitation,” Lab on a Chip, 11(6):1010-1012, 9 pages [NIH Public Access, NIH-PA Author Manuscript].;;Pitsillides et al., (Jun. 2003) “Selective cell targeting with light-absorbing microparticles and nanoparticles,” Biophys J, 84(6):4023-4032.;;Shirasaki et al., (Feb. 1, 2006) “On-Chip Cell Sorting System Using Laser-Induced Heating of a Thermoreversible Gelation Polymer to Control flow,” Analytical Chemistry, 78(3):695-701.;;Sun et al., (2007) “Design, simulation and experiment of electroosmotic microfluidic chip for cell sorting,” Sens. Actuators A. 133(2):340-348.;;Tandiono et al., (2010) “Creation of cavitation activity in a microfluidic device through acoustically driven capillary waves,” Lab Chip, 10:1848-1855.;;Vogel et al., (Dec. 2005) “Mechanisms of femtosecond laser nanosurgery of cells and tissues,” Applied Physics B—Lasers and Optics, 81:1015-1047.;;Wang et al., (2007) “High-density microfluidic arrays for cell cytotoxicity analysis,” Lab on a Chip, 7:740-745 [Downloaded by University of California—Los Angeles on Apr. 18, 2013 19:50:05.Published on Apr. 4, 2007 on http://pubs.rsc.org | doi:10.1039/B618734J].;;Wang et al., (Jan. 2005) “Microfluidic sorting of mammalian cells by optical force switching,” Nature Biotechnology, 23(1):83-87.;;Wu et al., (Jan. 18, 2010) “Image patterned molecular delivery into live cells using gold particle coated substrates,” Optics Express, 18(2):938-946.;;Wu et al., (2012) “Pulsed laser triggered high speed microfluidic fluorescence activated cell sorter,” Lab on a Chip, 12:1378-1383 [Downloaded by University of California—Los Angeles on Apr. 18, 2013 19:33:06. Published on Feb. 15, 2012 on http://pubs.rsc.org | doi:10.1039/C2LC21084C].;;Wu et al., (Oct. 6, 2008) “Pulsed laser triggered high speed microfluidic switch,” Appl. Phys. Lett. 93, 144102-1-3. [Downloaded Oct. 10, 2008 to 131.252.222.209. Redistribution subject to AIP license or copyright; see http://apl.aip.org/apl/copyright.jsp].;;Xu, Jie and Attinger, Daniel, (2008) “Drop on demand in a microfluidic chip,” J. Micromechanics and Microengineering, 18:065020, 11 pp [downloaded on Apr. 18, 2013 at 19:43, http://iopscience.iop.org/0960-1317/18/6/065020].;;Yao et al., (Nov./Dec. 2005) “Elevation of plasma membrane permeability by laser irradiation of selectively bound nanoparticles,” J Biomed Opt, 10(6):064012-1-064012-8.;;Yoshida et al., (Mar. 2005) “Enhancement of Chemical Selectivity by Microreactors,” Chemical Engineering & Technology, 28(3):259-266.;;Zeng et al., (2009) “Microvalve-actuated precise control of individual droplets in microfluidic devices,” Lab on a Chip, 9:1340-1343 [Downloaded by University of California—Los Angeles on Apr. 18, 2013 19:50:54. Published on Mar. 27, 2009 on http://pubs.rsc.org | doi:10.1039/B821803J].;;Zhong et al., (2008) “A microfluidic processor for gene expression profiling of single human embryonic stem cells,” Lab on a Chip, 8:68-74 [Downloaded on Apr. 18, 2013 19:20:57. Published on Nov. 2, 2007 on http://pubs.rsc.org | doi:10.1039/B712116D].;;Zhong et al., (2008) “Microfluidic Devices for Investigating Stem Cell Gene Regulation via Single-Cell Analysis,” Current Medicinal Chemistry, 15(28):2897-2900.;;Zwaan et al., (2007) “Controlled cavitation in microfluidics,” Phys. Rev. Lett., 98:2545, 4 pages.;;U.S. Office Action dated Feb. 16, 2017 issued in U.S. Appl. No. 15/094,919.;;U.S. Final Office Action dated Nov. 3, 2017 issued in U.S. Appl. No. 15/094,919.;;Australian Patent Examination Report No. 1 dated Nov. 27, 2017 issued in AU 2016234996.;;Japanese Decision of Rejection dated May 8, 2017 issued in JP 2014-556753.",ACTIVE
89,US,A1,US 2016/0158752 A1,053-868-565-912-859,2016-06-09,2016,US 201514930054 A,2015-11-02,US 201514930054 A;;US 201213370196 A;;US 201161442009 P,2011-02-11,HIGH-SPEED ON DEMAND DROPLET GENERATION AND SINGLE CELL ENCAPSULATION DRIVEN BY INDUCED CAVITATION,"Methods and devices for the formation of droplets of a first fluid in a second fluid and the encapsulation of particles or cells within such droplets are disclosed. Impetus for droplet formation is provided by the creation of a transient bubble, which may be induced using a pulsed laser. Droplet volume and the frequency at which droplets are formed can be controlled by modulation of the pulsed laser. The disclosed methods and devices are particularly suitable for use in microfluidic devices.",UNIV CALIFORNIA,CHIOU PEI-YU E;;WU TING-HSIANG S;;PARK SUNG-YONG;;TEITELL MICHAEL A,,https://lens.org/053-868-565-912-859,Patent Application,yes,0,8,27,27,0,B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;Y10T137/0318;;Y10T137/2496;;B01L3/502761;;G05D11/13;;B01J4/008;;B01J13/04;;B01J19/121;;B01L3/502715;;B01L3/502784;;G01N15/10;;G01N21/64;;B01J2219/00164;;B01J2219/0869;;B01J2219/12;;B01L2200/0668;;B01L2200/0673;;B01L2200/0647;;B01L2200/0636;;B01L2300/0816;;B01L2400/0403;;B01L2400/0442;;G01N2015/1481;;G01N2291/02433;;B01L3/502784;;B01L2200/0636;;B01L2200/0668;;B01L2200/0673;;B01L2300/0816;;B01L2400/0442;;B01J13/04;;G01N15/10;;G01N21/64;;G01N29/2418;;G01N2015/1481;;G01N2291/02433;;G05D11/13;;Y10T137/0318;;Y10T137/2496;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2400/0403,B01L3/00,,0,0,,,,ACTIVE
90,US,A1,US 2015/0307532 A1,009-440-926-056-304,2015-10-29,2015,US 201314646304 A,2013-11-19,US 201314646304 A;;US 201261728489 P;;CA 2013050884 W,2012-11-20,THIENOPYRIMIDINE INHIBITORS OF FARNESYL AND/OR GERANYLGERANYL PYROPHOSPHATE SYNTHASE,"The present invention relates to novel compounds, compositions containing same and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds;",UNIV MCGILL,TSANTRIZOS YOULA S;;POIRIER JUDES;;SEBAG MICHAEL;;BERGHUIS ALBERT;;PARK JAEOK;;WIM DE SCHUTTER JORIS,THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (2015-06-01),https://lens.org/009-440-926-056-304,Patent Application,yes,0,2,4,4,0,C07F9/6561;;C07F9/6561;;C07D495/04;;C07D495/04;;C07F9/58;;C07F9/58;;C07F9/6506;;C07F9/6506,C07F9/6561;;C07D495/04,,0,0,,,,DISCONTINUED
91,WO,A1,WO 2014/078957 A1,081-062-257-267-707,2014-05-30,2014,CA 2013050884 W,2013-11-19,US 201261728489 P,2012-11-20,THIENOPYRIMIDINE INHIBITORS OF FARNESYL AND/OR GERANYLGERANYL PYROPHOSPHATE SYNTHASE,"The present invention relates to novel compounds, compositions containing same and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds;",UNIV MCGILL,TSANTRIZOS YOULA S;;POIRIER JUDES;;SEBAG MICHAEL;;BERGHUIS ALBERT;;PARK JAEOK;;WIM DE SCHUTTER JORIS,,https://lens.org/081-062-257-267-707,Patent Application,yes,2,9,4,4,0,C07F9/6561;;C07F9/6561;;C07D495/04;;C07D495/04;;C07F9/58;;C07F9/58;;C07F9/6506;;C07F9/6506,C07F9/38;;A61K31/675;;C07D495/04,,12,9,033-891-695-868-403;;035-377-669-055-127;;043-246-884-630-323;;118-212-050-937-875;;135-510-348-133-476;;021-346-333-265-665;;012-949-194-702-867;;126-335-568-532-880;;013-340-753-879-922,10.1016/s0065-2725(08)60307-4;;10.1016/s0960-894x(99)00088-8;;10206538;;10.1248/yakushi1947.109.9_642;;23477945;;10.1016/j.bmc.2013.02.006;;23998921;;10.1021/jm400946f;;10.1002/jhet.5570300439;;17530808;;10.1021/cc070005t;;10.1002/chin.200416142;;10.1016/j.bmcl.2010.07.133;;20801032,"VARVOUNIS, G ET AL.: ""` Synthesis, Chemistry and Biological Properties of Thienopyrimidines"", ADVANCES IN HETEROCYCLIC CHEMISTRY, vol. 66, 1996, pages 193 - 283, XP055256242;;KATADA, J ET AL.: ""Cytotoxic effects of NSL-1406, a new thienopyrimidine derivative, on leukocytes and osteroclasts"", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 9, 1999, pages 797 - 802, XP004160476;;JORDIS, U ET AL.: ""'' 7, 9-dideaza-9-thiadenines'' (4-aminothieno/2,3-d/pyrimidines) as potential anticytokinines ''."", VESTN. SLOV. KEM. DRUS., vol. 33, no. 3, 1986, pages 217 - 238, XP009037662;;KONNO, S ET AL.: ""Studies on pyrimidine derivatives. XLII. Reactivity of 4-methyl group of 2,4-dimethylthieno[2,3-d]pyrimidine"", YAKUGAKU ZASSHI, vol. 109, 1989, pages 642 - 649, XP008059995;;KAPLINA, NV ET AL.: ""'Synthesis of Mono-and Dibromomethyl Derivatives of Fhieno[2,3-d]pyrimidines"", KHIMIKO-FARMATSEVTICHESKII ZHURNAL, vol. 21, no. 2, 1987, pages 126 - 129, XP055256609;;LEUNG, C-Y ET AL.: ""Discovery of thienopyrimidine-based inhibitors of the human famesyl pyrophosphate synthase - Parallel synthesis of analogs via a trimethylsilyl ylidene intermediate"", BIOORGANIC AND MEDZCINAL CHEMISTRY, vol. 21, 18 February 2013 (2013-02-18), pages 2229 - 2240, XP028596335;;LEUNG, C-Y ET AL.: ""Thienopyrimidine Bisphosphonate (ThPBP) inhibitors of the Human Famesyl Pyrophosphate Synthase: Optimization and Characterization of the Mode of Inhibition"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, 2 September 2013 (2013-09-02), pages 7939 - 7950, XP055256612;;CLARK, J ET AL.: ""Synthesis of Thieno[2,3-d]pyrimidines from 4,6,-dichloropyrimidine- 5-carbaldehydes"", J. HETEROCYCLIC CHEM., vol. 30, 1993, pages 1065, XP002312253;;BOGULUBSKY, AV ET AL.: ""Synthesis of Thieno[2,3-d]pyrimidin-2-ylmethanamine Combinatorial Library with Four Diversity Points"", J. COMB. CHEM., vol. 9, 2007, pages 661 - 667, XP055139751;;MUNCHHOF, MJ ET AL.: ""Design and SAR of thienopyrimidine and thienopyridine inhibitors ofVEGFR-2 kinase activity"", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 21 - 24, XP002399626;;DE SCHUTTER, JW ET AL.: ""Novel bisphosphonate inhibitors of the human famesyl pyrophosphate synthase"", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 20, 2010, pages 5781 - 5786, XP027273561;;See also references of EP 2922858A4",PENDING
92,US,B2,US 6754983 B2,106-695-264-714-064,2004-06-29,2004,US 5137102 A,2002-01-22,US 5137102 A;;US 62613900 A,2000-07-26,Article of footwear including a tented upper,"
    An article of footwear has an upper in a tented arrangement. The article of footwear includes a sole and an upper including a shroud. The article of footwear further includes a foot engaging system for joining a foot of a user to the sole, and a biasing system which includes one or more frame members that urges or influences the shroud away from the foot of the user. The one or more frame members may be coupled to the foot holding system on a medial and a lateral side. The article of footwear further includes a plurality of straps for holding the foot to the sole in which one of the straps engages the heel. The straps are located on an exterior surface of the shroud or alternatively they are located in the interior of the shroud. Air gaps are created between the shroud and the foot for ventilation. Several foot booties for holding a foot have aeration regions for providing air to ventilate the foot of a wearer. Further, the foot booties are combined with straps, in which the straps are disposed between the shroud and the foot booties. The upper has a flexible sheet of material that is interconnected with a plurality of frame members that urges the sheet away from the foot of a wearer. The upper may be removable and replaceable with the sole. 
",NIKE INC,HATFIELD TINKER L;;AVENI MICHAEL A;;FRITON MICHEAL R;;DOLAN ROBERT W;;PARK S H,NIKE INC (2002-04-26),https://lens.org/106-695-264-714-064,Granted Patent,yes,12,190,10,10,0,A43B3/163;;A43B3/24;;A43B3/242;;A43B7/02;;A43B7/06;;A43B7/1495;;A43B13/12;;A43B19/00;;A43B23/047;;A43B23/07;;A43B23/22;;A43C1/00;;A43B23/0235;;A43B23/0245;;A43B3/242;;A43B23/07;;A43B7/1495;;A43C1/00;;A43B19/00;;A43B7/02;;A43B13/12;;A43B23/047;;A43B23/22;;A43B3/24;;A43B7/06;;A43B3/163;;A43B23/0245;;A43B23/0235,A43B3/16;;A43B3/24;;A43B7/02;;A43B7/06;;A43B7/14;;A43B11/00;;A43B13/12;;A43B19/00;;A43B23/00;;A43B23/02;;A43B23/04;;A43B23/07;;A43B23/22;;A43C1/00,36/45;;X 36 72 R;;36/96;;36/101;;36/38;;X 36  71 R,0,0,,,,EXPIRED
93,US,A1,US 2012/0112998 A1,140-366-345-152-476,2012-05-10,2012,US 94377710 A,2010-11-10,US 94377710 A,2010-11-10,Sensor Control,"An apparatus includes sensors configured to sense optical information, assignment circuitry configured to assign a dominant status to one of the sensors and a nondominant status to another one of the sensors and control circuitry configured to output one or more commands based on sensed optical information and status. Various other apparatuses, systems, methods, etc., are also disclosed.",MORRIS JULIE ANNE;;RUTLEDGE JAMES S;;STRAZISAR BRADLEY PARK;;STEWART AARON MICHAEL;;JOHNSON JAY WESLEY,MORRIS JULIE ANNE;;RUTLEDGE JAMES S;;STRAZISAR BRADLEY PARK;;STEWART AARON MICHAEL;;JOHNSON JAY WESLEY,LENOVO (SINGAPORE) PTE. LTD (2010-11-03);;LENOVO PC INTERNATIONAL (2015-10-01),https://lens.org/140-366-345-152-476,Patent Application,yes,11,7,6,6,0,G06F1/1662;;G06F1/169;;G06F2203/0338;;G06F3/03547;;G06F1/1662;;G06F1/169;;G06F2203/0338;;G06F3/03547;;G06F3/0227;;G06F3/042,G06F3/033;;G06F3/02;;G06F3/042,345/157;;345/175;;345/168,0,0,,,,ACTIVE
94,EP,A1,EP 2922858 A1,172-822-410-617-24X,2015-09-30,2015,EP 13856515 A,2013-11-19,US 201261728489 P;;CA 2013050884 W,2012-11-20,THIENOPYRIMIDINE INHIBITORS OF FARNESYL AND/OR GERANYLGERANYL PYROPHOSPHATE SYNTHASE,,UNIV MCGILL,TSANTRIZOS YOULA S;;POIRIER JUDES;;SEBAG MICHAEL;;BERGHUIS ALBERT;;PARK JAEOK;;WIM DE SCHUTTER JORIS,,https://lens.org/172-822-410-617-24X,Patent Application,yes,0,0,4,4,0,C07F9/6561;;C07F9/6561;;C07D495/04;;C07D495/04;;C07F9/58;;C07F9/58;;C07F9/6506;;C07F9/6506,C07F9/58;;A61K31/675;;C07D495/04;;C07F9/6506;;C07F9/6561,,0,0,,,,DISCONTINUED
95,US,B2,US 9122323 B2,197-540-567-540-051,2015-09-01,2015,US 94377710 A,2010-11-10,US 94377710 A,2010-11-10,Sensor control,"An apparatus includes sensors configured to sense optical information, assignment circuitry configured to assign a dominant status to one of the sensors and a nondominant status to another one of the sensors and control circuitry configured to output one or more commands based on sensed optical information and status. Various other apparatuses, systems, methods, etc., are also disclosed.",MORRIS JULIE ANNE;;RUTLEDGE JAMES S;;STRAZISAR BRADLEY PARK;;STEWART AARON MICHAEL;;JOHNSON JAY WESLEY;;LENOVO SINGAPORE PTE LTD,MORRIS JULIE ANNE;;RUTLEDGE JAMES S;;STRAZISAR BRADLEY PARK;;STEWART AARON MICHAEL;;JOHNSON JAY WESLEY,LENOVO (SINGAPORE) PTE. LTD (2010-11-03);;LENOVO PC INTERNATIONAL (2015-10-01),https://lens.org/197-540-567-540-051,Granted Patent,yes,11,0,6,6,0,G06F1/1662;;G06F1/169;;G06F2203/0338;;G06F3/03547;;G06F1/1662;;G06F1/169;;G06F2203/0338;;G06F3/03547;;G06F3/0227;;G06F3/042,G06F3/0354;;G06F1/16,,0,0,,,,ACTIVE
96,US,A,US 6103990 A,073-931-913-670-791,2000-08-15,2000,US 15776498 A,1998-09-21,US 15776498 A,1998-09-21,Laser texturing system providing even heating of textured spots on a rotating disk,Laser texturing apparatus includes an acousto-optical modulator which deflects a continuous laser beam into a first optical projection path to texture a first side of a disk or into a second optical projection path to texture a second side of the disk. The modulator causes lateral movement of the laser beam in a first direction as it is initially deflected into the first optical projection path and at the end of its deflection into this path. The modulator also caused lateral movement of the laser beam in a second direction as it is initially deflected into the second optical path and at the end of its deflection into this path. Each optical projection path is configured so that this lateral movement is in the direction of movement of the disk being textured at the spots at which it is textured.,IBM,BARENBOIM MICHAEL;;KERSTENS PIETER J M;;PARK HEE KUWON;;SHEINER LEONARD S;;TAM ANDREW CHING,INTERNATIONAL BUSINESS MACHINES CORP (1998-11-20),https://lens.org/073-931-913-670-791,Granted Patent,yes,16,15,1,1,0,B23K26/067;;B23K26/0673;;B23K26/0823;;G11B5/6011;;G11B5/82;;G11B23/0028;;B23K26/0673;;B23K26/067;;G11B5/6011;;G11B5/82;;G11B23/0028;;B23K26/0823,B23K26/067;;B23K26/08;;G11B5/60;;G11B5/82;;G11B23/00,219/121.68;;219/121.73;;219/121.79,1,0,,,"J. Lekavich, Basics of Acousto Optic Devices, Lasers & Applications , Apr., 1996, pp. 59 64.",EXPIRED
97,US,A1,US 2015/0370362 A1,199-154-782-103-548,2015-12-24,2015,US 201514837103 A,2015-08-27,US 201514837103 A;;US 94377710 A,2010-11-10,SENSOR CONTROL,"An apparatus can include a left optical trackpad that, responsive to object sensing, outputs a left optical trackpad signal; a right optical trackpad that, responsive to object sensing, outputs a right optical trackpad signal; assignment circuitry that assigns a status to the optical trackpads that is a right hand dominant status or a left hand dominant status; and control circuitry that outputs one or more commands based at least in part on the status and at least one of the right optical trackpad signal and the left optical trackpad signal.",LENOVO SINGAPORE PTE LTD,MORRIS JULIE ANNE;;RUTLEDGE JAMES S;;STRAZISAR BRADLEY PARK;;STEWART AARON MICHAEL;;JOHNSON JAY WESLEY,,https://lens.org/199-154-782-103-548,Patent Application,yes,7,0,6,6,0,G06F1/1662;;G06F1/169;;G06F2203/0338;;G06F3/03547;;G06F1/1662;;G06F1/169;;G06F2203/0338;;G06F3/03547;;G06F3/0227;;G06F3/042,G06F3/042;;G06F3/02,,0,0,,,,INACTIVE
98,US,A1,US 2007/0169541 A1,053-915-587-566-191,2007-07-26,2007,US 23451105 A,2005-09-22,US 23451105 A,2005-09-22,Gas sensor based on dynamic thermal conductivity and molecular velocity,"An apparatus and method for gas detection. The apparatus comprises a) a sample chamber for holding a gas sample, b) a sealable vacuum port in fluid communication with the sample chamber, for evacuating the sample chamber, c) a sealable inlet port in fluid communication with the sample chamber, for introducing the gas sample into the evacuated sample chamber, and d) a thermal conductivity sensing element at least partly disposed within the sample chamber, for measuring the thermal conductivity of the gas sample. A gas sample released into the evacuated sample chamber requires a time interval to contact the thermal conductivity sensing element. The time interval is a measure of gas speed. Thermal conductivity and temperature of the gas sample are measured following determination of gas speed. By determining three parameters in a single sample of gas, different gas mixtures having similar thermal conductivities can be distinguished.",NORBECK JOSEPH N;;PARK CHAN S;;MC CLANAHAN MICHAEL;;HACKETT COLIN E;;HACKETT NORA A,NORBECK JOSEPH N;;PARK CHAN S;;MC CLANAHAN MICHAEL;;HACKETT COLIN E;;HACKETT NORA A,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2005-11-30),https://lens.org/053-915-587-566-191,Patent Application,yes,11,28,4,4,0,G01N1/24;;G01N25/18;;G01N33/005;;G01P5/12;;G01P5/12;;G01N1/24;;G01N33/005;;G01N25/18,G01N25/18;;G01F1/688;;G01K13/12,73/25.03;;73/861.95;;73/204.23;;73/198;;374/142,0,0,,,,INACTIVE
99,EP,A4,EP 2922858 A4,052-001-068-456-276,2016-06-15,2016,EP 13856515 A,2013-11-19,US 201261728489 P;;CA 2013050884 W,2012-11-20,THIENOPYRIMIDINE INHIBITORS OF FARNESYL AND/OR GERANYLGERANYL PYROPHOSPHATE SYNTHASE,,UNIV MCGILL,TSANTRIZOS YOULA S;;POIRIER JUDES;;SEBAG MICHAEL;;BERGHUIS ALBERT;;PARK JAEOK;;WIM DE SCHUTTER JORIS,,https://lens.org/052-001-068-456-276,Search Report,no,0,0,4,4,0,C07F9/6561;;C07F9/6561;;C07D495/04;;C07D495/04;;C07F9/58;;C07F9/58;;C07F9/6506;;C07F9/6506,C07F9/58;;A61K31/675;;C07D495/04;;C07F9/6506;;C07F9/6561,,2,0,,,No further relevant documents disclosed;;See also references of WO 2014078957A1,DISCONTINUED
100,US,B2,US 10048805 B2,144-212-156-801-530,2018-08-14,2018,US 201514837103 A,2015-08-27,US 201514837103 A;;US 94377710 A,2010-11-10,Sensor control,"An apparatus can include a left optical trackpad that, responsive to object sensing, outputs a left optical trackpad signal; a right optical trackpad that, responsive to object sensing, outputs a right optical trackpad signal; assignment circuitry that assigns a status to the optical trackpads that is a right hand dominant status or a left hand dominant status; and control circuitry that outputs one or more commands based at least in part on the status and at least one of the right optical trackpad signal and the left optical trackpad signal.",LENOVO SINGAPORE PTE LTD,GORDON JULIE ANNE;;RUTLEDGE JAMES S;;STRAZISAR BRADLEY PARK;;STEWART AARON MICHAEL;;JOHNSON JAY WESLEY,,https://lens.org/144-212-156-801-530,Granted Patent,yes,7,0,6,6,0,G06F1/1662;;G06F1/169;;G06F2203/0338;;G06F3/03547;;G06F1/1662;;G06F1/169;;G06F2203/0338;;G06F3/03547;;G06F3/0227;;G06F3/042,G06F3/042;;G06F1/16;;G06F3/02;;G06F3/0354,,0,0,,,,INACTIVE
101,CN,A,CN 102467250 A,198-401-897-901-194,2012-05-23,2012,CN 201110344315 A,2011-11-03,US 94377710 A,2010-11-10,Sensor control,"An apparatus includes sensors configured to sense optical information, assignment circuitry configured to assign a dominant status to one of the sensors and a nondominant status to another one of the sensors and control circuitry configured to output one or more commands based on sensed optical information and status. Various other apparatuses, systems, methods, etc., are also disclosed.",LENOVO SINGAPORE PTE LTD,MORRIS JULIE ANNE;;RUTLEDGE JAMES S;;STRAZISAR BRADLEY PARK;;STEWART AARON MICHAEL;;JOHNSON JAY WESLEY,,https://lens.org/198-401-897-901-194,Patent Application,no,2,1,6,6,0,G06F1/1662;;G06F1/169;;G06F2203/0338;;G06F3/03547;;G06F1/1662;;G06F1/169;;G06F2203/0338;;G06F3/03547;;G06F3/0227;;G06F3/042,G06F3/03;;G06F3/02;;G06F3/033,,0,0,,,,ACTIVE
102,US,A1,US 2019/0345078 A1,100-102-340-508-71X,2019-11-14,2019,US 201716337600 A,2017-09-29,US 201716337600 A;;US 201662419202 P;;US 201662419247 P;;US 201662410919 P;;US 201662402238 P;;US 201662414302 P;;US 201662410922 P;;US 2017/0054550 W,2016-09-30,"FORMING DIENES FROM CYCLIC ETHERS AND DIOLS, INCLUDING TETRAHYDROFURAN AND 2-METHYL-1,4-BUTANEDIOL","Forming a diene includes contacting a reactant including at least one of a cyclic ether and a diol with a heterogeneous acid catalyst to yield a reaction mixture including a diene. The heterogeneous acid catalyst includes at least one of a Lewis acid catalyst, a supported Lewis-acid catalyst, a Brnsted acid catalyst, a solid acid catalyst, a supported phosphoric acid catalyst, and a sulfonated catalyst. The dehydration of cyclic ethers and diols with high selectivity to yield dienes completes pathways for the production of dienes, such as isoprene and butadiene, from biomass in high yields, thereby promoting economical production of dienes from renewable resources.",ABDELRAHMAN OMAR A;;SPANJERS CHARLES S;;PARK DAE SUNG;;TSAPATSIS MICHAEL;;REN LIMIN;;DAUENHAUER PAUL J,ABDELRAHMAN OMAR A;;SPANJERS CHARLES S;;PARK DAE SUNG;;TSAPATSIS MICHAEL;;REN LIMIN;;DAUENHAUER PAUL J,REGENTS OF THE UNIVERSITY OF MINNESOTA (2019-07-11),https://lens.org/100-102-340-508-71X,Patent Application,yes,2,3,6,6,0,B01J37/28;;B01J29/40;;B01J29/7007;;B01J29/82;;B01J29/85;;B01J2229/16;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;Y02P20/582;;Y02P20/52;;B01J29/40;;B01J29/7007;;B01J29/85;;B01J37/28;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;C07C51/42;;C07C2521/04;;C07C2521/06;;C07C2521/08;;C07C2521/10;;C07C2521/12;;C07C2521/18;;C07C2523/10;;C07C2523/20;;C07C2527/167;;C07C2527/18;;C07C2527/188;;C07C2529/08;;B01J37/0201;;C07C2529/85;;C07C2529/82;;B01J2229/186;;B01J2229/18;;B01J2229/183;;B01J35/67;;B01J35/69,C07C1/24;;C07C51/42,,0,0,,,,ACTIVE
103,US,B2,US 9225446 B2,158-005-364-416-027,2015-12-29,2015,US 96008010 A,2010-12-03,US 96008010 A,2010-12-03,Methods and apparatus for minimizing wander generation in constant bit rate asynchronously mapped digital transport systems,"A client receive circuit receives client data from a network, decodes the client data and stores the client data within the memory. A frame transmit circuit is provided that includes a justification control logic and a framer and a justification control logic is provided that 1) determines each of a plurality of fill levels and 2) determines an average of the plurality of fill levels. The framer has circuitry to generate a wrapper including a justification opportunity having data based upon a difference between the average and a predetermined threshold.",WANDER ARVINDERPAL S;;SPRAGUE EDWARD E;;CHILLAL MALLIKARJUN;;PARANJAPE PRASAD;;PARK YEONGHO;;KUTTY K G MICHAEL;;INFINERA CORP,WANDER ARVINDERPAL S;;SPRAGUE EDWARD E;;CHILLAL MALLIKARJUN;;PARANJAPE PRASAD;;PARK YEONGHO;;KUTTY K G MICHAEL,INFINERA CORPORATION (2011-05-19),https://lens.org/158-005-364-416-027,Granted Patent,yes,6,0,2,2,0,H04J3/1658;;H04J3/1658;;H04J3/07;;H04J3/07,H04J3/16;;H04J3/07,,1,1,064-376-133-080-217,10.1109/icc.1997.595055,"Author: Peter Scholander, Chris Autry and Henry Owen Title: Mapping wander in sonet/sdh adaptive threshold modulation pointer processors Date: Jun. 1997 Publication: IEEE conference publication.",ACTIVE
104,US,A1,US 2005/0279916 A1,113-973-981-996-114,2005-12-22,2005,US 12071105 A,2005-05-03,US 12071105 A;;US 56747304 P;;US 65241905 P,2004-05-03,Image sensor package and fabrication method,An image sensor package is disclosed that reduces the overall size of known image sensor packages. The image sensor package includes an image sensor and image sensor controller that are arranged on a substrate so that the surfaces of the image sensor and image sensor controller are directly adjacent one another. A package in accordance with the present invention reduces the amount of space in the package by allowing at least one surface of the image sensor controller and at least one surface of the image sensor to be directly attached or connected to one another. Electrical conductive material in the nature of anisotropic conductive materials is also preferably applied to the substrate in the form of an adhesive layer to allow for the image sensor controller and the image sensor to be in electrical communication with one another.,TESSERA INC,KANG TECK-GYU;;ESTRELLA MICHAEL;;PARK JAE M;;THOMPSON KENNETH R;;MITCHELL CRAIG S;;HABA BELGACEM,TESSERA INC (2005-06-27),https://lens.org/113-973-981-996-114,Patent Application,yes,43,61,2,2,0,H01L27/14618;;H01L31/0203;;H04M2250/52;;H01L2224/32145;;H01L2224/32225;;H01L2224/48227;;H01L2224/4824;;H01L2224/73204;;H01L2224/73253;;H01L2924/15311;;H01L2924/15321;;H01L2924/15331;;H01L2924/07811;;H01L2224/16227;;H01L2924/15192;;H04N23/54;;H01L27/14618;;H01L31/0203;;H04M2250/52;;H01L2924/15331;;H01L2224/32145;;H01L2924/15311;;H01L2224/73253;;H01L2224/4824;;H01L2224/32225;;H01L2924/15321;;H01L2224/48227;;H01L2224/73204;;H01L2924/07811;;H04N23/54,H01L27/00;;H01L27/146;;H01L31/0203;;H04N5/225,250/208.1,0,0,,,,ACTIVE
105,US,B2,US 10919030 B2,159-128-755-395-426,2021-02-16,2021,US 201716337600 A,2017-09-29,US 201716337600 A;;US 201662419202 P;;US 201662419247 P;;US 201662410919 P;;US 201662402238 P;;US 201662414302 P;;US 201662410922 P;;US 2017/0054550 W,2016-09-30,"Forming dienes from cyclic ethers and diols, including tetrahydrofuran and 2-methyl-1,4-butanediol","Forming a diene includes contacting a reactant including at least one of a cyclic ether and a diol with a heterogeneous acid catalyst to yield a reaction mixture including a diene. The heterogeneous acid catalyst includes at least one of a Lewis acid catalyst, a supported Lewis-acid catalyst, a Brnsted acid catalyst, a solid acid catalyst, a supported phosphoric acid catalyst, and a sulfonated catalyst. The dehydration of cyclic ethers and diols with high selectivity to yield dienes completes pathways for the production of dienes, such as isoprene and butadiene, from biomass in high yields, thereby promoting economical production of dienes from renewable resources.",UNIV MINNESOTA,ABDELRAHMAN OMAR A;;SPANJERS CHARLES S;;PARK DAE SUNG;;TSAPATSIS MICHAEL;;REN LIMIN;;DAUENHAUER PAUL J,REGENTS OF THE UNIVERSITY OF MINNESOTA (2019-07-11),https://lens.org/159-128-755-395-426,Granted Patent,yes,27,0,6,6,0,B01J37/28;;B01J29/40;;B01J29/7007;;B01J29/82;;B01J29/85;;B01J2229/16;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;Y02P20/582;;Y02P20/52;;B01J29/40;;B01J29/7007;;B01J29/85;;B01J37/28;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;C07C51/42;;C07C2521/04;;C07C2521/06;;C07C2521/08;;C07C2521/10;;C07C2521/12;;C07C2521/18;;C07C2523/10;;C07C2523/20;;C07C2527/167;;C07C2527/18;;C07C2527/188;;C07C2529/08;;B01J37/0201;;C07C2529/85;;C07C2529/82;;B01J2229/186;;B01J2229/18;;B01J2229/183;;B01J35/67;;B01J35/69,C07C1/24;;B01J29/40;;B01J29/70;;B01J29/85;;B01J37/28;;C07C2/86;;C07C6/06;;C07C51/42,,51,42,066-047-071-802-303;;123-469-778-155-344;;001-257-671-378-160;;065-839-296-414-909;;069-809-046-857-553;;009-650-459-799-218;;018-562-220-888-880;;009-606-541-526-069;;013-651-853-825-815;;128-064-484-435-080;;059-567-684-687-120;;098-648-195-061-601;;057-532-463-884-232;;063-943-832-600-738;;063-278-878-784-256;;025-179-354-559-857;;048-231-544-969-259;;077-494-912-953-194;;021-528-524-085-218;;025-239-645-426-589;;022-238-280-831-712;;108-167-629-985-152;;034-091-146-308-770;;050-712-596-776-116;;047-741-444-168-482;;022-876-865-099-869;;004-507-110-607-419;;033-904-593-331-867;;038-038-551-106-059;;150-670-748-404-833;;055-144-252-904-849;;013-079-541-152-354;;065-809-338-900-36X;;014-877-133-100-718;;166-200-406-908-577;;154-604-984-527-106;;025-286-660-523-223;;010-500-246-698-650;;119-503-310-552-186;;036-803-919-357-175;;015-931-084-082-453;;118-564-821-194-969,10.1039/cc9960002365;;10.1039/c5gc02164b;;10.1039/c2ra21381h;;10.1039/c3gc40740c;;10.1021/ja2038358;;21736345;;10.1002/cctc.201601294;;10.1038/nmat1705;;16892049;;10.1038/nature08288;;19741706;;10.1021/cs300265d;;10.1016/j.apcata.2014.12.006;;10.1021/cr00035a007;;10.1007/bf00909833;;10.1021/ja00189a016;;10.1016/0921-3449(90)90018-y;;10.1039/b517510k;;10.1016/j.apcata.2005.10.054;;12405821;;10.1021/ja020947w;;23945710;;pmc3744081;;10.1038/srep02445;;10.1039/c5cy02211h;;10.1021/jp035110h;;21162573;;10.1021/ja107942n;;10.1016/0144-4565(84)90039-8;;16852024;;10.1021/jp0441893;;10.1021/cs100042r;;18179218;;10.1021/ja077711i;;24993100;;10.1039/c4cs00105b;;20136135;;10.1021/ja908382n;;22887922;;10.1002/cssc.201100780;;10.1016/j.catcom.2004.05.006;;10.1021/ja0478734;;15521742;;10.1107/s0021889895014191;;10.1007/bf01083812;;10.1007/bf00907677;;10.1021/ja01170a013;;10.1002/cctc.201600710;;10.1002/cctc.200900278;;10.1002/anie.200705755;;18435514;;10.1016/0144-2449(94)90134-1;;20437452;;10.1002/cssc.200900285;;10.1038/nchembio.580;;21602812;;10.1021/ja065071y;;17044675;;22745424;;10.1126/science.1221111,"Abdelrahman et al., “Biomass-Derived Butadiene by Dehydra-Decyclization of Tetrahydrofuran” ACS Sustain. Chem. Eng., 5:3732-6, Apr. 2017.;;Camblor et al., “Spontaneous nucleation and growth of pure silica zeolite-beta free of connectivity defects,” Chem. Comm., 2365-6, Jul. 1996.;;Chang et al., “Lewis acid zeolites for tandem Diels-Alder cycloaddition and dehydration of biomass-derived dimethylfuran and ethylene to renewable p-xylenem,” Green Chem, 18:1368-76, 2016.;;Chang et al., “Rapid synthesis of Sn-Beta for the isomerization of cellulosic sugars,” RSC Adv., 2(28):10475-7, Sep. 2012.;;Chang et al., “Ultra-selective cycloaddition of dimethylfuran for renewable p-xylene with H-BEA,” Green Chem., 16:585-88, 2014.;;Chia et al., “Selective Hydrogenolysis of Polyols and Cyclic Ethers over Bifunctional Surface Sites on Rhodium-Rhenium Catalysts” J. Am. Chem. Soc., 133:12675-89, Jul. 2011.;;Cho et al., “Renewable p-Xylene from 2,5-Dinethylfuran and Ethylene Using Phosphorus-Containing Zeolite Catalysts,” ChemCatChem., 9(3):398-402, Feb. 2017.;;Choi et al., “Amphiphilic organosilane-directed synthesis of crystalline zeolite with tunable mesoporosity,” Nat. Mater., 5: 718-23, Sep. 2006.;;Choi et al., “Stable single-unit-cell nanosheets of active and long-lived catalysts,” Nature, 461:246-9, Sep. 2009.;;Choudhary et al.,“Conversion of Xylose to Furfural Using Lewis and Brønsted Acid Catalysts in Aqueous Media,” ACS Catalysis 2(9):2022-8, Aug. 2012.;;Duan et al., “Efficient production of 1,3-butadiene in the catalytic dehydration of 2,3-butanediol,” Applied Catalysis A: General 491:163-9, Feb. 2015.;;Farneth and Gorte, “Methods for Characterizing Zeolite Acidity,” Chem. Rev., 95(3):615-35, May 1995.;;Freidlin and Sharf, “Two paths for the dehydration of 1,4-butandiol to divinyl with a tricalcium phosphate catalyst,” Bull. Acad. Sci. USSR, Div. Chem. Sci. 9(9):1577-9, Feb. 1960.;;Fyfe et al., “Detailed Investigation of the Lattice Structure of Zeolite ZSM-11 by a Combination of Solid-State NMR and Synchrotron X-ray Diffraction Techniques,” J. Am. Chem. Soc., 111(7):2470-4, Mar. 1989.;;Godawa et al., “Palladium catalyzed hydrogenation of furan: optimization of production conditions for tetrahydrofuran,” Resources, Conservation and Recycling 3(4):201-16, Jun. 1990.;;Gorte, “What do we know about the acidity of solid acids?,” Catalysis Letters, 62(1):1-13, Sep. 1999.;;Groen et al., “Desilication: on the controlled generation of mesoporosity in MFI zeolites,” Mater. Chem., 16:2121-31, Mar. 2006.;;Ichikawa et al., “Catalytic reaction of 1,3-butanediol over solid acids,” J. Mol. Catal. A: Chem. 256(1-2):106-12, Aug. 2006.;;Igarashi et al., “Dehydration of butanediols over CeO2 catalysts with different particle sizes,” Applied Catalysis A: General 300(1):50-7, Jan. 2006.;;Jeong et al., “Oriented Molecular Sieve Membranes by Heteroepitaxial Growth,” J. Am. Chem. Soc., 124(44):12966-8, Nov. 2002.;;Jiang et al. “Biodegradation-inspired bioproduction of methylacetoin and 2-methyl-2, 3-butanediol” Sci. Rep., 3:1-7, Aug. 2013.;;Jing et al., “Direct Dehydration of 1,3-butaneidol into butadiene over aluminosilicate catalysts,” Catal. Sci. Technol., 6(15):5830-40, Feb. 2016.;;Kragten et al., “Structure of the Silica Phase Extracted from Silica/(TPA)OH Solutions Containing Nanoparticles,” J. Phys. Chem. B, 107(37):10006-16, Sep. 2003.;;Lee et al., “Sub-40 nm Zeolite Suspensions via Disassembly of Three-Dimensionally Ordered Mesoporous-Imprinted Silicalite-1,” J. Am. Chem. Soc., 133(3):493-502, Jan. 2011.;;Lejemble et al., “From biomass to furan through decarbonylation of furfural under mild conditions,” Biomass, 4(4):263-74, Jan. 1984.;;Li et al., “Pure-Silica-Zeolite MEL Low-k Films from Nanoparticle Suspensions,” J. Phys. Chem. B., 109(18):8652-8, May 2005.;;Liu et al., Catalytic Behavior of Bronsted Acid Sites in MWW and MFI Zeolites with Dual Meso- and Microporosity ACS Catal., 1(1):7-17, Jan. 2011.;;Maheshwari et al., “Layer Structure Preservation during Swelling, Pillaring, and Exfoliation of a Zeolite Precursor,” J. Am. Chem. Soc., 130(4):1507-16, Jan. 2008.;;Makshina et al., “Review of old chemistry and new catalytic advances in the on-purpose synthesis of butadiene,” Chem. Soc. Rev., 43(22), 7917-53, Mar. 2014.;;Na et al., “Pillared MFI Zeolite Nanosheets of a single-Unit-Cell Thickness,” J. Am. Chem. Soc., 132(12):4169-77, Mar. 2010.;;Nair et al., “Zeolite-β grown epitaxially on SSZ-31 nanofibers,” Chem. Commun., 10:921-2, Mar. 1999.;;Pace et al., “2-Methyltetrahydrofuran (2-MeTHF): A Biomass-Derived Solvent with Broad Application in Organic Chemistry,” ChemSusChem., 5(8):1369-79, Aug. 2012.;;PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2017054550 dated Apr. 11, 2019, 7 pages.;;PCT International Search Report and Written Opinion in International Appln. No. PCT/US2017054550 dated Dec. 12, 2017, 13 pages.;;Roth et al., “MCM-36: The first pillared molecular sieve with zeolite properties,” Stud. Surf. Sci. and Catal., 94:301, Jan. 1995.;;Sato et al., “Dehydration of 1,4-butanediol into 3-buten-1-ol catalyzed by ceria,” Catal. Comm., 5(8):397-400, Aug. 2004.;;Sato et al., “Dehydration of diols catalyzed by CeO2,” J. Mol. Catal. A: Chem., 221(1-2):177-83, Nov. 2004.;;Sayari et al., “Simple Synthesis Route to Monodispersed SBA-15 Silica Rods,” J. Am. Chem. Soc., 126(44)14348-9, Oct. 2004.;;Schlenker et al., “Computed X-ray Powder Diffraction Patterns for Ultrasmall Zeolite Crystals,” J. Appl. Cryst., 29(2):178-85, Apr. 1996.;;Sharf et al., “Production of isoprene from formaldehyde and isobutylene through 3-methylbutanediol-1, 3,” Bull. Acad. Sci. USSR, Div. Chem. Sci., 14(9), 1621-3, Sep. 1965.;;Shuikin and An, “Dehydration of tetrahydropyran over TiO2—Al2O3,” Bull. Acad. Sci. USSR, Div. Chem. Sci., 9(8):1400-140, Jan. 1960.;;Smith and Fuzek, “Catalytic Hydrogenation of Furan and Substituted Furans on Platinum,” J. Am. Chem. Soc., 71(2):415-9, Feb. 1949.;;Spanjers et al., “Branched Diol Monomers from the Sequential Hydrogenation of Renewable Carboxylic Acids,” ChemCatChem., 8(19):3031-5, Oct. 2016.;;Tsapatsis et al., “A New, Yet Familiar, Lamellar Zeolite,” ChemCatChem., 2:246-8, Mar. 2010.;;Tsapatsis et al., “Pores by Pillaring: Not Always a Maze,” Angew. Chem. Int. Ed., 47(23):4262-3, May 2008.;;Van Koningsveld et al., “The monoclinic framework structure of zeolite H-ZSM-5. Comparison with the orthorhombic framework of as-synthesized ZSM-5”, Zeolites, 10:235-42, May 1990.;;Yang and Seng, “One-Step Catalytic Transformation of Carbohydrates and Cellulosic Biomass to 2,5-Dimethyltetrahydrofuran for Liquid Fuels,” ChemSusChem., 3(5):597-603, May 2010.;;Yim et al., “Metabolic engineering of Escherichia coli for direct production of 1,4-butanediol,” Nat. Chem. Biol., 7(7):445-52, May 2011.;;Yokoi et al.,“Periodic Arrangement of Silica Nanospheres Assisted by Amino Acids,” J. Am. Chem. Soc., 128(42) 13664-5, Oct. 2006.;;Zhang et al., “Synthesis of Self-Pillared Zeolite Nanosheets by Repetitive Branching,” Science 336(6089):1684-7, Jun. 2012.;;U.S. Appl. No. 16/337,603, filed Mar. 28, 2019, Hong Je Cho, Published.",ACTIVE
106,US,A1,US 2021/0085688 A1,167-459-943-132-670,2021-03-25,2021,US 201916970860 A,2019-02-20,US 201916970860 A;;US 201862632806 P;;US 201862744083 P;;US 2019/0018774 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I′: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG,DANA-FARBER CANCER INSTITUTE INC (2018-11-07),https://lens.org/167-459-943-132-670,Patent Application,yes,0,2,7,7,0,A61P35/00;;A61K31/5513;;A61K31/505;;A61K31/50;;A61K31/551,A61K31/50;;A61K31/551,,0,0,,,,DISCONTINUED
107,US,B2,US 7368695 B2,041-085-004-522-934,2008-05-06,2008,US 12071105 A,2005-05-03,US 12071105 A;;US 56747304 P;;US 65241905 P,2004-05-03,Image sensor package and fabrication method,An image sensor package is disclosed that reduces the overall size of known image sensor packages. The image sensor package includes an image sensor and image sensor controller that are arranged on a substrate so that the surfaces of the image sensor and image sensor controller are directly adjacent one another. A package in accordance with the present invention reduces the amount of space in the package by allowing at least one surface of the image sensor controller and at least one surface of the image sensor to be directly attached or connected to one another. Electrical conductive material in the nature of anisotropic conductive materials is also preferably applied to the substrate in the form of an adhesive layer to allow for the image sensor controller and the image sensor to be in electrical communication with one another.,TESSERA INC,KANG TECK-GYU;;ESTRELLA MICHAEL;;PARK JAE M;;THOMPSON KENNETH ROBERT;;MITCHELL CRAIG S;;HABA BELGACEM,TESSERA INC (2005-06-27),https://lens.org/041-085-004-522-934,Granted Patent,yes,44,48,2,2,0,H01L27/14618;;H01L31/0203;;H04M2250/52;;H01L2224/32145;;H01L2224/32225;;H01L2224/48227;;H01L2224/4824;;H01L2224/73204;;H01L2224/73253;;H01L2924/15311;;H01L2924/15321;;H01L2924/15331;;H01L2924/07811;;H01L2224/16227;;H01L2924/15192;;H04N23/54;;H01L27/14618;;H01L31/0203;;H04M2250/52;;H01L2924/15331;;H01L2224/32145;;H01L2924/15311;;H01L2224/73253;;H01L2224/4824;;H01L2224/32225;;H01L2924/15321;;H01L2224/48227;;H01L2224/73204;;H01L2924/07811;;H04N23/54,H01L27/00;;H01L27/146;;H01L31/0203;;H04N5/225,250/208.1;;257/434;;257/680,9,0,,,"U.S. Appl. No. 10/077,388, Fjelstad, Joseph.;;U.S. Appl. 60/403,939, filed Aug. 16, 2002, Bang, et al.;;Fjelstad, An Engineer's Guide to Flexible Circuit Technology (ElectroChemical Publications Limited 1997; ISBN 0901150347), pp. 148-149.;;Bang, U.S. Appl. No. 10/656,534, filed Sep. 5, 2003.;;Kim et al., U.S. Appl. No. 09/776,356, filed Feb. 2, 2001.;;""Megabyte Per Cubic Inch,"" Defense Science, May 1988, p. 56.;;""Three-Dimensional Packaging,"" Defense Science, May 1988, p. 65.;;Newsam, U.S. Appl. No. 60/314,042, filed Aug. 22, 2001.;;Mohammed, PCT/US02/26805, filed Aug. 22, 2002.",ACTIVE
108,US,B2,US 8377147 B2,155-425-921-139-475,2013-02-19,2013,US 30036907 A,2007-05-16,US 30036907 A;;US 63291407 A;;US 2005/0025383 W;;US 80095006 P;;US 58917104 P;;US 2007/0011727 W,2004-07-19,Control of materials and porous magnetic particles,"The present invention uses externally applied electromagnetic stimulus to control and heat porous magnetic particles and material associated with the particles. The particles contain magnetic material, such as superparamagnetic iron oxide and are infused with a material. Application of a DC magnetic field allows them to be moved with their infused material, and application of an AC RF electromagnetic field allows them to be heated with their infused material. The material can be infused into pores of the particles and the particles can also adhere to an aqueous droplet. The present invention also provides a multi-layer porous magnetic particle. The particle includes a host layer having pores sized to accept magnetic nanoparticles. Magnetic nanoparticles are infused within pores of the host layer. An encoding layer includes pores that define a spectral code. The pores in the encoding layer are sized to substantially exclude the magnetic nanoparticles. The encoding layer can also be a multi-layer, exhibiting, for example, a complex spectral code.",UNIV CALIFORNIA;;SAILOR MICHAEL J;;PARK JI-HO;;DERFUS AUSTIN;;SEGAL ESTER;;VECCHIO KENNETH S;;BHATIA SANGEETA N,SAILOR MICHAEL J;;PARK JI-HO;;DERFUS AUSTIN;;SEGAL ESTER;;VECCHIO KENNETH S;;BHATIA SANGEETA N,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2008-11-14),https://lens.org/155-425-921-139-475,Granted Patent,yes,13,0,2,9,0,B82Y25/00;;B82Y25/00;;H05B6/02;;H05B6/02;;H01F1/0063;;H01F1/0063;;Y10T428/29;;Y10T428/29;;Y10T428/2982;;Y10T428/2982;;Y10T428/2991;;Y10T428/2991;;Y10T428/32;;Y10T428/32,B32B15/00;;B44C1/22,977/962;;977/838;;977/960;;216/2;;216/22;;216/24;;216/39;;216/56;;428/357;;428/402;;428/403;;428/692.1;;435/6.1;;435/172.1;;435/173.1,48,47,029-534-770-201-298;;021-920-958-984-890;;073-395-311-714-017;;089-299-398-576-809;;060-482-434-464-314;;039-360-712-393-127;;075-918-469-781-626;;165-971-245-496-258;;158-018-243-890-032;;008-734-346-532-092;;025-603-721-778-120;;049-481-698-468-578;;023-824-063-998-098;;031-287-701-818-055;;092-935-050-498-961;;040-459-935-853-114;;167-000-712-287-879;;094-084-725-996-302;;016-991-177-646-730;;055-590-571-659-22X;;069-824-671-521-436;;006-635-038-974-976;;055-101-362-375-829;;048-096-877-121-134;;063-483-757-286-536;;007-581-909-909-279;;033-784-907-960-268;;063-099-001-050-447;;067-558-848-475-323;;013-074-071-792-660;;027-822-007-781-237;;066-602-040-009-740;;031-919-671-088-09X;;074-982-331-224-018;;051-373-498-893-872;;006-819-897-701-446;;078-805-287-223-103;;062-019-647-474-637;;011-848-780-353-584;;009-497-263-648-110;;029-931-838-267-525;;091-487-055-638-262;;067-129-928-554-034;;021-784-137-917-371;;007-920-898-231-864;;010-554-415-596-107;;001-438-326-792-136,10.1038/nature04163;;16193039;;10.1002/anie.200500620;;15892128;;10.1021/ed076p943;;10.1088/0022-3727/36/13/203;;pmc39285;;8643614;;10.1073/pnas.93.11.5556;;16201806;;10.1021/ja051381p;;15998056;;10.1021/ja052279v;;pmc1766325;;10.1021/la035027l;;10.1021/nl049488i;;11158672;;10.1126/science.291.5504.633;;10.1126/science.276.5313.779;;9115199;;12621418;;10.1038/422028a;;15472723;;10.1039/b405760k;;15531887;;10.1038/nmat1253;;10.1126/science.283.5398.57;;0009872739;;9872739;;11262165;;10.1006/abio.2000.4974;;10.1002/adma.200401880;;10.1038/415152a;;11805829;;10.1109/20.718537;;10.1038/nbt871;;14520403;;10.1021/ac990571d;;10.1126/science.288.5471.1624;;10834837;;12568626;;10.1021/ja021096v;;10.1063/1.1332799;;10.1088/0957-4484/16/8/041;;10.1038/45521;;10905340;;10.1021/ac991471a;;9582111;;10.1126/science.280.5366.1046;;10.1063/1.1797538;;10.1021/ja050249m;;15839641;;12925867;;10.1007/s00216-003-2144-2;;10.1016/s0925-4005(00)00350-6;;12947036;;10.1073/pnas.1233824100;;pmc196851;;10.1002/adma.200400713;;15608646;;10.1038/nmat1270;;9796420;;10.1021/ac980452i;;10.1039/b307628h;;15007455;;10.1088/0022-3727/36/13/201;;10.1039/b110474h;;15100841;;10.1080/02656730110116713;;12028637;;10.1039/b103846j;;15100888;;10.1038/78948;;10966639;;10.1016/s1389-1723(02)80202-x;;10.1263/jbb.94.606;;16233357;;10.1002/adma.200401738;;10.1126/science.1076996;;12351675;;10.1038/426515a;;14654830;;10.1126/science.296.5567.557;;11964485,"Atencia, J., et. al., ""Controlled microfluidic interfaces"", Nature 2005, 437, 648-655.;;Belder, D.,""Microfluidics with Droplets"", Angew. Chem. Int. Ed. 2005, 44, 3521-3522.;;Berger, P., et, al., ""Preparation and properties of an Aqueous Ferrofluid"", J. Chem. Educ. 1999; 76, 943-948.;;Berry, C. C., et, al., ""Functionalisation of magnetic nanoparticles for applications in biomedicine"", J. Phys. D-Appl. Phys. 2003, 36, R198-R206.;;Burns, M. A., et, al., ""Microfabricated structures for an integrated DNA analysis"", Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 5556-5561.;;Chan, E. M., et. al, ""High-Temperature Microfluidic Synthesis of CdSe Nanocrystals in Nanoliter Droplets"", J. Am. Chem. Soc. 2005, 127, 13854-13861.;;Chen, D. L., et. al., ""Using Microfluidics to Observe the Effect of Mixing on Nucleatin of Protein Crystals"", J. Am. Chem. Soc. 2005, 127, 9672-9673.;;Choi, S. H., et. al., ""Micrometer-Scaled Gradient Surfaces Generated Using Contact Printing of Octadecyltrichlorosilane"", Langmuir 2003, 19, 7427-7435.;;Cui, Y., et, al., ""Integration of Colloidal Nanocrystals into Lithographically Patterned Devices"", Nano Lett. 2004, 4, 1093-1098.;;Daniel, S., et. al., ""Fast Drop Movements Resulting from the Phase Change on a Gradient Surface"", Science 2001, 291, 633-636.;;Delamarche, E, et. al., ""Patterned Delivery of Immunoglobulins to Surfaces Using Microfluidic Networks"", Science 1997, 276, 779-781.;;DeMello, A. J., ""DNA amplification moves on"", Nature 2003, 422, 28-29.;;DeMello, A. J., et. al., ""Precise temperature control in microfluidic devices using Joule heating of ionic liquids"", Lab Chip 2004, 4, 417-419.;;Dorvee, J. R., et. al. ""Manipulation of liquid droplets using amphiphilic, magnetic one-dimensional photonic crystal chaperones"", Nature Mater. 2004, 3, 896-899.;;Gallardo, B. S., et. al., ""Electrochemical Principals for Active Control of Liquids on Submillimeter Scales"", Science 1999, 283, 57-60.;;Giordano, B. C., et. al., ""Polymerase Chain Reaction in the Polymeric Microchips: DNA Amplification in Less than 240 Seconds"", Anal. Biochem. 2001, 291, 124-132.;;Gunnarsson, K.; et. al., ""Programmable Motion and Separation of Single Magnetic Particles on Patterned Magnetic Surfaces"". Adv. Mater. 2005, 17, 1730-1734.;;Hamad-Schifferli, K., et. al., ""Remote electronic control of DNA hybridization through inductive coupling to an attached metal nanocrystal antenna"", Nature 2002, 415, 152-155.;;Hergt, R., et. al., ""Physical Limits of Hyperhtermia Using Magnetite Fine Particles"", IEEE Trans. Magn. 1998, 34, 3745-3754.;;Hong, J. W., et. al., ""Integrated nanoliter systems"", Nat. Biotechnol. 2003, 21, 1179-1183.;;Hosokawa, K., et. al., ""Handling of Picoliter Liquid Samples in a Poly(dimethylsiloxane)-Based Microfluidic Device"", Anal. Chem. 1999, 71, 4781-4785.;;Ichimura, K., et. al., ""Light-Driven Motion of Liquids on a Photoresponsive Surface"", Science 2000, 288, 1624-1626.;;Jin, R. C., et. al., ""What Controls the Melting Properties of DNA-Linked Gold Nanoparticle Assemblies?"", Am. Chem. Soc. 2003, 125, 1643-1654.;;Jones, T. B., et. al., ""Dielectrophoretic liquid actuation and nanodroplet formation"", J. Appl. Phys. 2001, 89, 1441-1448.;;Kalambur, V. S, et. al., ""In vitro characterization of movement, heating and visualization of magnetic nanoparticles for biomedical applications"", Nanotechnology 2005, 16, 1221-1233.;;Kataoka, D. E., et. al., ""Patterning liquid flow of the microscopic scale"", Nature 1999, 402, 794-797.;;Khandurina, J., et. al., ""Integrated System for Rapid PCR-Based DNA Analysis in Microfluidic Devices"", Anal. Chem. 2000, 72, 2995-3000.;;Kopp, M. U., et. al., ""Chemical Amplification: Continuous-Flow PCR on a Chip"", Science 1998, 280, 1046-1048.;;Kotz, K. T., et. al., ""Optical microfluidics"", Appl. Phys. Lett. 2004, 85, 2658-2660.;;Kotz, K. T., et. al, ""Optically Addressed Droplet-Based Protein Assay"", J. Am. Chem. Soc. 2005, 127, 5736-5737.;;Kricka, L., et. al., ""Microchip PCR"", Anal. Bioanal. Chem. 2003, 377, 820-825.;;Lagally, E. T., et. al., ""Monolithic integrated microfluidic DNA amplification and capillary electrophoresis analysis system"", Sens. Actuator B-Chem. 2000, 63, 138-146.;;Link, J. R., et. al., ""Smart dust: Self-assembling, self-orienting photonic crystals of porous Si"", Proc. Nat. Acad. Sci. 2003, 100, 10607-10610.;;Meade, S. O., et. al., ""Porous Silicon Photonic Crystals as Encoded Microcarriers"", Adv. Mater. 2004, 16, 1811-1814.;;Millman, J. R., et. al., ""Anisotropic particle synthesis in dielectrophoretically controlled microdroplet reactors"", Nat. Mater. 2005, 4, 98-102.;;Oda, R. P., et. al., ""Infared-Mediated Thermocycling for Ultrafast Polymerase Chain Reaction Amplification of DNA"", Anal. Chem. 1998, 70, 4361-4368.;;Paik, P., et. al., ""Rapid droplet mixers for digital microfluidic systems"", Lab Chip 2003, vol. 3, 253-259.;;Pankhurst, Q. A, et. al., ""Applications of magnetic nanoparticles in biomedicine"", J. Phys. D-Appl. Phys. 2003, 36, R167-R181.;;Pollack, M. G., et al., ""Electrowetting-based actuation of droplets for integrated microfluidics"", Lab Chip 2002, 2, 96-101.;;Rabin, Y., ""Is intracellular hyperthermia superior to extracellular hyperthermia in the thermal sense?"", Int. J. Hyperthermia 2002, 18, 194-202.;;Schnakenberg, U., et. al., ""NH/sub 4/OH-based etchants for silicon micromachining: influence of additives and stability of passivation layers"", Sens. Actuators A-Phys. 1991, 25, 1-7.;;Schneegass, I., et. al. ""Miniaturized flow-through PCR with different template types in a silicon chip thermocycler"", J. M. Lab Chip 2001, 1, 42-49.;;Selvin, P. R., ""The renaissance of fluorescence resonance energy transfer"", Nat. Struct. Biol. 2000, 7, 730-734.;;Shinkai, M., ""Functional Magnetic Particles for Medical Application"", J. Biosci. Bioeng. 2002, 94, 606-613.;;Takeuchi, S., et. al., ""An Axisymmetric Flow-Focusing Microfluidic Device"", Adv. Mater. 2005, 17, 1067-1072.;;Thorsen, T., et. al., ""Microfluidic Large-Scale Integration"", Science 2002, 298, 580-584.;;Velev, O. D, et. al., ""On-chip manipulation of free droplets,"" Nature 2003, 426, 515-516.;;Walker, N. J., ""A Technique Whose Time Has Come"", Science 2002, 296, 557-559.",INACTIVE
109,US,A1,US 2012/0144059 A1,010-984-450-774-028,2012-06-07,2012,US 96008010 A,2010-12-03,US 96008010 A,2010-12-03,Methods and Apparatus for Minimizing Wander Generation in Constant Bit Rate Asynchronously Mapped Digital Transport Systems,"A mapping system including a memory, a client receive circuit and a frame transmit circuit. The client receive circuit is adapted to receive client data from a network, decode the client data and store the client data within the memory. The frame transmit circuit includes a justification control log and a framer. The justification control logic is executed by one or more processor to 1) determine each of a plurality of fill levels, each of the plurality of fill levels being associated with an amount of client data in the memory at each of a plurality of corresponding one of a plurality of instants of time, and 2) determine an average of the plurality of fill levels. The framer has circuitry to generate a wrapper including at least a portion of client data from the memory, the wrapper having one or more justification opportunity having data based upon a difference between the average and a predetermined threshold. The mapping system can be an asynchronous mapping system.",WANDER ARVINDERPAL S;;SPRAGUE EDWARD E;;CHILLAL MALLIKARJUN;;PARANJAPE PRASAD;;PARK YEONGHO;;KUTTY K G MICHAEL,WANDER ARVINDERPAL S;;SPRAGUE EDWARD E;;CHILLAL MALLIKARJUN;;PARANJAPE PRASAD;;PARK YEONGHO;;KUTTY K G MICHAEL,INFINERA CORPORATION (2011-05-19),https://lens.org/010-984-450-774-028,Patent Application,yes,6,4,2,2,0,H04J3/1658;;H04J3/1658;;H04J3/07;;H04J3/07,G06F15/16,709/233;;709/236,1,1,064-376-133-080-217,10.1109/icc.1997.595055,"Author: Peter Scholander, Chris Autry and Henry Owen Title: Mapping wander in sonet/sdh adaptive threshold modulation pointer processors Date: 06-1997 Publication: IEEE conference publication",ACTIVE
110,WO,A1,WO 2018/064599 A1,110-876-276-031-92X,2018-04-05,2018,US 2017/0054550 W,2017-09-29,US 201662402238 P;;US 201662410919 P;;US 201662410922 P;;US 201662414302 P;;US 201662419202 P;;US 201662419247 P,2016-09-30,"FORMING DIENES FROM CYCLIC ETHERS AND DIOLS, INCLUDING TETRAHYDROFURAN AND 2-METHYL-1,4-BUTANEDIOL","Forming a diene includes contacting a reactant including at least one of a cyclic ether and a diol with a heterogeneous acid catalyst to yield a reaction mixture including a diene. The heterogeneous acid catalyst includes at least one of a Lewis acid catalyst, a supported Lewis-acid catalyst, a Brnsted acid catalyst, a solid acid catalyst, a supported phosphoric acid catalyst, and a sulfonated catalyst. The dehydration of cyclic ethers and diols with high selectivity to yield dienes completes pathways for the production of dienes, such as isoprene and butadiene, from biomass in high yields, thereby promoting economical production of dienes from renewable resources.",ABDELRAHMAN OMAR A;;SPANJERS CHARLES S;;PARK DAE SUNG;;TSAPATSIS MICHAEL;;REN LIMIN;;DAUNHAUER PAUL JAKOB,ABDELRAHMAN OMAR A;;SPANJERS CHARLES S;;PARK DAE SUNG;;TSAPATSIS MICHAEL;;REN LIMIN;;DAUNHAUER PAUL JAKOB,,https://lens.org/110-876-276-031-92X,Patent Application,yes,3,3,6,6,0,B01J37/28;;B01J29/40;;B01J29/7007;;B01J29/82;;B01J29/85;;B01J2229/16;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;Y02P20/582;;Y02P20/52;;B01J29/40;;B01J29/7007;;B01J29/85;;B01J37/28;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;C07C51/42;;C07C2521/04;;C07C2521/06;;C07C2521/08;;C07C2521/10;;C07C2521/12;;C07C2521/18;;C07C2523/10;;C07C2523/20;;C07C2527/167;;C07C2527/18;;C07C2527/188;;C07C2529/08;;B01J37/0201;;C07C2529/85;;C07C2529/82;;B01J2229/186;;B01J2229/18;;B01J2229/183;;B01J35/67;;B01J35/69,B01J19/10,,4,4,022-876-865-099-869;;077-494-912-953-194;;069-809-046-857-553;;080-416-720-151-028,24993100;;10.1039/c4cs00105b;;23945710;;pmc3744081;;10.1038/srep02445;;10.1021/ja2038358;;21736345;;10.1021/acssuschemeng.7b00745,"MAKSHINA ET AL.: ""Review of old chemistry and new catalytic advances in the on-purpose synthesis of butadiene"", CHEMICAL SOCIETY REVIEWS, vol. 43, 4 July 2014 (2014-07-04), pages 7917 - 7953, XP055515715;;JIANG ET AL.: ""Biodegradation-inspired bioproduction of methylacetoin and 2-methyl-2, 3- butanediol"", SCIENTIFIC REPORTS, vol. 3, no. 2445, 15 August 2013 (2013-08-15), pages 1 - 7, XP055515722;;CHIA ET AL.: ""Selective Hydrogenolysis of Polyols and Cyclic Ethers over Bifunctional Surface Sites on Rhodium-Rhenium Catalysts"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 133, no. 32, 7 July 2011 (2011-07-07), pages 12675 - 12689, XP002681777;;ABDELRAHMAN ET AL.: ""Biomass-Derived Butadiene by Dehydra-Decyclization of Tetrahydrofuran"", ACS SUSTAINABLE CHEMISTRY & ENGINEERING, vol. 5, no. 5, 4 April 2017 (2017-04-04), pages 3732 - 3736, XP055515731",PENDING
111,WO,A1,WO 2023/059825 A1,118-476-404-141-84X,2023-04-13,2023,US 2022/0045937 W,2022-10-06,US 202163252742 P,2021-10-06,3D AUXETIC STRUCTURES AND FABRICATION METHODS THEREOF,"Disclosed herein is an apparatus comprising: an auxetic unit-cell, each comprising: a first longitudinal beam, a second longitudinal beam fixably attached to the first longitudinal beam at a first hinge region, the second longitudinal beam is orthogonally disposed with respect to the first longitudinal beam; and a third longitudinal beam fixably attached to the first longitudinal beam at a second hinge region, the third longitudinal beam is orthogonally disposed with respect to the first and second longitudinal beams, wherein the first, second and third longitudinal beams all are different lengths, wherein the first and second hinge region, and the first and third longitudinal beam are configured to bend under load applied in a direction non-parallel to the longitudinal axis of the first longitudinal beam.",GEORGIA TECH RES INST;;UNIV EMORY;;PARK JEONG HUN;;HOLLISTER SCOTT J;;TUCKER SARAH JO;;WANG LIZHEN;;PARK HYUN JI;;DAVIS MICHAEL E;;RUTLEDGE SARAH K;;VERGA ADAM S,PARK JEONG HUN;;HOLLISTER SCOTT J;;TUCKER SARAH JO;;WANG LIZHEN;;PARK HYUN-JI;;DAVIS MICHAEL E;;RUTLEDGE SARAH K;;VERGA ADAM S,,https://lens.org/118-476-404-141-84X,Patent Application,yes,3,0,1,1,0,B29C64/10;;B33Y80/00;;B22F10/28;;B22F10/25;;A61L27/52;;A61L31/145,A61L31/02;;A61L31/16;;B22F3/105;;B29C64/10,,0,0,,,,PENDING
112,US,S,US D0489007 S,059-335-916-978-953,2004-04-27,2004,US 16091902 F,2002-05-17,US 16091902 F;;US 14010401 F,2001-04-11,Bottle upper,,CLOROX CO,HALL MICHAEL J;;RADAR JAMES E;;HEFTER KAREN S;;MINKLER DOUGLAS;;FLAGLER ROBERT;;SAYLER DAVID;;PARK ERIC,CLOROX COMPANY THE (2002-07-09),https://lens.org/059-335-916-978-953,Design Right,no,0,4,3,3,0,,,D 9550;;D9/571;;D9/575;;D9/555,0,0,,,,EXPIRED
113,US,A1,US 2009/0179171 A1,133-411-235-415-50X,2009-07-16,2009,US 30036907 A,2007-05-16,US 30036907 A;;US 63291407 A;;US 2005/0025383 W;;US 80095006 P;;US 58917104 P;;US 2007/0011727 W,2004-07-19,CONTROL OF MATERIALS AND POROUS MAGNETIC PARTICLES,"The present invention uses externally applied electromagnetic stimulus to control and heat porous magnetic particles and material associated with the particles. The particles contain magnetic material, such as superparamagnetic iron oxide and are associated with a material. Application of a DC magnetic field allows them to be moved with their associated material, and application of an AC RF electromagnetic field allows them to be heated with their associated material. The material can be associated with the particles by being contained in the pores of the particles, or in other cases the particles can adhere to the associated material, which can be an aqueous droplet. The present invention also provides a multi-layer porous magnetic particle. The particle includes a host layer having pores sized to accept magnetic nanoparticles. Magnetic nanoparticles are infused within pores of the host layer An encoding layer includes pores that define a spectral code. The pores in the encoding layer are sized to substantially exclude the magnetic nanoparticles. The encoding layer can also be a multi-layer, exhibiting, for example, a complex spectral code.",UNIV CALIFORNIA,SAILOR MICHAEL J;;PARK JI-HO;;DERFUS AUSTIN M;;SEGAL ESTER;;VECCHIO KENNETH S;;BHATIA SANGEETA N,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2008-11-14),https://lens.org/133-411-235-415-50X,Patent Application,yes,13,14,2,9,0,B82Y25/00;;B82Y25/00;;H05B6/02;;H05B6/02;;H01F1/0063;;H01F1/0063;;Y10T428/29;;Y10T428/29;;Y10T428/2982;;Y10T428/2982;;Y10T428/2991;;Y10T428/2991;;Y10T428/32;;Y10T428/32,H01F1/00;;H05B6/02,252 6251R;;219/600,0,0,,,,INACTIVE
114,WO,A3,WO 2008/027090 A3,093-729-793-749-775,2008-04-24,2008,US 2007/0011727 W,2007-05-16,US 80095006 P,2006-05-17,CONTROL OF MATERIALS AND POROUS MAGNETIC PARTICLES,"The present invention uses externally applied electromagnetic stimulus to control and heat porous magnetic particles and material associated with the particles. The particles contain magnetic material, such as superparamagnetic iron oxide and are associated with a material. Application of a DC magnetic field allows them to be moved with their associated material, and application of an AC RF electromagnetic field allows them to be heated with their associated material. The material can be associated with the particles by being contained in the pores of the particles, or in other cases the particles can adhere to the associated material, which can be an aqueous droplet. The present invention also provides a multi-layer porous magnetic particle. The particle includes a host layer having pores sized to accept magnetic nanoparticles. Magnetic nanoparticles are infused within pores of the host layer. An encoding layer includes pores that define a spectral code. The pores in the encoding layer are sized to substantially exclude the magnetic nanoparticles. The encoding layer can also be a multi-layer, exhibiting, for example, a complex spectral code.",UNIV CALIFORNIA;;SAILOR MICHAEL J;;PARK JI-HO;;DERFUS AUSTIN M;;SEGAL ESTER;;VECCHIO KENNETH S;;BHATIA SANGEETA N,SAILOR MICHAEL J;;PARK JI-HO;;DERFUS AUSTIN M;;SEGAL ESTER;;VECCHIO KENNETH S;;BHATIA SANGEETA N,,https://lens.org/093-729-793-749-775,Search Report,yes,5,0,2,9,0,B01J2219/00466;;B01J2219/00495;;B01J2219/005;;B01J2219/00502;;B01J2219/00563;;B01J2219/00576;;B01L3/502761;;B01L3/502792;;B01L7/52;;B01L2300/0896;;B01L2300/1816;;B01L2400/0415;;B01L2400/043;;B82Y25/00;;B82Y30/00;;H01F1/0063,H01L21/00;;G01N17/00,,0,0,,,,PENDING
115,WO,A2,WO 2008/027090 A2,051-778-623-796-736,2008-03-06,2008,US 2007/0011727 W,2007-05-16,US 80095006 P,2006-05-17,CONTROL OF MATERIALS AND POROUS MAGNETIC PARTICLES,"The present invention uses externally applied electromagnetic stimulus to control and heat porous magnetic particles and material associated with the particles. The particles contain magnetic material, such as superparamagnetic iron oxide and are associated with a material. Application of a DC magnetic field allows them to be moved with their associated material, and application of an AC RF electromagnetic field allows them to be heated with their associated material. The material can be associated with the particles by being contained in the pores of the particles, or in other cases the particles can adhere to the associated material, which can be an aqueous droplet. The present invention also provides a multi-layer porous magnetic particle. The particle includes a host layer having pores sized to accept magnetic nanoparticles. Magnetic nanoparticles are infused within pores of the host layer. An encoding layer includes pores that define a spectral code. The pores in the encoding layer are sized to substantially exclude the magnetic nanoparticles. The encoding layer can also be a multi-layer, exhibiting, for example, a complex spectral code.",UNIV CALIFORNIA;;SAILOR MICHAEL J;;PARK JI-HO;;DERFUS AUSTIN M;;SEGAL ESTER;;VECCHIO KENNETH S;;BHATIA SANGEETA N,SAILOR MICHAEL J;;PARK JI-HO;;DERFUS AUSTIN M;;SEGAL ESTER;;VECCHIO KENNETH S;;BHATIA SANGEETA N,,https://lens.org/051-778-623-796-736,Patent Application,yes,0,6,2,9,0,B01J2219/00466;;B01J2219/00495;;B01J2219/005;;B01J2219/00502;;B01J2219/00563;;B01J2219/00576;;B01L3/502761;;B01L3/502792;;B01L7/52;;B01L2300/0896;;B01L2300/1816;;B01L2400/0415;;B01L2400/043;;B82Y25/00;;B82Y30/00;;H01F1/0063,H01J37/02,,0,0,,,,PENDING
116,US,S,US D0480651 S,178-188-548-153-399,2003-10-14,2003,US 16091802 F,2002-05-17,US 16091802 F;;US 14010401 F,2001-04-11,Smooth bottle,,CLOROX CO,HALL MICHAEL J;;RADAR JAMES E;;HEFTER KAREN S;;MINKLER DOUGLAS;;FLAGLER ROBERT;;SAYLER DAVID;;PARK ERIC,,https://lens.org/178-188-548-153-399,Design Right,no,0,2,3,3,0,,,D 9550;;D9/571;;D9/575;;D9/555,0,0,,,,EXPIRED
117,US,A1,US 2007/0179973 A1,008-647-318-978-104,2007-08-02,2007,US 34151106 A,2006-01-30,US 34151106 A,2006-01-30,Status tool to expose metadata read and write queues,"A method to expose status information is provided. The status information is associated with metadata extracted from multimedia files and stored in a metadata database. The metadata information that is extracted from the multimedia files is stored in a read queue to allow a background thread to process the metadata and populate the metadata database. Additionally, the metadata database may be updated to include user-define metadata, which is written back to the multimedia files. The user-defined metadata is included in a write queue and is written to the multimedia files associated with the user-defined metadata. The status of the read and write queues are exposed to a user through a graphical user interface. The status may include the list of multimedia files included in the read and write queues, the priorities of each multimedia file, and the number of remaining multimedia files.",MICROSOFT CORP,BRODIE ALEXANDER S;;PERRY BENJAMIN L;;PARLIN DAVID R;;PARK JAE P;;GILMORE MICHAEL J;;DART SCOTT E,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2006-05-03),https://lens.org/008-647-318-978-104,Patent Application,yes,13,31,6,6,0,G06F16/48;;G06F16/48;;G06F9/50,G06F17/00,707/104.1,0,0,,,,INACTIVE
118,EP,A1,EP 3755330 A1,014-623-015-799-556,2020-12-30,2020,EP 19758033 A,2019-02-20,US 201862632798 P;;US 2019/0018770 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/014-623-015-799-556,Patent Application,yes,0,0,7,7,0,A61P35/00;;A61K31/506;;A61K31/496;;A61K45/06;;A61K31/427;;A61K31/496;;A61K31/497,A61K31/496;;A61K31/506;;A61P35/00,,0,0,,,,DISCONTINUED
119,AU,A1,AU 2019/225806 A1,082-645-945-468-554,2020-07-16,2020,AU 2019/225806 A,2019-02-20,US 201862744086 P;;US 201862632819 P;;US 2019/0018773 W,2018-02-20,Inhibitors of EGFR and methods of use thereof,"The application relates to a compound having Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/082-645-945-468-554,Patent Application,no,0,0,7,7,0,C07D403/04;;C07D243/38;;C07D243/08;;C07D403/10;;A61P35/00;;A61P35/00;;A61K31/5513;;C07D403/10,C07D243/38;;C07D403/04,,0,0,,,,DISCONTINUED
120,EP,A1,EP 3755337 A1,106-342-474-949-028,2020-12-30,2020,EP 19757001 A,2019-02-20,US 201862632806 P;;US 201862744083 P;;US 2019/0018774 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/106-342-474-949-028,Patent Application,yes,0,0,7,7,0,A61P35/00;;A61K31/5513;;A61K31/505;;A61K31/50;;A61K31/551,A61K31/551;;A61K31/506;;A61K45/06;;A61P35/00,,0,0,,,,DISCONTINUED
121,CA,A1,CA 3087288 A1,165-651-438-010-83X,2019-08-29,2019,CA 3087288 A,2019-02-20,US 201862632819 P;;US 201862744086 P;;US 2019/0018773 W,2018-02-20,INHIBITORS OF EGFR AND METHODS OF USE THEREOF,"The application relates to a compound having Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/165-651-438-010-83X,Patent Application,no,0,0,7,7,0,C07D403/04;;C07D243/38;;C07D243/08;;C07D403/10;;A61P35/00;;A61P35/00;;A61K31/5513;;C07D403/10,C07D243/38;;C07D403/04,,0,0,,,,PENDING
122,EP,A4,EP 3755337 A4,010-900-583-293-497,2021-11-03,2021,EP 19757001 A,2019-02-20,US 201862632806 P;;US 201862744083 P;;US 2019/0018774 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/010-900-583-293-497,Search Report,no,4,0,7,7,0,A61P35/00;;A61K31/5513;;A61K31/505;;A61K31/50;;A61K31/551,A61K31/551;;A61K31/506;;A61P35/00,,2,1,027-856-538-302-851,pmc6862338;;31749909;;10.1021/acsmedchemlett.9b00381,"DE CLERCQ DRIES J. H. ET AL: ""Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors"", vol. 10, no. 11, 14 November 2019 (2019-11-14), US, pages 1549 - 1553, XP055840334, ISSN: 1948-5875, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.9b00381> DOI: 10.1021/acsmedchemlett.9b00381;;See also references of WO 2019164949A1",DISCONTINUED
123,EP,A4,EP 3755330 A4,038-837-518-518-394,2021-11-24,2021,EP 19758033 A,2019-02-20,US 201862632798 P;;US 2019/0018770 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/038-837-518-518-394,Search Report,no,3,0,7,7,0,A61P35/00;;A61K31/506;;A61K31/496;;A61K45/06;;A61K31/427;;A61K31/496;;A61K31/497,A61K31/496;;A61K31/506;;A61P35/00,,2,1,031-543-089-667-886,pmc4929832;;27251290;;10.1038/nature17960,"YONG JIA ET AL: ""Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors"", NATURE, vol. 534, no. 7605, 25 May 2016 (2016-05-25), London, pages 129 - 132, XP055342543, ISSN: 0028-0836, DOI: 10.1038/nature17960;;See also references of WO 2019164945A1",DISCONTINUED
124,US,A1,US 2006/0060138 A1,045-275-413-051-603,2006-03-23,2006,US 18892205 A,2005-07-25,US 18892205 A;;US 61151204 P;;US 65361705 P,2004-09-20,Diffuser gravity support,"An apparatus and method for supporting a substantial center portion of a gas distribution plate is disclosed. At least one support member is capable of engaging and disengaging the diffuser with a mating connection without prohibiting flow of a gas or gasses through the diffuser and is designed to provide vertical suspension to a diffuser that is supported at its perimeter, or capable of supporting the diffuser without a perimeter support. In one aspect, the at least one support member is a portion of a gas delivery conduit and in another embodiment is a plurality of support members separated from the gas delivery conduit. The at least one support member is capable of translating vertical lift, or vertical compression to a center area of the diffuser. A method and apparatus for controlling gas flow from the gas delivery conduit to the gas distribution plate is also disclosed.",APPLIED MATERIALS INC,KELLER ERNST;;WHITE JOHN M;;TINER ROBIN L;;KUCERA JIRI;;CHOI SOO Y;;PARK BEOM S;;STARR MICHAEL,APPLIED MATERIALS INC (2005-08-18),https://lens.org/045-275-413-051-603,Patent Application,yes,98,163,6,19,0,C23C16/45565;;C23C16/45565;;H01J37/3244;;H01J37/3244,C23C16/00,118/715,0,0,,,,ACTIVE
125,AU,A1,AU 2019/225803 A1,118-559-110-681-414,2020-07-23,2020,AU 2019/225803 A,2019-02-20,US 201862632798 P;;US 2019/0018770 W,2018-02-20,Pharmaceutical combinations of EGFR inhibitors and methods of use thereof,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula I: (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I': (I'), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/118-559-110-681-414,Patent Application,no,0,0,7,7,0,A61P35/00;;A61K31/506;;A61K31/496;;A61K45/06;;A61K31/427;;A61K31/496;;A61K31/497,A61K31/496;;A61K31/506;;A61P35/00,,0,0,,,,DISCONTINUED
126,CA,A1,CA 3087797 A1,087-004-904-587-583,2019-08-29,2019,CA 3087797 A,2019-02-20,US 201862632806 P;;US 201862744083 P;;US 2019/0018774 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I': or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA-FARBER CANCER INSTITUTE INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/087-004-904-587-583,Patent Application,no,0,0,7,7,0,A61P35/00;;A61K31/5513;;A61K31/505;;A61K31/50;;A61K31/551,A61K31/551;;A61K31/506;;A61K45/06;;A61P35/00,,0,0,,,,PENDING
127,WO,A1,WO 2019/164948 A1,086-485-868-294-41X,2019-08-29,2019,US 2019/0018773 W,2019-02-20,US 201862632819 P;;US 201862744086 P,2018-02-20,INHIBITORS OF EGFR AND METHODS OF USE THEREOF,"The application relates to a compound having Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/086-485-868-294-41X,Patent Application,yes,5,0,7,7,0,C07D403/04;;C07D243/38;;C07D243/08;;C07D403/10;;A61P35/00;;A61P35/00;;A61K31/5513;;C07D403/10,C07D243/38;;C07D403/04,,1,0,,,See also references of EP 3755690A4,PENDING
128,US,A1,US 2021/0077469 A1,174-943-129-378-690,2021-03-18,2021,US 201916971021 A,2019-02-20,US 201916971021 A;;US 201862632798 P;;US 2019/0018770 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula I: (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I′: (I′), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/174-943-129-378-690,Patent Application,yes,0,0,7,7,0,A61P35/00;;A61K31/506;;A61K31/496;;A61K45/06;;A61K31/427;;A61K31/496;;A61K31/497,A61K31/427;;A61K31/496;;A61K31/497,,0,0,,,,DISCONTINUED
129,US,A1,US 2013/0132965 A1,186-684-403-135-248,2013-05-23,2013,US 201313745325 A,2013-01-18,US 201313745325 A;;US 201113165121 A;;US 34151106 A,2006-01-30,STATUS TOOL TO EXPOSE METADATA READ AND WRITE QUEUES,"A method to expose status information is provided. The status information is associated with metadata extracted from multimedia files and stored in a metadata database. The metadata information that is extracted from the multimedia files is stored in a read queue to allow a background thread to process the metadata and populate the metadata database. Additionally, the metadata database may be updated to include user-define metadata, which is written back to the multimedia files. The user-defined metadata is included in a write queue and is written to the multimedia files associated with the user-defined metadata. The status of the read and write queues are exposed to a user through a graphical user interface. The status may include the list of multimedia files included in the read and write queues, the priorities of each multimedia file, and the number of remaining multimedia files.",MICROSOFT CORP;;MICROSOFT CORP,BRODIE ALEXANDER S;;PERRY BENJAMIN L;;PARLIN DAVID R;;PARK JAE PUM;;GILMORE MICHAEL J;;DART SCOTT E,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2013-04-12),https://lens.org/186-684-403-135-248,Patent Application,yes,18,0,6,6,0,G06F16/48;;G06F16/48;;G06F9/50,G06F9/50,718/103;;718/104,2,1,096-991-459-732-196,10.1145/990064.990072,"Sarvas, Risto, et al., ""Metadata Creation System for Mobile Images"", MobiSys '04, Boston, MA, June 6-9, 2004, pp. 36-48.;;Wactlar, Howard D., et al., ""Digital Video Archives: Managing Through Metadata"", Building a National Strategy for Digital Preservation: Issues in Digital Media Archiving, National Digital Information Infrastructure and Preservation Program, Library of Congress, April 2002, pp. 1-14.",ACTIVE
130,CA,A1,CA 3087080 A1,008-743-250-455-429,2019-08-29,2019,CA 3087080 A,2019-02-20,US 201862632832 P;;US 201862744088 P;;US 2019/0018778 W,2018-02-20,DEGRADERS OF EGFR AND METHODS OF USE THEREOF,"The application relates to a compound having Formula X: (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/008-743-250-455-429,Patent Application,no,0,0,7,7,0,C07D401/14;;C07D471/04;;C07D243/38;;C07D403/04;;C07D403/10;;C07D401/06;;C07D417/06;;C07D403/06;;A61P35/00;;A61K45/06;;A61K47/55;;C07D209/08;;C07D243/38;;C07D277/30;;C07D401/12;;C07D403/04;;C07D403/10;;C07D403/12;;C07D417/12;;C07D471/04,C07D401/14;;C07D471/04,,0,0,,,,DISCONTINUED
131,EP,A1,EP 0503051 A1,044-167-110-052-671,1992-09-16,1992,EP 91918306 A,1991-09-25,US 59037590 A;;US 71709991 A;;US 9106911 W,1990-09-28,COLOR IMAGE PROCESSING SYSTEM FOR PREPARING A COMPOSITE IMAGE TRANSFORMATION MODULE FOR PERFORMING A PLURALITY OF SELECTED IMAGE TRANSFORMATIONS.,"Méthode et appareil servant à générer une configuration de valeurs de pixels modifiées en réaction à une configuration de valeurs de pixels d'entrée. L'appareil comprend une interface d'utilisateur pour recevoir une sélection par l'utilisateur d'une (de) transformation(s) d'une image devant être effectuée(s) sur la configuration de valeurs de pixels d'entrée. Un dispositif de stockage mémorise une pluralité de définitions de transformées, chaque définition de transformée comprenant des valeurs d'échantillonnage représentant un rapport entrée/sortie d'une transformation d'image. Un contrôleur de transformées sélectionne une pluralité de définitions de transformées en réaction à la sélection par l'utilisateur d'au moins une transformation d'image, et génère à partir de cette sélection une définition de transformée composite. La définition de transformée composite comprend des valeurs d'échantillonnage d'un rapport entrée/sortie d'une transformation d'image composite qui est équivalente à la (aux) transformation(s) d'image sélectionnée(s) par l'utilisateur. Les définitions de transformées mémorisées par le dispositif de stockage comprennent une pluralité de définitions de transformées prédéterminées. Une définition de transformée adaptée aux besoins de l'utilisateur peut être préparée conformément aux instructions particulières et être ajoutée à la pluralité de définitions de transformées mémorisées par le dispositif de stockage. Le contrôleur de transformées fonctionne essentiellement en temps réel, et met en oeuvre les sélections de l'utilisateur suffisamment rapidement pour permettre à l'utilisateur de dialoguer avec le système de traitement d'images jusqu'à obtention de la configuration de valeurs de pixels modifiées souhaitée.",EASTMAN KODAK CO,NEWMAN GARY H;;ENSCOE CHRISTOPHER J;;POE ROBERT F;;GREGORY H SCOTT JR;;SCHWARTZ MICHAEL S PARK AVENUE,,https://lens.org/044-167-110-052-671,Patent Application,yes,0,0,12,15,0,H04N1/46;;H04N1/60;;H04N1/6019;;H04N1/6058,G03F3/08;;H04N1/46;;H04N1/60,,1,0,,,See references of WO 9206557A1,EXPIRED
132,CA,A1,CA 3087800 A1,143-725-087-268-417,2019-08-29,2019,CA 3087800 A,2019-02-20,US 201862632800 P;;US 201862744082 P;;US 2019/0018765 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I': (I'), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA-FARBER CANCER INSTITUTE INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/143-725-087-268-417,Patent Application,no,0,0,7,7,0,A61P35/00;;A61K31/506;;A61K31/551;;A61P35/00;;A61K31/5513,A61K31/551;;A61K31/506;;A61P35/00,,0,0,,,,PENDING
133,EP,A1,EP 3755697 A1,158-189-445-020-154,2020-12-30,2020,EP 19756893 A,2019-02-20,US 201862632832 P;;US 201862744088 P;;US 2019/0018778 W,2018-02-20,DEGRADERS OF EGFR AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,"DANA-FARBER CANCER INSTITUTE, INC. (2021-06-02)",https://lens.org/158-189-445-020-154,Patent Application,yes,0,0,7,7,0,C07D401/14;;C07D471/04;;C07D243/38;;C07D403/04;;C07D403/10;;C07D401/06;;C07D417/06;;C07D403/06;;A61P35/00;;A61K45/06;;A61K47/55;;C07D209/08;;C07D243/38;;C07D277/30;;C07D401/12;;C07D403/04;;C07D403/10;;C07D403/12;;C07D417/12;;C07D471/04,C07D401/14;;C07D471/04,,0,0,,,,DISCONTINUED
134,US,B2,US 8375007 B2,003-871-250-453-401,2013-02-12,2013,US 201113165121 A,2011-06-21,US 201113165121 A;;US 34151106 A,2006-01-30,Status tool to expose metadata read and write queues,"A method to expose status information is provided. The status information is associated with metadata extracted from multimedia files and stored in a metadata database. The metadata information that is extracted from the multimedia files is stored in a read queue to allow a background thread to process the metadata and populate the metadata database. Additionally, the metadata database may be updated to include user-define metadata, which is written back to the multimedia files. The user-defined metadata is included in a write queue and is written to the multimedia files associated with the user-defined metadata. The status of the read and write queues are exposed to a user through a graphical user interface. The status may include the list of multimedia files included in the read and write queues, the priorities of each multimedia file, and the number of remaining multimedia files.",MICROSOFT CORP;;BRODIE ALEXANDER S;;PERRY BENJAMIN L;;PARLIN DAVID R;;PARK JAE PUM;;GILMORE MICHAEL J;;DART SCOTT E,BRODIE ALEXANDER S;;PERRY BENJAMIN L;;PARLIN DAVID R;;PARK JAE PUM;;GILMORE MICHAEL J;;DART SCOTT E,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14),https://lens.org/003-871-250-453-401,Granted Patent,yes,12,1,6,6,0,G06F16/48;;G06F16/48;;G06F9/50,G06F17/00;;G06F7/00,707/690;;707/805;;707/709,7,0,,,"Office Action in U.S. Appl. No. 11/341,511 mailed Jan. 3, 2011.;;Final Office Action in U.S. Appl. No. 11/341,511 mailed Jun. 7, 2010.;;Office Action in U.S. Appl. 11/341,511 mailed Dec. 4, 2009.;;Final Office Action in U.S. Appl. No. 11/341,511 mailed Aug. 11, 2009.;;Office Action in U.S. Appl. No. 11/341,511 mailed Jan. 12, 2009.;;Office Action in U.S. Appl. No. 11/341,511 mailed Aug. 6, 2008.;;Office Action in U.S. Appl. No. 11/341,511 mailed Jan. 23, 2008.",ACTIVE
135,US,A1,US 2021/0040088 A1,003-874-924-716-903,2021-02-11,2021,US 201916970931 A,2019-02-20,US 201916970931 A;;US 201862744085 P;;US 201862632817 P;;US 2019/0018772 W,2018-02-20,INHIBITORS OF EGFR AND METHODS OF USE THEREOF,"The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,DANA-FARBER CANCER INSTITUTE INC (2018-11-20),https://lens.org/003-874-924-716-903,Patent Application,yes,0,0,10,10,0,C07D243/38;;C07D403/04;;C07D401/14;;C07D403/10;;C07D401/06;;C07D417/06;;C07D471/04;;C07D403/06;;A61P35/00;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/14;;C07D417/14;;C07D471/04,C07D471/04;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/14;;C07D417/14,,0,0,,,,ACTIVE
136,EP,A4,EP 3755697 A4,012-856-730-092-351,2021-10-27,2021,EP 19756893 A,2019-02-20,US 201862632832 P;;US 201862744088 P;;US 2019/0018778 W,2018-02-20,DEGRADERS OF EGFR AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,"DANA-FARBER CANCER INSTITUTE, INC. (2021-06-02)",https://lens.org/012-856-730-092-351,Search Report,no,3,0,7,7,0,C07D401/14;;C07D471/04;;C07D243/38;;C07D403/04;;C07D403/10;;C07D401/06;;C07D417/06;;C07D403/06;;A61P35/00;;A61K45/06;;A61K47/55;;C07D209/08;;C07D243/38;;C07D277/30;;C07D401/12;;C07D403/04;;C07D403/10;;C07D403/12;;C07D417/12;;C07D471/04,C07D401/14;;A61K31/5513;;A61P35/00;;C07D243/38;;C07D401/06;;C07D403/04;;C07D403/06;;C07D403/10;;C07D417/06;;C07D471/04,,2,1,054-971-336-087-666,10.1016/j.bmcl.2007.02.050;;17368025,"MASTALERZ ET AL: ""Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 10, 27 April 2007 (2007-04-27), pages 2828 - 2833, XP022049596, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.02.050;;See also references of WO 2019164953A1",DISCONTINUED
137,US,A1,US 2020/0390783 A1,088-864-850-083-860,2020-12-17,2020,US 201916970881 A,2019-02-20,US 201916970881 A;;US 201862744086 P;;US 201862632819 P;;US 2019/0018773 W,2018-02-20,INHIBITORS OF EGFR AND METHODS OF USE THEREOF,"The application relates to a compound having Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,DANA-FARBER CANCER INSTITUTE INC (2021-01-06),https://lens.org/088-864-850-083-860,Patent Application,yes,0,1,7,7,0,C07D403/04;;C07D243/38;;C07D243/08;;C07D403/10;;A61P35/00;;A61P35/00;;A61K31/5513;;C07D403/10,A61K31/5513;;A61P35/00;;C07D403/10,,0,0,,,,DISCONTINUED
138,EP,A4,EP 3755689 A4,114-271-398-524-97X,2021-10-27,2021,EP 19757550 A,2019-02-20,US 201862632817 P;;US 201862744085 P;;US 2019/0018772 W,2018-02-20,INHIBITORS OF EGFR AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,"DANA-FARBER CANCER INSTITUTE, INC. (2021-06-02)",https://lens.org/114-271-398-524-97X,Search Report,no,0,0,10,10,0,C07D243/38;;C07D403/04;;C07D401/14;;C07D403/10;;C07D401/06;;C07D417/06;;C07D471/04;;C07D403/06;;A61P35/00;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/14;;C07D417/14;;C07D471/04,C07D243/08;;A61K31/5513;;A61P35/00;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/10;;C07D417/06;;C07D471/04,,1,1,054-971-336-087-666,10.1016/j.bmcl.2007.02.050;;17368025,"MASTALERZ ET AL: ""Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 10, 27 April 2007 (2007-04-27), pages 2828 - 2833, XP022049596, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.02.050",ACTIVE
139,US,A1,US 2020/0377477 A1,076-833-549-628-625,2020-12-03,2020,US 201916970874 A,2019-02-20,US 201916970874 A;;US 201862744089 P;;US 201862632830 P;;US 2019/0018753 W,2018-02-20,DEGRADERS OF EGFR AND METHODS OF USE THEREOF,"The application relates to a compound having Formula (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a N pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,DANA-FARBER CANCER INSTITUTE INC (2018-11-07),https://lens.org/076-833-549-628-625,Patent Application,yes,0,0,6,6,0,C07D401/14;;C07D243/38;;C07D243/08;;A61P35/00;;A61K45/06;;C07D243/38;;C07D403/04,C07D403/04;;C07D243/38,,0,0,,,,DISCONTINUED
140,AU,A1,AU 2019/225807 A1,105-899-646-786-651,2020-07-02,2020,AU 2019/225807 A,2019-02-20,US 201862744083 P;;US 201862632806 P;;US 2019/0018774 W,2018-02-20,Pharmaceutical combinations of EGFR inhibitors and methods of use thereof,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I': or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/105-899-646-786-651,Patent Application,no,0,0,7,7,0,A61P35/00;;A61K31/5513;;A61K31/505;;A61K31/50;;A61K31/551,A61K31/551;;A61K31/506;;A61K45/06;;A61P35/00,,0,0,,,,DISCONTINUED
141,CN,B,CN 1758826 B,086-215-661-784-382,2010-05-05,2010,CN 200510106396 A,2005-09-19,US 61151204 P;;US 65361705 P;;US 18892205 A,2004-09-20,Diffuser gravity support and method for depositting a film on a substrate,"An apparatus and method for supporting a substantial center portion of a gas distribution plate is disclosed. At least one support member is capable of engaging and disengaging the diffuser with a mating connection without prohibiting flow of a gas or gasses through the diffuser and is designed to provide vertical suspension to a diffuser that is supported at its perimeter, or capable of supporting the diffuser without a perimeter support. In one aspect, the at least one support member is a portion of a gas delivery conduit and in another embodiment is a plurality of support members separatedfrom the gas delivery conduit. The at least one support member is capable of translating vertical lift, or vertical compression to a center area of the diffuser. A method and apparatus for controllinggas flow from the gas delivery conduit to the gas distribution plate is also disclosed.",APPLIED MATERIALS INC,JIRI KUCERA;;PARK BEOM S;;ERNST KELLER;;MICHAEL STARR;;WHITE JOHN M;;CHOI SOO Y;;TINER ROBIN L,,https://lens.org/086-215-661-784-382,Granted Patent,no,0,0,13,19,0,C23C16/45565;;C23C16/45565;;C23C16/50;;H01J37/3244;;H01J37/32458;;H01J2237/3321,H05H1/42;;C23C16/50,,0,0,,,,ACTIVE
142,WO,A1,WO 2019/164947 A1,169-854-487-726-952,2019-08-29,2019,US 2019/0018772 W,2019-02-20,US 201862632817 P;;US 201862744085 P,2018-02-20,INHIBITORS OF EGFR AND METHODS OF USE THEREOF,"The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/169-854-487-726-952,Patent Application,yes,7,2,10,10,0,C07D243/38;;C07D403/04;;C07D401/14;;C07D403/10;;C07D401/06;;C07D417/06;;C07D471/04;;C07D403/06;;A61P35/00;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/14;;C07D417/14;;C07D471/04,C07D243/08,,28,11,065-431-777-462-371;;054-971-336-087-666;;007-364-858-655-289;;034-240-284-775-613;;054-516-386-763-584;;113-053-951-739-465;;030-422-278-655-49X;;074-767-360-392-430;;004-860-836-273-507;;043-341-927-505-035;;106-577-630-811-132,10.1016/j.ejmech.2015.12.007;;26735909;;10.1016/j.bmcl.2007.02.050;;17368025;;10.1002/jps.2600660104;;833720;;10.1002/ange.19660780803;;10.1007/bf02157171;;10.1021/ed041p116;;20033049;;pmc2879581;;10.1038/nature08622;;17349580;;10.1016/j.ccr.2006.12.017;;pmc1939942;;24019492;;10.1073/pnas.1220050110;;pmc3780914;;22579287;;10.1016/j.cell.2012.02.063;;10.1158/0008-5472.can-13-1145;;pmc3903789;;24063894,"KUMAR, C. P. ET AL.: ""Synthesis and biological evaluation of 5,10-dihydro- 11H-dibenzo[b,e][1,4]diazepin-11-one structural derivatives as anti-cancer and apoptosis inducing agents"", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 108, 2016, pages 674 - 686, XP029383507, doi:10.1016/j.ejmech.2015.12.007;;MASTALERZ ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, no. 10, 27 April 2007 (2007-04-27), pages 2828 - 2833;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;WIDDER ET AL.: ""Methods in Enzymology"", vol. 4, 1985, ACADEMIC PRESS;;T.W. GREENEP.G.M. WUTS: ""Design and Application of Prodrugs, Textbook of Drug Design and Development"", vol. 5, 1991, JOHN WILEY AND SONS, pages: 113 - 191;;BUNDGAARD ET AL., JOURNAL OF DRUG DELIVER REVIEWS, vol. 8, 1992, pages 1 - 38;;BUNDGAARD, J. OF PHARMACEUTICAL SCIENCES, vol. 77, 1988, pages 285;;""Prodrugs as Novel Drug Delivery Systems"", 1975, AMERICAN CHEMICAL SOCIETY;;""Hydrolysis In Drug And Prodrug Metabolism: Chemistry, Biochemistry And Enzymology"", 2002, JOHN WILEY AND SONS, LTD.;;CAHN ET AL., ANGEW. CHEM. INTER. EDIT., vol. 5, 1966, pages 385;;CAHN ET AL., ANGEW. CHEM., vol. 78, 1966, pages 413;;CAHNINGOLD, J. CHEM. SOC., 1951, pages 612;;CAHN ET AL., EXPERIENTIA, vol. 12, 1956, pages 81;;CAHN, J. CHEM. EDUC., vol. 41, 1964, pages 116;;SMITH, M. B.MARCH, J.: ""March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure"", 2001, JOHN WILEY & SONS;;GREENE, T.W.WUTS, P.G. M.: ""Protecting Groups in Organic Chemistry"", 1999, JOHN WILEY & SONS, INC, OR THE MERCK INDEX BY MERCK & CO.;;SAULNIER ET AL., BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 4, 1994, pages 1985;;JACQUES ET AL.: ""Enantiomers, Racemates, and Resolutions"", 1981, JOHN WILEY & SONS;;R. LAROCK: ""Comprehensive Organic Transformations"", 1989, VCH PUBLISHERS;;L. FIESERM. FIESER: ""Fieser and Fieser's Reagents for Organic Synthesis"", 1994, JOHN WILEY AND SONS;;L. PAQUETTE: ""Encyclopedia of Reagents for Organic Synthesis"", 1995, JOHN WILEY AND SONS;;ZHOU ET AL., NATURE, vol. 462, 2009, pages 1070 - 1074;;YUN ET AL., PNAS, vol. 105, 2008, pages 2070 - 2075;;YUN ET AL., CANCER CELL, vol. 11, 2007, pages 217 - 227;;RED BREWER ET AL., PNAS, vol. 110, 2013, pages E3595 - 3604;;SHAN ET AL., CELL, vol. 149, 2012, pages 860 - 870;;CHO ET AL., CANCER RES, vol. 73, 2013, pages 6770 - 6779;;See also references of EP 3755689A4",PENDING
143,US,A1,US 2011/0252069 A1,168-915-905-717-494,2011-10-13,2011,US 201113165121 A,2011-06-21,US 201113165121 A;;US 34151106 A,2006-01-30,STATUS TOOL TO EXPOSE METADATA READ AND WRITE QUEUES,"A method to expose status information is provided. The status information is associated with metadata extracted from multimedia files and stored in a metadata database. The metadata information that is extracted from the multimedia files is stored in a read queue to allow a background thread to process the metadata and populate the metadata database. Additionally, the metadata database may be updated to include user-define metadata, which is written back to the multimedia files. The user-defined metadata is included in a write queue and is written to the multimedia files associated with the user-defined metadata. The status of the read and write queues are exposed to a user through a graphical user interface. The status may include the list of multimedia files included in the read and write queues, the priorities of each multimedia file, and the number of remaining multimedia files.",MICROSOFT CORP,BRODIE ALEXANDER S;;PERRY BENJAMIN L;;PARLIN DAVID R;;PARK JAE PUM;;GILMORE MICHAEL J;;DART SCOTT E,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14),https://lens.org/168-915-905-717-494,Patent Application,yes,0,18,6,6,0,G06F16/48;;G06F16/48;;G06F9/50,G06F17/30,707/799;;X707E17011,0,0,,,,ACTIVE
144,EP,A1,EP 3755698 A1,115-669-389-068-796,2020-12-30,2020,EP 19757199 A,2019-02-20,US 201862632830 P;;US 201862744089 P;;US 2019/0018753 W,2018-02-20,DEGRADERS OF EGFR AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/115-669-389-068-796,Patent Application,yes,0,0,6,6,0,C07D401/14;;C07D243/38;;C07D243/08;;A61P35/00;;A61K45/06;;C07D243/38;;C07D403/04,C07D401/14,,0,0,,,,DISCONTINUED
145,EP,A1,EP 3755338 A1,121-206-734-535-33X,2020-12-30,2020,EP 19757103 A,2019-02-20,US 201862632800 P;;US 201862744082 P;;US 2019/0018765 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,"DANA-FARBER CANCER INSTITUTE, INC. (2021-06-02)",https://lens.org/121-206-734-535-33X,Patent Application,yes,0,0,7,7,0,A61P35/00;;A61K31/506;;A61K31/551;;A61P35/00;;A61K31/5513,A61K31/551;;A61K31/506;;A61P35/00,,0,0,,,,DISCONTINUED
146,WO,A1,WO 2019/164941 A1,145-064-445-108-171,2019-08-29,2019,US 2019/0018765 W,2019-02-20,US 201862632800 P;;US 201862744082 P,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I': (I'), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/145-064-445-108-171,Patent Application,yes,3,1,7,7,0,A61P35/00;;A61K31/506;;A61K31/551;;A61P35/00;;A61K31/5513,A61K31/551;;A61K31/506;;A61P35/00,,3,2,160-756-639-723-579;;105-183-771-681-53X,10.3978/j.issn.2218-6751.2015.07.19;;pmc4758967;;26958499;;23930994;;10.1021/jm400822z,"STINCHCOMBE, T. E.: ""AZD9291 in epidermal growth factor receptor inhibitor- resistant non-small- cell lung cancer"", TRANSLATIONAL LUNG CANCER RESEARCH, vol. 5, no. 1, 1 February 2016 (2016-02-01), pages 92 - 94, XP055632805;;WARD, R. A. ET AL.: ""Structure-and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, 2013, pages 7025 - 7048, XP002734712, doi:10.1021/jm400822z;;See also references of EP 3755338A4",PENDING
147,CA,A1,CA 3088972 A1,171-627-633-578-954,2019-08-29,2019,CA 3088972 A,2019-02-20,US 201862632798 P;;US 2019/0018770 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula I: (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I': (I'), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA-FARBER CANCER INSTITUTE INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/171-627-633-578-954,Patent Application,no,0,0,7,7,0,A61P35/00;;A61K31/506;;A61K31/496;;A61K45/06;;A61K31/427;;A61K31/496;;A61K31/497,A61K31/496;;A61K31/506;;A61P35/00,,0,0,,,,PENDING
148,US,B2,US 11584746 B2,031-304-313-752-156,2023-02-21,2023,US 201916970931 A,2019-02-20,US 201916970931 A;;US 201862744085 P;;US 201862632817 P;;US 2019/0018772 W,2018-02-20,Inhibitors of EGFR and methods of use thereof,"The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,DANA-FARBER CANCER INSTITUTE INC (2018-11-20),https://lens.org/031-304-313-752-156,Granted Patent,yes,10,0,10,10,0,C07D243/38;;C07D403/04;;C07D401/14;;C07D403/10;;C07D401/06;;C07D417/06;;C07D471/04;;C07D403/06;;A61P35/00;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/14;;C07D417/14;;C07D471/04,C07D471/04;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/14;;C07D417/14,,7,2,054-971-336-087-666;;065-431-777-462-371,10.1016/j.bmcl.2007.02.050;;17368025;;10.1016/j.ejmech.2015.12.007;;26735909,"Mastalerz et al., Novel C-5 Aminomethyl Pyrrolotriazine Dual Inhibitors of EGFR and HER2 Protein Tyrosine Kinases, Bioorganic & Medicinal Chemistry Letters, Elsevier, Amsterdam, NL, vol. 17,No. 10, Apr. 27, 2007, pp. 2828-2833.;;Kumar C.P., et al., Synthesis and Biological Evaluation of 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one Structural Derivatives As Anti-Cancer and Apoptosis Inducing Agents, European Journal of Medicinal Chemistry, vol. 108, 2016, pp. 674-686.;;PCT Application No. PCT/US19/18772, International Preliminary Report on Patentability, dated Aug. 27, 2020, 9 pages.;;U.S. Appl. No. 16/970,860, filed Aug. 18, 2020, Nathanael Gray, 2021/0085688, Mar. 25, 2021.;;U.S. Appl. No. 16/970,870, filed Aug. 18, 2020, Nathanael Gray, 2020/0385999, Dec. 3, 2020.;;U.S. Appl. No. 16/970,881, filed Aug. 18, 2020, Nathanael Gray, 2020/0390783, Dec. 17, 2020.;;U.S. Appl. No. 16/970,931, filed Aug. 18, 2020, Nathanael Gray, 2021/0040088, Feb. 11, 2021.",ACTIVE
149,EP,A1,EP 3755690 A1,050-787-563-389-79X,2020-12-30,2020,EP 19758285 A,2019-02-20,US 201862632819 P;;US 201862744086 P;;US 2019/0018773 W,2018-02-20,INHIBITORS OF EGFR AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,"DANA-FARBER CANCER INSTITUTE, INC. (2021-06-02)",https://lens.org/050-787-563-389-79X,Patent Application,yes,0,0,7,7,0,C07D403/04;;C07D243/38;;C07D243/08;;C07D403/10;;A61P35/00;;A61P35/00;;A61K31/5513;;C07D403/10,C07D243/38;;C07D403/04,,0,0,,,,DISCONTINUED
150,CA,A1,CA 3087716 A1,062-171-387-271-775,2019-08-29,2019,CA 3087716 A,2019-02-20,US 201862632817 P;;US 201862744085 P;;US 2019/0018772 W,2018-02-20,INHIBITORS OF EGFR AND METHODS OF USE THEREOF,"The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA-FARBER CANCER INSTITUTE INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/062-171-387-271-775,Patent Application,no,0,0,10,10,0,C07D243/38;;C07D403/04;;C07D401/14;;C07D403/10;;C07D401/06;;C07D417/06;;C07D471/04;;C07D403/06;;A61P35/00;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/14;;C07D417/14;;C07D471/04,C07D243/08,,0,0,,,,PENDING
151,EP,A4,EP 3755698 A4,077-930-076-713-766,2021-10-27,2021,EP 19757199 A,2019-02-20,US 201862632830 P;;US 201862744089 P;;US 2019/0018753 W,2018-02-20,DEGRADERS OF EGFR AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/077-930-076-713-766,Search Report,no,3,0,6,6,0,C07D401/14;;C07D243/38;;C07D243/08;;A61P35/00;;A61K45/06;;C07D243/38;;C07D403/04,C07D401/14;;A61K31/5513;;A61K45/06;;A61P35/00;;C07D243/08;;C07D243/38,,2,1,054-971-336-087-666,10.1016/j.bmcl.2007.02.050;;17368025,"MASTALERZ ET AL: ""Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 10, 27 April 2007 (2007-04-27), pages 2828 - 2833, XP022049596, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.02.050;;See also references of WO 2019164932A1",DISCONTINUED
152,WO,A1,WO 2019/164945 A1,083-095-041-499-879,2019-08-29,2019,US 2019/0018770 W,2019-02-20,US 201862632798 P,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula I: (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I': (I'), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC;;GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/083-095-041-499-879,Patent Application,yes,4,2,7,7,0,A61P35/00;;A61K31/506;;A61K31/496;;A61K45/06;;A61K31/427;;A61K31/496;;A61K31/497,A61K31/496;;A61K31/506;;A61P35/00,,2,1,143-841-630-576-146,10.1016/j.ejmech.2017.05.027;;28526474,"PATEL, H. ET AL.: ""Recent updates on third generation EGFR inhibitors and emergence off ourth generation EGFR inhibitors to combat C797S resistance"", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 142, 15 December 2017 (2017-12-15), pages 32 - 47, XP085264354;;See also references of EP 3755330A4",PENDING
153,EP,A4,EP 3755338 A4,144-848-708-220-00X,2021-11-03,2021,EP 19757103 A,2019-02-20,US 201862632800 P;;US 201862744082 P;;US 2019/0018765 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,"DANA-FARBER CANCER INSTITUTE, INC. (2021-06-02)",https://lens.org/144-848-708-220-00X,Search Report,no,4,0,7,7,0,A61P35/00;;A61K31/506;;A61K31/551;;A61P35/00;;A61K31/5513,A61K31/551;;A61K31/506;;A61P35/00,,2,1,027-856-538-302-851,pmc6862338;;31749909;;10.1021/acsmedchemlett.9b00381,"DE CLERCQ DRIES J. H. ET AL: ""Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors"", ACS MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 11, 14 November 2019 (2019-11-14), US, pages 1549 - 1553, XP055840334, ISSN: 1948-5875, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.9b00381> DOI: 10.1021/acsmedchemlett.9b00381;;See also references of WO 2019164941A1",DISCONTINUED
154,AU,A1,AU 2019/225743 A1,144-860-818-396-729,2020-07-02,2020,AU 2019/225743 A,2019-02-20,US 201862632830 P;;US 201862744089 P;;US 2019/0018753 W,2018-02-20,Degraders of EGFR and methods of use thereof,"The application relates to a compound having Formula (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/144-860-818-396-729,Patent Application,no,0,0,6,6,0,C07D401/14;;C07D243/38;;C07D243/08;;A61P35/00;;A61K45/06;;C07D243/38;;C07D403/04,C07D401/14,,0,0,,,,DISCONTINUED
155,AU,A1,AU 2019/225799 A1,196-549-960-629-946,2020-07-09,2020,AU 2019/225799 A,2019-02-20,US 201862632800 P;;US 201862744082 P;;US 2019/0018765 W,2018-02-20,Pharmaceutical combinations of EGFR inhibitors and methods of use thereof,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I': (I'), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/196-549-960-629-946,Patent Application,no,0,0,7,7,0,A61P35/00;;A61K31/506;;A61K31/551;;A61P35/00;;A61K31/5513,A61K31/551;;A61K31/506;;A61P35/00,,0,0,,,,DISCONTINUED
156,WO,A1,WO 2019/164949 A1,002-383-884-575-938,2019-08-29,2019,US 2019/0018774 W,2019-02-20,US 201862632806 P;;US 201862744083 P,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I': or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/002-383-884-575-938,Patent Application,yes,3,4,7,7,0,A61P35/00;;A61K31/5513;;A61K31/505;;A61K31/50;;A61K31/551,A61K31/551;;A61K31/506;;A61K45/06;;A61P35/00,,3,2,160-756-639-723-579;;105-183-771-681-53X,10.3978/j.issn.2218-6751.2015.07.19;;pmc4758967;;26958499;;23930994;;10.1021/jm400822z,"STINCHCOMBE, T. E.: ""AZD9291 in epidermal growth factor receptor inhibitor- resistant non-small- cell lung cancer"", TRANSLATIONAL LUNG CANCER RESEARCH, vol. 5, no. 1, February 2016 (2016-02-01), pages 92 - 94, XP055632805;;WARD, R. A. ET AL.: ""Structure-and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, 2013, pages 7025 - 7048, XP002734712, doi:10.1021/jm400822z;;See also references of EP 3755337A4",PENDING
157,WO,A1,WO 2019/164953 A1,010-890-166-964-185,2019-08-29,2019,US 2019/0018778 W,2019-02-20,US 201862632832 P;;US 201862744088 P,2018-02-20,DEGRADERS OF EGFR AND METHODS OF USE THEREOF,"The application relates to a compound having Formula X: (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase ( e.g. , cereblon), wherein the Targeting Ligand is of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/010-890-166-964-185,Patent Application,yes,5,3,7,7,0,C07D401/14;;C07D471/04;;C07D243/38;;C07D403/04;;C07D403/10;;C07D401/06;;C07D417/06;;C07D403/06;;A61P35/00;;A61K45/06;;A61K47/55;;C07D209/08;;C07D243/38;;C07D277/30;;C07D401/12;;C07D403/04;;C07D403/10;;C07D403/12;;C07D417/12;;C07D471/04,C07D401/14;;C07D471/04,,1,0,,,See also references of EP 3755697A4,PENDING
158,CA,A1,CA 3088561 A1,047-778-467-129-960,2019-08-29,2019,CA 3088561 A,2019-02-20,US 201862632830 P;;US 201862744089 P;;US 2019/0018753 W,2018-02-20,DEGRADERS OF EGFR AND METHODS OF USE THEREOF,"The application relates to a compound having Formula (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA-FARBER CANCER INSTITUTE INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/047-778-467-129-960,Patent Application,no,0,0,6,6,0,C07D401/14;;C07D243/38;;C07D243/08;;A61P35/00;;A61K45/06;;C07D243/38;;C07D403/04,C07D401/14,,0,0,,,,PENDING
159,AU,A1,AU 2019/225811 A1,085-693-866-399-090,2020-07-09,2020,AU 2019/225811 A,2019-02-20,US 201862744088 P;;US 201862632832 P;;US 2019/0018778 W,2018-02-20,Degraders of EGFR and methods of use thereof,"The application relates to a compound having Formula X: (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/085-693-866-399-090,Patent Application,no,0,0,7,7,0,C07D401/14;;C07D471/04;;C07D243/38;;C07D403/04;;C07D403/10;;C07D401/06;;C07D417/06;;C07D403/06;;A61P35/00;;A61K45/06;;A61K47/55;;C07D209/08;;C07D243/38;;C07D277/30;;C07D401/12;;C07D403/04;;C07D403/10;;C07D403/12;;C07D417/12;;C07D471/04,C07D401/14;;C07D471/04,,0,0,,,,DISCONTINUED
160,US,A1,US 2020/0377501 A1,170-890-388-074-868,2020-12-03,2020,US 201916970866 A,2019-02-20,US 201916970866 A;;US 201862632832 P;;US 201862744088 P;;US 2019/0018778 W,2018-02-20,DEGRADERS OF EGFR AND METHODS OF USE THEREOF,"The application relates to a compound having Formula X: (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,DANA-FARBER CANCER INSTITUTE INC (2018-11-07),https://lens.org/170-890-388-074-868,Patent Application,yes,0,1,7,7,0,C07D401/14;;C07D471/04;;C07D243/38;;C07D403/04;;C07D403/10;;C07D401/06;;C07D417/06;;C07D403/06;;A61P35/00;;A61K45/06;;A61K47/55;;C07D209/08;;C07D243/38;;C07D277/30;;C07D401/12;;C07D403/04;;C07D403/10;;C07D403/12;;C07D417/12;;C07D471/04,C07D471/04;;C07D209/08;;C07D243/38;;C07D277/30;;C07D401/12;;C07D403/04;;C07D403/10;;C07D403/12;;C07D417/12,,0,0,,,,DISCONTINUED
161,US,A1,US 2020/0375999 A1,178-713-555-710-424,2020-12-03,2020,US 201916970870 A,2019-02-20,US 201916970870 A;;US 201862744082 P;;US 201862632800 P;;US 2019/0018765 W,2018-02-20,PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF,"The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I′: (I′), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,DANA-FARBER CANCER INSTITUTE INC (2021-01-25),https://lens.org/178-713-555-710-424,Patent Application,yes,0,0,7,7,0,A61P35/00;;A61K31/506;;A61K31/551;;A61P35/00;;A61K31/5513,A61K31/5513;;A61P35/00,,0,0,,,,DISCONTINUED
162,US,B2,US 9292347 B2,004-191-222-157-91X,2016-03-22,2016,US 201313745325 A,2013-01-18,US 201313745325 A;;US 201113165121 A;;US 34151106 A,2006-01-30,Status tool to expose metadata read and write queues,"A method to expose status information is provided. The status information is associated with metadata extracted from multimedia files and stored in a metadata database. The metadata information that is extracted from the multimedia files is stored in a read queue to allow a background thread to process the metadata and populate the metadata database. Additionally, the metadata database may be updated to include user-define metadata, which is written back to the multimedia files. The user-defined metadata is included in a write queue and is written to the multimedia files associated with the user-defined metadata. The status of the read and write queues are exposed to a user through a graphical user interface. The status may include the list of multimedia files included in the read and write queues, the priorities of each multimedia file, and the number of remaining multimedia files.",MICROSOFT TECHNOLOGY LICENSING LLC,BRODIE ALEXANDER S;;PERRY BENJAMIN L;;PARLIN DAVID R;;PARK JAE PUM;;GILMORE MICHAEL J;;DART SCOTT E,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2013-04-12),https://lens.org/004-191-222-157-91X,Granted Patent,yes,18,0,6,6,0,G06F16/48;;G06F16/48;;G06F9/50,G06F17/30;;G06F9/50,,2,0,,,"Serves, Risto, et al., ""Metadata Creation System for Mobile Images"", MobiSys '04, Boston, MA, Jun. 6-9, 2004, pp. 36-48.;;Wactlar, Howard D., et al., ""Digital Video Archives: Managing Through Metadata"", Building a National Strategy for Digital Preservation: Issues in Digital Media Archiving, National Digital Information Infrastructure and Preservation Program, Library of Congress, Apr. 2002, pp. 1-14.",ACTIVE
163,EP,A4,EP 3755690 A4,155-682-610-409-260,2021-10-27,2021,EP 19758285 A,2019-02-20,US 201862632819 P;;US 201862744086 P;;US 2019/0018773 W,2018-02-20,INHIBITORS OF EGFR AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,"DANA-FARBER CANCER INSTITUTE, INC. (2021-06-02)",https://lens.org/155-682-610-409-260,Search Report,no,3,0,7,7,0,C07D403/04;;C07D243/38;;C07D243/08;;C07D403/10;;A61P35/00;;A61P35/00;;A61K31/5513;;C07D403/10,C07D243/38;;A61K31/5513;;A61P35/00;;C07D243/08;;C07D403/04;;C07D403/10,,2,1,054-971-336-087-666,10.1016/j.bmcl.2007.02.050;;17368025,"MASTALERZ ET AL: ""Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases"", 27 April 2007, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, PAGE(S) 2828 - 2833, ISSN: 0960-894X, XP022049596;;See also references of WO 2019164948A1",DISCONTINUED
164,EP,A1,EP 3755689 A1,169-561-963-744-731,2020-12-30,2020,EP 19757550 A,2019-02-20,US 201862632817 P;;US 201862744085 P;;US 2019/0018772 W,2018-02-20,INHIBITORS OF EGFR AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,"DANA-FARBER CANCER INSTITUTE, INC. (2021-06-02)",https://lens.org/169-561-963-744-731,Patent Application,yes,0,0,10,10,0,C07D243/38;;C07D403/04;;C07D401/14;;C07D403/10;;C07D401/06;;C07D417/06;;C07D471/04;;C07D403/06;;A61P35/00;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/14;;C07D417/14;;C07D471/04,C07D243/08,,0,0,,,,ACTIVE
165,AU,A1,AU 2019/225805 A1,111-717-240-211-281,2020-07-16,2020,AU 2019/225805 A,2019-02-20,US 201862744085 P;;US 201862632817 P;;US 2019/0018772 W,2018-02-20,Inhibitors of EGFR and methods of use thereof,"The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.",DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,,https://lens.org/111-717-240-211-281,Patent Application,no,0,0,10,10,0,C07D243/38;;C07D403/04;;C07D401/14;;C07D403/10;;C07D401/06;;C07D417/06;;C07D471/04;;C07D403/06;;A61P35/00;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/14;;C07D417/14;;C07D471/04,C07D243/08,,0,0,,,,DISCONTINUED
166,EP,B1,EP 3755689 B1,125-783-628-590-496,2023-12-06,2023,EP 19757550 A,2019-02-20,US 201862632817 P;;US 201862744085 P;;US 2019/0018772 W,2018-02-20,INHIBITORS OF EGFR AND METHODS OF USE THEREOF,,DANA FARBER CANCER INST INC,GRAY NATHANAEL S;;DE CLERCQ DRIES;;JANG JAEBONG;;JANNE PASI;;TO CIRIC;;ECK MICHAEL;;PARK EUNYOUNG;;HEPPNER DAVID,"DANA-FARBER CANCER INSTITUTE, INC. (2021-06-02)",https://lens.org/125-783-628-590-496,Granted Patent,yes,4,0,10,10,0,C07D243/38;;C07D403/04;;C07D401/14;;C07D403/10;;C07D401/06;;C07D417/06;;C07D471/04;;C07D403/06;;A61P35/00;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/14;;C07D417/14;;C07D471/04,C07D243/08;;A61K31/5513;;A61P35/00;;C07D243/38;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/10;;C07D417/06;;C07D471/04,,2,0,,,"MASTALERZ ET AL: ""Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 10, 27 April 2007 (2007-04-27), pages 2828-2833, XP022049596, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.02.050;;KUMAR, C. P. et al.: ""Synthesis and biological evaluation of 5,10-dihydro- 11H-dibenzo[b,e][1,4]diazepin-11-one structural derivatives as anti-cancer and apoptosis inducing agents"", European Journal of Medicinal Chemistry, vol. 108, 2016, pages 674-686, XP029383507, DOI: doi:10.1016/j.ejmech.2015.12.007",ACTIVE
167,US,B2,US 7987160 B2,149-491-226-109-491,2011-07-26,2011,US 34151106 A,2006-01-30,US 34151106 A,2006-01-30,Status tool to expose metadata read and write queues,"A method to expose status information is provided. The status information is associated with metadata extracted from multimedia files and stored in a metadata database. The metadata information that is extracted from the multimedia files is stored in a read queue to allow a background thread to process the metadata and populate the metadata database. Additionally, the metadata database may be updated to include user-define metadata, which is written back to the multimedia files. The user-defined metadata is included in a write queue and is written to the multimedia files associated with the user-defined metadata. The status of the read and write queues are exposed to a user through a graphical user interface. The status may include the list of multimedia files included in the read and write queues, the priorities of each multimedia file, and the number of remaining multimedia files.",MICROSOFT CORP,BRODIE ALEXANDER S;;PERRY BENJAMIN L;;PARLIN DAVID R;;PARK JAE PUM;;GILMORE MICHAEL J;;DART SCOTT E,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2006-05-03),https://lens.org/149-491-226-109-491,Granted Patent,yes,13,7,6,6,0,G06F16/48;;G06F16/48;;G06F9/50,G06F17/00;;G06F7/00,707/690;;707/805;;707/799,0,0,,,,INACTIVE
168,US,A1,US 2012/0113044 A1,175-003-725-881-109,2012-05-10,2012,US 94380010 A,2010-11-10,US 94380010 A,2010-11-10,Multi-Sensor Device,"A multi-sensor device includes an optical sensor portion and a capacitive sensor portion where the capacitive sensor portion borders the optical sensor portion. Various other devices, systems, methods, etc., are also disclosed.",STRAZISAR BRADLEY PARK;;MORRIS JULIE ANNE;;RUTLEDGE JAMES S;;STEWART AARON MICHAEL;;GANEY HARRISS CHRISTOPHER NEIL;;JOHNSON JAY WESLEY,STRAZISAR BRADLEY PARK;;MORRIS JULIE ANNE;;RUTLEDGE JAMES S;;STEWART AARON MICHAEL;;GANEY HARRISS CHRISTOPHER NEIL;;JOHNSON JAY WESLEY,LENOVO (SINGAPORE) PTE. LTD (2010-10-07),https://lens.org/175-003-725-881-109,Patent Application,yes,6,107,1,1,0,G06F1/169;;G06F3/0312;;G06F3/042;;G06F3/04883;;G06F3/0448;;G06F1/169;;G06F3/04883;;G06F3/042;;G06F3/0312;;G06F3/0448,G01R27/26;;G06F3/045;;G06F3/048;;H01J40/14,345/174;;250/221;;324/658;;715/764;;178/18.06,0,0,,,,DISCONTINUED
169,US,A1,US 2011/0192016 A1,076-972-097-171-096,2011-08-11,2011,US 92504710 A,2010-10-13,US 92504710 A;;US 27886609 P,2009-10-13,Energy conversion materials fabricated with boron nitride nanotubes (BNNTs) and BNNT polymer composites,"Electroactive actuation characteristics of novel BNNT based materials are described. Several series of BNNT based electroactive materials including BNNT/polyimide composites and BNNT films are prepared. The BNNT based electroactive materials show high piezoelectric coefficients, d 13 , about 14.80 pm/V as well as high electrostrictive coefficients, M 13 , 3.21×10 −16 pm 2 N 2 . The BNNT based electroactive materials will be used for novel electromechanical energy conversion devices.",NAT INST AEROSPACE ASSOCIATES;;USA AS REPRESENTED BY THE ADMINISTRATOR OF THE NAT AERONAUTICS AND SPACE ADMINISTRATION;;JEFFERSON SCIENCE ASS LLC,KANG JIN HO;;PARK CHEOL;;HARRISON JOYCELYN S;;SMITH MICHAEL W;;LOWTHER SHARON E;;KIM JAE-WOO;;SAUTI GODFREY,NATIONAL INSTITUTE OF AEROSPACE ASSOCIATES (2010-12-08);;UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (2011-04-07),https://lens.org/076-972-097-171-096,Patent Application,yes,10,27,11,11,0,B82Y30/00;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;H10N30/092;;B82Y30/00;;B82Y40/00;;C08J5/18;;C08K3/38;;G01R29/14;;Y10S977/778;;C08K2003/382;;H10N30/063;;H10N30/092;;B82Y40/00;;G01R29/14;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;B82Y30/00;;H10N30/063;;H10N30/00;;H10N30/092;;H10N30/1051;;H10N30/1061,H05K13/00;;B82Y30/00;;B82Y99/00;;H01L41/24;;H01L41/45,29/592.1;;X252 629 R;;977/837;;977/742,2,0,,,"Machine Language Translation (English) of Japanese Patent Publication, JP 2007-137720, July 2013.;;Machine Language Translation (English) of JP 2004-195718, March 2014.",ACTIVE
170,US,A1,US 2009/0074637 A1,159-135-066-581-27X,2009-03-19,2009,US 16435608 A,2008-06-30,US 16435608 A;;US 93383607 A;;US 85641506 P,2006-11-03,Optimized Modular Microfluidic Devices,"Passively aligned modular microfluidic devices, and a method for fabricating such passively aligned polymeric modular microfluidic devices have been reported. The modular units fabricated are plurality of integrated microdevices. Also reported are microfluidic devices wherein isolated temperature zones exist so that the temperature within each zone may be distinctly and accurately controlled, and a method for fabricating such microfluidic devices wherein there are isolated temperature zones so that the temperature within each zone may be distinctly and accurately controlled. Such devices allow one to define constant temperature zones along a microfluidic channel where different reactions or stages of reactions occur.",MURPHY MICHAEL C;;NIKITOPOULOS DIMITRIS E;;SOPER STEVEN A;;CHEN PIN-CHUAN;;PARK DANIEL S-W;;HUPERT MATEUSZ L,MURPHY MICHAEL C;;NIKITOPOULOS DIMITRIS E;;SOPER STEVEN A;;CHEN PIN-CHUAN;;PARK DANIEL S-W;;HUPERT MATEUSZ L,BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (2008-08-13),https://lens.org/159-135-066-581-27X,Patent Application,yes,11,1,1,1,0,B01L3/502707;;B01L3/502715;;B01L3/50851;;B01L7/525;;B01L7/54;;B01L2200/025;;B01L2200/028;;B01L2300/0829;;B01L2300/0887;;B01L3/502707;;B01L7/525;;B01L2200/028;;B01L2300/0829;;B01L7/54;;B01L3/50851;;B01L2300/0887;;B01L2200/025;;B01L3/502715,B01J19/00,422/206;;422/240,0,0,,,,DISCONTINUED
171,US,B2,US 10435293 B2,062-822-066-948-411,2019-10-08,2019,US 92504710 A,2010-10-13,US 92504710 A;;US 27886609 P,2009-10-13,Methods of manufacturing energy conversion materials fabricated with boron nitride nanotubes (BNNTs) and BNNT polymer composites,Formation of a boron nitride nanotube nanocomposite film by combining a boron nitride nanotube solution with a matrix such as a polymer or a ceramic to form a boron nitride nanotube/polyimide mixture and synthesizing a boron nitride nanotube/polyimide nanocomposite film as an electroactive layer.,KANG JIN HO;;PARK CHEOL;;HARRISON JOYCELYN S;;SMITH MICHAEL W;;LOWTHER SHARON E;;KIM JAE WOO;;SAUTI GODFREY;;NAT INSTITUTE OF AEROSPACE ASSOCIATES;;NASA,KANG JIN HO;;PARK CHEOL;;HARRISON JOYCELYN S;;SMITH MICHAEL W;;LOWTHER SHARON E;;KIM JAE-WOO;;SAUTI GODFREY,NATIONAL INSTITUTE OF AEROSPACE ASSOCIATES (2010-12-08);;UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (2011-04-07),https://lens.org/062-822-066-948-411,Granted Patent,yes,53,0,11,11,0,B82Y30/00;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;H10N30/092;;B82Y30/00;;B82Y40/00;;C08J5/18;;C08K3/38;;G01R29/14;;Y10S977/778;;C08K2003/382;;H10N30/063;;H10N30/092;;B82Y40/00;;G01R29/14;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;B82Y30/00;;H10N30/063;;H10N30/00;;H10N30/092;;H10N30/1051;;H10N30/1061,B82Y40/00;;B82Y30/00;;G01R29/14;;H01L41/00;;H01L41/08;;H01L41/293;;H01L41/37;;H01L41/45,,34,10,148-375-249-302-37X;;028-545-706-154-180;;106-755-242-905-62X;;158-993-678-159-285;;051-416-263-682-445;;116-290-035-251-390;;101-715-276-944-40X;;133-164-089-733-845;;002-090-129-616-75X;;027-855-040-906-653,10.1109/58.883518;;18238675;;10.1063/1.116874;;10.1002/adma.200700179;;10.1002/app.12096;;10.1002/polb.21601;;10.1103/physrevb.64.121405;;10.1002/adma.200702566;;10.1103/physrevb.68.241405;;10.1016/j.compscitech.2007.10.024;;10.1063/1.363981,"Machine Language Translation (English) of Japanese Patent Publication, JP 2007-137720, Jul. 2013.;;Machine Language Translation (English) of JP 2004-195718, Mar. 2014.;;Office Action in Canadian Patent Application No. 2,777,666, dated Oct. 24, 2016.;;Office Action in Canadian Patent Application No. 2,777,666, dated Sep. 25, 2017.;;Office Action in Canadian Patent Application No. 2,777,666, dated Sep. 14, 2018.;;Office Action in European Patent Application No. 10823735.5, dated Sep. 22, 2017.;;Office Action in European Patent Application No. 10823735.5, dated Sep. 21, 2018.;;Office Action in U.S. Appl. No. 13/694,325, dated Jun. 16, 2015.;;Office Action in U.S. Appl. No. 13/694,325, dated Mar. 29, 2016.;;Office Action in U.S. Appl. No. 13/694,325, dated Jan. 18, 2017.;;Office Action in U.S. Appl. No. 13/694,325, dated Aug. 17, 2017.;;Office Action in U.S. Appl. No. 13/694,325, dated Mar. 19, 2018.;;Office Action in U.S. Appl. No. 13/694,325, dated Oct. 25, 2018.;;Office Action in Japanese Application No. 2012-534160, dated Jan. 20, 2015.;;Office Action in Japanese Application No. 2012-534160, dated Feb. 20, 2015.;;Office Action in Korean Application No. 10-2012-7011165, dated Oct. 31, 2016.;;Office Action in Korean Application No. 10-2012-7011165, dated May 30, 2017.;;Cheng, Z.Y. et al; “Effect of High Energy Electron Irradiation on the Electromechanical Properties of Poly(vinylidene Fluoride-Trifluorethylene) 50/50 and 65/35 Copolymers,” IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 47, No. 6.;;Golberg, D. et al.; Nanotubes in Boron Nitride Laser Heated at High Pressure; Appl. Phy. Lett.; 69 (14), 2045-2047; 1996.;;Golberg, D. et al.; “Boron Nitride Nanotubes,” Advanced Materials, vol. 19, pp. 2413-2432, 2007 (20 pages).;;Griebel et al. Molecular dynamics simulations of boron-nitride nanotubes embedded in amorphous Si—B—N. INS Preprint No. 0501, 2005.;;Guillot, F.M. et al., “Electrostrictive Effect in Polyurethanes,” Journal of Applied Polymer Science, vol. 9, pp. 399-404 (2003) (6 pages).;;Harrison et al. “Polyethylene/Boron Composites for Radiation Shielding Applications,” Space Technology and Applications International Forum, American Institute of Physics (2008) (9 pages).;;Huang, C. et al., “Poly(vinylide fluoride-trifluoroethylene) Based High Performance Electroactive Polymers,” IEEE Transactions on Dielectrics and Electrical Insulation, vol. 11, No. 2; Apr. 2004 (13 pages).;;Kang, Jin Ho et al., “All-Organic Actuator Fabricated with Single Wall Carbon Nanotube Electrodes,” Journal of Polymer Science, Part B: Polymer Physics, vol. 46, pp. 2532-2538 (2008) (7 pages).;;Katsuda, Y. Reinforcement of precursor-derived Si—(B—)C—N ceramics with carbon nanotubes. Dissertation, Stuttgart, 2005.;;Lee et al.; Catalyst-Free Synthesis of Boron Nitride Single-Wall Nanotubes with a Preferred Zig-Zag Configuration; Physical Review B, vol. 64, 121405; 2001.;;Michalski, P.J. et al., “Continuum Theory for Piezoelectricity in Nanotubes and Nanowires,” Phys. Rev. Lett. 95, 116803, Jan. 11, 2005 (4 pages).;;Nakhmanson, S.M. et al., “Spontaneous polarization and piezoelectricity in boron nitride nanotubes,” The American Physical Society, Physical Review, vol. B 67, 235406 (2003) (5 pages).;;Park, C. et al., “Actuating Single Wall Carbon Nanotube-Polymer Composites: Intrinsic Unimorphs,” Advanced Materials, vol. 20, pp. 2074-2079 (2008) (6 pages).;;Sai, N. et al. “Microscopic theory for nanotube piezoelectricity,” Physical Review B 68, 241405(R) (2003) (3 pages).;;Salehi-Khojin et al: “Buckling of boron nitride nanotube reinforced piezoelectric polymeric composites subject to combined electro-thermo-mechanical loadings”, Composites Science and Technology, Elsevier, UK, vol. 68, No. 6, pp. 1489-1501, Oct. 30, 2007 (14 pages).;;Simpson, J.O. et al., “Novel Piezoelectric Polyimides,” Materials Research Society Symposium Proceedings, vol. 413 (1996) (6 pages).;;Zhang, Q.M. et al., “An experimental investigation of electromechanical responses in a polyurethane elastomer,” Journal of Applied Physics, vol. 81, 2770 (1997) (8 pages).",ACTIVE
172,KR,A,KR 20000028775 A,087-725-018-648-548,2000-05-25,2000,KR 19990042260 A,1999-10-01,US 10277398 P,1998-10-02,"CAPACITOR INK, DIELECTRIC GREEN TAPE, MULTI-LAYERED GREEN TAPE LAMINATE, RECLAIMING TYPE CAPACITOR AND PRODUCING METHOD THEREOF","PURPOSE: A multi-layered ceramic circuit board including a capacitor for embedding and a producing method are provided to have a high dielectric rate. CONSTITUTION: Electrodes(36,38,40,32) are screen-printed on green tape layers(30,32,34) of a high dielectric rate, and a via is formed on an electrode layer. Herein, the crossed electrodes are connected by a conductive via charge ink like the via(26,24), and a multi-layered capacitor deposit layer is prepared with the increased capacity of power stoppage. Thereby, the capacitor having the high dielectric rate is reduced even if the capacitor corresponding to a large dimension is not made up, and each capacitor is produced in a small size. When the capacitors are deposited together and connected each other in parallel, the high dielectric rate is obtained. In addition, the multi-layered capacitor deposit layer is combined or embedded within a common green tape supported by a metal supporting stand.",DAEWOO ELECTRONICS CO LTD;;SARNOFF CORP,RIBERATO MICHAEL JAMES;;SRIRAM ATTIGANALSARA YANASWAMI;;PRABU ASHOCNARAYAN;;KIM IN TAE;;MUN JE DO;;PARK YUN WHUI;;PARK SEONG DAE;;YU JU DONG;;TOMMY ELLEN S,,https://lens.org/087-725-018-648-548,Patent Application,no,0,1,20,20,0,C04B35/265;;C04B35/497;;H01F1/0027;;H01F17/0006;;H01F41/042;;H01F41/043;;H01F41/046;;H01G4/1254;;H01G4/30;;H05K1/0306;;H05K1/165;;H01G4/12;;H01F41/046;;H01F41/042;;H01F1/0027;;C04B35/265;;H01G4/30;;H01F41/043;;H01F17/0006;;H05K1/165;;C04B35/497;;H01G4/1254;;H05K1/0306,C04B35/26;;H01F5/00;;C04B35/497;;C08K3/22;;C08L101/00;;H01F1/00;;H01F17/00;;H01F41/04;;H01G4/12;;H01G4/30;;H05K1/03;;H05K1/16;;H05K3/46,,0,0,,,,EXPIRED
173,CA,A1,CA 2345764 A1,130-762-608-119-734,2000-04-13,2000,CA 2345764 A,1999-10-01,US 10277398 P;;US 9922890 W,1998-10-02,CAPACITANCE-COUPLED HIGH DIELECTRIC CONSTANT EMBEDDED CAPACITORS,"High dielectric constant capacitors are made from a dielectric ink (30, 32, 34) of lead-magnesium-niobate and lead oxide powders with a suitable organic vehicle which can be used to coat one or more glass-based green tapes. Burie d capacitors are made by coating an overlying and an underlying green tape wit h a conductor (36, 38, 40, 42) such as silver. Capacitors can also be made by adjusting the organic vehicle and forming a green tape from the dielectric powders. These dielectric green tapes each can be coated with a conductive layer and stacked, the conductive layers connected in parallel. The resultan t multilayer capacitors have a very high dielectric constant, while eliminatin g the need for very large area capacitors, as compared to single layer capacitors.",DAEWOO ELECTRONICS CO LTD;;SARNOFF CORP,TORMEY ELLEN S;;KIM IN-TAE;;PARK SUNG-DAE;;PRABHU ASHOK NARAYAN;;YU JOO-DONG;;LIBERATORE MICHAEL JAMES;;SREERAM ATTIGANAL NARAYANASWAM;;PARK YUN-HWI;;MUN JE-DO,,https://lens.org/130-762-608-119-734,Patent Application,no,0,0,20,20,0,C04B35/265;;C04B35/497;;H01F1/0027;;H01F17/0006;;H01F41/042;;H01F41/043;;H01F41/046;;H01G4/1254;;H01G4/30;;H05K1/0306;;H05K1/165;;H01G4/12;;H01F41/046;;H01F41/042;;H01F1/0027;;C04B35/265;;H01G4/30;;H01F41/043;;H01F17/0006;;H05K1/165;;C04B35/497;;H01G4/1254;;H05K1/0306,H01F5/00;;C04B35/26;;C04B35/497;;C08K3/22;;C08L101/00;;H01F1/00;;H01F17/00;;H01F41/04;;H01G4/12;;H01G4/30;;H05K1/03;;H05K1/16;;H05K3/46,,0,0,,,,EXPIRED
174,US,S,US D0486616 S,093-121-579-040-604,2004-02-10,2004,US 14015501 F,2001-04-11,US 14015501 F;;US 68943300 F,2000-10-11,Cleaning system,,CLOROX CO,HALL MICHAEL J;;RADER JAMES E;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;HEFTER KAREN S;;PORTICOS RICHARD;;PARK GENE;;MINKLER DOUGLAS;;SAYLER DAVID J;;PARK ERIC Y,CLOROX COMPANY THE (2001-08-16),https://lens.org/093-121-579-040-604,Design Right,no,0,14,4,6,0,,,D32/45,0,0,,,,EXPIRED
175,CA,C,CA 2345764 C,016-253-986-722-890,2008-01-29,2008,CA 2345764 A,1999-10-01,US 10277398 P;;US 9922890 W,1998-10-02,CAPACITANCE-COUPLED HIGH DIELECTRIC CONSTANT EMBEDDED CAPACITORS,"High dielectric constant capacitors are made from a dielectric ink (30, 32, 34) of lead-magnesium-niobate and lead oxide powders with a suitable organic vehicle which can be used to coat one or more glass- based green tapes. Buried capacitors are made by coating an overlying and an underlying green tape with a conductor (36, 38, 40, 42) such as silver. Capacitors can also be made by adjusting the organic vehicle and forming a green tape from the dielectric powders. These dielectric green tapes each can be coated with a conductive layer and stacked, the conductive layers connected in parallel. The resultan t multilayer capacitors have a very high dielectric constant, while eliminating the need for very large area capacitors, as compared to single layer capacitors.",DAEWOO ELECTRONICS CO LTD;;SARNOFF CORP,KIM IN-TAE;;MUN JE-DO;;LIBERATORE MICHAEL JAMES;;PRABHU ASHOK NARAYAN;;PARK YUN-HWI;;YU JOO-DONG;;TORMEY ELLEN S;;PARK SUNG-DAE;;SREERAM ATTIGANAL NARAYANASWAM,,https://lens.org/016-253-986-722-890,Granted Patent,no,0,0,20,20,0,C04B35/265;;C04B35/497;;H01F1/0027;;H01F17/0006;;H01F41/042;;H01F41/043;;H01F41/046;;H01G4/1254;;H01G4/30;;H05K1/0306;;H05K1/165;;H01G4/12;;H01F41/046;;H01F41/042;;H01F1/0027;;C04B35/265;;H01G4/30;;H01F41/043;;H01F17/0006;;H05K1/165;;C04B35/497;;H01G4/1254;;H05K1/0306,H01F5/00;;H01G4/06;;C04B35/26;;C04B35/497;;C08K3/22;;C08L101/00;;H01F1/00;;H01F17/00;;H01F41/04;;H01G4/12;;H01G4/30;;H05K1/03;;H05K1/16;;H05K3/46,,0,0,,,,EXPIRED
176,EP,A1,EP 1135783 A1,043-047-041-942-466,2001-09-26,2001,EP 99953023 A,1999-10-01,US 9922890 W;;US 10277398 P,1998-10-02,CAPACITANCE-COUPLED HIGH DIELECTRIC CONSTANT EMBEDDED CAPACITORS,,SARNOFF CORP;;DAEWOO ELECTRONICS CO LTD,LIBERATORE MICHAEL JAMES;;SREERAM ATTIGANAL NARAYANASWAM;;PRABHU ASHOK NARAYAN;;KIM IN-TAE;;MUN JE-DO;;PARK SUNG-DAE;;PARK YUN-HWI;;YU JOO-DONG;;TORMEY ELLEN S,,https://lens.org/043-047-041-942-466,Patent Application,yes,0,0,20,20,0,C04B35/265;;C04B35/497;;H01F1/0027;;H01F17/0006;;H01F41/042;;H01F41/043;;H01F41/046;;H01G4/1254;;H01G4/30;;H05K1/0306;;H05K1/165;;H01G4/12;;H01F41/046;;H01F41/042;;H01F1/0027;;C04B35/265;;H01G4/30;;H01F41/043;;H01F17/0006;;H05K1/165;;C04B35/497;;H01G4/1254;;H05K1/0306,C04B35/26;;C04B35/497;;C08K3/22;;C08L101/00;;H01F5/00;;H01F1/00;;H01F17/00;;H01F41/04;;H01G4/12;;H01G4/30;;H05K1/03;;H05K1/16;;H05K3/46,,0,0,,,,DISCONTINUED
177,WO,A1,WO 2000/021102 A1,166-164-078-420-592,2000-04-13,2000,US 9922890 W,1999-10-01,US 10277398 P,1998-10-02,CAPACITANCE-COUPLED HIGH DIELECTRIC CONSTANT EMBEDDED CAPACITORS,"High dielectric constant capacitors are made from a dielectric ink (30, 32, 34) of lead-magnesium-niobate and lead oxide powders with a suitable organic vehicle which can be used to coat one or more glass-based green tapes. Buried capacitors are made by coating an overlying and an underlying green tape with a conductor (36, 38, 40, 42) such as silver. Capacitors can also be made by adjusting the organic vehicle and forming a green tape from the dielectric powders. These dielectric green tapes each can be coated with a conductive layer and stacked, the conductive layers connected in parallel. The resultant multilayer capacitors have a very high dielectric constant, while eliminating the need for very large area capacitors, as compared to single layer capacitors.",SARNOFF CORP;;DAEWOO ELECTRONICS CO LTD,LIBERATORE MICHAEL JAMES;;SREERAM ATTIGANAL NARAYANASWAM;;PRABHU ASHOK NARAYAN;;KIM IN-TAE;;MUN JE-DO;;PARK SUNG-DAE;;PARK YUN-HWI;;YU JOO-DONG;;TORMEY ELLEN S,,https://lens.org/166-164-078-420-592,Patent Application,yes,7,0,20,20,0,C04B35/265;;C04B35/497;;H01F1/0027;;H01F17/0006;;H01F41/042;;H01F41/043;;H01F41/046;;H01G4/1254;;H01G4/30;;H05K1/0306;;H05K1/165;;H01G4/12;;H01F41/046;;H01F41/042;;H01F1/0027;;C04B35/265;;H01G4/30;;H01F41/043;;H01F17/0006;;H05K1/165;;C04B35/497;;H01G4/1254;;H05K1/0306,C04B35/26;;C04B35/497;;C08K3/22;;H01F5/00;;C08L101/00;;H01F1/00;;H01F17/00;;H01F41/04;;H01G4/12;;H01G4/30;;H05K1/03;;H05K1/16;;H05K3/46,,1,0,,,See also references of EP 1135783A4,PENDING
178,US,B1,US 6191934 B1,020-006-967-353-555,2001-02-20,2001,US 21166898 A,1998-12-14,US 21166898 A;;US 10277398 P,1998-10-02,High dielectric constant embedded capacitors,"High dielectric constant capacitors are made from a dielectric ink of lead-magnesium-niobate and lead oxide powders. Dielectric inks are made by mixing the dielectric powders with a suitable organic vehicle which can be used to coat one or more glass-based green tapes. Buried capacitors are made by coating an overlying and an underlying green tape with a conductor such as silver. Capacitors can also be made by adjusting the organic vehicle and forming a green tape from the dielectric powders. These dielectric green tapes each can be coated with a conductive layer and stacked, the conductive layers connected in parallel. The resultant multilayer capacitors have a very high dielectric constant, while eliminating the need for very large area capacitors, as compared to single layer capacitors.",SARNOFF CORP & CO LTD;;DAEWOO ELECTRONICS CO LTD,LIBERATORE MICHAEL JAMES;;SREERAM ATTIGANAL NARAYANASWAM;;PRABHU ASHOK NARAYAN;;KIM IN-TAE;;MUN JE-DO;;PARK SUNG-DAE;;PARK YUN-HWI;;YU JOO-DONG;;TORMEY ELLEN S,LAMINA LIGHTING INC (2006-06-14);;LIGHTING SCIENCE GROUP CORPORATION (2008-07-29);;DAEWOO ELECTRONICS CO. LTD (1998-12-10);;SARNOFF CORPORATION (1998-12-11),https://lens.org/020-006-967-353-555,Granted Patent,yes,8,14,20,20,0,C04B35/265;;C04B35/497;;H01F1/0027;;H01F17/0006;;H01F41/042;;H01F41/043;;H01F41/046;;H01G4/1254;;H01G4/30;;H05K1/0306;;H05K1/165;;H01G4/12;;H01F41/046;;H01F41/042;;H01F1/0027;;C04B35/265;;H01G4/30;;H01F41/043;;H01F17/0006;;H05K1/165;;C04B35/497;;H01G4/1254;;H05K1/0306,C04B35/26;;C04B35/497;;C08K3/22;;H01F5/00;;C08L101/00;;H01F1/00;;H01F17/00;;H01F41/04;;H01G4/12;;H01G4/30;;H05K1/03;;H05K1/16;;H05K3/46,361/313;;361/320;;361/321.2;;361/321.5;;501/137,1,0,,,"International Search Report for International PCT Application No. PCT/US99/22890 dated Mar. 14, 2000.",EXPIRED
179,EP,A4,EP 1135783 A4,078-252-227-642-851,2004-05-12,2004,EP 99953023 A,1999-10-01,US 9922890 W;;US 10277398 P,1998-10-02,CAPACITANCE-COUPLED HIGH DIELECTRIC CONSTANT EMBEDDED CAPACITORS,,SARNOFF CORP;;DAEWOO ELECTRONICS CO LTD,LIBERATORE MICHAEL JAMES;;SREERAM ATTIGANAL NARAYANASWAM;;PRABHU ASHOK NARAYAN;;KIM IN-TAE;;MUN JE-DO;;PARK SUNG-DAE;;PARK YUN-HWI;;YU JOO-DONG;;TORMEY ELLEN S,,https://lens.org/078-252-227-642-851,Search Report,no,4,0,20,20,0,C04B35/265;;C04B35/497;;H01F1/0027;;H01F17/0006;;H01F41/042;;H01F41/043;;H01F41/046;;H01G4/1254;;H01G4/30;;H05K1/0306;;H05K1/165;;H01G4/12;;H01F41/046;;H01F41/042;;H01F1/0027;;C04B35/265;;H01G4/30;;H01F41/043;;H01F17/0006;;H05K1/165;;C04B35/497;;H01G4/1254;;H05K1/0306,C04B35/26;;C04B35/497;;C08K3/22;;C08L101/00;;H01F5/00;;H01F1/00;;H01F17/00;;H01F41/04;;H01G4/12;;H01G4/30;;H05K1/03;;H05K1/16;;H05K3/46,,1,0,,,See also references of WO 0021102A1,DISCONTINUED
180,US,S,US D0486949 S,001-162-722-262-749,2004-02-17,2004,US 14015401 F,2001-04-11,US 14015401 F;;US 68943300 F,2000-10-11,Cradle for cleaning fluid reservoir,,CLOROX CO,HALL MICHAEL J;;RADER JAMES E;;HEFTER KAREN S;;MINKLER DOUGLAS;;FLAGLER ROBERT W;;SAYLER DAVID J;;PARK ERIC Y,CLOROX COMPANY THE (2001-08-20),https://lens.org/001-162-722-262-749,Design Right,no,0,4,4,6,0,,,D32/45,0,0,,,,EXPIRED
181,US,S,US D0488386 S,164-729-024-090-447,2004-04-13,2004,US 18619003 F,2003-07-10,US 18619003 F,2003-07-10,Smooth bottle with groove,,CLOROX CO,HALL MICHAEL J;;RADER JAMES E;;HEFTER KAREN S;;MINKLER DOUGLAS;;FLAGLER ROBERT W;;SAYLER DAVID J;;PARK ERIC Y,,https://lens.org/164-729-024-090-447,Design Right,no,0,3,1,1,0,,,D 9550;;D9/555;;D9/574,0,0,,,,EXPIRED
182,US,S,US D0485954 S,124-421-799-859-360,2004-01-27,2004,US 14010401 F,2001-04-11,US 14010401 F,2001-04-11,Cleaning fluid reservoir,,CLOROX CO,HALL MICHAEL J;;RADER JAMES E;;HEFTER KAREN S;;MINKLER DOUGLAS;;FLAGLER ROBERT W;;SAYLER DAVID J;;PARK ERIC Y,CLOROX COMPANY THE (2001-08-20),https://lens.org/124-421-799-859-360,Design Right,no,0,7,3,3,0,,,D32/45;;D32/30;;D9/338;;D9/520;;D9/522,0,0,,,,EXPIRED
183,US,B2,US 9399826 B2,103-080-281-984-218,2016-07-26,2016,US 201414278638 A,2014-05-15,US 201414278638 A,2014-05-15,Thin film deposition apparatus and thin film deposition method using electric field,"A thin film deposition apparatus and a thin film deposition method using an electric field are provided. The thin film deposition apparatus includes: a first substrate; a plurality of electrodes in a 2D arrangement on the first substrate; and a solution provided on the plurality of electrodes and in which charged nanoparticles are distributed, wherein the charged nanoparticles are selectively deposited on at least a part of the plurality of electrodes by independently applying a voltage to each of the plurality of electrodes.",SAMSUNG ELECTRONICS CO LTD;;UNIV CALIFORNIA,HEO JIN S;;PARK HWI-YEOL;;CHO KYUNG-HOON;;CHOI KYOUNG-HWAN;;KIM SE-JUNG;;HELLER MICHAEL J;;SONG YOUNG-JUN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2014-05-09);;SAMSUNG ELECTRONICS CO. LTD (2014-05-09),https://lens.org/103-080-281-984-218,Granted Patent,yes,14,0,4,4,0,C25D13/02;;C25D13/12;;C25D13/18;;C25D13/22;;C25D13/00;;C25D13/22;;C25D13/02;;C25D13/12;;C25D13/18,C25D13/00,,0,0,,,,ACTIVE
184,CN,A,CN 104290815 A,013-059-226-669-187,2015-01-21,2015,CN 201410342863 A,2014-07-18,US 201313946071 A,2013-07-19,Cradle assembly attachable to a vehicle,"A cradle assembly for a vehicle having an underbody is provided. The cradle assembly includes a cradle body attachable to the underbody of the vehicle by at least one fastener. The cradle body may define at least one pathway, which may have a first pathway portion and a second pathway portion between which the at least one fastener is movable. The at least one fastener may be positioned in the first pathway portion to enable the cradle body to be secured to the underbody, and in the second pathway portion to enable the cradle body to be separated from the underbody. The cradle body is configured to move with respect to the at least one fastener when an applied load on the vehicle is at or above a threshold magnitude.",GM GLOBAL TECH OPERATIONS INC,MOORE JOSEPH K;;MAZUR DMITRIY V;;MOLHEM ZOHIR;;RAY MICHAEL A;;XU QIANG;;KWON JINTEAK;;SANGHA BALBIR S;;PARK JONGMIN B,,https://lens.org/013-059-226-669-187,Patent Application,no,3,2,5,5,0,B62D21/09;;B62D21/155;;B62D27/065;;B62D27/065;;B62D21/09;;B62D21/155;;B62D27/065;;B62D21/09;;B62D21/12;;B62D21/155,B62D21/00,,0,0,,,,ACTIVE
185,US,A1,US 2015/0329984 A1,026-453-101-204-906,2015-11-19,2015,US 201414278638 A,2014-05-15,US 201414278638 A,2014-05-15,THIN FILM DEPOSITION APPARATUS AND THIN FILM DEPOSITION METHOD USING ELECTRIC FIELD,"A thin film deposition apparatus and a thin film deposition method using an electric field are provided. The thin film deposition apparatus includes: a first substrate; a plurality of electrodes in a 2D arrangement on the first substrate; and a solution provided on the plurality of electrodes and in which charged nanoparticles are distributed, wherein the charged nanoparticles are selectively deposited on at least a part of the plurality of electrodes by independently applying a voltage to each of the plurality of electrodes.",SAMSUNG ELECTRONICS CO LTD;;UNIV CALIFORNIA,HEO JIN S;;PARK HWI-YEOL;;CHO KYUNG-HOON;;CHOI KYOUNG-HWAN;;KIM SE-JUNG;;HELLER MICHAEL J;;SONG YOUNG-JUN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2014-05-09);;SAMSUNG ELECTRONICS CO. LTD (2014-05-09),https://lens.org/026-453-101-204-906,Patent Application,yes,1,2,4,4,0,C25D13/02;;C25D13/12;;C25D13/18;;C25D13/22;;C25D13/00;;C25D13/22;;C25D13/02;;C25D13/12;;C25D13/18,C25D13/00,,0,0,,,,ACTIVE
186,DE,A1,DE 102014109917 A1,031-473-956-236-136,2015-01-22,2015,DE 102014109917 A,2014-07-15,US 201313946071 A,2013-07-19,An ein Fahrzeug anbringbare Trägerbaugruppe,"Es ist eine Trägerbaugruppe für ein Fahrzeug mit einem Unterbau vorgesehen. Die Trägerbaugruppe umfasst einen Trägerkörper, der durch zumindest ein Befestigungselement an dem Unterbau des Fahrzeugs anbringbar ist. Der Trägerkörper kann zumindest einen Pfad definieren, der einen ersten Pfadabschnitt und einen zweiten Pfadabschnitt umfassen kann, zwischen denen das zumindest eine Befestigungselement beweglich ist. Das zumindest eine Befestigungselement kann in dem ersten Pfadabschnitt positioniert sein, um zu ermöglichen, dass der Trägerkörper an dem Unterbau befestigt ist, sowie in dem zweiten Pfadabschnitt, um zu ermöglichen, dass der Trägerkörper von dem Unterbau des Fahrzeugs getrennt wird. Der Trägerkörper ist ausgebildet, um sich bezogen auf das zumindest eine Befestigungselement zu bewegen, wenn eine auf das Fahrzeug ausgeübte Kraft bei einem Schwellenwertbetrag oder oberhalb dessen liegt.",GM GLOBAL TECH OPERATIONS INC,SANGHA BALBIR S;;MOORE JOSEPH K;;MOLHEM ZOHIR;;MAZUR DMITRIY V;;RAY MICHAEL A;;XU QIANG;;KWON JINTAEK;;PARK JONGMIN B,,https://lens.org/031-473-956-236-136,Patent Application,no,0,1,5,5,0,B62D21/09;;B62D21/155;;B62D27/065;;B62D27/065;;B62D21/09;;B62D21/155;;B62D27/065;;B62D21/09;;B62D21/12;;B62D21/155,B62D25/20,,0,0,,,,ACTIVE
187,DE,B4,DE 102014109917 B4,090-772-060-264-02X,2021-10-21,2021,DE 102014109917 A,2014-07-15,US 201313946071 A,2013-07-19,An ein Fahrzeug anbringbare Trägerbaugruppe,"Trägerbaugruppe (20) für ein Fahrzeug (10) mit einem Unterbau (12), wobei die Trägerbaugruppe umfasst:einen Trägerkörper (22), der an dem Unterbau (12) des Fahrzeugs (10) durch zumindest ein Befestigungselement (44) anbringbar ist, wobei der Trägerkörper (22) zumindest einen Pfad (134) definiert, in dem das zumindest eine Befestigungselement (44) positioniert wird, um den Trägerkörper (22) an dem Unterbau (12) des Fahrzeugs (10) zu befestigen,wobei der Trägerkörper (22) ausgebildet ist, um sich entlang des zumindest einen Befestigungselements (44) zu bewegen, wenn eine auf das Fahrzeug (10) ausgeübte Kraft bei einem Schwellenwertbetrag oder oberhalb dessen liegt, um zu ermöglichen, dass der Trägerkörper (22) von dem Unterbau (12) des Fahrzeugs (10) getrennt wird;eine erste Hülse (150), welche das zumindest eine Befestigungselement (44) in dem zumindest einen Pfad (134) im Wesentlichen umschließt, und eine zweite Hülse (148) um die erste Hülse (150) herum, wobei die zweite Hülse (148) an dem Trägerkörper (22) befestigt ist; undeine Scheibe (152), die zumindest eine Zunge (154) aufweist und mit dem zumindest einen Befestigungselement (44) in Kontakt steht,wobei die erste Hülse (150) auf der Scheibe (152) sitzt und die zweite Hülse (154) an der zumindest einen Zunge (154) sitzt undwobei die zumindest eine Zunge (154) ausgebildet ist, um von der Scheibe (152) getrennt zu werden oder sich zu verformen, wenn die auf das Fahrzeug (10) ausgeübte Kraft bei dem Schwellenwertbetrag oder oberhalb dessen liegt, um zu ermöglichen, dass der Trägerkörper (22) von dem Unterbau (12) des Fahrzeugs (10) getrennt wird.",GM GLOBAL TECH OPERATIONS LLC,SANGHA BALBIR S;;MOORE JOSEPH K;;MOLHEM ZOHIR;;MAZUR DMITRIY V;;RAY MICHAEL A;;XU QIANG;;KWON JINTAEK;;PARK JONGMIN B,,https://lens.org/090-772-060-264-02X,Granted Patent,no,4,0,5,5,0,B62D21/09;;B62D21/155;;B62D27/065;;B62D27/065;;B62D21/09;;B62D21/155;;B62D27/065;;B62D21/09;;B62D21/12;;B62D21/155,B62D25/20,,0,0,,,,ACTIVE
188,US,B2,US 8985630 B2,076-713-935-579-335,2015-03-24,2015,US 201313946071 A,2013-07-19,US 201313946071 A,2013-07-19,Cradle assembly attachable to a vehicle,"A cradle assembly for a vehicle having an underbody is provided. The cradle assembly includes a cradle body attachable to the underbody of the vehicle by at least one fastener. The cradle body may define at least one pathway, which may have a first pathway portion and a second pathway portion between which the at least one fastener is movable. The at least one fastener may be positioned in the first pathway portion to enable the cradle body to be secured to the underbody, and in the second pathway portion to enable the cradle body to be separated from the underbody. The cradle body is configured to move with respect to the at least one fastener when an applied load on the vehicle is at or above a threshold magnitude.",GM GLOBAL TECH OPERATIONS INC,SANGHA BALBIR S;;MOORE JOSEPH K;;MOLHEM ZOHIR;;MAZUR DMITRIY V;;RAY MICHAEL A;;XU QIANG;;KWON JINTAEK;;PARK JONGMIN B,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2013-08-16),https://lens.org/076-713-935-579-335,Granted Patent,yes,9,12,5,5,0,B62D21/09;;B62D21/155;;B62D27/065;;B62D27/065;;B62D21/09;;B62D21/155;;B62D27/065;;B62D21/09;;B62D21/12;;B62D21/155,B62D21/00;;B62D21/09;;B62D21/12;;B62D21/15,280/784;;280/124.109,0,0,,,,ACTIVE
189,US,A1,US 2015/0021891 A1,034-426-070-818-548,2015-01-22,2015,US 201313946071 A,2013-07-19,US 201313946071 A,2013-07-19,CRADLE ASSEMBLY ATTACHABLE TO A VEHICLE,"A cradle assembly for a vehicle having an underbody is provided. The cradle assembly includes a cradle body attachable to the underbody of the vehicle by at least one fastener. The cradle body may define at least one pathway, which may have a first pathway portion and a second pathway portion between which the at least one fastener is movable. The at least one fastener may be positioned in the first pathway portion to enable the cradle body to be secured to the underbody, and in the second pathway portion to enable the cradle body to be separated from the underbody. The cradle body is configured to move with respect to the at least one fastener when an applied load on the vehicle is at or above a threshold magnitude.",GM GLOBAL TECH OPERATIONS INC,SANGHA BALBIR S;;MOORE JOSEPH K;;MOLHEM ZOHIR;;MAZUR DMITRIY V;;RAY MICHAEL A;;XU QIANG;;KWON JINTEAK;;PARK JONGMIN B,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2013-08-16),https://lens.org/034-426-070-818-548,Patent Application,yes,9,10,5,5,0,B62D21/09;;B62D21/155;;B62D27/065;;B62D27/065;;B62D21/09;;B62D21/155;;B62D27/065;;B62D21/09;;B62D21/12;;B62D21/155,B62D21/09;;B62D21/15;;B62D21/12,280/784;;280/785,0,0,,,,ACTIVE
190,KR,A,KR 20150131893 A,045-114-139-931-108,2015-11-25,2015,KR 20140060487 A,2014-05-20,US 201414278638 A,2014-05-15,THIN FILM DEPOSITION APPARATUS USING ELECTRIC FILED AND THIN FILM DEPSOTION METHOD,"A thin film deposition apparatus and a thin film deposition method using an electric field are provided. The thin film deposition apparatus comprises: a first substrate; a plurality of electrodes in a 2D arrangement on the first substrate, whose voltage can be controlled; and a solution provided on the electrodes and in which charged nanoparticles are distributed, wherein the charged nanoparticles are selectively deposited on at least a part of the electrodes by independently applying a predetermined voltage to each of the electrodes.",SAMSUNG ELECTRONICS CO LTD;;UNIV CALIFORNIA,HEO JIN S;;PARK HWI YEOL;;CHO KYUNG HOON;;CHOI KYOUNG HWAN;;KIM SE JUNG;;HELLER MICHAEL J;;SONG YOUNG JUN,,https://lens.org/045-114-139-931-108,Patent Application,no,4,0,4,4,0,C25D13/02;;C25D13/12;;C25D13/18;;C25D13/22;;C25D13/00;;C25D13/22;;C25D13/02;;C25D13/12;;C25D13/18,H01L21/288;;H01L21/20;;H01L21/28,,0,0,,,,ACTIVE
191,AU,B2,AU 2018/206772 B2,073-116-382-389-616,2020-03-26,2020,AU 2018/206772 A,2018-07-19,AU 2018/206772 A;;AU 2015/267240 A;;US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness data aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/073-116-382-389-616,Granted Patent,no,2,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F3/048;;G16H50/70,,0,0,,,,ACTIVE
192,WO,A1,WO 2015/183828 A1,103-757-587-652-584,2015-12-03,2015,US 2015/0032474 W,2015-05-26,US 201462006032 P;;US 201562129945 P,2014-05-30,WELLNESS DATA AGGREGATOR,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/103-757-587-652-584,Patent Application,yes,7,19,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06F3/048;;G06Q10/06;;G16H50/70,,1,0,,,"""iPhone User Guide For iOS 7.1 Software"", 10 March 2014 (2014-03-10), pages 1 - 162, XP055207043, Retrieved from the Internet <URL:https://manuals.info.apple.com/en_US/iphone_ios7_user_guide.pdf> [retrieved on 20150810]",PENDING
193,EP,A1,EP 3550483 A1,164-462-572-563-612,2019-10-09,2019,EP 19163212 A,2015-05-26,US 201462006032 P;;US 201562129945 P;;EP 15730890 A;;US 2015/0032474 W,2014-05-30,MEDICAL IDENTIFICATION INFORMATION,"A computer-implemented method comprising: at an electronic device comprising a display: 
displaying, on the display, a graph comprising a first data-set representation of a first data set in which a first dependent variable varies as an independent variable changes and a second data-set representation of a second data set in which a second dependent variable varies as the independent variable changes, wherein the first data-set representation is associated with a first range of vertical positions within the graph and the second data-set representation is associated with a second range of vertical positions within the graph; 
detecting, at a respective location on the display, a user input; in response to detecting the user input: 
in accordance with a determination that the respective location is within the first range of vertical positions associated with the first data-set representation, displaying, on the display, an indication that the first data-set representation has been selected; and 
in accordance with a determination that the respective location is within the second range of vertical positions associated with the second data-set representation, displaying, on the display, an indication that the second data-set representation has been selected.
",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN OLIVIER;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/164-462-572-563-612,Patent Application,yes,31,11,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F1/16;;G06F3/048;;G06F3/0482;;G06F3/0488;;G06Q50/26;;G06Q50/32;;G16H10/60;;G16H50/30;;G16H50/70,,2,0,,,"""iPhone User Guide For iOS 7.1 Software"", 10 March 2014 (2014-03-10), pages 1 - 162, XP055207043, Retrieved from the Internet <URL:https://manuals.info.apple.com/en_US/iphone_ios7_user_guide.pdf> [retrieved on 20150810];;ANONYMOUS: ""Enhanced Multi-Level Precedence And Pre-emption Service"", 1 October 2013 (2013-10-01), XP055596404, Retrieved from the Internet <URL:https://de.wikipedia.org/w/index.php?title=Enhanced_Multi-Level_Precedence_And_Pre-emption_Service&oldid=123047429> [retrieved on 20190613]",DISCONTINUED
194,US,B2,US 10313506 B2,158-218-773-080-738,2019-06-04,2019,US 201514599425 A,2015-01-16,US 201514599425 A;;US 201462006032 P,2014-05-30,Wellness aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,SOLI CHRISTOPHER D;;YANG LAWRENCE Y;;PARK DENNIS S;;LEMAY STEPHEN O;;KEEN DANIEL S;;FOSTER JAMES H;;KENNEDY ZACHERY;;O'REILLY MICHAEL;;TRIBBLE GUY L;;WHITEHURST TODD K,APPLE INC (2015-03-23),https://lens.org/158-218-773-080-738,Granted Patent,yes,177,2,6,55,0,G16H40/63;;G16H10/60;;H04W4/14;;G16H40/67;;H04W4/90;;G16H40/63;;G16H10/60;;G16H40/67;;H04M1/72421;;H04M1/72424;;G16H20/40;;H04W4/14;;H04W88/02,G16H10/60;;G16H40/63;;G16H40/67;;H04M1/72421;;H04M1/72424;;H04W4/14;;H04W4/90;;H04W88/02,,92,0,,,"Non Final Office Action received for U.S. Appl. No. 14/503,072, dated Jan. 26, 2015, 12 pages.;;Non Final Office Action received for U.S. Appl. No. 14/503,296, dated Jan. 30, 2015, 16 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/503,372, dated Dec. 5, 2014, 11 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/503,381, dated May 13, 2015, 13 pages.;;Yang et al., U.S. Appl. No. 62/004,886, filed May 29, 2014, titled “User Interface for Payments”, 198 pages.;;Kamijo, Noboru, “Next Generation Mobile System—WatchPad1.5”, Available at “http://researcher.ibm.com/researcher/view_group_subpage.php?id=5617”, retrieved on Jul. 4, 2015, 2 pages.;;Lemay et al., U.S. Appl. No. 60/936,562, filed Jun. 20, 2007, titled “Portable Multifunction Device, Method, and Graphical User Interface for Playing Online Videos”, 61 pages.;;NDTV, “Sony SmartWatch 2 Launched in India for Rs. 14,990”, available at “http://gadgets.ndtv.com/others/news/sony-smartwatch-2-launched-in-india-for-rs-14990-420319”, Sep. 18, 2013, 4 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/053951, dated Dec. 8, 2014, 11 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/053957, dated Feb. 19, 2015, 11 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/053958, dated Feb. 19, 2015, 10 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/019321, dated Jun. 3, 2015, 11 pages.;;Apple, “iPhone User's Guide”, 2007, 137 pages.;;“Headset Button Controller v7.3 APK Full APP Download for Andriod, Blackberry, iPhone”, Jan. 27, 2014, 11 pages.;;Colt, Sam, “Here's One Way Apple's Smartwatch Could Be Better Than Anything Else”, Business Insider, Aug. 21, 2014, pp. 1-4.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/019322, dated Jun. 18, 2015, 16 pages.;;Final Office Action received for U.S. Appl. No. 14/503,296, dated Jul. 2, 2015, 7 pages.;;Yang et al., U.S. Appl. No. 62/006,211, filed Jun. 1, 2014, titled “Displaying Options, Assigning Notification, Ignoring Messages, and Simultaneous User Interface Displays in a Messaging Application”, 254 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/019320, dated Jul. 2, 2015, 14 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/025188, dated Jun. 23, 2015, 11 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/019298, dated Jul. 13, 2015, 17 pages.;;Fuji Film, “Taking Pictures Remotely : Free iPhone/Android App Fuji Film Camera Remote”, Available at <http://app.fujifilm-dsc.com/en/camera_remote/guide05.html>, Apr. 22, 2014, 3 pages.;;Playmemories Camera Apps, “PlayMemories Camera Apps Help Guide”, Available at <https://www.playmemoriescameraapps.com/portal/manual/IS9104-NPIA09014_00-F00002/en/index.html>, 2012, 3 pages.;;Techsmith, “Snagit 11-Snagit 11.4 Help”, Available at <http://assets.techsmith.com/Downloads/ua-tutorials-snagit-11/Snagit_11.pdf>, Jan. 2014, 146 pages.;;Xperia Blog, “Action Camera Extension Gives Smartwatch/Smartband Owners Ability to Control Sony Wireless Cameras”, Available at <http://www.xperiablog.net/2014/06/13/action-camera-extension-gives-smartwatchsmartband-owners-ability-to-control-sony-wireless-cameras/>, Jun. 13, 2014, 10 pages.;;Office Action received for Danish Patent Application No. PA201570666, dated Jun. 27, 2016, 4 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2013/073195, dated Jun. 7, 2016, 9 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/047282, dated May 9, 2016, 33 pages.;;Non Final Office Action received for U.S. Appl. No. 14/839,916, dated Feb. 4, 2016, 19 pages.;;Non Final Office Action received for U.S. Appl. No. 14/839,922, dated Feb. 25, 2016, 20 pages.;;Notice of Allowance received for Chinese Patent Application No. 201520358505.5, dated Jan. 13, 2016, 3 pages (2 pages of English Translation & 1 page of Official Copy).;;Office Action received for Danish Patent Application No. PA201570666, dated Feb. 2, 2016, 9 pages.;;Office Action received for Danish Patent Application No. PA201570668, dated Apr. 8, 2016, 8 pages.;;International Search Report received for PCT Patent Application No. PCT/US2013/073195, dated Jun. 23, 2014, 3 pages.;;Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US2015/047282, dated Dec. 22, 2015, 7 pages.;;“i Phone User Guide for iOS 7.1 Software”, available online at <https://manuals.info.apple.com/MANUALS/1000/MA1681/en_US/iphone_ios7_user_guide.pdf> retrived on Aug. 10, 2015, 162 pages.;;Office Action received for Australian Patent Application No. 2015100734, dated Jul. 29, 2015, 5 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/032474, dated Aug. 19, 2015, 8 pages.;;Final Office Action received for U.S. Appl. No. 14/839,922, dated Dec. 14, 2016, 22 pages.;;International Preliminary Report on Patentability Received for PCT Patent Application No. PCT/US2015/032474, dated Dec. 15, 2016, 7 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/839,922, dated Aug. 17, 2016, 25 pages.;;Notice of Allowance received for Danish Patent Application No. PA201570666, dated Sep. 15, 2016, 1 page.;;Notice of Allowance received for U.S. Appl. No. 14/839,916, dated Aug. 31, 2016, 11 pages.;;Office Action received for Australian Patent Application No. 2015312215, dated Oct. 13, 2016, 3 pages.;;Office Action Received for Danish Patent Application No. RA201670656, dated Nov. 3, 2016, 8 pages.;;Office Action received for Danish Patent Application No. PA201570668, dated Sep. 9, 2016, 3 pages.;;Office Action received for Korean Patent Application No. 10-2016-7033638, dated Jan. 31, 2017, 6 pages (2 pages of English Translation and 4 pages of Official Copy).;;Office Action received for Taiwanese Patent Application No. 104117509, dated Aug. 22, 2016, 6 pages (3 pages of English Translation and 3 pages of Official Copy).;;Office Action received for Taiwanese Patent Application No. 104128685, dated Jan. 4, 2017, 40 pages (15 pages of English Translation and 25 pages of Official Copy).;;Written Opinion received for PCT Patent Application No. PCT/US2013/073195, dated Jun. 23, 2014, 8 pages.;;Notice of Allowance received for Korean Patent Application No. 10-2016-7033638, dated May 31, 2017, 5 pages (2 pages of English Translation and 3 pages of Official Copy).;;Notice of Allowance received for Taiwanese Patent Application No. 104128685, dated May 3, 2017, 3 pages (Official Copy Only) (see attached 37 CFR § 1.98(a) (3)).;;Notice of Allowance received for U.S. Appl. No. 14/839,922, dated Jul. 6, 2017, 8 pages.;;Office Action received for Danish Patent Application No. PA201670656, dated Jun. 14, 2017, 3 pages.;;Office Action received for European Patent Application No. 15730890.9, dated Aug. 3, 2017, 4 pages.;;Office Action received for Japanese Patent Application No. 2016-535045, dated May 12, 2017, 10 pages (5 pages of English Translation and 5 pages of Official Copy).;;Office Action received for Japanese Patent Application No. 2016-557650, dated Aug. 10, 2017, 10 pages (5 pages of English Translation and 5 pages of Official Copy).;;Search Report and Opinion received for Danish Patent Application No. PA201770191, dated Jun. 30, 2017, 9 pages.;;Notice of Allowance received for Danish Patent Application No. PA201570668, dated Oct. 30, 2017, 2 pages.;;Notice of Acceptance received for Australian Patent Application No. 2015312215, dated Oct. 9, 2017, 3 pages.;;Notice of Allowance received for U.S. Appl. No. 14/839,922, dated Nov. 2, 2017, 8 pages.;;Office Action received for European Patent Application No. 15771747.1, dated Oct. 31, 2017, 7 pages.;;Advisory Action received for U.S. Appl. No. 14/839,922, dated Mar. 24, 2017, 4 pages.;;Intention to Grant received for Danish Patent Application No. PA201570668, dated Mar. 27, 2017, 2 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2015/047232, dated Mar. 16, 2017, 26 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2016/037686, dated Sep. 9, 2016, 19 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/839,916, dated May 1, 2017, 18 pages.;;Notice of Allowance received for Taiwanese Patent Application No. 104117509, dated Mar. 31, 2017, 3 pages (Official Copy Only) (see attached 37 CFR § 1.98(a) (3)).;;Office Action received for Australian Patent Application No. 2015267240, dated Apr. 10, 2017, 5 pages.;;Office Action received for Australian Patent Application No. 2015267240, dated Mar. 21, 2018, 5 pages.;;Office Action received for Chinese Patent Application No. 201510284850.3, dated Nov. 28, 2017, 15 pages (5 pages of English Translation and 10 pages of Official Copy).;;Notice of Acceptance received for Australian Patent Application No. 2015267240, dated Apr. 10, 2018, 3 pages.;;Office Action received for European Patent Application No. 13811085.3, dated Apr. 20, 2018, 15 pages.;;Office Action received for European Patent Application No. 18154145.9, dated Apr. 3, 2018, 6 pages.;;Notice of Allowance received for U.S. Appl. No. 14/839,922, dated Jan. 26, 2018, 2 pages.;;Office Action received for Danish Patent Application No. PA201770191, dated Jan. 25, 2018, 3 pages.;;Summons to attend oral proceedings received for European Patent Application No. 13811085.3, dated Jan. 26, 2018, 14 pages.;;Office Action received for Japanese Patent Application No. 2016-569945, dated Sep. 10, 2018, 11 pages (6 pages of English Translation and 5 pages of Official Copy).;;Non-Final Office Action received for U.S. Appl. No. 14/599,424, dated Jan. 17, 2018, 13 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/732,773, dated Jan. 19, 2018, 45 pages.;;Notice of Allowance received for U.S. Appl. No. 14/839,916, dated Jan. 10, 2018, 19 pages.;;Office Action received for Korean Patent Application No. 10-2016-7014577, dated Dec. 26, 2017, 14 pages (6 pages of English Translation and 8 pages of Official Copy).;;“Utilization of Galaxy S4-S Health, ChatOn and Samsung Hub”, Available at: http://seeit.kr/1263, Jun. 12, 2013, 25 pages (Official Copy only) (see attached 37 CFR § 1.98(a) (3)).;;Jenbsjourney, “Wondering About a Fitbit?”,Available at: https://jenbsjourney.blogspot.kr/2013/08/wondering-about-fitbit.html, Aug. 6, 2013, 12 pages.;;Extended European Search Report received for European Patent Application No. 18154145.9, dated Mar. 2, 2018, 8 pages.;;International Preliminary Report on Patentability received for PCT Application No. PCT/US2016/037686, dated Mar. 1, 2018, 12 pages.;;Notice of Allowance received for Japanese Patent Application No. 2016-535045, dated Mar. 2, 2018, 5 pages (2 pages of English Translation and 3 pages of Official Copy).;;Office Action received for Australian Patent Application No. 2018200428, dated Mar. 7, 2018, 4 pages.;;Office Action received for Chinese Patent Application No. 201510284850.3, dated Jul. 9, 2018, 11 pages (2 pages of English Translation and 9 pages of Official copy).;;Summons to Attend Oral Proceedings received for European Patent Application No. 15730890.9, mailed on Sep. 10, 2018, 11 pages.;;Office Action received for Chinese Patent Application No. 201580028677.9, dated May 25, 2018, 14 pages (4 pages of English Translation and 10 pages of Official copy).;;Office Action received for Japanese Patent Application No. 2016-569945, dated Nov. 10, 2017, 8 pages (4 pages of English Translation and 4 pages of Official Copy).",ACTIVE
195,US,B2,US 11430571 B2,192-958-548-545-136,2022-08-30,2022,US 201916388493 A,2019-04-18,US 201916388493 A;;US 201514599424 A;;US 201462006032 P,2014-05-30,Wellness aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,SOLI CHRISTOPHER D;;YANG LAWRENCE Y;;PARK DENNIS S;;LEMAY STEPHEN O;;KEEN DANIEL S;;FOSTER JAMES H;;KENNEDY ZACHERY;;O'REILLY MICHAEL;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/192-958-548-545-136,Granted Patent,yes,498,0,6,55,0,G16H40/63;;G16H10/60;;H04W4/14;;G16H40/67;;H04W4/90;;G16H40/63;;G16H10/60;;G16H40/67;;H04M1/72421;;H04M1/72424;;G16H20/40;;H04W4/14;;H04W88/02,G16H40/67;;G16H10/60;;G16H20/40;;G16H40/63;;H04M1/72421;;H04M1/72424;;H04W4/14;;H04W4/90;;H04W88/02,,413,0,,,"Applicant Initiated Interview Summary received for U.S. Appl. No. 16/389,722, dated Jul. 7, 2020, 5 pages.;;Notice of Allowance received for U.S. Appl. No. 15/554,204, dated Jul. 13, 2020, 10 pages.;;Advisory Action received for U.S. Appl. No. 14/839,922, dated Mar. 24, 2017, 4 pages.;;Extended European Search Report received for European Patent Application No. 18154145.9, dated Mar. 2, 2018, 8 pages.;;Final Office Action received for U.S. Appl. No. 14/599,424, dated Jun. 28, 2018, 12 pages.;;Final Office Action received for U.S. Appl. No. 14/599,425, dated May 19, 2017, 24 pages.;;Final Office Action received for U.S. Appl. No. 14/599,425, dated Oct. 8, 2015, 20 pages.;;Final Office Action received for U.S. Appl. No. 14/839,922, dated Dec. 14, 2016, 22 pages.;;Intention to Grant received for Danish Patent Application No. PA201570668, dated Mar. 27, 2017, 2 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2016/037686, dated Mar. 1, 2018, 12 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2013/073195, dated Jun. 16, 2016, 10 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2015/032474, dated Dec. 15, 2016, 7 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2015/047282, dated Mar. 16, 2017, 26 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/032474, dated Aug. 19, 2015, 8 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/047282, dated May 9, 2016, 33 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2016/037686, dated Sep. 9, 2016, 19 pages.;;International Search Report received for PCT Patent Application No. PCT/US2013/073195, dated Jun. 23, 2014, 3 pages.;;International Written Opinion received for PCT Patent Application No. PCT/US2013/073195, dated Jun. 23, 2014, 8 pages.;;Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US2015/047282, dated Dec. 22, 2015, 7 pages.;;“IPhone User Guide For iOS 7.1 Software”, available online at <https://manuals.info.apple.com/MANUALS/1000/MA1681/en_US/iphone_ios7_user_guide.pdf>, Mar. 10, 2014, pp. 1-162.;;Jenbsjourney, “Wondering About a Fitbit?”, Available at: https://jenbsjourney.blogspot.kr/2013/08/wondering-about-fitbit.html, Aug. 6, 2013, 12 pages.;;Kamijo, Noboru, “Next Generation Mobile System—WatchPad1.5”, Available at <http://researcher.ibm.com/researcher/view_group_subpage.php?id=5617>, retrieved on Jul. 4, 2015, 2 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/839,916, dated Feb. 4, 2016, 19 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/839,922, dated Feb. 25, 2016, 20 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/503,372, dated Dec. 5, 2014, 11 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/599,424, dated Jan. 17, 2018, 13 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/599,425, dated Jan. 11, 2018, 42 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/599,425, dated Mar. 17, 2015, 16 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/599,425, dated Oct. 26, 2016., 22 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/732,773, dated Jan. 19, 2018., 45 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/839,916, dated May 1, 2017, 18 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/839,922, dated Aug. 17, 2016, 25 pages.;;Notice of Acceptance received for Australian Patent Application No. 2015267240, dated Apr. 10, 2018, 3 pages.;;Notice of Acceptance received for Australian Patent Application No. 2015312215, dated Oct. 9, 2017, 3 pages.;;Notice of Allowance received for Chinese Patent Application No. 201520358505.5, dated Jan. 13, 2016, 3 pages (2 pages of English Translation and 1 page of Official Copy).;;Notice of Allowance received for Danish Patent Application No. PA201570666, dated Sep. 15, 2016, 1 page.;;Notice of Allowance received for Danish Patent Application No. PA201570668, dated Oct. 30, 2017, 2 pages.;;Notice of Allowance received for Japanese Patent Application No. 2016-535045, dated Mar. 2, 2018, 4 pages (1 page of English Translation and 3 pages of Official Copy).;;Notice of Allowance received for Korean Patent Application No. 10-2016-7033638, dated May 31, 2017, 5 pages (2 pages of English Translation and 3 pages of Official Copy).;;Notice of Allowance received for Taiwanese Patent Application No. 104117509, dated Mar. 31, 2017, 3 pages.;;Notice of Allowance received for Taiwanese Patent Application No. 104128685, dated May 3, 2017, 3 pages.;;Notice of Allowance received for U.S. Appl. No. 14/599,424, dated Dec. 13, 2018, 6 pages.;;Notice of Allowance received for U.S. Appl. No. 14/839,916, dated Aug. 31, 2016, 11 pages.;;Notice of Allowance received for U.S. Appl. No. 14/839,916, dated Jan. 10, 2018, 19 pages.;;Notice of Allowance received for U.S. Appl. No. 14/839,922, dated Jan. 26, 2018, 2 pages.;;Notice of Allowance received for U.S. Appl. No. 14/839,922, dated Jul. 6, 2017, 8 pages.;;Notice of Allowance received for U.S. Appl. No. 14/839,922, dated Nov. 2, 2017, 8 pages.;;Office Action received for Japanese Patent Application No. 2016-569945, dated Nov. 10, 2017, 8 pages (4 pages of English Translation and 4 pages of Official Copy).;;Office Action received for Australian Patent Application No. 2015100734, dated Jul. 29, 2015, 5 pages.;;Office Action received for Australian Patent Application No. 2015267240, dated Apr. 10, 2017, 5 pages.;;Office Action received for Australian Patent Application No. 2015267240, dated Mar. 21, 2018, 5 pages.;;Office Action received for Australian Patent Application No. 2015312215, dated Oct. 13, 2016, 3 pages.;;Office Action received for Australian Patent Application No. 2018200428, dated Mar. 7, 2018, 4 pages.;;Office Action received for Chinese Patent Application No. 201510284850.3, dated Jul. 9, 2018, 11 pages (2 pages of English Translation and 9 pages of Official copy).;;Office Action received for Chinese Patent Application No. 201510284850.3, dated Nov. 28, 2017, 15 pages (5 pages of English Translation and 10 pages of Official Copy).;;Office Action received for Chinese Patent Application No. 201580028677.9, dated May 25, 2018, 14 pages (4 pages of English Translation and 10 pages of Official copy).;;Office Action Received for Danish Patent Application No. PA201670656, dated Nov. 3, 2016, 8 pages.;;Office Action received for Danish Patent Application No. PA201570666, dated Feb. 2, 2016, 9 pages.;;Office Action received for Danish Patent Application No. PA201570666, dated Jun. 27, 2016, 4 pages.;;Office Action received for Danish Patent Application No. PA201570668, dated Apr. 8, 2016, 8 pages.;;Office Action received for Danish Patent Application No. PA201570668, dated Sep. 9, 2016, 3 pages.;;Office Action received for Danish Patent Application No. PA201670656, dated Jun. 14, 2017, 3 pages.;;Office Action received for Danish Patent Application No. PA201670656, dated May 30, 2018, 5 pages.;;Office Action received for Danish Patent Application No. PA201770191, dated Jan. 25, 2018, 3 pages.;;Office Action received for European Patent Application No. 13811085.3, dated Apr. 20, 2018, 15 pages.;;Office Action received for European Patent Application No. 15730890.9, dated Aug. 3, 2017, 4 pages.;;Office Action received for European Patent Application No. 18154145.9, dated Apr. 3, 2018, 6 pages.;;Office Action received for European Patent Application No. 15771747.1, dated Oct. 31, 2017, 7 pages.;;Office Action received for Japanese Patent Application No. 2016-535045, dated May 12, 2017, 10 pages (5 pages of English Translation and 5 pages of Official Copy).;;Office Action received for Japanese Patent Application No. 2016-557650, dated Apr. 13, 2018, 9 pages (5 pages of English Translation and 4 pages of Official Copy).;;Office Action received for Japanese Patent Application No. 2016-557650, dated Aug. 10, 2017, 10 pages (5 pages of English Translation and 5 pages of Official Copy).;;Office Action received for Japanese Patent Application No. 2016-569945, dated Sep. 10, 2018, 11 pages (6 pages of English Translation and 5 pages of Official Copy).;;Office Action received for Korean Patent Application No. 10-2016-7014577, dated Dec. 26, 2017, 14 pages (6 pages of English Translation and 8 pages of Official Copy).;;Office Action received for Korean Patent Application No. 10-2016-7033638, dated Jan. 31, 2017, 6 pages (2 pages of English Translation and 4 pages of Official Copy).;;Office Action received for Taiwanese Patent Application No. 104117509, dated Aug. 22, 2016, 6 pages (3 pages of English Translation and 3 pages of Official Copy).;;Office Action received for Taiwanese Patent Application No. 104128685, dated Jan. 4, 2017, 40 pages (15 pages of English Translation and 25 pages of Official Copy).;;Search Report and Opinion received for Danish Patent Application No. PA201770191, dated Jun. 30, 2017, 9 pages.;;Summons to Attend Oral Proceedings received for European Patent Application No. 13811085.3, mailed on Jan. 26, 2018, 14 pages.;;Summons to Attend Oral Proceedings received for European Patent Application No. 15730890.9, mailed on Sep. 10, 2018, 11 pages.;;Summons to Attend Oral Proceedings received for European Patent Application No. 15771747.1, mailed on May 25, 2018, 17 pages.;;“Utilization of Galaxy S4-S Health, ChatOn and Samsung Hub”, Available at: http://seeit.kr/1263, Jun. 12, 2013, 25 pages.;;Brief Communication Regarding Oral Proceedings received for European Patent Application No. 19724963.4, mailed on Jun. 22, 2021, 2 pages.;;European Search Report received for European Patent Application No. 21165295.3, dated Jun. 18, 2021, 4 pages.;;Final Office Action received for U.S. Appl. No. 16/145,033, dated Jul. 6, 2021, 113 pages.;;Notice of Acceptance received for Australian Patent Application No. 2020204259, dated Jun. 11, 2021, 3 pages.;;Office Action received for Australian Patent Application No. 2019266054, dated Jun. 29, 2021, 3 pages.;;Office Action received for European Patent Application No. 21165295.3, dated Jul. 1, 2021, 10 pages.;;Office Action received for European Patent Application No. 19724963.4, dated Jul. 28, 2020, 6 pages.;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 15/554,204, dated Jan. 31, 2020, 3 pages.;;Intention to Grant received for Danish Patent Application No. PA201870385, dated Jan. 24, 2020, 2 pages.;;Notice of Allowance received for Japanese Patent Application No. 2016-569945, dated Jan. 7, 2020, 4 pages (1 page of English Translation and 3 pages of Official Copy).;;Office Action received for Australian Patent Application No. 2018279037, dated Jan. 17, 2020, 4 pages.;;Summons to Attend Oral Proceedings received for European Patent Application No. 16804040.0, mailed on Jan. 24, 2020, 11 pages.;;Wikipedia, “Emoji”, Available online at: https://en.wikipedia.org/w/index.php?title=Emoji&oldid=648831795, Feb. 25, 2015, 12 pages.;;Wikipedia, “Emoticon”, Available online at: https://en.wikipedia.org/w/index.php?title=Emoticon&oldid=648776142, Feb. 25, 2015, 9 pages.;;Final Office Action received for U.S. Appl. No. 16/389,722, dated Dec. 8, 2020, 18 pages.;;Notice of Allowance received for U.S. Appl. No. 16/407,590, dated Dec. 16, 2020, 6 pages.;;Office Action received for Australian Patent Application No. 2020204259, dated Nov. 30, 2020, 8 pages.;;Office Action received for Australian Patent Application No. 2020204506, dated Dec. 7, 2020, 6 pages.;;Office Action received for European Patent Application No. 16762356.0, dated Dec. 11, 2020, 7 pages.;;Result of Consultation received for European Patent Application No. 17810749.6, dated Dec. 15, 2020, 3 pages.;;Advisory Action received for U.S. Appl. No. 16/377,892, dated Apr. 9, 2021, 4 pages.;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 16/377,892, dated Mar. 26, 2021, 2 pages.;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 16/378,136, dated Mar. 26, 2021, 2 pages.;;Notice of Allowance received for U.S. Appl. No. 16/407,590, dated Apr. 9, 2021, 3 pages.;;Notice of Allowance received for U.S. Appl. No. 16/407,590, dated Mar. 22, 2021, 6 pages.;;Office Action received for Chinese Patent Application No. 201680013193.1, dated Feb. 1, 2021, 8 pages (3 pages of English Translation and 5 pages of Official Copy).;;Summons to Attend Oral Proceedings received for European Patent Application No. 19724963.4, mailed on Dec. 23, 2020, 8 pages.;;Certificate of Examination received for Australian Patent Application No. 2018101855, dated Aug. 6, 2019, 02 pages.;;Office Action received for Australian Patent Application No. 2019100490, dated Jul. 26, 2019, 4 pages.;;Supplemental Notice of Allowance received for U.S. Appl. No. 14/863,069, dated Aug. 15, 2019, 3 pages.;;Supplementary European Search Report received for European Patent Application No. 17810749.6, dated Aug. 6, 2019, 6 pages.;;Certificate of Examination received for Australian Patent Application No. 2019100490, dated Oct. 16, 2019, 2 pages.;;Final Office Action received for U.S. Appl. No. 15/554,204, dated Oct. 31, 2019, 22 pages.;;Non-Final Office Action received for U.S. Appl. No. 15/614,121, dated Nov. 4, 2019, 44 pages.;;Advisory Action received for U.S. Appl. No. 16/389,722, dated Mar. 9, 2021, 5 pages.;;Notice of Acceptance received for Australian Patent Application No. 2017277971, dated Feb. 17, 2021, 3 pages.;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 17/068,386, dated Sep. 21, 2021, 2 pages.;;Minutes of the Oral Proceedings received for European Patent Application No. 19724963.4, mailed on Sep. 3, 2021, 6 pages.;;Notice of Allowance received for Japanese Patent Application No. 2020-010239, dated Sep. 3, 2021, 4 pages (1 page of English Translation and 3 pages of Official Copy).;;Notice of Allowance received for U.S. Appl. No. 16/377,892, dated Sep. 9, 2021, 9 pages.;;Notice of Allowance received for U.S. Appl. No. 16/378,136, dated Sep. 22, 2021, 7 pages.;;Office Action received for Australian Patent Application No. 2018206772, dated Nov. 6, 2019, 4 pages.;;Office Action received for Korean Patent Application No. 10-2019-7029673, dated Nov. 5, 2019, 10 pages (4 pages of English Translation and 6 pages of Official Copy).;;Internet Blog Post, “[PC] Pre-Customization of Black Desert's Characters”, Online Available at: https://blog.naver.com/hsh6051/220209813968,Dec. 14, 2014, 41 pages (21 pages of English translation and 20 pages of Official Copy).;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 16/407,590, dated Nov. 17, 2020, 6 pages.;;Office Action received for Japanese Patent Application No. 2019-151358, dated Oct. 2, 2020, 5 pages (2 pages of English Translation and 3 pages of Official Copy).;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 16/145,033, dated Jun. 29, 2020, 5 pages.;;Examiner's Answer to Appeal Brief received for U.S. Appl. No. 14/869,877, dated Jun. 26, 2020, 14 pages.;;Notice of Allowance received for Chinese Patent Application No. 201680008151.9, dated Jun. 16, 2020, 2 pages (1 page of English Translation and 1 page of Official Copy).;;Office Action received for Chinese Patent Application No. 201811330077.X, dated May 18, 2020, 9 pages (3 pages of English Translation and 6 pages of Official Copy).;;Intention to Grant received for European Patent Application No. 18213157.3, dated May 19, 2021, 8 pages.;;Notice of Allowance received for Chinese Patent Application No. 201680013193.1, dated May 7, 2021, 5 pages (1 page of English Translation and 4 pages of Official Copy).;;Notice of Allowance received for U.S. Appl. No. 16/377,892, dated May 24, 2021, 9 pages.;;Summons to Attend Oral Proceedings received for European Patent Application No. 16762356.0, mailed on May 10, 2021, 10 pages.;;Advisory Action received for U.S. Appl. No. 14/841,606, dated Feb. 28, 2019, 3 pages.;;Advisory Action received for U.S. Appl. No. 14/869,877, dated Jan. 5, 2017, 3 pages.;;Advisory Action received for U.S. Appl. No. 14/870,793, dated Apr. 13, 2017, 3 pages.;;Certification of Examination received for Australian Patent Application No. 2018100158, dated Oct. 23, 2018, 2 pages.;;Codrington, Simon, “Intuitive Scrolling Interfaces with CSS Scroll Snap Points”, Online Available at: https://www.sitepoint.com/intuitive-scrolling-interfaces-with-css-scroll-snap-points/,, Dec. 8, 2015, 14 pages.;;Decision to Grant received for European Patent Application No. 16706081.3, dated Nov. 29, 2018, 2 pages.;;Examiner's Answer to Appeal Brief received for U.S. Appl. No. 14/870,793, dated Apr. 16, 2018, 15 pages.;;Extended European Search Report received for European Patent Application No. 16762356.0, dated Nov. 9, 2018, 10 Pages.;;Extended European Search Report received for European Patent Application No. 16804040.0, dated Feb. 26, 2018, 9 pages.;;Extended European Search Report received for European Patent Application No. 18213157.3, dated Apr. 12, 2019, 8 pages.;;Final Office Action received for U.S. Appl. No. 14/599,425, dated Jun. 12, 2018, 45 pages.;;Final Office Action received for U.S. Appl. No. 14/841,606, dated Sep. 7, 2018, 34 pages.;;Final Office Action received for U.S. Appl. No. 14/863,069, dated Jul. 5, 2018, 19 pages.;;Final Office Action received for U.S. Appl. No. 14/864,759, dated Sep. 4, 2018, 24 pages.;;Final Office Action received for U.S. Appl. No. 14/869,877, dated Apr. 26, 2018, 18 pages.;;Final Office Action received for U.S. Appl. No. 14/869,877, dated Aug. 3, 2016, 13 pages.;;Final Office Action received for U.S. Appl. No. 14/870,726, dated Apr. 19, 2017, 17 pages.;;Final Office Action received for U.S. Appl. No. 14/870,793, dated Jan. 19, 2017, 16 pages.;;Final Office Action received for U.S. Appl. No. 15/614,121, dated Apr. 8, 2019, 32 pages.;;Intention to Grant received for European Patent Application No. 16706081.3, dated Jul. 18, 2018, 8 pages.;;Intention to Grant received for European Patent Application No. 16706081.3, dated Jun. 11, 2018, 7 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2015/053353, dated Sep. 21, 2017, 15 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2016/014997, dated Dec. 21, 2017, 16 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2016/016216, dated May 4, 2017, 14 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2016/021403, dated Sep. 21, 2017, 21 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2016/034175, dated Dec. 14, 2017, 14 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2017/035554, dated Dec. 20, 2018, 39 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2017/036608, dated Dec. 27, 2018, 12 pages.;;International Search Report & Written Opinion received for PCT Patent Application No. PCT/US2016/014997, dated Aug. 31, 2016, 21 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/053353, dated May 9, 2016, 21 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2016/016216, dated Jun. 27, 2016, 18 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2016/021403, dated May 12, 2016, 23 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2016/034175, dated Oct. 7, 2016, 17 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2017/035554, dated Sep. 22, 2017, 42 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2017/036608, dated Oct. 20, 2017, 15 pages.;;Invitation to Pay Addition Fees and Partial International Search Report received for PCT Patent Application No. PCT/US2016/014997, dated May 2, 2016, 5 pages.;;Invitation to Pay Addition Fees and Partial International Search Report received for PCT Patent Application No. PCT/US2016/016216, dated Apr. 20, 2016, 6 pages.;;Invitation to Pay Addition Fees received for PCT Patent Application No. PCT/US2017/036608, dated Aug. 14, 2017, 2 pages.;;Invitation to Pay Additional fees received for PCT Patent Application No. PCT/US2015/053353, dated Jan. 21, 2016, 7 pages.;;Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US2016/034175, dated Aug. 11, 2016, 3 pages.;;Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US2017/035554, dated Jul. 20, 2017, 2 pages.;;Invitation to Restrict or Pay Additional Fees received for PCT Patent Application No. PCT/US2016/016216, dated Dec. 19, 2016, 9 pages.;;IOS Security, “White Paper”, Available online at <https://web.archive.org/web/20150526223200/http://www.apple.com/business/docs/iOS_Security_Guide.pdf>, Apr. 2015, 55 pages.;;“Mugs”, Online Available at: https://web.archive.org/web/20151029034349/http://le-mugs.com/,, Oct. 29, 2015.;;Non Final Office Action received for U.S. Appl. No. 14/869,877, dated Jan. 29, 2016, 18 pages.;;Non Final Office Action received for U.S. Appl. No. 14/869,877, dated Jun. 16, 2017, 17 pages.;;Non Final Office Action received for U.S. Appl. No. 14/869,877, dated Oct. 5, 2018, 19 pages.;;Non Final Office Action received for U.S. Appl. No. 14/870,793, dated Apr. 19, 2016, 17 pages.;;Non-Final Office Action received for U.S. Appl. No. 15/554,204, dated Apr. 17, 2019, 19 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/841,606, dated Dec. 7, 2017, 30 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/841,606, dated May 8, 2019, 28 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/863,069, dated Oct. 5, 2017, 19 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/864,759, dated Mar. 20, 2018, 20 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/870,726, dated Sep. 16, 2016, 12 pages.;;Non-Final Office Action received for U.S. Appl. No. 15/614,121, dated Nov. 30, 2018, 28 pages.;;Notice of Acceptance received for Australian Patent Application No. 2016215440, dated Feb. 28, 2019, 3 pages.;;Notice of Acceptance received for Australian Patent Application No. 2016229847, dated Sep. 12, 2018, 3 pages.;;Notice of Allowance received for Chinese Patent Application No. 201580028677.9, dated Apr. 2, 2019, 2 pages (1 pages of English Translation and 1 pages of Official Copy).;;Notice of Allowance received for U.S. Appl. No. 14/599,425, dated Dec. 19, 2018, 9 pages.;;Notice of Allowance received for U.S. Appl. No. 14/863,069, dated Feb. 6, 2019, 6 pages.;;Notice of Allowance received for U.S. Appl. No. 14/864,759, dated Dec. 14, 2018, 10 pages.;;Notice of Allowance received for U.S. Appl. No. 14/870,726, dated Sep. 11, 2018, 9 pages.;;Notice of Allowance received for U.S. Appl. No. 15/616,480, dated Jan. 3, 2019, 8 pages.;;Office Action received for Australian Patent Application No. 2016100796, dated Aug. 26, 2016, 6 pages.;;Office Action received for Australian Patent Application No. 2016100796, dated Feb. 13, 2017, 4 pages.;;Office Action received for Australian Patent Application No. 2016215440, dated Jan. 22, 2019, 2 pages.;;Office Action received for Australian Patent Application No. 2016215440, dated Mar. 13, 2018, 3 pages.;;Office Action received for Australian Patent Application No. 2016229847, dated Jul. 3, 2018, 4 pages.;;Office Action received for Australian Patent Application No. 2016270323, dated Nov. 26, 2018, 4 pages.;;Office Action received for Australian Patent Application No. 2017100231, dated Apr. 13, 2017, 3 pages.;;Office Action received for Australian Patent Application No. 2017100667, dated Aug. 3, 2017, 9 pages.;;Office Action received for Australian Patent Application No. 2017101375, dated Dec. 1, 2017, 3 pages.;;Office Action received for Australian Patent Application No. 2017101375, dated Feb. 19, 2018, 4 pages.;;Office Action received for Australian Patent Application No. 2017286296, dated May 8, 2019, 4 pages.;;Office Action received for Australian Patent Application No. 2018100158, dated Apr. 23, 2018, 5 pages.;;Office Action received for Australian Patent Application No. 2018101855, dated Feb. 22, 2019, 4 pages.;;Office Action received for Australian Patent Application No. 2018206772, dated Apr. 1, 2019, 4 pages.;;Office Action received for Chinese Patent Application No. 201610371774.4, dated Dec. 19, 2018, 13 pages (5 pages of English Translation and 8 pages of Official copy).;;Office Action received for Chinese Patent Application No. 201620509515.9, dated Nov. 9, 2016, 2 pages (1 page of English Translation and 1 page of Official Copy).;;Office Action received for Danish Patent Application No. PA201670362, dated Jan. 29, 2018, 3 pages.;;Office Action received for Danish Patent Application No. PA201670362, dated Jun. 1, 2017, 6 pages.;;Office Action received for Danish Patent Application No. PA201670362, dated Nov. 21, 2016, 11 pages.;;Office Action received for Danish Patent Application No. PA201670749, dated Jan. 30, 2017, 11 pages.;;Office Action received for Danish Patent Application No. PA201670749, dated Oct. 3, 2017, 3 pages.;;Office Action received for Danish Patent Application No. PA201670751, dated Jan. 13, 2017, 9 pages.;;Office Action received for Danish Patent Application No. PA201670751, dated Nov. 13, 2017, 2 pages.;;Office Action received for Danish Patent Application No. PA201770423, dated Jun. 12, 2018, 7 pages.;;Office Action received for Danish Patent Application No. PA201770423, dated Mar. 29, 2019, 6 pages.;;Office Action received for European Patent Application No. 16804040.0, dated May 13, 2019, 12 pages.;;Office Action received for Japanese Patent Application No. 2017-545918, dated Sep. 14, 2018, 12 pages (7 pages of English Translation and 5 pages of Official copy).;;Office Action received for Japanese Patent Application No. 2017-562330, dated Jan. 18, 2019, 11 pages (6 pages of English Translation and 5 pages of Official Copy).;;Office Action received for Korean Patent Application No. 10-2017-7024570, dated Sep. 28, 2018, 14 pages (6 pages of English Translation and 8 pages of Official copy).;;Office Action received for Korean Patent Application No. 10-2017-7034558, dated Dec. 15, 2018, 15 pages (7 pages of English Translation and 8 pages of Official Copy).;;Office Action received for Taiwanese Patent Application No. 104132636, dated Dec. 13, 2018, 26 pages (9 pages of English Translation and 17 pages of Official Copy).;;Office Action received for Taiwanese Patent Application No. 104132636, dated Mar. 23, 2017, 25 pages (10 pages of English Translation and 15 pages of Official copy).;;Office Action received for Taiwanese Patent Application No. 104132636, dated Oct. 31, 2017, 10 pages (4 pages of English Translation and 6 pages of Official Copy).;;Partial Supplementary European Search Report received for European Patent Application No. 17810749.6, dated Apr. 25, 2019, 8 pages.;;Preliminary Opinion received for European Patent Application No. 15730890.9, dated Mar. 7, 2019, 4 pages.;;Razykdreviews, “In Depth Review of Apple Watch Activity and Workout App”, available at <URL: https://www.youtube.com/watch?v=GkKl3qlK0ow>, May 11, 2015, 1 page.;;Rizknows, “Garmin Connect Mobile App—Review#2”, https://www.youtube.com/watch?v=7my3wMpeRbE, Oct. 22, 2015, 1 page.;;Search Report and Opinion received for Danish Patent Application No. PA201770423, dated Oct. 4, 2017, 10 pages.;;Search Report and Opinion received for Danish Patent Application No. PA201870385, dated Nov. 16, 2018, 10 Pages.;;Supplemental Notice of Allowance received for U.S. Appl. No. 14/863,069 , dated Mar. 29, 2019, 3 pages.;;Supplemental Notice of Allowance received for U.S. Appl. No. 14/863,069, dated Mar. 1, 2019, 3 pages.;;Supplemental Notice of Allowance received for U.S. Appl. No. 14/870,726, dated Mar. 6, 2019, 6 pages.;;Supplemental Notice of Allowance received for U.S. Appl. No. 15/616,480, dated Mar. 28, 2019, 2 pages.;;Tweedie, Steven, “Create and Customize Your Own Emojis with ‘Makemoji’ for iPhone”, Available online at: http://www.businessinsider.com/create-custom-emojis-with-makemoji-app-2014-8, Aug. 19, 2014, 6 pages.;;Whitwam, Ryan, “Facer is Fast Becoming the De Facto Custom Watch Face Maker for Android Wear”, Available online at: http://www.androidpolice.com/2014/09/19/facer-is-fast-becoming-the-de-facto-custom-watch-face-maker-for-android-wear, Sep. 19, 2014, 11 pages.;;Written Opinion Issued from International Preliminary Examining Authority for PCT Application No. PCT/US2016/016216, dated Feb. 20, 2017, 12 pages.;;Decision to Refuse received for European Patent Application No. 17810749.6, dated Jan. 29, 2021, 24 pages.;;Final Office Action received for U.S. Appl. No. 16/377,892, dated Jan. 28, 2021, 11 pages.;;Final Office Action received for U.S. Appl. No. 16/378,136, dated Jan. 28, 2021, 9 pages.;;Minutes of the Oral Proceedings received for European Patent Application No. 17810749.6, mailed on Jan. 26, 2021, 8 pages.;;Notice of Allowance received for Chinese Patent Application No. 201710439448.7, dated Jan. 26, 2021, 2 pages (1 page of English Translation and 1 page of Official Copy).;;Notice of Allowance received for Japanese Patent Application No. 2019-151358, dated Jan. 22, 2021, 4 pages (1 pages of English Translation and 3 pages of Official Copy).;;Office Action received for Japanese Patent Application No. 2020-010239, dated Jan. 4, 2021, 6 pages (3 pages of English Translation and 3 pages of Official Copy).;;Result of Consultation received for European Patent Application No. 17810749.6, mailed on Jan. 18, 2021, 3 pages.;;Result of Consultation received for European Patent Application No. 17810749.6, mailed on Jan. 21, 2021, 18 pages.;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 16/389,722, dated Sep. 7, 2021, 4 pages.;;Non-Final Office Action received for U.S. Appl. No. 16/679,967, dated Sep. 2, 2021, 12 pages.;;Non-Final Office Action received for U.S. Appl. No. 17/116,775, dated Aug. 24, 2021, 20 pages.;;Office Action received for Australian Patent Application No. 2019266054, dated Aug. 23, 2021, 4 pages.;;Office Action received for Australian Patent Application No. 2018279037, dated Jun. 18, 2019, 5 pages.;;Board Opinion received for Chinese Patent Application No. 201510284850.3, mailed on Jul. 2, 2021, 13 pages (3 pages of English Translation and 10 pages of Official Copy).;;Non-Final Office Action received for U.S. Appl. No. 17/068,386, dated Jul. 15, 2021, 16 pages.;;Office Action received for Chinese Patent Application No. 201780034193.4, dated Jun. 8, 2021, 16 pages (7 pages of English Translation and 9 pages of Official Copy).;;Result of Consultation received for European Patent Application No. 19724963.4, mailed on Jul. 8, 2021, 3 pages.;;Decision on Appeal received for U.S. Appl. No. 14/863,099, mailed on Aug. 22, 2019, 9 pages.;;Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US2019/024790, dated Jul. 18, 2019, 10 pages.;;Office Action received for European Patent Application No. 17810749.6, dated Aug. 20, 2019, 9 pages.;;Office Action received for Japanese Patent Application No. 2016-569945, dated Jul. 29, 2019, 5 pages (2 pages of English Translation and 3 pages of Official Copy).;;Decision on Appeal received for U.S. Appl. No. 14/774,664, mailed on Sep. 12, 2019, 8 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/024790, dated Sep. 11, 2019, 18 pages.;;Office Action received for Danish Patent Application No. PA201870385, dated Aug. 23, 2019, 3 pages.;;Non-Final Office Action received for U.S. Appl. No. 16/363,945, dated Apr. 24, 2020, 13 pages.;;Office Action received for Chinese Patent Application No. 201710439448.7, dated Mar. 27, 2020, 13 pages (7 pages of English Translation and 6 pages of Official Copy).;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 16/145,033, dated Nov. 24, 2020, 4 pages.;;Decision to Refuse received for European Patent Application No. 16804040.0, dated Nov. 4, 2020, 18 pages. et al.",ACTIVE
196,CN,U,CN 205038629 U,043-817-674-421-642,2016-02-17,2016,CN 201520358505 U,2015-05-28,US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Healthy polymerizer,"This discloses the content and relates to an electronic equipment to relate to healthy polymerizer. This discloses the content and relates to polymerization and the healthy data of sharing. Can be by subscriber equipment from the outside or inside any number's of subscriber equipment sensor, type the user of healthy data or receive healthy data from other users or entity from manual. Subscriber equipment can save healthy data on subscriber equipment safely and the healthy data of storage on the remote data storehouse are treated in the transmission. The user of equipment can share the healthy data of the part or whole of healthy data with good friend, relative, nursing staff, medical services provider etc. Subscriber equipment can further show user's healthy data in the polymerization view of different kinds of healthy data. If received mandate, the healthy data that then also can look over other users from other users.",APPLE INC,DANIEL S KEEN;;ZACHERY KENNEDY;;LAWRENCE Y YANG;;DENNIS S PARK;;GUY L TRIBBLE;;MICHAEL O'REILLY;;STEPHEN O LEMAY;;CHRISTOPHER D SOLI;;JAMES H FOSTER;;TODD K WHITEHURST,,https://lens.org/043-817-674-421-642,Limited Patent,no,0,4,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06F3/0481;;G06F3/0484;;G06F3/0488;;G16H50/70,,0,0,,,,ACTIVE
197,US,A1,US 2019/0349463 A1,144-713-782-176-07X,2019-11-14,2019,US 201916388493 A,2019-04-18,US 201916388493 A;;US 201514599424 A;;US 201462006032 P,2014-05-30,WELLNESS AGGREGATOR,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,SOLI CHRISTOPHER D;;YANG LAWRENCE Y;;PARK DENNIS S;;LEMAY STEPHEN O;;KEEN DANIEL S;;FOSTER JAMES H;;KENNEDY ZACHERY;;O'REILLY MICHAEL;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/144-713-782-176-07X,Patent Application,yes,0,13,6,55,0,G16H40/63;;G16H10/60;;H04W4/14;;G16H40/67;;H04W4/90;;G16H40/63;;G16H10/60;;G16H40/67;;H04M1/72421;;H04M1/72424;;G16H20/40;;H04W4/14;;H04W88/02,G16H10/60;;G16H20/40;;G16H40/63;;G16H40/67;;H04M1/72421;;H04M1/72424;;H04W4/14;;H04W4/90,,0,0,,,,ACTIVE
198,AU,A1,AU 2018/206772 A1,131-283-668-855-299,2018-08-09,2018,AU 2018/206772 A,2018-07-19,AU 2018/206772 A;;AU 2015/267240 A;;US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness data aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/131-283-668-855-299,Patent Application,no,0,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F3/048;;G16H50/70,,0,0,,,,ACTIVE
199,AU,B2,AU 2020/204259 B2,012-808-003-081-713,2021-06-24,2021,AU 2020/204259 A,2020-06-26,AU 2020/204259 A;;AU 2018/206772 A;;AU 2015/267240 A;;US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness data aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/012-808-003-081-713,Granted Patent,no,3,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F3/048;;G16H50/70,,0,0,,,,ACTIVE
200,AU,A1,AU 2023/210654 A1,128-896-067-435-866,2023-08-24,2023,AU 2023/210654 A,2023-08-04,AU 2023/210654 A;;AU 2021/218036 A;;AU 2020/204259 A;;AU 2018/206772 A;;AU 2015/267240 A;;US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness data aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/128-896-067-435-866,Patent Application,no,0,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F3/048;;G06Q50/22,,0,0,,,,PENDING
201,AU,A1,AU 2020/204259 A1,104-145-980-325-343,2020-07-16,2020,AU 2020/204259 A,2020-06-26,AU 2020/204259 A;;AU 2018/206772 A;;AU 2015/267240 A;;US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness data aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/104-145-980-325-343,Patent Application,no,0,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F3/048;;G16H50/70,,0,0,,,,ACTIVE
202,AU,A1,AU 2021/218036 A1,169-819-950-231-270,2021-09-09,2021,AU 2021/218036 A,2021-08-17,AU 2021/218036 A;;AU 2020/204259 A;;AU 2018/206772 A;;AU 2015/267240 A;;US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness data aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/169-819-950-231-270,Patent Application,no,0,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F3/048;;G16H50/70,,0,0,,,,ACTIVE
203,US,B2,US 10270898 B2,179-623-396-021-556,2019-04-23,2019,US 201514599424 A,2015-01-16,US 201514599424 A;;US 201462006032 P,2014-05-30,Wellness aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,SOLI CHRISTOPHER D;;YANG LAWRENCE Y;;PARK DENNIS S;;LEMAY STEPHEN O;;KEEN DANIEL S;;FOSTER JAMES H;;KENNEDY ZACHERY;;O'REILLY MICHAEL;;TRIBBLE GUY L;;WHITEHURST TODD K,APPLE INC (2015-03-23),https://lens.org/179-623-396-021-556,Granted Patent,yes,169,6,6,55,0,G16H40/63;;G16H10/60;;H04W4/14;;G16H40/67;;H04W4/90;;G16H40/63;;G16H10/60;;G16H40/67;;H04M1/72421;;H04M1/72424;;G16H20/40;;H04W4/14;;H04W88/02,G16H10/60;;G16H40/63;;G16H40/67;;H04M1/72421;;H04M1/72424;;H04W4/14;;H04W4/90;;H04W88/02,,87,0,,,"Office Action received for Japanese Patent Application No. 2016-569945, dated Nov. 10, 2017, 8 pages (4 pages of English Translation).;;Office Action received for Danish Patent Application No. PA201670656, dated May 30, 2018, 5 pages.;;Office Action received for Japanese Patent Application No. 2016-557650, dated Apr. 13, 2018, 9 pages (5 pages of English Translation).;;Summons to Attend Oral Proceedings received for European Patent Application No. 15771747.1, dated May 25, 2018, 17 pages.;;Office Action received for Chinese Patent Application No. 201580028677.9, dated May 25, 2018, 14 pages (4 pages of English Translation).;;Office Action received for Japanese Patent Application No. 2016-569945, dated Sep. 10, 2018, 11 pages (6 pages of English Translation).;;Office Action received for Australian Patent Application No. 2015267240, dated Mar. 21, 2018, 5 pages.;;Office Action received for Chinese Patent Application No. 201510284850.3, dated Nov. 28, 2017, 15 pages (5 pages of English Translation).;;Advisory Action received for U.S. Appl. No. 14/839,922, dated Mar. 24, 2017, 4 pages.;;Intention to Grant received for Danish Patent Application No. PA201570668, dated Mar. 27, 2017, 2 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2015/047282, dated Mar. 16, 2017, 26 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2016/037686, dated Sep. 9, 2016, 19 pages.;;Office Action received for Danish Patent Application No. PA201570666, dated Jun. 27, 2016, 4 pages.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2013/073195, dated Jun. 7, 2016, 9 pages.;;Office Action received for Danish Patent Application No. PA201570668, dated Apr. 8, 2016, 8 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/047282, dated May 9, 2016, 33 pages.;;Office Action received for Chinese Patent Application No. 201510284850.3, dated Jul. 9, 2018, 11 pages (2 pages of English Translation).;;Summons to Attend Oral Proceedings received for European Patent Application No. 15730890.9, dated Sep. 10, 2018, 11 pages.;;Notice of Allowance received for U.S. Appl. No. 14/839,922, dated Jan. 26, 2018, 2 pages.;;Office Action received for Danish Patent Application No. PA201770191, dated Jan. 25, 2018, 3 pages.;;Summons to attend oral proceedings received for European Patent Application No. 13811085.3, dated Jan. 26, 2018, 14 pages.;;Office Action received for European Patent Application No. 15730890.9, dated Aug. 3, 2017, 4 pages.;;Office Action received for Japanese Patent Application No. 2016-557650, dated Aug. 10, 2017, 10 pages (5 pages of English Translation).;;Notice of Allowance received for U.S. Appl. No. 14/839,922, dated Jul. 6, 2017, 8 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/599,425, dated Jan. 11, 2018, 42 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/732,773, dated Jan. 19, 2018, 45 pages.;;Notice of Allowance received for U.S. Appl. No. 14/839,916, dated Jan. 10, 2018, 19 pages.;;Office Action received for Korean Patent Application No. 10-2016-7014577, dated Dec. 26, 2017, 14 pages (6 pages of English Translation).;;“Utilization of Galaxy S4—S Health, ChatOn and Samsung Hub”, Available at: http://seeit.kr/1263, Jun. 12, 2013, 25 pages (see attached 37 CFR § 1.98(a) (3)).;;Jenbsjourney, “Wondering About a Fitbit?”Available at: https://jenbsjourney.blogspot.kr/2013/08/wondering-about-fitbit.html, Aug. 6, 2013, 12 pages.;;Final Office Action received for U.S. Appl. No. 14/599,425, dated May 19, 2017, 24 pages.;;Notice of Allowance received for Korean Patent Application No. 10-2016-7033638, dated May 31, 2017, 5 pages (2 pages of English Translation).;;Notice of Allowance received for Taiwanese Patent Application No. 104128685, dated May 3, 2017, 3 pages (see attached 37 CFR § 1.98(a) (3)).;;Office Action received for Japanese Patent Application No. 2016535045, dated May 12, 2017, 10 pages (5 pages of English Translation).;;Office Action received for Danish Patent Application No. PA201670656, dated Jun. 14, 2017, 3 pages.;;Search Report and Opinion received for Danish Patent Application No, PA201770191, dated Jun. 30, 2017, 9 pages.;;Extended European Search Report received for European Patent Application No. 18154145.9, dated Mar. 2, 2018, 8 pages.;;International Preliminary Report on Patentability received for PCT Application No. PCT/US2016/037686, dated Mar. 1, 2018, 12 pages.;;Notice of Allowance received for Japanese Patent Application No. 2016-535045, dated Mar. 2, 2018, 5 pages (2 pages of English Translation).;;Office Action received for Australian Patent Application No. 2018200428, dated Mar. 7, 2018, 4 pages.;;Non Final Office Action received for U.S. Appl. No. 14/839,916, dated Feb. 4, 2016, 19 pages.;;Non Final Office Action received for U.S. Appl. No. 14/839,922, dated Feb. 25, 2016, 20 pages.;;Notice of Allowance received for Chinese Patent Application No. 201520358505.5, dated Jan. 13, 2016, 3 pages (2 pages of English Translation).;;Office Action received for Danish Patent Application No. PA201570666, dated Feb. 2, 2016, 9 pages.;;International Search Report received for PCT Patent Application No. PCT/US2013/073195, dated Jun. 23, 2014, 3 pages.;;Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US2015047282, dated Dec. 22, 2015, 7 pages.;;“i Phone User Guide for iOS 7.1 Software”, available online at <https://manuals.info.apple.com/Manuals/1000/MA1681/en_US/iphone_ios7_user_guide.pdf> retrieved on Aug. 10, 2015, 162 pages.;;Office Action received for Australian Patent Application No. 2015100734, dated Jul. 29, 2015, 5 pages.;;International Search Report and Written Opinion received for PCT Application No. PCT/US2015/032474, dated Aug. 19, 2015, 8 pages.;;Final Office Action received for U.S. Appl. No. 14/599,425, dated Oct. 8, 2015, 20 pages.;;Non Final Office Action received for U.S. Appl. No. 14/503,072, dated Jan. 26, 2015, 12 pages.;;Non Final Office Action received for U.S. Patent Application No. 14/503,296, dated Jan. 30, 2015, 16 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/503,372, dated Dec. 5, 2014, 11 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/503,381, dated May 13, 2015, 13 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/599,425, dated Mar. 17, 2015, 16 pages.;;Kamijo, Noboru, “Next Generation Mobile System—WatchPad1.5”, Available at “http://researcher.ibm.com/researcher/view_group_subpage.php?id=5617”, retrieved on Jul. 4, 2015, 2 pages.;;Lemay et al., U.S. Appl. No. 60/936,562, filed Jun. 20, 2007, titled “Portable Multifunction Device, Method, and Graphical User Interface for Playing Online Videos”, 61 pages.;;NDTV, “Sony SmartWatch 2 Launched in India for Rs. 14,990”, available at “http://gadgets.ndtv.com/others/news/sony-smartwatch-2-launched-in-india-for-rs-14990-420319”, Sep. 18, 2013, 4 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/053951, dated Dec. 8, 2014, 11 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/053957, dated Feb. 19, 2015, 11 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/053958, dated Feb. 19, 2015, 10 pages.;;Yang et al., U.S. Appl. No. 62/004,886, filed May 29, 2014, titled “User Interface for Payments”, 198 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/019321, dated Jun. 3, 2015, 11 pages.;;Apple, “iPhone User's Guide”, 2007, 137 pages.;;Final Office Action received for U.S. Appl. No. 14/839,922, dated Dec. 14, 2016, 22 pages.;;International Preliminary Report on Patentability Received for PCT Patent Application No. PCT/US2015/032474, dated Dec. 15, 2016, 7 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/599,425, dated Oct. 26, 2016, 22 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/839,922, dated Aug. 17, 2016, 25 pages.;;Notice of Allowance received for Danish Patent Application No. PA201570666, dated Sep. 15, 2016, 1 page.;;Notice of Allowance received for U.S. Appl. No. 14/839,916, dated Aug. 31, 2016, 11 pages.;;Office Action received for Australian Patent Application No. 2015312215, dated Oct. 13, 2016, 3 pages.;;Office Action Received for Danish Patent Application No. PA201670656, dated Nov. 3, 2016, 8 pages.;;Office Action received for Danish Patent Application No. PA201570668, dated Sep. 9, 2016, 3 pages.;;Office Action received for Korean Patent Application No. 10-2016-7033638, dated Jan. 31, 2017, 6 pages (2 pages of English Translation).;;Office Action received for Taiwanese Patent Application No. 104117509, dated Aug. 22, 2016, 6 pages (3 pages of English Translation).;;Office Action received for Taiwanese Patent Application No. 104128685, dated Jan. 4, 2017, 40 pages (15 pages of English Translation).;;Written Opinion received for PCT Patent Application No. PCT/US2013/073195, dated Jun. 23, 2014, 8 pages.;;Notice of Acceptance received for Australian Patent Application No. 2015267240, dated Apr. 10, 2018, 3 pages.;;Office Action received for European Patent Application No. 13811085.3, dated Apr. 20, 2018, 15 pages.;;Office Action received for European Patent Application No. 18154145.9, dated Apr. 3, 2018, 6 pages.;;Notice of Acceptance received for Australian Patent Application No. 2015312215, dated Oct. 9, 2017, 3 pages.;;Notice of Allowance received for U.S. Appl. No. 14/839,922, dated Nov. 2, 2017, 8 pages.;;Office Action received for European Patent Application No. 15771747,1, dated Oct. 31, 2017, 7 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/839,916, dated May 1, 2017, 18 pages.;;Notice of Allowance received for Taiwanese Patent Application No. 104117509, dated Mar. 31, 2017, 3 pages (see attached 37 CFR § 1.98(a) (3)).;;Office Action received for Australian Patent Application No. 2015267240, dated Apr. 10, 2017, 5 pages.;;Notice of Allowance received for Danish Patent Application No. PA201570668, dated Oct. 30, 2017, 2 pages.",ACTIVE
204,AU,A4,AU 2015/100734 A4,101-480-445-382-96X,2015-07-02,2015,AU 2015/100734 A,2015-05-29,US 2015/0032474 W;;US 201462006032 P;;US 201562129945 P,2014-05-30,Wellness aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received. Portable Multifunction Device 100 Speaker111 Optical Proximity Sensor ij4 Sensor 210 is SIM card slot 212 is headphone jack Touch Screen 112 Contact Intensity Sensor(s) Tactile OutpuT Generators) 167 Microphone Home (Accelenmeter(s) 113 ) 204 168 External Port 124",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/101-480-445-382-96X,Limited Patent,no,0,0,1,55,0,,G06Q50/22,,0,0,,,,INACTIVE
205,CN,A,CN 106415559 A,069-686-291-309-844,2017-02-15,2017,CN 201580028677 A,2015-05-26,US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness data aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/069-686-291-309-844,Patent Application,no,3,13,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G16H50/70,,0,0,,,,ACTIVE
206,EP,A1,EP 3105721 A1,062-506-323-550-750,2016-12-21,2016,EP 15730890 A,2015-05-26,US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,WELLNESS DATA AGGREGATOR,,APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,APPLE INC. (2018-08-01),https://lens.org/062-506-323-550-750,Patent Application,yes,0,1,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F3/048;;G16H50/70,,0,0,,,,DISCONTINUED
207,TW,B,TW I591504 B,092-413-706-001-965,2017-07-11,2017,TW 104117509 A,2015-05-29,US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness aggregator,,APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/092-413-706-001-965,Granted Patent,no,0,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G16H50/70,,0,0,,,,ACTIVE
208,JP,A,JP 2020075152 A,000-627-864-156-969,2020-05-21,2020,JP 2020010239 A,2020-01-24,JP 2016569945 A;;US 201562129945 P;;US 201462006032 P,2014-05-30,HEALTH DATA AGGREGATOR,"To provide a system that allows users to easily store, see, and share health data aggregated by various devices.SOLUTION: In a system 600, health data can be received by a user device from an arbitrary number of sensors in the outside 502-608 or in the inside 615 of the user device 610 or from a manually inputting user. The user device can store the health data on the user device securely (611), and transmit the health data to be stored in a remote database. The device user can share a part or all of the health data with friends, relatives, care-givers, health care providers, etc. The user device can further display the health data on the user in an aggregate view of different kinds of health data. Health data on other users may also be seen if permission is obtained from those users.SELECTED DRAWING: Figure 6",APPLE INC,LAWRENCE Y YANG;;JAMES H FOSTER;;DANIEL S KEEN;;ZACHERY KENNEDY;;LEMAY STEPHEN O;;MICHAEL O'REILLY;;DENNIS S PARK;;CHRISTOPHER D SOLI;;GUY L TRIBBLE;;TODD K WHITEHURST,,https://lens.org/000-627-864-156-969,Patent Application,no,0,1,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,A61B5/00;;G06F3/0481;;G06F3/0488;;G16H50/70,,0,0,,,,ACTIVE
209,CN,A,CN 105260078 A,157-560-314-216-736,2016-01-20,2016,CN 201510284850 A,2015-05-28,US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,WELLNESS DATA AGGREGATOR,"The invention relates to a WELLNESS DATA AGGREGATOR. The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,LAWRENCE Y YANG;;JAMES H FOSTER;;DENNIS S PARK;;TODD K WHITEHURST;;STEPHEN O LEMAY;;MICHAEL O'REILLY;;GUY L TRIBBLE;;DANIEL S KEEN;;ZACHERY KENNEDY;;CHRISTOPHER D SOLI,,https://lens.org/157-560-314-216-736,Patent Application,no,6,17,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06F3/0481;;G06F3/0484;;G06F3/0488;;G16H50/70,,0,0,,,,DISCONTINUED
210,AU,A1,AU 2015/267240 A1,178-915-041-698-072,2016-10-06,2016,AU 2015/267240 A,2015-05-26,US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness data aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/178-915-041-698-072,Patent Application,no,0,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F3/048;;G16H50/70,,0,0,,,,ACTIVE
211,TW,A,TW 201600991 A,089-028-273-719-63X,2016-01-01,2016,TW 104117509 A,2015-05-29,US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/089-028-273-719-63X,Patent of Addition,no,0,3,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,A61B5/00;;A61B5/11;;G16H50/70,,0,0,,,,ACTIVE
212,AU,B2,AU 2021/218036 B2,182-284-975-185-947,2023-05-18,2023,AU 2021/218036 A,2021-08-17,AU 2021/218036 A;;AU 2020/204259 A;;AU 2018/206772 A;;AU 2015/267240 A;;US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness data aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/182-284-975-185-947,Granted Patent,no,1,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F3/048;;G06Q50/22,,0,0,,,,ACTIVE
213,AU,B2,AU 2015/267240 B2,132-655-056-911-334,2018-04-19,2018,AU 2015/267240 A,2015-05-26,US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,Wellness data aggregator,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;WHITEHURST TODD K;;LEMAY STEPHEN O;;O'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L,,https://lens.org/132-655-056-911-334,Granted Patent,no,2,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F3/048;;G16H50/70,,0,0,,,,ACTIVE
214,US,A1,US 2003/0180083 A1,051-939-144-057-017,2003-09-25,2003,US 35129303 A,2003-01-24,US 35129303 A;;US 68943300 A;;US 19204000 P,2000-03-24,Cleaning pad with notches,"
   A cleaning pad for use on a cleaning system in which cleaning fluid or other liquid is dispensed onto a surface in front of a cleaning head portion, the cleaning pad comprising a central absorbent and scrubbing portion, a back edge portion for removably attaching the cleaning pad to the cleaning head portion, and a front edge portion for removably attaching the cleaning pad to the cleaning head portion, the front edge portion having a notch thereon, thereby allowing attachment of the cleaning pad to the cleaning head portion such that cleaning or other fluid can be dispensed from the cleaning head portion onto a surface in front of the cleaning head portion without interference by the cleaning pad. 
",HALL MICHAEL J.;;RADER JAMES E.;;ZHOU BOLI;;HEFTER KAREN S.;;SAYLER DAVID J.;;PARK ERIC Y.;;FLAGLER ROBERT W.;;HAUBRICH SCOTT T.;;MITRA SHUMANTA;;PORTICOS RICHARD;;PARK GENE,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID J;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD;;PARK GENE,CLOROX COMPANY THE (2001-07-09),https://lens.org/051-939-144-057-017,Patent Application,yes,15,13,14,33,0,A47L13/22;;A47L13/22;;A47L13/26;;A47L13/26;;A47L13/312;;A47L13/312;;A47L13/44;;A47L13/44,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,40114;;X40127;;401/278;;401/138,0,0,,,,DISCONTINUED
215,CA,A1,CA 3115737 A1,081-657-166-532-109,2020-04-16,2020,CA 3115737 A,2019-10-03,US 201862743233 P;;US 2019/0054484 W,2018-10-09,OSTOMY APPLIANCE HAVING CONDUCTIVE INK CIRCUIT FOR LEAKAGE DETECTION,An ostomy appliance includes a substrate and at least one Radio Frequency Identification (RFID) circuit disposed on the substrate. The RFID circuit includes a RFID transponder having an antenna and a conductive ink connected in series with the antenna and the RFID transponder. The conductive ink is configured to dissolve in response to exposure to moisture. The RFID circuit is in a closed condition when the conductive ink extends continuously between the RFID transponder and the antenna. The RFID circuit is in an open condition when at least a portion of the conductive ink is dissolved.,HOLLISTER INC,NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;CARLSSON JONAS P;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT,,https://lens.org/081-657-166-532-109,Patent Application,no,0,0,6,6,0,A61F5/445;;A61F5/4404;;A61F5/443;;A61F5/448;;G01M3/16,A61F5/445,,0,0,,,,PENDING
216,EP,A1,EP 3863575 A1,033-882-332-758-120,2021-08-18,2021,EP 19791093 A,2019-10-03,US 201862743233 P;;US 2019/0054484 W,2018-10-09,OSTOMY APPLIANCE HAVING CONDUCTIVE INK CIRCUIT FOR LEAKAGE DETECTION,,HOLLISTER INC,NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;CARLSSON JONAS P;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT,,https://lens.org/033-882-332-758-120,Patent Application,yes,0,0,6,6,0,A61F5/445;;A61F5/4404;;A61F5/443;;A61F5/448;;G01M3/16,A61F5/445,,0,0,,,,PENDING
217,CN,A,CN 112969434 A,127-335-747-590-150,2021-06-15,2021,CN 201980066169 A,2019-10-03,US 201862743233 P;;US 2019/0054484 W,2018-10-09,OSTOMY APPLIANCE HAVING CONDUCTIVE INK CIRCUIT FOR LEAKAGE DETECTION,An ostomy appliance includes a substrate and at least one radio frequency identification (RFID) circuit disposed on the substrate. The RFID circuit includes a RFID transponder having an antenna and a conductive ink connected in series with the antenna and the RFID transponder. The conductive ink is configured to dissolve in response to exposure to moisture. The RFID circuit is in a closed condition when the conductive ink extends continuously between the RFID transponder and the antenna. The RFID circuit is in an open condition when at least a portion of the conductive ink is dissolved.,HOLLISTER INC,NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;CARLSSON JONAS P;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT,,https://lens.org/127-335-747-590-150,Patent Application,no,10,1,6,6,0,A61F5/445;;A61F5/4404;;A61F5/443;;A61F5/448;;G01M3/16,A61F5/445,,0,0,,,,PENDING
218,US,A1,US 2021/0338471 A1,066-883-837-924-683,2021-11-04,2021,US 201917281142 A,2019-10-03,US 201917281142 A;;US 201862743233 P;;US 2019/0054484 W,2018-10-09,OSTOMY APPLIANCE HAVING CONDUCTIVE INK CIRCUIT FOR LEAKAGE DETECTION,An ostomy appliance includes a substrate and at least one Radio Frequency Identification (RFID) circuit disposed on the substrate. The RFID circuit includes a RFID transponder having an antenna and a conductive ink connected in series with the antenna and the RFID transponder. The conductive ink is configured to dissolve in response to exposure to moisture. The RFID circuit is in a closed condition when the conductive ink extends continuously between the RFID transponder and the antenna. The RFID circuit is in an open condition when at least a portion of the conductive ink is dissolved.,HOLLISTER INC,NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;CARLSSON JONAS P;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT,HOLLISTER INCORPORATED (2020-02-02);;LUNAR DESIGN LLC (2020-02-20),https://lens.org/066-883-837-924-683,Patent Application,yes,4,35,6,6,0,A61F5/445;;A61F5/4404;;A61F5/443;;A61F5/448;;G01M3/16,A61F5/44;;A61F5/443;;A61F5/448;;G01M3/16,,0,0,,,,PENDING
219,AU,A1,AU 2019/359129 A1,156-354-306-032-167,2021-05-13,2021,AU 2019/359129 A,2019-10-03,US 201862743233 P;;US 2019/0054484 W,2018-10-09,Ostomy appliance having conductive ink circuit for leakage detection,An ostomy appliance includes a substrate and at least one Radio Frequency Identification (RFID) circuit disposed on the substrate. The RFID circuit includes a RFID transponder having an antenna and a conductive ink connected in series with the antenna and the RFID transponder. The conductive ink is configured to dissolve in response to exposure to moisture. The RFID circuit is in a closed condition when the conductive ink extends continuously between the RFID transponder and the antenna. The RFID circuit is in an open condition when at least a portion of the conductive ink is dissolved.,HOLLISTER INC,NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;CARLSSON JONAS P;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT,,https://lens.org/156-354-306-032-167,Patent Application,no,0,0,6,6,0,A61F5/445;;A61F5/4404;;A61F5/443;;A61F5/448;;G01M3/16,A61F5/445,,0,0,,,,PENDING
220,WO,A1,WO 1993/018525 A1,002-754-123-096-860,1993-09-16,1993,US 9302061 W,1993-03-12,US 85066992 A;;US 85067792 A;;US 85156092 A,1992-03-13,SCANNING PROBE MICROSCOPE,"A scanning probe microscope (100) has a probe (101) removably mounted in the head (108), using kinematic mounting techniques. A motorized, non-stacked x, y coarse movement stage (116) is kinematically positioned with respect to the base (114). A motorized z coarse movement stage (112) positions the head kinematically with respect to the base (114) and allows the height, tilt and pitch of the probe (101) to be adjusted. The scanner (118) includes x, y and z sample position detectors which provide an accurate measurement of the position of the sample with respect to the probe. The outputs of the x, y and z position detectors may also be connected in feedback loops with the controller (110) to improve the performance of the scanning probe microscope (100). An optical viewing assembly (124) provides combined coaxial and oblique views of the cantilever (102) and sample (104). A graphical user interface has simultaneous on-screen optical and scanning probe microscope views.",PARK SCIENT INSTR CORP,LINKER FREDERICK I;;KIRK MICHAEL D;;SWIFT PETER R;;ALEXANDER JOHN D;;PARK SANG-IL;;PARK SUNG-IL;;SMITH IAN R;;PARISH DAVID M;;LEE JEONG HO;;HOWLAND REBECCA S,,https://lens.org/002-754-123-096-860,Patent Application,yes,13,25,9,21,0,G01Q30/04;;G01Q70/02;;G02B21/002;;G02B21/26;;Y10S977/851;;Y10S977/85;;G01Q30/025;;G01Q70/02;;G01Q30/04;;B82Y35/00;;G02B21/002;;G02B21/26;;Y10S977/851;;Y10S977/85;;G01Q30/025,G01Q30/02;;G01B21/30;;G01Q30/04;;G01Q60/00;;G01Q70/02;;G02B21/00;;G02B21/26;;G21K5/10;;H01J37/00;;H01J37/20;;H01J37/22,,1,0,,,See also references of EP 0746857A4,PENDING
221,EP,A1,EP 0746857 A1,122-499-437-487-501,1996-12-11,1996,EP 93907296 A,1993-03-12,US 9302061 W;;US 85066992 A;;US 85067792 A;;US 85156092 A,1992-03-13,SCANNING PROBE MICROSCOPE,,PARK SCIENT INSTR CORP,LINKER FREDERICK I;;KIRK MICHAEL D;;SWIFT PETER R;;ALEXANDER JOHN D;;PARK SANG-IL;;PARK SUNG-IL;;SMITH IAN R;;PARISH DAVID M;;LEE JEONG HO;;HOWLAND REBECCA S,,https://lens.org/122-499-437-487-501,Patent Application,yes,0,0,9,21,0,G01Q30/04;;G01Q70/02;;G02B21/002;;G02B21/26;;Y10S977/851;;Y10S977/85;;G01Q30/025;;G01Q70/02;;G01Q30/04;;B82Y35/00;;G02B21/002;;G02B21/26;;Y10S977/851;;Y10S977/85;;G01Q30/025,G01Q30/02;;G01B21/30;;G01Q30/04;;G01Q60/00;;G01Q70/02;;G02B21/00;;G02B21/26;;G21K5/10;;H01J37/00;;H01J37/20;;H01J37/22,,0,0,,,,DISCONTINUED
222,CN,A,CN 114995695 A,185-075-076-536-991,2022-09-02,2022,CN 202210618961 A,2015-05-28,US 201462006032 P;;US 201562129945 P;;CN 201510284850 A;;US 2015/0032474 W,2014-05-30,Healthy aggregator,"The invention relates to a healthy aggregator. The disclosure relates to aggregating and sharing health data. Health data may be received by a user device from any number of sensors external or internal to the user device, from users who manually enter health data, or from other users or entities. A user device may securely store health data on the user device and transmit the health data to be stored on a remote database. A user of the device may share part or all of the health data with friends, relatives, caregivers, medical service providers, etc. The user device may further display the user's health data in an aggregated view of different types of health data. If authorization has been received from other users, other user's health data may also be viewed.",APPLE INC,YANG LAWRENCE Y;;FOSTER JAMES H;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;O 'REILLY MICHAEL;;PARK DENNIS S;;SOLI CHRISTOPHER D;;TRIBBLE GUY L;;WHITEHURST TODD K,,https://lens.org/185-075-076-536-991,Patent Application,no,0,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06F3/0481;;G06F3/04847;;G06F3/04883;;G16H10/60;;G16H50/70,,0,0,,,,PENDING
223,EP,A4,EP 0746857 A4,190-302-614-966-613,2001-01-03,2001,EP 93907296 A,1993-03-12,US 9302061 W;;US 85066992 A;;US 85067792 A;;US 85156092 A,1992-03-13,SCANNING PROBE MICROSCOPE,,THERMOMICROSCOPES CORP,LINKER FREDERICK I;;KIRK MICHAEL D;;SWIFT PETER R;;ALEXANDER JOHN D;;PARK SANG-IL;;PARK SUNG-IL;;SMITH IAN R;;PARISH DAVID M;;LEE JEONG HO;;HOWLAND REBECCA S,,https://lens.org/190-302-614-966-613,Search Report,no,11,0,9,21,0,G01Q30/04;;G01Q70/02;;G02B21/002;;G02B21/26;;Y10S977/851;;Y10S977/85;;G01Q30/025;;G01Q70/02;;G01Q30/04;;B82Y35/00;;G02B21/002;;G02B21/26;;Y10S977/851;;Y10S977/85;;G01Q30/025,G01Q30/02;;G01Q30/04;;G01Q60/00;;G01B21/30;;G01Q70/02;;G02B21/00;;G02B21/26;;G21K5/10;;H01J37/00;;H01J37/20;;H01J37/22,,6,4,088-530-689-950-808;;038-345-015-857-940;;153-545-300-238-212;;125-783-626-336-136,10.1063/1.1140586;;10.1063/1.1140293;;10.1147/rd.351.0067;;10.1116/1.577105,"LANG C A ET AL: ""LOW-TEMPERATURE ULTRAHIGH-VACUUM SCANNING TUNNELING MICROSCOPE"", REVIEW OF SCIENTIFIC INSTRUMENTS, vol. 60, no. 10, 1 October 1989 (1989-10-01), pages 3109 - 3112, XP000071629;;DILELLA D P ET AL: ""CONTROL SYSTEMS FOR SCANNING TUNNELING MICROSCOPES WITH TUBE SCANNERS"", REVIEW OF SCIENTIFIC INSTRUMENTS, vol. 60, no. 6, June 1989 (1989-06-01), pages 997 - 1002, XP000035861;;PATENT ABSTRACTS OF JAPAN vol. 009, no. 332 (E - 370) 26 December 1985 (1985-12-26);;STOLL E P: ""PICTURE PROCESSING AND THREE-DIMENSIONAL VISUALIZATION OF DATA FROM SCANNING TUNNELING AND ATOMIC FORCE MICROSCOPY"", IBM JOURNAL OF RESEARCH AND DEVELOPMENT,US,IBM CORPORATION, ARMONK, vol. 35, no. 1 / 02, 1991, pages 67 - 77, XP000262739, ISSN: 0018-8646;;YASUTAKE M ET AL: ""SCANNING TUNNELING MICROSCOPE COMBINED WITH OPTICAL MICROSCOPE FOR LARGE SAMPLE MEASUREMENT"", JOURNAL OF VACUUM SCIENCE AND TECHNOLOGY: PART A,US,AMERICAN INSTITUTE OF PHYSICS. NEW YORK, vol. 8, no. 1, 1990, pages 350 - 353, XP000117305, ISSN: 0734-2101;;See also references of WO 9318525A1",DISCONTINUED
224,AU,A,AU 1993/037948 A,043-454-274-591-802,1993-10-05,1993,AU 1993/037948 A,1993-03-12,US 9302061 W;;US 85066992 A;;US 85067792 A;;US 85156092 A,1992-03-13,SCANNING PROBE MICROSCOPE,,PARK SCIENT INSTR CORP,LINKER FREDERICK I;;KIRK MICHAEL D;;SWIFT PETER R;;ALEXANDER JOHN D;;PARK SANG-IL;;PARK SUNG-IL;;SMITH IAN R;;PARISH DAVID M;;LEE JEONG HO;;HOWLAND REBECCA S,,https://lens.org/043-454-274-591-802,Patent Application,no,0,0,9,21,0,G01Q30/04;;G01Q70/02;;G02B21/002;;G02B21/26;;Y10S977/851;;Y10S977/85;;G01Q30/025;;G01Q70/02;;G01Q30/04;;B82Y35/00;;G02B21/002;;G02B21/26;;Y10S977/851;;Y10S977/85;;G01Q30/025,G01B21/30;;G01Q30/02;;G01Q30/04;;G01Q60/00;;G01Q70/02;;G02B21/00;;G02B21/26;;G21K5/10;;H01J37/00;;H01J37/20;;H01J37/22,,0,0,,,,PENDING
225,WO,A1,WO 2023/222832 A1,039-482-747-354-211,2023-11-23,2023,EP 2023063388 W,2023-05-17,EP 22174702 A,2022-05-20,SPHERICAL ELECTROMAGNETIC ACTUATOR AND METHOD FOR CONTROLLING A MAGENTIC FIELD THEREOF,"The invention relates to a spherical electromagnetic actuator. The spherical electromagnetic actuator including a spherical permanent magnet having a center region, a housing comprising a chamber enclosing the spherical magnet and having an inlet for receiving a fluid. The actuator further including three electromagnetic coil assemblies with each coil assembly having at least one coil and a virtual symmetry axis, and wherein the three electromagnetic coil assemblies are arranged such that the three respective symmetry axes intersect at a center region the spherical permanent magnet. The housing is arranged such that in operation the fluid causes the spherical magnet to levitate. And, in operation, the three electromagnetic coil assemblies provide a superpositioned magnetic field manipulating the orientation of the spherical magnet. The invention further relates to a method for controlling the magnetic field of at least one spherical magnetic actuator.",UNIV TWENTE;;KOREA INSTIITUTE OF MEDICAL MICROROBOTICS;;INDUSTRY FOUNDATION OF CHONNAM NAT,ALAA ELDIN ADEL MOHAMED MAHMOUD SADEK;;MINA MAGED MICHAEL FARAG;;SARTHAK MISRA;;ISLAM S M KHALIL;;PARK JONG OH;;KIM CHANG SEI,,https://lens.org/039-482-747-354-211,Patent Application,yes,10,0,2,2,0,H02K2201/18;;H02K26/00;;H02K41/031;;A61B34/73;;A61B1/00158;;H02K11/215;;H02K11/25;;H02K11/27;;H02K11/30,H02K26/00;;A61B1/00;;A61B34/00;;H02K11/215;;H02K11/25;;H02K11/27;;H02K11/30;;H02K41/03,,0,0,,,,PENDING
226,EP,A4,EP 2489064 A4,039-183-489-826-035,2014-02-19,2014,EP 10823735 A,2010-10-13,US 27886609 P;;US 92504710 A;;US 2010/0002737 W,2009-10-13,ENERGY CONVERSION MATERIALS FABRICATED WITH BORON NITRIDE NANOTUBES (BNNTS) AND BNNT POLYMER COMPOSITES,,NAT INST AEROSPACE ASSOCIATES;;US ADMINISTRATOR OF TH NAT AERONAUTICS AND SPACE ADMINISTRATION,KANG JIN HO;;PARK CHEOL;;HARRISSON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON;;KIM JEA-WOO;;LILLEHEI PETER T;;SAUTI GODFREY,,https://lens.org/039-183-489-826-035,Search Report,no,1,0,11,11,0,B82Y30/00;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;H10N30/092;;B82Y30/00;;B82Y40/00;;C08J5/18;;C08K3/38;;G01R29/14;;Y10S977/778;;C08K2003/382;;H10N30/063;;H10N30/092;;B82Y40/00;;G01R29/14;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;B82Y30/00;;H10N30/063;;H10N30/00;;H10N30/092;;H10N30/1051;;H10N30/1061,H01L41/37;;B82Y30/00;;H01L41/45,,3,2,051-416-263-682-445;;002-090-129-616-75X,10.1002/polb.21601;;10.1016/j.compscitech.2007.10.024,"JIN HO KANG ET AL: ""All-organic actuator fabricated with single wall carbon nanotube electrodes"", JOURNAL OF POLYMER SCIENCE PART B: POLYMER PHYSICS, vol. 46, no. 23, 1 December 2008 (2008-12-01), pages 2532 - 2538, XP055070679, ISSN: 0887-6266, DOI: 10.1002/polb.21601;;SALEHI-KHOJIN ET AL: ""Buckling of boron nitride nanotube reinforced piezoelectric polymeric composites subject to combined electro-thermo-mechanical loadings"", COMPOSITES SCIENCE AND TECHNOLOGY, ELSEVIER, UK, vol. 68, no. 6, 30 October 2007 (2007-10-30), pages 1489 - 1501, XP022527267, ISSN: 0266-3538, DOI: 10.1016/J.COMPSCITECH.2007.10.024;;See also references of WO 2011046602A1",DISCONTINUED
227,CA,A1,CA 2777666 A1,035-193-622-182-800,2011-04-21,2011,CA 2777666 A,2010-10-13,US 27886609 P;;US 92504710 A;;US 2010/0002737 W,2009-10-13,ENERGY CONVERSION MATERIALS FABRICATED WITH BORON NITRIDE NANOTUBES (BNNTS) AND BNNT POLYMER COMPOSITES,"Electroactive actuation characteristics of novel BNNT based materials are described. Several series of BNNT based electroactive materials including BNNT/polyimide composites and BNNT films are prepared. The BNNT based electroactive materials show high piezoelectric coefficients, d 13 , about 14.80 pm/V as well as high electrostrictive coefficients, M 13 , 3.21x1O-16 pm2/V2. The BNNT based electroactive materials will be used for novel electromechanical energy conversion devices.",NAT INST AEROSPACE ASSOCIATES;;US ADM NATI ONAL AERONAUTICS AND SPACE ADMINISTRATION,KANG JIN HO;;PARK CHEOL;;HARRISSON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON;;KIM JEA-WOO;;LILLEHEI PETER T;;SAUTI GODFREY,,https://lens.org/035-193-622-182-800,Patent Application,no,0,0,11,11,0,B82Y30/00;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;H10N30/092;;B82Y30/00;;B82Y40/00;;C08J5/18;;C08K3/38;;G01R29/14;;Y10S977/778;;C08K2003/382;;H10N30/063;;H10N30/092;;B82Y40/00;;G01R29/14;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;B82Y30/00;;H10N30/063;;H10N30/00;;H10N30/092;;H10N30/1051;;H10N30/1061,H01L41/45,,0,0,,,,ACTIVE
228,CA,C,CA 2777666 C,004-506-230-816-683,2021-01-05,2021,CA 2777666 A,2010-10-13,US 27886609 P;;US 92504710 A;;US 2010/0002737 W,2009-10-13,ENERGY CONVERSION MATERIALS FABRICATED WITH BORON NITRIDE NANOTUBES (BNNTS) AND BNNT POLYMER COMPOSITES,"Electroactive actuation characteristics of novel BNNT based materials are described. Several series of BNNT based electroactive materials including BNNT/polyimide composites and BNNT films are prepared. The BNNT based electroactive materials show high piezoelectric coefficients, d 13 , about 14.80 pm/V as well as high electrostrictive coefficients, M 13 , 3.21x1O-16 pm2/V2. The BNNT based electroactive materials will be used for novel electromechanical energy conversion devices.",NAT INSTITUTE OF AEROSPACE ASSOCIATES;;US ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION,KANG JIN HO;;PARK CHEOL;;HARRISSON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON;;KIM JEA-WOO;;LILLEHEI PETER T;;SAUTI GODFREY,,https://lens.org/004-506-230-816-683,Granted Patent,no,0,0,11,11,0,B82Y30/00;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;H10N30/092;;B82Y30/00;;B82Y40/00;;C08J5/18;;C08K3/38;;G01R29/14;;Y10S977/778;;C08K2003/382;;H10N30/063;;H10N30/092;;B82Y40/00;;G01R29/14;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;B82Y30/00;;H10N30/063;;H10N30/00;;H10N30/092;;H10N30/1051;;H10N30/1061,H01L41/37;;H01L41/45,,0,0,,,,ACTIVE
229,WO,A1,WO 2011/046602 A1,069-667-751-228-225,2011-04-21,2011,US 2010/0002737 W,2010-10-13,US 27886609 P;;US 92504710 A,2009-10-13,ENERGY CONVERSION MATERIALS FABRICATED WITH BORON NITRIDE NANOTUBES (BNNTS) AND BNNT POLYMER COMPOSITES,"Electroactive actuation characteristics of novel BNNT based materials are described. Several series of BNNT based electroactive materials including BNNT/polyimide composites and BNNT films are prepared. The BNNT based electroactive materials show high piezoelectric coefficients, d 13 , about 14.80 pm/V as well as high electrostrictive coefficients, M 13 , 3.21x1O -16 pm 2 /V 2 . The BNNT based electroactive materials will be used for novel electromechanical energy conversion devices.",NAT INST AEROSPACE ASSOCIATES;;NASA;;JEFFERSON SCIENCE ASS LLC,KANG JIN HO;;PARK CHEOL;;HARRISSON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON;;KIM JEA-WOO;;LILLEHEI PETER T;;SAUTI GODFREY,,https://lens.org/069-667-751-228-225,Patent Application,yes,4,5,11,11,0,B82Y30/00;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;H10N30/092;;B82Y30/00;;B82Y40/00;;C08J5/18;;C08K3/38;;G01R29/14;;Y10S977/778;;C08K2003/382;;H10N30/063;;H10N30/092;;B82Y40/00;;G01R29/14;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;B82Y30/00;;H10N30/063;;H10N30/00;;H10N30/092;;H10N30/1051;;H10N30/1061,H01L21/00;;H01L41/45,,1,0,,,See also references of EP 2489064A4,PENDING
230,EP,A1,EP 2489064 A1,146-152-294-299-906,2012-08-22,2012,EP 10823735 A,2010-10-13,US 27886609 P;;US 92504710 A;;US 2010/0002737 W,2009-10-13,ENERGY CONVERSION MATERIALS FABRICATED WITH BORON NITRIDE NANOTUBES (BNNTS) AND BNNT POLYMER COMPOSITES,,NAT INST AEROSPACE ASSOCIATES;;US ADMINISTRATOR OF TH NAT AERONAUTICS AND SPACE ADMINISTRATION,KANG JIN HO;;PARK CHEOL;;HARRISSON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON;;KIM JEA-WOO;;LILLEHEI PETER T;;SAUTI GODFREY,,https://lens.org/146-152-294-299-906,Patent Application,yes,0,0,11,11,0,B82Y30/00;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;H10N30/092;;B82Y30/00;;B82Y40/00;;C08J5/18;;C08K3/38;;G01R29/14;;Y10S977/778;;C08K2003/382;;H10N30/063;;H10N30/092;;B82Y40/00;;G01R29/14;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;B82Y30/00;;H10N30/063;;H10N30/00;;H10N30/092;;H10N30/1051;;H10N30/1061,H01L41/37;;B82Y30/00;;H01L41/45,,0,0,,,,DISCONTINUED
231,EP,A1,EP 3445337 A1,029-651-816-777-675,2019-02-27,2019,EP 17721286 A,2017-04-21,US 201662326046 P;;US 2017/0028955 W,2016-04-22,TWIN-SCREW DRY GRANULATION FOR PRODUCING SOLID FORMULATIONS,,UNIV MISSISSIPPI;;SCHERER TECHNOLOGIES LLC R P,REPKA MICHAEL ANDREW;;PARK JUN-BOM;;TIWARI ROSHAN VIJAY;;PATIL HEMLATA GUNGA;;MOROTT JOSEPH THOMAS JR;;LU WENLI;;UPADHYE SAMPADA BHASKAR;;VLADYKA RONALD S,,https://lens.org/029-651-816-777-675,Patent Application,yes,0,0,9,9,0,A61K9/1635;;A61K9/1641;;A61K9/1647;;A61K9/1652;;A61K9/1694;;A61K31/4178;;A61K31/519;;B29B7/482;;B29B7/489;;B29B9/06;;B29B9/14;;B29B7/90;;B29B7/726;;B29B7/82;;B29C48/2561;;B29C48/402;;B29C48/405;;B29C48/92;;B29C48/04;;B29B7/488;;A61K9/1652;;A61K9/1635;;A61K9/1647;;A61K9/1694;;A61K9/1641;;A61K9/0053;;A61K9/1682;;A61K9/2054;;A61K9/2095;;A61K31/4178;;A61K31/519;;B01J2/10,A61K9/16,,0,0,,,,ACTIVE
232,US,B1,US 6231137 B1,102-086-425-831-263,2001-05-15,2001,US 44012299 A,1999-11-15,US 44012299 A,1999-11-15,Combination countertop oven and cooling rack assembly,"A cooling or support rack is embedded into a work surface of a countertop at a position generally, directly in front of one or more doors of an oven arranged above the countertop. Preferably, the oven incorporates a pair of arcuate, sliding doors which are movable from a closed position to an open position wherein the doors do not extend over the cooling rack. The upper surface of the cooling rack is substantially flush with both the countertop and a lowermost cookware support surface within the oven such that cookware can be readily slid into and out of the oven.",MAYTAG CORP,LYE MICHAEL T;;MICHAS LUKE N;;HOWARD JEREMY C;;LAGUINIA EDGAR L;;AKERS ELIZABETH;;PARK SEUNG;;HARRISON MARC S;;WOODING PETER;;LANGMUIR JANE K,RHODE ISLAND SCHOOL OF DESIGN (1999-11-23);;MAYTAG CORPORATION (2000-05-25),https://lens.org/102-086-425-831-263,Granted Patent,yes,14,5,2,2,0,A47B77/08;;A47B77/08,A47B77/08,312/140.4;;312/238;;312/236,0,0,,,,EXPIRED
233,WO,A1,WO 2017/185040 A1,106-858-695-299-089,2017-10-26,2017,US 2017/0028955 W,2017-04-21,US 201662326046 P,2016-04-22,TWIN-SCREW DRY GRANULATION FOR PRODUCING SOLID FORMULATIONS,"A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.",UNIV MISSISSIPPI;;SCHERER TECHNOLOGIES LLC R P,REPKA MICHAEL ANDREW;;PARK JUN-BOM;;TIWARI ROSHAN VIJAY;;PATIL HEMLATA GUNGA;;MOROTT JOSEPH THOMAS JR;;LU WENLI;;UPADHYE SAMPADA BHASKAR;;VLADYKA RONALD S,,https://lens.org/106-858-695-299-089,Patent Application,yes,7,1,9,9,0,A61K9/1635;;A61K9/1641;;A61K9/1647;;A61K9/1652;;A61K9/1694;;A61K31/4178;;A61K31/519;;B29B7/482;;B29B7/489;;B29B9/06;;B29B9/14;;B29B7/90;;B29B7/726;;B29B7/82;;B29C48/2561;;B29C48/402;;B29C48/405;;B29C48/92;;B29C48/04;;B29B7/488;;A61K9/1652;;A61K9/1635;;A61K9/1647;;A61K9/1694;;A61K9/1641;;A61K9/0053;;A61K9/1682;;A61K9/2054;;A61K9/2095;;A61K31/4178;;A61K31/519;;B01J2/10,A61K9/16,,8,4,013-173-710-675-203;;013-900-482-532-910;;078-202-815-180-643;;094-434-675-224-757,15296958;;10.1016/j.ejpb.2004.04.014;;10.1016/j.ijpharm.2015.09.025;;26387621;;24114922;;10.1002/jps.23739;;16949222;;10.1016/j.ijpharm.2006.07.005,"M R THOMPSON ET AL: ""HEAT ACTIVATED DRY GRANULATION WITHIN THE TWIN SCREW GRANULATOR"", 25 May 2016 (2016-05-25), XP055384669, Retrieved from the Internet <URL:http://leaders.4spe.org/spe/conferences/antec2016/papers/228.pdf> [retrieved on 20170623];;PETER KLEINEBUDDE: ""Roll compaction/dry granulation: pharmaceutical applications"", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 58, 2004, pages 317 - 326, XP004526315, DOI: doi:10.1016/j.ejpb.2004.04.014;;MANIRUZZAMAN M; NAIR A; RENAULT M; NANDI U; SCOUTARIS N; FAMISH R; BRADLEY MS; SNOWDEN MJ; DOUROUMIS D: ""Continuous twin-screw granulation for enhancing the dissolution of poorly water soluble drug"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 496, no. L, 30 December 2015 (2015-12-30), pages 52 - 62;;MICHAEL R. THOMPSON: ""Hot-Melt Granulation in a Twin Screw Extruder: Effects of Processing on Formulations with Caffeine and Ibuprofen"", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 102, 2013, pages 4330 - 4336;;VAN MELKEBEKE ET AL.: ""Melt granulation using a twin-screw extruder: a case study"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 326, no. 1, 1 December 2006 (2006-12-01), pages 89 - 93, XP025113137, DOI: doi:10.1016/j.ijpharm.2006.07.005;;AULTON, PHARMACEUTICS, THE SCIENCE OF DOSAGE FORM DESIGN, 1988, pages 623 - 625;;""The Handbook of Pharmaceutical Excipients"", 2012, AMERICAN PHARMACEUTICALS ASSOCIATION;;""Remington: the Science and Practice of Pharmacy"", 2012, LIPPINCOTT WILLIAMS & WILKINS",PENDING
234,US,B2,US 10387516 B2,096-576-609-989-520,2019-08-20,2019,US 201715721577 A,2017-09-29,US 201715721577 A,2017-09-29,Selecting content with an external link for presentation based on user interaction with external content,"An online system receives posts that include links to various external pages and presents those posts to users of the online system. When the online system determines an opportunity to present a post to a particular viewing user of the online system, the online system determines a quality metric and an associated value score for the post. The quality metric is determined as a likelihood that the viewing user will view the external page for less than a threshold time period, and is used to adjust the associated value score. The online system compares the value score of the post to the value scores of other posts and selects one or more of the compared posts for presentation to the viewing user of the online system.",FACEBOOK INC,WANG LU;;GUO SHENGBO;;JACKSON GRACE LOUISE;;HENDRIX KRISTIN S;;ZHUO YUE;;PARK SEYOUNG;;ZHU YIXIAN;;LEGGETTER CHRISTOPHER JOHN;;LI JAMES;;BAILEY MICHAEL CHARLES,META PLATFORMS INC (2017-11-17),https://lens.org/096-576-609-989-520,Granted Patent,yes,17,0,2,2,0,G06Q30/02;;G06Q50/01;;H04L67/306;;H04L67/535;;G06Q50/01;;H04L67/306;;G06F16/9535;;G06F16/958;;G06F16/9574;;G06F16/9577;;G06Q30/02;;H04L67/535,G06F16/9535;;G06F16/957;;G06F16/958;;G06Q30/02;;G06Q50/00;;H04L29/08,,0,0,,,,ACTIVE
235,CA,A1,CA 2324722 A1,145-661-099-072-457,2001-05-15,2001,CA 2324722 A,2000-10-30,US 44012299 A,1999-11-15,COMBINATION COUNTERTOP OVEN AND COOLING RACK ASSEMBLY,"A cooling or support rack is embedded into a work surface of a countertop at a position generally, directly in front of one or more doors of an oven arranged above the countertop. Preferably, the oven incorporates a pair of arcuate, sliding doors which are movable from a closed position to an open position wherein the doors do not extend over the cooling rack. The upper surface of the cooling rack is substantially flush with both the countertop and a lowermost cookware support surface within the oven such that cookware can be readily slid into and out of the oven.",MAYTAG CORP,PARK SEUNG;;AKERS ELIZABETH;;LAGUINIA EDGAR L;;HOWARD JEREMY C;;WOODING PETER;;HARRISON MARC S;;LANGMUIR JANE K;;LYE MICHAEL T;;MICHAS LUKE W,,https://lens.org/145-661-099-072-457,Patent Application,no,0,0,2,2,0,A47B77/08;;A47B77/08,A47B77/08,,0,0,,,,DISCONTINUED
236,KR,A,KR 20120095889 A,051-098-686-471-729,2012-08-29,2012,KR 20127011165 A,2010-10-13,US 92504710 A;;US 27886609 P;;US 2010/0002737 W,2009-10-13,ENERGY CONVERSION MATERIALS FABRICATED WITH BORON NITRIDE NANOTUBES (BNNTS) AND BNNT POLYMER COMPOSITES,,NASA;;NAT INST AEROSPACE ASSOCIATES,KANG JIN HO;;PARK CHE OL;;HARRISSON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON;;KIM JEA WOO;;LILLEHEI PETER T;;SAUTI GODFREY,,https://lens.org/051-098-686-471-729,Patent Application,no,0,7,11,11,0,B82Y30/00;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;H10N30/092;;B82Y30/00;;B82Y40/00;;C08J5/18;;C08K3/38;;G01R29/14;;Y10S977/778;;C08K2003/382;;H10N30/063;;H10N30/092;;B82Y40/00;;G01R29/14;;Y10T29/42;;Y10T29/49005;;Y10T29/49155;;Y10T29/49002;;B82Y30/00;;H10N30/063;;H10N30/00;;H10N30/092;;H10N30/1051;;H10N30/1061,C08K3/38;;C08K7/00;;C08L79/08;;H01L41/45,,0,0,,,,ACTIVE
237,US,B2,US 11529313 B2,199-221-607-933-293,2022-12-20,2022,US 202016936008 A,2020-07-22,US 202016936008 A;;US 201715493568 A;;US 201662326046 P,2016-04-22,Twin-screw dry granulation for producing solid formulations,"A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.",SCHERER TECHNOLOGIES LLC R P;;UNIV MISSISSIPPI,UPADHYE SAMPADA BHASKAR;;VLADYKA RONALD S;;REPKA MICHAEL ANDREW;;PARK JUN-BOM;;TIWARI ROSHAN VIJAY;;PATIL HEMLATA GUNGA;;MOROTT JR JOSEPH THOMAS;;LU WENLI,R.P. SCHERER TECHNOLOGIES LLC (2020-09-22),https://lens.org/199-221-607-933-293,Granted Patent,yes,14,3,9,9,0,A61K9/1635;;A61K9/1641;;A61K9/1647;;A61K9/1652;;A61K9/1694;;A61K31/4178;;A61K31/519;;B29B7/482;;B29B7/489;;B29B9/06;;B29B9/14;;B29B7/90;;B29B7/726;;B29B7/82;;B29C48/2561;;B29C48/402;;B29C48/405;;B29C48/92;;B29C48/04;;B29B7/488;;A61K9/1652;;A61K9/1635;;A61K9/1647;;A61K9/1694;;A61K9/1641;;A61K9/0053;;A61K9/1682;;A61K9/2054;;A61K9/2095;;A61K31/4178;;A61K31/519;;B01J2/10,A61K9/16;;A61K9/00;;A61K9/20;;A61K31/4178;;A61K31/519;;B01J2/10,,18,6,013-173-710-675-203;;013-900-482-532-910;;064-855-680-711-397;;029-393-539-000-315;;094-434-675-224-757;;078-202-815-180-643,15296958;;10.1016/j.ejpb.2004.04.014;;10.1016/j.ijpharm.2015.09.025;;26387621;;10.1016/j.ijpharm.2016.07.035;;27452420;;10.1016/j.ajps.2016.08.005;;pmc7032224;;32104312;;16949222;;10.1016/j.ijpharm.2006.07.005;;24114922;;10.1002/jps.23739,"(1995). “The U.S. Pharmacopeia: The National Formulary,” USP 23, NF 18; 2 pages.;;Allen, Jr. et al. (2012). “Remington, The Science and Practice of Pharmacy,” 22nd Edition, vol. I, Gennaro, Ed., Lippincott Williams & Wilkins; 1942 pages.;;Allen, Jr. et al. (2012). “Remington, The Science and Practice of Pharmacy,” 22nd Edition, vol. II, Gennaro, Ed., Lippincott Williams & Wilkins: 1005 pages.;;Aulton, Michael E. ed. (1988)., “Pharmaceutics: The Science of Dosage Form Design,” Churchill Livingstone; 4 pages.;;Desai et al. (Mar. 2013). “Melt Granulation: An Alternative to Traditional Granulation Techniques,” Indian Drugs 50(3): 5-13.;;International Search Report and Written Opinion dated Jul. 7, 2017, directed to International Application No. PCT/2017/028955; 13 pages.;;Kleinebudde, Peter (2004). “Roll compaction/dry granulation: pharmaceutical applications,” European Journal of Pharmaceutics and Biopharmaceutics 58: 10 pages.;;Maniruzzaman et al. (Sep. 2015). “Continuous twin-screw granulation for enhancing the dissolution of poorly water soluble drug,” International Journal of Pharmaceutics 496; 11 pages.;;Monteyne et al. (Oct. 2016). “Stearic Acid and High Molecular Weight PEO as Matrix for the Highly Water Soluble Metoprolol Tartrate in Continuous Twin-Screw Melt Granulation,” International Journal of Pharmaceutics 512(1): 158-167.;;Office Action dated Jun. 16, 2020, directed to AR Application No. 20170101029; 6 pages.;;Rowe et al. ed. (2009). “Handbook of Pharmaceutical Excipients,” Sixth Edition, American Pharmaceuticals Association (2009); 917 pages.;;Thompson et al. (2016). “Heat Activated Dry Granulation Within the Twin Screw Granulator,” SPE ANTEC, Indianapolis; 6 pages.;;Upadhye et al., Office Action dated Aug. 9, 2018, directed to U.S. Appl. No. 15/493,568; 7 pages.;;Upadhye et al., Office Action dated Jun. 3, 2019, directed to U.S. Appl. No. 15/493,568; 7 pages.;;Upadhye et al., Office Action dated Oct. 10, 2019, directed to U.S. Appl. No. 15/493,568; 7 pages.;;Vaingankar et al. (Jan. 2017). “Continuous Melt Granulation to Develop High Drug Loaded Sustained Release Tablet of Metformin HCI,” Asian Journal of Pharmaceutical Sciences 12: 37-50.;;Van Melkebeke et al. (2006). “Melt granulation using a twin-screw extruder: A case study,” International Journal of Pharmaceutics, 326(1); 5 pages.;;Weatherley et al. (2013). “Hot-Melt Granulation in a Twin Screw Extruder: Effects of Processing on Formulations with Caffeine and Ibuprofen,” Journal of Pharmaceutical Sciences 102; 7 pages.",ACTIVE
238,US,A1,US 2020/0345643 A1,028-106-171-062-356,2020-11-05,2020,US 202016936008 A,2020-07-22,US 202016936008 A;;US 201715493568 A;;US 201662326046 P,2016-04-22,TWIN-SCREW DRY GRANULATION FOR PRODUCING SOLID FORMULATIONS,"A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.",SCHERER TECHNOLOGIES LLC R P;;UNIV MISSISSIPPI,UPADHYE SAMPADA BHASKAR;;VLADYKA RONALD S;;REPKA MICHAEL ANDREW;;PARK JUN-BOM;;TIWARI ROSHAN VIJAY;;PATIL HEMLATA GUNGA;;MOROTT JR JOSEPH THOMAS;;LU WENLI,R.P. SCHERER TECHNOLOGIES LLC (2020-09-22),https://lens.org/028-106-171-062-356,Patent Application,yes,0,0,9,9,0,A61K9/1635;;A61K9/1641;;A61K9/1647;;A61K9/1652;;A61K9/1694;;A61K31/4178;;A61K31/519;;B29B7/482;;B29B7/489;;B29B9/06;;B29B9/14;;B29B7/90;;B29B7/726;;B29B7/82;;B29C48/2561;;B29C48/402;;B29C48/405;;B29C48/92;;B29C48/04;;B29B7/488;;A61K9/1652;;A61K9/1635;;A61K9/1647;;A61K9/1694;;A61K9/1641;;A61K9/0053;;A61K9/1682;;A61K9/2054;;A61K9/2095;;A61K31/4178;;A61K31/519;;B01J2/10,A61K9/16;;A61K9/00;;A61K9/20;;A61K31/4178;;A61K31/519;;B01J2/10,,0,0,,,,ACTIVE
239,US,A1,US 2019/0102466 A1,125-090-781-468-196,2019-04-04,2019,US 201715721577 A,2017-09-29,US 201715721577 A,2017-09-29,SELECTING CONTENT WITH AN EXTERNAL LINK FOR PRESENTATION BASED ON USER INTERACTION WITH EXTERNAL CONTENT,"An online system receives posts that include links to various external pages and presents those posts to users of the online system. When the online system determines an opportunity to present a post to a particular viewing user of the online system, the online system determines a quality metric and an associated value score for the post. The quality metric is determined as a likelihood that the viewing user will view the external page for less than a threshold time period, and is used to adjust the associated value score. The online system compares the value score of the post to the value scores of other posts and selects one or more of the compared posts for presentation to the viewing user of the online system.",FACEBOOK INC,WANG LU;;GUO SHENGBO;;JACKSON GRACE LOUISE;;HENDRIX KRISTIN S;;ZHUO YUE;;PARK SEYOUNG;;ZHU YIXIAN;;LEGGETTER CHRISTOPHER JOHN;;LI JAMES;;BAILEY MICHAEL CHARLES,META PLATFORMS INC (2017-11-17),https://lens.org/125-090-781-468-196,Patent Application,yes,0,6,2,2,0,G06Q30/02;;G06Q50/01;;H04L67/306;;H04L67/535;;G06Q50/01;;H04L67/306;;G06F16/9535;;G06F16/958;;G06F16/9574;;G06F16/9577;;G06Q30/02;;H04L67/535,G06Q50/00;;H04L29/08,,0,0,,,,ACTIVE
240,US,A1,US 2023/0165799 A1,187-419-699-445-93X,2023-06-01,2023,US 202218074699 A,2022-12-05,US 202218074699 A;;US 202016936008 A;;US 201715493568 A;;US 201662326046 P,2016-04-22,TWIN-SCREW DRY GRANULATION FOR PRODUCING SOLID FORMULATIONS,"A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.",SCHERER TECHNOLOGIES LLC R P;;UNIV MISSISSIPPI,UPADHYE SAMPADA BHASKAR;;VLADYKA RONALD S;;REPKA MICHAEL ANDREW;;PARK JUN-BOM;;TIWARI ROSHAN VIJAY;;PATIL HEMLATA GUNGA;;MOROTT JR JOSEPH THOMAS;;LU WENLI,UNIVERSITY OF MISSISSIPPI (2017-05-11);;R.P. SCHERER TECHNOLOGIES LLC (2017-06-07),https://lens.org/187-419-699-445-93X,Patent Application,yes,3,0,9,9,0,A61K9/1635;;A61K9/1641;;A61K9/1647;;A61K9/1652;;A61K9/1694;;A61K31/4178;;A61K31/519;;B29B7/482;;B29B7/489;;B29B9/06;;B29B9/14;;B29B7/90;;B29B7/726;;B29B7/82;;B29C48/2561;;B29C48/402;;B29C48/405;;B29C48/92;;B29C48/04;;B29B7/488;;A61K9/1652;;A61K9/1635;;A61K9/1647;;A61K9/1694;;A61K9/1641;;A61K9/0053;;A61K9/1682;;A61K9/2054;;A61K9/2095;;A61K31/4178;;A61K31/519;;B01J2/10,A61K9/16;;A61K9/00;;A61K9/20;;A61K31/4178;;A61K31/519;;B01J2/10,,0,0,,,,PENDING
241,EP,B1,EP 3445337 B1,104-356-493-295-167,2021-03-24,2021,EP 17721286 A,2017-04-21,US 201662326046 P;;US 2017/0028955 W,2016-04-22,TWIN-SCREW DRY GRANULATION FOR PRODUCING SOLID FORMULATIONS,,UNIV MISSISSIPPI;;SCHERER TECHNOLOGIES LLC R P,REPKA MICHAEL ANDREW;;PARK JUN-BOM;;TIWARI ROSHAN VIJAY;;PATIL HEMLATA GUNGA;;MOROTT JOSEPH THOMAS JR;;LU WENLI;;UPADHYE SAMPADA BHASKAR;;VLADYKA RONALD S,,https://lens.org/104-356-493-295-167,Granted Patent,yes,1,1,9,9,0,A61K9/1635;;A61K9/1641;;A61K9/1647;;A61K9/1652;;A61K9/1694;;A61K31/4178;;A61K31/519;;B29B7/482;;B29B7/489;;B29B9/06;;B29B9/14;;B29B7/90;;B29B7/726;;B29B7/82;;B29C48/2561;;B29C48/402;;B29C48/405;;B29C48/92;;B29C48/04;;B29B7/488;;A61K9/1652;;A61K9/1635;;A61K9/1647;;A61K9/1694;;A61K9/1641;;A61K9/0053;;A61K9/1682;;A61K9/2054;;A61K9/2095;;A61K31/4178;;A61K31/519;;B01J2/10,A61K9/16,,1,0,,,"M R Thompson ET AL: ""HEAT ACTIVATED DRY GRANULATION WITHIN THE TWIN SCREW GRANULATOR"", , 25 May 2016 (2016-05-25), XP055384669, Retrieved from the Internet: URL:http://leaders.4spe.org/spe/conference s/antec2016/papers/228.pdf [retrieved on 2017-06-23]",ACTIVE
242,US,A1,US 2014/0222908 A1,137-252-776-934-257,2014-08-07,2014,US 201313757574 A,2013-02-01,US 201313757574 A,2013-02-01,METHODS AND SYSTEMS FOR A LOCATION-BASED ONLINE SOCIAL NETWORK,"Disclosed embodiments relate to a system and a method of managing an online social network having a plurality of neighborhoods. The system may receive a location from a user, and select, based on the location, a neighborhood from the plurality of neighborhoods. The system may further assign the user to the selected neighborhood and grant the user access to communications by users assigned to the selected neighborhood.",NEXTDOOR COM INC,PARK DAVID S;;BELL MADISON NIXON;;MUKHOPADHYAY RISHI;;KAEHLER THOMAS F;;HESCH JACOB L;;BROMAGE SEAN C;;BARTON RICH;;WIESEN DAVID MICHAEL;;SIMS RYAN PATRICK,NEXTDOOR.COM INC (2015-07-08),https://lens.org/137-252-776-934-257,Patent Application,yes,14,37,7,10,0,G06Q50/01;;H04W4/021;;G06Q10/10;;H04W4/21;;G06F16/29;;G06Q10/10;;H04W4/21;;G06F16/29;;H04W4/021;;G06Q50/01;;G06F3/0482;;G06F3/04842;;G06F3/04847,G06Q10/10;;H04W4/021;;H04W4/21,709/204,0,0,,,,DISCONTINUED
243,US,B1,US 6653321 B1,098-374-358-168-951,2003-11-25,2003,US 62820600 A,2000-07-28,US 62820600 A;;US 14644499 P,1999-07-29,Naphthylsulfonic acids and related compounds as glucose uptake agonists,"
    Methods for treating conditions associated with hyperglycemia, especially Type II diabetes, with novel naphthylsulfonic acids and related compounds. These compounds, as single stereoisomers or mixtures of stereoisomers, or their pharmaceutically acceptable salts, are useful in methods of stimulating the kinase activity of the insulin receptor, enhancing the activation of the insulin receptor by insulin, and stimulating the uptake of glucose into cells. A variety of antidiabetic compounds and pharmaceutical compositions comprising the antidiabetic compounds are also disclosed. 
",TELIK INC,SPEVAK WAYNE R;;SHI SONGYUAN;;MANCHEM PRASAD V V S V;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEON,TELIK INC (2000-10-19),https://lens.org/098-374-358-168-951,Granted Patent,yes,15,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;C07D215/40;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,514/307;;514/256;;514/311;;514/315;;514/319;;514/332;;514/357;;514/365;;514/374;;514/385;;514/415;;514/428;;514/438;;514/447;;514/451;;514/459;;514/461;;514/471;;514/521;;514/503;;514/568;;514/576;;514/613;;514/615;;514/619;;514/620;;544/238;;544/239;;544/240;;544/241;;544/242;;544/333;;544/334;;544/335;;544/336;;546/139;;546/146;;546/149;;546/152;;546/157;;546/162;;546/174;;546/175;;546/192;;546/195;;546/205;;546/206;;546/246;;546/247;;546/248;;548/146;;548/215;;548/233;;548/300.1;;548/326.5;;548/348.1;;548/349.1;;548/350.1;;548/469;;548/566;;549/139;;549/146;;549/149;;549/152;;549/157;;549/162;;549/174;;549/175;;549/192;;549/195;;549/205;;549/206;;549/246;;549/247;;549/248;;558/17;;562/54;;564/162;;564/163;;564/165;;564/169;;564/180;;564/185,2,0,,,"Database Chemabs ""OnLine"" Chemical Abstract Service, Columbus Ohio, US; STN, CAPLUS accession No. 1988:436172, XP002151699, abstract of YA. YA. Aleksandrovskii: Vopr. Med. Khim., vol. 34, No. 3, 1988, pp. 7-25.;;S. Budavari, et al., ""The Merck Index"", Twelfth Edition (1996), pp. 1541, entry 9181, Suramin sodium.",EXPIRED
244,PL,A1,PL 353359 A1,115-426-141-797-470,2003-11-17,2003,PL 35335900 A,2000-07-28,US 14644499 P,1999-07-29,NOVEL NAPHTHYLSULFONIC ACIDS AND RELATED COMPOUNDS AS GLUCOSE UPTAKE AGONISTS,,TELIK,SPEVAK WAYNE R;;SONGYUAN SHI;;PRASAD V V S V MANCHEM;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEONG,,https://lens.org/115-426-141-797-470,Patent Application,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;C07D215/40;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,EXPIRED
245,NO,D0,NO 20020425 D0,111-592-503-513-964,2002-01-28,2002,NO 20020425 A,2002-01-28,US 14644499 P;;US 0020909 W,1999-07-29,Nye naftylsulfonsyrer og beslektede forbindelser som glukoseopptaksagonister,,TELIK INC,SPEVAK WAYNE R;;SHI SONGYUAN;;MANCHEM PRASAD V V S V;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEONG,,https://lens.org/111-592-503-513-964,Patent Application,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,A61K31/167;;C07D215/40;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,PENDING
246,AR,A1,AR 114444 A1,100-775-683-080-934,2020-09-09,2020,AR P190100445 A,2019-02-22,US 201862634573 P,2018-02-23,MÉTODO DE SECUENCIACIÓN PARA TERAPIA DE CÉLULAS T CON CAR,La presente divulgación se refiere a métodos para tratar un paciente con cáncer mediante la administración al paciente de una composición que comprende células T con CAR y administrar al paciente una pequeña molécula ligada a una fracción del receptor mediante un conector. La presente divulgación asimismo se refiere a composiciones para su uso en dichos métodos.,ENDOCYTE INC;;PURDUE RESEARCH FOUNDATION;;SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE,PARK JULIE RUGGIERI;;PINTO NAVIN ROBERT CHARLES;;MATTHAEI JAMES;;JENSEN MICHAEL C;;LOW PHILIP S;;LU YINGJUAN J;;CHU HAIYAN;;LEAMON CHRISTOPHER P;;MESSMANN RICHARD,,https://lens.org/100-775-683-080-934,Patent Application,no,0,0,1,10,0,,A61K39/00;;C07K16/44;;C12N15/86,,0,0,,,,PENDING
247,EA,B1,EA 006704 B1,009-931-417-712-701,2006-02-24,2006,EA 200200095 A,2000-07-28,US 14644499 P;;US 0020909 W,1999-07-29,NAPHTHYLSULFONIC ACIDS AND RELATED COMPOUNDS AS GLUCOSE UPTAKE AGONISTS,"The invention relates to a compound of the formulawhere R1 is -C(O)R4, -SO2 R4 or –C(O)NHR4; and R3 is, independently, OH, -SO2OH, SO2NH2, -C(O)ORH or tetrazolyl; R4 is selected from the group comprising C1-C6alkyl, [optionally substituted with one or two carboxy, amino, phenyls (optionally substituted with one halogen, C1-C6alkyl or C1-C6alkoxy), phenyloxy (optionally substituted with one halogen, C1-C6alkoxy), naphthyl or naphthyloxyl, phenyl or naphthyl (each optionally with 1-3 halogens hydroxy, C1-C6alkyl, C1-C6alkyloxy, nitro, carboxy, sulfur or amino) or furanyl, pyridyl, quinoxalyl, or benzo[b]furanyl (each optionally substituted with one halogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, nitro, carboxy sulfur or amino); R7 is independently hydrogen or C1-C6alkyl or pharmaceutically acceptable salts thereof, and to the pharmaceutical composition comprising this compound, to a method for treating hyperglycemia, specially Type I and II diabetes, and to the use the compounds for manufacturing a medicament for the treatment of said diseases.",TELIK INC,SPEVAK WAYNE R;;SONGYAN SHI;;PRASAD V V S V MANCHEM;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JONG WONG,,https://lens.org/009-931-417-712-701,Granted Patent,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,C07C309/51;;A61K31/16;;C07D215/40;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/33;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,EXPIRED
248,IT,A1,IT TO20000745 A1,026-954-178-776-430,2002-01-28,2002,IT TO20000745 A,2000-07-28,US 14644499 P,1999-07-29,NUOVI ACIDI NAFTILSOLFONICI E COMPOSTI AD ESSI CORRELATI UTLI COME AGONISTI DELL'ASSORBIMENTO DEL GLUCOSIO.,,TELIK INC,SPEVAK WAYNE R;;SHI SONGYUAN;;MANCHEM PRASAD V V S V;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEONG,,https://lens.org/026-954-178-776-430,Patent Application,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,C07D215/40;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,PENDING
249,NO,L,NO 20020425 L,046-601-747-328-331,2002-03-25,2002,NO 20020425 A,2002-01-28,US 14644499 P;;US 0020909 W,1999-07-29,Nye naftylsulfonsyrer og beslektede forbindelser som glukoseopptakagonister,,TELIK INC,SPEVAK WAYNE R;;SHI SONGYUAN;;MANCHEM PRASAD V V S V;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEONG,,https://lens.org/046-601-747-328-331,Abstract,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,A61K31/167;;C07D215/40;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,PENDING
250,US,A1,US 2022/0304844 A1,140-887-328-984-362,2022-09-29,2022,US 202017616950 A,2020-06-15,US 202017616950 A;;US 202063029053 P;;US 202063028008 P;;US 201962861508 P;;US 2020/0037744 W,2019-06-14,LEAKAGE DETECTION SYSTEM FOR OSTOMY APPLIANCE,"An ostomy device includes a proximal side configured for attachment to a user, a distal side opposite to the proximal side, and a leakage detection sensor having electrically conductive circuitry supported on a support layer. The leakage detection sensor is configured to detect ostomy effluent by detecting a change in resistance in the electrically conductive circuitry. The ostomy device may be an ostomy appliance or an ostomy accessory.",HOLLISTER INC,CARLSSON JONAS P;;PARK RYAN S;;MUSINSKY STEPHANIE;;LIDDLE SCOTT E;;MATTHEWS KYLE A;;NOLAN MICHAEL P;;LATTANZI LAUREN M;;SMITH ANTHONY B;;AUGUSTYN CHRISTINA,HOLLISTER INCORPORATED (2020-07-01);;BLUR PRODUCT DEVELOPMENT (2020-07-24),https://lens.org/140-887-328-984-362,Patent Application,yes,0,2,6,6,0,A61F5/449;;A61F5/4404;;A61B5/0531;;G01N27/06;;A61F5/445;;A61F5/4404;;A61F5/4404;;A61F5/443;;G01M3/16,A61F5/44;;A61F5/443;;G01M3/16,,0,0,,,,PENDING
251,EP,A1,EP 3982890 A1,067-230-999-811-364,2022-04-20,2022,EP 20736819 A,2020-06-15,US 201962861508 P;;US 202063028008 P;;US 202063029053 P;;US 2020/0037744 W,2019-06-14,LEAKAGE DETECTION SYSTEM FOR OSTOMY APPLIANCE,,HOLLISTER INC,CARLSSON JONAS P;;PARK RYAN S;;MUSINSKY STEPHANIE;;LIDDLE SCOTT E;;MATTHEWS KYLE A;;NOLAN MICHAEL P;;LATTANZI LAUREN M;;SMITH ANTHONY B;;AUGUSTYN CHRISTINA,,https://lens.org/067-230-999-811-364,Patent Application,yes,0,0,6,6,0,A61F5/449;;A61F5/4404;;A61B5/0531;;G01N27/06;;A61F5/445;;A61F5/4404;;A61F5/4404;;A61F5/443;;G01M3/16,A61F5/445;;A61F5/44,,0,0,,,,PENDING
252,HU,A2,HU P0202168 A2,071-644-262-433-746,2002-10-28,2002,HU P0202168 A,2000-07-28,US 14644499 P,1999-07-29,NOVEL NAPHTHYLSULFONIC ACIDS AND RELATED COMPOUNDS AS GLUCOSE UPTAKE AGONISTS,,TELIK INC,KOZLOWSKI MICHAEL R;;LUM ROBERT T;;PARK JEONG WEONG;;PRASAD V V S V MANCHEM;;ROBINSON LOUISE;;SCHOW STEVEN R;;SONGYUAN SHI;;SPEVAK WAYNE R,,https://lens.org/071-644-262-433-746,Patent Application,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,A61K31/167;;C07D215/40;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,DISCONTINUED
253,CA,C,CA 2377668 C,199-608-179-532-632,2008-12-02,2008,CA 2377668 A,2000-07-28,US 14644499 P;;US 0020909 W,1999-07-29,NOVEL NAPHTHYLSULFONIC ACIDS AND RELATED COMPOUNDS AS GLUCOSE UPTAKE AGONISTS,"Methods for treating conditions associated with hyperglycemia, especially Ty pe II diabetes, with novel naphthyl- sulfonic acids and related compounds are provided. Compounds of formula (1) where: R1 and R2 are, independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, R3 is a substituent on the B ring; and is -SO2OR6, -C(O)OR6, -SO2NR62-C(O)NR62 or tetrazolyl; the linker -WY- between the naphthyl and phenyl intersects the A ring of the naphthyl and is, independently, -C(O)NR7-, -NR7C(O)-, -C(O)O-, -OC(O)-, -CH=CH-, -NR7CH2-, -CH2NR7-, -NR7C(O)NR7- - NR7C(O)O-, -OC(O)NR7-, -NR7SO2O-, -OSO2NR7-, -OC(O)O-, -SO2NR7-, -NR7SO2-, -OSO2-, or -SO20-; each R6 and R7 i s, independently, hydrogen or lower alkyl; optionally in the form of single stereoisomers or mixtures of stereoisomers, or the pharmaceutically acceptable salts thereof; are useful in methods of stimulating the kinase activity of the insulin receptor , enhancing the activation of the insulin receptor by insulin, and stimulating the uptake of glucose into cells. A variety of antidiabetic compounds and pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.",TELIK INC,PARK JEONG WEONG;;SONGYUAN SHI;;SPEVAK WAYNE R;;MANCHEM PRASAD V V S V;;SCHOW STEVEN R;;ROBINSON LOUISE;;KOZLOWSKI MICHAEL R;;LUM ROBERT T,,https://lens.org/199-608-179-532-632,Granted Patent,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,C07C309/51;;C07D215/40;;A61K31/167;;A61K31/18;;A61K31/185;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,EXPIRED
254,WO,A1,WO 2001/012591 A1,040-548-504-310-120,2001-02-22,2001,US 0020909 W,2000-07-28,US 14644499 P,1999-07-29,NOVEL NAPHTHYLSULFONIC ACIDS AND RELATED COMPOUNDS AS GLUCOSE UPTAKE AGONISTS,"Methods for treating conditions associated with hyperglycemia, especially Type II diabetes, with novel naphthylsulfonic acids and related compounds are provided. Compounds of formula (1) where: R?1 and R2¿ are, independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, R3 is a substituent on the B ring; and is -SO¿2OR?6, -C(O)OR6, -SO2NR62-C(O)NR62 or tetrazolyl; the linker -WY- between the naphthyl and phenyl intersects the A ring of the naphthyl and is, independently, -C(O)NR?7-, -NR7¿C(O)-, -C(O)O-, -OC(O)-, -CH=CH-, -NR7CH2-, -CH2NR?7-, -NR7C(O)NR7- -NR7¿C(O)O-, -OC(O)NR?7-, -NR7SO¿2O-, -OSO2NR7-, -OC(O)O-, -SO¿2?NR?7-, -NR7SO¿2-, -OSO2-, or -SO2O-; each R?6 and R7¿ is, independently, hydrogen or lower alkyl; optionally in the form of single stereoisomers or mixtures of stereoisomers, or the pharmaceutically acceptable salts thereof; are useful in methods of stimulating the kinase activity of the insulin receptor, enhancing the activation of the insulin receptor by insulin, and stimulating the uptake of glucose into cells. A variety of antidiabetic compounds and pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.",TELIK INC,SPEVAK WAYNE R;;SONGYUAN SHI;;PRASAD V V S V MANCHEM;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEONG,,https://lens.org/040-548-504-310-120,Patent Application,yes,2,10,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07D215/40;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,1,0,,,"DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002151699",PATENTED
255,TR,T2,TR 200200250 T2,021-652-346-502-012,2002-05-21,2002,TR 200200250 T,2000-07-28,US 14644499 P,1999-07-29,"Glukoz alma agonistleri olarak yeni naftilsülfonik asitler, ilgili bileşikler","Hiperglisemi, özellikle Tip II diyabet ile ilgili durumlarin yeni naftilsülfonik asitler ve ilgili bilesikler ile tedavi yöntemi sunulur. formül (1)'e ait ki buradaki:R1 ve R2 birbirinden bagimsiz olarak, hidrojen, alkil, ikame edilmis alkil, aril, ikame edilmis aril; R3,B halkasi üzerinde bir ikame edicidir ve -SO2OR6,-C(O)OR6,-SO2NR6 2,-C(O)NR6 2 veya tetrazolildir;istege bagli olarak tek bir stereoizomer veya stereoizomerler karisimi halindeki bilesikler veya bunlarin farmasötik açidan kabul edilebilir tuzlari, insülin alicisinin kinaz aktivitesinin uyarilmasi,insülin alicisinin insülin tarafindan aktiflestirilmesi ve hücrelere glukoz aliminin uyarilmasi yöntemlerinde kullanilir.Ayrica bir dizi anti-diyabetik bilesik ve anti-diyabetik bilesikleri içeren farmasötik kompozisyonlar açiklanir.",TELIK INC,SPEVAK WAYNE R;;SHI SONGYUAN;;MANCHEM PRASAD V V S V;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEONG,,https://lens.org/021-652-346-502-012,Patent Application,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,A61K31/167;;C07D215/40;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,PENDING
256,EP,A1,EP 1200396 A1,004-389-452-513-506,2002-05-02,2002,EP 00952351 A,2000-07-28,US 0020909 W;;US 14644499 P,1999-07-29,NAPHTHYLSULFONIC ACIDS AND RELATED COMPOUNDS AS GLUCOSE UPTAKE AGONISTS,,TELIK INC,SPEVAK WAYNE R;;SONGYUAN SHI;;PRASAD V V S V MANCHEM;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEONG,"TELIK, INC. (2003-10-01)",https://lens.org/004-389-452-513-506,Patent Application,yes,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,A61K31/16;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/33;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;C07C309/51;;A61P3/10;;C07D215/40;;A61P43/00;;C07C237/42;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,DISCONTINUED
257,BR,A,BR 0012836 A,110-958-978-339-442,2002-04-30,2002,BR 0012836 A,2000-07-28,US 14644499 P;;US 0020909 W,1999-07-29,Novos ácidos naftilsulfÈnicos e compostos correlatos como agonistas de absorção de glicose,"Patente de Invenção: ""NOVOS áCIDOS NAFTILSULFÈNICOS E COMPOSTOS CORRELATOS COMO AGONISTAS DE ABSORçãO DE GLICOSE"". Na presente invenção são proporcionados métodos para tratamento de condições associadas com hiperglicemia, especialmente diabetes Tipo II, com novos ácidos naftilsulfónicos e compostos correlatos. Compostos de fórmula (1) onde: R^ 1^ e R^ 2^ são, independentemente, hidrogênio, alquila, alquila substituída, arila, arila substituída, R^ 3^ é um substituinte no anel B; e é -SO~ 2~OR^ 6^ -C(O)OR^ 6^, -SO~ 2~NR^ 6^~ 2~, -C(O)NR^ 6^~ 2~ ou tetrazolila; o ligante -WY- entre a naftila e fenila intercepta o anel A da naftila e é, independentemente, -C(O)NR^ 7^-, -NR^ 7^C(O)-, -C(O)O-, -OC(O)-, -CH=CH-, -NR^ 7^CH~ 2~-, -CH~ 2~NR^ 7^-, -NR^ 7^C(O)NR^ 7^-, -NR^ 7^C(O)O-, -OC(O)NR^ 7^-, -NR^ 7^S0~ 2~0-, -OSO~ 2~NR^ 7^-, -OC(O)O-, -SO~ 2~NR^ 7^~ -NR^ 7^SO~ 2~-, -OSO~ 2~- ou -SO~ 2~O-; cada R^ 6^ e R^ 7^ é, independentemente, hidrogênio ou alquila inferior; opcionalmente, na forma de únicos esteroisómeros ou misturas de esteroisómeros, ou sais farmaceuticamente aceitáveis dos compostos; são úteis em métodos de estimulação da atividade quinase do receptor de insulina, aumento da ativação do receptor de insulina em relação a insulina, e estimulação da absorção de glicose nas células. São também apresentadas uma variedade de compostos antidiabéticos e composições farmacêuticas que compreendem os compostos antidiabéticos.",TELIK INC,SPEVAK WAYNE R;;SONGYUAN SHI;;PRASAD MANCHEM V V S V;;KOZLOWSKI MICHAEL R;;SHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEONG,,https://lens.org/110-958-978-339-442,Patent Application,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,C07D215/40;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,DISCONTINUED
258,CA,A1,CA 3143202 A1,179-272-472-492-092,2020-12-17,2020,CA 3143202 A,2020-06-15,US 201962861508 P;;US 202063028008 P;;US 202063029053 P;;US 2020/0037744 W,2019-06-14,LEAKAGE DETECTION SYSTEM FOR OSTOMY APPLIANCE,"An ostomy device includes a proximal side configured for attachment to a user, a distal side opposite to the proximal side, and a leakage detection sensor having electrically conductive circuitry supported on a support layer. The leakage detection sensor is configured to detect ostomy effluent by detecting a change in resistance in the electrically conductive circuitry. The ostomy device may be an ostomy appliance or an ostomy accessory.",HOLLISTER INC,CARLSSON JONAS P;;PARK RYAN S;;MUSINSKY STEPHANIE;;LIDDLE SCOTT E;;MATTHEWS KYLE A;;NOLAN MICHAEL P;;LATTANZI LAUREN M;;SMITH ANTHONY B;;AUGUSTYN CHRISTINA,,https://lens.org/179-272-472-492-092,Patent Application,no,0,0,6,6,0,A61F5/449;;A61F5/4404;;A61B5/0531;;G01N27/06;;A61F5/445;;A61F5/4404;;A61F5/4404;;A61F5/443;;G01M3/16,A61F5/445;;A61F5/44,,0,0,,,,PENDING
259,HK,B,HK 1046268 B,039-629-391-442-678,2007-09-07,2007,HK 02107735 A,2002-10-24,US 14644499 P;;US 0020909 W,1999-07-29,NOVEL NAPHTHYLSULFONIC ACIDS AND RELATED COMPOUNDS AS GLUCOSE UPTAKE AGONISTS,,TELIK INC,WAYNE R SPEVAK;;SHI SONGYUAN;;V V S V MANCHEM PRASAD;;MICHAEL R KOZLOWSKI;;STEVEN R SCHOW;;ROBERT T LUM;;LOUISE ROBINSON;;JEONG WEONG PARK,,https://lens.org/039-629-391-442-678,Granted Patent,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,C07C/;;A61K/;;C07D215/40;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D/;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,EXPIRED
260,TW,A,TW 202000229 A,086-013-864-138-940,2020-01-01,2020,TW 108106131 A,2019-02-22,US 201862634573 P;;US 201862656265 P;;US 201862724345 P;;US 201862736730 P,2018-02-23,Sequencing method for CAR T cell therapy,The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.,ENDOCYTE INC;;PURDUE RESEARCH FOUNDATION;;SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST,MESSMANN RICHARD;;LEAMON CHRISTOPHER P;;CHU HAIYAN;;LU YINGJUAN J;;LOW PHILIP S;;JENSEN MICHAEL C;;MATTHAEI JAMES;;PINTO NAVIN ROBERT CHARLES;;PARK JULIE RUGGIERI,,https://lens.org/086-013-864-138-940,Patent of Addition,no,0,0,9,10,0,C07K16/44;;C12N2740/16043;;A61P35/00;;A61K2039/545;;C07K14/7051;;C07K2317/622;;C07K2319/33;;C07K2319/03;;C07K2317/21;;C07K2317/92;;C07K2317/52;;C07K2317/53;;C07K2317/524;;C07K2317/41;;C07K2317/72;;A61K2239/38;;A61K39/4646;;A61K39/4631;;A61K39/464404;;A61K39/4611;;A61K47/551;;A61P35/00;;A61K35/17;;C07K14/705,A61K39/00;;C07K14/705;;C07K16/44;;C12N15/86,,0,0,,,,PENDING
261,AU,A1,AU 2020/290577 A1,133-066-763-611-542,2022-01-20,2022,AU 2020/290577 A,2020-06-15,US 201962861508 P;;US 202063028008 P;;US 202063029053 P;;US 2020/0037744 W,2019-06-14,Leakage detection system for ostomy appliance,"An ostomy device includes a proximal side configured for attachment to a user, a distal side opposite to the proximal side, and a leakage detection sensor having electrically conductive circuitry supported on a support layer. The leakage detection sensor is configured to detect ostomy effluent by detecting a change in resistance in the electrically conductive circuitry. The ostomy device may be an ostomy appliance or an ostomy accessory.",HOLLISTER INC,CARLSSON JONAS P;;PARK RYAN S;;MUSINSKY STEPHANIE;;LIDDLE SCOTT E;;MATTHEWS KYLE A;;NOLAN MICHAEL P;;LATTANZI LAUREN M;;SMITH ANTHONY B;;AUGUSTYN CHRISTINA,,https://lens.org/133-066-763-611-542,Patent Application,no,0,0,6,6,0,A61F5/449;;A61F5/4404;;A61B5/0531;;G01N27/06;;A61F5/445;;A61F5/4404;;A61F5/4404;;A61F5/443;;G01M3/16,A61F5/445;;A61F5/44,,0,0,,,,PENDING
262,IT,A0,IT TO20000745 A0,068-094-724-389-312,2000-07-28,2000,IT TO20000745 A,2000-07-28,US 14644499 P,1999-07-29,NUOVI ACIDI NAFTILSOLFONICI E COMPOSTI AD ESSI CORRELATI UTLI COME AGONISTI DELL'ASSORBIMENTO DEL GLUCOSIO.,,TELIK INC,SPEVAK WAYNE R;;SHI SONGYUAN;;MANCHEM PRASAD V V S V;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEONG,,https://lens.org/068-094-724-389-312,Patent Application,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,C07D215/40;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,PENDING
263,WO,A1,WO 2000/067750 A1,162-256-117-052-386,2000-11-16,2000,EP 0003417 W,2000-04-14,US 13265999 P,1999-05-05,FOOD PRODUCT,Food products containing isoflavones and calcium are taught where the weight ratio of isoflavones to calcium is from 1 to 2 to 1 to 50.,UNILEVER NV;;UNILEVER PLC;;LEVER HINDUSTAN LTD,HERZOG LESLIE J;;RAO SANITHA S;;PARK MATTHEW R;;CRUMP JOHN D;;BROWN CHARLES B;;REDDY PODUTOORI R;;CHEN MANDY K;;PATRICK MATTHEW;;BUDD MICHAEL,,https://lens.org/162-256-117-052-386,Patent Application,yes,6,16,3,3,0,A23D7/0056;;A23D7/015;;A23F3/14;;A23F3/30;;A23F3/34;;A23G3/346;;A23G9/32;;A23G2200/00;;A23L3/3499;;A23L3/3544;;A23V2002/00;;A23L27/60;;A23L33/105;;A23L33/11;;A23L33/16;;A23G9/32;;A23L3/3499;;A23D7/0056;;A23F3/30;;A23V2002/00;;A23G2200/00;;A23D7/015;;A23L3/3544;;A23G3/346;;A23F3/34;;A23F3/14;;A23L27/60;;A23L33/11;;A23L33/16;;A23L33/105,A23D7/005;;A23D7/015;;A23F3/14;;A23F3/30;;A23F3/34;;A23G3/34;;A23G9/32;;A23L1/30;;A23L1/304;;A23L3/3499;;A23L3/3544;;A23L27/60,,0,0,,,,PENDING
264,AU,B2,AU 773828 B2,030-419-956-276-441,2004-06-10,2004,AU 2000/065066 A,2000-07-28,US 14644499 P;;US 0020909 W,1999-07-29,Novel naphthylsulfonic acids and related compounds as glucose uptake agonists,,TELIK INC,SPEVAK WAYNE R;;SONGYUAN SHI;;PRASAD V V S V MANCHEM;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEONG,,https://lens.org/030-419-956-276-441,Granted Patent,no,1,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,C07D215/40;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,EXPIRED
265,AU,A,AU 2000/065066 A,116-678-597-720-102,2001-03-13,2001,AU 2000/065066 A,2000-07-28,US 14644499 P;;US 0020909 W,1999-07-29,Novel naphthylsulfonic acids and related compounds as glucose uptake agonists,,TELIK INC,SPEVAK WAYNE R;;SONGYUAN SHI;;PRASAD V V S V MANCHEM;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;PARK JEONG WEONG,,https://lens.org/116-678-597-720-102,Patent Application,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,C07D215/40;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,EXPIRED
266,CA,A1,CA 2377668 A1,154-273-068-478-448,2001-02-22,2001,CA 2377668 A,2000-07-28,US 14644499 P;;US 0020909 W,1999-07-29,NOVEL NAPHTHYLSULFONIC ACIDS AND RELATED COMPOUNDS AS GLUCOSE UPTAKE AGONISTS,"Methods for treating conditions associated with hyperglycemia, especially Ty pe II diabetes, with novel naphthylsulfonic acids and related compounds are provided. Compounds of formula (1) where: R1 and R2 are, independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, R3 is a substituent on the B ring; and is -SO2OR6, -C(O)OR6, -SO2NR62-C(O)NR62 or tetrazolyl; the linker -WY- between the naphthyl and phenyl intersects the A ring of the naphthyl and is, independently, -C(O)NR7-, -NR7C(O)-, -C(O)O-, - OC(O)-, -CH=CH-, -NR7CH2-, -CH2NR7-, -NR7C(O)NR7- -NR7C(O)O-, -OC(O)NR7-, - NR7SO2O-, -OSO2NR7-, -OC(O)O-, -SO2NR7-, -NR7SO2-, -OSO2-, or -SO2O-; each R 6 and R7 is, independently, hydrogen or lower alkyl; optionally in the form of single stereoisomers or mixtures of stereoisomers, or the pharmaceutically acceptable salts thereof; are useful in methods of stimulating the kinase activity of the insulin receptor, enhancing the activation of the insulin receptor by insulin, and stimulating the uptake of glucose into cells. A variety of antidiabetic compounds and pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.",TELIK INC,ROBINSON LOUISE;;SPEVAK WAYNE R;;MANCHEM PRASAD V V S V;;KOZLOWSKI MICHAEL R;;PARK JEONG WEONG;;SCHOW STEVEN R;;SONGYUAN SHI;;LUM ROBERT T,,https://lens.org/154-273-068-478-448,Patent Application,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,C07D215/40;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,EXPIRED
267,HK,A1,HK 1046268 A1,030-975-084-232-173,2003-01-03,2003,HK 02107735 A,2002-10-24,US 14644499 P;;US 0020909 W,1999-07-29,Novel naphthylsulfonic acids and related compoundsas glucose uptake agonists,,TELIK INC,SPEVAK WAYNE R;;SHI SONGYUAN;;PRASAD V V S V MANCHEM;;KOZLOWSKI MICHAEL R;;SCHOW STEVEN R;;LUM ROBERT T;;LOUISE ROBINSON;;WEONG PARK JEONG,,https://lens.org/030-975-084-232-173,Patent Application,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,C07C/;;A61K/;;C07D215/40;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D/;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,EXPIRED
268,WO,A1,WO 2000/067749 A1,065-362-180-734-075,2000-11-16,2000,EP 0003416 W,2000-04-14,US 13265899 P,1999-05-05,FOOD PRODUCT,"A food product containing isoflavones and flavanol is taught, where the weight ratio of isoflavones to flavanol is from 10 to 1 to 1 to 100.",UNILEVER NV;;UNILEVER PLC;;LEVER HINDUSTAN LTD,HERZOG LESLIE J;;RAO SANITHA S;;PARK MATTHEW R;;CRUMP JOHN D;;BROWN CHARLES B;;REDDY PODUTOORI R;;CHEN MANDY K;;PATRICK MATTHEW;;BUDD MICHAEL,,https://lens.org/065-362-180-734-075,Patent Application,yes,4,14,3,3,0,A23F3/14;;A23F3/30;;A23F3/34;;A23F3/405;;A23V2002/00;;A61K31/305;;A61K31/35;;A23L33/105;;A23L33/11;;A61K31/35;;A23F3/14;;A23V2002/00;;A23F3/30;;A23F3/34;;A61K31/305;;A23F3/405;;A23L33/105;;A23L33/11,A23F3/14;;A23F3/30;;A23F3/34;;A23F3/40;;A23L1/30;;A61K31/305;;A61K31/35,,0,0,,,,PENDING
269,CN,A,CN 116370749 A,127-681-049-708-037,2023-07-04,2023,CN 202310267643 A,2013-03-15,US 201261651322 P;;US 201261679117 P;;US 201213723238 A;;US 201213723242 A;;US 201213723235 A;;US 201213723253 A;;US 201213723251 A;;US 201213725790 A;;US 201213723239 A;;US 201213723244 A;;US 201213724568 A;;CN 201380039475 A;;US 2013/0032445 W;;US 2012/0071112 W;;US 2012/0071490 W;;US 2012/0071131 W;;US 2012/0071142 W,2012-05-24,Device for infusing fluid,"The invention relates to a device for infusing a fluid. A pump for pumping a fluid includes a tube platen, a plunger, a biasing member, inlet and outlet valves, an actuator mechanism, a position sensor, and a processor. The plunger is configured to actuate toward and away from the infusion tube when the tube platen is disposed opposite the plunger. The tube platen is capable of holding an intravenous infusion tube. The biasing member is configured to urge the plunger toward the tube platen.",DEKA PRODUCTS LP,KAMEN DEAN;;KERWIN JOHN M;;MURPHY COLIN H;;GRAY LARRY B;;PARK JONATHAN;;BAIER MICHAEL J;;LANGENFELD CHRISTOPHER C;;BIASI JOHN J;;VAN DER MERWE DIRK A;;BLUMBERG DAVID;;PLACE MICHAEL S;;SLATE MICHAEL J;;PAWLOWSKI DANIEL F;;SABIN ERIK N;;NORRIS MICHAEL G;;THERRIEN ALEXANDER R,,https://lens.org/127-681-049-708-037,Patent Application,no,0,0,43,815,0,A61M5/142;;A61M5/14216;;A61M5/168;;A61M5/16831;;A61M2005/16868;;A61M2205/502;;A61M2205/50;;A61M2205/3306;;A61M2205/18;;A61M5/142;;A61M5/14216;;A61M5/168;;A61M5/16831;;A61M2005/16868;;A61M2205/18;;A61M2205/3306;;A61M2205/50;;A61M2205/502;;A61M5/14212,A61M5/172;;A61M5/14;;A61M5/142;;G16H20/17,,0,0,,,,PENDING
270,US,A1,US 2017/0319486 A1,030-369-801-110-495,2017-11-09,2017,US 201715493568 A,2017-04-21,US 201715493568 A;;US 201662326046 P,2016-04-22,TWIN-SCREW DRY GRANULATION FOR PRODUCING SOLID FORMULATIONS,"A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.",CATALENT PHARMA SOLUTIONS INC;;UNIV MISSISSIPPI,UPADHYE SAMPADA BHASKAR;;VLADYKA R PH RONALD S;;REPKA MICHAEL ANDREW;;PARK JUN-BOM;;TIWARI ROSHAN VIJAY;;PATIL HEMLATA GUNGA;;MOROTT JR JOSEPH THOMAS;;LU WENLI,UNIVERSITY OF MISSISSIPPI (2017-05-11);;R. P. SCHERER TECHNOLOGIES LLC (2017-06-07),https://lens.org/030-369-801-110-495,Patent Application,yes,4,7,9,9,0,A61K9/1635;;A61K9/1641;;A61K9/1647;;A61K9/1652;;A61K9/1694;;A61K31/4178;;A61K31/519;;B29B7/482;;B29B7/489;;B29B9/06;;B29B9/14;;B29B7/90;;B29B7/726;;B29B7/82;;B29C48/2561;;B29C48/402;;B29C48/405;;B29C48/92;;B29C48/04;;B29B7/488;;A61K9/1652;;A61K9/1635;;A61K9/1647;;A61K9/1694;;A61K9/1641;;A61K9/0053;;A61K9/1682;;A61K9/2054;;A61K9/2095;;A61K31/4178;;A61K31/519;;B01J2/10,A61K9/16;;A61K9/00;;A61K9/20;;A61K31/4178;;A61K31/519;;B01J2/10,,0,0,,,,ACTIVE
271,EP,A4,EP 1196073 A4,081-231-380-766-16X,2003-09-17,2003,EP 01918964 A,2001-03-23,US 0109498 W;;US 19204000 P;;US 68943300 A,2000-03-24,ADVANCED CLEANING SYSTEM,,CLOROX CO,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD,,https://lens.org/081-231-380-766-16X,Search Report,no,4,0,14,33,0,A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44;;A47L13/22;;A47L13/44;;A47L13/26;;A47L13/312,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 1999, no. 14 22 December 1999 (1999-12-22);;See also references of WO 0172195A1",DISCONTINUED
272,CA,A1,CA 2408186 A1,156-249-200-411-383,2001-10-04,2001,CA 2408186 A,2001-03-23,US 19204000 P;;US 68943300 A;;US 0109498 W,2000-03-24,ADVANCED CLEANING SYSTEM,"An advanced cleaning system having a handle portion (400) with a proximal en d and a distal end, a cleaning head portion (300), the cleaning head portion (300) adapted for use with a removable cleaning pad (200), and a cleaning fluid reservoir (500) coupled to the cleaning head portion (300) such that cleaning fluid (502) is controllably allowed to flow via gravity onto the surface to be cleaned adjacent the cleaning head portion (300).",CLOROX CO,RADER JAMES E;;HALL MICHAEL J;;ZHOU BOLI;;PORTICOS RICHARD;;MITRA SHUMANTA;;SAYLER DAVID;;HEFTER KAREN S;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T,,https://lens.org/156-249-200-411-383,Patent Application,no,0,0,14,33,0,A47L13/22;;A47L13/22;;A47L13/26;;A47L13/26;;A47L13/312;;A47L13/312;;A47L13/44;;A47L13/44,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,,0,0,,,,EXPIRED
273,AU,B2,AU 2001/245978 B2,182-339-280-929-271,2001-10-08,2001,AU 2001/245978 A,2001-03-23,US 19204000 P;;US 68943300 A;;US 0109498 W,2000-03-24,Advanced cleaning system,,CLOROX CO,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD,,https://lens.org/182-339-280-929-271,Granted Patent,no,8,0,14,33,0,A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44;;A47L13/22;;A47L13/44;;A47L13/26;;A47L13/312,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,,0,0,,,,EXPIRED
274,CA,C,CA 2408186 C,098-775-437-483-957,2005-02-15,2005,CA 2408186 A,2001-03-23,US 19204000 P;;US 68943300 A;;US 0109498 W,2000-03-24,ADVANCED CLEANING SYSTEM,"An advanced cleaning system having a handle portion (400) with a proximal en d and a distal end, a cleaning head portion (300), the cleaning head portion (300) adapted for use with a removable cleaning pad (200), and a cleaning fluid reservoir (500) coupled to the cleaning head portion (300) such that cleaning fluid (502) is controllably allowed to flow via gravity onto the surface to be cleaned adjacent the cleaning head portion (300).",CLOROX CO,FLAGLER ROBERT W;;PARK ERIC Y;;PORTICOS RICHARD;;SAYLER DAVID;;HEFTER KAREN S;;ZHOU BOLI;;MITRA SHUMANTA;;HAUBRICH SCOTT T;;HALL MICHAEL J;;RADER JAMES E,,https://lens.org/098-775-437-483-957,Granted Patent,no,0,0,14,33,0,A47L13/22;;A47L13/22;;A47L13/26;;A47L13/26;;A47L13/312;;A47L13/312;;A47L13/44;;A47L13/44,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,,0,0,,,,EXPIRED
275,ZA,B,ZA 200200128 B,164-587-587-209-180,2003-04-07,2003,ZA 200200128 A,2002-01-07,US 14644499 P,1999-07-29,Novel naphtylsulfonic acids and related compounds as glucose uptake agonists.,,TELIK INC,SPEVAK WAYNE R;;MANCHEM PRASAD V V S V;;SCHOW STEVEN R;;ROBINSON LOUISE;;SONGYUAN SHI;;KOZLOWSKI MICHAEL R;;LUM ROBERT T;;PARK SOPHIA JEONG-WEON,,https://lens.org/164-587-587-209-180,Granted Patent,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;C07D215/40;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,EXPIRED
276,CA,C,CA 2484278 C,122-682-055-481-919,2008-07-08,2008,CA 2484278 A,2001-03-23,CA 2408186 A;;US 19204000 P;;US 68943300 A,2000-03-24,ADVANCED CLEANING SYSTEM,"An advanced cleaning system having a handle portion (400) with a proximal end and a distal end, a cleaning head portion (300), the cleaning head portion (300) adapted for use with a removable cleaning pad (200), and a cleaning fluid reservoir (500) coupled to the cleaning head portion (300) such that cleaning fluid (502) is controllably allowed to flow via gravity onto the surface to be cleaned adjacent the cleaning head portion (300)).",CLOROX CO,ZHOU BOLI;;MITRA SHUMANTA;;PORTICOS RICHARD;;RADER JAMES E;;HAUBRICH SCOTT T;;PARK ERIC Y;;FLAGLER ROBERT W;;HALL MICHAEL J;;HEFTER KAREN S;;SAYLER DAVID,,https://lens.org/122-682-055-481-919,Granted Patent,no,0,0,2,33,0,,A47L13/22;;A47L1/08,,0,0,,,,EXPIRED
277,WO,A1,WO 2001/072195 A1,177-249-379-504-716,2001-10-04,2001,US 0109498 W,2001-03-23,US 19204000 P;;US 68943300 A,2000-03-24,ADVANCED CLEANING SYSTEM,"An advanced cleaning system having a handle portion (400) with a proximal end and a distal end, a cleaning head portion (300), the cleaning head portion (300) adapted for use with a removable cleaning pad (200), and a cleaning fluid reservoir (500) coupled to the cleaning head portion (300) such that cleaning fluid (502) is controllably allowed to flow via gravity onto the surface to be cleaned adjacent the cleaning head portion (300).",CLOROX CO;;HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD,,https://lens.org/177-249-379-504-716,Patent Application,yes,3,24,14,33,0,A47L13/22;;A47L13/22;;A47L13/26;;A47L13/26;;A47L13/312;;A47L13/312;;A47L13/44;;A47L13/44,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,,1,0,,,See also references of EP 1196073A4,PATENTED
278,EP,A1,EP 1196073 A1,066-768-740-216-695,2002-04-17,2002,EP 01918964 A,2001-03-23,US 0109498 W;;US 19204000 P;;US 68943300 A,2000-03-24,ADVANCED CLEANING SYSTEM,,CLOROX CO,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD,,https://lens.org/066-768-740-216-695,Patent Application,yes,0,0,14,33,0,A47L13/22;;A47L13/22;;A47L13/26;;A47L13/26;;A47L13/312;;A47L13/312;;A47L13/44;;A47L13/44,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,,0,0,,,,DISCONTINUED
279,US,B2,US 10786459 B2,128-757-854-473-749,2020-09-29,2020,US 201715493568 A,2017-04-21,US 201715493568 A;;US 201662326046 P,2016-04-22,Twin-screw dry granulation for producing solid formulations,"A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.",SCHERER TECHNOLOGIES LLC R P;;UNIV MISSISSIPPI,UPADHYE SAMPADA BHASKAR;;VLADYKA R PH RONALD S;;REPKA MICHAEL ANDREW;;PARK JUN-BOM;;TIWARI ROSHAN VIJAY;;PATIL HEMLATA GUNGA;;MOROTT JR JOSEPH THOMAS;;LU WENLI,UNIVERSITY OF MISSISSIPPI (2017-05-11);;R. P. SCHERER TECHNOLOGIES LLC (2017-06-07),https://lens.org/128-757-854-473-749,Granted Patent,yes,11,3,9,9,0,A61K9/1635;;A61K9/1641;;A61K9/1647;;A61K9/1652;;A61K9/1694;;A61K31/4178;;A61K31/519;;B29B7/482;;B29B7/489;;B29B9/06;;B29B9/14;;B29B7/90;;B29B7/726;;B29B7/82;;B29C48/2561;;B29C48/402;;B29C48/405;;B29C48/92;;B29C48/04;;B29B7/488;;A61K9/1652;;A61K9/1635;;A61K9/1647;;A61K9/1694;;A61K9/1641;;A61K9/0053;;A61K9/1682;;A61K9/2054;;A61K9/2095;;A61K31/4178;;A61K31/519;;B01J2/10,A61K9/16;;A61K9/00;;A61K9/20;;A61K31/4178;;A61K31/519;;B01J2/10,,14,6,013-173-710-675-203;;094-434-675-224-757;;078-202-815-180-643;;013-900-482-532-910;;064-855-680-711-397;;029-393-539-000-315,15296958;;10.1016/j.ejpb.2004.04.014;;16949222;;10.1016/j.ijpharm.2006.07.005;;24114922;;10.1002/jps.23739;;10.1016/j.ijpharm.2015.09.025;;26387621;;10.1016/j.ijpharm.2016.07.035;;27452420;;10.1016/j.ajps.2016.08.005;;pmc7032224;;32104312,"Aulton, Michael E., “Pharmaceutics: The Science of Dosage Form Design,” (1988); 4 pages.;;Anonymous, “The U.S. Pharmacopeia: The National Formulary,” (1995) USP 23, NF 18; 2 pages.;;Kleinebudde, Peter, “Roll compaction/dry granulation: pharmaceutical applications,” (2004) European Journal of Pharmaceutics and Biopharmaceutics, vol. 58; 10 pages.;;Van Melkebeke, Barbara et al., “Melt granulation using a twin-screw extruder: A case study,” (2006) International Journal of Pharmaceutics, 326(1); 5 pages.;;Rowe, Raymond C., “Handbook of Pharmaceutical Excipients,” Sixth Edition, American Pharmaceuticals Association (2009); 917 pages.;;Allen, Jr., Loyd V. et al., “Remington, The Science and Practice of Pharmacy,” (2012) 22nd Edition, vol. I, Gennaro, Ed., Lippincott Williams & Wilkins; 1942 pages.;;Allen, Jr., Loyd V. et al., “Remington, The Science and Practice of Pharmacy,” (2012) 22nd Edition, vol. II, Gennaro, Ed., Lippincott Williams & Wilkins: 1005 pages.;;Weatherley, Sharleen et al., “Hot-Melt Granulation in a Twin Screw Extruder: Effects of Processing on Formulations with Caffeine and Ibuprofen,” (2013) Journal of Pharmaceutical Sciences, vol. 102; 7 pages.;;Maniruzzaman, Mohammed et al., “Continuous twin-screw granulation for enhancing the dissolution of poorly water soluble drug,” (2015) International Journal of Pharmaceutics 496; 11 pages.;;Thompson, M.R. et al., (2016) “Heat Activated Dry Granulation Within the Twin Screw Granulator,” SPE ANTEC, Indianapolis; 6 pages.;;International Search Report and Written Opinion dated Jul. 7, 2017, directed to International Application No. PCT/2017/028955; 13 pages.;;Desai et al. (Mar. 2013). “Melt Granulation: An Alternative to Traditional Granulation Techniques,” Indian Drugs 50(3): 5-13.;;Monteyne et al. (Oct. 2016). “Stearic Acid and High Molecular Weight PEO as Matrix for the Highly Water Soluble Metoprolol Tartrate in Continuous Twin-Screw Melt Granulation,” International Journal of Pharmaceutics 512(1): 158-167.;;Vaingankar et al. (Jan. 2017). “Continuous Melt Granulation to Develop High Drug Loaded Sustained Release Tablet of Metformin HCl,” Asian Journal of Pharmaceutical Sciences 12: 37-50.",ACTIVE
280,CA,A1,CA 2484278 A1,135-896-283-151-546,2001-10-04,2001,CA 2484278 A,2001-03-23,CA 2408186 A;;US 19204000 P;;US 68943300 A,2000-03-24,ADVANCED CLEANING SYSTEM,"An advanced cleaning system having a handle portion (400) with a proximal e nd and a distal end, a cleaning head portion (300), the cleaning head portion (300) adapted for use with a removable cleaning pad (200), and a cleaning fluid reservoir (500) coupled to the cleaning head portion (300) such that cleaning fluid (502) is controllably allowed to flow via gravity onto the surface to be cleaned adjacent the cleaning hea d portion (300)).",CLOROX CO,RADER JAMES E;;PARK ERIC Y;;FLAGLER ROBERT W;;SAYLER DAVID;;PORTICOS RICHARD;;HALL MICHAEL J;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;ZHOU BOLI;;HEFTER KAREN S,,https://lens.org/135-896-283-151-546,Patent Application,no,0,1,2,33,0,,A47L1/08;;A47L13/22,,0,0,,,,EXPIRED
281,CZ,A3,CZ 2002234 A3,093-640-649-452-52X,2002-06-12,2002,CZ 2002234 A,2000-07-28,US 14644499 P,1999-07-29,Novel naphthyl sulfonic acid and related compounds as agonists of glucose reception,,TELIK,SONGYUAN SHI;;PRASAD V V S V MANCHEM;;SCHOW STEVEN R;;LUM ROBERT T;;ROBINSON LOUISE;;SPEVAK WAYNE R;;KOZLOWSKI MICHAEL R;;PARK SOPHIA JEONG WEONG,,https://lens.org/093-640-649-452-52X,Patent Application,no,0,0,38,38,0,C07C237/42;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85;;A61P3/00;;A61P3/10;;A61P43/00;;C07C309/51;;C07D241/44;;C07D213/81;;C07C309/59;;C07D215/48;;C07D307/68;;C07D213/82;;C07C311/29;;C07C309/51;;C07C237/42;;C07D307/85;;C07C311/13;;C07C311/21,A61K31/167;;A61K31/18;;A61K31/192;;A61K31/198;;A61K31/341;;A61K31/343;;A61K31/4409;;A61K31/455;;A61K31/47;;A61K31/498;;A61P3/10;;A61P43/00;;C07C237/42;;C07D215/40;;C07C309/51;;C07C309/59;;C07C311/13;;C07C311/21;;C07C311/29;;C07C311/46;;C07D213/81;;C07D213/82;;C07D215/48;;C07D241/44;;C07D307/68;;C07D307/85,,0,0,,,,PENDING
282,WO,A2,WO 2020/076605 A2,138-256-997-347-210,2020-04-16,2020,US 2019/0054476 W,2019-10-03,US 201862743173 P;;US 201962803125 P,2018-10-09,OSTOMY APPLIANCE CONFIGURED FOR LEAKAGE DETECTION,"An ostomy appliance includes an ostomy hydrocolloid having a body-facing side, a pouch-facing side and a stoma opening, at least one fluid aperture formed in the body-facing side and at least one fluidic channel embedded in the ostomy hydrocolloid having a proximal portion disposed in fluid communication with the at least one fluid aperture. The ostomy appliance also includes at least one window formed in the pouch facing side, the at least one window aligned with a distal portion of the fluidic channel such that a portion of the fluidic channel is visible through the window. In another embodiment, an ostomy appliance includes a skin barrier material and an ultrasonic detection device for monitoring the skin barrier material.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT;;MUSINSKY STEPHANIE;;MATTHEWS KYLE,,https://lens.org/138-256-997-347-210,Patent Application,yes,1,4,9,9,0,A61F5/445;;A61F5/4401;;A61F5/445,A61F5/445,,0,0,,,,PENDING
283,WO,A3,WO 2020/076605 A3,051-583-839-773-461,2020-05-22,2020,US 2019/0054476 W,2019-10-03,US 201862743173 P;;US 201962803125 P,2018-10-09,OSTOMY APPLIANCE CONFIGURED FOR LEAKAGE DETECTION,"An ostomy appliance includes an ostomy hydrocolloid having a body-facing side, a pouch-facing side and a stoma opening, at least one fluid aperture formed in the body-facing side and at least one fluidic channel embedded in the ostomy hydrocolloid having a proximal portion disposed in fluid communication with the at least one fluid aperture. The ostomy appliance also includes at least one window formed in the pouch facing side, the at least one window aligned with a distal portion of the fluidic channel such that a portion of the fluidic channel is visible through the window. In another embodiment, an ostomy appliance includes a skin barrier material and an ultrasonic detection device for monitoring the skin barrier material.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT;;MUSINSKY STEPHANIE;;MATTHEWS KYLE,,https://lens.org/051-583-839-773-461,Search Report,yes,6,0,9,9,0,A61F5/445;;A61F5/4401;;A61F5/445,A61F5/445,,0,0,,,,PENDING
284,US,A1,US 2013/0119316 A1,050-732-063-131-989,2013-05-16,2013,US 201113068329 A,2011-05-09,US 201113068329 A;;US 39511310 P,2010-05-07,Boron nitride and boron nitride nanotube materials for radiation shielding,"Effective radiation shielding is required to protect crew and equipment in various fields including aerospace, defense, medicine and power generation. Light elements and in particular hydrogen are most effective at shielding against high-energy particles including galactic cosmic rays, solar energetic particles and fast neutrons. However, pure hydrogen is highly flammable, has a low neutron absorption cross-section, and cannot be made into structural components. Nanocomposites containing the light elements Boron, Nitrogen, Carbon and Hydrogen as well dispersed boron nano-particles, boron nitride nanotubes (BNNTs) and boron nitride nano-platelets, in a matrix, provide effective radiation shielding materials in various functional forms. Boron and nitrogen have large neutron absorption cross-sections and wide absorption spectra. The incorporation of boron and nitrogen containing nanomaterials into hydrogen containing matrices provides composites that can effectively shield against neutrons and a wide range of radiation species of all energies without fragmentation and the generation of harmful secondary particles.",SAUTI GODFREY;;PARK CHEOL;;KANG JIN HO;;KIM JAE-WOO;;HARRISON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON E;;LILLEHEI PETER T;;THIBEAULT SHEILA A;;NAT INST AEROSPACE ASSOCIATES;;THOMAS JEFFERSON NAT ACCELERATOR FACILITY;;AND SPACE ADMINISTRATION;;US ADM NAT AERONAUTIES,SAUTI GODFREY;;PARK CHEOL;;KANG JIN HO;;KIM JAE-WOO;;HARRISON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON E;;LILLEHEI PETER T;;THIBEAULT SHEILA A,NATIONAL INSTITUTE OF AEROSPACE ASSOCIATES (2011-05-09);;JEFFERSON SCIENCE ASSOCIATES LLC (2011-05-09);;UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (2012-01-30),https://lens.org/050-732-063-131-989,Patent Application,yes,0,17,6,6,0,G21F1/00;;G21F3/02;;G21F1/00;;G21F1/103,G21F1/10,252/478,0,0,,,,DISCONTINUED
285,US,B2,US 6986618 B2,052-546-979-026-293,2006-01-17,2006,US 60637003 A,2003-06-25,US 60637003 A;;US 23377302 A;;US 68943300 A;;US 31791101 P;;US 19204000 P,2000-03-24,Advanced cleaning system,"An advanced cleaning system having a handle portion with a proximal end and a distal end, a cleaning head portion, the cleaning head portion adapted for use with a removable cleaning pad, and a cleaning fluid reservoir fluidically coupled to the cleaning head portion such that cleaning fluid is controllably allowed to flow via gravity onto the surface to be cleaned adjacent the cleaning head portion.",CLOROX CO,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID J;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD,,https://lens.org/052-546-979-026-293,Granted Patent,yes,100,47,4,33,0,A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44;;A47L13/22;;A47L13/44;;A47L13/26;;A47L13/312,A46B11/00;;A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,401/140;;401/139;;401/138,21,0,,,"Webester's Third New international Dictionary, 1976 by G. & C. Merriam Co., pp. 2208-2209 and 2258-2259.;;Chemical Engineer's Handbook, 1973 by Robert H. perry and Cecil H. Chilton pp. 5-4, 18-58, and 18-59.;;U.S. Appl. No. 10/233,773 filed Aug. 30, 2002.;;U.S. Appl. No. 10/234,959 filed Aug. 30, 2002.;;U.S. Appl. No. 10/233,774 filed Aug. 30, 2002.;;U.S. Appl. No. 10/351,293 filed Jan. 24, 2003.;;U.S. Appl. No. 10/350,803 filed Jan. 24, 2003.;;U.S. Appl. No. 10/350,804 filed Jan. 24, 2003.;;U.S. Appl. No. 29/140,155 filed Apr. 11, 2001.;;U.S. Appl. No. 29/140,102 filed Apr. 11, 2001.;;U.S. Appl. No. 29/140,150 filed Apr. 11, 2001.;;U.S. Appl. No. 29/140,154 filed Apr. 11, 2001.;;U.S. Appl. No. 29/140,104 filed Apr. 11, 2001.;;U.S. Appl. No. 29/140,162 filed Apr. 11, 2001.;;U.S. Appl. No. 29/160,918 filed May 17, 2002.;;U.S. Appl. No. 29/160,919 filed May 17, 2002.;;U.S. Appl. No. 29/166,630 filed Aug. 30, 2002.;;U.S. Appl. No. 29/186,191 filed Jul. 10, 2003.;;U.S. Appl. No. 29/186,188 filed Jul. 10, 2003.;;U.S. Appl. No. 29/186,190 filed Jul. 10, 2003.;;U.S. Appl. No. 29/186,189 filed Jul. 10, 2003.",EXPIRED
286,WO,A1,WO 2011/139384 A1,050-222-254-838-231,2011-11-10,2011,US 2011/0000809 W,2011-05-09,US 201113068329 A;;US 39511310 P,2010-05-07,BORON NITRIDE AND BORON NITRIDE NANOTUBE MATERIALS FOR RADIATION SHIELDING,"Effective radiation shielding is required to protect crew and equipment in various fields including aerospace, defense, medicine and power generation. Light elements and in particular hydrogen are most effective at shielding against high-energy particles including galactic cosmic rays, solar energetic particles and fast neutrons. However, pure hydrogen is highly flammable, has a low neutron absorption cross-section, and cannot be made into structural components. Nanocomposites containing the light elements Boron, Nitrogen, Carbon and Hydrogen as well dispersed boron nano-particles, boron nitride nanotubes (BNNTs) and boron nitride nano- platelets,in a matrix, provide effective radiation shielding materials in various functional forms. Boron and nitrogen have large neutron absorption cross-sections and wide absorption spectra. The incorporation of boron and nitrogen containing nanomaterials into hydrogen containing matrices provides composites that can effectively shield against neutrons and a wide range of radiation species of all energies without fragmentation and the generation of harmful secondary particles.",NAT INST AEROSPACE ASSOCIATES;;NASA;;JEFFERSON SCIENCE ASS LLC;;KANG JIN HO;;KIM JAE-WOO;;HARRISON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON E;;LILLEHEI PETER T;;THIBEAULT SHEILA A,KANG JIN HO;;KIM JAE-WOO;;HARRISON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON E;;LILLEHEI PETER T;;THIBEAULT SHEILA A;;SAUTI GODFREY;;PARK CHEOL,,https://lens.org/050-222-254-838-231,Patent Application,yes,5,14,6,6,0,G21F1/00;;G21F3/02;;G21F1/00;;G21F1/103,G21F3/02,,0,0,,,,PENDING
287,US,A1,US 2004/0022575 A1,163-907-545-231-068,2004-02-05,2004,US 35080303 A,2003-01-24,US 35080303 A;;US 68943300 A;;US 19204000 P,2000-03-24,Method of cleaning a surface,"
   A method for cleaning a surface using a tool with both a cleaning head and a cleaning fluid reservoir housing coupled to an elongated handle, the method comprising the following steps: attaching a cleaning pad to the cleaning head; inserting a replaceable cleaning fluid reservoir into the housing; fluidically coupling the cleaning fluid reservoir to the cleaning head; dispensing controlled amounts of cleaning fluid from the reservoir onto a surface; and distributing the cleaning fluid evenly over the surface with the cleaning pad. 
",HALL MICHAEL J.;;RADER JAMES E.;;ZHOU BOLI;;HEFTER KAREN S.;;SAYLER DAVID J.;;PARK ERIC Y.;;FLAGLER ROBERT W.;;HAUBRICH SCOTT T.;;MITRA SHUMANTA;;PORTICOS RICHARD,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID J;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD,CLOROX COMPANY THE (2001-07-09),https://lens.org/163-907-545-231-068,Patent Application,yes,5,6,14,33,0,A47L13/22;;A47L13/22;;A47L13/26;;A47L13/26;;A47L13/312;;A47L13/312;;A47L13/44;;A47L13/44,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,40114;;X40127;;401/278,0,0,,,,EXPIRED
288,US,B2,US 10832182 B2,045-644-789-543-084,2020-11-10,2020,US 57771009 A,2009-10-12,US 57771009 A,2009-10-12,Method and system for managing a program relating to a product,"A method for managing a program relating to a product, the program including a plurality of program requirements for performing a plurality of program tasks, includes: (a) establishing a location reference system for a representation of the product in three dimensions; (b) identifying a plurality of task-loci in a display; the display presenting the representation of the product according to the location reference system; each respective task-locus of the plurality of task-loci being associated with a respective program task of the plurality of program tasks; (c) characterizing each respective task-locus associated with an accomplished respective program task as a respective completed task-locus; and (d) accounting for accomplishment of the respective program tasks by accounting for the respective completed task-loci.",FLOYD JOSEPH F;;HADLEY BRENT LOUIS;;EAMES PATRICK JAN;;SESNY PAUL A;;PATTERSON QUENTIN S;;MILLER STEPHEN PAUL;;COKER BRIAN LEE;;PARK CHUL Y;;BOYD MICHAEL W;;BOEING CO,FLOYD JOSEPH F;;HADLEY BRENT LOUIS;;EAMES PATRICK JAN;;SESNY PAUL A;;PATTERSON QUENTIN S;;MILLER STEPHEN PAUL;;COKER BRIAN LEE;;PARK CHUL Y;;BOYD MICHAEL W,BOEING COMPANY A CORPORATION OF DELAWARE (2009-10-04),https://lens.org/045-644-789-543-084,Granted Patent,yes,29,0,2,10,0,G06Q10/06;;G06Q10/06;;G06Q10/06313;;G06Q10/06313,G06Q10/06,,10,1,020-640-710-725-235,10.1109/wsc.2000.899721,"Douglas, Maintenance Performance Toolbox, Aeromagazine Quarterly, Qtr_01, 2007, p. 22-27.;;Nader, 787 Training for Pilots and Mechanics, Aeromagazine Quarterly, QTR_01, 2008, p. 6-15.;;Haber, 787 Maintenance Training, Boeing, Sep. 21, 2006, p. 1-30.;;Brown, Driving Digital Manufacturing to Reality, Proceedings of the 2000 Winter Simulation Conference, 2000, p. 224-28.;;Brown and Caddick, The Factory is Virual . . . The Savings are Real, RTO AVT Symposium on “Reduction of Military Vehicle Acquisition Time and Cost through Advanced Modelling and Virtual Simulation”, Paris, France, Apr. 22-25, 2002, p. 6-1 to 6-8.;;Asia Pacific, Japan Airlines: To Enter Innovative Maintenance Deal with Boeing Troubledd Company Reporter, Oct. 2005.;;AviationWeek, “Carribean Airlines selected Modules”, Apr. 1, 2007.;;3rd Dimension, Veritas et Visus, Mar. 2006, vol. 1, No. 8.;;Cortona 3D, Cortona3D RapidTag Powers Boeing's New Maintenance Performance Toolbox, Mar. 14, 2006.;;Extended EPO Search Report for related application 15189236.1 dated May 4, 2016, 7 pp.",ACTIVE
289,CA,A1,CA 2798747 A1,146-105-369-303-77X,2011-11-10,2011,CA 2798747 A,2011-05-09,US 39511310 P;;US 201113068329 A;;US 2011/0000809 W,2010-05-07,BORON NITRIDE AND BORON NITRIDE NANOTUBE MATERIALS FOR RADIATION SHIELDING,"Effective radiation shielding is required to protect crew and equipment in various fields including aerospace, defense, medicine and power generation. Light elements and in particular hydrogen are most effective at shielding against high-energy particles including galactic cosmic rays, solar energetic particles and fast neutrons. However, pure hydrogen is highly flammable, has a low neutron absorption cross-section, and cannot be made into structural components. Nanocomposites containing the light elements Boron, Nitrogen, Carbon and Hydrogen as well dispersed boron nano-particles, boron nitride nanotubes (BNNTs) and boron nitride nano- platelets,in a matrix, provide effective radiation shielding materials in various functional forms. Boron and nitrogen have large neutron absorption cross-sections and wide absorption spectra. The incorporation of boron and nitrogen containing nanomaterials into hydrogen containing matrices provides composites that can effectively shield against neutrons and a wide range of radiation species of all energies without fragmentation and the generation of harmful secondary particles.",NAT INST AEROSPACE ASSOCIATES;;US ADM NATI ONAL AERONAUTICS AND SPACE ADMINISTRATION;;JEFFERSON SCIENCE ASS LLC,KANG JIN HO;;KIM JAE-WOO;;HARRISON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON E;;LILLEHEI PETER T;;THIBEAULT SHEILA A;;SAUTI GODFREY;;PARK CHEOL,,https://lens.org/146-105-369-303-77X,Patent Application,no,0,0,6,6,0,G21F1/00;;G21F3/02;;G21F1/00;;G21F1/103,G21F3/02,,0,0,,,,DISCONTINUED
290,US,A1,US 2011/0087513 A1,042-107-202-599-239,2011-04-14,2011,US 57771009 A,2009-10-12,US 57771009 A,2009-10-12,METHOD AND SYSTEM FOR MANAGING A PROGRAM RELATING TO A PRODUCT,"A method for managing a program relating to a product, the program including a plurality of program requirements for performing a plurality of program tasks, includes: (a) establishing a location reference system for a representation of the product in three dimensions; (b) identifying a plurality of task-loci in a display; the display presenting the representation of the product according to the location reference system; each respective task-locus of the plurality of task-loci being associated with a respective program task of the plurality of program tasks; (c) characterizing each respective task-locus associated with an accomplished respective program task as a respective completed task-locus; and (d) accounting for accomplishment of the respective program tasks by accounting for the respective completed task-loci.",BOEING COMPANY A CORP OF DELAWARE,FLOYD JOSEPH F;;HADLEY BRENT LOUIS;;EAMES PATRICK JAN;;SESNY PAUL A;;PATTERSON QUENTIN S;;MILLER STEPHEN PAUL;;COKER BRIAN LEE;;PARK CHUL Y;;BOYD MICHAEL W,BOEING COMPANY A CORPORATION OF DELAWARE (2009-10-04),https://lens.org/042-107-202-599-239,Patent Application,yes,29,39,2,10,0,G06Q10/06;;G06Q10/06;;G06Q10/06313;;G06Q10/06313,G06Q10/00;;G06Q50/00,705/7.23,9,1,020-640-710-725-235,10.1109/wsc.2000.899721,"Douglas, Maintenance Performance Toolbox, Aeromagazine Quarterly, Qtr_01, 2007, pg. 22-27;;Nader, 787 Training for Pilots and Mechanics, Aeromagazine Quarterly, QTR_01, 2008, pg. 6-15;;Haber, 787 Maintenance Training, Boeing, 9/21/06, pg. 1-30;;Brown, Driving Digital Manufacturing to Reality, Proceedings of the 2000 Winter Simulation Conference, 2000, pg. 224-28;;Brown and Caddick, The Factory is Virual ...... The Savings are Real, RTO AVT Symposium on ""Reduction of Military Vehicle Acquisition Time and Cost through Advanced Modelling and Virtual Simulation"", Paris, France, 22-25 April 2002, pg. 6-1 to 6-8;;Asia Pacific, ""Japan Airlines: To Enter Innovative Maintenance Deal with Boeing Troubledd Company Reporter"", October 2005.;;AviationWeek, ""Carribean Airlines selected Modules"", April 1, 2007.;;3rd Dimension, Veritas et Visus, March 2006, Vol.1, No. 8.;;Cortona 3D, Cortona3D RapidTag Powers Boeing's New Maintenance Performance Toolbox, 14 March 2006.",ACTIVE
291,US,A1,US 2004/0253041 A1,049-835-623-848-088,2004-12-16,2004,US 60637003 A,2003-06-25,US 60637003 A;;US 23377302 A;;US 68943300 A;;US 31791101 P;;US 19204000 P,2000-03-24,Advanced cleaning system,"
   An advanced cleaning system having a handle portion with a proximal end and a distal end, a cleaning head portion, the cleaning head portion adapted for use with a removable cleaning pad, and a cleaning fluid reservoir fluidically coupled to the cleaning head portion such that cleaning fluid is controllably allowed to flow via gravity onto the surface to be cleaned adjacent the cleaning head portion. 
",HALL MICHAEL J.;;RADER JAMES E.;;ZHOU BOLI;;HEFTER KAREN S.;;SAYLER DAVID J.;;PARK ERIC Y.;;FLAGLER ROBERT W.;;HAUBRICH SCOTT T.;;MITRA SHUMANTA;;PORTICOS RICHARD,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID J;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD,,https://lens.org/049-835-623-848-088,Patent Application,yes,95,8,4,33,0,A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44;;A47L13/22;;A47L13/44;;A47L13/26;;A47L13/312,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,40114,0,0,,,,EXPIRED
292,US,B1,US 6540424 B1,057-701-057-845-056,2003-04-01,2003,US 68943300 A,2000-10-11,US 68943300 A;;US 19204000 P,2000-03-24,Advanced cleaning system,"
    An advanced cleaning system having a handle portion with a proximal end and a distal end, a cleaning head portion, the cleaning head portion adapted for use with a removable cleaning pad, and a cleaning fluid reservoir fluidically coupled to the cleaning head portion such that cleaning fluid is controllably allowed to flow via gravity onto the surface to be cleaned adjacent the cleaning head portion. 
",CLOROX CO,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID J;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD,CLOROX COMPANY THE (2001-01-25);;THE CLOROX COMPANY (2001-01-25);;ZIBA DESIGN INC (2001-07-09),https://lens.org/057-701-057-845-056,Granted Patent,yes,109,124,14,33,0,A47L13/22;;A47L13/22;;A47L13/26;;A47L13/26;;A47L13/312;;A47L13/312;;A47L13/44;;A47L13/44,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,401/140;;401/139;;401/138,3,0,,,"Internation Search Report, dated Sep. 5, 2001, 2 pages.;;Webester's Third New international Dictionary, 1976 by G. & C. Merriam Co., pp. 2208-2209 and 2258-2259.;;Chemical Engineers' Handbook, 1973 by Robert H. perry and Cecil H. Chilton pp. 5-4, 18-58 and 18-59.",EXPIRED
293,JP,A,JP 2004028991 A,183-148-473-134-808,2004-01-29,2004,JP 2003067209 A,2003-03-12,US 85066992 A;;US 85067792 A;;US 85156092 A,1992-03-13,SCANNING PROBE ELECTRON MICROSCOPE,"<P>PROBLEM TO BE SOLVED: To provide a scanning probe electron microscope (SFM) facilitating a change of probes while dispensing with adjustment for positioning a deflection detector after a change of probe. <P>SOLUTION: This scanning probe electron microscope 100 has a probe 101 removably mounted on a head 108 by a kinematic mounting technique. A motor-driven unstacked coarse x-y axis movable stage 116 is disposed on a base material 114. A motor-driven coarse biaxial movable stage 112 positions the head relative to the base material and enables the adjustment of the height, lateral slant, and longitudinal slant, of the probe. A scanner 118 includes x, y, and z axis specimen position detectors, and the outputs of the detectors are also connected to a controller 110 through a feedback loop for improving the performance of the microscope. An optical image observation assembly 124 provides a combined image of a concentric image with an oblique perspective image of a cantilever 102 and a specimen 104. <P>COPYRIGHT: (C)2004,JPO",THERMOMICROSCOPES CORP,LINKER FREDERICK I;;KIRK MICHAEL D;;SWIFT PETER R;;ALEXANDER JOHN D;;PARK SUNG-IL;;SMITH IAN R;;PARISH DAVID M;;LEE JEONG HO;;HOWLAND REBECCA S,,https://lens.org/183-148-473-134-808,Patent Application,no,0,8,9,21,0,G01Q30/04;;G01Q70/02;;G02B21/002;;G02B21/26;;Y10S977/851;;Y10S977/85;;G01Q30/025;;G01Q70/02;;G01Q30/04;;B82Y35/00;;G02B21/002;;G02B21/26;;Y10S977/851;;Y10S977/85;;G01Q30/025,G01Q30/02;;G01Q30/04;;G01B21/30;;G01Q60/00;;G01Q70/02;;G02B21/00;;G02B21/26;;G21K5/10;;H01J37/00;;H01J37/20;;H01J37/22,,0,0,,,,EXPIRED
294,EP,A1,EP 2567385 A1,106-695-599-969-501,2013-03-13,2013,EP 11777717 A,2011-05-09,US 201113068329 A;;US 39511310 P;;US 2011/0000809 W,2010-05-07,BORON NITRIDE AND BORON NITRIDE NANOTUBE MATERIALS FOR RADIATION SHIELDING,,NAT INST AEROSPACE ASSOCIATES;;GOVERNMENT OF THE US ADMINISTRATOR OF THE NAT AERONAUTICS AND SPACE ADM;;JEFFERSON SCIENCE ASS LLC,KANG JIN HO;;KIM JAE-WOO;;HARRISON JOYCELYN S;;SMITH MICHAEL W;;JORDAN KEVIN;;LOWTHER SHARON E;;LILLEHEI PETER T;;THIBEAULT SHEILA A;;SAUTI GODFREY;;PARK CHEOL,,https://lens.org/106-695-599-969-501,Patent Application,yes,0,0,6,6,0,G21F1/00;;G21F3/02;;G21F1/00;;G21F1/103,G21F3/02,,0,0,,,,DISCONTINUED
295,US,A1,US 2022/0071797 A1,042-349-530-332-578,2022-03-10,2022,US 202117524343 A,2021-11-11,US 202117524343 A;;US 202117265430 A;;US 2019/0054476 W;;US 201962803125 P;;US 201862743173 P,2018-10-09,OSTOMY APPLIANCE CONFIGURED FOR LEAKAGE DETECTION,"An ostomy appliance includes an ostomy hydrocolloid having a body-facing side, a pouch-facing side and a stoma opening, at least one fluid aperture formed in the body-facing side and at least one fluidic channel embedded in the ostomy hydrocolloid having a proximal portion disposed in fluid communication with the at least one fluid aperture. The ostomy appliance also includes at least one window formed in the pouch facing side, the at least one window aligned with a distal portion of the fluidic channel such that a portion of the fluidic channel is visible through the window. In another embodiment, an ostomy appliance includes a skin barrier material and an ultrasonic detection device for monitoring the skin barrier material.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,HOLLISTER INCORPORATED (2020-02-07);;BLUR PRODUCT DEVELOPMENT (2020-02-28);;LUNAR DESIGN LLC (2020-02-20),https://lens.org/042-349-530-332-578,Patent Application,yes,0,0,9,9,0,A61F5/445;;A61F5/4401;;A61F5/445,A61F5/445;;A61F5/44,,0,0,,,,PENDING
296,EP,B1,EP 3863573 B1,191-626-099-671-489,2024-03-06,2024,EP 19790398 A,2019-10-03,US 201862743261 P;;US 201962807504 P;;US 2019/0054496 W,2018-10-09,OSTOMY APPLIANCE COMPRISING THERMAL SENSORS,,HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,,https://lens.org/191-626-099-671-489,Granted Patent,yes,2,0,8,8,0,A61F5/445;;A61B5/0008;;A61B5/4851;;A61B2562/0271;;A61F5/443;;C08L33/10;;C08L75/04,A61F5/445,,0,0,,,,ACTIVE
297,WO,A1,WO 2020/076609 A1,039-130-047-884-669,2020-04-16,2020,US 2019/0054496 W,2019-10-03,US 201862743261 P;;US 201962807504 P,2018-10-09,OSTOMY APPLIANCE COMPRISING THERMAL SENSORS,"An ostomy appliance system includes an ostomy appliance having a stoma opening and a first electrical interface, and at least one thermal sensor configured to detect at least one thermal property, such as temperature, at the ostomy appliance, the at least one temperature sensor connected to the first electrical interface with electrical circuitry. A wearable device may be removably connected to the ostomy appliance and operably connected to the at least one thermal sensor. The wearable device includes a housing, a second electrical interface configured for electrical connection to the first electrical interface, a power supply and a controller operably connected to the power supply. The controller is configured to determine a condition of the ostomy appliance based on the at least one thermal property detected at the at least one thermal sensor. The wearable device may also include a wireless transceiver configured to communicate with a personal communication device.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,,https://lens.org/039-130-047-884-669,Patent Application,yes,8,13,8,8,0,A61F5/445;;A61B5/0008;;A61B5/4851;;A61B2562/0271;;A61F5/443;;C08L33/10;;C08L75/04,A61F5/445,,0,0,,,,PENDING
298,US,A1,US 2021/0244563 A1,186-076-931-017-537,2021-08-12,2021,US 201917265430 A,2019-10-03,US 201917265430 A;;US 201962803125 P;;US 201862743173 P;;US 2019/0054476 W,2018-10-09,OSTOMY APPLIANCE CONFIGURED FOR LEAKAGE DETECTION,"An ostomy appliance includes an ostomy hydrocolloid having a body-facing side, a pouch-facing side and a stoma opening, at least one fluid aperture formed in the body-facing side and at least one fluidic channel embedded in the ostomy hydrocolloid having a proximal portion disposed in fluid communication with the at least one fluid aperture. The ostomy appliance also includes at least one window formed in the pouch facing side, the at least one window aligned with a distal portion of the fluidic channel such that a portion of the fluidic channel is visible through the window. In another embodiment, an ostomy appliance includes a skin barrier material and an ultrasonic detection device for monitoring the skin barrier material.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,HOLLISTER INCORPORATED (2020-02-07);;BLUR PRODUCT DEVELOPMENT (2020-02-28);;LUNAR DESIGN LLC (2020-02-20),https://lens.org/186-076-931-017-537,Patent Application,yes,0,1,9,9,0,A61F5/445;;A61F5/4401;;A61F5/445,A61F5/445;;A61F5/44,,0,0,,,,ACTIVE
299,CN,A,CN 112739295 A,028-358-247-666-510,2021-04-30,2021,CN 201980058624 A,2019-10-03,US 201862743173 P;;US 201962803125 P;;US 2019/0054476 W,2018-10-09,OSTOMY APPLIANCE CONFIGURED FOR LEAKAGE DETECTION,"An ostomy appliance includes an ostomy hydrocolloid having a body-facing side, a pouch-facing side and a stoma opening, at least one fluid aperture formed in the body-facing side and at least one fluidic channel embedded in the ostomy hydrocolloid having a proximal portion disposed in fluid communication with the at least one fluid aperture. The ostomy appliance also includes at least one window formed in the pouch facing side, the at least one window aligned with a distal portion of the fluidic channel such that a portion of the fluidic channel is visible through the window. In another embodiment, an ostomy appliance includes a skin barrier material and an ultrasonic detection device for monitoring the skin barrier material.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,,https://lens.org/028-358-247-666-510,Patent Application,no,9,0,9,9,0,A61F5/445;;A61F5/4401;;A61F5/445,A61F5/445,,0,0,,,,PENDING
300,US,A1,US 2021/0386368 A1,161-526-844-574-528,2021-12-16,2021,US 201917282938 A,2019-10-03,US 201917282938 A;;US 201962807504 P;;US 201862743261 P;;US 2019/0054496 W,2018-10-09,OSTOMY APPLIANCE COMPRISING THERMAL SENSORS,"An ostomy appliance system includes an ostomy appliance having a stoma opening and a first electrical interface, and at least one thermal sensor configured to detect at least one thermal property, such as temperature, at the ostomy appliance, the at least one temperature sensor connected to the first electrical interface with electrical circuitry. A wearable device may be removably connected to the ostomy appliance and operably connected to the at least one thermal sensor. The wearable device includes a housing, a second electrical interface configured for electrical connection to the first electrical interface, a power supply and a controller operably connected to the power supply. The controller is configured to determine a condition of the ostomy appliance based on the at least one thermal property detected at the at least one thermal sensor. The wearable device may also include a wireless transceiver configured to communicate with a personal communication device.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,HOLLISTER INCORPORATED (2020-02-07);;BLUR PRODUCT DEVELOPMENT (2020-02-28);;LUNAR DESIGN LLC (2020-02-20),https://lens.org/161-526-844-574-528,Patent Application,yes,0,28,8,8,0,A61F5/445;;A61B5/0008;;A61B5/4851;;A61B2562/0271;;A61F5/443;;C08L33/10;;C08L75/04,A61B5/00;;A61F5/443;;C08L33/10;;C08L75/04,,0,0,,,,PENDING
301,CA,A1,CA 3115760 A1,189-145-164-006-84X,2020-04-16,2020,CA 3115760 A,2019-10-03,US 2019/0054496 W;;US 201862743261 P;;US 201962807504 P,2018-10-09,OSTOMY APPLIANCE COMPRISING THERMAL SENSORS,"An ostomy appliance system includes an ostomy appliance having a stoma opening and a first electrical interface, and at least one thermal sensor configured to detect at least one thermal property, such as temperature, at the ostomy appliance, the at least one temperature sensor connected to the first electrical interface with electrical circuitry. A wearable device may be removably connected to the ostomy appliance and operably connected to the at least one thermal sensor. The wearable device includes a housing, a second electrical interface configured for electrical connection to the first electrical interface, a power supply and a controller operably connected to the power supply. The controller is configured to determine a condition of the ostomy appliance based on the at least one thermal property detected at the at least one thermal sensor. The wearable device may also include a wireless transceiver configured to communicate with a personal communication device.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,,https://lens.org/189-145-164-006-84X,Patent Application,no,0,0,8,8,0,A61F5/445;;A61B5/0008;;A61B5/4851;;A61B2562/0271;;A61F5/443;;C08L33/10;;C08L75/04,A61F5/445,,0,0,,,,PENDING
302,US,B2,US 11202719 B2,056-333-595-814-836,2021-12-21,2021,US 201917265430 A,2019-10-03,US 201917265430 A;;US 201962803125 P;;US 201862743173 P;;US 2019/0054476 W,2018-10-09,Ostomy appliance configured for leakage detection,"An ostomy appliance includes an ostomy hydrocolloid having a body-facing side, a pouch-facing side and a stoma opening, at least one fluid aperture formed in the body-facing side and at least one fluidic channel embedded in the ostomy hydrocolloid having a proximal portion disposed in fluid communication with the at least one fluid aperture. The ostomy appliance also includes at least one window formed in the pouch facing side, the at least one window aligned with a distal portion of the fluidic channel such that a portion of the fluidic channel is visible through the window. In another embodiment, an ostomy appliance includes a skin barrier material and an ultrasonic detection device for monitoring the skin barrier material.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,HOLLISTER INCORPORATED (2020-02-07);;BLUR PRODUCT DEVELOPMENT (2020-02-28);;LUNAR DESIGN LLC (2020-02-20),https://lens.org/056-333-595-814-836,Granted Patent,yes,8,0,9,9,0,A61F5/445;;A61F5/4401;;A61F5/445,A61F5/445;;A61F5/44,,1,0,,,"International Preliminary Report on Patentability and Written Opinion issued by ISA/EPO in connection with PCT/US2019/054476 dated Apr. 8, 2021.",ACTIVE
303,AU,A1,AU 2019/359130 A1,152-707-426-263-66X,2021-05-13,2021,AU 2019/359130 A,2019-10-03,US 201962807504 P;;US 201862743261 P;;US 2019/0054496 W,2018-10-09,Ostomy appliance comprising thermal sensors,"An ostomy appliance system includes an ostomy appliance having a stoma opening and a first electrical interface, and at least one thermal sensor configured to detect at least one thermal property, such as temperature, at the ostomy appliance, the at least one temperature sensor connected to the first electrical interface with electrical circuitry. A wearable device may be removably connected to the ostomy appliance and operably connected to the at least one thermal sensor. The wearable device includes a housing, a second electrical interface configured for electrical connection to the first electrical interface, a power supply and a controller operably connected to the power supply. The controller is configured to determine a condition of the ostomy appliance based on the at least one thermal property detected at the at least one thermal sensor. The wearable device may also include a wireless transceiver configured to communicate with a personal communication device.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,,https://lens.org/152-707-426-263-66X,Patent Application,no,0,0,8,8,0,A61F5/445;;A61B5/0008;;A61B5/4851;;A61B2562/0271;;A61F5/443;;C08L33/10;;C08L75/04,A61F5/445,,0,0,,,,PENDING
304,EP,A1,EP 3863573 A1,029-868-868-624-846,2021-08-18,2021,EP 19790398 A,2019-10-03,US 201862743261 P;;US 201962807504 P;;US 2019/0054496 W,2018-10-09,OSTOMY APPLIANCE COMPRISING THERMAL SENSORS,,HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,,https://lens.org/029-868-868-624-846,Patent Application,yes,0,0,8,8,0,A61F5/445;;A61B5/0008;;A61B5/4851;;A61B2562/0271;;A61F5/443;;C08L33/10;;C08L75/04,A61F5/445,,0,0,,,,ACTIVE
305,EP,A2,EP 3863574 A2,077-106-556-401-408,2021-08-18,2021,EP 19791092 A,2019-10-03,US 201862743173 P;;US 201962803125 P;;US 2019/0054476 W,2018-10-09,OSTOMY APPLIANCE CONFIGURED FOR LEAKAGE DETECTION,,HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,,https://lens.org/077-106-556-401-408,Patent Application,yes,0,0,9,9,0,A61F5/445;;A61F5/4401;;A61F5/445,A61F5/445,,0,0,,,,PENDING
306,CA,A1,CA 3110380 A1,027-166-806-760-202,2020-04-16,2020,CA 3110380 A,2019-10-03,US 201862743173 P;;US 201962803125 P;;US 2019/0054476 W,2018-10-09,OSTOMY APPLIANCE CONFIGURED FOR LEAKAGE DETECTION,"An ostomy appliance includes an ostomy hydrocolloid having a body-facing side, a pouch-facing side and a stoma opening, at least one fluid aperture formed in the body-facing side and at least one fluidic channel embedded in the ostomy hydrocolloid having a proximal portion disposed in fluid communication with the at least one fluid aperture. The ostomy appliance also includes at least one window formed in the pouch facing side, the at least one window aligned with a distal portion of the fluidic channel such that a portion of the fluidic channel is visible through the window. In another embodiment, an ostomy appliance includes a skin barrier material and an ultrasonic detection device for monitoring the skin barrier material.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,,https://lens.org/027-166-806-760-202,Patent Application,no,0,0,9,9,0,A61F5/445;;A61F5/4401;;A61F5/445,A61F5/445,,0,0,,,,PENDING
307,AU,A1,AU 2019/359128 A1,051-925-662-773-569,2021-03-11,2021,AU 2019/359128 A,2019-10-03,US 201962803125 P;;US 201862743173 P;;US 2019/0054476 W,2018-10-09,Ostomy appliance configured for leakage detection,"An ostomy appliance includes an ostomy hydrocolloid having a body-facing side, a pouch-facing side and a stoma opening, at least one fluid aperture formed in the body-facing side and at least one fluidic channel embedded in the ostomy hydrocolloid having a proximal portion disposed in fluid communication with the at least one fluid aperture. The ostomy appliance also includes at least one window formed in the pouch facing side, the at least one window aligned with a distal portion of the fluidic channel such that a portion of the fluidic channel is visible through the window. In another embodiment, an ostomy appliance includes a skin barrier material and an ultrasonic detection device for monitoring the skin barrier material.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,,https://lens.org/051-925-662-773-569,Patent Application,no,0,0,9,9,0,A61F5/445;;A61F5/4401;;A61F5/445,A61F5/445,,0,0,,,,PENDING
308,CN,A,CN 112888408 A,062-276-877-189-935,2021-06-01,2021,CN 201980067003 A,2019-10-03,US 201862743261 P;;US 201962807504 P;;US 2019/0054496 W,2018-10-09,OSTOMY APPLIANCE COMPRISING THERMAL SENSORS,"An ostomy appliance system includes an ostomy appliance having a stoma opening and a first electrical interface, and at least one thermal sensor configured to detect at least one thermal property, such as temperature, at the ostomy appliance, the at least one temperature sensor connected to the first electrical interface with electrical circuitry. A wearable device may be removably connected to the ostomy appliance and operably connected to the at least one thermal sensor. The wearable device includes a housing, a second electrical interface configured for electrical connection to the first electrical interface, a power supply and a controller operably connected to the power supply. The controller is configured to determine a condition of the ostomy appliance based on the at least one thermal property detected at the at least one thermal sensor. The wearable device may also include a wireless transceiver configured to communicate with a personal communication device.",HOLLISTER INC,CARLSSON JONAS P;;NOLAN MICHAEL P;;AUGUSTYN CHRISTINA;;BARKER JAMES BRANDON;;PARK RYAN S;;JANIS SCOTT;;HENZE STEPHANIE;;WLEZIEN CHRISTOPHER MICHAEL;;SEKARAN SOMASUNDER VIJAY;;VERBRACKEL GERMAIN;;LANE ROBERT;;LIDDLE SCOTT E;;MUSINSKY STEPHANIE;;MATTHEWS KYLE A,,https://lens.org/062-276-877-189-935,Patent Application,no,4,0,8,8,0,A61F5/445;;A61B5/0008;;A61B5/4851;;A61B2562/0271;;A61F5/443;;C08L33/10;;C08L75/04,A61F5/445,,0,0,,,,ACTIVE
309,US,A1,US 2005/0059800 A1,043-834-434-735-532,2005-03-17,2005,US 86760004 A,2004-06-15,US 86760004 A;;US 47951703 P,2003-06-17,"Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl","In one embodiment, the present application relates to a process of making a compound of formula I: and to certain intermediate compounds that are made within the process of making the compound of formula I.",SCHERING CORP,SUDHAKAR ANANTHA;;DAHANUKAR VILAS;;ZAVIALOV ILIA A;;ORR CECILIA;;NGUYEN HOA N;;WEBER JUERGEN;;JEON INGYU;;CHEN MINZHANG;;GREEN MICHAEL D;;WONG GEORGE S;;PARK JEONGHAN;;IWAMA TETSUO,MERCK SHARP & DOHME CORP (2004-08-28),https://lens.org/043-834-434-735-532,Patent Application,yes,2,25,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07C271/22;;C07K5/02,530/331,0,0,,,,INACTIVE
310,AU,A,AU 1996/055395 A,156-156-064-593-06X,1996-10-23,1996,AU 1996/055395 A,1996-04-05,US 41959895 A;;US 9604909 W,1995-04-06,Anti-obesity agents,,AMYLIN PHARMACEUTICALS INC,BEELEY NIGEL;;RINK TIMOTHY J;;ALBRANDT KEITH ALAN;;SIERZEGA MICHAEL EDWARD;;JANES SUSAN M;;PRICKETT KATHRYN S;;PHELPS JULIE L;;CHUN MARK;;PARK DOUGLAS M;;BEIDLER DANIEL E,,https://lens.org/156-156-064-593-06X,Patent Application,no,0,0,2,2,0,A61K38/00;;C07K16/26;;C07K14/5759;;C07K2317/34,A61K38/00;;C07K14/575;;C07K16/26,,0,0,,,,PENDING
311,CN,B,CN 1805932 B,018-084-604-477-657,2011-05-18,2011,CN 200480016640 A,2004-06-15,US 2004/0018914 W;;US 47951703 P,2003-06-17,Process and intermediates for the preparation of hepatitis C virus protease inhibitor,"In one embodiment, the present application relates to a process of making a compound of formula (I): and to certain intermediate compounds that are made within the process of making the compound of formula (I).",SCHERING CORP,JEONGHAN PARK;;NGUYEN HOA N;;GREEN MICHAEL D;;CECILIA ORR;;INGYU JEON;;JUERGEN WEBER;;WONG GEORGE S;;VILAS DAHANUKAR;;ZAVIALOV ILIA A;;ANANTHA SUDHAKAR;;MINZHANG CHEN;;TETSUO IWAMA,MSD CORP. (2012-12-12),https://lens.org/018-084-604-477-657,Granted Patent,no,0,0,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07D209/52;;C07C237/14;;C07C271/22;;C07K5/02,,0,0,,,,INACTIVE
312,CN,A,CN 102199111 A,119-668-488-689-484,2011-09-28,2011,CN 201110073934 A,2004-06-15,US 47951703 P,2003-06-17,Process and intermediates for the preparation of hepatitis C virus protease inhibitor,"Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl. The present application relates to a process of making a compound of formula (I): and to certain intermediate compounds that are made within the process of making the compound of formula (I).",SCHERING CORP,ANANTHA SUDHAKAR;;VILAS DAHANUKAR;;ZAVIALOV ILIA A;;CECILIA ORR;;NGUYEN HOA N;;JUERGEN WEBER;;INGYU JEON;;MINZHANG CHEN;;GREEN MICHAEL D;;WONG GEORGE S;;JEONGHAN PARK;;TETSUO IWAMA,MSD CORP. (2012-12-12),https://lens.org/119-668-488-689-484,Patent Application,no,0,5,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07C271/22;;C07C231/12;;C07C237/14;;C07C269/06;;C07K5/02,,0,0,,,,INACTIVE
313,US,B2,US 7326795 B2,179-508-514-233-995,2008-02-05,2008,US 86760004 A,2004-06-15,US 86760004 A;;US 47951703 P,2003-06-17,"Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl","In one embodiment, the present application relates to a process of making a compound of formula I: and to certain intermediate compounds that are made within the process of making the compound of formula I.",SCHERING CORP,SUDHAKAR ANANTHA;;DAHANUKAR VILAS;;ZAVIALOV ILIA A;;ORR CECILIA;;NGUYEN HOA N;;WEBER JUERGEN;;JEON INGYU;;CHEN MINZHANG;;GREEN MICHAEL D;;WONG GEORGE S;;PARK JEONGHAN;;IWAMA TETSUO,MERCK SHARP & DOHME CORP (2004-08-28),https://lens.org/179-508-514-233-995,Granted Patent,yes,3,19,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07D209/52;;C07C233/08;;C07C271/22;;C07K5/02,548/515;;564/199,2,0,,,"International Search Report (PCT/US2004/018914)- 3pgs.;;U.S. Appl. No. 10/052,386, filed Jan. 18, 2002.",INACTIVE
314,CN,B,CN 102199111 B,033-038-780-156-197,2012-07-04,2012,CN 201110073934 A,2004-06-15,US 47951703 P,2003-06-17,Process and intermediates for the preparation of hepatitis C virus protease inhibitor,"Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl. The present application relates to a process of making a compound of formula (I): and to certain intermediate compounds that are made within the process of making the compound of formula (I).",SCHERING CORPORTAION,ANANTHA SUDHAKAR;;VILAS DAHANUKAR;;ZAVIALOV ILIA A;;CECILIA ORR;;NGUYEN HOA N;;JUERGEN WEBER;;INGYU JEON;;MINZHANG CHEN;;GREEN MICHAEL D;;WONG GEORGE S;;JEONGHAN PARK;;TETSUO IWAMA,MSD CORP. (2012-12-12),https://lens.org/033-038-780-156-197,Granted Patent,no,0,0,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07C271/22;;C07C231/12;;C07C237/14;;C07C269/06;;C07K5/02,,0,0,,,,INACTIVE
315,EP,A1,EP 1641754 A1,044-679-689-428-197,2006-04-05,2006,EP 04755225 A,2004-06-15,US 2004/0018914 W;;US 47951703 P,2003-06-17,"PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R, 2S, 5S)-3- AZABICYCLO[ 3, 1, 0]HEXANE-2-CARBOXAMIDE, N- [3-AMINO -1-(CYCLOBUTYLMETHYL)-2, 3-DIOXOPROPYL] ]-3- [ (2S)- 2-[[[1, 1-DIMETHYLETHYL ]AMINO]CARBONYLA MINO ]-3, 3-DIMETHYL-1-OXOBUTYL] -6, 6-DIMETHYL",,SCHERING CORP,SUDHAKAR ANANTHA;;DAHANUKAR VILAS;;ZAVIALOV ILIA A;;ORR CECILIA;;NGUYEN HOA N;;WEBER JUERGEN;;JEON INGYU;;CHEN MINZHANG;;GREEN MICHAEL D;;WONG GEORGE S;;PARK JEONGHAN;;IWAMA TETSUO,"MERCK SHARP & DOHME CORP., US (2013-05-16);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-16);;SCHERING CORPORATION, US (2013-03-19);;MERCK SHARP & DOHME CORP. (2012-10-23)",https://lens.org/044-679-689-428-197,Patent Application,yes,0,0,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07C271/22;;C07K5/02,,0,0,,,,ACTIVE
316,CA,C,CA 2526629 C,129-719-245-881-746,2012-10-02,2012,CA 2526629 A,2004-06-15,US 47951703 P;;US 2004/0018914 W,2003-06-17,"PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R,2S,5S)-3-AZABICYCLO[3,1,0]HEXANE-2-CARBOXAMIDE, N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL]-3-[(2S)-2-[[[1,1-DIMETHYLETHYL]AMINO]CARBONYLAMINO]-3,3-DIMETHYL-1-OXOBUTYL]-6,6-DIMETHYL","In one embodiment, the present application relates to a process of making a compound of formula (I): and to certain intermediate compounds that are made within the process of making the compound of formula (I).",SCHERING CORP,SUDHAKAR ANANTHA;;DAHANUKAR VILAS;;ZAVIALOV ILIA A;;ORR CECILIA;;NGUYEN HOA N;;WEBER JUERGEN;;JEON INGYU;;CHEN MINZHANG;;GREEN MICHAEL D;;WONG GEORGE S;;PARK JEONGHAN;;IWAMA TETSUO,,https://lens.org/129-719-245-881-746,Granted Patent,no,0,0,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07D209/52;;C07C237/14;;C07C271/22;;C07K5/02,,0,0,,,,INACTIVE
317,CA,A1,CA 2526629 A1,107-511-865-400-797,2004-12-29,2004,CA 2526629 A,2004-06-15,US 47951703 P;;US 2004/0018914 W,2003-06-17,"PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R,2S,5S)-3-AZABICYCLO[3,1,0]HEXANE-2-CARBOXAMIDE, N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL]]-3-[(2S)-2-[[[1,1-DIMETHYLETHYL]AMINO]CARBONYLAMINO]-3,3-DIMETHYL-1-OXOBUTYL]-6,6-DIMETHYL","In one embodiment, the present application relates to a process of making a compound of formula (I): and to certain intermediate compounds that are made within the process of making the compound of formula (I).",SCHERING CORP,PARK JEONGHAN;;DAHANUKAR VILAS;;ZAVIALOV ILIA A;;NGUYEN HOA N;;IWAMA TETSUO;;SUDHAKAR ANANTHA;;ORR CECILIA;;WEBER JUERGEN;;WONG GEORGE S;;GREEN MICHAEL D;;CHEN MINZHANG;;JEON INGYU,,https://lens.org/107-511-865-400-797,Patent Application,no,0,0,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07D209/52;;C07C237/14;;C07C271/22;;C07K5/02,,0,0,,,,INACTIVE
318,EP,B1,EP 1641754 B1,035-809-101-528-215,2008-03-26,2008,EP 04755225 A,2004-06-15,US 2004/0018914 W;;US 47951703 P,2003-06-17,"PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R, 2S, 5S)-3- AZABICYCLO[ 3, 1, 0]HEXANE-2-CARBOXAMIDE, N- [3-AMINO -1-(CYCLOBUTYLMETHYL)-2, 3-DIOXOPROPYL] ]-3- [ (2S)- 2-[[[1, 1-DIMETHYLETHYL ]AMINO]CARBONYLA MINO ]-3, 3-DIMETHYL-1-OXOBUTYL] -6, 6-DIMETHYL",,SCHERING CORP,SUDHAKAR ANANTHA;;DAHANUKAR VILAS;;ZAVIALOV ILIA A;;ORR CECILIA;;NGUYEN HOA N;;WEBER JUERGEN;;JEON INGYU;;CHEN MINZHANG;;GREEN MICHAEL D;;WONG GEORGE S;;PARK JEONGHAN;;IWAMA TETSUO,"MERCK SHARP & DOHME CORP., US (2013-05-16);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-16);;SCHERING CORPORATION, US (2013-03-19);;MERCK SHARP & DOHME CORP. (2012-10-23)",https://lens.org/035-809-101-528-215,Granted Patent,yes,1,0,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07D209/52;;C07C237/14;;C07C271/22;;C07K5/02,,0,0,,,,ACTIVE
319,WO,A1,WO 1996/031526 A1,135-002-953-603-463,1996-10-10,1996,US 9604909 W,1996-04-05,US 41959895 A,1995-04-06,ANTI-OBESITY AGENTS,"Proteins, including various dimeric and monomeric forms of the ob gene product, or modified ob protein-encoding DNA sequences, having anti-feeding activity and methods of preparing, purifying, formulating and using such proteins, for example, in the treatment of various feeding and metabolic disorders, including obesity and diabetes. Antibodies and immunoassays useful in the detection and quantitation of such proteins are also provided.",AMYLIN PHARMACEUTICALS INC;;BEELEY NIGEL;;RINK TIMOTHY J;;ALBRANDT KEITH ALAN;;SIERZEGA MICHAEL EDWARD;;JANES SUSAN M;;PRICKETT KATHRYN S;;PHELPS JULIE L;;CHUN MARK;;PARK DOUGLAS M;;BEIDLER DANIEL E,BEELEY NIGEL;;RINK TIMOTHY J;;ALBRANDT KEITH ALAN;;SIERZEGA MICHAEL EDWARD;;JANES SUSAN M;;PRICKETT KATHRYN S;;PHELPS JULIE L;;CHUN MARK;;PARK DOUGLAS M;;BEIDLER DANIEL E,,https://lens.org/135-002-953-603-463,Patent Application,yes,5,43,2,2,0,A61K38/00;;C07K16/26;;C07K14/5759;;C07K2317/34,A61K38/00;;C07K14/575;;C07K16/26,,8,8,053-428-207-984-829;;013-093-194-841-26X;;014-696-914-894-976;;068-786-103-270-121;;029-108-414-625-797;;042-505-271-220-468;;029-312-522-673-751;;067-808-973-531-645,7984236;;10.1038/372425a0;;7499416;;10.1074/jbc.270.48.28887;;10.1126/science.7624777;;7624777;;7624776;;10.1126/science.7624776;;7624778;;10.1126/science.7624778;;7984230;;10.1038/372406a0;;10.1038/377530a0;;7566151;;pmc40918;;10.1073/pnas.92.20.9034;;7568067,"NATURE, 01 December 1994, Vol. 372, ZHANG et al., ""Positional Cloning of the Mouse Obese Gene and its Human Homologue"", pages 425-432.;;JOURNAL OF BIOLOGICAL CHEMISTRY, 01 December 1995, Vol. 270, No. 48, HE et al., ""The Mouse Obese Gene"", pages 28887-28891.;;SCIENCE, 28 July 1995, Vol. 269, HALAAS et al., ""Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene"", pages 543-546.;;SCIENCE, 28 July 1995, Vol. 269, PELLEYMOUNTER et al., ""Effects of the Obese Gene Product on Body Weight Regulation in Ob/Ob Mice"", pages 540-543.;;SCIENCE, 28 July 1995, Vol. 269, CAMPFIELD et al., ""Recombinant Mouse ob Protein: Evidence for a Peripheral Signal Linking Adiposity and Central Neural Networks"", pages 546-549.;;NATURE, 01 December 1994, Vol. 372, RINK T.J., ""In Search of a Satiety Factor"", pages 406-407.;;NATURE, 12 October 1995, Vol. 377, STEPHENS et al., ""The Role of Neuropeptide Y in the Antiobesity Action of the Obese Gene Product"", pages 530-532.;;PROC. NATL. ACAD. SCI. U.S.A., September 1995, Vol. 92, MacDOUGALD et al., ""Regulated Expression of the Obese Gene Product (Leptin) in White Adipose Tissue and 3T3-L1 Adipocytes"", pages 9034-9037.",PENDING
320,WO,A1,WO 2004/113294 A1,120-977-614-134-223,2004-12-29,2004,US 2004/0018914 W,2004-06-15,US 47951703 P,2003-06-17,"PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R, 2S, 5S)-3-AZABICYCLO[3, 1, 0]HEXANE-2-CARBOXAMIDE, N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2, 3-DIOXOPROPYL] ]-3-[(2S)-2-[[[1, 1-DIMETHYLETHYL]AMINO]CARBONYLAMINO]-3, 3-DIMETHYL-1-OXOBUTYL]-6, 6-DIMETHYL","In one embodiment, the present application relates to a process of making a compound of formula (I): and to certain intermediate compounds that are made within the process of making the compound of formula (I).",SCHERING CORP;;SUDHAKAR ANANTHA;;DAHANUKAR VILAS;;ZAVIALOV ILIA A;;ORR CECILIA;;NGUYEN HOA N;;WEBER JUERGEN;;JEON INGYU;;CHEN MINZHANG;;GREEN MICHAEL D;;WONG GEORGE S;;PARK JEONGHAN;;IWAMA TETSUO,SUDHAKAR ANANTHA;;DAHANUKAR VILAS;;ZAVIALOV ILIA A;;ORR CECILIA;;NGUYEN HOA N;;WEBER JUERGEN;;JEON INGYU;;CHEN MINZHANG;;GREEN MICHAEL D;;WONG GEORGE S;;PARK JEONGHAN;;IWAMA TETSUO,,https://lens.org/120-977-614-134-223,Patent Application,yes,1,22,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07C271/22;;C07K5/02,,0,0,,,,PENDING
321,HK,A1,HK 1220527 A1,184-378-282-319-033,2017-05-05,2017,HK 16108493 A,2016-07-18,US 201462006032 P;;US 201562129945 P;;US 2015/0032474 W,2014-05-30,WELLNESS AGGREGATOR,,APPLE INC,LAWRENCE Y YANG LY;;JAMES H FOSTER JH;;DANIEL S KEEN DS;;ZACHERY KENNEDY Z;;STEPHEN O LEMAY SO;;MICHAEL OREILLY M;;DENNIS S PARK DS;;CHRISTOPHER D SOLI CD;;GUY L TRIBBLE GL;;TODD K WHITEHURST TK,,https://lens.org/184-378-282-319-033,Patent Application,no,0,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G16H50/70,,0,0,,,,PENDING
322,ZA,B,ZA 200509100 B,094-822-777-284-763,2011-06-29,2011,ZA 200509100 A,2005-11-10,US 47951703 P;;US 2004/0018914 W,2003-06-17,"PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R,2S,5S)-3-AZABICYCLO[3,1,0,]HEXANE-2-CARBOXAMIDE,N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DOIXOPROPYL]-3-[(2S)-2-[[[1,1-DIMETHYLETHYYL]AMINO]CARBONYLAMINO]-3,3-DIMETHYL-1-OXOBUTHYL]-6,6-DIMETHYL",,SCHERING CORP,IWAMA TETSUO;;WONG GEORGE S K;;WEBER JUERGEN;;ORR CECILIA;;DAHANUKAR VILAS;;PARK JEONGHAN;;JEON INGYU;;NGUYEN HOA N;;ZAVIALOV ILIA A;;GREEN MICHAEL D;;CHEN MINZHANG;;SUDHAKAR ANANTHA,,https://lens.org/094-822-777-284-763,Granted Patent,no,0,0,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07C271/22;;C07K5/02,,0,0,,,,ACTIVE
323,US,B2,US 7473250 B2,000-243-032-830-065,2009-01-06,2009,US 85098404 A,2004-05-21,US 85098404 A,2004-05-21,Ultrasound medical system and method,"An ultrasound medical system includes an interstitial end effector. The interstitial end effector is interstitially insertable into patient tissue, includes at least one medical-treatment ultrasound transducer, and includes at least one end-effector-tissue-track ablation device. One method for ultrasonically treating a lesion in a patient includes the steps of obtaining the interstitial end effector and inserting it into the patient creating a tissue track which is surrounded by patient tissue and which ends at the distal end of the inserted interstitial end effector. Other steps include ultrasonically ablating the lesion using the at-least-one medical-treatment ultrasound transducer, using the at-least-one end-effector-tissue-track ablation device to ablate the patient tissue surrounding the tissue track along substantially the entire tissue track, and withdrawing the end effector from the patient.",ETHICON ENDO SURGERY INC,MAKIN INDER RAJ S;;MAST T DOUGLAS;;SLAYTON MICHAEL H;;BARTHE PETER G;;MESSERLY JEFFREY D;;FAIDI WASEEM;;RUNK MEGAN M;;O'CONNOR BRIAN D;;PARK CHRISTOPHER J;;JAEGER PAUL M,CILAG GMBH INTERNATIONAL (2021-04-05);;ETHICON ENDO-SURGERY INC (2004-11-01);;ETHICON LLC (2016-12-30),https://lens.org/000-243-032-830-065,Granted Patent,yes,121,53,4,4,0,A61B5/4836;;A61B5/4836;;A61B5/053;;A61B8/13;;A61B8/4281;;A61B8/4281;;A61B8/4483;;A61B8/4483;;A61B17/2202;;A61B17/2202;;A61B18/06;;A61B18/08;;A61B18/12;;A61B18/1815;;A61B2090/378;;A61B2090/378;;A61N7/00,A61B18/18;;A61B17/22;;A61B19/00;;A61H1/00,606/27;;606/41,18,8,012-677-037-649-963;;018-474-830-859-761;;034-754-133-493-270;;085-088-175-816-531;;131-674-806-563-074;;130-943-831-164-477;;003-983-898-185-063;;017-235-593-694-793,8059487;;10.1016/0301-5629(94)90066-3;;10.1016/s0002-9378(00)33870-4;;10.1067/mob.2000.105347;;10920300;;10.1089/end.1997.11.191;;9181449;;10.1121/1.429476;;10923905;;10.1121/1.417359;;8865654;;8865655;;10.1121/1.417360;;10.1109/58.542050;;18244264;;10.1109/58.710592,"Hill, C.R. et al., Lesion Development In Focused Ultrasound Surgery: A General Model, Ultrasound in Med. & Biol., 1994, pp. 259-269, vol. 20, No. 3, Elsevier Science Ltd, New York, USA.;;Clare, M.C. et al., MRI Guided Focused Ultrasound Surgery (FUS) of uterine leiomyomas: A Feasibility Study, Workshop on MRI-Guided: Focused Ultrasound Surgery, 2002, Syllabus, International Society for Magnetic Resonance in Medicine.;;Vaezy, S. et al., Treatment Of Uterine Fibroid Tumors In A Nude Mouse Model Using High-Intensity Focused Ultrasound, Am J Obstet Gynecol, 2000, pp. 6-11, vol. 183, No. 1.;;Electrosurgical Devices, RF Generator and RITA Base Software, web pages from ritamedical.com.;;Watkins et al., ""High-intensity focused ultrasound ablation of the kidney in large animal model,"" J. Endourol., 11 (3), 191, abstract (Jun. 1997).;;Chavrier et al., ""Modeling of high-intensity focused ultrasound-induced lesions in the presence of cavitation bubbles,"" J. Acoust. Soc. Am. 108 (1), pp. 432-440 (Jul. 2000).;;Maass-Moreno, R. et al., ""Noninvasive temperature estimation in tissue via ultrasound echo-shifts. Part I. Analytical model,"" J. Acoust. Soc. Am., 100(4), Pt. 1, pp. 2514-2521 (Oct. 1996).;;Maass-Moreno, R. et al., ""Noninvasive temperature estimation in tissue via ultrasound echo-shifts. Part II. In vitro study,"" J. Acoust. Soc. Am., 100 (4), Pt. 1, pp. 2522-2530 (Oct. 1996).;;Seip, R. et al., ""Noninvasive Real-Time Multipoint Temperature Control for Ultrasound Phased Array Treatments,"" IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 43, No. 6, pp. 1063-1073 (Nov. 1996).;;Simon, C. et al., ""Two-Dimensional Temperature Estimation Using Diagnostic Ultrasound,"" IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 45, No. 4, pp. 1088-1099 (Apr. 1998).;;PCT, International Search Report, PCT/US02/16512 (dated Jul. 17, 2003; published Sep. 23, 2003).;;PCT, International Search Report, PCT/US02/16699 (dated Jul. 17, 2003; published Nov. 20, 2003).;;PCT, International Search Report, PCT/US02/16700 (dated Apr. 15, 2003; published Jul. 24, 2003).;;PCT, International Search Report, PCT/US02/16696 (dated Apr. 4, 2003; published Nov. 6, 2003).;;PCT, International Search Report, PCT/US02/16421 (dated Apr. 4, 2003; published Mar. 18, 2004).;;PCT, International Search Report, PCT/US02/16697 (dated Mar. 31, 2003; published Nov. 6, 2003).;;PCT, International Search Report, PCT/US02/16417 (dated Mar. 26, 2003; published Mar. 11, 2004).;;PCT, International Search Report, PCT/US02/16689 (dated Dec. 18, 2002; published Apr. 17, 2003).",ACTIVE
324,DE,T1,DE 380614 T1,177-751-150-462-654,1990-11-08,1990,DE 89907903 T,1989-06-21,US 8902726 W;;US 21149488 A;;US 36732289 A,1988-06-24,KARBOHYDRAT-SAHNEERSATZ.,,NUTRASWEET CO,"SINGER, S., NORMAN, HIGHLAND PARK, IL 60035, US;;CHANG, HSIEN-HSIN, LAKE ZURICH, IL 60047, US;;TANG, PAMELA, PALATINE, IL 60067, US;;DUNN, MICHAEL, JOHN, BUFFALO GROVE, IL 60089, US",,https://lens.org/177-751-150-462-654,Granted Patent,no,0,0,1,47,0,,A23C9/123;;A23C13/16;;A23C19/068;;A23G9/00;;A23L1/0522;;A23L7/10;;A23L27/60;;A23L29/20;;A23L29/256;;A23L29/269;;A23L33/00;;A23L33/20,,0,0,,,,EXPIRED
325,CN,A,CN 104884451 A,001-709-118-279-575,2015-09-02,2015,CN 201380042870 A,2013-06-11,US 2013/0045151 W;;US 201313796437 A;;CN 2012076748 W;;CN 201380042870 A,2012-06-12,Pyridinone and pyridazinone derivatives,"The present invention provides for compounds of formula (I) Wherein J is a group of formula lla or llb: A', A2, A3, A4, J, and X 3have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula 1.",ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;C SUN;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JOHN H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/001-709-118-279-575,Patent Application,no,5,8,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D213/74;;C07D403/12;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10,,0,0,,,,DISCONTINUED
326,US,A1,US 2013/0331382 A1,146-682-757-989-486,2013-12-12,2013,US 201313796437 A,2013-03-12,CN 2012076748 W,2012-06-12,Pyridinone and Pyridazinone Derivatives,"The present invention provides for compounds of formula (I) wherein A 1 , A 2 , A 3 , A 4 , J, and X 3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.",ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JOHN H;;LIU DACHUN;;SHEPPARD GEORGE S,ABBVIE INC (2013-06-26),https://lens.org/146-682-757-989-486,Patent Application,yes,0,58,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,A61K31/541;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K45/06;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D413/10;;C07D417/10,514/227.8;;544/239;;514/247;;546/302;;514/351;;544/238;;514/252.03;;514/252.02;;514/252.05;;514/252.04;;514/252.06;;544/114;;514/236.5;;544/60,4,0,,,"Ach, F., J. Chem. Soc., Abstr. 58, 70-1(1890) (CAS Abstract);;Knops et al., 24(29) TETRAHEDRON LETTS. 2973-6 (1983) (CAS Abstract);;Limaye et al., 3 J. UNIV. BOMBAY, SCI.: PHYS. SCI., MATH., BIO. SCI. & MED. 135-40 (1934) (CAS Abstract);;El-Mobayed et al., 8(3) ARAB GULF J. SCI. RES. 29-38 (1990) (citing CAS Abstract)",ACTIVE
327,AU,A1,AU 2018/200802 A1,156-445-631-752-460,2018-02-22,2018,AU 2018/200802 A,2018-02-02,AU 2018/200802 A;;AU 2013/274465 A;;US 201313796437 A;;CN 2012076748 W;;US 2013/0045151 W,2012-06-12,Pyridinone and pyridazinone derivatives,"PYRIDINONE AND PYRIDAZNONE DERIVATIVES Abstract The present invention provides for compounds of formula (I) wherein J is a group of formula Ila or Ilb: A1 , A2 , A', A4 , J, and X3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.",ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JOHN H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/156-445-631-752-460,Patent Application,no,0,0,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D213/74;;C07D403/12;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10,,0,0,,,,DISCONTINUED
328,EP,B8,EP 2858990 B8,166-513-067-839-817,2018-07-04,2018,EP 13731212 A,2013-06-11,CN 2012076748 W;;US 201313796437 A;;US 2013/0045151 W,2012-06-12,PYRIDINONE AND PYRIDAZINONE DERIVATIVES,,ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JAMES H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/166-513-067-839-817,Amended Patent,yes,18,0,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D403/12;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10,,7,0,,,"W. J. COATES ET AL: ""One-Pot Preparation of 6-Substituted 3(2 H )-Pyridazinones from Ketones"", SYNTHESIS, vol. 1993, no. 03, 1 January 1993 (1993-01-01), pages 334-342, XP055072041, ISSN: 0039-7881, DOI: 10.1055/s-1993-25861;;BABU G SUNDAR ET AL: ""Amine-constrained pyridazinone histamine Hreceptor antagonists"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 21, no. 18, 20 June 2011 (2011-06-20) , pages 5543-5546, XP028267903, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2011.06.094 [retrieved on 2011-07-26];;DIDEM TIRYAKI ET AL: ""Synthesis of some new 2,6-disubstituted-3(2H)-pyridazinone derivatives and investigation of their analgesic, anti-inflammatory and antimicrobial activities"", MEDICINAL CHEMISTRY RESEARCH, vol. 22, no. 6, 29 September 2012 (2012-09-29), pages 2553-2560, XP055073436, ISSN: 1054-2523, DOI: 10.1007/s00044-012-0253-1;;YAMADA TOSHIHIRO ET AL: ""Pyridazinones. IV. Synthesis, antisecretory and antiulcer activities of urea derivatives"", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 18, no. 3, 1 January 1983 (1983-01-01), pages 209-214, XP009171600, ISSN: 0223-5234;;SHATALOV G V ET AL: ""Vinylation of 3-pyridazones"", CHIMIJA GETEROCIKLIÈESKICH SOEDINENIJ : NAUÈNO-TEORETIÈESKIJ URNAL = CHEMISTRY OF HETEROCYCLIC COMPOUNDS, AKADEMIJA NAUK LATVIJSKOJ SSR <RIGA>, no. 3, 1 January 1980 (1980-01-01), pages 394-397, XP009171599, ISSN: 0453-8234;;ABDEL HAKEEM MAHA ET AL: ""Design and synthesis of new 6-substituted pyridazine derivatives as hypotensive agents"", BULLETIN OF THE FACULTY OF PHARMACY, CAIRO UNIVERSITY, FACULTY OF PHARMACY, EGYPT, vol. 46, no. 3, 1 January 2008 (2008-01-01), pages 45-56, XP009171642, ISSN: 0575-1373;;HEWINGS D S ET AL: ""3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 54, no. 19, 13 October 2011 (2011-10-13), pages 6761-6770, XP002689396, ISSN: 0022-2623, DOI: 10.1021/JM200640V [retrieved on 2011-09-06]",ACTIVE
329,TW,A,TW 201410651 A,028-062-049-085-501,2014-03-16,2014,TW 102120995 A,2013-06-13,CN 2012076748 W;;US 201313796437 A,2012-06-12,Pyridinone and pyridazinone derivatives,"The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, J, and X3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.",ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JOHN H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/028-062-049-085-501,Patent of Addition,no,0,0,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D213/60;;A61K31/4418;;A61K31/4427;;A61K31/4545;;A61K31/497;;A61K31/50;;A61K31/506;;A61K31/5355;;A61K31/5365;;A61P29/00;;A61P35/00;;C07D237/14;;C07D401/02;;C07D401/14;;C07D403/02;;C07D405/02;;C07D409/04;;C07D413/10;;C07D417/02;;C07D498/04,,0,0,,,,INACTIVE
330,AU,A1,AU 2013/274465 A1,076-857-083-931-222,2014-12-18,2014,AU 2013/274465 A,2013-06-11,US 201313796437 A;;CN 2012076748 W;;US 2013/0045151 W,2012-06-12,Pyridinone and pyridazinone derivatives,"The present invention provides for compounds of formula (I) Wherein J is a group of formula lla or llb: A', A",ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JOHN H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/076-857-083-931-222,Patent Application,no,0,0,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D403/12;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10,,0,0,,,,DISCONTINUED
331,US,A1,US 2008/0287837 A1,081-917-288-252-269,2008-11-20,2008,US 14563508 A,2008-06-25,US 14563508 A;;US 85098404 A,2004-05-21,ULTRASOUND MEDICAL SYSTEM AND METHOD,"An ultrasound medical system includes an interstitial end effector. The interstitial end effector is interstitially insertable into patient tissue, includes at least one medical-treatment ultrasound transducer, and includes at least one end-effector-tissue-track ablation device. One method for ultrasonically treating a lesion in a patient includes the steps of obtaining the interstitial end effector and inserting it into the patient creating a tissue track which is surrounded by patient tissue and which ends at the distal end of the inserted interstitial end effector. Other steps include ultrasonically ablating the lesion using the at-least-one medical-treatment ultrasound transducer, using the at-least-one end-effector-tissue-track ablation device to ablate the patient tissue surrounding the tissue track along substantially the entire tissue track, and withdrawing the end effector from the patient.",ETHICON ENDO SURGERY INC,MAKIN INDER RAJ S;;MAST T DOUGLAS;;SLAYTON MICHAEL H;;BARTHE PETER G;;MESSERLY JEFFREY D;;FAIDI WASEEM;;RUNK MEGAN M;;O'CONNOR BRIAN D;;PARK CHRISTOPHER J;;JAEGER PAUL M,CILAG GMBH INTERNATIONAL (2021-04-05);;ETHICON ENDO-SURGERY INC (2004-11-01);;ETHICON LLC (2016-12-30),https://lens.org/081-917-288-252-269,Patent Application,yes,101,38,4,4,0,A61B5/4836;;A61B5/4836;;A61B5/053;;A61B8/13;;A61B8/4281;;A61B8/4281;;A61B8/4483;;A61B8/4483;;A61B17/2202;;A61B17/2202;;A61B18/06;;A61B18/08;;A61B18/12;;A61B18/1815;;A61B2090/378;;A61B2090/378;;A61N7/00,A61N7/00;;A61B17/22;;A61B18/04;;A61B19/00;;A61H1/00,601/2;;606/27,0,0,,,,DISCONTINUED
332,KR,A,KR 20150023723 A,184-596-596-056-382,2015-03-05,2015,KR 20157000767 A,2013-06-11,CN 2012076748 W;;US 201313796437 A;;US 2013/0045151 W,2012-06-12,PYRIDINONE AND PYRIDAZINONE DERIVATIVES,,ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JAMES H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/184-596-596-056-382,Patent Application,no,0,1,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D401/02;;A61K31/4427;;A61K31/4545;;A61K31/497;;A61K31/501;;C07D213/60;;C07D403/02,,0,0,,,,DISCONTINUED
333,EP,A1,EP 2858990 A1,015-273-879-544-71X,2015-04-15,2015,EP 13731212 A,2013-06-11,CN 2012076748 W;;US 201313796437 A;;US 2013/0045151 W,2012-06-12,PYRIDINONE AND PYRIDAZINONE DERIVATIVES,,ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JOHN H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/015-273-879-544-71X,Patent Application,yes,0,0,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D403/12;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10,,0,0,,,,ACTIVE
334,MX,A,MX 2014015158 A,050-116-103-739-333,2015-09-08,2015,MX 2014015158 A,2013-06-11,CN 2012076748 W;;US 201313796437 A;;US 2013/0045151 W,2012-06-12,PYRIDINONE AND PYRIDAZINONE DERIVATIVES.,"The present invention provides for compounds of formula (I) Wherein J is a group of formula lla or llb: A', A2, A3, A4, J, and X 3have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula 1.",ABBVIE INC,PRATT JOHN K;;WANG LE;;WENDT MICHAEL D;;PARK CHANG H;;MCDANIEL KEITH F;;LIU DACHUN;;SHEPPARD GEORGE S;;SUN CHAOHONG;;HUBBARD ROBERT D;;SOLTWEDEL TODD N;;HOLMES JAMES H,,https://lens.org/050-116-103-739-333,Patent Application,no,0,0,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D403/12;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10,,0,0,,,,PENDING
335,BR,A2,BR 112014031234 A2,125-381-399-911-29X,2017-06-27,2017,BR 112014031234 A,2013-06-11,US 2013/0045151 W;;CN 2012076748 W;;US 201313796437 A,2012-06-12,derivados de piridinona e piridazinona,"resumo derivados de piridinona e piridazinona a presente invenção fornece os compostos da fórmula (i) (i) em que a1, a2, a3, a4, j e x3 têm qualquer um entre os valores definidos no relatório descritivo, e sais farmaceuticamente aceitáveis dos mesmos, os quais são úteis como agentes no tratamento de doenças e condições, incluindo doenças infla-matórias, diabetes, obesidade, câncer e aids. composições farmacêuticas compre-endendo um ou mais compostos da fórmula i também são fornecidas.",ABBVIE INC,CHANG H PARK;;CHAOHONG SUN;;DACHUN LIU;;GEORGE S SHEPPARD;;JAMES H HOLMS;;JOHN K PRATT;;KEIYH F MCDANIEL;;LE WANG;;MICHAEL D WENDT;;ROBERT D HUBBARD;;TODD N SOLTWEDEL,,https://lens.org/125-381-399-911-29X,Patent Application,no,0,0,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10,,0,0,,,,DISCONTINUED
336,TW,B,TW I592398 B,099-463-668-802-699,2017-07-21,2017,TW 102120995 A,2013-06-13,CN 2012076748 W;;US 201313796437 A,2012-06-12,Pyridinone and pyridazinone derivatives,,ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JOHN H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/099-463-668-802-699,Granted Patent,no,0,1,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,,,0,0,,,,INACTIVE
337,US,A1,US 2005/0261611 A1,123-508-966-184-90X,2005-11-24,2005,US 85098404 A,2004-05-21,US 85098404 A,2004-05-21,Ultrasound medical system and method,"An ultrasound medical system includes an interstitial end effector. The interstitial end effector is interstitially insertable into patient tissue, includes at least one medical-treatment ultrasound transducer, and includes at least one end-effector-tissue-track ablation device. One method for ultrasonically treating a lesion in a patient includes the steps of obtaining the interstitial end effector and inserting it into the patient creating a tissue track which is surrounded by patient tissue and which ends at the distal end of the inserted interstitial end effector. Other steps include ultrasonically ablating the lesion using the at-least-one medical-treatment ultrasound transducer, using the at-least-one end-effector-tissue-track ablation device to ablate the patient tissue surrounding the tissue track along substantially the entire tissue track, and withdrawing the end effector from the patient.",MAKIN INDER RAJ S;;MAST T D;;SLAYTON MICHAEL H;;BARTHE PETER G;;MESSERLY JEFFREY D;;FAIDI WASEEM;;RUNK MEGAN M;;O'CONNOR BRIAN D;;PARK CHRISTOPHER J;;JAEGER PAUL M,MAKIN INDER RAJ S;;MAST T D;;SLAYTON MICHAEL H;;BARTHE PETER G;;MESSERLY JEFFREY D;;FAIDI WASEEM;;RUNK MEGAN M;;O'CONNOR BRIAN D;;PARK CHRISTOPHER J;;JAEGER PAUL M,CILAG GMBH INTERNATIONAL (2021-04-05);;ETHICON ENDO-SURGERY INC (2004-11-01);;ETHICON LLC (2016-12-30),https://lens.org/123-508-966-184-90X,Patent Application,yes,99,7,4,4,0,A61B5/4836;;A61B5/4836;;A61B5/053;;A61B8/13;;A61B8/4281;;A61B8/4281;;A61B8/4483;;A61B8/4483;;A61B17/2202;;A61B17/2202;;A61B18/06;;A61B18/08;;A61B18/12;;A61B18/1815;;A61B2090/378;;A61B2090/378;;A61N7/00,A61B17/22;;A61B19/00;;A61H1/00,601/2,0,0,,,,ACTIVE
338,HK,A1,HK 1209109 A1,102-178-622-601-81X,2016-03-24,2016,HK 15109749 A,2015-10-06,US 2013/0045151 W;;CN 2012076748 W;;US 201313796437 A,2012-06-12,PYRIDINONE AND PYRIDAZINONE DERIVATIVES,,ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JOHN H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/102-178-622-601-81X,Patent Application,no,0,0,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D/,,0,0,,,,PENDING
339,EP,B1,EP 2858990 B1,101-344-968-379-86X,2018-05-16,2018,EP 13731212 A,2013-06-11,CN 2012076748 W;;US 201313796437 A;;US 2013/0045151 W,2012-06-12,PYRIDINONE AND PYRIDAZINONE DERIVATIVES,,ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JAMES H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/101-344-968-379-86X,Granted Patent,yes,18,0,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D403/12;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10,,7,0,,,"W. J. COATES ET AL: ""One-Pot Preparation of 6-Substituted 3(2 H )-Pyridazinones from Ketones"", SYNTHESIS, vol. 1993, no. 03, 1 January 1993 (1993-01-01), pages 334-342, XP055072041, ISSN: 0039-7881, DOI: 10.1055/s-1993-25861;;BABU G SUNDAR ET AL: ""Amine-constrained pyridazinone histamine Hreceptor antagonists"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 21, no. 18, 20 June 2011 (2011-06-20) , pages 5543-5546, XP028267903, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2011.06.094 [retrieved on 2011-07-26];;DIDEM TIRYAKI ET AL: ""Synthesis of some new 2,6-disubstituted-3(2H)-pyridazinone derivatives and investigation of their analgesic, anti-inflammatory and antimicrobial activities"", MEDICINAL CHEMISTRY RESEARCH, vol. 22, no. 6, 29 September 2012 (2012-09-29), pages 2553-2560, XP055073436, ISSN: 1054-2523, DOI: 10.1007/s00044-012-0253-1;;YAMADA TOSHIHIRO ET AL: ""Pyridazinones. IV. Synthesis, antisecretory and antiulcer activities of urea derivatives"", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 18, no. 3, 1 January 1983 (1983-01-01), pages 209-214, XP009171600, ISSN: 0223-5234;;SHATALOV G V ET AL: ""Vinylation of 3-pyridazones"", CHIMIJA GETEROCIKLIÈESKICH SOEDINENIJ : NAUÈNO-TEORETIÈESKIJ URNAL = CHEMISTRY OF HETEROCYCLIC COMPOUNDS, AKADEMIJA NAUK LATVIJSKOJ SSR <RIGA>, no. 3, 1 January 1980 (1980-01-01), pages 394-397, XP009171599, ISSN: 0453-8234;;ABDEL HAKEEM MAHA ET AL: ""Design and synthesis of new 6-substituted pyridazine derivatives as hypotensive agents"", BULLETIN OF THE FACULTY OF PHARMACY, CAIRO UNIVERSITY, FACULTY OF PHARMACY, EGYPT, vol. 46, no. 3, 1 January 2008 (2008-01-01), pages 45-56, XP009171642, ISSN: 0575-1373;;HEWINGS D S ET AL: ""3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 54, no. 19, 13 October 2011 (2011-10-13), pages 6761-6770, XP002689396, ISSN: 0022-2623, DOI: 10.1021/JM200640V [retrieved on 2011-09-06]",ACTIVE
340,SG,A,SG 11201408186T A,116-720-357-511-711,2015-01-29,2015,SG 11201408186T A,2013-06-11,CN 2012076748 W;;US 201313796437 A;;US 2013/0045151 W,2012-06-12,PYRIDINONE AND PYRIDAZINONE DERIVATIVES,,ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JOHN H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/116-720-357-511-711,Unknown,no,0,0,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D403/12;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10,,0,0,,,,PENDING
341,DE,T2,DE 602004012746 T2,095-695-467-942-721,2009-04-09,2009,DE 602004012746 T,2004-06-15,US 47951703 P;;US 2004/0018914 W,2003-06-17,"Verfahren und Zwischenprodukte zur Herstellung von (1R,2S,5S)-3-Azabicyclo[3,1,0]Hexane-2-Carboxamide,N-[3-Amino-1-(Cyclobutylmethyl)-2,3-Dioxopropyl]]-3-[( 2S)-2-[[[1,1-Dimethylethyl]Amino]Carbonylamino]-3,3-Dimethyl-1-Oxobutyl]-6,6-Dimethyl",,SCHERING CORP,SUDHAKAR ANANTHA;;DAHANUKAR VILAS RADHIKA NILA;;ZAVIALOV ILIA A;;ORR CECILIA;;NGUYEN HOA N;;WEBER JUERGEN;;JEON INGYU;;CHEN MINZHANG;;GREEN MICHAEL D;;WONG GEORGE S;;PARK JEONGHAN;;IWAMA TETSUO,,https://lens.org/095-695-467-942-721,Granted Patent,no,0,0,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07D209/52;;C07C237/14;;C07C271/22;;C07K5/02,,0,0,,,,ACTIVE
342,DE,D1,DE 602004012746 D1,043-306-883-571-976,2008-05-08,2008,DE 602004012746 T,2004-06-15,US 47951703 P;;US 2004/0018914 W,2003-06-17,"VERFAHREN UND ZWISCHENPRODUKTE ZUR HERSTELLUNG VON (1R,2S,5S)-3-AZABICYCLOÄ3,1,0ÜHEXANE-2-CARBOXAMIDE,N-Ä3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYLÜ Ü-3-Ä(2S)-2-ÄÄÄ1,1-DIMETHYLETHYLÜAMINOÜCARBONYLAMINOÜ-3,3-DIMETHYL-1-OXOBUTYLÜ-6,6-DIMETHYL",,SCHERING CORP,SUDHAKAR ANANTHA;;DAHANUKAR VILAS RADHIKA NILA;;ZAVIALOV ILIA A;;ORR CECILIA;;NGUYEN HOA N;;WEBER JUERGEN;;JEON INGYU;;CHEN MINZHANG;;GREEN MICHAEL D;;WONG GEORGE S;;PARK JEONGHAN;;IWAMA TETSUO,,https://lens.org/043-306-883-571-976,Granted Patent,no,0,0,21,21,0,C07C271/22;;C07K5/0202;;C07C2601/04;;A61P31/14;;A61P43/00;;C07K5/0202;;C07C271/22;;C07C2601/04,C07D209/52;;C07C237/14;;C07C271/22;;C07K5/02,,0,0,,,,ACTIVE
343,WO,A1,WO 2013/188381 A1,104-315-672-049-585,2013-12-19,2013,US 2013/0045151 W,2013-06-11,CN 2012076748 W;;US 201313796437 A,2012-06-12,PYRIDINONE AND PYRIDAZINONE DERIVATIVES,"The present invention provides for compounds of formula (I) Wherein J is a group of formula lla or llb: A', A 2 , A3, A4, J, and X 3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula 1.",ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JOHN H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/104-315-672-049-585,Patent Application,yes,41,52,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D213/74;;C07D403/12;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10,,40,28,036-121-275-120-173;;040-923-521-330-58X;;082-059-560-105-355;;021-480-438-604-43X;;012-833-064-507-129;;041-645-169-942-34X;;094-226-858-544-634;;158-100-821-718-318;;007-670-026-986-849;;003-873-243-561-921;;027-193-314-557-690;;055-652-991-212-767;;128-952-603-599-578;;086-005-686-222-444;;124-864-354-614-750;;053-125-588-187-197;;075-842-203-736-897;;006-794-777-498-57X;;049-214-828-980-62X;;063-434-787-171-827;;040-081-313-970-111;;007-913-191-371-892;;068-656-513-877-430;;064-792-862-161-861;;077-295-491-167-117;;007-364-858-655-289;;007-856-972-371-459;;024-397-233-272-023,10.1055/s-1993-25861;;21824776;;10.1016/j.bmcl.2011.06.094;;10.1007/s00044-012-0253-1;;pmc3188285;;10.1021/jm200640v;;021851057;;21851057;;18039861;;10.1128/mcb.01020-07;;pmc2223388;;18406326;;pmc2387119;;10.1016/j.molcel.2008.01.018;;21814200;;10.1038/nature10334;;pmc3328300;;21949397;;pmc3189078;;10.1073/pnas.1108190108;;pmc3679520;;21964340;;10.1038/nature10509;;10.1128/mcb.01365-08;;19103749;;pmc2643823;;10.1038/nature09589;;pmc5415086;;21068722;;10.1074/jbc.m112.359505;;22645123;;pmc3436579;;pmc3025494;;21189220;;10.1016/j.molcel.2005.06.027;;016109376;;16109376;;pmc3420011;;10.1016/j.cell.2012.06.045;;22901802;;10.1358/dof.1996.021.11.383118;;10.1021/jm9509556;;8576909;;10.1021/ol026902h;;12659549;;10.1002/jps.2600640306;;1151621;;10.1002/jlcr.2580361004;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;13719049;;10.1111/j.1749-6632.1960.tb39109.x;;13776654;;10.1111/j.1749-6632.1960.tb39105.x;;10.1021/cr00039a007;;10.1002/0471220574;;10.1002/jps.2600660104;;833720;;9190929;;16490778;;10.1177/1087057105285611,"W. J. COATES ET AL: ""One-Pot Preparation of 6-Substituted 3(2 H )-Pyridazinones from Ketones"", SYNTHESIS, vol. 1993, no. 03, 1 January 1993 (1993-01-01), pages 334 - 342, XP055072041, ISSN: 0039-7881, DOI: 10.1055/s-1993-25861;;BABU G SUNDAR ET AL: ""Amine-constrained pyridazinone histamine Hreceptor antagonists"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 21, no. 18, 20 June 2011 (2011-06-20), pages 5543 - 5546, XP028267903, ISSN: 0960-894X, [retrieved on 20110726], DOI: 10.1016/J.BMCL.2011.06.094;;DIDEM TIRYAKI ET AL: ""Synthesis of some new 2,6-disubstituted-3(2H)-pyridazinone derivatives and investigation of their analgesic, anti-inflammatory and antimicrobial activities"", MEDICINAL CHEMISTRY RESEARCH, vol. 22, no. 6, 29 September 2012 (2012-09-29), pages 2553 - 2560, XP055073436, ISSN: 1054-2523, DOI: 10.1007/s00044-012-0253-1;;YAMADA TOSHIHIRO ET AL: ""Pyridazinones. IV. Synthesis, antisecretory and antiulcer activities of urea derivatives"", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 18, no. 3, 1 January 1983 (1983-01-01), pages 209 - 214, XP009171600, ISSN: 0223-5234;;SHATALOV G V ET AL: ""Vinylation of 3-pyridazones"", CHIMIJA GETEROCIKLIÈESKICH SOEDINENIJ : NAUÈNO-TEORETIÈESKIJ URNAL = CHEMISTRY OF HETEROCYCLIC COMPOUNDS, AKADEMIJA NAUK LATVIJSKOJ SSR <RIGA>, no. 3, 1 January 1980 (1980-01-01), pages 394 - 397, XP009171599, ISSN: 0453-8234;;ABDEL HAKEEM MAHA ET AL: ""Design and synthesis of new 6-substituted pyridazine derivatives as hypotensive agents"", BULLETIN OF THE FACULTY OF PHARMACY, CAIRO UNIVERSITY, FACULTY OF PHARMACY, EGYPT, vol. 46, no. 3, 1 January 2008 (2008-01-01), pages 45 - 56, XP009171642, ISSN: 0575-1373;;HEWINGS D S ET AL: ""3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 54, no. 19, 13 October 2011 (2011-10-13), pages 6761 - 6770, XP002689396, ISSN: 0022-2623, [retrieved on 20110906], DOI: 10.1021/JM200640V;;YANG ET AL., MOL. CELL. BIOL., vol. 28, 2008, pages 967 - 976;;LEROY ET AL., MOL. CELL, vol. 30, 2008, pages 51 - 60;;ZUBER ET AL., NATURE, vol. 478, 2011, pages 524 - 528;;MERTZ ET AL., PROC. NAT'1. ACAD. SCI., vol. 108, 2011, pages 16669 - 16674;;DELMORE ET AL., CELL, vol. 146, 2011, pages 1 - 14;;DAWSON ET AL., NATURE, vol. 478, 2011, pages 529 - 533;;HUANG ET AL., MOL. CELL. BIOL., vol. 29, 2009, pages 1375 - 1387;;NICODEME ET AL., NATURE, vol. 468, 2010, pages 1119 - 1123;;ZHANG ET AL., J. BIOL. CHEM., vol. 287, 2012, pages 28840 - 28851;;DENIS, DISCOVERY MEDICINE, vol. 10, 2010, pages 489 - 499;;JANG ET AL., MOL. CELL, vol. 19, 2005, pages 523 - 534;;BANERJEE ET AL., J. LEUKOCYTE BIOL.;;MATZUK ET AL., CELL, vol. 150, 2012, pages 673 - 684;;""IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry"", PURE APPL. CHEM., vol. 45, 1976, pages 13 - 10;;LIZONDO, J ET AL., DRUGS FUT, vol. 21, no. 11, 1996, pages 1116;;BRICKNER, S J ET AL., JMED CHEM, vol. 39, no. 3, 1996, pages 673;;MALLESHAM, B ET AL., ORG LETT, vol. 5, no. 7, 2003, pages 963;;BLAKE ET AL., 1. PHARM. SCI., vol. 64, no. 3, 1975, pages 367 - 391;;FOSTER ET AL.: ""Advances in Drug Research"", vol. 14, 1985, ACADEMIC PRESS, pages: 2 - 36;;KATO ET AL., J. LABELLED COMP. RADIOPHARMACEUT., vol. 36, no. 10, 1995, pages 927 - 932;;KUSHNER ET AL., CAN. J. PHYSIOL. PHARMACOL., vol. 77, 1999, pages 79 - 88;;CZAJKA D M; FINKEL A J, ANN. N.Y. ACAD. SCI., vol. 84, 1960, pages 770;;THOMSON J F, ANN. NEW YORK ACAD. SCI, vol. 84, 1960, pages 736;;CZAKJA D M ET AL., AM. J. PHYSIOL., vol. 201, 1961, pages 357;;BLAGOJEVIC N ET AL.: ""Dosimetry & Treatment Planning for Neutron Capture Therapy"", 1994, ADVANCED MEDICAL PUBLISHING, pages: 125 - 134;;DIABETES METAB., vol. 23, 1997, pages 251;;N. MIYAMA; A. SUZUKI, CHEM. REV., vol. 95, 1995, pages 2457 - 2483;;J. ORGANOMET. CHEM., vol. 576, 1999, pages 147 - 148;;T. GREENE; P. WUTS: ""Protecting Groups in Organic Synthesis"", 1999, JOHN WILEY & SONS;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;""Methods in Cell Biology"", vol. XIV, 1976, ACADEMIC PRESS, pages: 33;;V.R. SUTTON; D.L. VAUX; J.A. TRAPANI, J. OFLMMUNOLOGY, vol. 158, no. 12, 1997, pages 5783;;EASTWOOD ET AL., J BIOMOL SCREEN, vol. 11, 2006, pages 253 - 261",PENDING
344,US,B2,US 9561231 B2,185-271-753-099-847,2017-02-07,2017,US 201313796437 A,2013-03-12,CN 2012076748 W,2012-06-12,Pyridinone and pyridazinone derivatives,"The present invention provides for compounds of formula (I) wherein A 1 , A 2 , A 3 , A 4 , J, and X 3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.",ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JAMES H;;LIU DACHUN;;SHEPPARD GEORGE S,ABBVIE INC (2013-06-26),https://lens.org/185-271-753-099-847,Granted Patent,yes,99,4,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,A61K31/541;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K45/06;;C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04,,53,38,010-716-122-610-971;;007-364-858-655-289;;049-214-828-980-62X;;075-842-203-736-897;;035-521-638-563-085;;030-741-326-093-62X;;036-121-275-120-173;;131-991-682-925-350;;007-913-191-371-892;;014-213-884-274-004;;007-670-026-986-849;;063-091-639-997-908;;128-952-603-599-578;;088-576-942-688-246;;021-480-438-604-43X;;109-891-422-290-250;;003-873-243-561-921;;086-005-686-222-444;;063-434-787-171-827;;040-081-313-970-111;;041-645-169-942-34X;;053-125-588-187-197;;006-794-777-498-57X;;124-864-354-614-750;;158-100-821-718-318;;064-792-862-161-861;;027-193-314-557-690;;157-074-667-552-192;;040-923-521-330-58X;;091-732-862-062-93X;;068-656-513-877-430;;082-059-560-105-355;;019-260-952-017-75X;;012-833-064-507-129;;055-652-991-212-767;;094-226-858-544-634;;009-909-596-207-418;;084-822-208-568-325,22802445;;10.1189/jlb.0312165;;pmc3501896;;10.1002/jps.2600660104;;833720;;10.1002/jps.2600640306;;1151621;;10.1021/jm9509556;;8576909;;21568322;;10.1021/jm200108t;;10.1016/b978-0-12-396493-9.00001-7;;22520470;;10.1055/s-1993-25861;;10.1016/b978-0-08-021019-3.50003-1;;13719049;;10.1111/j.1749-6632.1960.tb39109.x;;13719048;;10.1152/ajplegacy.1961.201.2.357;;pmc3679520;;21964340;;10.1038/nature10509;;21889194;;10.1016/j.cell.2011.08.017;;pmc3187920;;pmc3025494;;21189220;;20871596;;pmc3010259;;10.1038/nature09504;;pmc3188285;;10.1021/jm200640v;;021851057;;21851057;;10.1021/jm300915b;;22924434;;10.1128/mcb.01365-08;;19103749;;pmc2643823;;10.1016/j.molcel.2005.06.027;;016109376;;16109376;;10.1002/jlcr.2580361004;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;18406326;;pmc2387119;;10.1016/j.molcel.2008.01.018;;10.1358/dof.1996.021.11.383118;;10.1021/ol026902h;;12659549;;pmc3420011;;10.1016/j.cell.2012.06.045;;22901802;;21949397;;pmc3189078;;10.1073/pnas.1108190108;;10.1021/cr00039a007;;10.1038/nature09589;;pmc5415086;;21068722;;10.1016/j.tips.2011.12.002;;22277300;;21824776;;10.1016/j.bmcl.2011.06.094;;10.1016/s0022-328x(98)01055-9;;13776654;;10.1111/j.1749-6632.1960.tb39105.x;;10.1007/s00044-012-0253-1;;19883376;;10.1042/bj20090928;;pmc2819394;;18039861;;10.1128/mcb.01020-07;;pmc2223388;;10.1074/jbc.m112.359505;;22645123;;pmc3436579;;21814200;;10.1038/nature10334;;pmc3328300;;24261714;;10.1517/13543776.2014.859244;;2118183;;10.1021/jm00171a005,"Ach, F., J. Chem. Soc., Abstr. 58, 70-1(1890) (CAS Abstract).;;Knops et al., 24(29) Tetrahedron Letts. 2973-6 (1983) (CAS Abstract).;;Limaye et al., 3 J. Univ. Bombay, Sci.: Phys. Sci., Math., Bio. Sci. & Med. 135-40 (1934) (CAS Abstract).;;El-Mobayed et al., 8(3) Arab Gulf J. Sci. Res. 29-38 (1990) (citing CAS Abstract).;;Banerjee C., et al., ""BET Bromodomain Inhibition as a Novel Strategy for Reactivation of HIV-1,"" Journal of Leukocyte Biology, 2012, vol. 92 (6), pp. 1147-1154.;;Berge, S. M. et al., ""Pharmaceutical Salts,"" Journal of Pharmaceutical Sciences, 1977, vol. 66 (1), pp. 1-19.;;Blagojevic, N. et al., ""Role of heavy water in Boron Neutron Capture Therapy,"" Topics in Dosimetry & Treatment Planning for Neutron Capture Therapy, 1994, pp. 125-134.;;Blake, M. I. et al., ""Studies With Deuterated Drugs,"" Journal of Pharmaceutical Sciences, 1975, vol. 64 (3), pp. 367-391.;;Brickner, S.J. et al., ""Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections,"" Journal of Medicinal Chemistry, 1996, vol. 39 (3), pp. 673-679.;;Chung C.W., et al., ""Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains,"" Journal of Medicinal Chemistry, 2011, vol. 54 (11), pp. 3827-3838.;;Chung C.W., ""Small Molecule Bromodomain Inhibitors: Extending the Druggable Genome,"" Progress in Medicinal Chemistry, 2012, vol. 51, pp. 1-55.;;Coates W.J., et al., ""One-Pot Preparation of 6-Substituted 3(2H)-Pyridazinones from Ketones,"" Synthesis, 1993, vol. 1993 (3), pp. 334-342.;;Cross, L.C. et al., ""IUPAC Commission on Nomenclature of Organic Chemistry: Rules for the Nomenclature of Organic Chemistry, Section E: Stereochemistry,"" Pure and Applied Chemistry, 1976, vol. 45, pp. 13-30.;;Czajka, D. M. et al., ""Effect of Deuterium Oxide on the Reproductive Potential of Mice,"" Annals of the New York Academy of Sciences, 1960, vol. 84, pp. 770-779.;;Czajka, D. M. et al., ""Physiological Effects of Deuterium on Dogs,"" American Journal of Physiology, 1961, vol. 201 (2), pp. 357-362.;;Dawson M.A., et al., ""Inhibition of BET Recruitment to Chromatin as an Effective Treatment for MLL-fusion Leukaemia,"" Nature, 2011, vol. 478 (7370), pp. 529-533.;;Delmore J.E., et al., ""BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc,"" Cell, 2011, vol. 146 (6), pp. 904-917.;;Denis G.V., ""Bromodomain Coactivators in Cancer, Obesity, type 2 Diabetes, and Inflammation,"" Discovery Medicine, 2010, vol. 10 (55), pp. 489-499.;;Filippakopoulos P., et al., ""Selective Inhibition of BET Bromodomains,"" Nature, 2010, vol. 468 (7327), pp. 1067-1073.;;Foster, A. B. et al., ""Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design,"" Advances in Drug Research, 1985, vol. 14, pp. 2-36.;;Greene T.W., et al., in: Protective Groups in Organic Synthesis, 3rd Edition, John Wiley and Sons, Inc., 1999, Preface, Table of Contents, Abbreviations.;;Hewings D.s., et al., ""3,5-Dimethylisoxazoles Act as Acetyl-Lysine-Mimetic Bromodomain Ligands,"" Journal of Medicinal Chemistry, 2011, vol. 54 (19), pp. 6761-6770.;;Hewings D.S., et al., ""Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain-acetyl-lysine Interactions,"" Journal of Medicinal Chemistry, 2012, vol. 55 (22), pp. 9393-9413.;;Huang B., et al., ""Brd4 Coactivates Transcriptional Activation of NF-kappaB via Specific Binding to Acetylated RelA,"" Molecular and Cellular Biology, 2009, vol. 29 (5), pp. 1375-1387.;;International Search Report and Written Opinion for Application No. PCT/CN2012/076748, mailed on 21 Mar. 2013, 14 pages.;;International Search Report and Written Opinion for Application No. PCT/US2013/045151, mailed on Aug. 16, 2013, 20 pages.;;International Search Report for Application No. PCT/EP2010/066695, mailed on Feb. 7, 2011, 2 pages.;;Jang M.K., et al., ""The Bromodomain Protein Brd4 is a Positive Regulatory Component of P-TEFb and Stimulates RNA Polymerase II-dependent Transcription,"" Molecular Cell, 2005, vol. 19 (4), pp. 523-534.;;Kato, S. et al., ""Synthesis of Deuterated Mosapride Citrate,"" Journal of Labelled Compounds and Radiopharmaceuticals, 1995, vol. 36 (10), pp. 927-932.;;Kushner, et al., ""Pharmacological uses and perspectives of heavy water and deuterated compounds,"" Canadian Journal of Physiology and Pharmacology, 1999, vol. 77 (2), pp. 79-88.;;Leroy G., et al., ""The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to Transcription,"" Molecular Cell, 2008, vol. 30 (1), pp. 51-60.;;Lizondo, J. et al., ""Linezolid: Oxazolidinone antibacterial,"" Drugs of the Future, 1996, vol. 21 (11), pp. 1116-1123.;;Maha A.H., et al., ""Design and Synthesis of New 6-Substituted Pyridazine Derivatives as Hypotensive Agents,"" Bulletin of the Faculty of Pharmacy, 2008, vol. 46 (3), pp. 45-56.;;Mallesham, B. et al., ""Highly Efficient Cul-Catalyzed Coupling of Aryl Bromides With Oxazolidinones Using Buchwald's Protocol: A Short Route to Linezolid and Toloxatone,"" Organic Letters, 2003, vol. 5 (7), pp. 963-965.;;Matzuk M.M., et al., ""Small-molecule Inhibition of BRDT for Male Contraception,"" Cell, 2012, vol. 150 (4), pp. 673-684.;;Mertz J.A., et al., ""Targeting MYC Dependence in Cancer by Inhibiting BET Bromodomains,"" Proceedings of the National Academy of Sciences, 2011, vol. 108 (40), pp. 16669-16674.;;Miyaura N., et al., ""Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds,"" Chemical Reviews, 1995, vol. 95 (7), pp. 2457-2483.;;Nicodeme E., et al., ""Suppression of Inflammation by a Synthetic Histone Mimic,"" Nature, 2010, vol. 468 (7327), pp. 1119-1123.;;Prescott D.M., ""Methods in Cell Biology"", Academic Press, 1976, Table of Contents.;;Prinjha R.K., et al., ""Place your BETs: the Therapeutic Potential of Bromodomains,"" Trends in Pharmacological Sciences, 2012, vol. 33 (3), pp. 146-153.;;Shatalov G.V., et al., ""Vinylation of 3-Pyridazones,"" Chemistry of Heterocyclic Compounds, 1980, No. 3, pp. 394-397.;;Sundar B.G., et al., ""Amine-Constrained Pyridazinone Histamine H, Receptor Antagonists,"" Bioorganic & Medicinal Chemistry Letters, 2011, vol. 21 (18), pp. 5543-5546.;;Suzuki A., ""Recent Advances in the Cross-Coupling Reactions of organoboron Derivates with organic Electrophiles, 1995-1998,"" Journal of Organometallic Chemistry, 1999, vol. 576, pp. 147-168.;;Thomson, J.F., ""Physiological Effects of D20 in Mammals,"" Annals of the New York Academy of Sciences, 1960, vol. 84, pp. 736-744.;;Tiryaki D., et al., ""Synthesis of Some New 2,6-Disubstituded-3(2H)-Pyridazinone Derivatives and Investigation of their Analgesic, Anti-Inflammatory and Antimicrobial Activities,"" Medicinal Chemistry Research, 2012, vol. 22 (6), pp. 2553-2560.;;Toshihiro Y., et al., ""Pyridazinones. IV. Synthesis, Antisecretory and Antiulcer Activities of Urea Derivatives,"" European Journal of Medicinal Chemistry, 1983, vol. 18 (3), pp. 209-214.;;Wang F., et al., ""Brd2 Disruption in Mice Causes Severe Obesity without Type 2 Diabetes,"" Biochemical Journal, 2010, vol. 425, pp. 71-83.;;Yang Z., et al., ""Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis to Promote G1 Gene Expression and Cell Cycle Progression,"" Molecular and Cellular Biology, 2008, vol. 28 (3), pp. 967-976.;;Zhang G., et al., ""Down-regulation of NF-kappaB Transcriptional Activity in HIV-associated Kidney Disease by BRD4 Inhibition,"" Journal of Biological Chemistry, 2012, vol. 287 (34), pp. 28840-28851.;;Zuber J., et al., ""RNAi Screen Identifies Brd4 as a Therapeutic Target in Acute Myeloid Leukaemia,"" Nature, 2011, vol. 478 (7370), pp. 524-528.;;Garnier J.M., et al., ""BET Bromodomain Inhibitors: A Patent Review,"" Expert Opinion on Therapeutic Patents, 2014, vol. 24 (2), pp. 185-199.;;Roberts D.A., et al., ""1,2,4-Triazolo[4,3-a]pyrazine Derivatives with Human Renin Inhibitory Activity. 1. Synthesis and Biological Properties of Alkyl Alcohol and Statine Derivatives,"" Journal of Medicinal Chemistry, 1990, vol. 33 (9), pp. 2326-2334.;;Supplementary European Search Report for Application No. EP12878861, mailed on Oct. 9, 2015, 8 pages.",ACTIVE
345,CA,A1,CA 2875016 A1,177-171-812-087-03X,2013-12-19,2013,CA 2875016 A,2013-06-11,CN 2012076748 W;;US 201313796437 A;;US 2013/0045151 W,2012-06-12,PYRIDINONE AND PYRIDAZINONE DERIVATIVES,"The present invention provides for compounds of formula (I) Wherein J is a group of formula lla or llb: A', A2, A3, A4, J, and X 3have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula 1.",ABBVIE INC,HUBBARD ROBERT D;;WANG LE;;PARK CHANG H;;SUN CHAOHONG;;MCDANIEL KEITH F;;PRATT JOHN K;;SOLTWEDEL TODD N;;WENDT MICHAEL D;;HOLMS JAMES H;;LIU DACHUN;;SHEPPARD GEORGE S,,https://lens.org/177-171-812-087-03X,Patent Application,no,0,7,38,38,0,C07D213/30;;C07D213/64;;C07D213/68;;C07D213/74;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68;;C07D237/14;;A61K45/06;;C07D213/64;;C07D401/04;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/04;;A61P31/04;;A61P31/18;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/02;;A61P5/14;;A61P9/00;;A61P3/10;;A61K31/4412;;A61K31/50;;A61K31/501;;A61K31/5377;;A61K31/541;;A61K45/06;;C07D213/60;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/02;;C07D403/04;;C07D403/10;;C07D403/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10;;C07D417/04;;C07D417/10;;C07D417/12;;C07D498/04;;A61K31/435;;A61K31/50;;A61K31/501;;A61K31/5377;;C07D213/64;;C07D237/14;;C07D401/04;;C07D401/10;;C07D403/04;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D413/10;;C07D417/04;;A61K31/541;;C07D237/14;;A61K31/50;;A61K45/06;;C07D213/64;;A61K31/4412;;C07D401/04;;A61K31/501;;C07D403/04;;C07D401/10;;C07D403/10;;C07D417/10;;C07D413/10;;A61K31/5377;;C07D403/12;;C07D401/14;;C07D213/74;;C07D213/81;;C07D401/02;;C07D401/12;;C07D407/04;;C07D407/12;;C07D409/04;;C07D417/04;;C07D417/12;;C07D498/04;;C07D213/30;;C07D213/68,C07D213/74;;C07D403/12;;C07D213/81;;C07D237/14;;C07D401/02;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/10;;C07D407/04;;C07D407/12;;C07D409/04;;C07D413/10,,0,0,,,,DISCONTINUED
346,AT,T1,AT E133545 T1,143-112-093-112-337,1996-02-15,1996,AT 90900642 T,1989-11-17,US 28877288 A,1988-12-21,VERFAHREN FÜR LASERINDUZIERTE FLUORESZENZ VON GEWEBE,A method for laser induced fluorescence of tissue in which laser radiation is used to illuminate and induce fluorescence in the tissue under study to determine the chemical composition or pathologic condition of tissue. The laser radiation and the retrieved fluorescing radiation can be conveyed through a catheter using an array of optical fiber. The fluorescence spectrum of the tissue can be displayed and analyzed to obtain information regarding the chemical composition and medical condition of the tissue inside the human body.,MASSACHUSETTS INST TECHNOLOGY,KITTRELL CARTER;;COTHREN ROBERT M;;FELD MICHAEL S;;BARAGA JOSEPH J;;AN KYUNGWON;;RICHARDS-KORTUM REBECCA;;RAVA RICHARD P;;PARK YOUNG D;;MEHTA ANAND;;TARONI PAOLA;;TONG LUCENE;;DASARI RAMACHANDRA RAO,,https://lens.org/143-112-093-112-337,Granted Patent,no,0,0,8,8,0,A61B5/0071;;A61B5/0075;;A61B5/0084;;A61B5/1459;;A61B18/245;;A61B2562/0238;;A61B5/0084;;A61B5/0071;;A61B5/0075;;A61B5/1459;;A61B18/245;;A61B2562/0238,A61B5/00;;A61B18/24,,0,0,,,,DISCONTINUED
347,WO,A1,WO 1990/006718 A1,053-029-959-821-899,1990-06-28,1990,US 8905174 W,1989-11-17,US 28877288 A,1988-12-21,A METHOD FOR LASER INDUCED FLUORESCENCE OF TISSUE,A method for laser induced fluorescence of tissue in which laser radiation is used to illuminate and induce fluorescence in the tissue under study to determine the chemical composition or pathologic condition of tissue. The laser radiation and the retrieved fluorescing radiation can be conveyed through a catheter using an array of optical fiber. The fluorescence spectrum of the tissue can be displayed and analyzed to obtain information regarding the chemical composition and medical condition of the tissue inside the human body.,MASSACHUSETTS INST TECHNOLOGY,KITTRELL CARTER;;COTHREN ROBERT M;;FELD MICHAEL S;;BARAGA JOSEPH J;;AN KYUNGWON;;RICHARDS-KORTUM REBECCA;;RAVA RICHARD P;;PARK YOUNG D;;MEHTA ANAND;;TARONI PAOLA;;TONG LUCENE;;DASARI RAMACHANDRA RAO,,https://lens.org/053-029-959-821-899,Patent Application,yes,6,33,8,8,0,A61B5/0071;;A61B5/0075;;A61B5/0084;;A61B5/1459;;A61B18/245;;A61B2562/0238;;A61B5/0084;;A61B5/0071;;A61B5/0075;;A61B5/1459;;A61B18/245;;A61B2562/0238,A61B5/00;;A61B18/24,,2,2,170-740-304-342-404;;008-872-164-195-326,10.1109/jqe.1987.1073221;;10.1109/jqe.1984.1072322,"IEEE Journal of Quantum Electronics, Volume QE-23, No. 10, October 1987, IEEE, (New York, N.Y., US), M. SARTORI et al.: ""Autofluorescence Maps of Atherosclerotic Human Arteries - A New Technique in Medical Imaging"", pages 1794-1797;;IEEE Journal of Quantum Electronics, Volume QE-20, No. 12, December 1984, R.R. ALFANO et al.: ""Laser Induced Fluorescence Spectroscopy from Native Cancerous and Normal Tissue"", pages 1507-1511",PATENTED
348,EP,B1,EP 0449883 B1,162-130-786-794-578,1996-01-31,1996,EP 90900642 A,1989-11-17,US 28877288 A;;US 8905174 W,1988-12-21,A METHOD FOR LASER INDUCED FLUORESCENCE OF TISSUE,A method for laser induced fluorescence of tissue in which laser radiation is used to illuminate and induce fluorescence in the tissue under study to determine the chemical composition or pathologic condition of tissue. The laser radiation and the retrieved fluorescing radiation can be conveyed through a catheter using an array of optical fiber. The fluorescence spectrum of the tissue can be displayed and analyzed to obtain information regarding the chemical composition and medical condition of the tissue inside the human body.,MASSACHUSETTS INST TECHNOLOGY,KITTRELL CARTER;;COTHREN ROBERT M;;FELD MICHAEL S;;BARAGA JOSEPH J;;AN KYUNGWON;;RICHARDS-KORTUM REBECCA;;RAVA RICHARD P;;PARK YOUNG D;;MEHTA ANAND;;TARONI PAOLA;;TONG LUCENE;;DASARI RAMACHANDRA RAO,,https://lens.org/162-130-786-794-578,Granted Patent,yes,0,0,8,8,0,A61B5/0071;;A61B5/0075;;A61B5/0084;;A61B5/1459;;A61B18/245;;A61B2562/0238;;A61B5/0084;;A61B5/0071;;A61B5/0075;;A61B5/1459;;A61B18/245;;A61B2562/0238,A61B5/00;;A61B18/24,,1,0,,,"Spectroscopy of Biological Systems; edited by Clark et al. 1986; Mantsch et al: ""Resolution enhancement of infrared spectra of biological systems""",EXPIRED
349,EP,A1,EP 0449883 A1,110-714-366-846-581,1991-10-09,1991,EP 90900642 A,1989-11-17,US 28877288 A;;US 8905174 W,1988-12-21,A METHOD FOR LASER INDUCED FLUORESCENCE OF TISSUE.,A method for laser induced fluorescence of tissue in which laser radiation is used to illuminate and induce fluorescence in the tissue under study to determine the chemical composition or pathologic condition of tissue. The laser radiation and the retrieved fluorescing radiation can be conveyed through a catheter using an array of optical fiber. The fluorescence spectrum of the tissue can be displayed and analyzed to obtain information regarding the chemical composition and medical condition of the tissue inside the human body.,MASSACHUSETTS INST TECHNOLOGY,KITTRELL CARTER;;COTHREN ROBERT M;;FELD MICHAEL S;;BARAGA JOSEPH J;;AN KYUNGWON;;RICHARDS-KORTUM REBECCA;;RAVA RICHARD P;;PARK YOUNG D;;MEHTA ANAND;;TARONI PAOLA;;TONG LUCENE;;DASARI RAMACHANDRA RAO,,https://lens.org/110-714-366-846-581,Patent Application,yes,0,3,8,8,0,A61B5/0071;;A61B5/0075;;A61B5/0084;;A61B5/1459;;A61B18/245;;A61B2562/0238;;A61B5/0084;;A61B5/0071;;A61B5/0075;;A61B5/1459;;A61B18/245;;A61B2562/0238,A61B5/00;;A61B18/24,,0,0,,,,EXPIRED
350,US,A,US 5419323 A,082-929-591-853-889,1995-05-30,1995,US 72046591 A,1991-08-29,US 72046591 A;;US 8905174 W;;US 28877288 A,1988-12-21,Method for laser induced fluorescence of tissue,A method for laser induced fluorescence of tissue in which laser radiation is used to illuminate and induce fluorescence in the tissue under study to determine the chemical composition or pathologic condition of tissue. The laser radiation and the retrieved fluorescing radiation can be conveyed through a catheter using an array of optical fiber. The fluorescence spectrum of the tissue can be displayed and analyzed to obtain information regarding the chemical composition and medical condition of the tissue inside the human body.,MASSACHUSETTS INST TECHNOLOGY,KITTRELL CARTER;;COTHREN ROBERT M;;FELD MICHAEL S;;BARAGA JOSEPH J;;AN KYUNGWON;;RICHARDS-KORTUM REBECCA;;RAVA RICHARD P;;PARK YOUNG D;;MEHTA ANAND;;TARONI PAOLA;;TONG LUCENE;;DASARI RAMACHANDRA R,,https://lens.org/082-929-591-853-889,Granted Patent,yes,15,393,8,8,0,A61B5/0071;;A61B5/0075;;A61B5/0084;;A61B5/1459;;A61B18/245;;A61B2562/0238;;A61B5/0084;;A61B5/0071;;A61B5/0075;;A61B5/1459;;A61B18/245;;A61B2562/0238,A61B5/00;;A61B18/24,128/653.1,8,6,043-978-116-057-396;;116-112-055-473-28X;;043-825-203-324-512;;002-465-385-045-982;;040-302-158-493-752;;008-872-164-195-326,10.1117/12.937371;;10.1109/jqe.1986.1072884;;18223878;;10.1364/ao.24.002280;;3352449;;10.1002/lsm.1900080104;;10.1364/ol.10.000056;;19724344;;10.1109/jqe.1984.1072322,"Goth et al., Multifiber Optically Shielded Catheter For Laser Angiosurgery Optical Fibers in Medicine II 713:58 63 (1986).;;Cothren et al. Controlled Light Delivery For Laser Angiosurgery J. Quantum Elec. QE 22 (Jan. 1986).;;Kittrell et al. Diagnosis of Fibrous Arterial Atherosclerosis Using Fluorscence Applied Optics 24(15):2280 2281 (Aug. 1 1985).;;Hoyt et al., Remote Biomedical Spectroscopic Imaging of Human Artery Wall Lasers in Surgery and Medicine 8:1 9 (1988).;;Satori et al., Autofluorescence Maps of Atherosclerotic Human Arteries A New Techniques in Medical Imaging J. Quantum Elec. QE 23 (10:1794 1797 (Oct. 1987).;;Montan et al. Multicolor Imaging and Contrast Enhancement in Cancer tumor Localization Using Laser induced Fluorescence in Hematoporphyrin derivative bearing Tissue Optics Letters 10(2):56 58 (Feb. 1985.;;Andersson et al., Tumour Localization By Means of Laser Inducted Fluorescence in Hematoporphyrin Derivative (HPD) Bearing Tissue Proc. Seventh Int l Conf. Hawaii :401 406 (Jun. 24 28, 1985).;;Alfano et al., Laser Induced Fluorescence Spectroscopy From Native Cancerous and Normal Tissue J. Quantum Elec. QE 20(12):1507 1511 (Dec. 1984).",EXPIRED
351,MY,A,MY 137843 A,037-727-820-924-197,2009-03-31,2009,MY PI20033315 A,2003-09-03,US 40802902 P,2002-09-04,PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS,"IN ITS MANY EMBODIMENTS, THE PRESENT INVENTION PROVIDES A NOVEL CLASS OF PYRAZOLO<1 ,5-A]PYRIMIDINE COMPOUNDS AS INHIBITORS OF CYE/IN DEPENDENT KINASES, METHODS OF PREPARING SUCH COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING ONE OR MORE SUCH COMPOUNDS, METHODS OF PREPARING PHARMACEUTICAL FORMULATIONS COMPRISING ONE OR MORE SUCH COMPOUNDS, AND METHODS OF TREATMENT, PREVENTION, INHIBITION, OR AMELIORATION OF ONE OR MORE DISEASES ASSOCIATED WITH THE CDKS USING SUCH COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;MIN HE ZHEN;;ANTHONY JAMES RAY;;HAENGSOON PARK;;KAMIL PARUCH;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;ALVAREZ CARMEN S;;TIN-YAU CHAN;;CHAD KNUTSON;;MADISON VINCENT S,,https://lens.org/037-727-820-924-197,Granted Patent,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61P25/00;;A61P35/00;;C07D487/04,,0,0,,,,EXPIRED
352,MY,A,MY 145332 A,085-394-330-470-565,2012-01-31,2012,MY PI20071385 A,2003-09-03,US 40802902 P,2002-09-04,TRISUBSTITUTED 4-AMINOPYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS,"IN ITS MANY EMBODIMENTS , THE PRESENT INVENTION PROVIDES A NOVEL CLASS OF PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS INHIBITORS OF CYCLIN DEPENDENT KINASES, METHODS OF PREPARING SUCH COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING ONE OR MORE SUCH COMPOUNDS, METHODS OF PREPARING PHARMACEUTICAL FORMULATIONS COMPRISING ONE OR MORE SUCH COMPOUNDS, AND METHODS OF TREATMENT, PREVENTION, INHIBITION, OR AMELIORATION OF ONE OR MORE DISEASES ASSOCIATED WITH THE CDKs USING SUCH COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS .",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;MIN HE ZHEN;;ANTHONY JAMES RAY;;HAENGSOON PARK;;KAMIL PARUCH;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;ALVAREZ CARMEN S;;TIN-YAU CHAN;;CHAD KNUTSON;;MADISON VINCENT S,,https://lens.org/085-394-330-470-565,Granted Patent,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61K31/519;;A61P25/00;;A61P35/00;;C07D487/04,,0,0,,,,EXPIRED
353,US,A,US 5562100 A,187-706-674-275-032,1996-10-08,1996,US 24908694 A,1994-05-25,US 24908694 A;;US 8234293 A;;US 92015192 A;;US 28877288 A,1988-12-21,Method for laser induced fluorescence of tissue,A method for laser induced fluorescence of tissue in which laser radiation is used to illuminate and induce fluorescence in the tissue under study to determine the chemical composition or pathologic condition of tissue. The laser radiation and the retrieved fluorescing radiation can be conveyed through a catheter using an array of optical fiber. The fluorescence spectrum of the tissue can be displayed and analyzed to obtain information regarding the chemical composition and medical condition of the tissue inside the human body.,MASSACHUSETTS INST TECHNOLOGY,KITTRELL CARTER;;COTHREN ROBERT M;;FELD MICHAEL S;;BARAGA JOSEPH J;;AN KYUNGWON;;RICHARDS-KORTUM REBECCA;;RAVA RICHARD P;;PARK YOUNG D;;MEHTA ANAND V;;TARONI PAOLA;;TONG LUCENE;;DASARI RAMACHANDRA R,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1996-04-26),https://lens.org/187-706-674-275-032,Granted Patent,yes,20,283,8,8,0,A61B5/0071;;A61B5/0075;;A61B5/0084;;A61B5/1459;;A61B18/245;;A61B2562/0238;;A61B5/0084;;A61B5/0071;;A61B5/0075;;A61B5/1459;;A61B18/245;;A61B2562/0238,A61B5/00;;A61B18/24,128/665,9,0,,,"P. Jansson, Deconvolution With Application In Spectroscopy (1984) Chapter 1, pp. 1 33, Chapter 5, pp. 136 152.;;Publication of Alfan et al. (1984), IEEE vol. QE 20, No. 12, pp. 1507 1511.;;Publication of Sartori et al. (1984), IEEE vol. QE 23, No. 10, pp. 1794 1797.;;Publication of Kittrell et al. (1985), Laser Radiation to produce tissue fluorescence spectra.;;Publication of Hoyt et al, Use of Laser induced fluorescence of tissue.;;Publication of Cothren et al. (1986), Laser catheter for controlled delivery of laser radiation to tissue in vivo.;;Publication of Cothren et al. (1986), Laser catheters to provide a spectral representation or map of tissue.;;Publication of Montan et al. (1985), Laser induced fluorescence of tissue to aid in cancerous tissue.;;Publication of Andersson et al. (1985), Laser induced fluorescence of tissue to aid in cancerous tissue.",EXPIRED
354,JP,A,JP 2012088310 A,124-553-996-801-349,2012-05-10,2012,JP 2011222401 A,2011-10-07,US 90950510 A,2010-10-21,COMMUNICATION SYSTEM FOR TURBINE ENGINE,"PROBLEM TO BE SOLVED: To provide a communication system for a turbine engine.SOLUTION: The communication system includes: a sensor 25 to measure a condition at a point 20 of measurement interest defined on a rotor 12 of a turbine at a radial direction distance from a centerline 122 about which the rotor 12 is rotatable; wiring which is disposed on the rotor 12 at a radial direction distance from the centerline 122, and includes a first wiring section 40 coupled to the sensor, a second wiring section 60, and a first connection 50 by which the first and second wiring sections 40, 60 are connectable; a second connection 70 by which the second wiring section 60 transmits a signal reflective of the detected condition to a non-rotating recording element 75; and a temperature compensation module 65 disposed on the second wiring section 60 to adjust the signal.",GEN ELECTRIC,KURT KRAMER SCHLEIF;;GREGORY QUENTIN BROWN;;PHILIP MICHAEL CARUSO;;FERNANDO JORGE CASANOVA;;CHOI SONG-WOO;;CUMMINS JOSEF S;;MATTHEW RYAN FARTHROUGH;;ANDREW CLIFFORD HART;;ROBERT DAVID JONES;;PARK YEONG JONG;;FRANCESCO SORANNA,,https://lens.org/124-553-996-801-349,Patent Application,no,8,0,7,7,0,F01D21/003;;F01D21/003;;F05D2220/31;;F05D2220/31,G01L19/00,,0,0,,,,INACTIVE
355,US,B2,US 6893180 B2,113-553-263-460-007,2005-05-17,2005,US 35080303 A,2003-01-24,US 35080303 A;;US 68943300 A;;US 19204000 P,2000-03-24,Method of cleaning a surface,"A method for cleaning a surface using a tool with both a cleaning head and a cleaning fluid reservoir housing coupled to an elongated handle, the method comprising the following steps: attaching a cleaning pad to the cleaning head; inserting a replaceable cleaning fluid reservoir into the housing; fluidically coupling the cleaning fluid reservoir to the cleaning head; dispensing controlled amounts of cleaning fluid from the reservoir onto a surface; and distributing the cleaning fluid evenly over the surface with the cleaning pad.",CLOROX CO,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID J;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD;;MINKLER DOUGLAS J;;OLSEN SHARON,CLOROX COMPANY THE (2001-07-09),https://lens.org/113-553-263-460-007,Granted Patent,yes,101,55,14,33,0,A47L13/22;;A47L13/22;;A47L13/26;;A47L13/26;;A47L13/312;;A47L13/312;;A47L13/44;;A47L13/44,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,401/140;;401/138,21,0,,,"Webester's Third New international Dictionary, 1976 by G. & C. Merriam Co., pp. 2208-2209 and 2258-2259.;;Chemical Engineers' Handbook, 1973 by Robert H. perry and Cecil H. Chilton pp. 5-4, 18-58 and 18-59.;;U.S. Appl. No. 10/233,773, filed Aug. 30, 2002.;;U.S. Appl. No. 10/234,959, filed Aug. 30, 2002.;;U.S. Appl. No. 10/233,774, filed Aug. 30, 2002.;;U.S. Appl. No. 10/351,293, filed Jan. 24, 2003.;;U.S. Appl. No. 10/350,804, filed Jan. 24, 2003.;;U.S. Appl. No. 10/606,370, filed on Jun. 25, 2003.;;U.S. Appl. No. 29/140,155, filed on Apr. 11, 2001.;;U.S. Appl. No. 29/140,102, filed on Apr. 11, 2001.;;U.S. Appl. No. 29/140,150, filed on Apr. 11, 2001.;;U.S. Appl. No. 29/140,154, filed on Apr. 11, 2001.;;U.S. Appl. No. 29/140,104, filed on Apr. 11, 2001.;;U.S. Appl. No. 29/1470,162, filed on Apr. 11, 2001.;;U.S. Appl. No. 29/160,918, filed on May 17, 2002.;;U.S. Appl. No. 29/160,919, filed on May 17, 2002.;;U.S. Appl. No. 29/166,630, filed on Aug. 30, 2002.;;U.S. Appl. No. 291/186,191 filed on Jul. 10, 2003.;;U.S. Appl. No. 29/186,188, filed on Jul. 10, 2003.;;U.S. Appl. No. 29/186,188, filed on Jul. 10, 2003.;;U.S. Appl. No. 29/186,189, filed on Jul. 10, 2003.",EXPIRED
356,US,B2,US 6986619 B2,007-896-700-451-03X,2006-01-17,2006,US 85901904 A,2004-06-02,US 85901904 A;;US 35080303 A;;US 68943300 A;;US 31791101 P;;US 19204000 P,2000-03-24,Method of cleaning a surface,"A method for cleaning a surface using a tool with both a cleaning head and a cleaning fluid reservoir housing coupled to an elongated handle, the method comprising the following steps: attaching a cleaning pad to the cleaning head; inserting a replaceable cleaning fluid reservoir into the housing; fluidically coupling the cleaning fluid reservoir to the cleaning head; dispensing controlled amounts of cleaning fluid from the reservoir onto a surface; and distributing the cleaning fluid evenly over the surface with the cleaning pad.",CLOROX CO,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID J;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD;;MINKLER DOUGLAS J;;OLSEN SHARON,CLOROX COMPANY THE (2001-07-09),https://lens.org/007-896-700-451-03X,Granted Patent,yes,100,43,14,33,0,A47L13/22;;A47L13/22;;A47L13/26;;A47L13/26;;A47L13/312;;A47L13/312;;A47L13/44;;A47L13/44,A46B11/00;;A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,401/140;;401/138,7,0,,,"Webester's Third New international Dictionary, 1976 by G. & C. Merriam Co., pp. 2208-2209 and 2258-2259.;;Chemical Engineers' Handbook, 1973 by Robert H. perry and Cecil H. Chilton pp. 5-4, 18-58 and 18-59.;;U.S. Appl. No. 10/233,773 filed Aug. 30, 2002.;;U.S. Appl. No. 10/234,959 filed Aug. 30, 2002.;;U.S. Appl. No. 10/233,774 filed Aug. 30, 2002.;;U.S. Appl. No. 10/351,293 filed Jan. 24, 2003.;;U.S. Appl. No. 10/350,804 filed Jan. 24, 2003.",EXPIRED
357,US,A1,US 2004/0216771 A1,082-424-114-112-937,2004-11-04,2004,US 85901904 A,2004-06-02,US 85901904 A;;US 35080303 A;;US 68943300 A;;US 31791101 P;;US 19204000 P,2000-03-24,Method of cleaning a surface,"
   A method for cleaning a surface using a tool with both a cleaning head and a cleaning fluid reservoir housing coupled to an elongated handle, the method comprising the following steps: attaching a cleaning pad to the cleaning head; inserting a replaceable cleaning fluid reservoir into the housing; fluidically coupling the cleaning fluid reservoir to the cleaning head; dispensing controlled amounts of cleaning fluid from the reservoir onto a surface; and distributing the cleaning fluid evenly over the surface with the cleaning pad. 
",HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID J;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD;;MINKLER DOUGLAS J;;OLSEN SHARON,HALL MICHAEL J;;RADER JAMES E;;ZHOU BOLI;;HEFTER KAREN S;;SAYLER DAVID J;;PARK ERIC Y;;FLAGLER ROBERT W;;HAUBRICH SCOTT T;;MITRA SHUMANTA;;PORTICOS RICHARD;;MINKLER DOUGLAS J;;OLSEN SHARON,CLOROX COMPANY THE (2001-07-09),https://lens.org/082-424-114-112-937,Patent Application,yes,91,1,14,33,0,A47L13/22;;A47L13/22;;A47L13/26;;A47L13/26;;A47L13/312;;A47L13/312;;A47L13/44;;A47L13/44,A46B11/04;;A47L13/22;;A47L13/26;;A47L13/312;;A47L13/44,134 034000;;134 006000,0,0,,,,EXPIRED
358,JP,A,JP 2012088311 A,156-735-539-174-51X,2012-05-10,2012,JP 2011222403 A,2011-10-07,US 90942210 A,2010-10-21,SENSOR PACKAGING OF A TURBINE ENGINE,"PROBLEM TO BE SOLVED: To provide a sensor packaging of a turbine engine.SOLUTION: The turbine 10 includes a rotor 12 rotatable around its center axis 122, a sensor 25 for measuring a state of a measurement object point 20 designated on the rotor 12 at a point radially apart from the center axis 122 by a certain distance, a communication system 30 that transmits the state measurement value from the sensor 25 to a non-rotational recording system 75, and a probe holder that fixes the sensor 25 and a part of the communication system 30 to a point on the rotor 12, which is proximate to the measurement object point 20.",GEN ELECTRIC,KURT KRAMER SCHLEIF;;GREGORY QUENTIN BROWN;;PHILIP MICHAEL CARUSO;;FERNANDO JORGE CASANOVA;;CHOI SONG-WOO;;CUMMINS JOSEF S;;MATTHEW RYAN FARTHROUGH;;ANDREW CLIFFORD HART;;ROBERT DAVID JONES;;PARK YEUNG JONG;;FRANCESCO SORANNA,,https://lens.org/156-735-539-174-51X,Patent Application,no,0,0,6,6,0,F01D17/08;;F05D2270/301;;G01L19/0681;;G01L23/26;;F01D17/02;;F02C9/28;;F01D21/003;;F01D17/08;;F05D2270/301;;G01L19/0681;;G01L23/26;;F01D17/02;;F02C9/28;;F01D21/003,G01L19/00,,0,0,,,,PENDING
359,EP,A2,EP 1060851 A2,013-897-550-853-739,2000-12-20,2000,EP 00304897 A,2000-06-09,US 13849599 P,1999-06-10,Table saw,"The table saw disclosed herein includes a table, a saw assembly pivotally attached to the table, the saw assembly comprising an arbor movable relative to the table, a bevel shaft operatively connected to the saw assembly for pivoting the saw assembly, and a height shaft operatively connected to the saw assembly for moving the arbor relative to the table, wherein distance between the height shaft and the table is larger than distance between the bevel shaft and the table. Also disclosed is a saw includes a table having a first miter gauge slot, a base supporting the table, a saw assembly pivotably connected to at least one of the table and the base for carrying a rotatable cutting tool so that the tool protrudes through and above the table, at least part of the saw assembly being underneath the table, the saw assembly comprising a cradle, and a sector gear connected to the cradle, and a first bevel stop disposed underneath the first miter gauge slot, wherein the first bevel stop can contact the sector gear when the saw assembly is pivoted in one direction.",BLACK & DECKER INC,PARK JAMES R;;PUZIO DANIEL;;ROHR LEWIS H;;GEHRET ROBERT S;;O'BANION MICHAEL;;WELSH ROBERT P;;STUMPF WILLIAM R;;BEAN FREDERICK R;;MERHAR III CARL F;;LIVINGSTON SCOTT M;;DUNCANSON DAVID E;;AYALA ADAN,,https://lens.org/013-897-550-853-739,Patent Application,yes,1,3,17,22,0,B23D45/067;;B23D45/068;;B27B5/243;;B27B5/29;;Y10T83/6612;;Y10T83/7726;;Y10T83/7872;;Y10T83/7705;;Y10T83/9457;;Y10T83/8773;;Y10T83/773;;Y10T83/6612;;Y10T83/7726;;Y10T83/7872;;Y10T83/7705;;Y10T83/9457;;Y10T83/8773;;Y10T83/773;;B27B5/29;;B27B5/243;;B23D45/068;;B23D45/067,B23D45/06;;B27B5/24,,0,0,,,,DISCONTINUED
360,EP,A3,EP 1060851 A3,085-672-656-853-846,2004-08-18,2004,EP 00304897 A,2000-06-09,US 13849599 P,1999-06-10,Table saw,"The table saw disclosed herein includes a table, a saw assembly pivotally attached to the table, the saw assembly comprising an arbor movable relative to the table, a bevel shaft operatively connected to the saw assembly for pivoting the saw assembly, and a height shaft operatively connected to the saw assembly for moving the arbor relative to the table, wherein distance between the height shaft and the table is larger than distance between the bevel shaft and the table. Also disclosed is a saw includes a table having a first miter gauge slot, a base supporting the table, a saw assembly pivotably connected to at least one of the table and the base for carrying a rotatable cutting tool so that the tool protrudes through and above the table, at least part of the saw assembly being underneath the table, the saw assembly comprising a cradle, and a sector gear connected to the cradle, and a first bevel stop disposed underneath the first miter gauge slot, wherein the first bevel stop can contact the sector gear when the saw assembly is pivoted in one direction.",BLACK & DECKER INC,PARK JAMES R;;PUZIO DANIEL;;ROHR LEWIS H;;GEHRET ROBERT S;;O'BANION MICHAEL;;WELSH ROBERT P;;STUMPF WILLIAM R;;BEAN FREDERICK R;;MERHAR III CARL F;;LIVINGSTON SCOTT M;;DUNCANSON DAVID E;;AYALA ADAN,,https://lens.org/085-672-656-853-846,Search Report,yes,3,0,17,22,0,B23D45/067;;B23D45/068;;B27B5/243;;B27B5/29;;Y10T83/6612;;Y10T83/7726;;Y10T83/7872;;Y10T83/7705;;Y10T83/9457;;Y10T83/8773;;Y10T83/773;;Y10T83/6612;;Y10T83/7726;;Y10T83/7872;;Y10T83/7705;;Y10T83/9457;;Y10T83/8773;;Y10T83/773;;B27B5/29;;B27B5/243;;B23D45/068;;B23D45/067,B23D45/06;;B27B5/24,,0,0,,,,DISCONTINUED
361,US,A1,US 2004/0028043 A1,144-705-528-677-32X,2004-02-12,2004,US 20974302 A,2002-07-31,US 20974302 A,2002-07-31,Method and apparatus for virtualizing storage devices inside a storage area network fabric,"
   Placing virtualization agents in the switches which comprise the SAN fabric. Higher level virtualization management functions are provided in an external management server. Conventional HBAs can be utilized in the hosts and storage units. In a first embodiment, a series of HBAs are provided in the switch unit. The HBAs connect to bridge chips and memory controllers to place the frame information in dedicated memory. Routine translation of known destinations is done by the HBA, based on a virtualization table provided by a virtualization CPU. If a frame is not in the table, it is provided to the dedicated RAM. Analysis and manipulation of the frame headers is then done by the CPU, with a new entry being made in the HBA table and the modified frames then redirected by the HBA into the fabric. This can be done in either a standalone switch environment or in combination with other switching components located in a director level switch. In an alternative embodiment, specialized hardware scans incoming frames and detects the virtualized frames which need to be redirected. The redirection is then handled by translation of the frame header information by hardware table-based logic and the translated frames are then returned to the fabric. Handling of frames not in the table and setup of hardware tables is done by an onboard CPU. 
",BROCADE COMM SYSTEMS INC,MAVELI NAVEEN S;;WALTER RICHARD A;;COSTANTINO CIRILLO L;;ROY SUBHOJIT;;ALONSO CARLOS;;PONG MICHAEL YIU-WING;;KRAKIRIAN SHAHE H;;ARUMILLI SUBBARAO;;ISIP VINCENT;;CHUNG DANIEL JI YONG PARK;;ELSTAD STEPHEN D;;MAKISHIMA DENNIS H,BROCADE COMMUNICATIONS SYSTEMS INC (2002-10-06),https://lens.org/144-705-528-677-32X,Patent Application,yes,7,101,1,1,0,H04L49/15;;H04L49/30;;H04L49/357;;H04L49/358;;H04L49/505;;H04L69/22;;H04L9/40;;H04L49/118;;H04L49/357;;H04L49/505;;H04L49/358;;H04L49/15;;H04L49/10;;H04L49/30;;H04L69/22;;H04L9/40,H04L12/56;;H04L29/06,370/392;;370/401,0,0,,,,DISCONTINUED
362,US,A1,US 2022/0064205 A1,153-298-983-751-289,2022-03-03,2022,US 201917299087 A,2019-12-03,US 201917299087 A;;US 201862775094 P;;US 2019/0064137 W,2018-12-04,PROCESS FOR THE PREPARATION OF A CYCLIC DINUCLEOTIDE,"The invention generally relates to an improved processes for the preparation of a cyclic dinucleotide which is useful as a STING agonist of the following formula (I), involving the use of compounds A and B.",BRISTOL MYERS SQUIBB CO,SCHMIDT MICHAEL ANTHONY;;KENDALL PARK BIN ZHENG;;COHEN BENJAMIN M;;ROGERS AMANDA J;;WARREN CHANGXIA YUAN;;ZHU JASON J;;HANG CHAO;;TREITLER DANIEL S;;FREITAG ADAM JOSEP;;PURDUM GEOFFREY EUGENE;;YU MIAO;;SEZEN EDMONDS MELDA;;GUO SIWEI,,https://lens.org/153-298-983-751-289,Patent Application,yes,0,0,13,13,0,C07H21/02;;C07H1/00;;C07H1/00;;C07H21/02;;C07H21/02;;C07H19/167;;C07H1/00;;C07H1/00;;C07H19/16;;C07H19/20;;C07H21/00,C07H21/00;;C07H1/00;;C07H19/16;;C07H19/20,,0,0,,,,PENDING
363,CN,A,CN 113906419 A,130-199-127-940-96X,2022-01-07,2022,CN 202080038868 A,2020-03-24,US 201962822948 P;;US 201962855842 P;;US 2020/0024486 W,2019-03-24,USER INTERFACES FOR A MEDIA BROWSING APPLICATION,"In some embodiments, an electronic device presents a plurality of representations of content items in a unified media browsing application. In some embodiments, an electronic device presents information on representations of content items. In some embodiments, an electronic device display content in a unified media browsing application. In some embodiments, an electronic device links to an account for a primary content provider. In some embodiments, an electronic device restricts access to content based on the geographic location of the device. In some embodiments, an electronic device presents playback menus during playback of content in a unified media browsing application. In some embodiments, an electronic device displays user interfaces specific to respective content items. In some embodiments, an electronic device displays content items.",APPLE INC,VINNA FREDRIC;;DOMM DREW R;;CIELAK MATTHEW J;;BALSAMO TITO LLOYD;;TAN-ANG JEFF;;PARK DENNIS S;;DAVYDOV ANTON M;;CHRISTIE BENJAMIN;;JUSTIN GAUSSOIN;;CARPENTER WILLIAM D;;EVASHEVSKI MICHAEL;;LINDHOLM ERIK;;ALBUQUERQUE FERNANDO;;ELLINGFORD CHRISTOPHER;;TRAN CHRISTINE E,,https://lens.org/130-199-127-940-96X,Patent Application,no,0,0,5,5,0,G06F21/36;;H04L67/025;;H04L67/12;;H04L67/125;;H04L67/535;;H04L67/55;;H04L67/52;;H04H20/38;;H04N21/4312;;H04N21/47205,G06F21/30;;G06F21/50,,0,0,,,,PENDING
364,WO,A1,WO 2020/198238 A1,035-267-781-328-829,2020-10-01,2020,US 2020/0024486 W,2020-03-24,US 201962822948 P;;US 201962855842 P,2019-03-24,USER INTERFACES FOR A MEDIA BROWSING APPLICATION,"In some embodiments, an electronic device presents a plurality of representations of content items in a unified media browsing application. In some embodiments, an electronic device presents information on representations of content items. In some embodiments, an electronic device display content in a unified media browsing application. In some embodiments, an electronic device links to an account for a primary content provider. In some embodiments, an electronic device restricts access to content based on the geographic location of the device. In some embodiments, an electronic device presents playback menus during playback of content in a unified media browsing application. In some embodiments, an electronic device displays user interfaces specific to respective content items. In some embodiments, an electronic device displays content items.",APPLE INC,VINNA FREDRIC;;DOMM DREW R;;CIELAK MATTHEW J;;BALSAMO TITO LLOYD;;TAN-ANG JEFF;;PARK DENNIS S;;DAVYDOV ANTON M;;CHRISTIE BENJAMIN;;GAUSSOIN JUSTIN;;CARPENTER WILLIAM D;;EVASHEVSKI MICHAEL;;LINDHOLM ERIK;;ALBUQUERQUE FERNANDO;;ELLINGFORD CHRISTOPHER;;TRAN CHRISTINE E,,https://lens.org/035-267-781-328-829,Patent Application,yes,29,0,5,5,0,G06F21/36;;H04L67/025;;H04L67/12;;H04L67/125;;H04L67/535;;H04L67/55;;H04L67/52;;H04H20/38;;H04N21/4312;;H04N21/47205,G06F21/30;;G06F21/50,,0,0,,,,PENDING
365,EP,A1,EP 3928228 A1,094-011-821-887-942,2021-12-29,2021,EP 20718506 A,2020-03-24,US 201962822948 P;;US 201962855842 P;;US 2020/0024486 W,2019-03-24,USER INTERFACES FOR A MEDIA BROWSING APPLICATION,,APPLE INC,VINNA FREDRIC;;DOMM DREW R;;CIELAK MATTHEW J;;BALSAMO TITO LLOYD;;TAN-ANG JEFF;;PARK DENNIS S;;DAVYDOV ANTON M;;CHRISTIE BENJAMIN;;GAUSSOIN JUSTIN;;CARPENTER WILLIAM D;;EVASHEVSKI MICHAEL;;LINDHOLM ERIK;;ALBUQUERQUE FERNANDO;;ELLINGFORD CHRISTOPHER;;TRAN CHRISTINE E,,https://lens.org/094-011-821-887-942,Patent Application,yes,0,0,5,5,0,G06F21/36;;H04L67/025;;H04L67/12;;H04L67/125;;H04L67/535;;H04L67/55;;H04L67/52;;H04H20/38;;H04N21/4312;;H04N21/47205,G06F21/30;;G06F21/50,,0,0,,,,PENDING
366,US,A1,US 2002/0194971 A1,144-169-940-326-840,2002-12-26,2002,US 19482502 A,2002-07-12,US 19482502 A;;US 32861499 A;;US 21346698 A;;US 7470698 P,1998-02-13,Table saw,"
   A table saw including a base, a main table supported by the base, first and second rails attached to the table, a sliding table fixedly attached to the rails and sliding along the longitudinal axis of the rails and a cross-cut table slidably movable in a direction perpendicular to the longitudinal axis of the rails. The cross-cut table may be adjusted to ensure movement parallel to a blade protruding from the main table. An improved miter gauge assembly is also disclosed. An improved fence assembly is further disclosed herein. In addition, a table saw having an improved panel and leg construction is disclosed herein. 
",PARK JAMES;;GEHRET ROBERT S.;;LIVINGSTON SCOTT;;O'BANION MICHAEL L.;;WELSH ROBERT P.;;TAYLOR WILLIAM SCOTT;;HUSTON TODD L.;;ZEHR EDWIN G.;;STROPKAY SCOTT;;WEISSBURG DAVID LOUIS;;NICHOLS MARK ALLEN;;STUMPF WILLIAM R.;;ROHR LEWIS HAMPTON;;TEW HENRY LOUIS;;PALADINO THOMAS S.;;EICHELBERGER PAUL;;DUNCANSON DAVID EDMUND;;HOLLEMAN JERRY WAYNE;;AYALA ADAN,PARK JAMES;;GEHRET ROBERT S;;LIVINGSTON SCOTT;;O'BANION MICHAEL L;;WELSH ROBERT P;;TAYLOR WILLIAM SCOTT;;HUSTON TODD L;;ZEHR EDWIN G;;STROPKAY SCOTT;;WEISSBURG DAVID LOUIS;;NICHOLS MARK ALLEN;;STUMPF WILLIAM R;;ROHR LEWIS HAMPTON;;TEW HENRY LOUIS;;PALADINO THOMAS S;;EICHELBERGER PAUL;;DUNCANSON DAVID EDMUND;;HOLLEMAN JERRY WAYNE;;AYALA ADAN,,https://lens.org/144-169-940-326-840,Patent Application,yes,0,21,10,32,0,B23D47/025;;B27B5/222;;B27B25/10;;B27B27/02;;B27B27/08;;B27B27/10;;Y10T83/762;;Y10T83/858;;Y10T83/7567;;Y10T83/6632;;Y10T83/73;;Y10T83/6612;;Y10T83/7709;;Y10T83/6614;;Y10T83/748;;Y10T83/6609;;Y10T83/929;;Y10T83/8773;;Y10T83/773;;Y10T83/762;;Y10T83/858;;Y10T83/7567;;Y10T83/6632;;Y10T83/73;;Y10T83/6612;;Y10T83/7709;;Y10T83/6614;;Y10T83/748;;Y10T83/6609;;Y10T83/929;;Y10T83/8773;;Y10T83/773;;B27B25/10;;B27B27/02;;B23D47/025;;B27B27/08;;B27B5/222;;B27B27/10,B23D47/02;;B27B5/22;;B27B27/02,83/477.2;;83/435.14,0,0,,,,EXPIRED
367,DE,D1,DE 60313872 D1,070-575-132-653-254,2007-06-28,2007,DE 60313872 T,2003-09-03,US 40802902 P;;US 0327491 W,2002-09-04,"PYRAZOLOÄ1,5-AÜPYRIMIDINE ALS HEMMSTOFFE CYCLIN-ABHÄNGIGER KINASEN",,SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,"PHARMACOPEIA, LLC (N.D.GES.D. STAATES DELAWARE, US (2011-03-10);;SCHERING CORP., KENILWORTH, N.J., US (2011-03-10);;PHARMACOPEIA,INC. (N. D. GES. D. STAATES DELAW, US (2009-01-29)",https://lens.org/070-575-132-653-254,Granted Patent,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,C07D487/04;;A61K31/519;;A61P25/00;;A61P35/00,,0,0,,,,EXPIRED
368,PE,A1,PE 20041000 A1,154-565-441-473-763,2004-12-29,2004,PE 2003000900 A,2003-09-04,US 40802902 P,2002-09-04,PIRAZOLOPIRIMIDINAS COMO INHIBIDORES DE LA QUINASA DEPENDIENTES DE CICLINA,"SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R ES ARILO, SUSTITUIDO O NO; R2 ES ALQUINILALQUILO, CN, ALQUILO, ENTRE OTROS; R3 ES H, HALOGENO, ALQUILO, ENTRE OTROS; R4 ES H, HALO, ALQUILO. SON COMPUESTOS PREFERIDOS: A, B, C, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA SIENDO INHIBIDORES DE CINASA DE PROTEINAS UTILES EN EL TRATAMIENTO DE CANCER, INFLAMACION, ARTRITIS, ENFERMEDADES VIRALES Y ENFERMEDADES NEURODEGENERATIVAS, CARDIOVASCULARES Y FUNGICAS",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;CHAN TIN-YAU;;PARUCH KAMIL;;KNUTSON CHAD;;JAMES RAY ANTHONY;;DILLARD LAWRENCE W;;DWYER MICHAEL P;;FISCHMANN THIERRY O;;MADISON VINCENT;;TRAN VINH D;;PARK HAENGSOON;;HE ZHEN MIN;;GUZI TIMOTHY J;;ALVAREZ CARMEN S,,https://lens.org/154-565-441-473-763,Patent Application,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61P25/00;;A61P35/00;;C07D487/04,,0,0,,,,EXPIRED
369,AU,A1,AU 2003/298571 A1,069-145-894-411-352,2004-04-08,2004,AU 2003/298571 A,2003-09-03,US 40802902 P;;US 0327491 W,2002-09-04,NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS,,SCHERING CORP,DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;GUZI TIMOTHY J;;PARUCH KAMIL,"PHARMACOPEIA, INC.; SCHERING CORPORATION (2007-09-13)",https://lens.org/069-145-894-411-352,Patent Application,no,0,1,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61P25/00;;A61P35/00;;C07D487/04,,0,0,,,,EXPIRED
370,CN,B,CN 1701073 B,079-759-976-748-740,2011-06-22,2011,CN 03824701 A,2003-09-03,US 0327491 W;;US 40802902 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,TIN-YAU CHAN;;DILLARD LAWRENCE W;;DWYER MICHAEL P;;FISCHMANN THIERRY O;;DOLL RONALD J;;ALVAREZ CARMEN S;;KAMIL PARUCH;;ANTHONY JAMES RAY;;CHAD KNUTSON;;VINCENT MADISON;;MIN HE ZHEN;;TRAN VINH D;;GIRIJAVALLABHAN VIYYOOR M;;HAENGSOON PARK;;GUZI TIMOTHY J,MSD CORP. (2012-12-05),https://lens.org/079-759-976-748-740,Granted Patent,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,C07D487/04;;A61K31/519;;A61P25/00;;A61P35/00;;C07D231/00;;C07D239/00,,0,0,,,,EXPIRED
371,TW,A,TW 200413376 A,130-613-015-977-080,2004-08-01,2004,TW 92124336 A,2003-09-03,US 40802902 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1, 5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;CARMEN S ALVAREZ;;TIN-YAU CHAN;;CHAD KNUTSON;;VINCENT MADISON;;THIERRY O FISCHMANN;;LAWRENCE W DILLARD;;VINH D TRAN;;ZHEN MIN HE;;RAY ANTHONY JAMES;;HAENGSOON PARK,,https://lens.org/130-613-015-977-080,Patent of Addition,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,C07D487/04;;A61K31/505;;A61P25/00;;A61P35/00,,0,0,,,,EXPIRED
372,KR,A,KR 20050033659 A,180-143-744-119-465,2005-04-12,2005,KR 20057003527 A,2005-02-28,US 40802902 P,2002-09-04,"PYRAZOLO[1,5-A]PYRIMIDINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS","In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",PHARMACOPEIA DRUG DISCOVERY;;SCHERING CORP,ALVAREZ CARMEN S;;CHAN TIN-YAU;;DILLARD LAWRENCE W;;DOLL RONALD J;;DWYER MICHAEL P;;FISCHMANN THIERRY O;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;GUZI TIMOTHY J;;HE ZHEN MIN;;JAMES RAY ANTHONY;;KNUTSON CHAD;;MADISON VINCENT;;PARK HAENGSOON;;PARUCH KAMIL;;TRAN VINH D,,https://lens.org/180-143-744-119-465,Patent Application,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61P25/00;;A61P35/00;;C07D487/04,,0,0,,,,DISCONTINUED
373,AU,B2,AU 2003/298571 B2,197-713-068-326-82X,2006-10-19,2006,AU 2003/298571 A,2003-09-03,US 40802902 P;;US 0327491 W,2002-09-04,"Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors",,MERCK SHARP & DOHME;;PHARMACOPEIA INC,DILLARD LAWRENCE W;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;FISCHMANN THIERRY O;;GUZI TIMOTHY J;;CHAN TIN-YAU;;HE ZHEN MIN;;ALVAREZ CARMEN S;;PARUCH KAMIL;;DWYER MICHAEL P;;JAMES RAY ANTHONY;;MADISON VINCENT;;TRAN VINH D;;DOLL RONALD J;;PARK HAENGSOON;;KNUTSON CHAD,"PHARMACOPEIA, INC.; SCHERING CORPORATION (2007-09-13)",https://lens.org/197-713-068-326-82X,Granted Patent,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,C07D487/04;;A61P25/00;;A61P35/00,,0,0,,,,EXPIRED
374,EP,A2,EP 1534712 A2,198-113-348-276-510,2005-06-01,2005,EP 03796321 A,2003-09-03,US 0327491 W;;US 40802902 P,2002-09-04,"PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS",,SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,"MERCK SHARP & DOHME CORP., US (2013-05-16);;PHARMACOPEIA DRUG DISCOVERY, INC. (2005-06-08);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-16);;PHARMACOPEIA, LLC (N.D.GES.D. STAATES DELAWARE, US (2022-09-29);;PHARMACOPEIA INC, US (2013-03-19);;PHARMACOPEIA LLC, US (2013-03-19);;SCHERING CORPORATION (2005-06-08);;SCHERING CORPORATION, US (2013-03-19);;MERCK SHARP & DOHME LLC, RAHWAY, US (2022-09-29);;MERCK SHARP  DOHME CORP., RAHWAY, US (2013-05-16)",https://lens.org/198-113-348-276-510,Patent Application,yes,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61P25/00;;A61P35/00;;C07D487/04,,0,0,,,,EXPIRED
375,HK,A1,HK 1071572 A1,014-812-577-008-974,2005-07-22,2005,HK 05104747 A,2005-06-07,US 40802902 P;;US 0327491 W,2002-09-04,"PyrazoloÄ1,5-AÜpyrimidine compounds as cyclin dependent kinase inhibitors",,SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DOLL RONALD J;;DWYER MICHAEL P;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;KNUTSON CHAD,,https://lens.org/014-812-577-008-974,Patent Application,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,C07D/;;A61K/;;A61P/;;A61P25/00;;A61P35/00;;C07D487/04,,0,0,,,,DISCONTINUED
376,WO,A2,WO 2004/026229 A2,043-784-991-015-332,2004-04-01,2004,US 0327491 W,2003-09-03,US 40802902 P,2002-09-04,NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides a novel class of pyrazolo⏧1,5-a&rsqb;pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,,https://lens.org/043-784-991-015-332,Patent Application,yes,0,79,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61P25/00;;A61P35/00;;C07D487/04,,0,0,,,,PATENTED
377,CA,A1,CA 2497544 A1,126-546-359-224-021,2004-04-01,2004,CA 2497544 A,2003-09-03,US 40802902 P;;US 0327491 W,2002-09-04,"PYRAZOLO[1,5-A]PYRIMIDINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS","In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinase s, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",PHARMACOPEIA DRUG DISCOVERY;;SCHERING CORP,PARK HAENGSOON;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;JAMES RAY ANTHONY;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;GUZI TIMOTHY J;;KNUTSON CHAD;;MADISON VINCENT;;HE ZHEN MIN;;TRAN VINH D;;DILLARD LAWRENCE W;;CHAN TIN-YAU;;FISCHMANN THIERRY O;;ALVAREZ CARMEN S,,https://lens.org/126-546-359-224-021,Patent Application,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61P25/00;;A61P35/00;;C07D487/04,,0,0,,,,EXPIRED
378,CA,C,CA 2497544 C,010-489-300-764-74X,2010-11-02,2010,CA 2497544 A,2003-09-03,US 40802902 P;;US 0327491 W,2002-09-04,"PYRAZOLO[1,5-A]PYRIMIDINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS","In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,,https://lens.org/010-489-300-764-74X,Granted Patent,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,C07D487/04;;A61K31/519;;A61P25/00;;A61P35/00;;C07D231/00;;C07D239/00,,0,0,,,,EXPIRED
379,US,B2,US 7514442 B2,068-288-042-642-582,2009-04-07,2009,US 39567606 A,2006-03-31,US 39567606 A;;US 65377603 A;;US 40802902 P,2002-09-04,Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;ALVAREZ CARMEN S;;CHAN TIN YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/068-288-042-642-582,Granted Patent,yes,32,1,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61K31/519;;A61P25/00;;A61P35/00;;A61P35/04;;C07D487/04,514/259.3;;544/281;;514/263.32;;514/252.17;;514/183;;514/81;;514/110;;514/234.2;;514/252.16;;514/151;;514/8;;514/9;;514/27;;514/167;;514/15;;514/221;;514/245;;424/649;;424/94.4,21,15,046-267-734-266-687;;011-413-668-915-089;;107-715-444-078-941;;041-549-446-256-496;;094-016-430-416-433;;032-700-699-523-938;;011-413-668-915-089;;046-267-734-266-687;;080-412-881-865-322;;054-343-072-168-181;;024-579-812-539-076;;018-866-961-404-161;;061-867-406-774-861;;154-728-053-610-213;;101-930-819-275-444,12783600;;10.1517/eoid.12.6.955.21792;;10.1517/13543784.12.6.955;;15882121;;10.1517/13543784.14.4.457;;10.1111/j.1432-1033.1997.t01-2-00527.x;;9030781;;9269999;;10.1248/cpb.47.928;;10434395;;10.1248/cpb.10.620;;15882121;;10.1517/13543784.14.4.457;;12783600;;10.1517/eoid.12.6.955.21792;;10.1517/13543784.12.6.955;;10.1111/j.1432-1033.1994.00771.x;;7925396;;12190313;;10.1021/jm0201520;;12519061;;10.1021/jm020319p;;319236;;10.1021/jm00212a021;;10.1200/jco.1998.16.9.2986;;9738567;;10699068;;10.1093/jnci/92.5.376;;10.1002/jhet.5570220303,"Fischer, P.M.; Gianella-Borradori, A.; CDK inhibitors in clinical development for the treatment of cancer, Expert. Opin. Investig. Drugs; 2003; 12(6); 955-970.;;Fischer, P.M.; Gianella-Borradori, A.; Recent progress in the discovery and development of cyclin-dependent kinase inhibitors, Expert. Opin. Investig. Drugs; 2005; 14(4); 457-477.;;Colorectal Cancer Coalition (http://www.fightcolorectalcancer.org/patients/diagnosis.rctreatment.htm)., downloaded Jan. 24, 2008.;;Meijer et al., ""Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5"", Eur. J. Biochem, 243:527-536 (1997).;;Bible et al., ""Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration"", Cancer Research, 57:3375-3380 (Aug. 15, 1997).;;Shiota et al., ""Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo [1,5-alpha]pyrimidine Derivatives"", Chem. Pharm. Bull., 47(7): 928-938 (1999).;;Makisumi, Yasuo ""Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-alpha]pyrimidines"", Chem. Pharm. Bull(1962), 10:620-626.;;Fischer, Peter M. et al., ""Recent progress in the discovery and development of cyclin-dependent kinase inhibitors"", Expert Opinion on Investigational Drugs, 14(4): 457-477 (Apr. 2005).;;Fischer, Peter M. et al., ""CDK inhibitors in clinical development for the treatment of cancer"", Expert Opinion on Investigational Drugs, 12(6): 955-970 (Jun. 2003).;;Vesely et al., ""Inhibition of Cyclin-Dependent Kinases by Purine Analogues"", Eur. J. Biochem, 224: 771-786 (1994).;;Kim et al., ""Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities"", Journal of Medical Chemistry, Page EST:22.3, A-W.;;Mettey et al., ""Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects"", J. Med. Chem., 46(2): 222-236 (2003).;;Novinson et al., ""Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo [1,5-alpha]pyrimidines"", J. Med. Chem., 20(2): 296-299 (1977).;;Senderowicz et al., ""Phase I Trial of Continous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor. in Patients with Refractory Neoplasmns"", Journal of Clinical Oncology, 16(9): 2986-2999 (Sep. 1998).;;Senderowicz et al., ""Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators"", J. National Cancer Institute, 92(5): 376-387 (Mar. 1, 2000).;;Chemical Abstract No. 63:10201. English Translation of JP 40002672.;;Chemical Abstract No. 65:108095 English Translation of JP 41014423.;;Chemical Abstract No. 66:10957 English Translation of JP 41015583.;;Chemical Abstract No. 66:10952 English Translation of JP 41016288.;;Chemical Abstract No. 105: 226617 English Translation of JP 61057587.;;Robins et al., ""Purine Analog Inhibitors of Xanthine Oxidase-Structure Activity Relationships and Proposed Binding of the Molybdenum Cofactor"", J. Heterocyclic Chem., 22:601-634 (1985).",EXPIRED
380,US,B2,US 7067661 B2,195-865-951-399-18X,2006-06-27,2006,US 65377603 A,2003-09-03,US 65377603 A;;US 40802902 P,2002-09-04,Pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02);;PHARMACOPEIA DRUG DISCOVERY (2003-09-25);;PHARMACOPEIA INC (2004-05-21),https://lens.org/195-865-951-399-18X,Granted Patent,yes,22,5,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,C07D487/04;;A61P25/00;;A61P35/00,544/281,11,10,154-728-053-610-213;;080-412-881-865-322;;054-343-072-168-181;;024-579-812-539-076;;018-866-961-404-161;;061-867-406-774-861;;107-715-444-078-941;;041-549-446-256-496;;094-016-430-416-433;;032-700-699-523-938,10699068;;10.1093/jnci/92.5.376;;10.1111/j.1432-1033.1994.00771.x;;7925396;;12190313;;10.1021/jm0201520;;12519061;;10.1021/jm020319p;;319236;;10.1021/jm00212a021;;10.1200/jco.1998.16.9.2986;;9738567;;10.1111/j.1432-1033.1997.t01-2-00527.x;;9030781;;9269999;;10.1248/cpb.47.928;;10434395;;10.1248/cpb.10.620,"Senderowicz et al., ""Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators"", National Cancer Institute, 92(5): 376-387, Mar. 1, 2000.;;Translation of WO 03/91256, (62 pages).;;Vesely et al., ""Inhibition of Cyclin-Dependent Kinases by Purine Analogues"", Eur. J. Biochem (1994), 224: 771-786.;;Kim et al., ""Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities"", Journal of Medical Chemistry, Page EST:22.3, A-W.;;Melley et al., ""Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects"", J. Med. Chem. (2003), 46(2):222-236.;;Navinson et al., ""Synthesis and Antifungal Properties of Certain 7-Aklylaminopyrazolo[1,5-alpha]pyrimidines"", J. Med. Chem. (1977), 20(2):296-299.;;Senderowicz et al., ""Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms"", Journal of Clinical Oncology (Sep. 1998), 16(9): 2986-2999.;;Meijer et al., ""Biochemical and Cellular Effects of Roscavitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5"", Eur. J. Biochem. (1997), 243:527-536.;;Bible et al., ""Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration"", Cancer Research (Aug. 15, 1997), 57: 3375-3380.;;Shiota et al., ""Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-alpha]pyrimidine Derivatives"", Chem. Pharm. Bull. (1999), 47(7):928-938.;;Yasuo Makizumi, ""Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-alpha]pyrimidines."", Chem. Pharm. Bull (1962), 10:620-626.",ACTIVE
381,US,A1,US 2004/0106624 A1,060-719-007-161-354,2004-06-03,2004,US 65377603 A,2003-09-03,US 65377603 A;;US 40802902 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"
   In its many embodiments, the present invention provides a novel class of pyrazolo1,5-apyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. 
",GUZI TIMOTHY J.;;PARUCH KAMIL;;DWYER MICHAEL P.;;DOLL RONALD J.;;GIRIJAVALLABHAN VIYYOOR M.;;ALVAREZ CARMEN S.;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O.;;DILLARD LAWRENCE W.;;TRAN VINH D.;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02);;PHARMACOPEIA DRUG DISCOVERY (2003-09-25);;PHARMACOPEIA INC (2004-05-21),https://lens.org/060-719-007-161-354,Patent Application,yes,10,9,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61P25/00;;A61P35/00;;C07D487/04,514/252.16;;514/259.3;;544/281,0,0,,,,EXPIRED
382,US,A1,US 2006/0178371 A1,059-310-417-295-639,2006-08-10,2006,US 39567606 A,2006-03-31,US 39567606 A;;US 65377603 A;;US 40802902 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",PAHRMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN M;;JAMES RAY A;;PARK HAENGSOON,MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/059-310-417-295-639,Patent Application,yes,14,5,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61K31/519;;A61K31/525;;A61K31/66;;A61K31/704;;A61K31/7048;;A61P25/00;;A61P35/00;;C07D487/04,514/252.16;;544/281;;514/259.3;;514/251;;514/109;;514/34;;514/283;;514/290;;514/27;;514/449;;514/492;;600/1;;424/649,0,0,,,,EXPIRED
383,TW,B,TW I329645 B,054-219-460-600-804,2010-09-01,2010,TW 92124336 A,2003-09-03,US 40802902 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,,SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,TIMOTHY J GUZI;;KAMIL PARUCH;;MICHAEL P DWYER;;RONALD J DOLL;;VIYYOOR MOOPIL GIRIJAVALLABHAN;;CARMEN S ALVAREZ;;TIN-YAU CHAN;;CHAD KNUTSON;;VINCENT MADISON;;THIERRY O FISCHMANN;;LAWRENCE W DILLARD;;VINH D TRAN;;ZHEN MIN HE;;RAY ANTHONY JAMES;;HAENGSOON PARK,,https://lens.org/054-219-460-600-804,Granted Patent,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,,,0,0,,,,EXPIRED
384,WO,A3,WO 2004/026229 A3,141-926-297-320-250,2004-06-17,2004,US 0327491 W,2003-09-03,US 40802902 P,2002-09-04,"PYRAZOLO[1,5-A]PYRIMIDINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS","In its many embodiments, the present invention provides a novel class of pyrazolo⏧1,5-a&rsqb;pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,,https://lens.org/141-926-297-320-250,Search Report,yes,4,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,A61P25/00;;A61P35/00;;C07D487/04,,1,1,154-728-053-610-213,10699068;;10.1093/jnci/92.5.376,"SENDEROWICZ A M ET AL: ""PRECLINICAL AND CLINICAL DEVELOPMENT OF CYCLIN-DEPENDENT KINASE MODULATORS"", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 92, no. 5, 1 March 2000 (2000-03-01), pages 376 - 387, XP001097834, ISSN: 0027-8874",PATENTED
385,EP,A1,EP 0652871 A1,166-022-706-388-113,1995-05-17,1995,EP 93917939 A,1993-07-28,GB 9301599 W;;GB 9216123 A;;GB 9216238 A;;GB 9216231 A;;GB 9220957 A;;GB 9222821 A;;GB 9222934 A;;GB 9223583 A;;GB 9226242 A;;GB 9226360 A;;GB 9301277 A;;GB 9307318 A,1992-07-29,BENZODIAZEPINE DERIVATIVES.,"PCT No. PCT/GB93/01599 Sec. 371 Date Jan. 26, 1995 Sec. 102(e) Date Jan. 26, 1995 PCT Filed Jul. 28, 1993 PCT Pub. No. WO94/03437 PCT Pub. Date Feb. 17, 1994Compounds of Formula (I), and salts and prodrugs thereof, wherein R1 represents H, optionally substituted C1-6alkyl or C3-7cycloalkyl; R2 is NHR12 or (CH2)sR13 where 5 is 0, 1 or 2; R3 represents C1-6alkyl, halo or NR6R7; R4 and R5 are H, C1-12alkyl optionally substituted by NR9R9' or an azacyclic or azabicyclic group, optionally substituted C4-9cycloalkyl, C4-9cycloalkyl C1-4alkyl, aryl, arylC1-6alkyl or azacyclic or azabicyclic groups, or R4 and R5 together form the residue of an optionally substituted azacyclic or azabicyclic ring system; x is 0, 1, 2 or 3; R12 is optionally substituted phenyl or pyridyl; R13 represents a group (A) wherein R14 is H or C1-6alkyl; R15 is H, C1-6alkyl, halo or NR6R7; and the dotted line is an optional covalent bond; are CCK and/or gastrin antagonists useful in therapy. <IMAGE> (I) <IMAGE> (A)",MERCK SHARP & DOHME,CASTRO PINEIRO JOSE LUIS;;CARLING WILLIAM ROBERT THE COL;;CHAMBERS MARK STUART PARK AVEN;;FLETCHER STEPHEN ROBERT CLIPPE;;HOBBS SARAH CHRISTINE GOODWIN;;MATASSA VICTOR GIULIO THE DUCK;;MOORE KEVIN WILLIAM WHITE HART;;SHOWELL GRAHAM ANDREW BEEHIVE;;RUSSEL MICHAEL GEOFFREY NEIL S,,https://lens.org/166-022-706-388-113,Patent Application,yes,0,0,17,34,0,C07D221/24;;C07D243/14;;C07D401/04;;C07D401/12;;C07D403/04;;C07D453/06;;C07D487/08;;C07D491/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/30;;A61P27/06;;A61P35/00;;A61P39/00;;A61P43/00;;C07D401/04;;C07D491/10;;C07D221/24;;C07D487/08;;C07D401/12;;C07D243/14;;C07D453/06;;C07D403/04,A61K31/55;;A61K31/551;;A61K31/5513;;A61P1/00;;A61P1/04;;A61P1/12;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/30;;A61P27/06;;A61P35/00;;A61P39/00;;A61P43/00;;C07D221/24;;C07D243/14;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D403/14;;C07D413/04;;C07D453/06;;C07D471/08;;C07D487/08;;C07D491/10;;C07D491/107;;C07D491/113,,0,0,,,,EXPIRED
386,EP,B1,EP 1534712 B1,185-306-885-249-904,2007-05-16,2007,EP 03796321 A,2003-09-03,US 0327491 W;;US 40802902 P,2002-09-04,"PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS",,SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,"MERCK SHARP & DOHME CORP., US (2013-05-16);;PHARMACOPEIA DRUG DISCOVERY, INC. (2005-06-08);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-16);;PHARMACOPEIA, LLC (N.D.GES.D. STAATES DELAWARE, US (2022-09-29);;PHARMACOPEIA INC, US (2013-03-19);;PHARMACOPEIA LLC, US (2013-03-19);;SCHERING CORPORATION (2005-06-08);;SCHERING CORPORATION, US (2013-03-19);;MERCK SHARP & DOHME LLC, RAHWAY, US (2022-09-29);;MERCK SHARP  DOHME CORP., RAHWAY, US (2013-05-16)",https://lens.org/185-306-885-249-904,Granted Patent,yes,4,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,C07D487/04;;A61K31/519;;A61P25/00;;A61P35/00,,1,0,,,"SENDEROWICZ A M ET AL: ""PRECLINICAL AND CLINICAL DEVELOPMENT OF CYCLIN-DEPENDENT KINASE MODULATORS"" JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 92, no. 5, 1 March 2000 (2000-03-01), pages 376-387, XP001097834 ISSN: 0027-8874",EXPIRED
387,JP,A,JP 2010180235 A,019-406-673-253-214,2010-08-19,2010,JP 2010088212 A,2010-04-06,US 40802902 P,2002-09-04,NEW PYRAZOLOPYRIMIDINE AS CYCLIN-DEPENDENT KINASE INHIBITOR,"<P>PROBLEM TO BE SOLVED: To provide a compound useful for treating, preventing or ameliorating a disease or disorder associated with a CDK. <P>SOLUTION: A novel class of a pyrazolo[1,5-α]pyrimidine compound as an inhibitor of a cyclin-dependent kinase is provided in its many embodiments. A pharmacologically acceptable salt or solvate of the compound, a method for preparing such a compound, a method for preparing a pharmacological composition comprising one or more such compounds, and a method for treating, preventing, inhibiting or restoring from one or more diseases associated with a CDK using such a compound or such a pharmacological composition are also provided. <P>COPYRIGHT: (C)2010,JPO&INPIT",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,,https://lens.org/019-406-673-253-214,Patent Application,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,C07D487/04;;A61K31/519;;A61K31/5377;;A61K45/00;;A61P1/04;;A61P1/16;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;C07D519/00,,0,0,,,,DISCONTINUED
388,DE,T2,DE 60313872 T2,169-111-897-292-117,2008-01-17,2008,DE 60313872 T,2003-09-03,US 40802902 P;;US 0327491 W,2002-09-04,"PYRAZOLOÄ1,5-AÜPYRIMIDINE ALS HEMMSTOFFE CYCLIN-ABHÄNGIGER KINASEN",,SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;ALVAREZ CARMEN S;;CHAN TIN-YAU;;KNUTSON CHAD;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON,"PHARMACOPEIA, LLC (N.D.GES.D. STAATES DELAWARE, US (2011-03-10);;SCHERING CORP., KENILWORTH, N.J., US (2011-03-10);;PHARMACOPEIA,INC. (N. D. GES. D. STAATES DELAW, US (2009-01-29)",https://lens.org/169-111-897-292-117,Granted Patent,no,0,0,32,32,0,C07D487/04;;A61P1/04;;A61P1/16;;A61P11/02;;A61P13/08;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/02;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/10;;A61P31/12;;A61P31/14;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/06;;A61P9/10;;C07D487/04;;A61K31/519;;C07D487/04,C07D487/04;;A61K31/519;;A61P25/00;;A61P35/00,,0,0,,,,EXPIRED
389,WO,A1,WO 2008/130570 A1,025-818-992-464-375,2008-10-30,2008,US 2008/0004907 W,2008-04-16,US 78884707 A,2007-04-20,NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA INC;;GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT S;;FISCHMANN THIERRY O;;KIRSCHMEIER PAUL;;BANNERJI RAJAT;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHENMIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS W,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT S;;FISCHMANN THIERRY O;;KIRSCHMEIER PAUL;;BANNERJI RAJAT;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHENMIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS W,,https://lens.org/025-818-992-464-375,Patent Application,yes,1,34,7,7,0,A61K31/33;;A61K31/4965;;A61K31/497;;A61K31/519;;A61K31/535;;A61K31/555;;A61K31/56;;A61K31/655;;A61K31/675;;A61K31/7004;;A61K45/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/33;;A61K31/555;;A61K31/56;;A61K31/4965;;A61K31/519;;A61K31/497;;A61K31/655;;A61K31/675;;A61K45/06;;A61K31/535;;A61K31/7004;;A61K33/243,A61K31/519;;A61K33/243;;A61P35/00,,0,0,,,,PENDING
390,MY,A,MY 149044 A,014-674-840-445-184,2013-07-15,2013,MY PI20050514 A,2005-02-08,US 77698804 A,2004-02-11,PYRAZOLOPYRIMIDINES - DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS,"IN ITS MANY EMBODIMENTS, THE PRESENT INVENTION PROVIDES A NOVEL CLASS OF PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS INHIBITORS OF CYCLIN DEPENDENT KINASES, METHODS OF PREPARING SUCH COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING ONE OR MORE SUCH COMPOUNDS, METHODS OF PREPARING PHARMACEUTICAL FORMULATIONS COMPRISING ONE OR MORE SUCH COMPOUNDS, AND METHODS OF TREATMENT, PREVENTION, INHIBITION, OR AMELIORATION OF ONE OR MORE DISEASES ASSOCIATED WITH THE CDKs USING SUCH COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS.",MERCK SHARP & DOHME;;PHARMACOPEIA LLC,TIMOTHY GUZI;;MADISON VINCENT S;;TIN-YAU CHAN;;VINCENT MADISON;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;MIN HE ZHEN;;ANTHONY JAMES RAY;;HAENGSOON PARK;;PARADKAR VIDYADHAR M;;KAMIL PARUCH;;WALSH HOBBS DOUGLAS;;DWYER MICHAEL P;;DOLL RONALD J;;MOOPIL GIRIJAVALLABHAN VIYYOOR;;ALAN MALLAMS;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;JOCELYN RIVERA,,https://lens.org/014-674-840-445-184,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495,,0,0,,,,ACTIVE
391,CA,A1,CA 2685278 A1,103-309-882-268-308,2008-10-30,2008,CA 2685278 A,2008-04-16,US 78884707 A;;US 2008/0004907 W,2007-04-20,NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinase s, methods of preparing such compounds, pharmaceutical compositions containi ng one or more such compounds, methods of preparing pharmaceutical formulati ons comprising one or more such compounds, and methods of treatment, prevent ion, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",PHARMACOPEIA LLC;;SCHERING CORP,MADISON VINCENT S;;PARADKAR VIDYADHAR M;;FISCHMANN THIERRY O;;JAMES RAY ANTHONY;;BANNERJI RAJAT;;ALVAREZ CARMEN S;;MALLAMS ALAN;;GIRIJAVALLABHAN VIYYOOR M;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;PARK HAENGSOON;;KIRSCHMEIER PAUL;;DOLL RONALD;;DWYER MICHAEL P;;PARUCH KAMIL;;GUZI TIMOTHY J;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHENMIN;;HOBBS DOUGLAS W,,https://lens.org/103-309-882-268-308,Patent Application,no,0,0,7,7,0,A61K31/33;;A61K31/4965;;A61K31/497;;A61K31/519;;A61K31/535;;A61K31/555;;A61K31/56;;A61K31/655;;A61K31/675;;A61K31/7004;;A61K45/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/33;;A61K31/555;;A61K31/56;;A61K31/4965;;A61K31/519;;A61K31/497;;A61K31/655;;A61K31/675;;A61K45/06;;A61K31/535;;A61K31/7004;;A61K33/243,A61K31/519;;A61K33/243;;A61P35/00,,0,0,,,,DISCONTINUED
392,CN,A,CN 116615229 A,191-771-790-450-382,2023-08-18,2023,CN 202180075160 A,2021-09-03,US 202163211337 P;;US 2021/0048976 W,2021-06-16,Method for determining biological cells,"Disclosed herein are methods for assays on biological cells, including general functional assays. Also disclosed herein are methods of barcoding the 5 '-terminus of RNA from a biological cell and methods of preparing expression constructs from barcoded RNA. Barcoded RNAs may encode proteins of interest, such as B cell receptor (BCR) heavy and light chain sequences. The expression constructs can be generated alone or in a paired/multiplexed manner, allowing for rapid re-expression of individual proteins or protein complexes.",BERKELEY LIGHTS INC,KUBIT MICHAEL ANDREW;;MAST JONATHAN D;;J J KIM;;OLSEN ANDERS GOERUP;;NG PATRICK L;;IVERSON ANTHONY L;;KUBATUR SUBRAMANYA S;;PAI VISHNU HARI THI;;PARK MINYOUNG;;DONG PEI-YAN;;BRIGGS JASON C;;INGRAM PETER N;;DALY KEVIN E;;SANSARB MICHAEL;;MCEWEN JASON M;;HIGA ADRIENNE T;;ZHOU HUA;;HU ZHIQIANG;;TENNEY JOHN A,,https://lens.org/191-771-790-450-382,Patent Application,no,0,0,1,8,0,,A61K39/00,,0,0,,,,PENDING
393,PE,A1,PE 20090156 A1,023-422-292-598-256,2009-02-26,2009,PE 2008000660 A,2008-04-16,US 78884707 A,2007-04-20,NUEVAS PIRAZOLOPIRIMIDINAS COMO INHIBIDORES DE QUINASAS DEPENDIENTES DE CICLINAS,"SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UN DERIVADO DE PIRAZOLO[1,5-a]PIRIMIDINA TAL COMO LOS COMPUESTOS DE FORMULA (i), (ii), (iii), ENTRE OTROS, LOS CUALES SON INHIBIDORES DE LA QUINASA DEPENDIENTE DE CICLINA 1 (CDK1) Y 2 (CDK2); B) UN AGENTE ANTICANCERIGENO TAL COMO CISPLATINO, DOXORUBICINA, TAXOTERE, ETOPOSIDO, IRINOTECAN, TOPOTECAN, DOCETAXEL, TAMOXIFENO, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE TUMOR DE VEJIGA, CANCER DE PULMON, DE ESOFAGO, DE OVARIO, DE PANCREAS, LEUCEMIA, FIBROSARCOMA, MELANOMA",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABAHN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT S;;FISHMANN THIERRY O;;KIRSCHMEIER PAUL;;BANNERJI RAJAT;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHENMIN;;JAMES RAY ANTHONY;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH;;PARUCH KAMIL;;PARK HAENGSOON,,https://lens.org/023-422-292-598-256,Patent Application,no,0,0,7,7,0,A61K31/33;;A61K31/4965;;A61K31/497;;A61K31/519;;A61K31/535;;A61K31/555;;A61K31/56;;A61K31/655;;A61K31/675;;A61K31/7004;;A61K45/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/33;;A61K31/555;;A61K31/56;;A61K31/4965;;A61K31/519;;A61K31/497;;A61K31/655;;A61K31/675;;A61K45/06;;A61K31/535;;A61K31/7004;;A61K33/243,A61K31/519;;A61K33/243;;A61P35/00,,0,0,,,,DISCONTINUED
394,US,B2,US 8673924 B2,128-928-389-654-133,2014-03-18,2014,US 78884707 A,2007-04-20,US 78884707 A;;US 39607906 A;;US 77698804 A;;US 65454603 A;;US 42195902 P;;US 40802702 P,2002-09-04,"Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors","In its many embodiments, the present invention provides a method of inhibiting one or more cyclin dependent kinases in a patient comprising administering to said patient a therapeutically effective amount of at least one pyrazolo[1,5-a]pyrimidine compound or a pharmaceutical composition comprising such compound, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. An example pyrazolo[1,5-a]pyrimidine compound useful in the present invention is shown below:",GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT S;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHENMIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH;;KIRSCHMEIER PAUL;;BANNERJI RAJAT;;MERCK SHARP & DOHME;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT S;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHENMIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH;;KIRSCHMEIER PAUL;;BANNERJI RAJAT,PHARMACOPEIA LLC (2009-02-20);;MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/128-928-389-654-133,Granted Patent,yes,24,10,7,7,0,A61K31/33;;A61K31/4965;;A61K31/497;;A61K31/519;;A61K31/535;;A61K31/555;;A61K31/56;;A61K31/655;;A61K31/675;;A61K31/7004;;A61K45/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/33;;A61K31/555;;A61K31/56;;A61K31/4965;;A61K31/519;;A61K31/497;;A61K31/655;;A61K31/675;;A61K45/06;;A61K31/535;;A61K31/7004;;A61K33/243,C07D487/04;;A61K31/519;;A61K33/243;;A61P35/00,514/259.3;;544/281,34,25,046-267-734-266-687;;011-413-668-915-089;;001-516-175-552-397;;006-339-151-174-691;;007-364-858-655-289;;041-549-446-256-496;;034-490-877-066-275;;018-148-915-769-649;;054-734-661-818-718;;036-585-909-845-260;;098-240-271-315-476;;055-053-624-219-364;;054-343-072-168-181;;082-783-197-553-627;;032-700-699-523-938;;107-715-444-078-941;;140-892-824-216-510;;018-866-961-404-161;;055-811-904-890-881;;026-938-695-606-093;;061-867-406-774-861;;094-016-430-416-433;;097-535-408-440-641;;080-412-881-865-322;;045-547-738-858-508,12783600;;10.1517/eoid.12.6.955.21792;;10.1517/13543784.12.6.955;;15882121;;10.1517/13543784.14.4.457;;10.1016/s0169-409x(01)00097-7;;11325474;;10.1021/ar00046a004;;10.1002/jps.2600660104;;833720;;9269999;;9371237;;10.1021/jm970493r;;10.1016/0378-5173(86)90055-4;;10.1021/ol0343616;;12688761;;10.1002/jhet.5570280520;;10.1007/bf00910055;;10.1093/oxfordjournals.jbchem.a124771;;7592534;;12190313;;10.1021/jm0201520;;11741470;;10.1021/jm015545y;;10.1248/cpb.10.620;;10.1111/j.1432-1033.1997.t01-2-00527.x;;9030781;;817024;;10.1021/jm00226a014;;319236;;10.1021/jm00212a021;;7593329;;10.1242/jcs.108.8.2897;;10.1055/s-2000-6749;;10.1200/jco.1998.16.9.2986;;9738567;;10.1248/cpb.47.928;;10434395;;10.1021/jo981423a;;10.1111/j.1432-1033.1994.00771.x;;7925396;;10.1016/j.lungcan.2013.11.020;;24388167,"Fischer, P.M.; Gianella-Borrador A.;CDK inhibitors in clinical development for the treatmentof cancer, Expert. Opin. Investig. Drugs; 2003; 12(6); 955-970.;;Fischer, P.M.; Gianella-Borradori, A.; Recent progress in the discovery and development of cyclin-dependent kinase inhibitors, I Expert. Opin. Investig. Drugs; 2005; 14(4); 457-477. I.;;Wolff, Manfred E. ""Burger's Medicinal Chemistry, 5ed, Part I"", John Wiley & Sons, 1995, pp. 975-977.;;Banker, G.S. et al, ""Modern Pharmaceutics, 3ed."", Marcel Dekker, New York, 1996, pp. 451 and 596.;;Vippagunta et. al., ""Crystalline Solids,"" Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).;;Gavezzotti, ""Are Crystal Structures Predicatable?"" Acc. Chem. Res., vol. 27, pp. 309-314 (1994).;;Anderson et al, ""Preparation of Water-Soluble Compounds Through Salt Formation"", The Practice of Medicinal Chemistry, pp. 739-754 (1996).;;Berge et al, ""Pharmaceutical Salts"", Journal of Pharmaceutical Sciences, vol. 66, No. 1, pp. 1-19 (1977).;;Bible et al., ""Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration"", Cancer Research, vol. 57, pp. 3375-3380 (Aug. 15, 1997).;;Feng et al, ""Discovery of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors Incorporating Aminopyridyl Moieties at the P1 Position"", J. Med. Chem., vol. 40, pp. 3726-3733 (1997).;;Gennaro (ed.), ""Remington's Pharmaceutical Sciences"", 18th Edition, Mack Publishing Co., Easton, Pennsylvania (1990).;;Gould, ""Salt Selection for Basic Drugs"", International J. of Pharmaceutics, vol. 33, pp. 201-217 (1986).;;Greene et al, Protective Groups in Organic Synthesis, Wiley, New York (1981).;;Gudmundsson et al, Synthesis of Novel Imidazo[1,2-alpha]pyridines with Potent Activity Against Herpesviruses, Organic Letters, vol. 5, No. 8, pp. 1369-1372 (2003).;;Gupton et al, An Alternative Preparation of the 2-Dimethylaminomethylene-1,3-bis (dimethylimmonio)propane Salt from Phosphonoacetic Acids and Some Applications in Heterocyclic Synthesis, J. Heterocyclic Chem., vol. 28, pp. 1281-1285 (1991).;;Heinisch et al, ""Synthesen und Reaktionen von Pyridazinderivaten, 3. Mitt."", Monatschefte fur Chemie, vol. 104, pp. 1372-1382 (1973).;;Higuchi et al, ""Pro-Drugs as Novel Delivery Systems"", vol. 14, A.C.S. Symposium Series (1987).;;Hosoi et al, ""Evidence for cdk5 as a Major Activity Phosphorylating Tau Protein in Porcine Brain Extract"", J. Biochem., vol. 117, pp. 741-749 (1995).;;Kim et al, ""Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities"", Journal of Medical Chemistry, vol. 45, pp. 3905-3927 (2002).;;López-Rodriguez et al, Design, Synthesis and Biological Evaluation of Novel Arachidonic Acid Derivatives as Highly Potent and Selective Endocannabinoid Transporter Inhibitors, J. Med. Chem., vol. 44, pp. 4505-4508 (2001).;;Makisumi, ""Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-alpha]pyrimidines"", Chem. Pharm. Bull., vol. 10, pp. 620-626 (1962).;;Meijer et al, ""Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5"", Eur. J. Biochem, vol. 243, pp. 527-536 (1997).;;Novinson et al, ""Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-alphas-triazines1"" Journal of Medicinal Chemistry, vol. 19, No. 4, pp. 517-520 (1976).;;Novinson et al, ""Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-alpha]pyrimidines"", J. Med. Chem., vol. 20, No. 2, pp. 296-299 (1977).;;Ongkeko et al, ""Inactivation of Cdc2 Increases the Level of Apoptosis Induced by DNA Damage"", J. Cell Sci., vol. 108, p. 2897 (1995).;;Ragan et al, ""Shock Sensitivity of a Vinamidinium Bis-Perchlorate Reagent and Demonstration of a Lower Energy Alternative"", Synlett, vol. 8, pp. 1172-1174 (2000).;;Roche, ""Bioreversible Carriers in Drug Design"", American Pharmaceutical Association and Pergamon Press (1987).;;Senderowicz et al, ""Phase I Trial of Continous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasmns"", Journal of Clinical Oncology, vol. 16, No. 9, pp. 2986-2999 (Sep. 1998).;;Shiota et al, ""Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo [1,5-alpha]pyrimidine Derivatives"", Chem. Pharm. Bull., vol. 47, No. 7, pp. 928-938 (1999).;;Shiota et al, ""Regioselective Reactions of Organozinc Reagents with 2,4-Dichloroquinoline and 5,7-Dichloropyrazolo[1,5-alpha]pyrimidine"", Journal of Organic Chemistry, vol. 64, pp. 453-457 (1999).;;Vesely et al, ""Inhibition of Cyclin-Dependent Kinases by Purine Analogues"", Eur. J. Biochem, vol. 224, pp. 771-786 (1994).;;The Orange Book (Food & Drug Administration, Washington, DC (http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, May 6, 2010.;;International Search Report for related case PCT/US2008/004907, mailed Jul. 1, 2008.;;Brief Report: Randomized Phase 2 Study of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Erlotinib in Patients with Non-Small Cell Lung Cancer, 18 pages.",ACTIVE
395,US,A1,US 2022/0262509 A1,050-968-198-177-555,2022-08-18,2022,US 202217735395 A,2022-05-03,US 202217735395 A;;US 202016820383 A;;US 201514732773 A;;US 2013/0073195 W;;US 2015/0032474 W;;US 201514599424 A;;US 201562129945 P;;US 201462006032 P,2013-12-04,WELLNESS AGGREGATOR,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.",APPLE INC,PAHWA AROON;;BEBERG ADAM L;;DAVYDOV ANTON M;;EDWARDS DYLAN ROSS;;EUN CHRISTINE;;GREER STEPHANIE;;KEEN DANIEL S;;KENNEDY ZACHERY;;LEMAY STEPHEN O;;LYNCH KEVIN;;MARIC NATALIA C;;MINJACK ZACHURY;;MISTRI AFSHAD M;;NAG DIVYA;;NOVICK GREGORY;;O'REILLY MICHAEL;;PARK DENNIS S;;PITSCHEL DONALD W;;SOLI CHRISTOPHER D;;TICKNER SIMON;;WEBER REBECCA L;;YANG LAWRENCE Y,,https://lens.org/050-968-198-177-555,Patent Application,yes,5,16,2,55,0,G06Q50/01;;G16H10/60;;G16H50/30;;G16H50/70;;G16H40/67;;G16H40/67;;G06Q50/01;;G16H80/00;;G16H50/70;;G16H50/30;;G16H10/60,G16H40/67;;G06Q50/00;;G16H10/60;;G16H50/30;;G16H50/70;;G16H80/00,,0,0,,,,PENDING
396,TW,A,TW 200904443 A,157-642-499-823-338,2009-02-01,2009,TW 97113985 A,2008-04-17,US 78884707 A,2007-04-20,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1, 5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT S;;FISCHMANN THIERRY O;;KIRSCHMEIER PAUL;;BANNERJI RAJAT;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHENMIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/157-642-499-823-338,Patent of Addition,no,0,0,7,7,0,A61K31/33;;A61K31/4965;;A61K31/497;;A61K31/519;;A61K31/535;;A61K31/555;;A61K31/56;;A61K31/655;;A61K31/675;;A61K31/7004;;A61K45/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/33;;A61K31/555;;A61K31/56;;A61K31/4965;;A61K31/519;;A61K31/497;;A61K31/655;;A61K31/675;;A61K45/06;;A61K31/535;;A61K31/7004;;A61K33/243,A61K31/519;;A61K33/243;;A61P35/00,,0,0,,,,PENDING
397,US,A1,US 2008/0050384 A1,194-603-278-305-780,2008-02-28,2008,US 78884707 A,2007-04-20,US 78884707 A;;US 39607906 A;;US 77698804 A;;US 65454603 A;;US 42195902 P;;US 40802702 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SHERING CORP AND PHARMACOPEIA,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT S;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHENMIN;;JAMES RAY A;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS W;;KIRSCHMEIER PAUL;;BANNERJI RAJAT,PHARMACOPEIA LLC (2009-02-20);;MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/194-603-278-305-780,Patent Application,yes,8,12,7,7,0,A61K31/33;;A61K31/4965;;A61K31/497;;A61K31/519;;A61K31/535;;A61K31/555;;A61K31/56;;A61K31/655;;A61K31/675;;A61K31/7004;;A61K45/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/33;;A61K31/555;;A61K31/56;;A61K31/4965;;A61K31/519;;A61K31/497;;A61K31/655;;A61K31/675;;A61K45/06;;A61K31/535;;A61K31/7004;;A61K33/243,A61K31/519;;A61K31/33;;A61K31/4965;;A61K31/497;;A61K31/535;;A61K31/56;;A61K31/655;;A61K31/675;;A61K31/7004;;A61K33/243;;A61K33/36;;A61K38/46;;A61K39/395;;A61P19/02;;A61P29/00;;A61P35/00;;A61P43/00,424/141.1;;424/130.1;;424/623;;424/649;;424/94.6;;514/151;;514/177;;514/178;;514/180;;514/182;;514/183;;514/234.5;;514/252.12;;514/255.05;;514/255.06;;514/259.3;;514/48;;514/49;;514/90,0,0,,,,EXPIRED
398,EP,A1,EP 4053767 A1,175-944-756-427-042,2022-09-07,2022,EP 22170561 A,2015-05-26,US 201462006032 P;;US 201562129945 P;;EP 19163212 A;;EP 15730890 A;;US 2015/0032474 W,2014-05-30,METHOD FOR DISPLAYING AND SELECTING DATA,,APPLE INC,YANG LAWRENCE Y;;SOLI CHRISTOPHER D;;LEMAY STEPHEN O;;MISTRI AFSHAD M;;KENEDY ZACHERY;;DAVYDOV ANTON M;;MINJACK ZACHURY;;EDWARDS DYLAN R;;BEBERG ADAM L;;PARK DENNIS S;;PAHWA AROON;;WEBER REBECCA L;;NAG DIVYA;;LYNCH KEVIN;;LYSIK STACEY;;NOVICK GREGORY;;MARIC NATALIA;;PITSCHEL DONALD W;;KEEN DANIEL S;;FOSTER JAMES H;;GREER STEPHANIE;;TICKNER SIMON;;EUN CHRISTINE;;O'REILLY MICHAEL,,https://lens.org/175-944-756-427-042,Patent Application,yes,30,0,27,55,0,G06F1/1694;;G06F3/0482;;G06F2200/1637;;G06F3/04886;;G16H50/30;;G16H10/60;;G16H50/70;;G06Q10/06;;G06Q50/22;;G16H50/30;;G16H10/60,G06Q10/06;;G06F1/16;;G06F3/048;;G06F3/0482;;G06F3/0488;;G06Q50/26;;G06Q50/32;;G16H10/60;;G16H50/30;;G16H50/70,,1,0,,,"""iPhone User Guide For iOS 7.1 Software"", 10 March 2014 (2014-03-10), pages 1 - 162, XP055207043, Retrieved from the Internet <URL:https://manuals.info.apple.com/en_US/iphone_ios7_user_guide.pdf> [retrieved on 20150810]",PENDING
399,EP,A1,EP 4123657 A1,133-223-068-385-367,2023-01-25,2023,EP 22194355 A,2013-12-04,EP 22194355 A;;EP 13811085 A;;US 2013/0073195 W,2013-12-04,PRESENTATION OF PHYSIOLOGICAL DATA,"The present disclosure relates to aggregating and sharing wellness data. The wellness data can be received by a user device from any number of sensors external or internal to the user device, from a user manually entering the wellness data, or from other users or entities. The user device can securely store the wellness data on the user device and transmit the wellness data to be stored on a remote database. A user of the device can share some or all of the wellness data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's wellness data in an aggregated view of different types of wellness data. Wellness data of other users can also be viewed if authorizations from those users have been received.
",APPLE INC,SOLI CHRISTOPHER D;;DAVYDOV ANTON M;;KENNEDY ZACHERY;;MINJACK ZACHERY;;PARK DENNIS S;;EDWARDS DYLAN R;;BEBERG ADAM L;;YANG LAWRENCE Y;;EUN CHRISTINE;;GREER STEPHANIE;;KEEN DANIEL S;;LEMAY STEPHEN O;;LYNCH KEVIN;;MARIC NATALIA;;NAG DIVYA;;NOVICK GREGORY;;O'REILLY MICHAEL;;PAHWA AROON;;PITSCHEL DONALD W;;MISTRI AFSHAD M;;TICKNER SIMON;;WEBER REBECCA L;;BLAHNIK JAY J;;FOSTER JAMES H;;LYSIK STACEY,,https://lens.org/133-223-068-385-367,Patent Application,yes,3,0,17,55,0,G16H10/60;;G16H40/67;;G16H10/60;;G16H80/00;;G16H40/20;;G16H10/60;;G16H40/67,G16H10/60,,0,0,,,,PENDING
400,JP,A,JP 2023100666 A,108-910-490-629-724,2023-07-19,2023,JP 2023065859 A,2023-04-13,JP 2023065859 A;;JP 2021131726 A;;JP 2020000492 A,2020-01-06,PRESENTATION OF PHYSIOLOGICAL DATA,"To provide processing for aggregating and sharing health data.SOLUTION: Health data may be received by a user device from any number of external or internal sensors of the user device, from a user manually entering wellness data, or from other users or entities. The user device may securely store the health data on the user device and transmit the health data to be stored on a remote database. A user of the device may share some or all of the health data with friends, relatives, caregivers, healthcare providers, or the like. The user device can further display a user's health data in an aggregated view of different types of health data. Health data of other users may also be perused when authorizations from those users have been received.SELECTED DRAWING: None",APPLE INC,CHRISTOPHER D SOLI;;LAWRENCE Y YANG;;STEPHEN O LEMAY;;AFSHAD M MISTRI;;ZACHERY KENNEDY;;ANTON M DAVIDOFF;;ZACHURY MINJACK;;DYLAN R EDWARDS;;ADAM L BEBERG;;DENNIS S PARK;;AROON PAHWA;;REBECCA L WEBER;;DIVYA NAG;;KEVIN LYNCH;;STACEY LYSIK;;GREGORY NOVICK;;NATALIA MARIC;;DONALD W PITSCHEL;;DANIEL S KEEN;;JAMES H FOSTER;;STEPHANIE GREER;;JAY J BLAHNIK;;CHRISTINE EUN;;MICHAEL O'REILLY;;GUY L TRIBBLE;;TODD K WHITEHURST,,https://lens.org/108-910-490-629-724,Patent Application,no,0,0,5,9,0,,A61B5/00;;G16H10/60,,0,0,,,,PENDING
401,MY,A,MY 138201 A,093-064-781-736-914,2009-05-29,2009,MY PI20033337 A,2003-09-03,US 40802702 P;;US 42195902 P,2002-09-04,NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS,"IN ITS MANY EMBODIMENTS, THE PRESENT INVENTION PROVIDES A NOVEL CLASS OF PYRAZOLO[1 ,5-A]PYRIMIDINE COMPOUNDS AS INHIBITORS OF CYCLIN DEPENDENT KINASES, METHODS OF PREPARING SUCH COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING ONE OR MORE SUCH COMPOUNDS, METHODS OF PREPARING PHARMACEUTICAL FORMULATIONS COMPRISING ONE OR MORE SUCH COMPOUNDS, AND METHODS OF TREATMENT, PREVENTION, INHIBITION, OR AMELIORATION OF ONE OR MORE DISEASES ASSOCIATED WITH THE CDKS USING SUCH COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,TIMOTHY GUZI;;TIN-YAU CHAN;;VINCENT MADISON;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;MIN HE ZHEN;;ANTHONY JAMES RAY;;HAENGSOON PARK;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH;;KAMIL PARUCH;;DWYER MICHAEL P;;DOLL RONALD J;;MOOPIL GIRIJAVALLABHAN VIYYOOR;;ALAN MALLAMS;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;JOCELYN RIVERA,,https://lens.org/093-064-781-736-914,Granted Patent,no,4,0,18,52,0,A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04,,0,0,,,,EXPIRED
402,EC,A,EC SP066763 A,197-116-138-865-98X,2006-11-16,2006,EC SP066763 A,2006-08-09,US 77698804 A;;US 65454603 A;;US 42195902 P;;US 40802702 P,2002-09-04,PIRAZOLOPIRIMIDINAS NOVEDOSAS COMO INHIBIDORES DE QUINASA CICLINA-DEPENDIENTES,"En sus numerosas realizaciones, la presente invención provee una clase novedosa de compuestos derivados de pirazolo[1,5-a]pirimidina como inhibidores de quinasas ciclina-dependientes, métodos para preparar tales compuestos, composiciones farmacéuticas que contienen uno o más de tales compuestos, métodos para preparar formulaciones farmacéuticas que comprenden uno o más de tales compuestos y métodos de tratamiento, prevención, inhibición o alivio de una o más enfermedades asociadas con las CDKs usando tales compuestos o composiciones farmacéuticas.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,CHAN TIN-YAU;;HOBBS DOUGLAS W;;GUZI TIMOTHY J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;KEERTIKAR KARTIK M;;JAMES RAY A;;DWYER MICHAEL;;PARUCH KAMIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;RIVERA JOCELYN;;MADISON VINCENT;;FISCHMANN THIERRY O;;DOLL RONALD J;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;PARK HAENGSOON;;PARADKAR VIDYADHAR M,,https://lens.org/197-116-138-865-98X,Patent Application,no,0,0,5,52,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P35/04;;C07D487/04,A61K31/495;;A61P35/00;;C07D487/04,,0,0,,,,PENDING
403,CN,B,CN 1946725 B,012-674-843-720-038,2011-02-23,2011,CN 200580012293 A,2005-02-08,US 2005/0003859 W;;US 77698804 A,2004-02-11,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of oneor more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,KAMIL PARUCH;;VINCENT MADISON;;DWYER MICHAEL P;;MIN HEZHEN;;DILLARD LAWRENCE W;;ANTHONY JAMES RAY;;GUZI TIMOTHY J;;JOCELYN RIVERA;;TIN-YAU CHAN;;DOLL RONALD J;;ALVAREZ CARMEN S;;ALAN MALLAMS;;KEERTIKAR KARTIK M;;GIRIJAVALLABHAN VIYYOOR M;;TRAN VINH D;;PARADKAR VIDYADHAR M;;WALSH HOBBS DOUGLAS;;FISCHMANN THIERRY O;;HAENGSOON PARK,MSD CORP. (2012-12-19),https://lens.org/012-674-843-720-038,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61P35/00,,0,0,,,,ACTIVE
404,BR,B8,BR PI0314001 B8,183-264-239-045-418,2021-05-25,2021,BR 0314001 A,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",MERCK SHARP & DOHME;;PHARMACOPEIA DRUG DISCOVERY INC;;PHARMACOPEIA LLC;;SCHERING CORP,MICHAEL P DWYER;;ALAN MALLAMS;;CARMEN S ALVAREZ;;DOUGLAS WALSH HOBBS;;HAENGSOON PARK;;JOCELYN RIVERA;;KAMIL PARUCH;;KARTIK M KEERTIKAR;;LAWRENCE W DILLARD;;RAY ANTHONY JAMES;;RONALD J DOLL;;THIERRY O FISCHMANN;;TIMOTHY GUZI;;TIN-YAU CHAN;;VIDYADHAR M PARADKAR;;VINCENT MADISON;;VINH D TRAN;;VIYYOOR MOOPIL GIRIJAVALLABHAN;;ZHEN MIN HE,"PHARMACOPEIA LLC (US) ; MERCK SHARP AND DOHME LLC (US) (2023-04-25);;MERCK SHARP AND DOHME CORP. (US) ; PHARMACOPEIA LLC (US) (2018-07-24);;PHARMACOPEIA DRUG DISCOVERY,INC. (US) ; MERCK SHAR (2018-07-10);;MERCK SHARP AND DOHME CORP. (US) ; PHARMACOPEIA LL (2018-07-24);;PHARMACOPEIA DRUG DISCOVERY,INC. (US) , MERCK SHAR (2013-10-22)",https://lens.org/183-264-239-045-418,Amended Patent,no,0,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04;;A61K31/519;;A61P31/00;;A61P35/00,,0,0,,,,EXPIRED
405,BR,B1,BR PI0314001 B1,078-772-466-916-169,2018-10-23,2018,BR 0314001 A,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",MERCK SHARP & DOHME;;PHARMACOPEIA DRUG DISCOVERY INC;;PHARMACOPEIA LLC;;SCHERING CORP,ALAN MALLAMS;;CARMEN S ALVAREZ;;DOUGLAS WALSH HOBBS;;HAENGSOON PARK;;JOCELYN RIVERA;;KAMIL PARUCH;;KARTIK M KEERTIKAR;;LAWRENCE W DILLARD;;MICHAEL P DWYER;;RAY ANTHONY JAMES;;RONALD J DOLL;;THIERRY O FISCHMANN;;TIMOTHY GUZI;;TIN-YAU CHAN;;VIDYADHAR M PARADKAR;;VINCENT MADISON;;VINH D TRAN;;VIYYOOR MOOPIL GIRIJAVALLABHAN;;ZHEN MIN HE,"PHARMACOPEIA LLC (US) ; MERCK SHARP AND DOHME LLC (US) (2023-04-25);;MERCK SHARP AND DOHME CORP. (US) ; PHARMACOPEIA LLC (US) (2018-07-24);;PHARMACOPEIA DRUG DISCOVERY,INC. (US) ; MERCK SHAR (2018-07-10);;MERCK SHARP AND DOHME CORP. (US) ; PHARMACOPEIA LL (2018-07-24);;PHARMACOPEIA DRUG DISCOVERY,INC. (US) , MERCK SHAR (2013-10-22)",https://lens.org/078-772-466-916-169,Granted Patent,no,0,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04;;A61K31/519;;A61P31/00;;A61P35/00,,0,0,,,,EXPIRED
406,BR,A,BR 0314001 A,103-531-396-429-871,2005-07-05,2005,BR 0314001 A,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,Pirazolopirimidinas como inibidores de cinase dependente de ciclina,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,"PHARMACOPEIA LLC (US) ; MERCK SHARP AND DOHME LLC (US) (2023-04-25);;MERCK SHARP AND DOHME CORP. (US) ; PHARMACOPEIA LLC (US) (2018-07-24);;PHARMACOPEIA DRUG DISCOVERY,INC. (US) ; MERCK SHAR (2018-07-10);;MERCK SHARP AND DOHME CORP. (US) ; PHARMACOPEIA LL (2018-07-24);;PHARMACOPEIA DRUG DISCOVERY,INC. (US) , MERCK SHAR (2013-10-22)",https://lens.org/103-531-396-429-871,Patent Application,no,0,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04,,0,0,,,,EXPIRED
407,EC,A,EC SP11005642 A,183-578-040-499-270,2011-10-31,2011,EC SP11005642 A,2011-09-01,US 40802702 P;;US 42195902 P,2002-09-04,NUEVOS PIRAZOLOPIRIMIDINAS COMO INHIBIDORES DE QUINASA DEPENDIENTES DE CICLINAS,"En sus muchas realizaciones, la presente invención provee una nueva clase de compuestos de pirazolo [1,5-a] pirimidina como inhibidores de las quinasas dependientes de ciclina, métodos para preparar dichos compuestos, composiciones farmacéuticas que contienen uno o más de dichos compuestos, métodos para la preparación de formulaciones farmacéuticas que comprenden uno o más de dichos compuestos, y métodos para el tratamiento, prevención, inhibición, o mejoría de una o más enfermedades asociadas con las CDK usando dichos compuestos o composiciones farmacéuticas.",SCHERING CORP;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;KEERTIKAR KARTIK M;;JAMES RAY A;;DWYER MICHAEL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;RIVERA JOCELYN;;CHAN TIN YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHENMIN;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;PARUCH KAMIL;;HOBBS DOUGLAS WALSH,,https://lens.org/183-578-040-499-270,Patent Application,no,0,0,18,52,0,A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/519,,0,0,,,,PENDING
408,HK,A1,HK 1071756 A1,057-184-710-712-828,2005-07-29,2005,HK 05104852 A,2005-06-08,US 0327555 W;;US 40802702 P;;US 42195902 P,2002-09-04,PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;DWYER MICHAEL P;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/057-184-710-712-828,Patent Application,no,0,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,A61K/;;C07D/;;C07D487/04,,0,0,,,,DISCONTINUED
409,HR,T1,HR P20110245 T1,108-177-617-946-550,2011-04-30,2011,HR P20110245 T,2011-04-04,US 77698804 A;;US 2005/0003859 W,2004-02-11,PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS,"Spoj, naznačen time što ima formulu: ili njegova farmaceutski prihvatljiva sol ili solvat. Patent sadrži još 21 patentni zahtjev.",SCHERING CORP;;PHARMACOPEIA,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/108-177-617-946-550,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61P35/00,,0,0,,,,ACTIVE
410,CA,C,CA 2555345 C,174-873-930-855-690,2010-01-26,2010,CA 2555345 A,2005-02-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/174-873-930-855-690,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61P35/00,,0,0,,,,ACTIVE
411,TW,A,TW 200410973 A,004-195-304-938-814,2004-07-01,2004,TW 92124347 A,2003-09-03,US 40802702 P;;US 42195902 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo [1,5-a] pyrimidine compounds as inhibitors of cydin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;ALAN MALLAMS;;CARMEN S ALVAREZ;;KARTIK M KEERTIKAR;;JOCELYN RIVERA;;TIN-YAU CHAN;;VINCENT MADISON;;THIERRY O FISCHMANN;;LAWRENCE W DILLARD;;VINH D TRAN;;ZHEN MIN HE;;RAY ANTHONY JAMES;;HAENGSOON PARK;;VIDYADHAR M PARADKAR;;DOUGLAS WALSH HOBBS,,https://lens.org/004-195-304-938-814,Patent of Addition,no,0,0,18,52,0,A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04,,0,0,,,,EXPIRED
412,SI,T1,SI 1537116 T1,008-908-763-658-769,2010-09-30,2010,SI 200331849 T,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W;;EP 03794592 A,2002-09-04,PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES,,SCHERING CORP;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/008-908-763-658-769,Granted Patent,no,0,0,3,52,0,,C07D487/00;;A61K31/00,,0,0,,,,EXPIRED
413,EP,A2,EP 1720882 A2,040-935-183-431-174,2006-11-15,2006,EP 05722809 A,2005-02-08,US 2005/0003859 W;;US 77698804 A,2004-02-11,PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS,,SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,"MERCK SHARP & DOHME LLC, US (2023-01-17);;PHARMACOPEIA, LLC; US (2022-10-18);;PHARMACOPEIA, LLC (2012-07-13);;MERCK SHARP & DOHME LLC (2023-03-01);;PHARMACOPEIA, LLC, SAN DIEGO, CA, US (2022-10-07);;MERCK SHARP & DOHME LLC, RAHWAY, US (2022-09-29);;MERCK SHARP & DOHME CORP. (2012-10-24);;PHARMACOPEIA, INC. (2008-09-24);;PHARMACOPEIA, LLC, SAN DIEGO, US (2022-09-29);;MERCK SHARP & DOHME CORP., RAHWAY, NJ, US (2012-09-27);;MERCK SHARP & DOHME CORP., US (2013-05-16);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-16);;MERCK SHARP & DOHME CORP.; US (2012-12-18);;MERCK SHARP & DOHME LLC; US (2022-12-14);;PHARMACOPEIA, LLC, US (2023-01-17);;SCHERING CORPORATION (2009-12-23);;MERCK SHARP & DOHME LLC, RAHWAY, NJ, US (2022-10-07);;SCHERING CORPORATION, US (2013-03-19)",https://lens.org/040-935-183-431-174,Patent Application,yes,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61P35/00,,0,0,,,,ACTIVE
414,WO,A2,WO 2005/077954 A2,099-914-408-542-317,2005-08-25,2005,US 2005/0003859 W,2005-02-08,US 77698804 A,2004-02-11,PYRAZOLOPYRIMIDINES-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides pyrazolo⏧1,5-a&rsqb;pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY;;GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/099-914-408-542-317,Patent Application,yes,0,66,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K31/495;;C07D487/04,,0,0,,,,PENDING
415,PT,E,PT 1537116 E,179-417-817-880-248,2010-09-03,2010,PT 03794592 T,2003-09-03,US 40802702 P;;US 42195902 P,2002-09-04,PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES,,SCHERING CORP;;PHARMACOPEIA LLC,DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;CHAN TIN-YAU;;GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/179-417-817-880-248,Granted Patent,no,0,0,18,52,0,A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/519,,0,0,,,,EXPIRED
416,DE,D1,DE 60332846 D1,003-342-974-797-521,2010-07-15,2010,DE 60332846 T,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,ZUR BEHANDLUNG VON KREBSERKRANKUNGEN GEEIGNETE PYRAZOLOPYRIMIDINE,,PHARMACOPEIA LLC;;SCHERING CORP,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/003-342-974-797-521,Granted Patent,no,0,0,18,52,0,A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/519,,0,0,,,,EXPIRED
417,WO,A3,WO 2005/077954 A3,012-535-180-516-57X,2005-10-13,2005,US 2005/0003859 W,2005-02-08,US 77698804 A,2004-02-11,PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides pyrazolo⏧1,5-a&rsqb;pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY;;GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/012-535-180-516-57X,Search Report,yes,7,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K31/495;;C07D487/04,,0,0,,,,PENDING
418,DK,T3,DK 1720882 T3,164-746-119-048-844,2011-04-11,2011,DK 05722809 T,2005-02-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,Pyrazolopyrimidin-derivater som cyclin-afhængige kinaseinhibitorer,,SCHERING CORP;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/164-746-119-048-844,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61P35/00,,0,0,,,,ACTIVE
419,US,B2,US 11423095 B2,188-480-411-853-280,2022-08-23,2022,US 202017011928 A,2020-09-03,US 202017011928 A,2020-09-03,Prediction-based action-recommendations in a cloud system,"Methods, systems, and computer storage media for providing action-recommendations (e.g., save action, collaboration action, and upload action) using cloud system operations in a cloud system. For example, action-recommendations are predicted using usage data of applications and communicated to a user (e.g., via a prompt) such that the user elects to perform or not perform the action-recommendation. In operation, usage data for an application and an action-recommendation profile are accessed. Determining that an action-recommendation should be generated is based on the usage data and the action-recommendation profile. The determination is further based on action scores and thresholds (e.g., save action, collaboration action, upload action). When the action scores meet certain thresholds, the action-recommendation is generated as a save-action-recommendation, a collaboration-action-recommendation, or an upload-action-recommendation. Based on generating the action-recommendation, an action recommendation interface element (e.g., an action prompt or action dialog) is generated to perform a corresponding action.",MICROSOFT TECHNOLOGY LICENSING LLC,SAEZ WILLIAM N;;GUPTA PRAMOD KUMAR;;VARSHNEY SIDHIKA;;YANG JICHEN;;HERZOG JOE A;;SANTOS MICHAEL M;;RICHARDSON RANSOM L;;LI YIMENG;;PUNJABI YASH RAVI;;GILL TEJPRAKASH S;;CHILDERS TRACY A;;CHEN SIQING;;HU RUI;;PARK JINNIE;;SCHERRER ELIJAH JOHN;;LI RAYMOND C;;KARMY TACLA JUAN ANTONIO;;NAKHRE PRIYA TUSHAR;;BASIA ANSHUL;;MILIĆEVIĆ DAVID,MICROSOFT TECHNOLOGY LICENSING LLC (2020-09-02),https://lens.org/188-480-411-853-280,Granted Patent,yes,8,0,2,2,0,G06F16/93;;G06F16/9035;;G06F16/335;;H04L67/10;;H04L67/30;;H04L67/06;;H04L67/535;;G06N20/00;;G06F16/93;;G06F9/5072;;G06N5/04;;H04L67/306;;H04L67/535,G06F16/93;;G06F9/50;;G06N5/04;;H04L67/306;;H04L67/50,,6,4,109-914-857-760-505;;022-901-283-556-232;;080-230-349-435-855;;069-058-869-041-948,10.1145/1998076.1998121;;10.1007/s10489-017-1086-x;;10.1002/meet.2011.14504801025;;24991920;;pmc4081126;;10.1371/journal.pone.0101214,"Chen, et al., “CollabSeer: A Search Engine for Collaboration Discovery”, In Proceedings of the 11th annual international ACM/IEEE joint conference on Digital libraries, Jun. 13, 2011, 10 Pages.;;Chuan, et al., “Link prediction in co-authorship networks based on hybrid content similarity metric”, In Journal of Applied Intelligence, vol. 48, Dec. 5, 2017, 17 Pages.;;Lee, et al., “Recommending Future Collaborators using Social Features and MeSH terms”, In Proceedings of the American Society for Information Science and Technology vol. 48, Issue 1, Oct. 9, 2011. 9 Pages.;;Shuvayan, Das, “Beginners Guide to learn about Content Based Recommender”, Retrieved from: https://www.analyticsvidhya.com/blog/2015/08/beginners-guide-learn-content-based-recommender-systems/, Aug. 11, 2015, 35 Pages.;;Night, Jack, “Overview of co-authoring in SharePoint Server”, Retrieved from: https://docs.microsoft.com/en-us/sharepoint/governance/co-authoring-overview, Mar. 7, 2018, 6 Pages.;;Yu, et al., “Predicting Co-Author Relationship in Medical Co-Authorship Networks”, In Journal of Plos One, vol. 09, Issue 7, Jul. 3, 2014, pp. 1-7.",ACTIVE
420,TW,A,TW 200528112 A,190-152-170-616-493,2005-09-01,2005,TW 94104016 A,2005-02-05,US 77698804 A,2004-02-11,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/190-152-170-616-493,Patent of Addition,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K31/5377;;A61K31/495;;A61K31/519;;C07D487/04,,0,0,,,,ACTIVE
421,BR,B1,BR PI0507644 B1,039-019-129-485-703,2021-01-26,2021,BR PI0507644 A,2005-02-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,pirazolopirimidinas como inibidores de cinase dependente de ciclina,"pirazolopirimidinas como inibidores de cinase dependente de ciclina. em suas muitas modalidades, a presente invenção fornece uma classe nova de compostos de pirazol[1,5-a]pirimidina como inibidores de cinases dependentes de ciclina, métodos de preparar tais compostos, composições farmacêuticas contendo um ou mais tais compostos, métodos de preparar formulações farmacêuticas compreendendo um ou mais tais compostos e métodos de tratamento, prevenção, inibição ou melhora de uma ou mais doenças associadas às cdks usando tais compostos ou composições farmacêuticas.",MERCK SHARP & DOHME;;PHARMACOPEIA DRUG DISCOVERY INC;;PHARMACOPEIA LLC;;SCHERING CORP,ALAN MALLAMS;;CARMEN S ALVAREZ;;DOUGLAS WALSH HOBBS;;HAENGSOON PARK;;JOCELYN RIVERA;;KAMIL PARUCH;;KARTIK M KEERTIKAR;;LAWRENCE W DILLARD;;MICHAEL P DWYER;;RAY ANTHONY JAMES;;RONALD J DOLL;;THIERRY O FISCHMANN;;TIMOTHY J GUZI;;TIN-YAU CHAN;;VIDYADHAR M PARADKAR;;VINCENT MADISON;;VINH D TRAN;;VIYYOOR MOOPIL GIRIJAVALLABHAN;;ZHEN MIN HE,"PHARMACOPEIA DRUG DISCOVERY, INC. (US) , MERCK SHA (2013-10-22);;PHARMACOPEIA, LLC (US) ; MERCK SHARP AND DOHME LLC (US) (2023-04-25);;MERCK SHARP AND DOHME CORP. (US) , PHARMACOPEIA, L (2014-05-20)",https://lens.org/039-019-129-485-703,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K31/495;;A61K35/00;;C07D487/04,,0,0,,,,ACTIVE
422,CA,A1,CA 2497440 A1,033-947-887-667-032,2004-03-18,2004,CA 2497440 A,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides a novel class of pyrazolo~1,5-a~pyrimidine compounds as inhibitors of cyclin dependent kinase s, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;DWYER MICHAEL P;;MALLAMS ALAN;;HOBBS DOUGLAS WALSH;;PARUCH KAMIL;;PARADKAR VIDYADHAR M;;GUZI TIMOTHY J;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;CHAN TIN-YAU;;RIVERA JOCELYN;;ALVAREZ CARMEN S;;TRAN VINH D;;KEERTIKAR KARTIK M;;PARK HAENGSOON;;JAMES RAY ANTHONY;;HE ZHEN MIN,,https://lens.org/033-947-887-667-032,Patent Application,no,0,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04,,0,0,,,,EXPIRED
423,PL,A1,PL 375697 A1,053-895-700-671-618,2005-12-12,2005,PL 37569703 A,2003-09-03,US 40802702 P;;US 42195902 P,2002-09-04,PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS,"W wielu wykonaniach niniejszy wynalazek dostarcza nowej klasy pirazolo[1,5-a]pirymidynowych związków jako inhibitorów zależnych od cykliny kinaz, sposobów wytwarzania takich związków, farmaceutycznych kompozycji zawierających jeden lub więcej taki związek, sposobów wytwarzania farmaceutycznych preparatów zawierających jeden lub więcej taki związek i sposobów leczenia, zapobiegania, hamowania lub łagodzenia jednej lub więcej chorób związanych z CDK z użyciem takich związków albo farmaceutycznych kompozycji.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/053-895-700-671-618,Patent Application,no,0,0,18,52,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00,C07D487/04,,0,0,,,,EXPIRED
424,WO,A1,WO 2004/022561 A1,156-897-113-491-309,2004-03-18,2004,US 0327555 W,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/156-897-113-491-309,Patent Application,yes,5,194,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04,,1,1,024-579-812-539-076,12519061;;10.1021/jm020319p,"Y. METTEY ET AL., J. MED. CHEM., vol. 46, 2003, pages 222 - 236",PATENTED
425,ZA,B,ZA 200606573 B,022-420-351-632-94X,2009-10-28,2009,ZA 200606573 A,2006-08-07,US 77698804 A,2004-02-11,Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors,,SCHERING CORP PHARMACOPEIA DRU,GUZI TIMOTHY J;;DWYER MICHAEL P;;MOOPIL GIRIJAVALLABHAN VIYYOOR;;ALVAREZ CARMEN S;;JOCELYN RIVERA;;VINCENT MADISON;;DILLARD LAWRENCE W;;MIN HE ZHEN;;HAENGSOON PARK;;WALSH HOBBS DOUGLAS;;KAMIL PARUCH;;DOLL RONALD J;;ALAN MALLAMS;;KEERTIKAR KARTIK M;;TIN-YAU CHAN;;FISCHMANN THIERRY O;;THAN VINH D;;ANTHONY JAMES RAY;;PARADKAR VIDYADHAR M,,https://lens.org/022-420-351-632-94X,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K/;;A61K31/495;;A61P/;;C07D/;;C07D487/04,,0,0,,,,ACTIVE
426,AU,A1,AU 2003/263071 A1,022-995-987-747-504,2004-03-29,2004,AU 2003/263071 A,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP,MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH;;GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU,"MERCK SHARP & DOHME LLC (2022-12-01);;PHARMACOPEIA, INC.; SCHERING CORPORATION (2007-09-13);;PHARMACOPEIA, INC. (2022-12-01)",https://lens.org/022-995-987-747-504,Patent Application,no,0,3,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04,,0,0,,,,EXPIRED
427,AU,B2,AU 2003/263071 B2,093-584-791-395-817,2007-03-15,2007,AU 2003/263071 A,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,Pyrazolopyrimidines as cyclin-dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",MERCK SHARP & DOHME LLC;;PHARMACOPEIA INC,RIVERA JOCELYN;;DWYER MICHAEL P;;JAMES RAY ANTHONY;;FISCHMANN THIERRY O;;CHAN TIN-YAU;;HE ZHEN MIN;;HOBBS DOUGLAS WALSH;;PARUCH KAMIL;;MALLAMS ALAN;;MADISON VINCENT;;DOLL RONALD J;;TRAN VINH D;;GUZI TIMOTHY J;;PARADKAR VIDYADHAR M;;ALVAREX CARMEN S;;KEERTIKAR KARTIK M;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;PARK HAENGSOON;;DILLARD LAWRENCE W,"MERCK SHARP & DOHME LLC (2022-12-01);;PHARMACOPEIA, INC.; SCHERING CORPORATION (2007-09-13);;PHARMACOPEIA, INC. (2022-12-01)",https://lens.org/093-584-791-395-817,Granted Patent,no,1,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04,,2,0,,,Reg No. 104933-64-4;;Reg No. 167371-46-2,EXPIRED
428,DK,T3,DK 1537116 T3,124-949-999-890-894,2010-09-27,2010,DK 03794592 T,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,Pyrazolopyrimidiner egnede til behandling af cancersygdomme,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA LLC,CHAN TIN-YAU;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;GUZI TIMOTHY J;;PARUCH KAMIL;;MADISON VINCENT;;HOBBS DOUGLAS WALSH,,https://lens.org/124-949-999-890-894,Granted Patent,no,0,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04;;A61K31/519,,0,0,,,,EXPIRED
429,NZ,A,NZ 539165 A,013-387-397-023-607,2008-03-28,2008,NZ 53916503 A,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,Pyrazolopyrimidines as cyclin-dependent kinase inhibitors,"Disclosed are pyrazolo[1,5-a]pyrimidines of formula I wherein the substituents are as defined in the specification. Compounds of the type disclosed are protein kinase inhibitors (for example MAPK/ERK and GSK3beta) useful in the treatment of diseases such as cancer, inflammation, arthritis, viral disease, neurodegenerative diseases, cardiovascular diseases and fungal diseases.",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,"PHARMACOPEIA, LLC, NZ (2022-10-13);;PHARMACOPEIA, INC., US (2007-11-30);;PHARMACOPEIA, LLC, US (2010-08-27);;MERCK SHARP +  DOHME LLC, US (2022-10-13);;SCHERING CORPORATION, US (2010-08-27)",https://lens.org/013-387-397-023-607,Patent Application,no,0,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04,,0,0,,,,DISCONTINUED
430,CA,C,CA 2497440 C,053-936-982-889-735,2011-03-22,2011,CA 2497440 A,2003-09-03,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides a novel class of pyrazolo~1,5-a~pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/053-936-982-889-735,Granted Patent,no,0,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04;;A61K31/519;;C07D231/00;;C07D239/00,,0,0,,,,EXPIRED
431,ES,T3,ES 2359410 T3,121-236-091-037-907,2011-05-23,2011,ES 05722809 T,2005-02-08,US 77698804 A,2004-02-11,DERIVADOS DE PIRAZOLOPIRIMIDINA COMO INHIBIDORES DE QUINASAS CICLINA-DEPENDIENTES.,Un compuesto de la fórmula: **Fórmula** o una sal o solvato farmacéuticamente aceptable del mismo.,SCHERING CORP;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/121-236-091-037-907,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61P35/00,,0,0,,,,ACTIVE
432,DE,D1,DE 602005025733 D1,140-225-869-903-462,2011-02-17,2011,DE 602005025733 T,2005-02-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,PYRAZOLOPYRIMIDINDERIVATE ALS INHIBITOREN DER CYCLINABHÄNGIGEN KINASE,,PHARMACOPEIA LLC;;SCHERING CORP,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/140-225-869-903-462,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61P35/00,,0,0,,,,ACTIVE
433,US,A1,US 2022/0067106 A1,184-422-261-707-702,2022-03-03,2022,US 202017011928 A,2020-09-03,US 202017011928 A,2020-09-03,PREDICTION-BASED ACTION-RECOMMENDATIONS IN A CLOUD SYSTEM,"Methods, systems, and computer storage media for providing action-recommendations (e.g., save action, collaboration action, and upload action) using cloud system operations in a cloud system. For example, action-recommendations are predicted using usage data of applications and communicated to a user (e.g., via a prompt) such that the user elects to perform or not perform the action-recommendation. In operation, usage data for an application and an action-recommendation profile are accessed. Determining that an action-recommendation should be generated is based on the usage data and the action-recommendation profile. The determination is further based on action scores and thresholds (e.g., save action, collaboration action, upload action). When the action scores meet certain thresholds, the action-recommendation is generated as a save-action-recommendation, a collaboration-action-recommendation, or an upload-action-recommendation. Based on generating the action-recommendation, an action recommendation interface element (e.g., an action prompt or action dialog) is generated to perform a corresponding action.",MICROSOFT TECHNOLOGY LICENSING LLC,SAEZ WILLIAM N;;GUPTA PRAMOD KUMAR;;VARSHNEY SIDHIKA;;YANG JICHEN;;HERZOG JOE A;;SANTOS MICHAEL M;;RICHARDSON RANSOM L;;LI YIMENG;;PUNJABI YASH RAVI;;GILL TEJPRAKASH S;;CHILDERS TRACY A;;CHEN SIQING;;HU RUI;;PARK JINNIE;;SCHERRER ELIJAH JOHN;;LI RAYMOND C;;KARMY TACLA JUAN ANTONIO;;NAKHRE PRIYA TUSHAR;;BASIA ANSHUL;;MILICEVIC DAVID,MICROSOFT TECHNOLOGY LICENSING LLC (2020-09-02),https://lens.org/184-422-261-707-702,Patent Application,yes,0,11,2,2,0,G06F16/93;;G06F16/9035;;G06F16/335;;H04L67/10;;H04L67/30;;H04L67/06;;H04L67/535;;G06N20/00;;G06F16/93;;G06F9/5072;;G06N5/04;;H04L67/306;;H04L67/535,G06F16/93;;G06F9/50;;G06N5/04,,0,0,,,,ACTIVE
434,US,A1,US 2007/0054906 A1,196-933-198-004-923,2007-03-08,2007,US 39600106 A,2006-03-31,US 39600106 A;;US 65454603 A;;US 42195902 P;;US 40802702 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN M;;JAMES RAY A;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS W,MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/196-933-198-004-923,Patent Application,yes,15,5,5,52,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P35/04;;C07D487/04,A61K31/5377;;A61K31/519;;C07D487/04,514/234.5;;544/281;;514/252.16;;514/259.3;;544/117,0,0,,,,EXPIRED
435,NZ,A,NZ 590480 A,199-921-724-720-040,2012-05-25,2012,NZ 59048005 A,2005-02-08,US 77698804 A,2004-02-11,"7-Amino-pyrazolo[1,5-a]pyrimidine derivatives as cyclin dependent kinase inhibitors","Disclosed are specific 7-amino-pyrazolo[1,5-a]pyrimidine compounds as represented by the general formula (I), wherein R2 is a group such as alkyl, cycloalkyl, or bromo; R3 is a group such as phenyl, an alkylamino group, or a nitrogen linked heterocycle; R4 is hydrogen; and R is an arylmethyl group or a heteroarylmethyl group. Some of the specific compounds disclosed herein include 3-ethyl-5-(2-(hydroxyethyl)-piperidin-1-yl)-7-[{ (pyridin-3-yl)methyl} amino]-pyrazolo[1,5-a]pyrimidine; 3-ethyl-5-[{ 2-(hydroxymethyl)-cyclohexy} amino]-7-[{ (2-amino-pyrimidin-5-yl)methyl} amino]-pyrazolo[1,5-a]pyrimidine, 5-ethoxy-3-[{ (3-ethyl-5-phenyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino} methyl]-pyridine N-oxide, 3-[{ (3-cyclopropyl-5-(2-(hydroxyethyl)-piperidin-1-yl)-pyrazolo[1,5-a]pyrimidin-7-yl)amino} methyl]-pyridine N-oxide and 3-[{ (3-ethyl-5-(2-(hydroxyethyl)-piperidin-1-yl)-pyrazolo[1,5-a]pyrimidin-7-yl)amino} methyl]-pyridine N-oxide. Further disclosed is a pharmaceutical composition which comprises at least one compound as defined above or a pharmaceutically acceptable salt or solvate thereof in combination with at least one pharmaceutically acceptable carrier for the treatment of cancer, squamous cell carcinoma, leukemia, fibrosarcoma, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer, Kaposi's sarcoma etc.",SCHERING CORP;;PHARMACOPEIA LLC,DWYER MICHAEL P;;GUZI TIMOTHY J;;PARUCH KAMIL;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,"PHARMACOPEIA, LLC, NZ (2022-10-13);;PHARMACOPEIA, LLC, US (2011-06-30);;MERCK SHARP +  DOHME LLC, US (2022-10-13);;SCHERING CORPORATION, US (2011-06-30)",https://lens.org/199-921-724-720-040,Patent Application,no,0,1,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/4162;;A61K31/495;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
436,CY,T1,CY 1112400 T1,061-596-177-852-018,2015-12-09,2015,CY 111100349 T,2011-04-05,EP 05722809 A;;US 77698804 A,2004-02-11,ΠΑΡΑΓΩΓΑ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΕΞΑΡΤΩΜΕΝΗΣ ΑΠΟ ΚΥΚΛΙΝΗ ΚΙΝΑΣΗΣ,"Στις πολλές πραγματοποιήσεις αυτής, η παρούσα εφεύρεση παρέχει μια νέα κατηγορία ενώσεων πυραζολο[1,5-α]πυριμιδίνης ως αναστολείς των εξαρτώμενων από κυκλίνη κινασών, μεθόδους παρασκευής τέτοιων ενώσεων, φαρμακευτικές συνθέσεις που περιέχουν μία ή περισσότερες τέτοιες ενώσεις, μεθόδους παρασκευής φαρμακοτεχνικών μορφών που περιλαμβάνουν μία ή περισσότερες τέτοιες ενώσεις και μεθόδους θεραπείας, αποτροπής, αναστολής ή ανακούφισης μιας ή περισσοτέρων ασθενειών που συνδυάζονται με τις CDKs χρησιμοποιώντας τέτοιες ενώσεις ή φαρμακευτικές συνθέσεις.",SCHERING CORP,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/061-596-177-852-018,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61P35/00,,0,0,,,,ACTIVE
437,CA,A1,CA 2555345 A1,084-513-224-564-51X,2005-08-25,2005,CA 2555345 A,2005-02-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides pyrazolo[1,5- a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition , or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,CHAN TIN-YAU;;RIVERA JOCELYN;;KEERTIKAR KARTIK M;;ALVAREZ CARMEN S;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;HE ZHEN MIN;;TRAN VINH D;;MALLAMS ALAN;;PARK HAENGSOON;;JAMES RAY ANTHONY;;GUZI TIMOTHY J;;PARUCH KAMIL;;DOLL RONALD J;;DWYER MICHAEL P;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH;;GIRIJAVALLABHAN VIYYOOR MOOPIL,,https://lens.org/084-513-224-564-51X,Patent Application,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61P35/00,,0,0,,,,ACTIVE
438,BR,A,BR PI0507644 A,188-492-423-179-244,2007-04-17,2007,BR PI0507644 A,2005-02-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,pirazolopirimidinas como inibidores de cinase dependente de ciclina,"""PIRAZOLOPIRIMIDINAS COMO INIBIDORES DE CINASE DEPENDENTE DE CICLINA"". Em suas muitas modalidades, a presente invenção fornece uma classe nova de compostos de pirazol¢1,5-a!pirimidina como inibidores de cinases dependentes de ciclina, métodos de preparar tais compostos, composições farmacêuticas contendo um ou mais tais compostos, métodos de preparar formulações farmacêuticas compreendendo um ou mais tais compostos e métodos de tratamento, prevenção, inibição ou melhora de uma ou mais doenças associadas às CDKs usando tais compostos ou composições farmacêuticas.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH;;GUZI TIMOTHY J,"PHARMACOPEIA DRUG DISCOVERY, INC. (US) , MERCK SHA (2013-10-22);;PHARMACOPEIA, LLC (US) ; MERCK SHARP AND DOHME LLC (US) (2023-04-25);;MERCK SHARP AND DOHME CORP. (US) , PHARMACOPEIA, L (2014-05-20)",https://lens.org/188-492-423-179-244,Patent Application,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61K35/00,,0,0,,,,ACTIVE
439,US,A1,US 2007/0037824 A1,015-533-262-794-717,2007-02-15,2007,US 65454603 A,2003-09-03,US 65454603 A;;US 40802702 P;;US 42195902 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN M;;JAMES RAY A;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS W,MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02);;PHARMACOPEIA DRUG DISCOVERY (2004-03-30);;PHARMACOPEIA INC (2004-05-21),https://lens.org/015-533-262-794-717,Patent Application,yes,10,9,5,52,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P35/04;;C07D487/04,C07D487/02;;A61K31/519;;C07D487/04,514/252.16;;544/281;;514/259.3,0,0,,,,EXPIRED
440,CY,T1,CY 1110666 T1,017-896-437-651-693,2015-06-11,2015,CY 101100638 T,2010-07-08,EP 03794592 A;;US 40802702 P;;US 42195902 P,2002-09-04,ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΕΣ ΚΑΤΑΛΛΗΛΕΣ ΓΙΑ ΘΕΡΑΠΕΙΑ ΚΑΡΚΙΝΙΚΩΝ ΝΟΣΩΝ,"Στις πολλές πραγματοποιήσεις της, η παρούσα εφεύρεση παρέχει μια νέα τάξη ενώσεων pyrazolo[1,5-a]pyrimidine ως αναστολείς κυκλινο-εξαρτώμενων κινασών, μεθόδους παρασκευής τέτοιων ενώσεων, φαρμακευτικές συνθέσεις που περιλαμβάνουν μια ή περισσότερες τέτοιες ενώσεις, μεθόδους παρασκευής φαρμακευτικών συνθέσεων που περιλαμβάνουν μια ή περισσότερες τέτοιες ενώσεις, και μεθόδους θεραπείας, πρόληψης, καταστολής ή βελτίωσης μιας ή περισσοτέρων νόσων που σχετίζονται με τις CDKs χρησιμοποιώντας τέτοιες ενώσεις ή φαρμακευτικές συνθέσεις.",SCHERING CORP,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/017-896-437-651-693,Granted Patent,no,0,0,18,52,0,A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/519,,0,0,,,,ACTIVE
441,PE,A1,PE 20050774 A1,028-077-572-421-866,2005-10-31,2005,PE 2005000156 A,2005-02-10,US 77698804 A,2004-02-11,PIRAZOLOPIRIMIDINAS COMO INHIBIDORES DE QUINASA CICLINA-DEPENDIENTES,"SE REFIERE A PIRAZOLO[1,5-a]PIRIMIDINA DE FORMULA I DONDE R ES ALQUILO, ALQUENILO, ALQUINILO, ARILALQUILO, ARILALQUENILO, CICLOALQUILO, ENTRE OTROS; R2 ES R9, ALQUILO, ALQUENILO, ALQUINILO, CF3, HETEROCICLILO, HETEROCICLILO, ALQUINILALQUILO, CICLOALQUILO, ENTRE OTROS; R3 ES H, HALOGENO, -NR5R6, -OR6, SR6, ALQUILO, ALQUINILO, ENTRE OTROS; R4 ES H, HALO, ALQUILO; R5 ES H, ALQUILO, ARILO, CICLOALQUILO; R6 ES H, ALQUILO, ALQUENILO, ARILO, ARILALQUILO, ENTRE OTROS. R9 ES ARILO CON 1-3 GRUPOS ARILO, HETEROARILO, FENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS LOS GRUPOS DE FORMULA a, b, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE QUINASA CICLINA-DEPENDIENTES",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/028-077-572-421-866,Patent Application,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K31/495;;A61P35/00;;C07D487/04,,0,0,,,,ACTIVE
442,BR,B8,BR PI0507644 B8,066-241-185-109-004,2021-05-25,2021,BR PI0507644 A,2005-02-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,pirazolopirimidinas como inibidores de cinase dependente de ciclina,"pirazolopirimidinas como inibidores de cinase dependente de ciclina. em suas muitas modalidades, a presente invenção fornece uma classe nova de compostos de pirazol[1,5-a]pirimidina como inibidores de cinases dependentes de ciclina, métodos de preparar tais compostos, composições farmacêuticas contendo um ou mais tais compostos, métodos de preparar formulações farmacêuticas compreendendo um ou mais tais compostos e métodos de tratamento, prevenção, inibição ou melhora de uma ou mais doenças associadas às cdks usando tais compostos ou composições farmacêuticas.",MERCK SHARP & DOHME;;PHARMACOPEIA DRUG DISCOVERY INC;;PHARMACOPEIA LLC;;SCHERING CORP,MICHAEL P DWYER;;ALAN MALLAMS;;CARMEN S ALVAREZ;;DOUGLAS WALSH HOBBS;;HAENGSOON PARK;;JOCELYN RIVERA;;KAMIL PARUCH;;KARTIK M KEERTIKAR;;LAWRENCE W DILLARD;;RAY ANTHONY JAMES;;RONALD J DOLL;;THIERRY O FISCHMANN;;TIMOTHY J GUZI;;TIN-YAU CHAN;;VIDYADHAR M PARADKAR;;VINCENT MADISON;;VINH D TRAN;;VIYYOOR MOOPIL GIRIJAVALLABHAN;;ZHEN MIN HE,"PHARMACOPEIA DRUG DISCOVERY, INC. (US) , MERCK SHA (2013-10-22);;PHARMACOPEIA, LLC (US) ; MERCK SHARP AND DOHME LLC (US) (2023-04-25);;MERCK SHARP AND DOHME CORP. (US) , PHARMACOPEIA, L (2014-05-20)",https://lens.org/066-241-185-109-004,Amended Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K31/495;;A61K35/00;;C07D487/04,,0,0,,,,ACTIVE
443,PL,T3,PL 1720882 T3,085-933-928-647-943,2011-08-31,2011,PL 05722809 T,2005-02-08,US 77698804 A;;EP 05722809 A;;US 2005/0003859 W,2004-02-11,PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS,,PHARMACOPEIA LLC;;MERCK SHARP & DOHME,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/085-933-928-647-943,Patent Application,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61P35/00,,0,0,,,,PENDING
444,JP,A,JP 2010180234 A,085-792-419-852-045,2010-08-19,2010,JP 2010088210 A,2010-04-06,US 40802702 P;;US 42195902 P,2002-09-04,PYRAZOLOPYRIMIDINE AS CYCLIN-DEPENDENT KINASE INHIBITOR,"<P>PROBLEM TO BE SOLVED: To provide a compound useful as a protein kinase inhibitor. <P>SOLUTION: A new class of a pyrazolo[1,5-a]pyrimidine compound represented by the formula as an inhibitor of a cyclin-dependent kinase is provided in many embodiments. A method for preparing such a compound, a pharmacological composition comprising one or more such compounds, a method for preparing a pharmacological formulation comprising one or more such compounds, and a method for treating, preventing, inhibiting or ameliorating one or more diseases associated with a CDK using such a compound or such a pharmacological composition are also provided. <P>COPYRIGHT: (C)2010,JPO&INPIT",SCHERING CORP;;PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/085-792-419-852-045,Patent Application,no,0,11,18,52,0,A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/519;;A61K31/5377;;A61K31/551;;A61K45/00;;A61P35/00;;A61P35/02;;A61P43/00;;C07D519/00,,0,0,,,,DISCONTINUED
445,US,B2,US 7807683 B2,123-940-754-186-180,2010-10-05,2010,US 39600106 A,2006-03-31,US 39600106 A;;US 65454603 A;;US 42195902 P;;US 40802702 P,2002-09-04,N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/123-940-754-186-180,Granted Patent,yes,31,0,5,52,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P35/04;;C07D487/04,A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;C07D487/04,514/259.3;;544/281;;514/263.32;;514/252.17;;514/183;;514/81;;514/110;;514/234.2;;514/252.16;;514/151;;514/8;;514/9;;514/27;;514/167;;514/15;;514/221;;514/245;;424/649;;424/94.4,25,14,046-267-734-266-687;;011-413-668-915-089;;101-930-819-275-444;;080-412-881-865-322;;054-343-072-168-181;;024-579-812-539-076;;018-866-961-404-161;;061-867-406-774-861;;107-715-444-078-941;;041-549-446-256-496;;094-016-430-416-433;;032-700-699-523-938;;011-413-668-915-089;;046-267-734-266-687,12783600;;10.1517/eoid.12.6.955.21792;;10.1517/13543784.12.6.955;;15882121;;10.1517/13543784.14.4.457;;10.1002/jhet.5570220303;;10.1111/j.1432-1033.1994.00771.x;;7925396;;12190313;;10.1021/jm0201520;;12519061;;10.1021/jm020319p;;319236;;10.1021/jm00212a021;;10.1200/jco.1998.16.9.2986;;9738567;;10.1111/j.1432-1033.1997.t01-2-00527.x;;9030781;;9269999;;10.1248/cpb.47.928;;10434395;;10.1248/cpb.10.620;;15882121;;10.1517/13543784.14.4.457;;12783600;;10.1517/eoid.12.6.955.21792;;10.1517/13543784.12.6.955,"Fischer, P.M.; Gianella-Borradori, A.; CDK inhibitors in clinical development for the treatment of cancer, Expert. Opin. Investig. Drugs; 2003; 12(6); 955-970.;;Fischer, P.M.; Gianella-Borradori, A.; Recent progress in the discovery and development of cyclin-dependent kinase inhibitors, Expert. Opin. Investig. Drugs; 2005; 14(4); 457-477.;;Hirai, K., JP 61057587, CAS printout and machine translated abstract.;;Chemical Abstract No. 63:10201 English Translation of JP 40002672.;;Chemical Abstract No. 65:108095 English Translation of JP 41014423.;;Chemical Abstract No. 66:10957 English Translation of JP 41015583.;;Chemical Abstract No. 66:10952 English Translation of JP 41016288.;;Chemical Abstract No. 105:226617 English Translation of JP 61057587.;;Robins et al., ""Purina Analog Inhibitors of Xanthine Oxidase-Structure Activity Relationships and Proposed Binding of the Molybdenum Cofactor"", J. Heterocyclic Chem., 22:601-634 (1985).;;Vesely et al., ""Inhibition of Cyclin-Dependent Kinases by Purine Analogues"", Eur. J. Biochem, 224: 771-786 (1994).;;Kim et al., ""Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities"", Journal of Medical Chemistry, p. EST:22.3, A-W.;;Mettey et al., ""Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects"", J. Med. Chem., 46(2): 222-236 (2003).;;Novinson et al., ""Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-alpha]pyrimidines"", J. Med. Chem., 20(2); 296-299 (1977).;;Senderowicz et al., ""Phase I Trial of Continous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasmns"", Journal of Clinical Oncology,16(9): 2986-2999 (Sep. 1998).;;Meijer et al., ""Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2. CDK2 and CDK5"", Eur. J. Biochem, 243:527-536 (1997).;;Bible et al., ""Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration"", Cancer Research, 57: 3375-3380 (Aug. 15, 1997).;;Shiota et al., ""Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo [1,5-alpha]pyrimidine Derivatives"", Chem. Pharm. Bull., 47(7): 928-938 (1999).;;Makisumi, Yasuo ""Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-alpha]pyrimidines"", Chem. Pharm. Bull (1962), 10: 620-626.;;West, Anthony R., ""Solid State Chemistry and Its Applications"", Wiley, New York, 358 and 365 (1988).;;Fischer, Peter M. et al., ""Recent progress in the discovery and development of cyclindependent kinase inhibitors"", Expert Opinion on Investigational Drugs, 14(4): 457-477 (Apr. 2005).;;Fischer, Peter M. et al., ""CDK inhibitors in clinical development for the treatment of cancer"", Expert Opinion on Investigational Drugs, 12(6): 955-970 (Jun. 2003).;;Translation of WO 03/091256, ""A Rising Sun Communications Ltd. Translation Product"", (1-62), Nov. 6, 2003.;;PCT International Search Report dated Dec. 29, 2003 for corresponding PCT Application No. PCT/US03/27555, date of mailing, Dec. 29, 2003.;;Translation of WO 03/91256, ""A Rising Sun Communications Ltd. Translation Product"", (1-62).;;PCT International Search Report dated Dec. 29, 2003 for corresponding PCT Application No. PCT/US03/27555.",ACTIVE
446,GR,T3,GR 3036924 T3,165-799-180-975-095,2002-01-31,2002,GR 20010401745 T,2001-10-18,GB 9216123 A;;GB 9216238 A;;GB 9216231 A;;GB 9220957 A;;GB 9222821 A;;GB 9222934 A;;GB 9223583 A;;GB 9226242 A;;GB 9226360 A;;GB 9301277 A;;GB 9307318 A;;GB 9301599 W,1992-07-29,BENZODIAZEPINE DERIVATIVES.,"PCT No. PCT/GB93/01599 Sec. 371 Date Jan. 26, 1995 Sec. 102(e) Date Jan. 26, 1995 PCT Filed Jul. 28, 1993 PCT Pub. No. WO94/03437 PCT Pub. Date Feb. 17, 1994Compounds of Formula (I), and salts and prodrugs thereof, wherein R1 represents H, optionally substituted C1-6alkyl or C3-7cycloalkyl; R2 is NHR12 or (CH2)sR13 where 5 is 0, 1 or 2; R3 represents C1-6alkyl, halo or NR6R7; R4 and R5 are H, C1-12alkyl optionally substituted by NR9R9' or an azacyclic or azabicyclic group, optionally substituted C4-9cycloalkyl, C4-9cycloalkyl C1-4alkyl, aryl, arylC1-6alkyl or azacyclic or azabicyclic groups, or R4 and R5 together form the residue of an optionally substituted azacyclic or azabicyclic ring system; x is 0, 1, 2 or 3; R12 is optionally substituted phenyl or pyridyl; R13 represents a group (A) wherein R14 is H or C1-6alkyl; R15 is H, C1-6alkyl, halo or NR6R7; and the dotted line is an optional covalent bond; are CCK and/or gastrin antagonists useful in therapy. <IMAGE> (I) <IMAGE> (A)",MERCK SHARP & DOHME,CASTRO PINEIRO JOSE LUIS;;CARLING WILLIAM ROBERT;;CHAMBERS MARK STUART;;FLETCHER STEPHEN ROBERT CLIPPE;;HOBBS SARAH CHRISTINE GOODWIN;;MATASSA VICTOR GIULIO;;MOORE KEVIN WILLIAM;;SHOWELL GRAHAM ANDREW BEEHIVE;;RUSSEL MICHAEL GEOFFREY NEIL S;;CARLING WILLIAM ROBERT THE COL;;CHAMBERS MARK STUART PARK AVEN;;MATASSA VICTOR GIULIO THE DUCK;;MOORE KEVIN WILLIAM WHITE HART,,https://lens.org/165-799-180-975-095,Granted Patent,no,0,0,17,34,0,C07D221/24;;C07D243/14;;C07D401/04;;C07D401/12;;C07D403/04;;C07D453/06;;C07D487/08;;C07D491/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/30;;A61P27/06;;A61P35/00;;A61P39/00;;A61P43/00;;C07D401/04;;C07D491/10;;C07D221/24;;C07D487/08;;C07D401/12;;C07D243/14;;C07D453/06;;C07D403/04,A61K31/55;;A61K31/551;;A61K31/5513;;A61P1/00;;A61P1/04;;A61P1/12;;A61P25/00;;A61P25/04;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/30;;A61P27/06;;A61P35/00;;A61P39/00;;A61P43/00;;C07D221/24;;C07D243/14;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D403/14;;C07D413/04;;C07D453/06;;C07D471/08;;C07D487/08;;C07D491/10;;C07D491/107;;C07D491/113,,0,0,,,,EXPIRED
447,TW,B,TW I344468 B,197-189-039-735-87X,2011-07-01,2011,TW 92124347 A,2003-09-03,US 40802702 P;;US 42195902 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,,SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,TIMOTHY J GUZI;;KAMIL PARUCH;;MICHAEL P DWYER;;RONALD J DOLL;;VIYYOOR MOOPIL GIRIJAVALLABHAN;;ALAN MALLAMS;;CARMEN S ALVAREZ;;KARTIK M KEERTIKAR;;JOCELYN RIVERA;;TIN-YAU CHAN;;VINCENT MADISON;;THIERRY O FISCHMANN;;LAWRENCE W DILLARD;;VINH D TRAN;;ZHEN MIN HE;;RAY ANTHONY JAMES;;HAENGSOON PARK;;VIDYADHAR M PARADKAR;;DOUGLAS WALSH HOBBS,,https://lens.org/197-189-039-735-87X,Granted Patent,no,0,0,18,52,0,A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,,,0,0,,,,EXPIRED
448,US,A1,US 2004/0209878 A1,141-615-948-710-095,2004-10-21,2004,US 77698804 A,2004-02-11,US 77698804 A;;US 65454603 A;;US 40802702 P;;US 42195902 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"
   In its many embodiments, the present invention provides a novel class of pyrazolo1,5-apyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. 
",SCHERING CORP AND PHARMACOPEIA,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,PHARMACOPEIA DRUG DISCOVERY INC (2005-01-24);;MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02);;PHARMACOPEIA DRUG DISCOVERY (2004-03-30),https://lens.org/141-615-948-710-095,Patent Application,yes,0,83,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K31/495;;C07D487/04,514 234500;;514 252160;;514 259300;;514 117000;;514 280000,0,0,,,,EXPIRED
449,AU,B2,AU 2005/212409 B2,044-635-950-374-31X,2011-12-01,2011,AU 2005/212409 A,2005-02-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA INC,JOCELYN RIVERA;;MOOPIL GIRIJAVALLABHAN VIYYOOR;;DWYER MICHAEL P;;HAENGSOON PARK;;DOLL RONALD J;;ALAN MALLAMS;;WALSH HOBBS DOUGLAS;;TIN-YAU CHAN;;ANTHONY JAMES RAY;;MIN HE ZHEN;;TRAN VINH D;;FISCHMANN THIERRY O;;GUZI TIMOTHY J;;PARADKAR VIDYADHAR M;;KAMIL PARUCH;;DILLARD LAWRENCE W;;VINCENT MADISON;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M,"MERCK SHARP & DOHME LLC (2022-12-01);;SCHERING CORPORATION; PHARMACOPEIA, INC. (2007-09-13);;PHARMACOPEIA, INC. (2022-12-01)",https://lens.org/044-635-950-374-31X,Granted Patent,no,8,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495,,0,0,,,,ACTIVE
450,EP,B1,EP 1537116 B1,179-032-357-270-803,2010-06-02,2010,EP 03794592 A,2003-09-03,US 0327555 W;;US 40802702 P;;US 42195902 P,2002-09-04,PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,"MERCK SHARP & DOHME LLC, US (2023-01-17);;PHARMACOPEIA, LLC; US (2022-10-18);;PHARMACOPEIA, LLC (2012-07-13);;MERCK SHARP & DOHME LLC (2023-02-24);;PHARMACOPEIA, LLC, SAN DIEGO, CA, US (2022-10-06);;MERCK SHARP & DOHME LLC, RAHWAY, US (2022-09-29);;MERCK SHARP & DOHME CORP. (2012-10-24);;PHARMACOPEIA, INC. (2008-09-24);;PHARMACOPEIA, LLC, SAN DIEGO, US (2022-09-29);;MERCK SHARP & DOHME CORP., RAHWAY, NJ, US (2012-09-28);;MERCK SHARP & DOHME CORP., US (2013-09-30);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-16);;MERCK SHARP & DOHME CORP.; US (2013-01-11);;MERCK SHARP & DOHME LLC; US (2022-12-29);;PHARMACOPEIA, LLC, US (2023-01-17);;SCHERING CORPORATION (2009-12-23);;MERCK SHARP & DOHME LLC, RAHWAY, NJ, US (2022-10-06);;SCHERING CORPORATION, US (2013-03-19);;MERCK SHARP  DOHME CORP., RAHWAY, US (2013-05-16)",https://lens.org/179-032-357-270-803,Granted Patent,yes,2,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04;;A61K31/519,,10,2,101-930-819-275-444;;018-866-961-404-161,10.1002/jhet.5570220303;;319236;;10.1021/jm00212a021,"DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; retrieved from STN Database accession no. 1965:410201;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; retrieved from STN Database accession no. 1966:508095;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; retrieved from STN Database accession no. 1967:10952;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; retrieved from STN Database accession no. 1986:626617;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; retrieved from STN Database accession no. 1967:10957;;ROBINS R.K. ET AL.: ""Purine Analog Inhibitors of Xanthine Oxidase - Structure Activity Relationships and proposed Binding of the Molybdenum Cofactor"", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 22, 1985, PROVO, UT; US, pages 601 - 634, XP002162763, DOI: doi:10.1002/jhet.5570220303;;NOVINSON T. ET AL.: ""Synthesis and Antifungal properties of Certain 7-Alkylaminopyrazolo[1,5-a]pyrimidines"", JOURNAL OF MEDICINAL CHEMISTRY., vol. 20, no. 2, 1977, AMERICAN CHEMICAL SOCIETY. WASHINGTON; US, pages 296 - 299, XP002970049;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 April 2001 (2001-04-22), XP001167121, retrieved from STN Database accession no. 1965:410200;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 April 2001 (2001-04-22), XP001167122, retrieved from STN Database accession no. 1965:410199;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 April 2001 (2001-04-22), retrieved from STN Database accession no. 1965:29698",EXPIRED
451,PE,A1,PE 20050956 A1,195-921-594-490-818,2005-11-19,2005,PE 2004000076 A,2004-01-20,PE 2004000076 A,2004-01-20,"PIRAZOLO[1,5-a]PIRIMIDINAS COMO INHIBIDORES DE QUINASA DEPENDIENTES DE CICLINAS","SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R ES ALQUILO, ALQUENILO, ALQUINILO, ARILALQUILO, CICLOALQUILO, ALQUINILALQUILO, ENTRE OTROS; R2 ES R9, ALQUILO, CF3, HETEROCICLILALQUILO, HALOGENO, ARILALQUILO, ARILO, ENTRE OTROS; R3 ES H, HALOGENO, -OR6, -SR6, ALQUILO, ARILO, ARILALQUILO, ENTRE OTROS; R6 ES H, ALQUILO, ALQUENILO, ARILO, ARILALQUILO, HETEROARILO, HETEROCICLILO, HETEROARILO SUSTITUIDO O NO, ENTRE OTROS; R9 ES HALOGENO, -CN, -C(O)R6, -OR6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: A, B, C, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINASA UTILES EN EL TRATAMIENTO DE CANCER, INFLAMACION, ARTRITIS, ENFERMEDADES VIRALES, ENTRE OTROS",PHARMACOPEIA INC;;SCHERING CORP,DWYER MICHAEL P;;DOLL RONALD J;;HE ZHEN MIN;;JAMES RAY ANTHONY;;RIVERA JOCELYN;;MADISON VINCENT;;DILLARD LAWRENCE W;;ALVAREZ CARMEN S;;PARUCH KAMIL;;GUZI TIMOTHY J;;PARK HAENGSOON;;FISCHMANN THIERRY O;;CHAN TIN YAU;;KEERTIKAR KARTIK M;;HOBBS DOUGLAS WALSH;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;TRAN VINH D;;PARADKAR VIDYADHAR M,,https://lens.org/195-921-594-490-818,Patent Application,no,0,0,1,1,0,,A61K31/519;;A61P35/00;;C07D487/04,,0,0,,,,EXPIRED
452,EP,B1,EP 1720882 B1,111-511-909-403-266,2011-01-05,2011,EP 05722809 A,2005-02-08,US 2005/0003859 W;;US 77698804 A,2004-02-11,PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS,,SCHERING CORP;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,"MERCK SHARP & DOHME LLC, US (2023-01-17);;PHARMACOPEIA, LLC; US (2022-10-18);;PHARMACOPEIA, LLC (2012-07-13);;MERCK SHARP & DOHME LLC (2023-03-01);;PHARMACOPEIA, LLC, SAN DIEGO, CA, US (2022-10-07);;MERCK SHARP & DOHME LLC, RAHWAY, US (2022-09-29);;MERCK SHARP & DOHME CORP. (2012-10-24);;PHARMACOPEIA, INC. (2008-09-24);;PHARMACOPEIA, LLC, SAN DIEGO, US (2022-09-29);;MERCK SHARP & DOHME CORP., RAHWAY, NJ, US (2012-09-27);;MERCK SHARP & DOHME CORP., US (2013-05-16);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-16);;MERCK SHARP & DOHME CORP.; US (2012-12-18);;MERCK SHARP & DOHME LLC; US (2022-12-14);;PHARMACOPEIA, LLC, US (2023-01-17);;SCHERING CORPORATION (2009-12-23);;MERCK SHARP & DOHME LLC, RAHWAY, NJ, US (2022-10-07);;SCHERING CORPORATION, US (2013-03-19)",https://lens.org/111-511-909-403-266,Granted Patent,yes,7,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61P35/00,,0,0,,,,ACTIVE
453,EP,A1,EP 1537116 A1,163-239-608-477-575,2005-06-08,2005,EP 03794592 A,2003-09-03,US 0327555 W;;US 40802702 P;;US 42195902 P,2002-09-04,PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,"MERCK SHARP & DOHME LLC, US (2023-01-17);;PHARMACOPEIA, LLC; US (2022-10-18);;PHARMACOPEIA, LLC (2012-07-13);;MERCK SHARP & DOHME LLC (2023-02-24);;PHARMACOPEIA, LLC, SAN DIEGO, CA, US (2022-10-06);;MERCK SHARP & DOHME LLC, RAHWAY, US (2022-09-29);;MERCK SHARP & DOHME CORP. (2012-10-24);;PHARMACOPEIA, INC. (2008-09-24);;PHARMACOPEIA, LLC, SAN DIEGO, US (2022-09-29);;MERCK SHARP & DOHME CORP., RAHWAY, NJ, US (2012-09-28);;MERCK SHARP & DOHME CORP., US (2013-09-30);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-16);;MERCK SHARP & DOHME CORP.; US (2013-01-11);;MERCK SHARP & DOHME LLC; US (2022-12-29);;PHARMACOPEIA, LLC, US (2023-01-17);;SCHERING CORPORATION (2009-12-23);;MERCK SHARP & DOHME LLC, RAHWAY, NJ, US (2022-10-06);;SCHERING CORPORATION, US (2013-03-19);;MERCK SHARP  DOHME CORP., RAHWAY, US (2013-05-16)",https://lens.org/163-239-608-477-575,Patent Application,yes,0,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04;;A61K31/519,,0,0,,,,EXPIRED
454,TW,B,TW I393566 B,197-905-529-874-367,2013-04-21,2013,TW 94104016 A,2005-02-05,US 77698804 A,2004-02-11,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,,MERCK SHARP & DOHME;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/197-905-529-874-367,Granted Patent,no,3,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K31/495;;C07D487/04,,1,0,,,CA 1986:626617,ACTIVE
455,AT,T1,AT E494287 T1,032-783-749-152-140,2011-01-15,2011,AT 05722809 T,2005-02-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,PYRAZOLOPYRIMIDINDERIVATE ALS INHIBITOREN DER CYCLINABHÄNGIGEN KINASE,,SCHERING CORP;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/032-783-749-152-140,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K31/495;;C07D487/04,,0,0,,,,ACTIVE
456,HK,A1,HK 1090926 A1,042-490-311-405-135,2007-01-05,2007,HK 06112804 A,2006-11-22,US 2005/0003859 W;;US 77698804 A,2004-02-11,PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS,,SCHERING CORP;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;PARUCH KAMIL;;DOLL RONALD J;;DWYER MICHAEL P;;MALLAMS ALAN;;ALVAREZ CARMEN S;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;KEERTIKAR KARTIK M;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;HOBBS DOUGLAS WALSH,,https://lens.org/042-490-311-405-135,Patent Application,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K/;;A61K31/495;;A61P/;;C07D/;;C07D487/04,,0,0,,,,PENDING
457,US,B1,US 7161003 B1,111-876-472-480-075,2007-01-09,2007,US 65454603 A,2003-09-03,US 65454603 A;;US 40802702 P;;US 42195902 P,2002-09-04,Pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02);;PHARMACOPEIA DRUG DISCOVERY (2004-03-30);;PHARMACOPEIA INC (2004-05-21),https://lens.org/111-876-472-480-075,Granted Patent,yes,22,30,5,52,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P35/04;;C07D487/04,C07D487/04,544/281,13,11,011-413-668-915-089;;046-267-734-266-687;;080-412-881-865-322;;054-343-072-168-181;;024-579-812-539-076;;018-866-961-404-161;;061-867-406-774-861;;107-715-444-078-941;;041-549-446-256-496;;094-016-430-416-433;;032-700-699-523-938,15882121;;10.1517/13543784.14.4.457;;12783600;;10.1517/eoid.12.6.955.21792;;10.1517/13543784.12.6.955;;10.1111/j.1432-1033.1994.00771.x;;7925396;;12190313;;10.1021/jm0201520;;12519061;;10.1021/jm020319p;;319236;;10.1021/jm00212a021;;10.1200/jco.1998.16.9.2986;;9738567;;10.1111/j.1432-1033.1997.t01-2-00527.x;;9030781;;9269999;;10.1248/cpb.47.928;;10434395;;10.1248/cpb.10.620,"West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.;;Peter M Fischer, Athos Gianella-Borradori, Expert Opinion on Investigational Drugs, Apr. 2005, vol. 14, No. 4, pp. 457-477.;;Peter M Fischer, Athos Gianella-Borradori, Expert Opinion on Investigational Drugs, Jun. 2003, vol. 12, No. 6, pp. 955-970.;;Vesely et al., ""Inhibition of Cyclin-Dependent Kinases by Purine Analogues"", Eur. J. Biochem (1994), 224: 771-786.;;Kim et al., ""Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities"", Journal of Medical Chemistry, p. EST:22.3, A-W.;;Mettey et al., ""Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects"", J. Med. Chem. (2003), 46(2): 222-236.;;Novinson et al., ""Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1.5-alpha]pyrimidines"", J. Med. Chem. (1977), 20(2): 296-299.;;Senderowicz et al., ""Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhitibor, in Patients with Refractory Neoplasms"", Journal of Clinical Oncology (Sep. 1998), 16(9): 2986-2999.;;Meijer et al., ""Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5"", Eur. J. Biochem. (1997), 243:527-536.;;Bible et al., ""Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration"", Cancer Research (Aug. 15, 1997), 57: 3375-3380.;;Shiota et al., ""Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1.5-alpha]pyrimidine Derivatives"", Chem. Pharm. Bull. (1999), 47(7): 928-938.;;Yasuo Makisumi, ""Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1.5-alpha]pyrimidines."", Chem. Pharm. Bull (1962), 10: 620-626.;;Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62).",ACTIVE
458,JP,A,JP 2010215675 A,012-870-286-853-089,2010-09-30,2010,JP 2010157338 A,2010-07-09,US 77698804 A,2004-02-11,PYRAZOLOPYRIMIDINE DERIVATIVE AS CYCLIN DEPENDENT KINASE INHIBITOR,"<P>PROBLEM TO BE SOLVED: To provide cyclin dependent kinase inhibitors. <P>SOLUTION: The invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing one or more kind of such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. <P>COPYRIGHT: (C)2010,JPO&INPIT",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/012-870-286-853-089,Patent Application,no,17,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/437;;A61K31/444;;A61K31/495;;A61K31/519;;A61K31/5355;;A61K41/00;;A61K45/00;;A61P35/00;;A61P35/02;;A61P43/00;;C07D453/02,,3,0,,,"JPN6010003837; Ｊ．Ｍｅｄ．Ｃｈｅｍ．，（）１９７７），２０（２），ｐ．２９６-９;;JPN6010003835; Ｊ．Ｈｅｔｅｒｏｃｙｃｌ．Ｃｈｅｍ．，（１９８５），２２，ｐ．６０１-３４;;JPN6012058097; 薬学雑誌 Ｖｏｌ．８４，Ｎｏ．１１, 1964, ｐ．１１１３-１１１８",DISCONTINUED
459,AU,C1,AU 2005/212409 C1,038-798-050-677-090,2012-07-19,2012,AU 2005/212409 A,2005-02-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",MERCK SHARP & DOHME LLC;;PHARMACOPEIA INC,PARADKAR VIDYADHAR M;;TRAN VINH D;;CHAN TIN-YAU;;ALVAREZ CARMEN S;;PARUCH KAMIL;;HE ZHEN MIN;;PARK HAENGSOON;;MADISON VINCENT;;GUZI TIMOTHY J;;MALLAMS ALAN;;KEERTIKAR KARTIK M;;JAMES RAY ANTHONY;;FISCHMANN THIERRY O;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;RIVERA JOCELYN;;HOBBS DOUGLAS WALSH;;DILLARD LAWRENCE W;;DWYER MICHAEL P;;DOLL RONALD J,"MERCK SHARP & DOHME LLC (2022-12-01);;SCHERING CORPORATION; PHARMACOPEIA, INC. (2007-09-13);;PHARMACOPEIA, INC. (2022-12-01)",https://lens.org/038-798-050-677-090,Amended Patent,no,8,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495,,0,0,,,,ACTIVE
460,US,A1,US 2007/0054925 A1,060-174-760-866-47X,2007-03-08,2007,US 39607906 A,2006-03-31,US 39607906 A;;US 77698804 A;;US 65454603 A;;US 42195902 P;;US 40802702 P,2002-09-04,Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",PHARMACOPEIA INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN M;;JAMES RAY A;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS W,,https://lens.org/060-174-760-866-47X,Patent Application,yes,10,7,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K31/519;;A61K31/495;;C07D487/04,514/259.3;;544/281,0,0,,,,DISCONTINUED
461,KR,A,KR 20050057120 A,145-316-875-878-107,2005-06-16,2005,KR 20057003655 A,2003-09-03,US 0327555 W;;US 40802702 P;;US 42195902 P,2002-09-04,PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENG SOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/145-316-875-878-107,Patent Application,no,0,0,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04,,0,0,,,,EXPIRED
462,KR,A,KR 20060127130 A,194-414-681-838-920,2006-12-11,2006,KR 20067016132 A,2005-02-08,US 2005/0003859 W;;US 77698804 A,2004-02-11,PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENG SOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/194-414-681-838-920,Patent Application,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495,,0,0,,,,ACTIVE
463,AU,A1,AU 2005/212409 A1,002-266-782-803-765,2005-08-25,2005,AU 2005/212409 A,2005-02-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors,,PHARMACOPEIA DRUG DISCOVERY;;SCHERING CORP,RIVERA JOCELYN;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;DWYER MICHAEL P;;PARK HAENGSOON;;DOLL RONALD J;;MALLAMS ALAN;;HOBBS DOUGLAS WALSH;;CHAN TIN-YAU;;JAMES RAY ANTHONY;;HE ZHEN MIN;;TRAN VINH D;;FISCHMANN THIERRY O;;GUZI TIMOTHY J;;PARADKAR VIDYADHAR M;;PARUCH KAMIL;;DILLARD LAWRENCE W;;MADISON VINCENT;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M,"MERCK SHARP & DOHME LLC (2022-12-01);;SCHERING CORPORATION; PHARMACOPEIA, INC. (2007-09-13);;PHARMACOPEIA, INC. (2022-12-01)",https://lens.org/002-266-782-803-765,Patent Application,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,A61K31/495;;C07D487/04,,0,0,,,,ACTIVE
464,PL,B1,PL 224879 B1,146-145-291-602-871,2017-02-28,2017,PL 37569703 A,2003-09-03,US 40802702 P;;US 42195902 P,2002-09-04,PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS,"W wielu wykonaniach niniejszy wynalazek dostarcza nowej klasy pirazolo[1,5-a]pirymidynowych związków jako inhibitorów zależnych od cykliny kinaz, sposobów wytwarzania takich związków, farmaceutycznych kompozycji zawierających jeden lub więcej taki związek, sposobów wytwarzania farmaceutycznych preparatów zawierających jeden lub więcej taki związek i sposobów leczenia, zapobiegania, hamowania lub łagodzenia jednej lub więcej chorób związanych z CDK z użyciem takich związków albo farmaceutycznych kompozycji.",SCHERING CORP;;PHARMACOPEIA DRUG DISCOVERY INC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/146-145-291-602-871,Granted Patent,no,0,0,18,52,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00,C07D487/04;;A61K31/519;;A61P35/00,,0,0,,,,EXPIRED
465,CN,A,CN 116209672 A,195-771-362-631-035,2023-06-02,2023,CN 202180049677 A,2021-05-25,US 202063051474 P;;US 202063067593 P;;US 2021/0034069 W,2020-07-14,SARSCOV-2 INHIBITORS,"Disclosed are polypeptide inhibitors of SARS-CoV-2 comprising an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 17, SEQ ID NO: 19 to SEQ ID NO: 21, SEQ ID NO: 23 to SEQ ID NO: 34, and SEQ ID NO: 100 to SEQ ID NO: 101, and their use for treating and limiting the development of SARS-CoV-2 infection.",UNIV WASHINGTON;;UNIV NORTHWESTERN;;WASHINGTON UNIV OF ST LOUIS,CAO LINA;;COVENTRY BRIAN;;GOLESHNIK IGOR;;MILLER LYLE;;BECK DANIELA;;L KOZODOY;;BOWEN JEFFREY;;CARTER LARRY;;KEYES JOSEPH B;;DIAMOND MITCHELL;;ERDMANN NIKLAS;;HUNT ALEXANDER;;JAVITT MICHAEL C;;GOHARA JR CHARLES J;;PARK YUNSU;;RAVICHANDRAN RAJASEKARAN;;STEWART LANCE JOHN;;WISLER DOUGLAS;;WOJCELI BODO;;WALLS ANDREW C;;WU KENONG;;S BOYKEN;;UEDA GIRISH,,https://lens.org/195-771-362-631-035,Patent Application,no,0,0,7,8,0,A61P31/14;;C07K14/00;;A61P31/14;;C07K14/001;;C12N15/63,C07K14/00,,0,0,,,,PENDING
466,SI,T1,SI 1720882 T1,033-148-350-442-668,2011-05-31,2011,SI 200531260 T,2005-02-08,US 77698804 A;;US 2005/0003859 W;;EP 05722809 A,2004-02-11,PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS,,SCHERING CORP;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,,https://lens.org/033-148-350-442-668,Granted Patent,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/00;;A61K31/495;;A61P35/00;;C07D487/04,,0,0,,,,ACTIVE
467,US,B2,US 7119200 B2,085-947-434-978-563,2006-10-10,2006,US 77698804 A,2004-02-11,US 77698804 A;;US 65454603 A;;US 40802702 P;;US 42195902 P,2002-09-04,Pyrazolopyrimidines as cyclin dependent kinase inhibitors,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",PHARMACOPEIA DRUG DISCOVERY,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,PHARMACOPEIA DRUG DISCOVERY INC (2005-01-24);;MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02);;PHARMACOPEIA DRUG DISCOVERY (2004-03-30),https://lens.org/085-947-434-978-563,Granted Patent,yes,21,44,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495,544/281,18,16,011-413-668-915-089;;046-267-734-266-687;;080-412-881-865-322;;054-343-072-168-181;;024-579-812-539-076;;018-866-961-404-161;;061-867-406-774-861;;107-715-444-078-941;;041-549-446-256-496;;094-016-430-416-433;;032-700-699-523-938;;036-624-218-655-088;;076-527-077-365-576;;055-811-904-890-881;;097-535-408-440-641;;140-892-824-216-510,15882121;;10.1517/13543784.14.4.457;;12783600;;10.1517/eoid.12.6.955.21792;;10.1517/13543784.12.6.955;;10.1111/j.1432-1033.1994.00771.x;;7925396;;12190313;;10.1021/jm0201520;;12519061;;10.1021/jm020319p;;319236;;10.1021/jm00212a021;;10.1200/jco.1998.16.9.2986;;9738567;;10.1111/j.1432-1033.1997.t01-2-00527.x;;9030781;;9269999;;10.1248/cpb.47.928;;10434395;;10.1248/cpb.10.620;;9357535;;10.1021/jm970396y;;10.1021/jo00046a045;;7593329;;10.1242/jcs.108.8.2897;;10.1021/jo981423a;;817024;;10.1021/jm00226a014,"West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.;;Peter M Fischer, Athos Gianella-Borradori, Expert Opinion on Investigational Drugs, Apr. 2005, vol. 14, No. 4, pp. 457-477.;;Peter M Fischer, Athos Gianella-Borradori, Expert Opinion on Investigational Drugs, Jun. 2003, vol. 12, No. 6, pp. 955-970.;;Vesely et al., ""Inhibition of Cyclin-Dependent Kinases by Purine Analogues"", Eur. J. Biochem (1994), 224: 771-786.;;Kim et al., ""Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities"", Journal of Medical Chemistry, (2002), 45: 3905-3927.;;Mettey et al., ""Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects"", J. Med. Chem. (2003), 46(2): 222-236.;;Novinson et al., ""Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-a]pyrimidines"", J. Med. Chem. (1977), 20(2): 296-299.;;Senderowicz et al., ""Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms"", Journal of Clinical Oncology (Sep. 1998), 16(9): 2986-2999.;;Meijer et al., ""Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5"", Eur. J. Biochem. (1997), 243:527-536.;;Bible et al., ""Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration"", Cancer Research (Aug. 15, 1997), 57: 3375-3380.;;Shiota et al., ""Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-alpha]pyrimidine Derivatives"", Chem. Pharm. Bull. (1999), 47(7): 928-938.;;Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62).;;Yasuo Makisumi, ""Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-alpha]pyrimidines."", Chem. Pharm. Bull (1962), 10: 620-626.;;Cai et al., ""5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, Systemically Active and Broad Spectrum Antagonists for NMDA/glycine, AMPA, and Kainate Receptors"", J. Med. Chem. (1997), 40:3679-3686.;;Bruce L. Finkelstein, ""Regioselective Lithiation and Reaction of [1,2,4]Triazolo[1,5-a]pyridine and Pyrazolo[1,5-a]pyridine"", J. Org. Chem., (1992), 57: 5538-5540.;;Ongkeko et al., ""Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage"", Journal of Cell Science (1995), 108: 2897-2904.;;Shiota et al., ""Regioselective Reactions of Organozinc Reagents with 2,4-Dichloroquinoline and 5,7-Dichloropyrazolo[1,5-a]pyrimidine"", J. Org. Chem. (1999), 64: 453-457.;;Novinson et al., ""Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-alphas-triazines<SUP>1</SUP>"", Journal of Medicinal Chemistry, (1976), 19(4): 517-520.",EXPIRED
468,EP,B1,EP 2194058 B1,023-835-648-337-459,2013-11-27,2013,EP 10152446 A,2003-09-03,EP 03794592 A;;US 40802702 P;;US 42195902 P,2002-09-04,Pyrazolopyrimidines suitable for the treatment of cancer diseases,,MERCK SHARP & DOHME;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN K;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN D;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,"PHARMACOPEIA, LLC, SAN DIEGO, US (2022-09-29);;MERCK SHARP & DOHME LLC; US (2022-09-22);;PHARMACOPEIA, LLC (2012-08-15);;MERCK SHARP & DOHME LLC, RAHWAY, US (2022-09-29);;MERCK SHARP & DOHME CORP. (2012-08-15)",https://lens.org/023-835-648-337-459,Granted Patent,yes,0,0,18,52,0,A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/519,,2,0,,,"DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 April 2001 (2001-04-22), TAKAMIZAWA AKIRA ET AL: ""PYRAZOLOPYRIMIDINE DERIVATIVES"" XP001167121 retrieved from STN Database accession no. 1965:410200 & JP 40 002671 B (SHIONOGI & CO., LTD.) 11 February 1965 (1965-02-11);;DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 April 2001 (2001-04-22), TAKAMIZAWA AKIRA ET AL: ""PYRAZOLOPYRIMIDINE DERIVATIVES"" XP001167122 retrieved from STN Database accession no. 1965:410199 & JP 40 002670 B (SHIONOGY & CO., LTD.) 11 February 1965 (1965-02-11)",EXPIRED
469,NO,B1,NO 337520 B1,132-559-887-032-111,2016-05-02,2016,NO 20064046 A,2006-09-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,"Pyrazolopyrimidinderivater som syklinavhengige kinaseinhibitorer, anvendelse derav for fremstilling av et medikament og farmasøytiske preparater som inneholder én eller flere slike forbindelser.",,PHARMACOPEIA DRUG DISCOVERY INC;;MERCK SHARP & DOHME,MADISON VINCENT STEWART;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;PARADKAR VIDYADHAR MADHAV;;GUZI TIMOTHY J;;CHAN TIN-YAU;;DOLL RONALD J;;KEERTIKAR KARTIK M;;JAMES RAY ANTHONY;;DWYER MICHAEL;;MALLAMS ALAN K;;RIVERA JOCELYN D;;FISCHMANN THIERRY O;;TRAN VINH D;;HE ZHEN MIN;;PARK HAENGSOON;;HOBBS DOUGLAS WALSH;;PARUCH KAMIL;;ALVAREZ CARMEN S;;DILLARD LAWRENCE W,"PHARMACOPEIA DRUG DISCOVERY INC, US (2022-11-28);;MERCK SHARP AND DOHME CORP, US (2012-09-24)",https://lens.org/132-559-887-032-111,Granted Patent,no,5,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61K31/519;;A61P35/00,,0,0,,,,ACTIVE
470,NO,L,NO 20051647 L,108-658-501-369-402,2005-06-03,2005,NO 20051647 A,2005-04-04,US 40802702 P;;US 42195902 P;;US 0327555 W,2002-09-04,Pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",PHARMACOPEIA DRUG DISCOVERY,MADISON VINCENT STEWART;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;ALVAREZ CARMEN S;;PARADKAR VIDYADHAR MADHAV;;GUZI TIMOTHY J;;CHAN TIN-YAU;;DOLL RONALD J;;KEERTIKAR KARTIK M;;JAMES RAY ANTHONY;;DWYER MICHAEL;;MALLAMS ALAN K;;PARUCH KAMIL;;RIVERA JOCELYN D;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;PARK HAENGSOON;;HOBBS DOUGLAS WALSH,,https://lens.org/108-658-501-369-402,Abstract,no,0,1,21,52,0,C07D487/04;;A61P11/06;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/00;;C07D487/04,C07D487/04,,0,0,,,,PENDING
471,EP,A1,EP 2194058 A1,137-025-285-347-672,2010-06-09,2010,EP 10152446 A,2003-09-03,EP 03794592 A;;US 40802702 P;;US 42195902 P,2002-09-04,Pyrazolopyrimidines suitable for the treatment of cancer diseases,"In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.",SCHERING CORP;;PHARMACOPEIA LLC,GUZI TIMOTHY J;;PARUCH KAMIL;;DWYER MICHAEL P;;DOLL RONALD J;;GIRIJAVALLABHAN VIYYOOR M;;MALLAMS ALAN K;;ALVAREZ CARMEN S;;KEERTIKAR KARTIK M;;RIVERA JOCELYN D;;CHAN TIN-YAU;;MADISON VINCENT;;FISCHMANN THIERRY O;;DILLARD LAWRENCE W;;TRAN VINH D;;HE ZHEN MIN;;JAMES RAY ANTHONY;;PARK HAENGSOON;;PARADKAR VIDYADHAR M;;HOBBS DOUGLAS WALSH,"PHARMACOPEIA, LLC, SAN DIEGO, US (2022-09-29);;MERCK SHARP & DOHME LLC; US (2022-09-22);;PHARMACOPEIA, LLC (2012-08-15);;MERCK SHARP & DOHME LLC, RAHWAY, US (2022-09-29);;MERCK SHARP & DOHME CORP. (2012-08-15)",https://lens.org/137-025-285-347-672,Patent Application,yes,25,5,18,52,0,A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/519,,28,14,024-579-812-539-076;;061-867-406-774-861;;080-412-881-865-322;;107-715-444-078-941;;054-343-072-168-181;;007-364-858-655-289;;018-148-915-769-649;;041-549-446-256-496;;035-726-419-435-947;;082-783-197-553-627;;034-490-877-066-275;;054-734-661-818-718;;098-240-271-315-476;;094-016-430-416-433,12519061;;10.1021/jm020319p;;10.1200/jco.1998.16.9.2986;;9738567;;10.1111/j.1432-1033.1994.00771.x;;7925396;;10.1111/j.1432-1033.1997.t01-2-00527.x;;9030781;;12190313;;10.1021/jm0201520;;10.1002/jps.2600660104;;833720;;10.1016/0378-5173(86)90055-4;;9269999;;10.1021/jo00229a019;;11741470;;10.1021/jm015545y;;9371237;;10.1021/jm970493r;;10.1021/ol0343616;;12688761;;10.1007/bf00910055;;10.1248/cpb.47.928;;10434395,"DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 April 2001 (2001-04-22), TAKAMIZAWA AKIRA ET AL: ""PYRAZOLOPYRIMIDINE DERIVATIVES"", XP001167121, retrieved from STN Database accession no. 1965:410200;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 April 2001 (2001-04-22), TAKAMIZAWA AKIRA ET AL: ""PYRAZOLOPYRIMIDINE DERIVATIVES"", XP001167122, retrieved from STN Database accession no. 1965:410199;;Y. METTEY ET AL., J. MED. CHEM., vol. 46, 2003, pages 222 - 236;;A. M. SANDEROWICZ ET AL., J. CLIN. ONCOL., vol. 16, 1998, pages 2986 - 2999;;J. VESELY ET AL., EUR. J. BIOCHEM., vol. 224, 1994, pages 771 - 786;;I. MEIJER ET AL., EUR. J. BIOCHEM., vol. 243, 1997, pages 527 - 536;;K. S. KIM ET AL., J. MED. CHEM., vol. 45, 2002, pages 3905 - 3927;;CHEM. PHARM. BULL., vol. 47, 1999, pages 928;;J. MED. CHEM., vol. 20, 1977, pages 296;;J. MED. CHEM., 1976, pages 19 517;;CHEM. PHARM. BULL., 1962, pages 10 620;;T. HIGUCHI; V. STELLA: ""Bioreversible Carriers in Drug Design"", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, article ""Pro-drugs as Novel Delivery Systems"";;S. BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. L, 1977, pages 1 - 19;;P. GOULD, INTERNATIONAL J. OF PHARMACEUTICS, vol. 33, 1986, pages 201 - 217;;ANDERSON ET AL.: ""The Practice of Medicinal Chemistry"", 1996, ACADEMIC PRESS;;J. BIOCHEM, vol. 117, 1995, pages 741 - 749;;J. CELL SCI., vol. 108, 1995, pages 2897;;CANCER RESEARCH, vol. 57, 1997, pages 3375;;A. GENNARO: ""Remington's Pharmaceutical Sciences, 18th Edition,"", 1990, MACK PUBLISHING CO.;;K. O. OLSEN, J. ORG. CHEM., vol. 52, 1987, pages 4531 - 4536;;J. MED. CHEM., vol. 44, 2001, pages 4505 - 4508;;J. MED. CHEM., vol. 40, 1997, pages 3726 - 3733;;J. ORG. CHEM., vol. 64, 1999, pages 330;;GUPTON, J. HETEROCYCLIC CHEM., vol. 28, 1991, pages 1281;;RAGAN, SYNLETT, vol. 8, 2000, pages 1172 - 1174;;ORG. LETT., vol. 5, 2003, pages 1369 - 1372;;MONATSHEFTE FUR CHEMIE, vol. 104, 1973, pages 1372 - 1382;;CHEM. PHARM. BULL., vol. 47, 1999, pages 928 - 938",EXPIRED
472,NO,L,NO 20064046 L,043-100-535-443-157,2006-11-10,2006,NO 20064046 A,2006-09-08,US 77698804 A;;US 2005/0003859 W,2004-02-11,Pyrazolpyrimidinderivater som syklinavhengige kinaseinhibitorer,"I dens mange utførelsesformer tilveiebringer den foreliggende oppfinnelse en ny klasse av pyrazolo[1,5-a]-pyrimidinforbindelser som inhibitorer for syklinavhengige kinaser, fremgangsmåter for fremstilling av slike forbindelser, farmasøytiske preparater som inneholder én eller flere slike forbindelser, fremgangsmåter for fremstilling av farmasøytiske preparater som omfatter én eller flere slike forbindelser, og fremgangsmåter for behandling, profylakse, inhibering eller lindring av én eller flere sykdommer forbundet med CDK-ene under anvendelse av slike forbindelser eller farmasøytiske preparater.",PHARMACOPEIA DRUG DISCOVERY,MADISON VINCENT STEWART;;GIRIJAVALLABHAN VIYYOOR MOOPIL;;PARADKAR VIDYADHAR MADHAV;;GUZI TIMOTHY J;;CHAN TIN-YAU;;DOLL RONALD J;;KEERTIKAR KARTIK M;;JAMES RAY ANTHONY;;DWYER MICHAEL;;MALLAMS ALAN K;;RIVERA JOCELYN D;;FISCHMANN THIERRY O;;TRAN VINH D;;HE ZHEN MIN;;PARK HAENGSOON;;HOBBS DOUGLAS WALSH;;PARUCH KAMIL;;ALVAREZ CARMEN S;;DILLARD LAWRENCE W,"PHARMACOPEIA DRUG DISCOVERY INC, US (2022-11-28);;MERCK SHARP AND DOHME CORP, US (2012-09-24)",https://lens.org/043-100-535-443-157,Abstract,no,0,0,45,45,0,A61K31/495;;C07D487/04;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/12;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04;;A61K31/495;;A61K31/519;;C07D487/04;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/495;;A61K31/519,,0,0,,,,ACTIVE
473,KR,A,KR 20230034252 A,125-285-236-760-757,2023-03-09,2023,KR 20230023706 A,2023-02-22,US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;KR 20220061486 A,2020-02-14,USER INTERFACES FOR WORKOUT CONTENT,"일부 실시예들에서, 전자 디바이스는 완료된 운동들에 기초하여 개인화된 운동 제안들을 디스플레이하는 것과 관련된 기법들을 수행한다. 일부 실시예들에서, 전자 디바이스는 오디오 기반 운동을 시작하는 것과 관련된 기법들을 수행한다. 일부 실시예들에서, 전자 디바이스는 운동 콘텐츠의 재생 동안 운동에 관한 정보를 디스플레이하는 것과 관련된 기법들을 수행한다. 일부 실시예들에서, 전자 디바이스는 사용자들의 그룹에 대한 사용자의 신체적 활동에 관한 정보를 디스플레이하는 것과 관련된 기술들을 수행한다. 일부 실시예들에서, 전자 디바이스는 다수의 디바이스들 사이에서 운동 콘텐츠의 디스플레이를 조정하는 것에 관련된 기법들을 수행한다.",APPLE INC,DEVINE LYNNE;;ANGELONE JOEL J;;ARNEY JULIE A;;BACHMAN CHANDLER S;;BEDEKAR NIHARIKA MILIND;;BLAHNIK JAY K;;BUTCHER GARY IAN;;CANAVAN KRISTIN M;;CHAN JOSEPH Y;;CHAO EDWARD;;CLARK DAVID S;;CORMICAN NEIL P;;D'AURIA ANTHONY;;DRELL BRIAN R;;DYE ALAN C;;FAN HANWEN;;FELTON NICHOLAS D;;FORD MICHAEL D;;GILRAVI EAMON F;;HAGLUNDS ANDERS K;;HALES ERIN B;;HONG ZHENG X;;LAREAU BRETT L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCATEE KEVIN TYLER;;PANESAR PARRY;;PARK DENNIS S;;PATANKAR AALHAD R;;PATTON JENNIFER D;;PEDERSEN EMILY;;RUANGCHAN DANVIN;;SANDERS CHRISTOPHER JOHN;;SUNDSTROM MATTHEW J;;TAN ANG JEFF;;VALENCIA PAZ EDUARDO;;WHITE BRADY J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD POLICARPO BONILLA JR;;YOUNG NEALON,,https://lens.org/125-285-236-760-757,Patent Application,no,3,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,G16H20/30;;A63B24/00;;A63B71/06;;G06F3/0482;;G16H10/60,,0,0,,,,ACTIVE
474,KR,A,KR 20230132742 A,151-377-558-211-911,2023-09-18,2023,KR 20230114488 A,2023-08-30,US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;KR 20200123840 A,2020-02-14,USER INTERFACES FOR WORKOUT CONTENT,"일부 실시예들에서, 전자 디바이스는 완료된 운동들에 기초하여 개인화된 운동 제안들을 디스플레이하는 것과 관련된 기법들을 수행한다. 일부 실시예들에서, 전자 디바이스는 오디오 기반 운동을 시작하는 것과 관련된 기법들을 수행한다. 일부 실시예들에서, 전자 디바이스는 운동 콘텐츠의 재생 동안 운동에 관한 정보를 디스플레이하는 것과 관련된 기법들을 수행한다. 일부 실시예들에서, 전자 디바이스는 사용자들의 그룹에 대한 사용자의 신체적 활동에 관한 정보를 디스플레이하는 것과 관련된 기술들을 수행한다. 일부 실시예들에서, 전자 디바이스는 다수의 디바이스들 사이에서 운동 콘텐츠의 디스플레이를 조정하는 것에 관련된 기법들을 수행한다.",APPLE INC,DEVINE LYNNE;;ANGELONE JOEL J;;ARNEY JULIE A;;BACHMAN CHANDLER S;;BEDEKAR NIHARIKA MILIND;;BLAHNIK JAY K;;BUTCHER GARY IAN;;CANAVAN KRISTIN M;;CHAN JOSEPH Y;;CHAO EDWARD;;CLARK DAVID S;;CORMICAN NEIL P;;D'AURIA ANTHONY;;DRELL BRIAN R;;DYE ALAN C;;FAN HANWEN;;FELTON NICHOLAS D;;FORD MICHAEL D;;GILRAVI EAMON F;;HAGLUNDS ANDERS K;;HALES ERIN B;;HONG ZHENG X;;LAREAU BRETT L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCATEE KEVIN TYLER;;PANESAR PARRY;;PARK DENNIS S;;PATANKAR AALHAD R;;PATTON JENNIFER D;;PEDERSEN EMILY;;RUANGCHAN DANVIN;;SANDERS CHRISTOPHER JOHN;;SUNDSTROM MATTHEW J;;TAN ANG JEFF;;VALENCIA PAZ EDUARDO;;WHITE BRADY J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD POLICARPO BONILLA JR;;YOUNG NEALON,,https://lens.org/151-377-558-211-911,Patent Application,no,0,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,G16H20/30;;A63B24/00;;A63B71/06;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,,0,0,,,,PENDING
475,AU,A1,AU 2023/285859 A1,035-874-796-796-945,2024-01-18,2024,AU 2023/285859 A,2023-12-21,AU 2023/285859 A;;AU 2022/202977 A;;AU 2020/239752 A;;DK PA202070615 A;;DK PA202070616 A;;US 202062977076 P;;DK PA202070612 A;;DK PA202070613 A;;US 202063036374 P;;US 202063078311 P,2020-02-14,User interfaces for workout content,"A method, comprising a computer system that is in communication with a display generation component and one or more input devices: detecting, via the one or more input devices, a user input corresponding to a request to display a workout user interface; and in response to the request to display the workout user interface: in accordance with a determination that the computer system meets proximity criteria relative to a single external electronic device of a first type: initiating a process to display, via the display generation component, a first workout suggestion user interface, wherein the first workout suggestion user interface displays one or more workout suggestions associated with the single external electronic device, and in accordance with a determination that the computer system meets proximity criteria relative to at least a first external electronic device of the first type and a second external electronic device of the first type: initiating a process to display, via the display generation component, a disambiguation user interface different from the first workout suggestion user interface, wherein the disambiguation user interface includes: a first selectable user interface object associated with the first external electronic device that, when selected, initiates a process for displaying a second workout suggestion user interface associated with the first external electronic device, wherein the second workout suggestion user interface displays one or more workout suggestions associated with the first external electronic device, and a second selectable user interface object associated with the second external electronic device that, when selected, initiates a process for displaying a third workout suggestion user interface different from the second workout suggestion user interface and associated with the second external electronic device, wherein the third workout suggestion user interface displays one or more workout suggestions associated with the second external electronic device.",APPLE INC,DEVINE LYNNE;;ANGELONE JOEL J;;ARNEY JULIE;;BEDEKAR NIHARIKA;;BLAHNIK JAY;;BUTCHER GARY IAN;;CHAO EDWARD;;CLARK DAVID;;D'AURIA ANTHONY;;FORD MICHAEL D;;HALES ERIN B;;HONG ZHENG (VINCENT) X;;WIEBE MOLLY;;BACHMAN CHANDLER S;;CANAVAN KRISTIN M;;CHAN JOSEPH Y;;CORMICAN NEIL P;;DRELL BRIAN R;;DYE ALAN C;;FAN HANWEN;;FELTON NICHOLAS D;;GILRAVI EAMON F;;HAGLUNDS ANDERS K;;LAREAU BRETT L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCATEE KEVIN TYLER;;PANESAR PARRY;;PARK DENNIS S;;PATANKAR AALHAD R;;PATTON JENNIFER D;;PEDERSEN EMILY;;RUANGCHAN DANVIN;;SANDERS CHRISTOPHER JOHN;;SUNDSTROM MATTHEW J;;TAN-ANG JEFF;;VALENCIA PAZ EDUARDO;;WHITE BRADY J;;WILLIAMS ALED HYWEL;;WOOD JR POLICARPO BONILLA;;YOUNG NEALON,,https://lens.org/035-874-796-796-945,Patent Application,no,0,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,A63B24/00;;A63B71/06;;G06F3/01;;G06Q10/06,,0,0,,,,PENDING
476,AU,B2,AU 2022/202977 B2,065-701-881-282-984,2023-10-05,2023,AU 2022/202977 A,2022-05-04,AU 2022/202977 A;;AU 2020/239752 A;;DK PA202070615 A;;DK PA202070616 A;;US 202062977076 P;;DK PA202070612 A;;DK PA202070613 A;;US 202063036374 P;;US 202063078311 P,2020-02-14,User interfaces for workout content,"In some embodiments, an electronic device performs techniques related to displaying personalized workout suggestions based on completed workouts. In some embodiments, an electronic device performs techniques related to starting an audio-based workout. In some embodiments, an electronic device performs techniques related to displaying information about a workout during playback of workout content. In some embodiments, an electronic device performs techniques related to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques related to coordinating display of workout content among multiple devices.",APPLE INC,DEVINE LYNNE;;ANGELONE JOEL J;;ARNEY JULIE;;BEDEKAR NIHARIKA;;BLAHNIK JAY;;BUTCHER GARY IAN;;CHAO EDWARD;;CLARK DAVID;;D'AURIA ANTHONY;;FORD MICHAEL D;;HALES ERIN B;;HONG ZHENG (VINCENT) X;;WIEBE MOLLY;;BACHMAN CHANDLER S;;CANAVAN KRISTIN M;;CHAN JOSEPH Y;;CORMICAN NEIL P;;DRELL BRIAN R;;DYE ALAN C;;FAN HANWEN;;FELTON NICHOLAS D;;GILRAVI EAMON F;;HAGLUNDS ANDERS K;;LAREAU BRETT L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCATEE KEVIN TYLER;;PANESAR PARRY;;PARK DENNIS S;;PATANKAR AALHAD R;;PATTON JENNIFER D;;PEDERSEN EMILY;;RUANGCHAN DANVIN;;SANDERS CHRISTOPHER JOHN;;SUNDSTROM MATTHEW J;;TAN-ANG JEFF;;VALENCIA PAZ EDUARDO;;WHITE BRADY J;;WILLIAMS ALED HYWEL;;WOOD JR POLICARPO BONILLA;;YOUNG NEALON,,https://lens.org/065-701-881-282-984,Granted Patent,no,0,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,A63B24/00;;A63B71/06;;G06F3/01;;G06Q10/06,,0,0,,,,ACTIVE
477,WO,A3,WO 2021/163388 A3,066-767-248-801-054,2021-09-30,2021,US 2021/0017736 W,2021-02-11,US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 202017031543 A,2020-02-14,USER INTERFACES FOR WORKOUT CONTENT,"In some embodiments, an electronic device performs techniques related to displaying personalized workout suggestions based on completed workouts. In some embodiments, an electronic device performs techniques related to starting an audio-based workout. In some embodiments, an electronic device performs techniques related to displaying information about a workout during playback of workout content. In some embodiments, an electronic device performs techniques related to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques related to coordinating display of workout content among multiple devices.",APPLE INC,DEVINE LYNNE;;ANGELONE JOEL J;;ARNEY JULIE A;;BACHMAN CHANDLER;;BEDEKAR NIHARIKA MILIND;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KRISTIN MICHELE;;CHAN JOSEPH;;CHAO EDWARD;;CLARK DAVID;;CORMICAN NEIL;;D’AURIA ANTHONY;;DRELL BRIAN;;FAN HANWEN;;FELTON NICHOLAS;;FORD MICHAEL B;;GILRAVI EAMON F;;HAGLUNDS ANDERS K;;HALES ERYN;;HONG ZHENG X;;LAREAU BRETT L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCATEE KEVIN TYLER;;PANESAR PARRY;;PARK DENNIS S;;PATANKAR AALHAD R;;PATTON JENNIFER D;;PEDERSEN EMILY;;RUANGCHAN DANVIN;;SANDERS CHRISTOPHER JOHN;;SUNDSTROM MATTHEW J;;TAN-ANG JEFF;;VALENCIA PAZ EDUARDO;;WHITE BRADY J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD JR;;YOUNG NEAL,,https://lens.org/066-767-248-801-054,Search Report,yes,6,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,G06F3/0482;;A61B5/00;;A63B24/00;;G06F3/0488;;G09B19/00,,0,0,,,,PENDING
478,WO,A4,WO 2021/163388 A4,164-869-793-557-253,2021-11-25,2021,US 2021/0017736 W,2021-02-11,US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 202017031543 A,2020-02-14,USER INTERFACES FOR WORKOUT CONTENT,"In some embodiments, an electronic device performs techniques related to displaying personalized workout suggestions based on completed workouts. In some embodiments, an electronic device performs techniques related to starting an audio-based workout. In some embodiments, an electronic device performs techniques related to displaying information about a workout during playback of workout content. In some embodiments, an electronic device performs techniques related to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques related to coordinating display of workout content among multiple devices.",APPLE INC,DEVINE LYNNE;;ANGELONE JOEL J;;ARNEY JULIE A;;BACHMAN CHANDLER;;BEDEKAR NIHARIKA MILIND;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KRISTIN MICHELE;;CHAN JOSEPH;;CHAO EDWARD;;CLARK DAVID;;CORMICAN NEIL;;D’AURIA ANTHONY;;DRELL BRIAN;;FAN HANWEN;;FELTON NICHOLAS;;FORD MICHAEL B;;GILRAVI EAMON F;;HAGLUNDS ANDERS K;;HALES ERYN;;HONG ZHENG X;;LAREAU BRETT L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCATEE KEVIN TYLER;;PANESAR PARRY;;PARK DENNIS S;;PATANKAR AALHAD R;;PATTON JENNIFER D;;PEDERSEN EMILY;;RUANGCHAN DANVIN;;SANDERS CHRISTOPHER JOHN;;SUNDSTROM MATTHEW J;;TAN-ANG JEFF;;VALENCIA PAZ EDUARDO;;WHITE BRADY J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD JR;;YOUNG NEAL,,https://lens.org/164-869-793-557-253,Patent Application,yes,0,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,G06F3/0482;;A61B5/00;;A63B24/00;;G06F3/0488;;G09B19/00,,0,0,,,,PENDING
479,WO,A2,WO 2021/163388 A2,095-506-457-182-962,2021-08-19,2021,US 2021/0017736 W,2021-02-11,US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 202017031543 A,2020-02-14,USER INTERFACES FOR WORKOUT CONTENT,"In some embodiments, an electronic device performs techniques related to displaying personalized workout suggestions based on completed workouts. In some embodiments, an electronic device performs techniques related to starting an audio-based workout. In some embodiments, an electronic device performs techniques related to displaying information about a workout during playback of workout content. In some embodiments, an electronic device performs techniques related to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques related to coordinating display of workout content among multiple devices.",APPLE INC,DEVINE LYNNE;;ANGELONE JOEL J;;ARNEY JULIE A;;BACHMAN CHANDLER;;BEDEKAR NIHARIKA MILIND;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KRISTIN MICHELE;;CHAN JOSEPH;;CHAO EDWARD;;CLARK DAVID;;CORMICAN NEIL;;D’AURIA ANTHONY;;DRELL BRIAN;;FAN HANWEN;;FELTON NICHOLAS;;FORD MICHAEL B;;GILRAVI EAMON F;;HAGLUNDS ANDERS K;;HALES ERYN;;HONG ZHENG X;;LAREAU BRETT L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCATEE KEVIN TYLER;;PANESAR PARRY;;PARK DENNIS S;;PATANKAR AALHAD R;;PATTON JENNIFER D;;PEDERSEN EMILY;;RUANGCHAN DANVIN;;SANDERS CHRISTOPHER JOHN;;SUNDSTROM MATTHEW J;;TAN-ANG JEFF;;VALENCIA PAZ EDUARDO;;WHITE BRADY J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD JR;;YOUNG NEAL,,https://lens.org/095-506-457-182-962,Patent Application,yes,31,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,G06F3/0482;;A61B5/00;;A63B24/00;;G06F3/0488;;G09B19/00,,0,0,,,,PENDING
480,EP,A1,EP 4202619 A1,166-124-047-838-746,2023-06-28,2023,EP 23153900 A,2021-02-11,US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 202017031543 A;;EP 21714460 A;;US 2021/0017736 W,2020-02-14,USER INTERFACES FOR WORKOUT CONTENT,"In some embodiments, an electronic device performs techniques related to displaying personalized workout suggestions based on completed workouts. In some embodiments, an electronic device performs techniques related to starting an audio-based workout. In some embodiments, an electronic device performs techniques related to displaying information about a workout during playback of workout content. In some embodiments, an electronic device performs techniques related to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques related to coordinating display of workout content among multiple devices.
",APPLE INC,DEVINE LYNNE;;ANGELONE JOEL J;;ARNEY JULIE A;;BACHMAN CHANDLER;;BEDEKAR NIHARIKA MILIND;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KRISTIN MICHELE;;CHAN JOSEPH;;CHAO EDWARD;;CLARK DAVID;;CORMICAN NEIL;;D'AURIA ANTHONY;;DRELL BRIAN;;DYE ALAN C;;FAN HANWEN;;FELTON NICHOLAS;;FORD MICHAEL D;;GILRAVI EAMON F;;HAGLUNDS ANDERS K;;HALES ERYN;;HONG ZHENG X;;LAREAU BRETT L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCATEE KEVIN TYLER;;PANESAR PARRY;;PARK DENNIS S;;PATANKAR AALHAD R;;PATTON JENNIFER D;;PEDERSEN EMILY;;RUANGCHAN DANVIN;;SANDERS CHRISTOPHER JOHN;;SUNDSTROM MATTHEW J;;TAN-ANG JEFF;;VALENCIA PAZ EDUARDO;;WHITE BRADY J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD JR POLICARPO BONILLA;;YOUNG NEALON,,https://lens.org/166-124-047-838-746,Patent Application,yes,33,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,G06F3/0482;;A61B5/00;;A61B5/024;;A63B24/00;;G06F3/0488;;G06F3/04883;;G09B19/00;;G16H20/30;;G16H40/63,,0,0,,,,PENDING
481,CN,A,CN 116700581 A,183-958-364-297-549,2023-09-05,2023,CN 202310828052 A,2021-02-11,US 202017031543 A;;CN 202180014493 A;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 2021/0017736 W,2020-02-14,User interface for fitness content,"The invention relates to a user interface for fitness content. In some embodiments, an electronic device performs techniques that involve displaying personalized fitness suggestions based on completed fitness. In some embodiments, an electronic device performs techniques that involve starting audio-based fitness. In some embodiments, an electronic device performs techniques relating to displaying information about fitness during playback of fitness content. In some embodiments, an electronic device performs techniques relating to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques relating to coordinating the display of fitness content among a plurality of devices.",APPLE INC,L DEVINE;;ANGELON JOHN J;;ARNEY JULIE A;;BACHMANN CHRISTIAN;;BEDEKAR NAVEEN M;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KEVIN M;;CHEN JIAN;;CHAO ERIC;;CLARKE DAVID;;KMIECKEN NINA;;DARIAN ALEXANDER;;DREYER BERND;;ALAN C DYE;;FAN HUA;;N FELTON;;FORD MICHAEL D;;GILAVI ELIEL F;;HAGLUNZ ALFRED K;;HALES EDWIN;;HONG ZHENG X;;LARROW BRIAN L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCCARTY KEVIN THOMAS;;PANESAR PRADEEP;;PARK DOO S;;PATANKAR ASHUTOSH R;;PATTON JOHN DAVID;;PEDERSEN ERIC;;NGUYEN CHAN DUC;;SANDERS CHRISTOPHER J;;M J SUNDSTROM;;CHEN JERRY;;VALENCIA PAZ EDUARDO;;WHITE BRIAN J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD POLICARPO BONILLA JR;;YANG NILES,,https://lens.org/183-958-364-297-549,Patent Application,no,0,0,5,62,0,G06F3/04847;;G06F3/0485;;G06F3/04883;;G06F21/31;;G16H20/30;;G06F3/01,G06F3/04847;;G06F3/01;;G06F3/0485;;G06F3/04883;;G06F21/31;;G16H20/30,,0,0,,,,PENDING
482,CN,A,CN 117055776 A,022-596-430-008-300,2023-11-14,2023,CN 202311059240 A,2021-02-11,US 202017031543 A;;CN 202180014493 A;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 2021/0017736 W,2020-02-14,User interface for fitness content,"The invention relates to a user interface for fitness content. In some embodiments, an electronic device performs techniques that involve displaying personalized fitness suggestions based on completed fitness. In some embodiments, an electronic device performs techniques that involve starting audio-based fitness. In some embodiments, an electronic device performs techniques relating to displaying information about fitness during playback of fitness content. In some embodiments, an electronic device performs techniques relating to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques relating to coordinating the display of fitness content among a plurality of devices.",APPLE INC,L DEVINE;;ANGELON JOHN J;;ARNEY JULIE A;;BACHMANN CHRISTIAN;;BEDEKAR NAVEEN M;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KEVIN M;;CHEN JIAN;;CHAO ERIC;;CLARKE DAVID;;KMIECKEN NINA;;DARIAN ALEXANDER;;DREYER BERND;;ALAN C DYE;;FAN HUA;;N FELTON;;FORD MICHAEL D;;GILAVI ELIEL F;;HAGLUNZ ALFRED K;;HALES EDWIN;;HONG ZHENG X;;LARROW BRIAN L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCCARTY KEVIN THOMAS;;PANESAR PRADEEP;;PARK DOO S;;PATANKAR ASHUTOSH R;;PATTON JOHN DAVID;;PEDERSEN ERIC;;NGUYEN CHAN DUC;;SANDERS CHRISTOPHER J;;M J SUNDSTROM;;CHEN JERRY;;VALENCIA PAZ EDUARDO;;WHITE BRIAN J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD POLICARPO BONILLA JR;;YANG NILES,,https://lens.org/022-596-430-008-300,Patent Application,no,0,0,5,62,0,G06F3/04847;;G06F3/0485;;G06F3/04883;;G06F21/31;;G16H20/30;;G06F3/01,G06F3/04817;;G06F3/01;;G06F3/04847;;G06F3/0485;;G06F3/04883;;G06F21/31;;G16H20/30,,0,0,,,,PENDING
483,EP,A1,EP 4198698 A1,063-218-935-415-920,2023-06-21,2023,EP 23153898 A,2021-02-11,US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 202017031543 A;;EP 21714460 A;;US 2021/0017736 W,2020-02-14,USER INTERFACES FOR WORKOUT CONTENT,"In some embodiments, an electronic device performs techniques related to displaying personalized workout suggestions based on completed workouts. In some embodiments, an electronic device performs techniques related to starting an audio-based workout. In some embodiments, an electronic device performs techniques related to displaying information about a workout during playback of workout content. In some embodiments, an electronic device performs techniques related to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques related to coordinating display of workout content among multiple devices.
",APPLE INC,DEVINE LYNNE;;ANGELONE JOEL J;;ARNEY JULIE A;;BACHMAN CHANDLER;;BEDEKAR NIHARIKA MILIND;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KRISTIN MICHELE;;CHAN JOSEPH;;CHAO EDWARD;;CLARK DAVID;;CORMICAN NEIL;;D'AURIA ANTHONY;;DRELL BRIAN;;DYE ALAN C;;FAN HANWEN;;FELTON NICHOLAS;;FORD MICHAEL D;;GILRAVI EAMON F;;HAGLUNDS ANDERS K;;HALES ERYN;;HONG ZHENG X;;LAREAU BRETT L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCATEE KEVIN TYLER;;PANESAR PARRY;;PARK DENNIS S;;PATANKAR AALHAD R;;PATTON JENNIFER D;;PEDERSEN EMILY;;RUANGCHAN DANVIN;;SANDERS CHRISTOPHER JOHN;;SUNDSTROM MATTHEW J;;TAN-ANG JEFF;;VALENCIA PAZ EDUARDO;;WHITE BRADY J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD JR POLICARPO BONILLA;;YOUNG NEALON,,https://lens.org/063-218-935-415-920,Patent Application,yes,34,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,G06F3/0482;;A61B5/00;;A61B5/024;;A63B24/00;;A63B71/06;;G06F3/0488;;G06F3/04883;;G09B19/00;;G16H20/30;;G16H40/63,,0,0,,,,PENDING
484,CN,A,CN 115698926 A,017-933-902-407-005,2023-02-03,2023,CN 202180014493 A,2021-02-11,DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 202017031543 A;;US 2021/0017736 W,2020-02-14,User interface for fitness content,"In some embodiments, an electronic device performs techniques that involve displaying personalized fitness suggestions based on completed fitness. In some embodiments, an electronic device performs techniques that involve starting audio-based fitness. In some embodiments, an electronic device performs techniques relating to displaying information about fitness during playback of fitness content. In some embodiments, an electronic device performs techniques relating to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques relating to coordinating the display of fitness content among a plurality of devices.",APPLE INC,L DEVINE;;ANGELON JOHN J;;ARNEY JULIE A;;BACHMANN CHRISTIAN;;BEDEKAR NAVEEN M;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KEVIN M;;CHEN JIAN;;CHAO ERIC;;CLARKE DAVID;;KMIECKEN NINA;;DARIAN ALEXANDER;;DREYER BERND;;ALAN C DYE;;FAN HUA;;N FELTON;;FORD MICHAEL D;;GILAVI ELIEL F;;HAGLUNZ ALFRED K;;HALES EDWIN;;HONG ZHENG X;;LARROW BRIAN L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCCARTY KEVIN THOMAS;;PANESAR PRADEEP;;PARK DOO S;;PATANKAR ASHUTOSH R;;PATTON JOHN DAVID;;PEDERSEN ERIC;;NGUYEN CHAN DUC;;SANDERS CHRISTOPHER J;;M J SUNDSTROM;;CHEN JERRY;;VALENCIA PAZ EDUARDO;;WHITE BRIAN J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD POLICARPO BONILLA JR;;YANG NILES,,https://lens.org/017-933-902-407-005,Patent Application,no,0,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,G06F3/0482;;A61B5/00;;A63B24/00;;G06F3/0488;;G09B19/00,,0,0,,,,PENDING
485,EP,A2,EP 4104045 A2,000-596-647-271-574,2022-12-21,2022,EP 21714460 A,2021-02-11,US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 202017031543 A;;US 2021/0017736 W,2020-02-14,USER INTERFACES FOR WORKOUT CONTENT,,APPLE INC,DEVINE LYNNE;;ANGELONE JOEL J;;ARNEY JULIE A;;BACHMAN CHANDLER;;BEDEKAR NIHARIKA MILIND;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KRISTIN MICHELE;;CHAN JOSEPH;;CHAO EDWARD;;CLARK DAVID;;CORMICAN NEIL;;D'AURIA ANTHONY;;DRELL BRIAN;;DYE ALAN C;;FAN HANWEN;;FELTON NICHOLAS;;FORD MICHAEL D;;GILRAVI EAMON F;;HAGLUNDS ANDERS K;;HALES ERYN;;HONG ZHENG X;;LAREAU BRETT L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCATEE KEVIN TYLER;;PANESAR PARRY;;PARK DENNIS S;;PATANKAR AALHAD R;;PATTON JENNIFER D;;PEDERSEN EMILY;;RUANGCHAN DANVIN;;SANDERS CHRISTOPHER JOHN;;SUNDSTROM MATTHEW J;;TAN-ANG JEFF;;VALENCIA PAZ EDUARDO;;WHITE BRADY J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD JR POLICARPO BONILLA;;YOUNG NEAL,,https://lens.org/000-596-647-271-574,Patent Application,yes,0,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,G06F3/0482;;A61B5/00;;A63B24/00;;G06F3/0488;;G09B19/00,,0,0,,,,PENDING
486,EP,A1,EP 4198699 A1,056-869-935-850-434,2023-06-21,2023,EP 23153899 A,2021-02-11,US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 202017031543 A;;EP 21714460 A;;US 2021/0017736 W,2020-02-14,USER INTERFACES FOR WORKOUT CONTENT,"In some embodiments, an electronic device performs techniques related to displaying personalized workout suggestions based on completed workouts. In some embodiments, an electronic device performs techniques related to starting an audio-based workout. In some embodiments, an electronic device performs techniques related to displaying information about a workout during playback of workout content. In some embodiments, an electronic device performs techniques related to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques related to coordinating display of workout content among multiple devices.
",APPLE INC,DEVINE LYNNE;;ANGELONE JOEL J;;ARNEY JULIE A;;BACHMAN CHANDLER;;BEDEKAR NIHARIKA MILIND;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KRISTIN MICHELE;;CHAN JOSEPH;;CHAO EDWARD;;CLARK DAVID;;CORMICAN NEIL;;D'AURIA ANTHONY;;DRELL BRIAN;;DYE ALAN C;;FAN HANWEN;;FELTON NICHOLAS;;FORD MICHAEL D;;GILRAVI EAMON F;;HAGLUNDS ANDERS K;;HALES ERYN;;HONG ZHENG X;;LAREAU BRETT L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCATEE KEVIN TYLER;;PANESAR PARRY;;PARK DENNIS S;;PATANKAR AALHAD R;;PATTON JENNIFER D;;PEDERSEN EMILY;;RUANGCHAN DANVIN;;SANDERS CHRISTOPHER JOHN;;SUNDSTROM MATTHEW J;;TAN-ANG JEFF;;VALENCIA PAZ EDUARDO;;WHITE BRADY J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD JR POLICARPO BONILLA;;YOUNG NEALON,,https://lens.org/056-869-935-850-434,Patent Application,yes,33,0,39,62,0,A61B5/742;;G06F3/0482;;G06F3/04883;;G09B19/0038;;G16H20/30;;A61B5/024;;A61B5/0022;;G16H40/63;;G06F3/048;;G06F21/35;;G16H20/30;;A63B71/0622;;A63B24/0075;;A63B2071/0625;;G06F3/0481;;G06F3/04842;;G06F3/0485;;G06F3/04883;;G06Q50/22,G06F3/0482;;A61B5/00;;A61B5/024;;A63B24/00;;G06F3/048;;G06F3/04883;;G09B19/00;;G16H20/30;;G16H40/63,,0,0,,,,PENDING
487,CN,A,CN 116820299 A,100-376-444-706-006,2023-09-29,2023,CN 202310774963 A,2021-02-11,US 202017031543 A;;CN 202180014493 A;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 2021/0017736 W,2020-02-14,User interface for fitness content,"The invention relates to a user interface for fitness content. In some embodiments, an electronic device performs techniques that involve displaying personalized fitness suggestions based on completed fitness. In some embodiments, an electronic device performs techniques that involve starting audio-based fitness. In some embodiments, an electronic device performs techniques relating to displaying information about fitness during playback of fitness content. In some embodiments, an electronic device performs techniques relating to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques relating to coordinating the display of fitness content among a plurality of devices.",APPLE INC,L DEVINE;;ANGELON JOHN J;;ARNEY JULIE A;;BACHMANN CHRISTIAN;;BEDEKAR NAVEEN M;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KEVIN M;;CHEN JIAN;;CHAO ERIC;;CLARKE DAVID;;KMIECKEN NINA;;DARIAN ALEXANDER;;DREYER BERND;;ALAN C DYE;;FAN HUA;;N FELTON;;FORD MICHAEL D;;GILAVI ELIEL F;;HAGLUNZ ALFRED K;;HALES EDWIN;;HONG ZHENG X;;LARROW BRIAN L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCCARTY KEVIN THOMAS;;PANESAR PRADEEP;;PARK DOO S;;PATANKAR ASHUTOSH R;;PATTON JOHN DAVID;;PEDERSEN ERIC;;NGUYEN CHAN DUC;;SANDERS CHRISTOPHER J;;M J SUNDSTROM;;CHEN JERRY;;VALENCIA PAZ EDUARDO;;WHITE BRIAN J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD POLICARPO BONILLA JR;;YANG NILES,,https://lens.org/100-376-444-706-006,Patent Application,no,0,0,5,62,0,G06F3/04847;;G06F3/0485;;G06F3/04883;;G06F21/31;;G16H20/30;;G06F3/01,G06F3/0482;;A61B5/00;;A63B24/00;;G06F3/04883;;G09B19/00,,0,0,,,,PENDING
488,CN,A,CN 116820300 A,004-401-704-286-75X,2023-09-29,2023,CN 202310775734 A,2021-02-11,US 202017031543 A;;CN 202180014493 A;;DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 2021/0017736 W,2020-02-14,User interface for fitness content,"The invention relates to a user interface for fitness content. In some embodiments, an electronic device performs techniques that involve displaying personalized fitness suggestions based on completed fitness. In some embodiments, an electronic device performs techniques that involve starting audio-based fitness. In some embodiments, an electronic device performs techniques relating to displaying information about fitness during playback of fitness content. In some embodiments, an electronic device performs techniques relating to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques relating to coordinating the display of fitness content among a plurality of devices.",APPLE INC,L DEVINE;;ANGELON JOHN J;;ARNEY JULIE A;;BACHMANN CHRISTIAN;;BEDEKAR NAVEEN M;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KEVIN M;;CHEN JIAN;;CHAO ERIC;;CLARKE DAVID;;KMIECKEN NINA;;DARIAN ALEXANDER;;DREYER BERND;;ALAN C DYE;;FAN HUA;;N FELTON;;FORD MICHAEL D;;GILAVI ELIEL F;;HAGLUNZ ALFRED K;;HALES EDWIN;;HONG ZHENG X;;LARROW BRIAN L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCCARTY KEVIN THOMAS;;PANESAR PRADEEP;;PARK DOO S;;PATANKAR ASHUTOSH R;;PATTON JOHN DAVID;;PEDERSEN ERIC;;NGUYEN CHAN DUC;;SANDERS CHRISTOPHER J;;M J SUNDSTROM;;CHEN JERRY;;VALENCIA PAZ EDUARDO;;WHITE BRIAN J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD POLICARPO BONILLA JR;;YANG NILES,,https://lens.org/004-401-704-286-75X,Patent Application,no,0,0,5,62,0,G06F3/04847;;G06F3/0485;;G06F3/04883;;G06F21/31;;G16H20/30;;G06F3/01,G06F3/0482;;A61B5/00;;A63B24/00;;G06F3/04883;;G09B19/00,,0,0,,,,PENDING
489,CN,A,CN 115562537 A,064-740-377-986-232,2023-01-03,2023,CN 202211193170 A,2021-02-11,DK PA202070612 A;;DK PA202070613 A;;DK PA202070615 A;;DK PA202070616 A;;US 202062977076 P;;US 202063036374 P;;US 202063078311 P;;US 202017030318 A;;US 202017030321 A;;US 202017030337 A;;US 202017030340 A;;US 202017030343 A;;US 202017031543 A;;CN 202180014493 A,2020-02-14,User interface for fitness content,"The invention relates to a user interface for fitness content. In some embodiments, an electronic device performs techniques that involve displaying personalized fitness suggestions based on completed fitness. In some embodiments, an electronic device performs techniques that involve starting audio-based fitness. In some embodiments, an electronic device performs techniques relating to displaying information about fitness during playback of fitness content. In some embodiments, an electronic device performs techniques relating to displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques relating to coordinating the display of fitness content among a plurality of devices.",APPLE INC,L DEVINE;;ANGELON JOHN J;;ARNEY JULIE A;;BACHMANN CHRISTIAN;;BEDEKAR NAVEEN M;;BLAHNIK JAY;;BUTCHER GARY IAN;;CANAVAN KEVIN M;;CHEN JIAN;;CHAO ERIC;;CLARKE DAVID;;KMIECKEN NINA;;DARIAN ALEXANDER;;DREYER BERND;;ALAN C DYE;;FAN HUA;;N FELTON;;FORD MICHAEL D;;GILAVI ELIEL F;;HAGLUNZ ALFRED K;;HALES EDWIN;;HONG ZHENG X;;LARROW BRIAN L;;LEMAY STEPHEN O;;LYNCH KEVIN;;MCCARTY KEVIN THOMAS;;PANESAR PRADEEP;;PARK DOO S;;PATANKAR ASHUTOSH R;;PATTON JOHN DAVID;;PEDERSEN ERIC;;NGUYEN CHAN DUC;;SANDERS CHRISTOPHER J;;M J SUNDSTROM;;CHEN JERRY;;VALENCIA PAZ EDUARDO;;WHITE BRIAN J;;WIEBE MOLLY PRAY;;WILLIAMS ALED HYWEL;;WOOD POLICARPO BONILLA JR;;YANG NILES,,https://lens.org/064-740-377-986-232,Patent Application,no,7,0,5,62,0,G06F3/04847;;G06F3/0485;;G06F3/04883;;G06F21/31;;G16H20/30;;G06F3/01,G06F3/04817;;G06F3/01;;G06F3/04847;;G06F3/0485;;G06F3/04883;;G06F21/31;;G16H20/30,,0,0,,,,PENDING
